

(11) **EP 1 422 218 A1**

(12) **EUROPEAN PATENT APPLICATION**
 published in accordance with Art. 158(3) EPC

(43) Date of publication:
26.05.2004 Bulletin 2004/22

(21) Application number: **02749384.0**

(22) Date of filing: **08.08.2002**

(51) Int Cl.⁷: **C07D 207/38**, C07D 403/04,
 C07D 405/04, C07D 405/06,
 C07D 413/04, C07D 401/04,
 C07D 413/06, C07D 407/06,
 C07D 417/06, C07D 409/06,
 C07D 403/06, C07D 409/14,
 C07D 311/56, C07D 307/46,
 A61K 31/4025, A61K 31/4245,
 A61K 31/4427, A61K 31/4709,
 A61K 31/506

(86) International application number:
PCT/JP2002/008108

(87) International publication number:
WO 2003/016275 (27.02.2003 Gazette 2003/09)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
IE IT LI LU MC NL PT SE SK TR
 Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **10.08.2001 JP 2001245071**
05.12.2001 JP 2001370860
28.06.2002 JP 2002191483

(71) Applicant: **SHIONOGI & CO., LTD.**
Osaka-shi, Osaka 541-0045 (JP)

(72) Inventors:
 • **KIYAMA, Ryuichi, c/o Shionogi & Co., Ltd**
Osaka-shi, Osaka 553-0002 (JP)



- **KANDA, Yasuhiko, c/o Shionogi & Co., Ltd**
Osaka-shi, Osaka 553-0002 (JP)
- **TADA, Yukio, c/o Shionogi & Co., Ltd**
Osaka-shi, Osaka 553-0002 (JP)
- **FUJISHITA, Toshio, c/o Shionogi & Co., Ltd**
Osaka-shi, Osaka 553-0002 (JP)
- **KAWASUJI, Takashi, c/o Shionogi & Co., Ltd**
Osaka-shi, Osaka 553-0002 (JP)
- **TAKECHI, Shozo, c/o Shionogi & Co., Ltd**
Osaka-shi, Osaka 553-0002 (JP)
- **FUJI, Masahiro, c/o Shionogi & Co., Ltd**
Osaka-shi, Osaka 553-0002 (JP)

(74) Representative: **VOSSIUS & PARTNER**
Siebertstrasse 4
81675 München (DE)

(54) **ANTIVIRAL AGENT**

(57) The present invention provides an integrase inhibitor. The inventors have found the following compound of formula (I) possessing an integrase inhibitory activity.

(wherein, R^C and R^D taken together with the neighboring carbon atoms form a ring which may be a condensed ring, Y is hydroxy, mercapto or amino; Z is O, S or NH; R^A is a group shown by



(wherein, C ring is N-containing aromatic heterocycle or the like)

EP 1 422 218 A1

Description

Technical Field


- 5 **[0001]** The present invention relates to an antiviral agent, especially, a compound having an α -hydroxy- α , β unsaturated ketone as a partial structure, and a pharmaceutical composition as an integrase inhibitor containing the same.

Background Art

- 10 **[0002]** Among viruses, human immunodeficiency virus (HIV), a kind of retrovirus, is known to cause acquired immunodeficiency syndrome (AIDS). The therapeutic agent for AIDS is mainly selected from the group of reverse transcriptase inhibitors (e.g., AZT, 3TC) and protease inhibitors (e.g., Indinavir), but they are proved to be accompanied by side effects such as nephropathy and the emergence of resistant viruses. Thus, the development of anti-HIV agents having the other mechanism of action has been desired.
- 15 **[0003]** On the other hand, a combination therapy is reported to be effective in the treatment for acquired immunodeficiency syndrome because of the frequent emergence of the resistant mutant in Balzarini, J. et al, Proc. Natl. Acad. Sci. USA 1996, 93, p13152-13157. Reverse transcriptase inhibitors and protease inhibitors are clinically used as an anti-HIV agent, however, agents having the same mechanism of action often show the cross-resistance or only an additional activity. Therefore, anti-HIV agents having the other mechanism of action are desired.
- 20 **[0004]** Examples of the integrase inhibitor include 1,3-dioxobutanoic acids and 1,3-propanediones described in WO99/50245, WO99/62520, WO99/62897, WO99/62513, WO00/39086, and WO01/00578. Another integrase inhibitor is acrylic acid derivative described in WO01/17968. The other recently reported types are aza- or polyazaphthalenylcarboamide derivative described in WO2002/30426, WO2002/30930, WO2002/30931, and WO2002/36734.
- 25 **[0005]** A compound having a similar structure to the present invention compound is N-substituted-3-carboamide-4-hydroxy-5-oxo-3-pyrroline derivative with an anti-inflammatory effect described in Eur. J. Med. Chemical-Chim. Ther. (1979), 14(2), 189-190. Pharmazie (1997), 52(4), 276-278 discloses 1-methyl-4-arylcarbamido-2,3-dioxopyrrolidine derivative as an intermediate. WO92/06954 discloses pyrolizinedione derivative with an inhibitory effect on aldose reductase. J. Med. Chemical (1976), 19(1), 172-173 discloses N-substituted -4,5-dioxopyrrolidine-3-carboxyanilide derivative with anti-inflammatory effect. Journal of Physical Chemistry A (2002), 106(11), 2497-2504 discloses pyrimidine derivative without mentioning any pharmaceutical use.
- 30 **[0006]** T'ai-wan K'b Hsueh (1997), 31(3-4), 130-135 discloses 3-hydroxy-7-(phenylmethoxy)-2-(2-quinolinyl)-4H-1-benzopyrane-4-one. Examples of a compound having a structure of "4H-1-benzopyrane-4-one" include flavonoid derivative with anti-HIV activity described in ① J. Nat. Prod. (2001), 64(4), 546-548, ② Anticancer Res. (2000), 20(4), 2525-2536, ③ WO98/11889, ④ Pharmazie (1998), 53(8), 512-517, though the action of mechanism is not mentioned therein.
- 35


Disclosure of Invention

- 40 **[0007]** Under the above circumstance, the development of a novel integrase inhibitor has been desired.
- [0008]** The present inventors have intensively studied to find a novel antiviral agent, the following compound (I), its prodrug, or a pharmaceutically acceptable salt or solvate thereof, possessing an integrase inhibitory activity;




(wherein, R^C and R^D taken together with the neighboring carbon atoms may form a ring, and the ring may be a condensed ring; Y is hydroxy, mercapto or amino; Z is O, S or NH; R^A is shown by

55



(wherein, C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is N atom; the broken line shows the presence or absence of a bond.) or by



(wherein, X is O, S or NH ; R^B is a substituent selected from substitution group A) ; at least one of the ring formed by R^C and R^D , C ring or R^B is substituted with a group of $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 and Z^3 are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene ; Z^2 is a bond, optionally substituted alkylene, optionally substituted alkenylene, $-CH(OH)-$, $-S-$, $-SO-$, $-SO_2-$, $-SO_2NR^2-$, $-NR^2SO_2-$, $-O-$, $-NR^2-$, $-NR^2CO-$, $-CONR^2-$, $-C(=O)-O-$, $-O-C(=O)-$ or $-CO-$; R^2 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heteroaryl ; R^1 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle) ;


the ring formed by R^C and R^D , C ring or R^B is optionally substituted with a non-interfering substituent at any position other than that where the group of $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as defined above) locates; substitution group A : hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxyalkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthioalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkyl-carbonyl, alkylcarbonyloxy, hydrazino, morpholino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl alkyl, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted aryl thio, optionally substituted heteroarylthio, optionally substituted aralkylthio, optionally substituted heteroarylalkylthio, optionally substituted aralkylthio, optionally substituted heteroarylalkylthio, optionally substituted aryloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted arylthioalkyl, optionally substituted heteroarylthioalkyl, optionally substituted arylsulfonyl, optionally substituted heteroarylsulfonyl, optionally substituted aralkylsulfonyl and optionally substituted heteroarylalkylsulfonyl.) (hereafter referred to as "the present invention compound").

[0009] The present inventors further found that the present invention compound and a pharmaceutical composition containing the same are useful as antiviral agent, antiretrovirus agent, anti-HIV agent, anti-HTLV-1 (Human T cell leukemia virus type 1) agent, anti-FIV (Feline immunodeficiency virus) agent, and anti-SIV (Simian immunodeficiency virus) agent, esp., anti-HIV agent and an integrase inhibitor, whereby to achieve the present invention..


[0010] The present invention provides the present invention compound, its prodrug, a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition containing the same as an active ingredient, antiviral agent, anti-HIV agent, an integrase inhibitor, and anti-HIV mixture. These are useful as anti-HIV agent as well as anti-AIDS agent for diseases such as AIDS, its related clinical syndrome, e.g., AIDS related complication (ARC), persistent generalized lymphadenopathy (PGL), Kaposi sarcoma, pneumocystis carini pneumonia, sudden thrombocytopenic purpura, AIDS related neurological symptom, for example, AIDS dementia complications, AIDS-associated encephalopathy multiple sclerosis or tropical spastic paraparesis, and anti-HIV antibody positive and HIV positive symptom in asymptomatic patients.

[0011] The present invention relates to:


(1) a pharmaceutical composition containing as an active ingredient a compound of formula (I) :



(wherein, R^C and R^D taken together with the neighboring carbon atoms form a ring which may be a condensed ring, Y is hydroxy, mercapto or amino; Z is O, S or NH; R^A is a group shown by



(wherein, C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is non-substituted N atom; the broken line shows the presence or absence of a bond.) or by



(wherein, X is O, S or NH; R^B is a substituent selected from substitution group A); at least one of the ring formed by R^C and R^D , C ring or R^B is substituted with a group of $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 and Z^3 are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene; Z^2 is a bond, optionally substituted alkylene, optionally substituted alkenylene, $-CH(OH)-$, $-S-$, $-SO-$, $-SO_2-$, $-SO_2NR^2-$, $-NR^2SO_2-$, $-O-$, $-NR^2-$, $-NR^2CO-$, $-CONR^2-$, $-C(=O)-O-$, $-O-C(=O)-$ or $-CO-$; R^2 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heteroaryl; R^1 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle);

the ring formed by R^C and R^D , C ring or R^B is optionally substituted with a non-interfering substituent at any position other than that where the group of $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as defined above) locates;

substitution group A consists of: hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxyalkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthioalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkyl carbonyl, alkyl carbonyloxy, hydrazino, morpholino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl alkyl, optionally substituted aryl oxy, optionally substituted heteroaryl oxy, optionally substituted aryl thio, optionally substituted heteroaryl thio, optionally substituted aralkyloxy, optionally substituted heteroaryl alkyl oxy, optionally substituted aralkylthio, optionally substituted heteroaryl alkylthio, optionally substituted aryl oxyalkyl, optionally substituted heteroaryl oxyalkyl, optionally substituted aryl thioalkyl, optionally substituted heteroaryl thioalkyl, optionally substituted arylsulfonyl, optionally substituted heteroarylsulfonyl, optionally substituted aralkylsulfonyl and optionally substituted heteroaryl alkylsulfonyl, its prodrug, or a pharmaceutically acceptable salt or solvate thereof, for use as an integrase inhibitor. In detail, the invention relates to the following (2) to (120).

(2) A pharmaceutical composition of above (1) wherein the ring formed by R^C and R^D is a 5- to 6-membered ring which may contain a hetero atom(s) and be condensed with.

(3) A pharmaceutical composition of above (2) wherein the ring formed by R^C and R^D is a 5- to 6-membered ring

which may contain a hetero atom(s) of O and/or N and be condensed with a benzene ring.

(4) A pharmaceutical composition of above (3) wherein the ring formed by R^C and R^D is a 5-membered ring which contains a hetero atom(s) of N.

(5) A pharmaceutical composition of above (3) wherein the ring formed by R^C and R^D is a 6-membered ring which contains a hetero atom(s) of O and is condensed with a benzene ring.


(6) A pharmaceutical composition of above (3) wherein the ring formed by R^C and R^D is a 6-membered ring which contains a hetero atom(s) of N and is condensed with a benzene ring.

(7) A pharmaceutical composition of above (3) wherein the ring formed by R^C and R^D is a 6-membered ring which contains a hetero atom(s) of O.

(8) A pharmaceutical composition of above (3) wherein the ring formed by R^C and R^D is a 6-membered ring which contains a hetero atom(s) of N.


(9) A pharmaceutical composition of above (1) wherein the ring formed by R^C and R^D is a 6-membered carbocycle.

(10) A pharmaceutical composition of above (4) which contains as an active ingredient a compound of formula (II-1):




(wherein, Y, Z, C ring, Z1, Z2, Z3, R1 and the broken line is the same as above (1); R^3 , R^4 , R^5 and R^{19} are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(11) A pharmaceutical composition of above (4) which contains as an active ingredient a compound of formula (III-1):




(wherein, X, Y, Z, R^B , Z1, Z2, Z3 and R1 are the same as above (1); R^5 , R^6 , R^7 and R^{19} are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.


(12) A pharmaceutical composition of above (3) which contains as an active ingredient a compound of formula (II-2):




(wherein Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line is the same as above (1) ; R³, R⁴ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.
 (13) A pharmaceutical composition of above (3) which contains as an active ingredient a compound of formula (III-2) :



(wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ is the same as above (1) ; R⁶, R⁷ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.
 (14) A pharmaceutical composition of above (3) which contains as an active ingredient a compound of formula (IV-1) :




(wherein, Y, Z, C ring and the broken line are the same as above (1) ; R⁸, R⁹ and R¹⁰ are each independently a non-interfering substituent ; at least one of R^E and R^F is shown by -Z¹-Z²-Z³-R¹ (wherein, Z¹, Z², Z³ and R¹ are the same as above (1)) and the other is a non-interfering substituent, or R^E and R^F taken together with the neighboring carbon atoms may form a ring shown by :




(wherein, R¹¹ to R¹³ are each independently a non-interfering substituent, Z¹, Z², Z³ and R¹ are the same as above (1)), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(15) A pharmaceutical composition of above (5) which contains as an active ingredient a compound of formula (IV-2):




(wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as above (1); R⁸ to R¹³ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(16) A pharmaceutical composition of above (3) which contains as an active ingredient a compound of formula (V-1):




(wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as above (1); R⁹ and R¹⁰ are each independently a non-interfering substituent; R^E and R^F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms may form a ring shown by:




(wherein, R^{11} to R^{14} are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof..

(17) A pharmaceutical composition of above (5) which contains as an active ingredient a compound of formula (V-2):




(wherein, Y , Z , C ring, Z^1 , Z^2 , Z^3 , R^1 and the broken line are the same as above (1); R^9 to R^{14} are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(18) A pharmaceutical composition of above (3) which contains as an active ingredient a compound of formula (VI-1):




(wherein, Y , Z , C ring, Z^1 , Z^2 , Z^3 , R^1 and the broken line are the same as above (1); R^9 , R^{10} and R^{15} are each independently a non-interfering substituent; R^E and R^F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms may form a ring shown by




(wherein, R¹¹ to R¹⁴ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(19) A pharmaceutical composition of above (6) which contains as an active ingredient a compound of formula (VI-2):




(wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as above (1); R⁹ to R¹⁵ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof).

(20) A pharmaceutical composition of above (3) which contains as an active ingredient a compound of formula (VII-1):




(wherein, X, Y, Z, R⁸, Z¹, Z², Z³ and R¹ are the same as above (1); W¹ is-O or-N (-R^G); R^G is a non-interfering substituent; R⁶ and R⁷ are each independently a non-interfering substituent; R^E and R^F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms form a ring shown by



(wherein, R¹¹ to R¹⁴ are each independently a non-interfering substituent)), its prodrug or pharmaceutically acceptable salt or solvate thereof.


ceptable salt or solvate thereof.

(21) A pharmaceutical composition of above (3) which contains as an active ingredient a compound of formula (VII-2):




(wherein, X , Y , Z , R^8 , Z^1 , Z^2 , Z^3 and R^1 are the same as above (1); W^1 is $-O$ or $-N(-R^G)-$; R^G is a non-interfering substituent; R^6 , R^7 , R^{11} to R^{14} are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(22) A pharmaceutical composition of above (3) which contains as an active ingredient a compound of formula (VII-3):



(wherein, X , Y , Z , R^8 , Z^1 , Z^2 , Z^3 and R^1 are the same as above (1); W^1 is $-O$ or $-N(-R^G)-$; R^G is a non-interfering substituent; R^6 and R^7 are each independently a non-interfering substituent; R^E and R^F are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.


(23) A pharmaceutical composition of above (9) which contains as an active ingredient a compound of formula (VIII-1):



(wherein, X , Y , Z , R^8 , Z^1 , Z^2 , Z^3 and R^1 are the same as above (1); R^6 and R^7 are each independently a non-interfering substituent; R^E and R^F are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.


(24) A pharmaceutical composition of above (9) which contains as an active ingredient a compound of formula

(VIII-2) :




(wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as above (1); R^E and R^F are each independently a non-interfering substituent; R⁹ and R¹⁰ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(25) A pharmaceutical composition of above (8) which contains as an active ingredient a compound of formula (IX-1) :




(wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as above (1); R⁶ and R⁷ are each independently a non-interfering substituent; R^F and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or its solvate thereof.

(26) A pharmaceutical composition of above (8) which contains as an active ingredient a compound of formula (IX-2):




(wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as above (1); R⁹ and R¹⁰ are each independently a non-interfering substituent; R^F and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(27) A pharmaceutical composition of above (4) which contains as an active ingredient a compound of formula (X-1):




(wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as above (1); R⁵, R^{5'}, R⁶ and R⁷ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(28) A pharmaceutical composition of above (4) which contains as an active ingredient a compound of formula (X-2):




(wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as above (1); R⁵, R^{5'}, R⁹ and R¹⁰ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(29) A pharmaceutical composition of above (7) which contains as an active ingredient a compound of formula (XI-1):




(wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as above (1); R⁶, R⁷, R^F and R^G are each independently a non-interfering substituent; the broken line (---) shows the presence or absence of a bond), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(30) A pharmaceutical composition of above (7) which contains as an active ingredient a compound of formula (XI-2):




(wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line (—) are the same as above (1) R⁹, R¹⁰, R^F and R^G are each independently a non-interfering substituent; the broken line (—) shows the presence or absence of a bond), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(31) A pharmaceutical composition of above (8) which contains as an active ingredient a compound of formula (XII-1):




(wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as above (1); R⁶, R⁶, R⁷, R^F and R^G are each independently a non-interfering substituent; the broken line (—) shows the presence or absence of a bond), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(32) A pharmaceutical composition of above (8) which contains as an active ingredient a compound of formula (XII-2):




(wherein, Y, Z, C ring, Z¹, Z², Z³, and R¹ are the same as above (1); R⁵, R⁹, R¹⁰, R^F and R^G are each independently a non-interfering substituent; the broken line (—) shows the presence or absence of a bond), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(33) A pharmaceutical composition of above (8) which contains as an active ingredient a compound of formula (XIII-1):



15 (wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as above (1); R⁵, R⁶, R⁷ and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(34) A pharmaceutical composition of above (8) which contains as an active ingredient a compound of formula (XIII-2):




(wherein, Y, Z, C ring, Z¹, Z², Z³ and R¹ are the same as above (1); R⁵, R⁹, R¹⁰ and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

35 (35) A pharmaceutical composition of any one of (1) to (34), wherein the non-interfering substituents are independently selected from hydrogen, halogen, alkoxy, carbonyl, carboxy, alkyl, alkoxy, alkoxyalkyl, nitro, hydroxy, hydroxyalkyl, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthioalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, oxo, thio, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkylcarbonyl, alkylcarbonyloxy, hydrazino, morpholino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted arylthio, optionally substituted heteroarylthio, optionally substituted aralkyloxy, optionally substituted heteroarylalkyloxy, optionally substituted aralkylthio, optionally substituted heteroarylalkylthio, optionally substituted aryloxyalkyl, optionally substituted heteroarylalkoxyalkyl, optionally substituted arylthioalkyl, optionally substituted heteroarylthioalkyl, optionally substituted arylsulfonyl, optionally substituted heteroarylsulfonyl, optionally substituted aralkylsulfonyl and optionally substituted heteroarylalkylsulfonyl.


(36) A method for prevention or treatment of AIDS or AIDS-related complication, comprising administration of a pharmaceutical composition of any one of above (1) to (35).

(37) Use of a compound of any one of above (1) to (35) for preparing a pharmaceutical composition as an integrase inhibitor.


(38) A compound of formula(I-Q): Q - Z¹-Z²-Z³-R¹, its prodrug or pharmaceutically acceptable salt or solvate thereof, wherein, Z¹, Z², Z³ and R¹ are the same as above (1); Q is shown by any one of the following formulae:




(wherein, C ring is the same as above (1) ; Y is hydroxy ; Z is O ; R³, R⁴, R⁵ and R¹⁹ are the same as above (10)),



(wherein, X is O; Y and Z are the same as above; R⁵, R⁶, R⁷ and R¹⁹ are the same as above (11) ; R^B is optionally substituted aryl , optionally substituted heteroaryl , optionally substituted cycloalkyl , optionally substituted cycloalkenyl or optionally substituted heterocycle),




(wherein, C ring is the same as above (1) ; Y and Z are the same as above ; R³, R⁴ and R¹⁹ are the same as above (10)),




EP 1 422 218 A1


(wherein, X, Y, Z and R^B are the same as above; R⁶, R⁷ and R¹⁹ are the same as above (11)),




(wherein, C ring is the same as above (1) ; Y and Z are the same as above ; R⁸ to R¹⁰ are the same as above (14); W¹ is the same as above (20) ; R¹⁶ is a non-interfering substituent),



(wherein, C ring is the same as above (1) ; Y and Z are the same as above ; R⁸ to R¹³ are the same as above (14) ; W¹ is the same as above (20)),




(wherein, C ring is the same as above (1) ; Y and Z are the same as above ; R⁹ to R¹⁴ is the same as above (16) ; W¹ is the same as above (20)),




EP 1 422 218 A1


(wherein, C ring is the same as above (1); Y and Z are the same as above; W¹ is the same as above (20); R⁹ and R¹⁰ are the same as above (14); R¹⁷ and R¹⁸ are each independently a non-interfering substituent),




(wherein, X, Y, Z and R^B are the same as above; W¹ is the same as above (20); R⁶ and R⁷ are the same as above (11); R¹¹ to R¹⁴ are the same as above (16)),




(wherein, X, Y, Z and R^B are the same as above; W¹ is the same as above (20); R⁶ and R⁷ are the same as above (11); R¹⁷ and R¹⁸ are each independently a non-interfering substituent):




(wherein, X, Y, Z and R^B are the same as above; R⁶ and R⁷ are the same as above (11); R¹⁷ and R¹⁸ are each independently a non-interfering substituent),




(wherein, C ring is the same as above (1); Y and Z are the same as above; R⁹ and R¹⁰ are the same as above (14); R¹⁷ and R¹⁸ are the same as defined above),



(wherein, X, Y, Z and R^B are the same as above; R⁵ is the same as above (10); R⁶ and R⁷ are the same as above (11); R¹⁷ and R¹⁸ are the same as defined above),




(wherein, C ring is the same as above (1); Y and Z are the same as above; R⁵ is the same as above (10); R⁹ and R¹⁰ are the same as above (14); R¹⁷ and R¹⁸ are the same as defined above),




EP 1 422 218 A1


(wherein, X,Y,Z and R^B are the same as above ; R⁵ and R^{5'} are the same as above (27) ; R⁶ and R⁷ are the same as above (11)),




(wherein, C ring is the same as above (1) ; Y and Z are the same as above ; R⁵ and R^{5'} are the same as above (27) ; R⁹ and R¹⁰ are the same as above (14)) :




(wherein, X , Y, Z and R^B are the same as above ; R⁶ and R⁷ are the same as above (11) ; R¹⁷ and R¹⁸ are the same as above, the broken line(—) shows the presence or absence of a bond),




(wherein, C ring is the same as above (1); Y and Z are the same as above; R⁹ and R¹⁰ are the same as above (14) ; R¹⁷ and R¹⁸ are the same as above, the broken line(—) shows the presence or absence of a bond),




(wherein, X, Y, Z and R^B are the same as above ; R⁵, R⁶ and R⁷ are the same as above (11) ; R¹⁷ and R¹⁸ are the same as above, the broken line(—) shows the presence or absence of a bond),



(wherein, C ring is the same as above (1) ; Y and Z are the same as above ; R⁵ is the same as above (10); R⁹ and R¹⁰ are the same as above (14); R¹⁷ and R¹⁸ are the same as above, the broken line(—) shows the presence or absence of a bond),




(wherein, X, Y, Z and R^B are the same as above; R⁵, R⁶ and R⁷ are the same as above (11) ; R¹⁸ is the same as defined above), and




(wherein, C ring is the same as above (1); Y and Z are the same as above; R⁵ is the same as above (10); R⁹ and

EP 1 422 218 A1

R¹⁰ are the same as above (14); R¹⁸ is the same as defined above);
provided that excluded are compounds, wherein Z¹ is a bond, Z² is -O-, Z³ is methylene, R¹ is phenyl, and Q is a
group of the formula:




(wherein, R⁸ to R¹³ are hydrogens, Y is hydroxy, Z is O, W is -O-, and C ring is quinoline-2-yl) or the formula:



wherein, R⁹ and R¹⁰ are the same as above, R¹⁷ is alkyl, R¹⁸ is hydrogen, Y is hydroxy, Z is O, C ring is dihydropyrimidine).

(39) A compound of above (38), shown by formula (II-1):




(wherein, Y is hydroxy; Z is O; C ring, Z¹, Z², Z³ and R¹ are the same as above (1); R³, R⁴, R⁵ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(40) A compound of above (39), wherein Z¹ and Z³ are each independently a bond or alkylene; Z² is a bond or -O-; R¹ is optionally substituted aryl or optionally substituted heteroaryl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(41) A compound of above (39), wherein C ring is pyrimidine-4-yl or 1,3,4-oxadiazole-2-yl; Z¹ is a bond; Z² is -O or alkylene; Z³ is a bond or alkylene; R¹ is aryl optionally substituted with halogen; R³, R⁴ and R¹⁹ are hydrogens;

EP 1 422 218 A1

R⁵ is alkyl, aralkyl, cycloalkyl, aryl or alkoxy, its prodrug or pharmaceutically acceptable salt or solvate thereof.
(42) A compound of above (38), shown by formula (III-1):




(wherein, X is O; Y is hydroxy; Z is O; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle; Z¹, Z², Z³ and R¹ are the same as above (1); R⁵, R⁶, R⁷ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(43) A compound of above (39) or (42), wherein R⁵ is hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxyalkyl, alkenyl, alkoxycarbonylalkyl or heteroarylalkyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(44) A compound of above (42), wherein R^B is fran-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(45) A compound of above (42), wherein R^B is aryl or fran-2-yl; Z¹ and Z³ are bonds; Z² is alkylene; R¹ is aryl optionally substituted with halogen; R⁶, R⁷ and R¹⁹ are hydrogens; R⁵ is alkyl, cycloalkyl, alkoxy, aryl optionally substituted with alkoxy, hydroxyalkyl, alkenyl, aralkyl, alkoxycarbonylalkyl, or pyridine-2-ylmethyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(46) A compound of above (38), shown by formula (II-2):




(wherein, Y is hydroxy; Z is O; C ring, Z¹, Z², Z³ and R¹ are the same as above (1); R³, R⁴ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(47) A compound of above (46), wherein Z¹ and Z³ are each independently a bond or alkylene; Z² is a bond or -O-; R¹ is optionally substituted aryl or optionally substituted heteroaryl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(48) A compound of above (46), wherein C ring is pyrimidine-4-yl or 1,3,4-oxadiazole-2-yl; Z¹ is a bond; Z² is -O or alkylene; Z³ is a bond or alkylene; R¹ is aryl optionally substituted with halogen; R³, R⁴ and R¹⁹ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(49) A compound of above (38) shown by formula (III-2):




(wherein, X is O; Y is hydroxy; Z is O; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle; Z¹, Z², Z³ and R¹ are the same as above (1); R⁶, R⁷ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(50) A compound of above (49), wherein R^B is fran-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(51) A compound of above (49), wherein R^B is aryl or fran-2-yl; Z¹ and Z³ are bonds; Z² is alkylene; R¹ is aryl optionally substituted with halogen; R⁶, R⁷ and R¹⁹ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.


(52) A compound of above (38), shown by formula (IV-2):



(wherein, Y is hydroxy; Z is O; C ring, Z¹, Z², Z³ and R¹ are the same as above (1); R⁸ to R¹³ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(53) A compound of above (52), wherein C ring is pyridine-2-yl, 1,2,4-triazole-3-yl or imidazole-2-yl optionally substituted with alkyl; Z¹ is a bond; Z² is -O-; Z³ is alkylene; R¹ is aryl optionally substituted with halogen; R⁸ to R¹³ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(54) A compound of above (38), shown by formula (V-2):




(wherein, Y is hydroxy ; Z is O ; C ring, Z¹, Z², Z³ and R¹ are the same as above (1) ; R⁹ to R¹⁴ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(55) A compound of above (52) or (54), wherein Z¹ and Z³ are each independently a bond or alkylene ; Z² is a bond or - O - ; R¹ is optionally substituted aryl or optionally substituted heteroaryl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(56) A compound of above (54), wherein C ring is 1,3,4-oxadiazole-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁹ to R¹⁴ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(57) A compound of above (38), shown by formula (VI-2):




(wherein, Y is hydroxy ; Z is O ; C ring, Z¹, Z², Z³ and R¹ are the same as above (1) ; R⁹ to R¹⁵ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(58) A compound of above (57), wherein, R¹⁵ is hydrogen or alkyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(59) A compound of above (57), wherein C ring is 1,3,4-oxadiazole-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁹ to R¹⁴ are hydrogens ; R¹⁵ is hydrogen or alkyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(60) A compound of above (38), shown by formula (VII-4) :




(wherein, X is O ; Y is hydroxy ; Z is O ; W² is -O or -NH- ; R^B is optionally substituted aryl , optionally substituted heteroaryl , optionally substituted cycloalkyl , optionally substituted cycloalkenyl or optionally substituted heterocycle ; Z¹, Z², Z³ and R¹ are the same as above (1) ; R⁶, R⁷, R¹¹ to R¹⁴ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(61) A compound of above (60), wherein R^B is fran-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(62) A compound of above (60), wherein R^B is fran-2-yl; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁶, R⁷, R¹¹ to R¹⁴ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(63) A compound of above (38), shown by formula (VII-5):




(wherein, X is O ; Y is hydroxy ; Z is O ; W² is -O or -NH- ; R^B is optionally substituted aryl , optionally substituted heteroaryl , optionally substituted cycloalkyl , optionally substituted cycloalkenyl or optionally substituted heterocycle ; Z¹, Z², Z³ and R¹ are the same as above (1) ; R⁶, R⁷, R^E and R^F are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(64) A compound of above (63), wherein, R^B is fran-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(65) A compound of above (63), wherein, R^B is fran-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁶, R⁷, R^E and R^F are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(66) A compound of above (38), shown by formula (VIII-1) :




(wherein, X is O ; Y is hydroxy ; Z is O; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle ; Z¹, Z², Z³ and R¹ are the same as above (1) ; R⁶, R⁷, R^E and R^F are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(67) A compound of above (66), wherein R^B is fran-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.


(68) A compound of above (66), wherein R^B is fran-2-yl; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁶, R⁷, R^E and R^F are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(69) A compound of above (38), shown by formula (VIII-2) :



(wherein, Y is hydroxy ; Z is O ; C ring, Z¹, Z², Z³ and R¹ are the same as above (1) ; R⁹, R¹⁰, R^E and R^F are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(70) A compound of above (38), shown by formula (IX-1):



(wherein, X is O; Y is hydroxy ; Z is O; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle; Z¹, Z², Z³ and R¹


EP 1 422 218 A1

are the same as above (1) ; R^6, R^7, R^F and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(71) A compound of above (70), wherein, R^B is *fran*-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.


(72) A compound of above (70), wherein, R^B is *fran*-2-yl ; Z^1 and Z^3 are bonds ; Z^2 is alkylene ; R^1 is aryl optionally substituted with halogen ; R^6, R^7, R^F and R^G are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(73) A compound of above (38), shown by formula (IX-2):



(wherein, Y is hydroxy ; Z is O ; C ring, Z^1, Z^2, Z^3 and R^1 are the same as above (1) ; R^9, R^{10}, R^F and R^G are each independently a non-interfering substituent, provided that when R^G is hydrogen and R^F is alkyl, C ring is not dihydropyrimidine), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(74) A compound of above (38), shown by formula (X-1):




(wherein, X is O ; Y is hydroxy ; Z is O ; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle ; Z^1, Z^2, Z^3 and R^1 are the same as above (1) ; $R^5, R^{5'}, R^6$ and R^7 are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.


(75) A compound of above (74), wherein R^B is *fran*-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(76) A compound of above (74), wherein R^B is *fran*-2-yl ; Z^1 and Z^3 are bonds ; Z^2 is alkylene ; R^1 is aryl optionally substituted with halogen ; R^6, R^7, R^5 and $R^{5'}$ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(77) A compound of above (38), shown by formula (X-2):



(wherein, Y is hydroxy ; Z is O ; C ring, Z¹, Z², Z³ and R¹ are the same as above (1) ; R⁵, R^{5'}, R⁹ and R¹⁰ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.
 (78) A compound of above (38), shown by formula (XI-1):




(wherein, X is O; Y is hydroxy ; Z is O; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle ; Z¹, Z², Z³ and R¹ are the same as above (1) ; R⁶, R⁷, R^F and R^G are each independently a non-interfering substituent, the broken line(—) shows the presence or absence of a bond), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(79) A compound of above (78), wherein, R^B is fran-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(80) A compound of above (78), wherein, R^B is fran-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁶, R⁷, R^F and R^G are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(81) A compound of above (38), shown by (XI-2):



(wherein, Y is hydroxy ; Z is O ; C ring, Z¹, Z², Z³ and R¹ are the same as above (1) ; R⁹, R¹⁰, R^F and R^G are each independently a non-interfering substituent, the broken line(—) shows the presence or absence of a bond), its

(82) A compound of above (38), shown by (XII-1):




(84) A compound of above (82), wherein, R^B is fran-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁶, R⁷, R^F and R^G are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(85) A compound of above (38), shown by formula (XII-2):



(86) A compound of above (38), shown by formula (XIII-1):




(wherein, X is O; Y is hydroxy; Z is O; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle; Z¹, Z², Z³ and R¹ are the same as above (1); R⁵, R⁶, R⁷ and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(87) A compound of above (86), wherein, R^B is *trans*-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(88) A compound of above (86), wherein, R^B is *trans*-2-yl; Z¹ and Z³ are bonds; Z² is alkylene; R¹ is aryl optionally substituted with halogen; R⁶, R⁷ and R^G are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(89) A compound of above (38), shown by formula (XIII-2):



(wherein, Y is hydroxy; Z is O; C ring, Z¹, Z², Z³ and R¹ are the same as above (1); R⁵, R⁹, R¹⁰ and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(90) A compound of above (38), (39), (46), (52), (54), (57), (69), (73), (77), (81), (85) or (89), wherein C ring is optionally substituted pyridine-2-yl, optionally substituted pyrimidine-4-yl, optionally substituted 1,3,4-oxadiazole-2-yl, optionally substituted 1,2,4-triazole-3-yl or optionally substituted imidazole-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(91) A compound of above (38), (39), (46), (52), (54), (57), (69), (73), (77), (81), (85) or (89), wherein Z¹ and Z³ are each independently a bond or alkylene; Z² is a bond or -O-; R¹ is optionally substituted aryl or optionally substituted heteroaryl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(92) A compound of above (38), (39), (46), (52), (54), (57), (69), (73), (77), (81), (85) or (89), wherein C ring is pyrimidine-4-yl or 1,3,4-oxadiazole-2-yl; Z¹ is a bond; Z² is -O or alkylene; Z³ is a bond or alkylene; R¹ is aryl optionally substituted with halogen; R³, R⁴ and R¹⁹ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(93) A compound of above (38), (39), (42), (46), (49), (52), (54), (57), (60), (63), (66), (69), (70), (73), (74), (77), (78), (81), (82), (85), (86) or (89), wherein each non-interfering substituent is independently selected from hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxy alkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthio alkyl, haloalkyl, haloalkoxy, haloalkoxy alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, oxo, thioxo, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkyl carbonyl, alkyl


carbonyloxy, hydrazino, morpholino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl alkyl, optionally substituted aryl oxy, optionally substituted heteroaryl oxy, optionally substituted aryl thio, optionally substituted heteroaryl thio, optionally substituted aralkyloxy, optionally substituted heteroaryl alkyl oxy, optionally substituted aralkylthio, optionally substituted heteroaryl alkylthio, optionally substituted aryl oxyalkyl, optionally substituted heteroaryl oxyalkyl, optionally substituted aryl thioalkyl, optionally substituted heteroaryl thioalkyl, optionally substituted arylsulfonyl, optionally substituted heteroarylsulfonyl, optionally substituted aralkylsulfonyl and optionally substituted heteroaryl alkylsulfonyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(94) A compound of above (38), (39), (42), (46), (49), (52), (54), (57), (60), (63), (66), (69), (70), (73), (74), (77), (78), (81), (82), (85), (86) or (89), wherein Z^1 , Z^2 and Z^3 are not bonds at the same, its prodrug or pharmaceutically acceptable salt or solvate thereof.


(95) A compound of above (94), wherein R^1 is phenyl optionally substituted with halogen, Z^1 is a bond, Z^2 is alkylene or -O-, Z^3 is a bond or alkylene, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(96) A compound of above (95), wherein R^1 is 4-fluorophenyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.


(97) A compound of the formula (I) :



(wherein, R^C and R^D taken together with the neighboring carbon atoms form 5- or 6-membered heterocycle which may contain O and/or N atom and be condensed with a benzene ring ; Y is hydroxy, mercapto or amino ; Z is O, S or NH ; R^A is shown of the formula :



(wherein, C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is unsubstituted N atom. the broken line shows the presence or absence of a bond.) or the formula :



(wherein, X is O, S or NH ; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle) ; at least one of the ring formed by R^C and R^D , C ring and R^B is substituted with a group of the formula : $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 and Z^3 are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene ; Z^2 is a bond, optionally substituted alkylene, optionally substituted alkenylene, -CH(OH)-, -S-, -SO-, -SO₂-, -SO₂N(R²)-, -N(R²)SO₂-, -O-, -N(R²)-, -N(R²)CO-, -CON(R²)-, -C(=O)-O-, -O-C(=O)- or -CO- ; R² is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heteroaryl ; R¹ is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle) ; and

the ring formed by R^C and R^D , C ring or R^B is optionally substituted with 1 to 3 substituents selected from hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxyalkyl, alkenyl, alkoxyalkyl, heteroarylalkyl and hydroxy, at any position except where the above the formula : - $Z^1 - Z^2 - Z^3 - R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as defined above) locates, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(98) A compound of above (97), wherein the ring formed by R^C and R^D is 5- or 6-membered heterocycle which may contain O and/or N atom and be condensed with benzene ring ; Y is hydroxy; Z is O ; X is O ; the ring formed by R^C and R^D is optionally substituted with 1 to 3 substituents selected from hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxy alkyl, optionally substituted amino, hydroxyalkyl, alkenyl, alkoxyalkyl, heteroarylalkyl and heteroaryl alkyl, and C ring and R^B are each independently optionally substituted with 1 to 3 substituents selected from alkyl, amino, halogen and hydroxy, its prodrug or pharmaceutically acceptable salt or solvate thereof.

(99) A compound of above (97) or (98), wherein at least one of the ring formed by R^C and R^D , C ring and R^B is substituted with a group of the formula : - $Z^1 - Z^2 - Z^3 - R^1$ (wherein Z^1 is a bond or alkylene ; Z^2 is alkylene or - O - ; Z^3 is a bond or alkylene ; R^1 is optionally substituted aryl or optionally substituted heteroaryl), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(100) A pharmaceutical composition comprising a compound of any one of above (38) to (99), its prodrug or pharmaceutically acceptable salt or solvate thereof.

(101) A pharmaceutical composition of above (100) which is an enzyme inhibitor.

(102) A pharmaceutical composition of above (100) which is a nucleic acid-related enzyme inhibitor.

(103) A pharmaceutical composition of above (100) which is an HIV integrase inhibitor.

(104) A pharmaceutical composition of above (100) which is an anti-HIV agent.

(105) A pharmaceutical composition of above (100) which is a critical prevention or treatment agent for AIDS or a AIDS-related complication.


(106) A mixture of a pharmaceutical composition of above (103) in combination with a reverse transcriptase inhibitor and/or a protease inhibitor.

(107) A pharmaceutical composition of above (100) which can enhance the anti-HIV activity of a reverse transcriptase inhibitor and/or a protease inhibitor.


(108) A method for prevention or treatment of AIDS or a AIDS-related complication which comprises administration of a compound of any one of (38) to (99).

(109) Use of a compound of any one of (38) to (99) for preparing a pharmaceutical composition as an integrase inhibitor.

(110) A process for preparing a compound of the formula (III-1) :



(wherein, X, Y, Z, R^B , R^5 to R^7 , R^{19} , Z^1 to Z^3 and R^1 are the same as defined below) which comprises reacting a compound of the formula (K) :



(wherein, X is O ; Y is hydroxy ; Z is O ; L is a leaving group ; R^B , Z^1 , Z^2 , Z^3 and R^1 are the same as above (1) ; R^6 and R^7 are the same as above (11)) with a compound of the formula : $R^5N H_2$ (wherein, R^5 is a non-interfering substituent) and a compound of the formula : $R^{19}CHO$ (wherein, R^{19} is a non-interfering substituent).

(111) A process for preparing a compound of the formula (III-1) of above (110), wherein, R^B is heteroaryl ; R^6 and R^7 do not substitute on R^B ; L is alkoxy ; Z^1 and Z^3 are bonds ; Z^2 is alkylene ; R^1 is optionally substituted phenyl.

(112) A process for preparing a compound of the formula (III-1) of above (110), wherein Z^2 is methylene ; R^1 is 4-fluorophenyl.

(113) A process for preparing a compound of the formula (III-1) of above (112), wherein the compound of the formula (K) is 4-[5-(4-fluorobenzyl)franz-2-yl]-2-hydroxy-4-oxo-2-butenic acid alkyl ester.

(114) A process for preparing a compound of the formula (III-1) of above (110) to (113), wherein compounds shown of the formula : $R^5N H_2$ and $R^{19}CHO$ are selected from the following groups ;

compound of the formula : R^5NH_2

cyclopropylamine, cyclobutylamine, cyclopentylamine, cycloleucine, cyclohexylamine, 1-aminocyclohexanecarboxylic acid, 1-ethynylcyclohexylamine, 1,2-diaminocyclohexan, 2-methylcyclohexylamine, 2,3-dimethylcyclohexylamine, 4-methylcyclohexylamine, aminomethylcyclohexan, 1,3-cyclohexan bis(methylamine), 1-amino-5,6,7,8-tetrahydronaphthalene, 1,2,3,4-tetrahydro-1-naphthylamine, cyclooctylamine, 2-amino-1-propene-1,1,3-tricarbonitril, diaminomaleonitril, S-methyl-L-cysteine, L-aspartic acid, L-leucine, DL-homoserine, D-methionine, L-allylglycine, L-glutamic acid, 2-amino-1,3,4-thiadiazole, 2-amino-5-mercapto-1,3,4-thiadiazole, 2-amino-5-ethyl-1,3,4-thiadiazole, 3,5-dimethylpyrazole-1-carboamide, 5-amino-3-methylisoxazole, 3-amino-5-methylisoxazole, 2-(2-amino ethyl)-1-methylpyrrolidine, 1-(2-amino ethyl)pyrrolidine, 1-(3-amino propyl)-2-pyrrolidinone, furfurylamine, 1-aminoindan, 5-aminoindan, 1-naphthylamine, 2-naphthylamine, cycloheptylamine, D-tert-leucine, DL-valine, DL-isoleucine, D-serine, guanidoacetic acid, creatine, D-allothreonine, 2-amino-2-methyl-1,3-propanediol, tris(hydroxy methyl)aminomethane, DL-2-amino-3-methyl-1-butanol, L-isoleucinol, D-leucinol, L-methioninol, DL-penicillamine, DL-cysteine, DL-homocysteine, 1-acetyl-3-thiosemicarbazide, 1-acetyl-2-thiourea, N-methylthiourea, ethylthiourea, allylthiourea, dithioamide, histamine, 3-amino-1,2,4-triazole, 3-amino-5-mercapto-1,2,4-triazole, 3-amino-5-methylthio-1,2,4-triazole, 3,5-diamino-1,2,4-triazole, 3-aminopyrazole, 3-amino-4-cyanopyrazole, 3-aminopyrazole-4-carboxylic acid, L-prolineamide, 2-amino-2-thiazoline, 2-aminothiazole, 2-amino-5-nitrothiazole, 2-amino-4-methylthiazole, D-cycloserine, tetrahydrofurfurylamine, 2-aminopurine, 2-aminobenzimidazole, 5-amino indole, 4-aminopyrazolo[3,4-D]pyrimidine, 6-aminoindazole, 8-azaadenine, 3,4-methylenedioxyaniline, N-(2-aminoethyl)piperazine, nipecotamide, 4-(aminomethyl)piperidine, 5-aminouracil, 5-azacytosine, cytosine, 5-fluorocytosine, 4-amino-2,6-dihydroxypyrimidine, 2-aminopyrimidine, 2-amino-4-chloro-6-methylpyrimidine, 2-amino-4,6-dihydroxypyrimidine, 2-amino-4-hydroxy-6-methylpyrimidine, 4-chloro-2,6-diaminopyrimidine, 2,4-diamino-6-hydroxypyrimidine, 2,4,6-triaminopyrimidine, 2-amino-4-methylpyrimidine, 2-amino-4,6-dimethylpyrimidine, 2-amino-5-nitro pyrimidine, 4-aminopyrimidine, 4,5-diaminopyrimidine, 4,5-diamino-6-hydroxy pyrimidine, pyrazineamide, aminopyrazine, 3-aminopyrazine E-2-carboxylic acid, 4-(2-aminoethyl)morpholine, N-(3-aminopropyl)morpholine, nicotineamide N-oxide, 3-amino-2-chloropyridine, 5-amino-2-chloropyridine, 5-amino-2-methoxypyridine, 3-hydroxypicolineamide, 2-aminopyridine, 2-amino-3-nitropyridine, 2-amino-3-hydroxy pyridine, 2-aminonicotinic acid, 2,3-diaminopyridine, 2-amino-3-methylpyridine, 2-amino-4-methylpyridine, 2-amino-4,6-dimethylpyridine, 2-amino-5-chloropyridine, 2-amino-5-nitropyridine, 6-aminonicotinic acid, 6-aminonicotinamide, 2-amino-5-methylpyridine, 2,6-diaminopyridine, 2-amino-6-methylpyridine, 6-methylnicotinamide, 2-(aminomethyl)pyridine, 2-(2-aminoethyl)pyridine, nicotinamide, thionicotinamide, 3-aminopyridine, 3,4-diaminopyridine, 3-(aminomethyl)pyridine, isonicotinamide, 4-aminopyridine, 4-(aminomethyl)pyridine, 3-amino-1,2,4-triazine, 3-amino-5,6-dimethyl-1,2,4-triazine, 1-(2-aminoethyl)piperidine, 3-aminoquinoline, 5-aminoquinoline, 6-aminoquinoline, 8-aminoquinoline, 5-aminoisoquinoline, nitroguanidine, cyanamide, thiosemicarbazide, an-

iline, 2-aminobenzonitril, 2-fluoro aniline, 2,4-difluoroaniline, 2,4,5-trifluoroaniline, 2,4,6-trifluoroaniline, 2,5-difluoro aniline, 2-fluoro-5-methylaniline, 2,6-difluoroaniline, 2-chloroaniline, 2-chloro-4-methylaniline, 2-chloro-5-methylaniline, 2-chloro-6-methylaniline, O-nitroaniline, anisidine, O-phenetidine, 2-aminophenol, 6-amino-m-cresol, 2-amino-4-chlorophenol, 2-amino-4-methylphenol, 2-aminothiophenol, 2-(methylthio)aniline, anthranilic acid, 2'-aminoacetophenone, 2-isopropenylaniline, 2-isopropylaniline, o-phenylenediamine, 3,4-diaminotoluene, 4,5-dimethyl-1,2-phenylenediamine, o-toluidine, 2,3-dimethylaniline, 4-methoxy-2-methylaniline, 2,4-dimethylaniline, 2,4,6-tri methylaniline, 2,5-dimethylaniline, 2-isopropyl-6-methylaniline, 2,6-dimethylaniline, 2-aminobenzyl alcohol, 2-ethylaniline, 2-ethyl-6-methylaniline, 2,6-diethylaniline, 2-aminophenetyl alcohol, 3-aminobenzonitril, 3-fluoroaniline, 3-fluoro-o-anisidine, 3-fluoro-2-methylaniline, 3,4-difluoroaniline, 3-fluoro-4-methylaniline, 3,5-difluoro aniline, 5-fluoro-2-methylaniline, 3-chloroaniline, 3-chloro-2-methylaniline, 3-chloro-4-fluoroaniline, 3-chloro-4-methylaniline, 5-chloro-2-methylaniline, m-nitroaniline, m-anisidine, m-phenetidine, 3-aminophenol, 3-amino -o-cresol, 3-aminothiophenol, 3-(methylthio)aniline, 3-aminobenzoic acid, 3-aminoacetophenone, 3-(1-hydroxy ethyl) aniline, m-phenylenediamine, 2,6-diaminotoluene, 2,4-diaminotoluene, m-toluidine, 3,4-dimethylaniline, 3,5-dimethylaniline, 2-methoxy-5-methylaniline, 3-aminobenzyl alcohol, 3-ethylaniline, 4-aminobenzonitril, 4-fluoroaniline, 4-fluoro-2-methylaniline, 4-chloroaniline, 4-chloro-2-methylaniline, p-nitroaniline, N,N-dimethylp-phenylenediamine, p-anisidine, p-phenetidine, 4-aminophenol, 4-amino-m-cresol, 4-amino-2,5-dimethylphenol, 4-amino-o-cresol, 4-aminothiophenol, 4-(methylthio)aniline, 4-aminobenzoic acid, 4-aminoacetophenone, 4-tert-butylaniline, 4-isopropylaniline, p-phenylenediamine, p-toluidine, 4-aminophenylacetoneitril, 4-ethylaniline, 4-aminophenetyl alcohol, 4-propylaniline, 4-N-butylaniline, formamide, hydroxyurea, phenylurea, cyanoacetylurea, methylurea, ethylurea, allylurea, N-butylurea, N,N-dimethylurea, 1,1-diethylurea, phenylcarbamate, tert-butylcarbamate, methylcarbamate, ethylcarbamate, butylcarbamate, benzamide, 2-fluorobenzamide, salicylamide, 2-aminobenzamide, O-toluamide, 3-fluorobenzamide, 3-aminobenzamide, m-toluamide, 4-fluorobenzamide, 4-hydroxybenzamide, 4-aminobenzamide, p-toluamide, ethyl oxamate, oxamide, 2,2,2-trifluoroacetamide, trimethylacetamide, 2,2-dichloroacetamide, 2-chloropropionamide, lactamide, methacrylamide, isobutylamide, urea, acetamide, cyanoacetamide, 2-bromoacetamide, fluoroacetamide, 2-chloro acetamide, N-acetylglucineamide, acrylic amide, cinnamamide, malonamide, propionamide, 3-chloropropionamide, 2-aminoisobutanoic acid, tert-utylamine, 2-amino-2-methyl-1-propanol, tert-octylamine, 1,2-diamino-2-methylpropane, tert-amylamine, 1,1-diethylpropargylamine, thiobenzamide, (R)-(-)-2-phenylglycinol, thiourea, DL- α -methylbenzylamine, thioacetamide, 3-aminocrotonitril, methyl 3-aminocrotonate, ethyl 3-aminocrotonate, D-alanine, 1,2-dimethylpropylamine, isopropylamine, 2-amino-1-methoxypropane, DL-2-amino-1-propanol, ethyl 3-amino butylate, DL- β -amino -n-butanoic acid, 1,3-dimethylbutylamine, 1,2-diaminopropane, 1-methyl-3-phenylpropylamine, 2-amino-6-methylheptane, DL-2-amino butanoic acid, sec-butylamine, (+/-)-2-amino -1-butanol, 3-amino pentane, D-norvaline, D-norleucine, 2-aminoheptane, 2-amino-octane, methylamine, benzylamine, 2-fluorobenzylamine, 2-chlorobenzylamine, 2-methoxybenzylamine, 2-methylbenzylamine, 3-fluorobenzyl amine, 3-methoxybenzylamine, 3-methylbenzylamine, m-xylylenediamine, 4-fluorobenzylamine, 4-chlorobenzylamine, 4-methoxybenzylamine, 4-methylbenzyl amine, glycine, 2,2,2-trifluoroethyl amine, aminoacetoaldehyde dimethyl acetal, amino acetoaldehyde diethyl acetal, 2-amino-1-phenylethanol, DL-isoserine, 1-amino-2-propanol, 3-amino-1,2-propanediol, DL-4-amino-3-hydroxybutanoic acid, 1,3-diamino-2-hydroxypropane, 2-phenylpropylamine, DL-3-aminoisobutanoic acid, isobutylamine, 2-methylbutylamine, 2-ethylhexylamine, ethylamine, N-phenylethylenediamine, N-acetylethylenediamine, N-isopropylethylenediamine, N-methylethylenediamine, N-ethylethylenediamine, 2-(2-aminoethylamino)ethanol, diethylene-diamine, N-(n-propyl)ethylenediamine, N,N-dimethylethylenediamine, N,N-diethylethylenediamine, tris(2-aminoethyl)amine, 2-methoxyethylamine, 2-(2-aminoethoxy)ethanol, ethanolamine, phenethylamine, thyramine, 2-(4-aminophenyl)ethylamine, 2-(p-tri l)ethylamine, taurine, propargylamine, allylamine, β -alanine, 3,3-dimethylbutylamine, isoamylamine, ethylenediamine, propylamine, N-isopropyl-1,3-propanediamine, N-methyl-1,3-propanediamine, N-(2-aminoethyl)-1,3-propanediamine, N-propyl-1,3-propanediamine, 3,3'-diaminodipropylamine, N,N-dimethyl-1,3-propanediamine, N,N-bis(3-aminopropyl)methylamine, N,N-diethyl-1,3-propanediamine, 3-isopropoxypropylamine, 3-ethoxypropylamine, 3-amino -1-propanol, 3-phenylpropylamine, 4-aminobutanoic acid, 1,3-diaminopropane, 4-amino -1-butanol, 4-phenylbutylamine, 5-aminovalelerianic acid, 1,4-diaminobutane, N-amylamine, 5-amino-1-pentanol, 6-aminocaproic acid, 1,5-diaminopentane, hexylamine, 6-amino-1-haxanol, 7-aminoheptanoic acid, 1,6-hexandiamine, n-heptylamine, 1,7-diaminoheptane, octylamine, 1,8-diamino-octane, nonylamine, cyclohexane carboamide, 2,2-dimethyl-1,3-propanediamine, 2-n-propylaniline, DL-2-amino-1-pentanol, DL-2-amino-1-haxanol, 1-(3-aminopropyl)imidazole, p-xylylenediamine, 1-amino cyclopropane-1-carboxylic acid, cyanothioacetamide, 2,4-difluorobenzylamine, 2,5-difluorobenzylamine, 2,6-difluorobenzylamine, 3,4-difluorobenzylamine, 2-methyl-3-thiosemicarbazide, 5-amino-2-methoxyphenol, 4-sec-butylaniline, 2,3-difluoroaniline, thiophene-2-carboamide, 1-amino-1-cyclopentanemethanol, 3-methyladenine, 1-methyladenine, 4-chloro-2-fluoroaniline, 5-amino-1-ethylpyrazole, 2,3-diaminotoluene, butylamine, 4-chloro-o-phenylenediamine, 1-(trimethylsilylmethyl)urea, 2,3,4-trifluoro aniline, 2-(1-cyclohexanyl)ethylamine, 3-amino-2-butenethioamide, 2,3,6-trifluoro aniline, 1,5-diamino-2-methylpentane, amidinothiourea, 3-ethynylaniline, N,N-bis(2-hydroxyethyl)ethylenediamine,

3-methoxypropylamine, 4-aminostyrene, 2-amino-6-fluorobenzonitrile, 3-amino-5-hydroxypyrazole, 2,4-diamino-6-methyl-1,3,5-triazine, pyridine-2-carboamide, 1-aminoisoquinoline, 4-chloro-1,3-phenylenediamine, 2-chloro ethylcarbamate, amide fumarate, acetoacetamide, N-N-butylethylenediamine, 3-butoxypropylamine, cyclopropanemethylamine, 5-aminoindazole, 2,4-diamino pyrimidine, α -ethylbenzylamine, 3-aminoisoxazole, chlorodifluoroacetamide, 1,8-diamino-3,6-dioxaoctane, 2-sec-butylaniline, 3-chlorobenzylamine, 2-fluoro-4-methylaniline, 1-(4-fluorophenyl)ethylamine, 4-aminophthalonitrile, adenine, 2-chloro-4-fluoroaniline, semicarbazide, (R)-(-)-1-cyclohexylethylamine, 5-amino-o-cresol, N,N,2,2-tetramethyl-1,3-propanediamine, 2,2-diethoxyacetamide, 3-amino-5,5-dimethyl-2-cyclohexane-1-one, propylcarbamate, glycolamide, 2-amino-1,3-propanediol, thiophene-2-ethylamine, 2,5-dimethyl-1,4-phenylenediamine, 2-amino-4-methoxy-6-methyl-1,3,5-triazine, 2-phenoxyethylamine, 4-amino-2-mercaptopyrimidine, creatinine, 2-amino-4-methoxy-6-methylpyrimidine, 3,5-difluorobenzylamine, (1R,2R)-(-)-1,2-diaminocyclohexane, (1S,2S)-(+)-1,2-diaminocyclohexane, D-aspartic acid, DL-aspartic acid, DL-leucine, D-leucine, L-homoserine, DL-methionine, L-methionine, DL-allylglycine, D-glutamic acid, L-leucinol, DL-threonine, cis-1,2-diamino cyclohexane, trans-1,2-cyclohexanediamine, L-tert-leucine, D-valine, L-valine, D-iso leucine, L-isoleucine, DL-serine, L-serine, L-allo-threonine, D-threonine, L-threonine, L-valinol, D-valinol, L-cysteine, DL-cycloserine, L-cycloserine, L-asparagine, (S)-(+)-2-phenylglycinol, (R)-(+)-1-phenylethylamine, L-(-)- α -methylbenzylamine, DL-alanine, L-alanine, L-alaninol, D-alaninol, D-(-)-2-aminobutanoic acid, L- α -amino-n-butanoic acid, (R)-(-)-2-aminobutane, (S)-(+)-2-aminobutane, (S)-(+)-2-amino-1-butanol, (R)-(-)-2-amino-1-butanol, DL-norvaline, L-norvaline, DL-norleucine, L-norleucine, (R)-(-)-1-amino-2-propanol, (S)-(+)-1-amino-2-propanol, (S)-(-)-2-methylbutylamine, DL-leucine, L-lysine, L-lysine, (S)-(+)-1-cyclohexylethylamine, ethyl thiooxamate, 2-amino-5-methylbenzyl alcohol, 2-amino-3-methylbenzyl alcohol, 3-amino-2-methylbenzyl alcohol, 3-fluoro-4-methoxyaniline, 3-amino-4-methylbenzyl alcohol, 5-methoxy-2-methylaniline, 2-amino-m-cresol, trans-1,4-diaminocyclohexane, 3-amino-5-methylpyrazole, 2,3-diaminophenol, 1-piperidinecarboamide, 6-amino-1-methyluracil, 3-fluorophenethylamine, 2-aminobenzylamine, 2-methoxy-6-methylaniline, 2-fluoro phenethylamine, 4-aminobenzylamine, 1-acetylguanidine, D-homoserine, 2-amino-5-methylthiazole, maleamine acid, (S)-(+)-tetrahydrofurfurylamine, 2-aminobenzyl cyanide, 4-amino-2-chlorophenol, 2-amino-4,5-dicyanoimidazole, 4-amino-6-methoxypyrimidine, 2-tert-butylaniline, 2-(4-fluorophenyl)ethylamine, 1,3-diamino pentane, 2-amino-1-methylbenzimidazole, 5-methylfurfurylamine, (R)-(+)-1-(p-tri l)ethylamine, (S)-(-)-1-(p-tri l)ethylamine, 3-amino-1,2,4-triazole-5-carboxylic acid, muscimol, 4-ethylaniline, 2-amino-4-methylbenzonitril, 2-amino-5-methylthio-1,3,4-thiadiazole, 1-(aminocarbonyl)-1-cyclopropanecarboxylic acid, cis-4-aminocyclohexanecarboxylic acid, (S)-(+)-2-(aminomethyl)pyrrolidine, 5-amino-4-nitroimidazole, 3-amino-1-propanolviny l aether, thioethylene diamine, isopropyl-diethylene triamine, L-tert-leucinol, N-methyl-1,2-phenylenediamine, (R)-(-)-tetrahydrofurfurylamine, L-(-)-lactamide, (R)-(+)-lactamide, (S)-(+)-2,2-dimethylcyclopropanecarboamide, (1S,2R)-(-)-cis-1-amino-2-indanol, (1R,2S)-(+)-cis-1-amino-2-indanol, (R)-(-)-1-aminoindane, (S)-(+)-1-aminoindane, (R)-2-phenyl-1-propylamine, (S)-2-phenyl-1-propylamine, D-methioninol, (R)-2-amino-1-phenylethanol, 2-amino-4,5-dimethyl-3-furancarboxitrile, N-hexylethylenediamine, (S)-(-)-4-amino-2-hydroxybutanoic acid, (S)-3-amino-1,2-propanediol, (R)-3-amino-1,2-propanediol, 4-aminoindole, (R)-(-)-tert-leucinol and 2-amino-5-fluoropyridine.

compound of the formula : R¹⁹ CHO

formaldehyde, ethyl 2-formyl-1-cyclopropanecarboxylate, cyclohexanecarbaldehyde, 1,2,3,6-tetrahydrobenzaldehyde, 1-methylpyrrole-2-carbaldehyde, furfural, 5-nitro-2-furaldehyde, 5-methylfurfural, 5-hydroxymethyl-2-furaldehyde, 3-(2-furyl)acrolein, benzaldehyde, 2-fluorobenzaldehyde, 2-chloro benzaldehyde, o-anisaldehyde, salicylaldehyde, 3-fluoro-2-hydroxybenzaldehyde, 2,3-dihydroxybenzaldehyde, 2,5-dihydroxybenzaldehyde, o-naphthalaldehyde, o-tolaldehyde, 2,4-dimethylbenzaldehyde, mesitaldehyde, 2,5-dimethylbenzaldehyde, 3-cyanobenzaldehyde, 3-fluorobenzaldehyde, 3-chlorobenzaldehyde, 3-methoxybenzaldehyde, 3-hydroxybenzaldehyde, 3,4-dihydroxybenzaldehyde, isonaphthalaldehyde, m-tolaldehyde, 4-cyanobenzaldehyde, 4-fluorobenzaldehyde, 4-chlorobenzaldehyde, 4-dimethylaminobenzaldehyde, p-anisaldehyde, imidazole-2-carbaldehyde, pyrrole-2-carbaldehyde, 2-thiophenecarbaldehyde, 3-methylthiophene-2-carbaldehyde, 5-methyl-2-thiophenecarbaldehyde, 3-thiophenecarbaldehyde, indole-3-carbaldehyde, 2-pyridinecarbaldehyde, 6-methyl-2-pyridinecarbaldehyde, 3-pyridinecarbaldehyde, 4-pyridinecarbaldehyde, 4-hydroxybenzaldehyde, terenaphthalaldehyde, cuminaldehyde, p-tolaldehyde, 4-ethyl benzaldehyde, glyoxal, glyoxylic acid, methyl glyoxal, trimethylacetaldehyde, D-(-)-erythrose, 2-phenylpropionaldehyde, methacrolein, 3-ethoxymethacrolein, alpha-methylcinnamaldehyde, trans-2-methyl-2-butenal, 2-methyl-2-pentenal, isobutylaldehyde, 2,6-dimethyl-5-hepten-1-ol, 2-methylbutylaldehyde, 2-ethylbutylaldehyde, 2-methylpentanal, 2-ethylhexanal, acetaldehyde, chloro acetaldehyde, phenylacetaldehyde, phenylpropargyl aldehyde, acrolein, 3-(dimethylamino) acrolein, trans-cinnamaldehyde, crotonaldehyde, 2,4-hexadienal, trans,trans-2,4-heptadienal, trans,trans-2,4-nonadienal, trans-2-hexenal, trans-2,cis-6-nonadien-1-al, trans-2-heptenal, trans-2-octenal, trans-2-nonenal, isovaleraldehyde, propionaldehyde, 3-phenylpropionaldehyde, 3-(methylthio)propionaldehyde, butylaldehyde, glutaraldehyde, valeraldehyde, hexanal, heptaldehyde, octanal, nonanal, trans-2-pentenal, 2,4-dimethyl-2,6-heptadienal, 2,6-pyridinedicarbaldehyde, 2-ethylacrolein, 3-methyl-2-butenal, 2,3-difluorobenzaldehyde, 2,6-difluorobenzaldehyde,

2,4-difluorobenzaldehyde, 2,5-difluorobenzaldehyde, 3,4-difluorobenzaldehyde, 3,5-difluorobenzaldehyde, 3-furaldehyde, 3,5,5-trimethylhexanal, 3-phenylbutylaldehyde, 2,2-dimethyl-4-pentenal, 2,4-dihydroxybenzaldehyde, cyclopropanecarbaldehyde, 4-hydroxy-3-methylbenzaldehyde, benzo[b]furan-2-carbaldehyde, 3,5-dihydroxybenzaldehyde, 3,4-dimethylbenzaldehyde, 2-cyanobenzaldehyde, 5-ethyl-2-furaldehyde, 2-hydroxy-3-methylbenzaldehyde, 3,3-dimethylbutylaldehyde, 5-chloro-2-thiophenecarbaldehyde, 3,4-dihydro-2H-pyran-2-carbaldehyde, D-glyceroaldehyde, DL-glyceroaldehyde, 3-fluoro-2-methylbenzaldehyde, 3-dimethylamino-2-methyl-2-propenal, 3,5-dimethylbenzaldehyde, 4,5-dimethyl-2-furancarbaldehyde, 4-vinylbenzaldehyde, 2,6-dimethylbenzaldehyde, 2-octanal, dimethoxyacetaldehyde, 2-deoxy-D-ribose, 2-formyl thiazole, 5-ethyl-2-thiophenecarbaldehyde, glyoxylic acid, 4-pyridinecarbaldehyde-N-oxide, 5-norbornene-2-carbaldehyde, 4-formylimidazole, 5-methylimidazole-4-carbaldehyde, 5-formyluracil, 2,3-thiophenedicarbaldehyde, thiophene-2,5-dicarbaldehyde, 2,3-o-isopropylidene-D-glyceroaldehyde, 2-hydroxy-5-methylbenzaldehyde, 1-cyclohexane-1-carbaldehyde, 2,3-dimethylbenzaldehyde, 1-methyl-2-imidazolecarbaldehyde, vinylbenzaldehyde, 4-fluoro-3-methylbenzaldehyde, 3-fluoro-4-methylbenzaldehyde, tetrahydrofuran-3-carbaldehyde, 2-fluoro-5-formyl benzonitrile, indole-5-carbaldehyde, 4-acetylbenzaldehyde, 3-vinylbenzaldehyde and 2-fluoro-5-methylbenzaldehyde.

(115) A process for preparing a compound of the formula (III-1) of above (110), wherein the compound of formula (K) is 4-[5-(4-fluorobenzyl)franz-2-yl]-2-hydroxy-4-oxo-2-butenic acid alkyl ester and compounds shown of the formula: R^5NH_2 and $R^{19}CHO$ are each selected from the groups of above (114).

(116) A compound of formula (III-1) prepared by the process of any one of above (110) to (114).

(117) A compound of formula (III-1) prepared by the process of (115).


(118) A library of compounds prepared by the process of above (115).

(119) A pharmaceutical composition comprising as an effective ingredient a compound of above (117).

(120) A pharmaceutical composition as an integrase inhibitor comprising as an effective ingredient a compound of above (117).

[0012] The present invention is explained in detail below.

Characteristics of a compound of the formula (I) :




(wherein, R^C, R^D, Y, Z and R^A are the same as defined above) includes the followings:

1) R^C and R^D taken together with the neighboring carbon atoms may form a ring, and the ring may be a condensed ring,


2) Y is hydroxy, mercapto or amino,

3) Z is O, S or NH,

4) R^A is shown by the formula :



(wherein, C ring is the same as defined above) or the formula:



(wherein, X and R^B are the same as defined above),

5) C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is N atom,

6) X is O, S or NH,

7) R^B is a substituent selected from substitution group A,

8) at least one of the ring formed by R^C and R^D, C ring or R^B is substituted with a group of the formula: - Z¹ - Z² - Z³ - R¹ (wherein, Z¹ and Z³ are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene; Z² is a bond, optionally substituted alkylene, optionally substituted alkenylene, -CH(OH)-, -S-, -SO-, -SO₂-, -SO₂NR²-, -NR²SO₂-, -O-, -NR²-, -NR²CO-, -CONR²-, -C(=O)-O-, -O-C(=O)- or -CO-; R² is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heteroaryl; R¹ is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle),

9) the ring formed by R^C and R^D, C ring or R^B is optionally substituted with a non-interfering substituent at any position other than that where the group of - Z¹ - Z² - Z³ - R¹ (wherein, Z¹, Z², Z³ and R¹ is the same as defined above) locates,

10) substitution group A consists of: hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxyalkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthioalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfa-moyl, sulfoamino, formyl, alkylcarbonyl, alkyl carbonyloxy, hydrazino, morpholino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl alkyl, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted arylthio, optionally substituted heteroarylthio, optionally substituted aralkyloxy, optionally substituted heteroarylalkyloxy, optionally substituted aralkylthio, optionally substituted heteroaryl alkylthio, optionally substituted aryl oxyalkyl, optionally substituted heteroaryl oxyalkyl, optionally substituted aryl thioalkyl, optionally substituted heteroaryl thioalkyl, optionally substituted arylsulfonyl, optionally substituted heteroarylsulfonyl, optionally substituted aralkylsulfonyl and optionally substituted heteroarylalkylsulfonyl,

[0013] The ring formed by R^C and R^D includes a 4 - to 9-membered carbocycle or heterocycle, which may be condensed with the other ring (e.g., 4 - to 9 -membered carbocycle or heterocycle, or a condensed ring thereof). Preferred is a 5 - to 7-membered carbocycle or heterocycle, more preferred is 5 - or 6 -membered carbocycle or heterocycle, and their condensed ring with the other ring (e.g., 5 - or 6 -membered carbocycle or heterocycle). Further preferred rings formed by R^C and R^D are the following cases. The heteroaryl used below refers to a ring containing 1 to 4 hetero atom(s) (O, O or S).

1) The ring is 5 - or 6 -membered one which may contain a hetero atom(s),

2) The ring is 5 - or 6 -membered heterocycle containing a hetero atom(s),

3) The ring is 5 - or 6 -membered heterocycle which may contain O and/or N atom,

4) The ring is 5 - or 6 -membered heterocycle which contains O and/or N atom,

5) The ring is 5 - or 6 -membered heterocycle which contains N atom,

6) The ring is 5 - or 6 -membered heterocycle which contains O atom,


7) The ring is 5 -membered heterocycle which contains N atom,

8) The ring is 6 -membered heterocycle which contains O atom,

9) The ring is 6 -membered carbocycle, and

10) The ring is one of above 1) to 9) which is condensed with the other ring, 10) The ring is heterocycle which consists of the ring of above 1) to 9) condensed with a benzene ring.

[0014] Examples of the ring formed by R^C and R^D include the followings:




(wherein, Z is the same as above (1))

[0015] Among the above, preferred are the followings:

- 1) The ring is 5-membered N-containing heterocycle,
- 2) The ring is 6-membered O-containing heterocycle,
- 3) The ring is 6-membered N-containing heterocycle,
- 4) The ring is 6-membered O-containing heterocycle condensed with benzene ring, and
- 5) The ring is 6-membered N-containing heterocycle condensed with benzene ring,

[0016] Further preferred rings are shown below



[0017] The ring formed by R^C and R^D may be substituted, at any substitutable position of C atom or N atom constructing the ring, with a group of the formula: $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as defined above.) or a non-interfering substituent.

[0018] The compound of the formula (I) is characterized in that at least one of the ring formed by R^C and R^D , C ring and R^B is substituted with a group of the formula: $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as defined above.).

[0019] Examples of the formula: $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 , Z^2 , Z^3 , and R^1 are the same as defined above.) include $-R^1$, $-CH_2-R^1$, $-CH=CH-R^1$, $-CH(OH)-R^1$, $-S-R^1$, $-SO-R^1$, $-SO_2-R^1$, $-SO_2NH-R^1$, $-NHSO_2-R^{one}$ or $-NH-R^1$, $-NH-CO-R^1$, $-CONH-R^1$, $-C(=O)-O-R^1$, $-O-C(=O)-R^1$, $-CO-R^1$, $-C_2H_4-R^1$, $-CH=CH-CH_2-R^1$, $-CH(OH)-CH_2-R^1$, $-S-CH_2-R^1$,

-SO-CH₂-R¹, -SO₂-CH₂-R¹, -SO₂NH-CH₂-R¹, -NH SO₂-CH₂-R¹, -O-CH₂-R¹, -NH-CH₂-R¹, -NHCO-CH₂-R¹,
 -CONH-CH₂-R¹, -C(=O)-O-CH₂-R¹, -O-C(=O)-CH₂-R¹, -CO-CH₂-R¹, -CH=CH-CH=CH-R¹, -CH=CH-CH(OH)-R¹,
 -CH=CH-S-R¹, -CH=CH-SO-R¹, -CH=CH-SO₂-R¹, -CH=CH-SO₂NH-R¹, -CH=CH-NHSO₂-R¹, -CH=CH-O-R¹,
 -CH=CH-NH-R¹, -CH=CH-NHCO-R¹, -CH=CH-CONH-R¹, -CH=CH-C(=O)-O-R¹, -CH=CH-O-C(=O)-R¹,
 5 -CH=CH-CO-R¹, -CH₂-CH=CH-R¹, -CH₂-CH(OH)-R¹, -CH₂-S-R¹, -CH₂-SO-R¹, -CH₂-SO₂-R¹, -CH₂-SO₂NH-R¹,
 -CH₂-NHSO₂-R¹, -CH₂-O-R¹, -CH₂-NH-R¹, -CH₂-NHCO-R¹, -CH₂-CONH-R¹, -CH₂-C(=O)-O-R¹, -CH₂-O-C(=O)-R¹,
 -CH₂-CO-R¹, -CH(OH)-CH=CH-R¹, -S-CH=CH-R¹, -SO-CH=CH-R¹, -SO₂-CH=CH-R¹, -SO₂NH-CH=CH-R¹,
 -NHSO₂-CH=CH-R¹, -O-CH=CH-R¹, -NH-CH=CH-R¹, -NHCO-CH=CH-R¹, -CONH-CH=CH-R¹, -C(=O)
 -O-CH=CH-R¹, -O-C(=O)-CH=CH-R¹, -CO-CH=CH-R¹, -C₃H₆-R¹, -CH₂-CH=CH-CH₂-R¹, -CH₂-CH(OH)-CH₂-R¹,
 10 -CH₂-S-CH₂-R¹, -CH₂-SO-CH₂-R¹, -CH₂-SO₂-CH₂-R¹, -CH₂-SO₂NH-CH₂-R¹, -CH₂-NHSO₂-CH₂-R¹, -CH₂-O-CH₂-
 R¹, -CH₂-NH-CH₂-R¹, -CH₂-NHCO-CH₂-R¹, -CH₂-CONH-CH₂-R¹, -CH₂-C(=O)-O-CH₂-R¹, -CH₂-O-C(=O)-CH₂-R¹,
 -CH₂-C O-CH₂-R¹, -C₂H₄-CH=CH-R¹, -CH₂-CH=CH-CH=CH-R¹, -CH₂-CH(OH)-CH=CH-R¹, -CH₂-S-CH=CH-R¹,
 -CH₂-SO-CH=CH-R¹, -CH₂-SO₂-CH=CH-R¹, -CH₂-SO₂NH-CH=CH-R¹, -CH₂-NHSO₂-CH=CH-R¹, -CH₂-O-C
 H=CH-R¹, -CH₂-NH-CH=CH-R¹, -CH₂-NHCO-CH=CH-R¹, -CH₂-CONH-CH=CH-R¹, -CH₂-C(=O)-O-CH=CH-R¹,
 15 -CH₂-O-C(=O)-CH=CH-R¹, -C H₂-CO-CH=CH-R¹, -CH=CH-C₂H₄-R¹, -CH=CH-CH=CH-CH₂-R¹, -CH=CH-CH(OH)
 -CH₂-R¹, -CH=CH-S-CH₂-R¹, -CH=CH-SO-CH₂-R¹, -CH=CH-SO₂-CH₂-R¹, -CH=CH-SO₂NH-CH₂-R¹,
 -CH=CH-NHSO₂-CH₂-R¹, -CH=CH-O-CH₂-R¹, -CH=CH-NH-CH₂-R¹, -CH=CH-NHCO-CH₂-R¹, -CH=CH-CONH-CH₂-
 R¹, -CH=CH-C(=O)-O-CH₂-R¹, -CH=CH-O-C(=O)-C H₂-R^{one} or -CH=CH-CO-CH₂-R¹ (wherein, R¹ is optionally
 20 substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl,
 or optionally substituted heterocycle).


[0020] Preferable examples of -Z¹-Z²-Z³-R¹ (wherein, Z¹, Z², Z³, and R¹ are the same as defined above.) are shown below.

- 1) Z¹ and Z³ are bonds,
- 2) Z¹ and Z³ are bonds, Z² is a bond, -C O-, -O-, -S-, -S O₂ or lower alkylene (esp., -C H₂-, -(C H₂)₂-),
- 3) Z¹ and Z³ are bonds, Z² is a bond, -CO-, -O-, -S-, -SO₂ or lower alkylene (esp., -CH₂-, -(CH₂)₂-), R¹ is optionally substituted aryl or optionally substituted heteroaryl,
- 4) Z¹ and Z³ are bonds, Z² is -SO₂-, -CH₂- or -C₂H₄-, R¹ is optionally substituted aryl (esp., phenyl),
- 5) Z¹ is a bond or alkylene, Z³ is a bond, Z² is optionally substituted alkylene, alkenylene or -O-, R¹ is optionally substituted aryl, optionally substituted heteroaryl or optionally substituted cycloalkyl,
- 6) Z¹ is a bond or alkylene,
- 7) Z¹ is a bond,
- 8) Z² is a bond, alkylene, -SO₂ or -O-,
- 9) Z² is a bond, alkylene or -O-,
- 10) Z² is alkylene or -O-,
- 11) Z³ is a bond or alkylene,
- 12) R¹ is optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl,
- 13) R¹ is optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle or optionally substituted aryl,
- 14) R¹ is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle,
- 15) R¹ is optionally substituted aryl,
- 16) Z¹ and Z³ are bonds, Z² is alkylene, R¹ is optionally substituted aryl,
- 17) Z¹ is a bond or alkylene, Z³ is a bond, Z² is optionally substituted alkylene, alkenylene, -S or -O-, R¹ is optionally substituted aryl, optionally substituted heteroaryl or optionally substituted cycloalkyl,
- 18) Z¹ and Z³ are each independently a bond or alkylene; Z² is a bond or -O-; R¹ is optionally substituted aryl or optionally substituted heteroaryl,
- 19) Z¹, Z² and Z³ are not bonds at the same time,
- 20) R¹ is phenyl optionally substituted with halogen, Z¹ is a bond, Z² is alkylene or -O-, Z³ is a bond or alkylene,
- 21) R¹ is 4-fluorophenyl, Z¹ is a bond, Z² is alkylene or -O-, Z³ is a bond or alkylene.

[0021] Examples of the formula: -Z¹-Z²-Z³-R¹ include phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 3,4-difluorophenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 4-bromophenyl, 4-biphenyl, benzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2-chlorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 2,4-difluorobenzyl, 2,6-difluorobenzyl, 2,5-difluorobenzyl, 3,4-difluorobenzyl, 3,6-difluorobenzyl, 4-methylbenzyl, 3-trifluoromethylbenzyl, 4-trifluoromethylbenzyl, 4-hydroxybenzyl, 4-methoxybenzyl, 4-bromobenzyl, 4-phenylbenzyl, 2-phenylethyl, 2-(2-fluorophenyl)ethyl, 2-(3-fluorophenyl)ethyl, 2-(4-fluorophenyl)ethyl, 2-(2-chloroph-

enyl)ethyl, 2-(3-chlorophenyl)ethyl, 2-(4-chlorophenyl)ethyl, 2-(2,4-difluorophenyl)ethyl, 2-(2,6-difluorophenyl)ethyl, 2-(2,5-difluorophenyl)ethyl, 2-(3,4-difluorophenyl)ethyl, 2-(4-methylphenyl)ethyl, 2-(3-trifluoromethylphenyl)ethyl, 2-(4-trifluoromethylphenyl)ethyl, 2-(4-hydroxyphenyl)ethyl, 2-(4-methoxyphenyl)ethyl, 2-(4-bromophenyl)ethyl, 2-(4-biphenyl)ethyl, benzenesulfonyl, 2-fluorobenzenesulfonyl, 3-fluorobenzenesulfonyl, 4-fluorobenzenesulfonyl, 2-chlorobenzenesulfonyl, 3-chlorobenzenesulfonyl, 4-chlorobenzenesulfonyl, 2,4-difluorobenzenesulfonyl, 2,6-difluorobenzenesulfonyl, 2,5-difluorobenzenesulfonyl, 3,4-difluorobenzenesulfonyl, 4-methylbenzenesulfonyl, 3-trifluoromethylbenzenesulfonyl, 4-trifluoromethylbenzenesulfonyl, 4-hydroxybenzenesulfonyl, 4-methoxybenzenesulfonyl, 4-bromobenzenesulfonyl, 4-phenylbenzenesulfonyl, phenylthio, 2-fluorophenylthio, 3-fluorophenylthio, 4-fluorophenylthio, 2-chlorophenylthio, 3-chlorophenylthio, 4-chlorophenylthio, 2,4-difluorophenylthio, 2,6-difluorophenylthio, 2,5-difluorophenylthio, 3,4-difluorophenylthio, 4-methylphenylthio, 3-trifluoromethylphenylthio, 4-trifluoromethylphenylthio, 4-hydroxyphenylthio, 4-methoxyphenylthio, 4-bromophenylthio, 4-biphenylthio, phenoxy, 2-fluorophenoxy, 3-fluorophenoxy, 4-fluorophenoxy, 2-chlorophenoxy, 3-chlorophenoxy, 4-chlorophenoxy, 2,4-difluorophenoxy, 2,6-difluorophenoxy, 2,5-difluorophenoxy, 3,4-difluorophenoxy, 4-methylphenoxy, 3-trifluoromethylphenoxy, 4-trifluoromethylphenoxy, 4-hydroxyphenoxy, 4-methoxyphenoxy, 4-bromophenoxy, 4-phenylphenoxy, benzoyl, 2-fluorobenzoyl, 3-fluorobenzoyl, 4-fluorobenzoyl, 2-chlorobenzoyl, 3-chlorobenzoyl, 4-chlorobenzoyl, 2,4-difluorobenzoyl, 2,6-difluorobenzoyl, 2,5-difluorobenzoyl, 3,4-difluorobenzoyl, 4-methylbenzoyl, 3-trifluoromethylbenzoyl, 4-trifluoromethylbenzoyl, 4-hydroxybenzoyl, 4-methoxybenzoyl, 4-bromobenzoyl, 4-phenylbenzoyl, 2-thienyl, 3-thienyl, furfuryl, 3-furylmethyl, (2-chlorothiophene-3-yl)methyl, 2-picolyl, 3-picolyl, 4-picolyl, (2-fluoropyridine-3-yl)methyl, (2-fluoropyridine-5-yl)methyl, (5-fluoropyridine-2-yl)methyl, benzyloxy, 4-fluorobenzyloxy, 2-phenylethoxy, and 2-(4-fluorophenyl)ethyl oxy.

[0022] A group of the formula :




(wherein, C ring is N-containing aromatic heterocycle wherein at least one atom neighboring to the atom at the bonding-position is N atom. the broken line shows the presence or absence of a bond) means heteroaryl wherein at least one atom neighboring to the atom at the bonding-position is non-substituted N atom.

[0023] C ring may contain a hetero atom(s) other than the N atom shown in the above formula. The atoms constituting C ring include C, O, N and S. The bonds constituting C ring include a single bond or double bond. C ring is a monocyclic ring or condensed ring (e.g., di- to penta-cyclic condensed ring) and preferred is a monocyclic ring or di-cyclic condensed ring, and more preferred is a monocyclic ring.


[0024] A monocyclic heteroaryl of C ring means 5- to 8-membered heteroaryl wherein one atom neighboring to the atom at the bonding-position is non-substituted N atom and which may contain further 1 to 4 of O, S and/or N atom, and preferably 5- or 6-membered heteroaryl. The examples include imidazole-2-yl, imidazole-4-yl, pyrazole-3-yl, triazole-3-yl, tetrazole-5-yl, oxazole-2-yl, oxazole-4-yl, isoxazole-3-yl, thiazole-2-yl, thiazole-4-yl, 1,3,4-thiadiazole-2-yl, 1,2,4-thiadiazole-5-yl, 1,2,4-thiadiazole-3-yl, 1,3,4-oxadiazole-2-yl, 1,2,4-oxadiazole-5-yl, 1,2,4-oxadiazole-3-yl, isothiazole-3-yl, pyridine-2-yl, pyridazine-3-yl, pyridazine-2-yl, pyrimidine-2-yl, pyrimidine-4-yl, and furazan-3-yl.

[0025] Preferred is imidazole-2-yl, 1,2,4-triazole-3-yl, tetrazole-5-yl, oxazole-2-yl, thiazole-2-yl, 1,3,4-thiadiazole-2-yl, 1,2,4-thiadiazole-5-yl, 1,2,4-thiadiazole-3-yl, 1,3,4-oxadiazole-2-yl, 1,2,4-oxadiazole-5-yl, 1,2,4-oxadiazole-3-yl, pyrimidine-2-yl, and pyridine-2-yl, more preferred is pyridine-2-yl, pyrimidine-2-yl, 1,3,4-oxadiazole-2-yl, 1,2,4-triazole-3-yl, and imidazole-2-yl.

[0026] A condensed heteroaryl of C ring means the above monocyclic heteroaryl which is condensed with 1 to 4 of 5- to 8-membered aromatic carbocycle and/or with another 5- to 8-membered aromatic heterocycle optionally containing 1 to 4 of O, S, and/or N atom(s). The aromatic ring to be condensed is preferably 5- or 6-membered one, such as benzimidazole-2-yl, benzoxazole-2-yl, quinoxaline-2-yl, cinnoline-3-yl, quinazoline-2-yl, quinazoline-4-yl, quinoline-2-yl, phthalazine-1-yl, isoquinoline-1-yl, isoquinoline-3-yl, purine-2-yl, purine-6-yl, purine-8-yl, pteridine-2-yl, pteridine-4-yl, pteridine-6-yl, pteridine-7-yl, and phenanthridine-6-yl. Preferred is benzimidazole-2-yl, benzoxazole-2-yl, quinazoline-2-yl, purine-2-yl, purine-8-yl, pteridine-2-yl, quinoline-2-yl, isoquinoline-1-yl, and isoquinoline-3-yl, and more preferred is quinoline-2-yl, isoquinoline-1-yl, and isoquinoline-3-yl. More preferred is of the formula:



10



15




20

[0028] R^n_{0-1} (n is an integer more than 0) is R^n_0 or R^n_1 . R^n_0 means "non-substrated with R^n ", and R^n_1 means "substituted with R^n ".

A compound of the formula (I) :


25



35

(wherein, R^C and R^D taken together with the neighboring carbon atoms may form 5-to 6-membered heterocycle which may contain O and/or N atom and may be condensed with benzene ring; Y is hydroxy, mercapto or amino; Z is O, S or NH; R^A is the formula :


40



45

(wherein, C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is N atom, and the broken line shows the presence or absence of a bond) or the formula :

50



55

41

cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle);

at least one of the ring formed by R^C and R^D , C ring or R^B is substituted with a group of the formula: $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 and Z^3 are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene; Z^2 is a bond, optionally substituted alkylene, optionally substituted alkenylene, $-CH(OH)-$, $-S-$, $-SO-$, $-SO_2-$, $-SO_2NR^2-$, $-NR^2SO_2-$, $-O-$, $-NR^2-$, $-NR^2CO-$, $-CONR^2-$, $-C(=O)-O-$, $-O-C(=O)-$ or $-CO-$; R^2 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heteroaryl; R^1 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle);


the ring formed by R^C and R^D , C ring or R^B may be substituted, at any position other than that which is substituted with the formula: $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as defined above) locates, with 1 to 3 groups selected from hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxy alkyl, optionally substituted amino, hydroxyalkyl, alkenyl, alkoxy carbonyl alkyl, heteroarylalkyl and hydroxy.

[0030] A compound of the above formula (I), wherein the ring formed by R^C and R^D is a 5- or 6-membered heterocycle which contains O and/or N atom and may be condensed with a benzene ring; Y is hydroxy; Z is O; X is O; the ring formed by R^C and R^D is substituted, at any possible position other than that which is substituted with a group of the formula: $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as defined above), with 1 to 3 of substituents selected from hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxyalkyl, alkenyl, alkoxy carbonylalkyl and heteroaryl alkyl, C ring and R^B are each independently substituted with 1 to 3 of substituents selected from alkyl, amino, halogen and hydroxy.


[0031] A compound wherein at least one of the ring formed by R^C and R^D , C ring or R^B is substituted with a group of the formula: $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 is a bond or alkylene; Z^2 is alkylene or $-O-$; Z^3 is a bond or alkylene; R^1 is optionally substituted aryl or optionally substituted heteroaryl).

[0032] Further preferred compounds are as follows.


A compound of the formula (I-Q): $Q-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as above (1); Q is a group of the formula:




of the formula:




of the formula:




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :




of the formula :



of the formula :




or of the formula :




[0033] Further preferred are the followings:


A compound of the formula:




15 A compound of the formula:




A compound of the formula:




A compound of the formula:




15 A compound of the formula:




30 (wherein, at least one of R^E and R^F is a group of the formula : -Z¹-Z²-Z³-R¹, the other is a non-interfering substituent or R^E and R^F taken together with the neighboring carbon atoms may form a ring of the formula :




50 A compound of the formula:




A compound of the formula:




(wherein, R^E and R^F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms may form a ring of the formula:




A compound of the formula:




A compound of the formula:




(wherein, R^E and R^F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms may form a ring of the formula :




A compound of the formula:




A compound of the formula:




(wherein, R^E and R^F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms may form a ring of the formula:




A compound of the formula:




A compound of the formula:




(wherein, R^E and R^F are each independently a non-interfering substituent) A compound of the formula:




(wherein, R^E and R^F are each independently a non-interfering substituent) A compound of the formula:




(wherein, R^E and R^F are each independently a non-interfering substituent) A compound of the formula:




15 (wherein, R^F and R^G are each independently a non-interfering substituent) A compound of the formula:




30 (wherein, R^F and R^G are each independently a non-interfering substituent) A compound of the formula:




45 A compound of the formula:



A compound of the formula:




(wherein, R^F and R^G are each independently a non-interfering substituent) A compound of the formula:




(wherein, R^F and R^G are each independently a non-interfering substituent)


A compound of the formula:



15 (wherein, R^F and R^G are each independently a non-interfering substituent)
A compound of the formula:



30 (wherein, R^F and R^G are each independently a non-interfering substituent)
A compound of the formula:



50 (wherein, R^G is a non-interfering substituent)
A compound of the formula:



(wherein, R^G is a non-interfering substituent)

In the above shown compounds, R^6 , R^7 and a group of the formula : $-Z^1-Z^2-Z^3-R^1$ are substituents on R^B . The definition of each symbol is explained below.

[0034] X is 0, S or NH and preferred is 0,

[0035] Y is hydroxy, mercapto or amino and preferred is hydroxy.

[0036] Z is O, S or NH and preferred is O.

[0037] C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is N atom and preferred is optionally substituted pyridine-2-yl, optionally substituted pyrimidine-4-yl or optionally substituted 1,3,4-oxadiazole-2-yl.

[0038] R^B is a substituent selected from substitution group A and preferred is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle.

[0039] R¹ is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle.

[0040] Z¹ and Z³ are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene.

[0041] Z² is a bond, optionally substituted alkylene, optionally substituted alkenylene, -C H(OH)-, -S-, -SO-, -SO₂-, -SO₂NR²-, -NR²SO₂-, -O-, -NR²-, -NR²CO-, -CON R²-, -C(=O)-O-, -O-C(=O) or -CO-,

[0042] R² is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heteroaryl.

[0043] W^1 is -O or -N(-R^G)-,

[0044] R³ to R¹⁹ and R^G are each independently a non-interfering substituent,

[0045] R^G is preferably hydrogen or alkyl.

[0046] Examples of R^B include a substituent selected from substitution group A. substitution group A:

hydrogen, halogen, alkoxy, carbonyl, carboxy, alkyl, alkoxy, alkoxyalkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthioalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkylcarbonyl, alkyl carbonyloxy, hydrazino, morpholino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl alkyl, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted arylthio, optionally substituted heteroarylthio, optionally substituted aralkyloxy, optionally substituted heteroarylalkyloxy, optionally substituted aralkylthio, optionally substituted heteroarylalkylthio, optionally substituted aralkoxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted arylthioalkyl, optionally substituted heteroarylthioalkyl, optionally substituted arylsulfonyl, optionally substituted heteroarylsulfonyl, optionally substituted aralkylsulfonyl and optionally substituted heteroaryl alkylsulfonyl.

[0047] Preferred are alkoxy carbonyl, carboxy, alkyl, alkoxy, alkoxyalkyl, hydroxy, alkenyl, alkynyl, alkylsulfonfyl, optionally substituted amino, alkylthio, alkylthioalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, alkyl carbonyl, alkyl carbonyloxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted aryl oxy, optionally substituted heteroaryl oxy, optionally substituted aryl thio, optionally substituted heteroaryl thio, optionally substituted aralkyloxy, optionally substituted heteroaryl alkyl oxy, optionally substituted aralkylthio, optionally substituted heteroaryl alkylthio, optionally substituted aryl oxyalkyl, optionally substituted heteroaryl oxyalkyl, optionally substituted arylthioalkyl, optionally substituted heteroarylthioalkyl, optionally substituted heteroarylsulfonfyl, optionally substituted heteroarylsulfonfyl, optionally substituted aralkylsulfonfyl, optionally substituted het-

eroaryl alkylsulfonfyl. More preferred are alkyl, hydroxy, alkoxy, optionally substituted amino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle. Most preferred are optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle.

[0048] Preferable R^B of the above formula (III-1), (III-2), (VII-1), (VII-2), (VII-3), (VII-4), (VII-5), (VIII-1), (IX-1), (X-1), (XI-1), (XII-1) and (XIII-1) includes optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl alkyl, optionally substituted aryl oxy, optionally substituted heteroaryloxy, optionally substituted arylthio, optionally substituted heteroarylthio, optionally substituted aralkyloxy, optionally substituted heteroaryl alkyloxy, optionally substituted aralkylthio, optionally substituted heteroarylalkylthio, optionally substituted aryloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted arylthioalkyl, optionally substituted heteroarylthioalkyl, optionally substituted arylsulfonfyl, optionally substituted heteroarylsulfonfyl, optionally substituted aralkylsulfonfyl, optionally substituted heteroarylalkylsulfonfyl. More preferred are optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle. Most preferred are optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle.

[0049] The ring formed by R^C and R^D , C ring and R^B are optionally substituted with a non-interfering substituent(s). The substituent may locate at one or more, preferably one to five, any substitutable positions.

[0050] The non-interfering substituent means any substituent not interfering with the integrase inhibitory activity. The non-interfering substituent can be selected based on the determined integrase inhibitory activity and drug design using computer, as well as molecular weight, an der Waals' radius, electrostatic characteristic of the substituent.

[0051] Preferred examples of the non-interfering substituent include hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxy alkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonfyl, optionally substituted amino, alkylthio, alkylthio alkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, oxo, thioxo, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkylcarbonyl, alkylcarbonyloxy, hydrazino, morpholino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl alkyl, optionally substituted aryl oxy, optionally substituted heteroaryl oxy, optionally substituted aryl thio, optionally substituted heteroaryl thio, optionally substituted aralkyloxy, optionally substituted heteroaryl alkyl oxy, optionally substituted aralkylthio, optionally substituted heteroaryl alkylthio, optionally substituted aryl oxyalkyl, optionally substituted heteroaryl oxyalkyl, optionally substituted aryl thioalkyl, optionally substituted heteroaryl thioalkyl, optionally substituted arylsulfonfyl, optionally substituted heteroarylsulfonfyl, optionally substituted aralkylsulfonfyl and optionally substituted heteroaryl alkylsulfonfyl.

[0052] More preferred non-interfering substituents include hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxy alkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonfyl, optionally substituted amino, alkylthio, alkylthio alkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, oxo, thioxo, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkylcarbonyl, alkylcarbonyloxy, hydrazino, morpholino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl alkyl, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted arylthio, optionally substituted heteroarylthio, optionally substituted aralkyloxy, optionally substituted heteroaryl alkyloxy, optionally substituted aralkylthio, optionally substituted heteroaryl alkylthio, optionally substituted aryloxyalkyl, optionally substituted heteroaryl oxyalkyl, optionally substituted arylthioalkyl, optionally substituted heteroaryl thioalkyl, optionally substituted arylsulfonfyl, optionally substituted heteroarylsulfonfyl, optionally substituted aralkylsulfonfyl and optionally substituted heteroaryl alkylsulfonfyl.

[0053] Most preferred non-interfering substituents include hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxyalkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonfyl, optionally substituted amino, alkylthio, alkylthioalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, oxo, thioxo, cyano, mercapto, optionally substituted carbamoyl, formyl, alkylcarbonyl, alkylcarbonyloxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted arylthio, optionally substituted heteroarylthio, optionally substituted aralkyloxy, optionally substituted heteroaryl alkyloxy, optionally substituted aralkylthio, optionally substituted heteroaryl alkylthio, optionally substituted aryl oxyalkyl, optionally substituted heteroaryl oxyalkyl, optionally substituted aryl thioalkyl, optionally substituted heteroaryl thioalkyl, optionally substituted arylsulfonfyl, optionally substituted heteroarylsulfonfyl, optionally substituted aralkylsulfonfyl and optionally substituted heteroaryl alkylsulfonfyl.

[0054] Examples of non-interfering substituent on the ring formed by R^C and R^D (e.g., non-interfering substituent of R^{19} , R^E , R^F , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^G) are preferably hydrogen, halogen, alkyl, aralkyl, cycloalkyl, optionally

substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxy alkyl, alkenyl, alkoxyalkylalkyl, heteroarylalkyl or hydroxy.

[0055] R⁵ and R^{5'} are each preferably hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxy alkyl, alkenyl, alkoxyalkylalkyl or heteroarylalkyl.

[0056] Examples of non-interfering substituent on C ring (e.g., non-interfering substituent of R³, R⁴, R⁸, R⁹ and R¹⁰) are preferably halogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxy alkyl, alkenyl, alkoxyalkylalkyl, heteroarylalkyl or hydroxy, and more preferred is hydrogen, alkyl, amino, halogen or hydroxy.

[0057] Examples of non-interfering substituent on R^B (e.g., non-interfering substituent of R⁶ and R⁷) are preferably halogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxy alkyl, alkenyl, alkoxyalkylalkyl, heteroarylalkyl or hydroxy, and more preferred is hydrogen, alkyl, amino, halogen, hydroxy.

[0058] Terms used herein are explained below. Each term, by itself or in combination with others, is defined as follows.

[0059] "alkylene" means C1 to C6 straight or branched chain alkylene, for example, methylene, ethylene, trimethylene, propylene, tetramethylene, ethylethylene, pentamethylene or hexamethylene. Preferred is C1 to C4 straight alkylene, for example, methylene, ethylene, trimethylene or tetramethylene.

[0060] "alkenylene" is C2 to C6 straight or branched chain alkenylene derived from the above "alkylene" having one or more of double bond, for example, vinylene, propenylene or butenylene. Preferred is C2 to C3 straight alkenylene, for example, vinylene or propenylene.

[0061] "alkyl" means C1 to C10 straight or branched chain alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, isohexyl, n-heptyl, n-octyl, n-nonyl, n-decyl. Preferred is C1 to C6 alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, isohexyl.

[0062] "alkenyl" means C2 to C8 straight or branched chain alkenyl derived from the above "alkyl" having one or more double, for example, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 3-methyl-2-butenyl.

[0063] "aryl" means monocyclic aromatic hydrocarbon group (e.g., phenyl) or polycyclic aromatic hydrocarbon group (e.g., 1-naphthyl, 2-naphthyl, 1-anthryl, 2-anthryl, 9-anthryl, 1-phenantryl, 2-phenantryl, 3-phenantryl, 4-phenantryl, 9-phenantryl). Preferred is phenyl or naphthyl (e.g., 1-naphthyl, 2-naphthyl).

[0064] "heteroaryl" means monocyclic aromatic heterocyclic group and condensed aromatic heterocyclic group.

[0065] "monocyclic aromatic heterocyclic group" means 5- to 8-membered aromatic ring which may contain 1 to 4 of O, S and/or N atom and has a bonding radical at any substitutable position.

[0066] "condensed aromatic heterocyclic group" is a condensed ring formed by condensing a 5- to 8-membered aromatic ring which may contain 1 to 4 of O, S and/or N atom with a 1 to 4 of 5- to 8-membered aromatic carbocycle or the other 5- to 8-membered aromatic heterocycle, and the condensed ring has a bonding radical at any substitutable position.

[0067] Examples of "heteroaryl" include furyl (e.g., 2-furyl, 3-furyl), thienyl (e.g., 2-thienyl, 3-thienyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), imidazolyl (e.g., 1-imidazolyl, 2-imidazolyl, 4-imidazolyl), pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), triazolyl (e.g., 1, 2, 4-triazole-1-yl, 1,2,4-triazole-3-yl, 1,2,4-triazole-4-yl), tetrazolyl (e.g., 1-tetrazolyl, 2-tetrazolyl, 5-tetrazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), thiadiazolyl, isothiazolyl (e.g., 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), furazanyl (e.g., 3-furazanyl), pyradinyl (e.g., 2-pyradinyl), oxadiazolyl (e.g., 1, 3, 4-oxadiazole-2-yl), benzofuryl (e.g., 2-benzo[b]furyl, 3-benzo[b]furyl, 4-benzo[b]furyl, 5-benzo[b]furyl, 6-benzo[b]furyl, 7-benzo[b]furyl), benzo thienyl (e.g., 2-benzo[b]thienyl, 3-benzo[b]thienyl, 4-benzo[b]thienyl, 5-benzo[b]thienyl, 6-benzo[b]thienyl, 7-benzo[b]thienyl), benzimidazolyl (e.g., 1-benzoimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl), dibenzo furyl, benzooxazolyl, quinoxalyl (e.g., 2-quinoxalyl, 5-quinoxalyl, 6-quinoxalyl), cinnolyl (e.g., 3-cinnolyl, 4-cinnolyl, 5-cinnolyl, 6-cinnolyl, 7-cinnolyl, 8-cinnolyl), quinazolyl (e.g., 2-quinazolyl, 4-quinazolyl, 5-quinazolyl, 6-quinazolyl, 7-quinazolyl, 8-quinazolyl), quinolyl (e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), phthalazinyl (e.g., 1-phthalazinyl, 5-phthalazinyl, 6-phthalazinyl), isoquinolyl (e.g., 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), purinyl, pteridinyl (e.g., 2-pteridinyl, 4-pteridinyl, 6-pteridinyl, 7-pteridinyl), carbazolyl, phenanthridinyl, acridinyl (e.g., 1-acridinyl, 2-acridinyl, 3-acridinyl, 4-acridinyl, 9-acridinyl), indolyl (e.g., 1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), isoindolyl, phenazinyl (e.g., 1-phenazinyl, 2-phenazinyl) or phenothiadiazinyl (e.g., 1-phenothiadiazinyl, 2-phenothiadiazinyl, 3-phenothiadiazinyl, 4-phenothiadiazinyl).

[0068] "cycloalkyl" means C3 to C10 cyclic saturated hydrocarbon group, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl. Preferred is C3 to C6 cycloalkyl, for example, cyclopentyl, cyclohexyl.

[0069] "cycloalkenyl" means C3 to C10 cyclic non-aromatic hydrocarbon group, for example, cyclopropenyl (e.g.,

1-cyclopropenyl), cyclobutenyl (e.g., 1-cyclobutenyl), cyclopentenyl (e.g., 1-cyclopenten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl), cyclohexenyl (e.g., 1-cyclohexene-1-yl, 2-cyclohexene-1-yl, 3-cyclohexene-1-yl), cycloheptenyl (e.g., 1-cycloheptenyl), cycloctenyl (e.g., 1-cycloctenyl). Preferred is 1-cyclohexene-1-yl, 2-cyclohexene-1-yl, 3-cyclohexene-1-yl.

[0070] "heterocycle" means non-aromatic heterocyclic group which contains at least one of N, O, and S atom and has a bonding radical at any substitutable position, for example, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, piperidino, 2-piperidino, 3-piperidil, 4-piperidil, 1-piperazinyl, 2-piperazinyl, 2-morpholinyl, 3-morpholinyl, morpholino, tetrahydropyranyl. The "non-aromatic heterocyclic group" is saturated or unsaturated.

[0071] The alkyl of "alkoxy" is the same as above "alkyl", and "alkoxy" includes for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy. Preferred is methoxy, ethoxy.

[0072] "alkoxycarbonyl" means carbonyl substituted with the above "alkoxy", including for example, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl.

[0073] "alkoxyalkyl" means the above "alkyl" substituted with the above "alkoxy", including for example, methoxymethyl, ethoxymethyl, n-propoxymethyl, isopropoxymethyl, n-butoxymethyl, isobutoxymethyl, tert-butoxymethyl, methoxyethyl, ethoxyethyl, n-propoxyethyl, isopropoxyethyl, n-butoxyethyl, isobutoxyethyl, tert-butoxyethyl.

[0074] "alkynyl" means C2 to C8 alkynyl derived from the above "alkyl" having one or more of triple bond, including for example, ethynyl, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl, 3-butylnyl.

[0075] "alkylsulfonyl" means sulfonyl substituted with the above "alkyl", including for example, methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, n-pentylsulfonyl, isopentylsulfonyl, neopentylsulfonyl, tert-pentylsulfonyl, n-hexylsulfonyl, isohexylsulfonyl, n-heptylsulfonyl, n-octylsulfonyl, n-nonylsulfonyl, n-desylsulfonyl.

[0076] "optionally substituted amino" is substituted or unsubstituted amino.

[0077] "optionally substituted carbamoyl" is substituted or unsubstituted carbamoyl.

[0078] Examples of the substituent of "optionally substituted amino" and "optionally substituted carbamoyl" includes alkyl (e.g., methyl, ethyl, dimethyl), alkoxyalkyl (e.g., ethoxymethyl, ethoxyethyl), acyl (e.g., formyl, acetyl, benzoyl, toluoyl), aralkyl (e.g., benzyl, trityl), hydroxy.

[0079] "alkylthio" means sulfur atom substituted with the above "alkyl", including for example, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio, n-pentylthio, isopentylthio, neopentylthio, tert-pentylthio, n-hexylthio, isohexylthio, n-heptylthio, n-octylthio, n-nonylthio, n-desylthio. Preferred is sulfur atom substituted with C1 to C6 alkyl.

[0080] "alkylthioalkyl" means the above "alkyl" substituted with the above "alkylthio", including for example, methylthiomethyl, ethylthiomethyl, n-propylthiomethyl, isopropylthiomethyl, n-butylthiomethyl, isobutylthiomethyl, sec-butylthiomethyl, tert-butylthiomethyl, n-pentylthiomethyl, isopentylthiomethyl, neopentylthiomethyl, tert-pentylthiomethyl, n-hexylthiomethyl, isohexylthiomethyl, n-heptylthiomethyl, n-octylthiomethyl, n-nonylthiomethyl, n-desylthiomethyl, methylthioethyl, ethylthioethyl, n-propylthioethyl, isopropylthioethyl, n-butylthioethyl, isobutylthioethyl, sec-butylthioethyl, tert-butylthioethyl, n-pentylthioethyl, isopentylthioethyl, neopentylthioethyl, tert-pentylthioethyl, n-hexylthioethyl, isohexylthioethyl, n-heptylthioethyl, n-octylthioethyl, n-nonylthioethyl, n-desylthioethyl. Preferred is C1 to C6 alkylthio.

[0081] "haloalkyl" means the above "alkyl" substituted with one or more of halogen. Preferred is halogenated C1 to C3 alkyl, for example, trifluoromethyl, chloromethyl, dichloromethyl, 1,1-dichloroethyl, 2,2,2-trichloroethyl.

[0082] "haloalkoxy" means O substituted with the above "haloalkyl", including for example, trifluoromethoxy, chloromethoxy, dichloromethoxy, 1,1-dichloroethoxy, 2,2,2-trichloroethoxy.

[0083] "haloalkoxyalkyl" means the above "alkyl" substituted with the above "haloalkoxy", including for example, trifluoromethoxymethyl, chloromethoxymethyl, dichloromethoxymethyl, 1,1-dichloroethoxymethyl, 2,2,2-trichloroethoxymethyl, trifluoromethoxyethyl, chloromethoxyethyl, dichloromethoxyethyl, 1,1-dichloroethoxyethyl, 2,2,2-trichloroethoxyethyl.

[0084] "alkylcarbonyl" means carbonyl substituted with the above "alkyl", including for example, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl, lauroyl.

[0085] "alkylcarbonyloxy" means O substituted with the above "alkylcarbonyl", including for example, acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, valeryloxy, isovaleryloxy, pivaloyloxy, hexanoyloxy, octanoyloxy, lauroyloxy.

[0086] "aralkyl" means the above "alkyl" substituted with 1 to 3 of the above "aryl", including for example, benzyl, diphenylmethyl, triphenylmethyl, phenetyl, 1-naphthylmethyl, 2-naphthylmethyl.

[0087] "heteroarylalkyl" means the above "alkyl" substituted with 1 to 3 of the above "heteroaryl". Preferred is heteroarylalkyl having C1 to C4 alkyl, esp., C1 or C2 alkyl, for example, furylmethyl, thienylmethyl, pyrrolylmethyl, imidazolylmethyl, pyrazolylmethyl, triazolylmethyl, tetrazolylmethyl, oxazolylmethyl, isoxazolylmethyl, thiazolylmethyl, thia-

diazolylmethyl, isothiazolylmethyl, pyridyl methyl, pyridazinylmethyl, pirimidinylmethyl, furazanylmethyl, pyrazinylmethyl, ozadiazolylmethyl, benzofurylmethyl, benzothienylmethyl, benzimidazolyl methyl, dibenzofurylmethyl, benzoxazolylmethyl, quinoxalilmethyl, cinnolinylmethyl, quinazolilmethyl, quinolilmethyl, phthalazinylmethyl, isoquinolylmethyl, purilmethyl, pteridinylmethyl, carbazolylmethyl, phenantridinylmethyl, acridinylmethyl, indolyl methyl, isoindolylmethyl, phenadinylmethyl, phenothiadinylmethyl, furylethyl, thienylethyl, pyrrolylethyl, imidazolylethyl, pyrazolylethyl, triazolylethyl, tetrazolylethyl, oxazolylethyl, isoxazolylethyl, thiazolylethyl, thiadiazolylethyl, isothiazolylethyl, pyridylethyl, pyridazinylethyl, pirimidinylethyl, furazanylethyl, pyrazinylethyl, oxadiazolylethyl, benzofurylethyl, benzothienylethyl, benzimidazolyl ethyl, dibenzofurylethyl, benzoxazolylethyl, quinoxalylethyl, cinnolinylethyl, quinazolilethyl, quinolilethyl, phthalazinylethyl, isoquinolilethyl, purilethyl, pteridinylethyl, carbazolylethyl, phenantridinylethyl, acridinylethyl, indolyl ethyl, isoindolylethyl, phenadinylethyl or phenothiadinylethyl.

[0088] In the definitions of "aryloxy", "heteroaryloxy", "arylthio", "heteroarylthio", "aralkyloxy", "heteroarylalkyloxy", "aralkylthio", "heteroarylalkylthio", "aryloxyalkyl", "heteroaryloxyalkyl", "arylthioalkyl", "heteroarylthioalkyl", "arylsulfonyl", "heteroarylsulfonyl", "aralkylsulfonyl" and "heteroarylalkylsulfonyl", each term of "aryl", "aralkyl", "heteroaryl", "heteroaryl alkyl" and "alkyl" is the same as mentioned above.

[0089] Each group of "optionally substituted alkylene", "optionally substituted alkenylene", "optionally substituted alkyl", "optionally substituted alkenyl", "optionally substituted aryl", "optionally substituted heteroaryl", "optionally substituted cycloalkyl", "optionally substituted cycloalkenyl", "optionally substituted heterocycle", "optionally substituted aralkyl", "optionally substituted heteroarylalkyl", "optionally substituted aryloxy", "optionally substituted heteroaryloxy", "optionally substituted arylthio", "optionally substituted heteroarylthio", "optionally substituted aralkyloxy", "optionally substituted heteroarylalkyloxy", "optionally substituted aralkylthio", "optionally substituted heteroarylalkylthio", "optionally substituted aryl oxyalkyl", "optionally substituted heteroaryloxyalkyl", "optionally substituted aryl thioalkyl", "optionally substituted heteroarylthioalkyl", "optionally substituted arylsulfonyl", "optionally substituted heteroarylsulfonyl", "optionally substituted aralkylsulfonyl" and "optionally substituted heteroarylalkylsulfonyl" may have 1 to 4, same or different substituent at any substitutable position. The substituent is selected from those which do not interfere with the integraseinhibitory activity, as well as the case of above mentioned "non-interfering substituent". Examples of the substituent include hydroxy, carboxy, halogen (F, Cl, Br, I), haloalkyl (e.g. CF₃, CH₂CF₃, CH₂CCl₃), alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy), alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl), nitro, nitroso, optionally substituted amino (e.g., alkylamino (e.g., methylamino, ethylamino, dimethylamino), acylamino (e.g., acetyl amino, benzoylamino), aralkylamino (e.g., benzylamino, tritylamino), hydroxy amino), azide, aryl (e.g., phenyl), aralkyl (e.g., benzyl), cyano, isocyano, isocyanate, thiocyanate, isothiocyanate, mercapto, alkylthio (e.g., methylthio), alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl), optionally substituted carbamoyl, sulfamoyl, acyl (e.g., formyl, acetyl), formyloxy, haloformyl, oxazolo, thioformyl, thiocarboxy, dithio carboxy, thiocarbamoyl, sulfinio, sulfoamino, hydrazino, azide, ureido, amidino, guanidino.


[0090] In the definition of R¹, the substituent of "optionally substituted aryl", "optionally substituted heteroaryl", "optionally substituted cycloalkyl", "optionally substituted cycloalkenyl", and "optionally substituted heterocycle" is preferably hydroxy, carboxy, halogen (F, Cl, Br, I), haloalkyl (e.g., CF₃, CH₂CF₃, CH₂CCl₃), alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy), alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl), nitro, optionally substituted amino (e.g., alkylamino (e.g., methylamino, ethylamino, dimethylamino), acylamino (e.g., acetyl amino, benzoylamino), aralkylamino (e.g., benzylamino, tritylamino), hydroxy amino), azide, aryl (e.g., phenyl), aralkyl (e.g., benzyl), cyano, mercapto, alkylthio (e.g., methylthio), alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl), optionally substituted carbamoyl, sulfamoyl, acyl (e.g., formyl, acetyl), formyl oxy, thiocarbamoyl, sulfoamino, hydrazino, azide, ureido, amidino, guanidino. More preferred is alkyl, haloalkyl, halogen (e.g., F, Cl, Br), alkoxy and further preferred is methoxy. Preferred is mono- or disubstituted one.

[0091] In the definition of Z¹, Z² and Z³, the substituent of "optionally substituted alkylene" and "optionally substituted alkenylene" is preferably hydroxy, carboxy, halogen (e.g., F, Cl, Br, I), haloalkyl (e.g., CF₃, CH₂CF₃, CH₂CCl₃), alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy), alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl), optionally substituted amino (e.g., alkylamino (e.g., methylamino, ethyl amino, dimethylamino), acylamino (e.g., acetyl amino, benzoylamino), aralkylamino (e.g., benzylamino, tritylamino), hydroxy amino), aryl (e.g., phenyl), aralkyl (e.g., benzyl), cyano, mercapto, alkylthio (e.g., methylthio), alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl), optionally substituted carbamoyl, sulfamoyl, acyl (e.g., formyl, acetyl), formyloxy, thiocarbamoyl, sulfoamino, hydrazino, azide, ureido, amidino, guanidino.

[0092] When a non-interfering substituent is "optionally substituted aryl", "optionally substituted heteroaryl", "optionally substituted cycloalkyl", "optionally substituted cycloalkenyl", "optionally substituted heterocycle", "optionally substituted aralkyl", "optionally substituted heteroarylalkyl", "optionally substituted aryloxy", "optionally substituted heteroaryloxy", "optionally substituted arylthio", "optionally substituted heteroarylthio", "optionally substituted aralkyloxy",

"optionally substituted heteroaryl alkyloxy", "optionally substituted aralkylthio", "optionally substituted heteroaryl alkylthio", "optionally substituted aryl oxyalkyl", "optionally substituted heteroaryl oxyalkyl", "optionally substituted aryl thioalkyl", "optionally substituted heteroaryl thioalkyl", "optionally substituted arylsulfonyl", "optionally substituted heteroarylsulfonyl", "optionally substituted aralkylsulfonyl" or "optionally substituted heteroaryl alkylsulfonyl", the substituent is preferably hydroxy, carboxy, halogen (e.g., F, Cl, Br, I), haloalkyl (e.g., CF₃, CH₂CF₃, CH₂CCl₃), alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy), alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl), nitro, optionally substituted amino (e.g., alkylamino (e.g., methylamino, ethyl amino, dimethylamino), acylamino (e.g., acetyl amino, benzoylamino), aralkylamino (e.g., benzylamino, tritylamino), hydroxyamino), azide, aryl (e.g., phenyl), aralkyl (e.g., benzyl), cyano, mercapto, alkylthio (e.g., methylthio), alkylsulfonyl (e.g., methanesulfonyl, etahnesulfonyl), optionally substituted carbamoyl, sulfamoyl, acyl (e.g., formyl, acetyl), formyloxy, thiocarbamoyl, sulfoamino, hydrazino, azide, ureido, amidino, guanidino. More preferred is alkyl, haloalkyl, halogen (e.g., F, Cl, Br), alkoxy (e.g., methoxy). Preferred is mono- or di-substituted one.

[0093] The present invention includes the above mentioned compounds, prodrug, pharmaceutically acceptable salt and solvate thereof, as well as all tautomers and geometrical isomers. For example, keto/enol tautomers of the formula (I) are included in the present invention compounds. The compounds of formula (XIII-1) and (XIII-2) may include the following tautomers:



[0094] A prodrug is a derivative of a compound of the present invention having a group which can be decomposed chemically or metabolically, and such a prodrug is converted to a pharmaceutically active compound of the present invention by means of solvolysis or by placing the compound in vivo under a physiological condition. Method for the selection and process of an appropriate prodrug derivative are described in the literature such as Design of Prodrugs, Elsevier and Amsterdam 1985.

[0095] It is known that HIV multiplies vigorously in a lymph node even in the asymptomatic term. Thus a prodrug of a compound of the present invention is preferably a lymph-directivity one. The diseases caused by HIV include AIDS cerebrum symptom. Thus a preferable prodrug of a compound of the present invention is a brain-directivity one. As these lymph-directivity prodrug and brain-directivity prodrug, the following prodrugs with high lipophilicity are preferable.

[0096] When a compound of the present invention has a carboxyl group, an ester derivative prepared by reacting a basal acid compound with a suitable alcohol or an amide derivative prepared by reacting a basal acid compound with a suitable amine is exemplified as a prodrug. A especially preferred ester derivative as a prodrug is methylester, ethylester, n-propylester, isopropylester, n-butylester, isobutylester, tert-butylester, morpholinoethylester or N,N-diethylglycolamidoester.

[0097] When a compound of the present invention has a hydroxy group, an acyloxy derivative prepared by reacting a compound having a hydroxyl group with a suitable acylhalide or a suitable acid anhydride is exemplified as a prodrug. A especially preferred acyloxy derivative as a prodrug is -O(=O)-CH₃, -OC(=O)-C₂H₅, -OC(=O)-(tert-Bu), -OC(=O)-C₁₅H₃₁, -OC(=O)-(m-COONa-Ph), -OC(=O)-CH₂CH₂COONa, -O(C=O)-CH(NH₂)CH₃ or -OC(=O)-CH₂-N(CH₃)₂.

[0098] When a compound of the present invention has an amino group, an amide derivative prepared by reacting a compound having amino with a suitable acid halide or a suitable acid anhydride is exemplified as a prodrug. A especially preferred amide derivative as a prodrug is -NHC(=O)-(CH₂)₂₀CH₃ or -NHC(=O)-CH(NH₂)CH₃.

[0099] For example, a prodrug can be produced by the chemical modification of Y. For example, Y is substituted with acyl and it is examined whether the prodrug is converted to a compound of the present invention by means of solvolysis or by placing the compound under a physiological condition or not. Therefore, even if Y is a substituent except for hydroxy, mercapto or amino, a compound converted to hydroxy, mercapto or amino by means of solvolysis or by placing the compound under a physiological condition is contained in prodrugs of the present invention and the present invention. For example, a compound converted to the present invention compound in phosphate buffer (pH7.4)-ethanol or plasma is a compound of the present invention.

[0100] Pharmaceutically acceptable salts of a compound of the present invention include, as basic salts, for example, alkali metal salts such as sodium or potassium salts; alkaline-earth metal salts such as calcium or magnesium salts;

ammonium salts; aliphatic amine salts such as trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine or procaine salts; aralkyl amine salts such as N, N-dibenzylethylenediamine salts; heterocyclic aromatic amine salts such as pyridine salts, picoline salts, quinoline salts or isoquinoline salts; quaternary ammonium salts such as tetramethylammonium salts, tetraethylammonium salts, benzyltrimethylammonium salts, benzyltriethylammonium salts, benzyltributylammonium salts, methyltrioctylammonium salts or tetrabutylammonium salts; and basic amino acid salts such as arginine salts or lysine salts. Acid salts include, for example, mineral acid salts such as hydrochloride, sulfates salts, nitrate salts, phosphates salts, carbonates salts, hydrogencarbonates or perchlorate; organic acid salts such as acetates, propionates, lactates, maleates, fumarates, tararic acid salts, malates, citrates salts, or ascorbates; sulfonates such as methanesulfonates, isethionates, benzenesulfonates, or p-toluenesulfonates; and acidic amino acid salts such as aspartates or glutamates.


[0101] Furthermore, various solvates of a compound of the present invention, for example, monosolvate, disolvate, monohydrate or dihydrate are also within the scope of the present invention.

[0102] The term "inhibit" means that a compound of the present invention suppresses the action of integrase.

[0103] The term "pharmaceutically acceptable" means harmless with respect to the prevention and the treatment.

Best Mode for Carrying Out the Invention

[0104] The general method for the production of a compound of the present invention is explained below.



(wherein, C ring, R⁵, Y, Z and the broken line are the same as above; L¹ and L² are leaving groups such as alkoxy; Hal is halogen; n is an integer of 0 or more, C ring may be substituted with a group of the formula : -Z¹-Z²-Z³-R¹ (wherein Z¹, Z², Z³ and R¹ are the same as above) and/or a non-interfering substituent.)

Process A1

[0105] This process is for reacting compound of the formula (A1) with compound of the formula : R⁵NH₂ to give compound of the formula (B1).

[0106] Examples of compound of the formula (A1) include heteroarylalkyl halides.

[0107] Examples of compound of the formula : R⁵NH₂ include alkylamine (e.g., methylamine, ethylamine, n-propylamine, isopropylamine, n-butylamine, tert-butylamine, 2-ethylpropyl), cycloalkylamine (e.g., cyclohexylamine), arylamine (e.g., aniline), alkoxyamine (e.g., tert-butoxyamine), aralkylamine (e.g., benzylamine).

[0108] Examples of solvent include dimethylformamide, alcohol (e.g., methanol, ethanol).

[0109] This process may be conducted in the presence of base (e.g. sodium hydrogencarbonate, potassium carbonate).

Process B


[0110] This process is for reacting compound of the formula (B1) with compound of the formula : L¹-C(=Y)-C(=Z)-L² in the presence of base to give compound of the formula (I-A).

[0111] Examples of compound of the formula : L¹-C(=Y)-C(=Z)-L² include oxalic acid dimethyl, oxalic acid diethyl.

[0112] Examples of base include metal alcoholate (e.g. sodium methoxide, sodium ethoxide).

[0113] Examples of reaction solvent include alcohol (e.g., methanol, ethanol).

[0114] Compound (B1) can be prepared by the following process.



(wherein, C ring, n, R^5 and the broken line are the same as defined above)

15 Process A2


[0115] This process is for reacting compound of the formula (A2), in the presence of a reductant, with compound of the formula : R^5NH_2 to give compound of the formula (B1).

[0116] Examples of compound of the formula (A2) include heteroarylalkyl.

[0117] Examples of compound of the formula : R^5NH_2 include amine as used in Process A 1.

[0118] Examples of reductant include $NaBH_3CN$.

[0119] Examples of reaction solvent include alcohol (e.g., methanol, ethanol).



(wherein, C ring, R^5 and the broken line are the same as above)


35 Process A3

[0120] This process is for reacting compound of the formula (A3) with compound of the formula: R^5NH_2 to give compound of the formula (B2).

[0121] Examples of compound of the formula (A3) include vinyl pyrimidine (e.g., 4-vinyl-6-phenethylpyrimidine).

[0122] Examples of compound of the formula : R^5NH_2 include amine as used in Process A 1.

[0123] Examples of reaction solvent include alcohol (e.g., methanol, ethanol).



(wherein, Y , Z , R^5 , n are the same as above ; R is of the formula : $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as above) or a non-interfering substituent)

Process C

[0124] This process is for condensing compound of the formula (C) with compound of the formula : $R-C(=O)-NH-NH_2$ to give compound of the formula (D). Y is preferably protected in advance.

[0125] Examples of compound of the formula (C) include 2,5-dihydro-1-isopropyl-5-oxo-4-hydroxy-1H-pyrrole-3-carboxylic acid, and examples of its protected type include 2,5-dihydro-1-isopropyl-5-oxo-4-methoxy-1H-pyrrole-3-carboxylic acid.

[0126] Examples of compound of the formula : $R-C(=O)-NH-NH_2$ include acetyl hydrazine (e.g., phenylacetyl hydrazine, *p*-fluorophenylacetyl hydrazine).

[0127] Examples of condensing agent include DCC (dicyclohexylcarbodiimide), WSCD (1-ethyl-3-(3-dimethylamino-propyl)carbodiimide), HOBt (1-hydroxybenzotriazole),

[0128] Examples of reaction solvent include tetrahydrofuran, dimethylformamide.

Process D



[0129] This process is for halogenating compound of the formula (D), followed by treating with a base, to give compound of the formula (I-B).

[0130] Halogenation can be conducted by reacting compound of the formula (D) with bromine or the like in the presence of triphenylphosphine.

[0131] Examples of base include triethylamine.

[0132] Examples of reaction solvent include methylene chloride.

[0133] In Process C and D where Y is protected in advance, deprotection of Y can be conducted by reacting trimethylsilyl chloride in the presence of NaI in acetonitrile.




15 (wherein, R^5 , Y, Z, n, R^B and Hal are the same as defined above. R^B is optionally substituted with a group of the formula : $-\text{Z}^1\text{-Z}^2\text{-Z}^3\text{-R}^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as above) and/or a non-interfering substituent.)

20 Process E 1

[0134] This process is for reacting compound of the formula (E1) with compound of the formula : R^5NH_2 to give compound of the formula (F1), according to Process A 1.

25 Process F



[0135] This process is for reacting compound of the formula (F1) with compound of the formula : $\text{L}^1\text{-C(=Y)-C(=Z)-L}^2$ in the presence of a base to give compound of the formula (I-C), according to Process B.



40 (wherein, R^B , R^5 and X are the same as defined above)

Process E2

45 [0136] This process is for reacting compound of the formula (E2) with compound of the formula : R^5NH_2 to give compound of the formula (F), according to Process A 3.



(wherein, n, R⁵, X, R^B, Hal and Y are the same as above; L is a leaving group)

Process G1

[0137] This process is for reacting compound of the formula (G1) with compound of the formula : R⁵NH₂ to give compound of the formula (H1), according to Process E1.

Process H


[0138] This process is for reacting compound of the formula (H1) with compound of the formula R^BLi to give compound of the formula (H1). The amino group in the formula (H1) is preferably protected in advance.

[0139] Examples of compound of the formula (H1) include 3-alkylamino propanic acid methylmethoxyamide (e.g., 3-methylamino propanic acid methylmethoxyamide, 3-ethyl amino propanic acid methylmethoxyamide, 3-n-propylamino propanic acid methylmethoxyamide, 3-n-butylamino propanic acid methylmethoxyamide, 3-ethyl propylamino propanic acid methylmethoxyamide, 3-tert-butylamino propanic acid methylmethoxyamide), 3-cycloalkyl amino propanic acid methylmethoxyamide (e.g., 3-cyclopropylaminopropanic acid methylmethoxyamide, 3-cyclopentylaminopropanic acid methylmethoxyamide, 3-cyclohexylaminopropanic acid methylmethoxyamide), 3-alkoxyaminopropanic acid methylmethoxyamide (e.g., 3-(2-methoxyethyl amino)propanic acid methylmethoxyamide), 3-alkenyl amino propanic acid methylmethoxyamide (e.g., 3-allylamino propanic acid methylmethoxyamide), 3-heterocyclealkylamino propanic acid methylmethoxyamide (e.g., 3-pyrrolidil propanic acid methylmethoxyamide, 3-morpholil ethyl propanic acid methylmethoxyamide). Examples of its protected type include compounds wherein the amino group is protected with Boc group (tert-butoxycarbonyl). The protection can be conducted by reacting compound of the formula (H1) with Boc₂O in an alcohol (e.g., methanol, ethanol).

[0140] Examples of compound of the formula : R^BLi include 5-(p-fluorobenzyl)fron-2-yllithium. Compound of the formula : R^BLi can be prepared by reacting compound of the formula : R^BBr with butyl lithium.

Process J


[0141] This process is for reacting compound of the formula (J) with compound of the formula : L¹-C(=Y)-C(=Z)-L² in the presence of a base to give compound of the formula (I-D), according to Process B and Process F.



(wherein, L, R⁵ and X are the same as defined above)

Process G2

[0142] This process is for reacting compound of the formula (G2) with compound of the formula : R⁵NH₂ to give compound of the formula (H2), according to Process A 3 and Process E 2.



(wherein, X is O ; Y is hydroxy ; Z is O ; R⁶, R⁷, R⁵ and R¹⁹ are non-interfering substituents ; L is a leaving group ; R^B, Z¹, Z², Z³ and R¹ are the same as above (1))

Process K

[0143] This process is for reacting compound of the formula (K) with compound of the formula : R⁵NH₂ and compound of the formula: R¹⁹CHO to give compound of the formula (III), according to Zhurnal Organicheskoi Khimii, Vol. 22, No. 8, pp. 1749-1756.

[0144] Examples of compound of the formula (K) include that wherein, R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, or optionally substituted heterocycle, such as 2-hydroxy-4-oxo-4-aryl-2-butenic acid alkyl ester, 2-hydroxy-4-oxo-4-heteroaryl-2-butenic acid alkyl ester, 2-hydroxy-4-oxo-4-cycloalkyl-2-butenic acid alkyl ester, 2-hydroxy-4-oxo-4-cycloalkenyl-2-butenic acid alkyl ester, 2-hydroxy-4-oxo-4-heterocycle-2-butenic acid alkyl ester wherein the aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycle are substituted with a group of the formula: -Z¹-Z²-Z³-R¹ (wherein, Z¹, Z², Z³ and R¹ are the same as defined above). Examples thereof include 4-(4-benzyloxybenzyl)-2-hydroxy-4-oxo-2-butenic acid methylester, 4-[4-(4-fluorobenzyloxy)benzyl]-2-hydroxy-4-oxo-2-butenic acid methylester, 4-(5-benzylfranzyl)-2-hydroxy-4-oxo-2-butenic acid methylester, 4-[5-(4-fluorobenzyl)franzyl]-2-hydroxy-4-oxo-2-butenic acid methylester. These compounds can be prepared according to the method described in WO00/39086.

[0145] Examples of compound of the formula : R⁵NH₂ include alkylamine (e.g., methylamine, ethyl amine, n-propylamine, isopropylamine, n-butylamine, tert-butylamine, 2-ethyl propyl), cycloalkylamine (e.g., cyclohexylamine), arylamine (e.g., aniline), alkoxyamine (e.g., tert-butoxyamine), aralkylamine (e.g., benzylamine). Compound of the formula : R⁵NH₂ may be used in an amount of 1 to 3 mol equivalent, preferably 1 to 2 mol equivalent per compound of the formula (K).

[0146] Examples of compound of the formula : R¹⁹CHO include optionally substituted arylaldehyde (e.g., benzaldehyde), optionally substituted heteroaryl aldehyde (e.g., furfural), alkylaldehyde (e.g., acetaldehyde), alkenylaldehyde, cycloalkyl aldehyde (e.g., cyclopropylaldehyde, cyclohexylaldehyde), formaldehyde and/or polymer thereof (formalin aqueous solution can be used.).

[0147] Compound of the formula : R¹⁹CHO can be used in an amount of 1 to 3 mol equivalent, preferably 1 to 2 mol equivalent per compound of the formula (K).

[0148] Examples of leaving group include alkoxy.

[0149] The reaction temperature is 0°C to 100°C, preferably room temperature to 50 °C, more preferably room temperature to 30°C.

[0150] Examples of reaction solvent include dioxane, ethanol, dimethylformamide, tetrahydrofuran, acetonitrile, or a mixture thereof. Preferred is dioxane. This process may be conducted in the presence of a base. This process is conducted for example as follows. To a solution or suspension of compound of the formula (K) in an organic solvent, were added compound of the formula : R⁵NH₂ and compound of the formula : R¹⁹CHO successively or simultaneously, and the mixture was stirred for several hours (preferably, 0.5 to 24 hours, more preferably 0.5 to 5 hour) at room temperature to 50°C. The reaction mixture was added to dil. hydrochloric acid, which was extracted with an organic solvent such as ethyl acetate, washed with saturated saline, dried, and evaporated under reduced pressure to give crystals of compound of the formula (III). Alternatively, addition of an organic solvent such as methanol or aether can

give the crystal of compound of the formula (III). In case such a crystal can not obtained, purification with silica gel chromatography gives compound of the formula (III). In addition, the adding order of each compound of the formula : R^5NH_2 , formula : $R^{19}CHO$ and the formula (K) is optional.


[0151] In this process, the present invention compound of the formula (III) can be readily prepared. Compound of the formula : R^5NH_2 or $R^{19}CHO$ can be synthesized or commercially available.

[0152] This process can be conducted by the method used in the combinatorial chemistry (e.g., parallel synthesis). For example, to each well of a plate with 96 holes, are added an organic solvent (e.g., dioxane), compound of the formula (K), compound of the formula : R^5NH_2 and compound of the formula : $R^{19}CHO$, which is shaken at room temperature to 50°C, then evaporated to remove the organic solvent to give a library of compounds of the formula (III). In this process, generation of by-products can be controlled at low level, thus the evaporation of the used organic solvent readily give an sample for the bioassay.

[0153] This process can be conducted as a routine work, thus useful for preparing lots of compounds having various substituents in a short period of time. Namely, reaction of various kinds of compounds of the formula (K), the formula : R^5NH_2 and the formula : $R^{19}CHO$, each basic structure being fixed, gives several ten to several ten thousands of compounds, from which a compound having the most suitable substituent is selected to give a compound of the present invention with high activity.

[0154] The library of the present invention compound can consists of 2 or more compounds obtained by the above method. The library means a group consisting of 2 or more compounds having a common partial structure. Examples of the common partial structure include a pyrrolinone structure. The pyrrolinone structure is preferably substituted with hydroxy and a group of the formula: $-C(=O)-R^B-Z^1-Z^2-Z^3-R^1$. A compound having such a common partial structure possesses an HIV integrase inhibitory activity and a library consisting of such compounds is useful for screening an anti-HIV agent, AIDS-treating agent etc., as well as other medicines. In order to obtain a particularly useful information on Structure Activity Relationship (SAR), the library is a group preferably consisting of 10 or more compounds, more preferably 50 or more. The library of the present invention comprises at least one compound of the present invention. Thus, a compound included in the library is very useful for screening a compound possessing a potent HIV integrase inhibitory activity.

[0155] A preferable starting material is of the formula (K) :



(wherein, X is O ; Y is hydroxy ; Z is O ; R^B is heteroaryl ; R^B is not substituted with R^6 and R^7 ; L is alkoxy ; Z and Z^3 are bonds ; Z^2 is alkylene ; R^1 is optionally substituted phenyl)

[0156] A more preferable starting material of the formula (K) is a compound wherein X is O ; Y is hydroxy ; Z is O ; R^B is heteroaryl ; R^B is not substituted with R^6 and R^7 ; L is alkoxy ; Z^1 and Z^3 are bonds ; Z^2 is methylene ; R^1 is 4-fluorophenyl. Further preferred is 4-[5-(4-fluorobenzyl)franz-2-yl]-2-hydroxy-4-oxo-2-butenic acid alkyl ester.


[0157] For use to the production of the present compound, the following compounds of the formula : R^5NH_2 or $R^{19}CHO$ can be selected from commercially available amine and aldehyde with reference to molecular weight thereof. Compound of the formula: R^5NH_2 can be selected from amine shown below:

cyclopropylamine, cyclobutylamine, cyclopentylamine, cyclohexylamine, 1-aminocyclohexan carboxylic acid, 1-ethylcyclohexylamine, 1,2-diaminocyclohexan, 2-methylcyclohexylamine, 2,3-dimethylcyclohexylamine, 4-methylcyclohexylamine, amino methylcyclohexan, 1,3-cyclohexan bis(methylamine), 1-amino-5,6,7,8-tetrahydronaphthalene, 1,2,3,4-tetrahydro-1-naphthylamine, cyclooctylamine, 2-amino-1-propene-1,1,3-tricarbonitril, diaminomaleonitril, S-methyl L-cystein, L-aspartic acid, L-leucine, DL-homoserine, D-methionine, L-allylglycine, L-glutamic acid, 2-amino-1,3,4-thiadiazole, 2-amino-5-mercapto-1,3,4-thiadiazole, 2-amino-5-ethyl-1,3,4-thiadiazole, 3,5-dimethylpyrazole-1-carboamide, 5-amino-3-methylisoxazole, 3-amino-5-methylisoxazole, 2-(2-aminoethyl)-1-methylpyrrolidine, 1-(2-aminoethyl)pyrrolidine, 1-(3-aminopropyl)-2-pyrrolidinone, furfurylamine, 1-amino indan, 5-aminoindan, 1-naphthylamine, 2-naphthylamine, cycloheptylamine, D-tert-leucine, DL-valine, DL-isoleucine, D-serine, guanidoacetic acid, creatine, D-allothreonine, 2-amino-2-methyl-1,3-propanediol,

tris(hydroxymethyl)aminomethane, DL-2-amino-3-methyl-1-nutaol, L-isoleucinol, D-leucinol, L-methioninol, DL-penicilamine, DL-cysteine, DL-homocysteine, 1-acetyl-3-thiosemicarbazide, 1-acetyl-2-thiourea, N-methylthiourea, ethyl thiourea, allylthiourea, dithioamide, histamine, 3-amino-1,2,4-triazole, 3-amino-5-mercapto-1,2,4-triazole, 3-amino-5-methylthio-1,2,4-triazole, 3,5-diamino-1,2,4-triazole, 3-aminopyrazole, 3-amino-4-cyanopyrazole, 3-aminopyrazole-4-carboxylic acid, L-prolineamide, 2-amino-2-thiazoline, 2-amino thiazole, 2-amino-5-nitrothiazole, 2-amino-4-methylthiazole, D-cycloserine, tetra hydrofurfurylamine, 2-aminopurine, 2-aminobenzimidazole, 5-aminindole, 4-amino pyrazolo[3,4-D]pyrimidine, 6-aminindazole, 8-azaadenine, 3,4-methylenedioxyaniline, N-(2-aminoethyl)piperazine, nipecotamide, 4-(aminomethyl)piperidine, 5-aminouracil, 5-azacytosine, cytosine, 5-fluorocytosine, 4-amino-2,6-dihydroxypyrimidine, 2-amino pyrimidine, 2-amino-4-chloro-6-methylpyrimidine, 2-amino-4,6-dihydroxypyrimidine, 2-amino-4-hydroxy-6-methylpyrimidine, 4-chloro-2,6-diaminopyrimidine, 2,4-diamino-6-hydroxypyrimidine, 2,4,6-triaminopyrimidine, 2-amino-4-methylpyrimidine, 2-amino-4,6-dimethylpyrimidine, 2-amino-5-nitropyrimidine, 4-aminopyrimidine, 4,5-diaminopyrimidine, 4,5-diamino-6-hydroxypyrimidine, pyrazineamide, aminopyrazine, 3-aminopyrazine E-2-carboxylic acid, 4-(2-aminoethyl)morpholine, N-(3-aminopropyl) morpholine, nicotinamide N-oxide, 3-amino-2-chloropyridine, 5-amino-2-chloro pyridine, 5-amino-2-methoxypyridine, 3-hydroxypicolineamide, 2-aminopyridine, 2-amino-3-nitropyridine, 2-amino-3-hydroxypyridine, 2-aminonicotinic acid, 2,3-diamino pyridine, 2-amino-3-methylpyridine, 2-amino-4-methylpyridine, 2-amino-4,6-dimethylpyridine, 2-amino-5-chloropyridine, 2-amino-5-nitropyridine, 6-aminonicotinic acid, 6-aminonicotinamide, 2-amino-5-methylpyridine, 2,6-diamino pyridine, 2-amino-6-methylpyridine, 6-methylnicotinamide, 2-(aminomethyl)pyridine, 2-(2-aminoethyl)pyridine, nicotinamide, thionicotinamide, 3-aminopyridine, 3,4-diaminopyridine, 3-(aminomethyl)pyridine, isonicotinamide, 4-aminopyridine, 4-(aminomethyl)pyridine, 3-amino-1,2,4-triazine, 3-amino-5,6-dimethyl-1,2,4-triazine, 1-(2-aminoethyl)piperidine, 3-aminoquinoline, 5-aminoquinoline, 6-aminoquinoline, 8-aminoquinoline, 5-aminoisoquinoline, nitroguanidine, cyanamide, thiosemicarbazide, aniline, 2-aminobenzonitril, 2-fluoroaniline, 2,4-difluoroaniline, 2,4,5-trifluoroaniline, 2,4,6-trifluoroaniline, 2,5-difluoroaniline, 2-fluoro-5-methylaniline, 2,6-difluoroaniline, 2-chloroaniline, 2-chloro-4-methylaniline, 2-chloro-5-methylaniline, 2-chloro-6-methylaniline, O-nitroaniline, O-anisidine, O-phenetidine, 2-aminophenol, 6-amino-m-cresol, 2-amino-4-chlorophenol, 2-amino-4-methylphenol, 2-aminothiophenol, 2-(methylthio)aniline, anthranilic acid, 2'-aminoacetophenone, 2-isopropenylaniline, 2-isopropylaniline, o-phenylenediamine, 3,4-diaminotoluene, 4,5-dimethyl-1,2-phenylenediamine, o-toluidine, 2,3-dimethylaniline, 4-methoxy-2-methylaniline, 2,4-dimethylaniline, 2,4,6-trimethylaniline, 2,5-dimethylaniline, 2-isopropyl-6-methylaniline, 2,6-dimethylaniline, 2-aminobenzyl alcohol, 2-ethyl-aniline, 2-ethyl-6-methylaniline, 2,6-diethylaniline, 2-aminophenetyl alcohol, 3-amino benzonitril, 3-fluoroaniline, 3-fluoro-o-anisidine, 3-fluoro-2-methylaniline, 3,4-difluoroaniline, 3-fluoro-4-methylaniline, 3,5-difluoroaniline, 5-fluoro-2-methylaniline, 3-chloroaniline, 3-chloro-2-methylaniline, 3-chloro-4-fluoroaniline, 3-chloro-4-methylaniline, 5-chloro-2-methylaniline, m-nitroaniline, m-anisidine, m-phenetidine, 3-aminophenol, 3-amino -o-cresol, 3-aminothiophenol, 3-(methylthio)aniline, 3-aminobenzoic acid, 3-amino acetophenone, 3-(1-hydroxyethyl)aniline, m-phenylenediamine, 2,6-diaminotoluene, 2,4-diaminotoluene, m-toluidine, 3,4-dimethylaniline, 3,5-dimethylaniline, 2-methoxy-5-methylaniline, 3-aminobenzyl alcohol, 3-ethylaniline, 4-aminobenzonitril, 4-fluoro aniline, 4-fluoro-2-methylaniline, 4-chloroaniline, 4-chloro-2-methylaniline, p-nitro aniline, N,N-dimethyl-p-phenylenediamine, p-anisidine, p-phenetidine, 4-amino phenol, 4-amino-m-cresol, 4-amino-2,5-dimethylphenol, 4-amino-o-cresol, 4-amino thiophenol, 4-(methylthio)aniline, 4-aminobenzoic acid, 4-aminoacetophenone, 4-tert-butylaniline, 4-isopropylaniline, p-phenylenediamine, p-toluidine, 4-amino phenylacetoneitrile, 4-ethylaniline, 4-aminophenetyl alcohol, 4-propylaniline, 4-N-butylaniline, formamide, hydroxyurea, phenylurea, cyanoacetylurea, methylurea, ethylurea, arylurea, N-butylurea, N,N-dimethylurea, 1,1-diethylurea, phenylcarbamate, tert-butylcarbamate, methylcarbamate, ethylcarbamate, butylcarbamate, benzamide, 2-fluorobenzamide, salicylamide, 2-aminobenzamide, O-toluamide, 3-fluorobenzamide, 3-aminobenzamide, m-toluamide, 4-fluorobenzamide, 4-hydroxybenzamide, 4-aminobenzamide, p-toluamide, ethyl oxamate, oxamide, 2,2,2-trifluoroacetamide, trimethylacetamide, 2,2-dichloroacetamide, 2-chloropropionamide, lactamide, methacrylamide, isobutylamide, urea, acetamide, cyanoacetamide, 2-bromo acetamide, fluoroacetamide, 2-chloroacetamide, N-acetylglucineamide, acrylamide, cinnamamide, malonamide, propionamide, 3-chloropropionamide, 2-aminoisobutanoic acid, tert-butylamine, 2-amino-2-methyl-1-propanol, tert-octylamine, 1,2-diamino-2-methylpropane, tert-amylamine, 1,1-diethylpropargylamine, thiobenzamide, (R)-(-)-2-phenylglycinol, thiourea, DL- α -methylbenzylamine, thioacetamide, 3-aminocrotonitril, methyl- 3-aminocrotonate, ethyl 3-aminocrotonate, D-alanine, 1,2-dimethylpropylamine, isopropylamine, 2-amino-1-methoxypropane, DL-2-amino-1-propanol, ethyl 3-aminobutylate, DL- β -amino-n-butanoic acid, 1,3-dimethylbutylamine, 1,2-diaminopropane, 1-methyl-3-phenylpropylamine, 2-amino-6-methylhaptane, DL-2-aminobutanoic acid, sec-butylamine, (+/-)-2-amino -1-butanol, 3-aminopentan, D-norvaline, D-norleucine, 2-aminoheptane, 2-aminooctane, methylamine, benzylamine, 2-fluorobenzylamine, 2-chlorobenzylamine, 2-methoxybenzylamine, 2-methylbenzylamine, 3-fluorobenzylamine, 3-methoxybenzylamine, 3-methylbenzylamine, m-xylyldiamine, 4-fluorobenzyl amine, 4-chlorobenzylamine, 4-methoxybenzylamine, 4-methylbenzylamine, glycine, 2,2,2-trifluoroethylamine, aminoacetaldehyde dimethyl acetal, aminoacetaldehyde diethyl acetal, 2-amino-

1-phenylethanol, DL-isoserine, 1-amino-2-propanol, 3-amino-1,2-propanediol, DL-4-amino-3-hydroxybutanoic acid, 1,3-diamino-2-hydroxypropane, 2-phenylpropylamine, DL-3-amino isobutanoic acid, isobutylamine, 2-methylbutylamine, 2-ethylhexylamine, ethylamine, N-phenylethylenediamine, N-acetythylenediamine, N-isopropylethylenediamine, N-methylethylenediamine, N-ethylethylenediamine, 2-(2-aminoethylamino)ethanol, diethylenediamine, N-(n-propyl)ethylenediamine, N,N-dimethylethylenediamine, N,N-diethylethylenediamine, tris(2-aminoethyl)amine, 2-methoxyethylamine, 2-(2-aminoethoxy)ethanol, ethanolamine, phenethylamine, thyramine, 2-(4-aminophenyl)ethylamine, 2-(p-tri l)ethylamine, taurine, propargylamine, allylamine, β -alanine, 3,3-dimethylbutylamine, isoamylamine, ethylenediamine, propylamine, N-isopropyl-1,3-propanediamine, N-methyl-1,3-propanediamine, N-(2-aminoethyl)-1,3-propanediamine, N-propyl-1,3-propanediamine, 3,3'-diaminodipropylamine, N,N-dimethyl-1,3-propanediamine, N,N-bis(3-aminopropyl)methylamine, N,N-diethyl-2,3-propanediamine, 3-isopropoxypropylamine, 3-ethoxypropylamine, 3-amino-1-propanol, 3-phenylpropylamine, 4-aminobutanoic acid, 1,3-diaminopropane, 4-amino-1-butanol, 4-phenylbutylamine, 5-aminovaleuranic acid, 1,4-diaminobutane, N-amylamine, 5-amino-1-pentanol, 6-aminocaproic acid, 1,5-diaminopentane, hexylamine, 6-amino-1-hexanol, 7-aminoheptanoic acid, 1,6-hexandiamine, n-heptylamine, 1,7-diaminoheptane, octylamine, 1,8-diaminooctane, nonylamine, cyclohexancarboamide, 2,2-dimethyl-1,3-propanediamine, 2-n-propylaniline, DL-2-amino-1-pentanol, DL-2-amino-1-hexanol, 1-(3-aminopropyl)imidazole, p-xylendiamine, 1-aminocyclopropane-1-carboxylic acid, cyanothioacetamide, 2,4-difluorobenzylamine, 2,5-difluorobenzyl amine, 2,6-difluorobenzylamine, 3,4-difluorobenzylamine, 2-methyl-3-thiosemicarbazide, 5-amino-2-methoxyphenol, 4-sec-butylaniline, 2,3-difluoroaniline, thiophene-2-carboamide, 1-amino-1-cyclopentanmethanol, 3-methyladenine, 1-methyladenine, 4-chloro-2-fluoroaniline, 5-amino-1-ethylpyrazole, 2,3-diaminotoluene, butylamine, 4-chloro-o-phenylenediamine, 1-(trimethylsilylmethyl)urea, 2,3,4-trifluoroaniline, 2-(1-cyclohexenyl)ethylamine, 3-amino-2-butenethioamide, 2,3,6-trifluoroaniline, 1,5-diamino-2-methylpentane, amidinothiourea, 3-ethynylaniline, N,N-bis(2-hydroxyethyl)ethylenediamine, 3-methoxypropylamine, 4-aminostyrene, 2-amino-6-fluorobenzonitril, 3-amino-5-hydroxypyrazole, 2,4-diamino-6-methyl-1,3,5-triazine, pyridine-2-carboamide, 1-aminoisoquinoline, 4-chloro-1,3-phenylenediamine, 2-chloroethylcarbamate, fumaramide, acetamide, N-N-butylethylenediamine, 3-butoxypropylamine, cyclopropanemethylamine, 5-aminoindazole, 2,4-diamino pyrimidine, α -ethylbenzylamine, 3-aminoisoxazole, chlorodifluoroacetamide, 1,8-diamino-3,6-dioxaoctane, 2-sec-butylaniline, 3-chlorobenzylamine, 2-fluoro-4-methylaniline, 1-(4-fluorophenyl)ethylamine, 4-aminophthalonitrile, adenine, 2-chloro-4-fluoroaniline, semicarbazide, (R)-(-)-1-cyclohexylethylamine, 5-amino-o-cresol, N,N,2,2-tetramethyl-1,3-propanediamine, 2,2-diethoxyacetamide, 3-amino-5,5-dimethyl-2-cyclohexene-1-one, propylcarbamate, glycolamide, 2-amino-1,3-propanediol, thiophene-2-ethylamine, 2,5-dimethyl-1,4-phenylenediamine, 2-amino-4-methoxy-6-methyl-1,3,5-triazine, 2-phenoxyethylamine, 4-amino-2-mercaptopyrimidine, creatinine, 2-amino-4-methoxy-6-methylpyrimidine, 3,5-difluorobenzylamine, (1R,2R)-(-)-1,2-diamino cyclohexan, (1S,2S)-(+)-1,2-diamino cyclohexan, D-aspartic acid, DL-aspartic acid, DL-leucine, D-leucine, L-homoserine, DL-methionine, L-methionine, DL-allylglycine, D-glutamic acid, L-leucinol, DL-threonine, cis-1,2-diamino cyclohexan, trans-1,2-cyclohexandiamine, L-tert-leucine, D-valine, L-valine, D-iso leucine, L-iso leucine, DL-serine, L-serine, L-allothreonine, D-threonine, L-threonine, L-valinol, D-valinol, L-cysteine, DL-cycloserine, L-cycloserine, L-asparagine, (S)-(+)-2-phenylglycinol, (R)-(+)-1-phenylethylamine, L-(-)- α -methylbenzylamine, DL-alanine, L-alanine, L-alaninol, D-alaninol, D-(-)-2-aminobutanoic acid, L- α -amino-n-butanoic acid, (R)-(-)-2-aminobutane, (S)-(+)-2-aminobutane, (S)-(+)-2-amino-1-butanol, (R)-(-)-2-amino-1-butanol, DL-norvaline, L-norvaline, DL-norleucine, L-norleucine, (R)-(-)-1-amino-2-propanol, (S)-(+)-1-amino-2-propanol, (S)-(-)-2-methylbutylamine, DL-lysine, L-lysine, DL-tert-leucine, (S)-(+)-1-cyclohexylethylamine, ethylthiooxamate, 2-amino-5-methylbenzyl alcohol, 2-amino-3-methylbenzyl alcohol, 3-amino-2-methylbenzyl alcohol, 3-fluoro-4-methoxyaniline, 3-amino-4-methylbenzyl alcohol, 5-methoxy-2-methylaniline, 2-amino-m-cresol, trans-1,4-diaminocyclohexan, 3-amino-5-methylpyrazole, 2,3-diaminophenol, 1-piperidinecarboamide, 6-amino-1-methyluracil, 3-fluorophenethylamine, 2-aminobenzylamine, 2-methoxy-6-methylaniline, 2-fluorophenethylamine, 4-aminobenzylamine, 1-acetylguanidine, D-homoserine, 2-amino-5-methylthiazole, (S)-(+)-tetrahydrofurfurylamine, 2-amino benzylcyanide, 4-amino-2-chlorophenol, 2-amino-4,5-dicyanoimidazole, 4-amino-6-methoxypyrimidine, 2-tert-butylaniline, 2-(4-fluorophenyl)ethylamine, 1,3-diamino pentane, 2-amino-1-methylbenzimidazole, 5-methylfurfurylamine, (R)-(+)-1-(p-tri l)ethylamine, (S)-(-)-1-(p-tri l)ethylamine, 3-amino-1,2,4-triazole-5-carboxylic acid, muscimol, 4-ethynylaniline, 2-amino-4-methylbenzonitril, 2-amino-5-methylthio-1,3,4-thiadiazole, 1-(aminocarbonyl)-1-cyclopropanecarboxylic acid, cis-4-amino cyclohexancarboxylic acid, (S)-(+)-2-(aminomethyl)pyrrolidine, 5-amino-4-nitro imidazole, 3-amino-1-propanol vinyl ether, thioethylenediamine, isopropyl-diethylene triamine, L-tert-leucinol, N-methyl-1,2-phenylenediamine, (R)-(-)-tetra hydrofurfurylamine, L-(-)-lactamide, (R)-(+)-lactamide, (S)-(+)-2,2-dimethylcyclopropanecarboamide, (1S,2R)-(-)-cis-1-amino-2-indanol, (1R,2S)-(+)-cis-1-amino-2-indanol, (R)-(-)-1-aminoindane, (S)-(+)-1-aminoindane, (R)-2-phenyl-1-propylamine, (S)-2-phenyl-1-propylamine, D-methioninol, (R)-2-amino-1-phenylethanol, 2-amino-4,5-dimethyl-3-furancarboxitrile, N-hexylethylenediamine, (S)-(-)-4-amino-2-hydroxybutanoic acid, (S)-3-amino-1,2-propandiol, (R)-3-amino-1,2-propandiol, 4-aminoindole, (R)-(-)-tert-leucinol and 2-amino-5-fluoro pyridine.

[0158] Compound of the formula : $R^{19}CHO$ can be selected from aldehyde shown below. formaldehyde, ethyl 2-formyl-1-cyclopropanecarboxylate, cyclohexancarboaldehyde, 1,2,3,6-tetrahydrobenzaldehyde, 1-methylpyrrole-2-carboaldehyde, furfural, 5-nitro-2-furaldehyde, 5-methylfurfural, 5-hydroxymethyl-2-furaldehyde, 3-(2-furyl)acrolein, benzaldehyde, 2-fluorobenzaldehyde, 2-chlorobenzaldehyde, o-anisaldehyde, salicylaldehyde, 3-fluoro-2-hydroxybenzaldehyde, 2,3-dihydroxybenzaldehyde, 2,5-dihydroxybenzaldehyde, o-naphthalaldehyde, o-tolaldehyde, 2,4-dimethylbenzaldehyde, mesitaldehyde, 2,5-dimethylbenzaldehyde, 3-cyano benzaldehyde, 3-fluorobenzaldehyde, 3-chlorobenzaldehyde, 3-methoxybenzaldehyde, 3-hydroxybenzaldehyde, 3,4-dihydroxybenzaldehyde, isonaphthalaldehyde, m-tolaldehyde, 4-cyanobenzaldehyde, 4-fluorobenzaldehyde, 4-chlorobenzaldehyde, 4-dimethylaminobenzaldehyde, p-anisaldehyde, imidazole-2-carboaldehyde, pyrrole-2-carboaldehyde, 2-thiophenecarboaldehyde, 3-methylthiophene-2-carboaldehyde, 5-methyl-2-thiophenecarboaldehyde, 3-thiophenecarboaldehyde, indole-3-carboaldehyde, 2-pyridinecarboaldehyde, 6-methyl-2-pyridinecarboaldehyde, 3-pyridinecarboaldehyde, 4-pyridinecarboaldehyde, 4-hydroxybenzaldehyde, terenaphthalaldehyde, cuminaldehyde, p-tolaldehyde, 4-ethylbenzaldehyde, glyoxal, glyoxylic acid, methylglyoxal, trimethylacetoaldehyde, D-(-)-erythrose, 2-phenylpropionaldehyde, methacrolein, 3-ethoxy methacrolein, alpha-methylcinnamaldehyde, trans-2-methyl-2-butenal, 2-methyl-2-pentenal, isobutylaldehyde, 2,6-dimethyl-5-hepten-1-al, 2-methylbutylaldehyde, 2-ethylbutylaldehyde, 2-methylpental, 2-ethylhexal, acetoaldehyde, chloroacetoaldehyde, phenylacetoaldehyde, phenylpropargylaldehyde, acrolein, 3-(dimethylamino)acrolein, trans-cinnamaldehyde, crotonaldehyde, 2,4-haxadienal, trans,trans-2,4-heptadienal, trans,trans-2,4-nonadienal, trans-2-hexanal, trans-2,cis-6-nonadien-1-al, trans-2-heptanal, trans-2-octanal, trans-2-nonenal, isovaleraldehyde, propionaldehyde, 3-phenylpropionaldehyde, 3-(methylthio)propionaldehyde, butylaldehyde, glutaraldehyde, valeraldehyde, haxanal, heptaldehyde, octanal, nanal, trans-2-pentenal, 2,4-dimethyl-2,6-heptadienal, 2,6-pyridinedicarboaldehyde, 2-ethylacrolein, 3-methyl-2-butenal, 2,3-difluoro benzaldehyde, 2,6-difluorobenzaldehyde, 2,4-difluorobenzaldehyde, 2,5-difluoro benzaldehyde, 3,4-difluorobenzaldehyde, 3,5-difluorobenzaldehyde, 3-fulaldehyde, 3,5,5-trimethylhaxanal, 3-phenylbutylaldehyde, 2,2-dimethyl-4-pentenal, 2,4-dihydroxybenzaldehyde, cyclopropanecarboaldehyde, 4-hydroxy-3-methylbenzaldehyde, benzo[b]furan-2-carboaldehyde, 3,5-dihydroxybenzaldehyde, 3,4-dimethylbenzaldehyde, 2-cyanobenzaldehyde, 5-ethyl-2-furaldehyde, 2-hydroxy-3-methylbenzaldehyde, 3,3-dimethylbutylaldehyde, 5-chloro-2-thiophenecarboaldehyde, 3,4-dihydro-2H-pyran-2-carboaldehyde, D-glyceroaldehyde, DL-glyceroaldehyde, 3-fluoro-2-methylbenzaldehyde, 3-dimethylamino-2-methyl-2-propenal, 3,5-dimethylbenzaldehyde, 4,5-dimethyl-2-furancarboaldehyde, 4-vinylbenzaldehyde, 2,6-dimethylbenzaldehyde, 2-octynal, dimethoxyacetoaldehyde, 2-deoxy-D-ribose, 2-formyl thiazole, 5-ethyl-2-thiophenecarboaldehyde, glyoxylic acid, 4-pyridinecarboaldehyde-N-oxide, 5-norbornen-2-carboaldehyde, 4-formylimidazole, 5-methylimidazole-4-carboaldehyde, 5-formyluracil, 2,3-thiophenedicarboaldehyde, thiophene-2,5-dicarboaldehyde, 2,3-o-isopropylidene-D-glyceroaldehyde, 2-hydroxy-5-methylbenzaldehyde, 1-cyclohexene-1-carboaldehyde, 2,3-dimethylbenzaldehyde, 1-methyl-2-imidazolecarboaldehyde, vinylbenzaldehyde, 4-fluoro-3-methylbenzaldehyde, 3-fluoro-4-methylbenzaldehyde, tetrahydrofran-3-carboaldehyde, 2-fluoro-5-formyl benzonitril, indole-5-carboaldehyde, 4-acetylbenzaldehyde, 3-vinylbenzaldehyde and 2-fluoro-5-methylbenzaldehyde.



(wherein, C ring, Z and Y are the same as above ; benzene ring and/or C ring of the formula (L) and/or (IV) are optionally substituted with a group of the formula : - $Z^1 - Z^2 - Z^3 - R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as above) and/or a non-interfering substituent.)

Process L


[0159] This process is for reacting compound of the formula (L) with hydrogen peroxide in the presence of a base to give compound of the formula (I-F).

[0160] Examples of compound of the formula (L) include 4-(benzyloxy)-2-(1-oxo-3-(2-pyridyl)-2-propenyl)phenol, 4-(p-fluorobenzyloxy)-2-(1-oxo-3-(2-pyridyl)-2-propenyl)phenol, 4-(phenetyloxy)-2-(1-oxo-3-(2-pyridyl)-2-propenyl)phenol, 4-(p-fluoro phenetyloxy)-2-(1-oxo-3-(2-pyridyl)-2-propenyl)phenol, 4-(phenetyl)-2-(1-oxo-3-(2-pyridyl)-2-propenyl)phenol, 4-(p-fluorophenetyl)-2-(1-oxo-3-(2-pyridyl)-2-propenyl)phenol.

[0161] Examples of base include 2N NaOH aq. solution.

[0162] Examples of hydrogen peroxide include 30% hydrogen peroxide.

[0163] Examples of reaction solvent include alcohol (e.g., methanol, ethanol).




15 (wherein, Y, Z, C ring are the same as above ; benzene ring and/or C ring of the formula (M) or (I-F) is optionally substituted with a group of the formula : -Z¹-Z²-Z³ - R¹ (wherein, Z¹, Z², Z³ and R¹ are the same as above) and/or a non-interfering substituent.)

Process L2

20 [0164] This process is for reacting compound of the formula (M) with a base to give compound of the formula (I-F). Y is preferably protected in advance. Examples of compound of the formula (M) include 2-(2-benzoyloxy-1-oxoethyl)-3-methoxyphenyl-2-picolinate.

[0165] Examples of base include NaH.

25 [0166] Examples of solvent include dimethylformamide.



50 (wherein, W is -O or -N(-R¹⁵)- ; L is a leaving group such as alkoxy ; Y, Z and R are the same as defined above)

Process N

55 [0167] This process is for reacting compound of the formula (N) with compound of the formula: R-C(=O)-NH-NH₂ in the presence of a condensing agent to give compound of the formula (O). Y and/or Z is preferably protected in advance. The process may be conducted as well as Process C.

[0168] Examples of compound of the formula (N) include 3-hydroxy-4-oxo-1H-quinoline-2-carboxylic acid, 3-hydroxy-4-oxo-1-methyl-1H-quinoline-2-carboxylic acid, 3-hydroxy-4-oxo-4H-chromene-2-carboxylic acid. Examples of its pro-

tected type include 2-ethoxycarbonyl-3-methoxy-1H-quinoline-4-one, 2-ethoxycarbonyl-3-methoxy-1-methyl-1H-quinoline-4-one, 3-benzyloxy-4-oxo-4H-chromene-2-carboxylic acid ethyl ester, 3-methoxy-4-oxo-4H-chromene-2-carboxylic acid ethyl ester. These compounds can be prepared according to the method of J.Heterocyclic Chem, 24, p1649, 1987.

Process M


[0169] This process is for preparing compound of the formula (I-G) from compound of the formula (O). The process, oxadiazole ring formation from diacylhydrazine, can be conducted by heating diacylhydrazine together with phosphorus oxychloride or thionyl chloride.

[0170] The reaction temperature is 50 to 100°C, preferably 80 to 100°C.

[0171] The process can also be conducted in the presence of triethylamine dibromotri phenylphospholan. In this case, the reaction temperature is 0 to 100°C, preferably 0 to 30°C. The reaction solvents include dichloromethane and tetrahydrofran.

Process O

[0172] This process is for halogenating compound of the formula (N), followed by treating with a base, to give compound of the formula (I-G), as well as Process O.




(wherein, W is -O or -N(-R¹⁵)-; Y, Z and R are the same as defined above; the benzene ring of the formula (N) or (O) is optionally substituted with a group of the formula: -Z¹-Z²-Z³-R¹ (wherein, Z¹, Z², Z³ and R¹ are the same as above) and/or a non-interfering substituent.

Process P

[0173] This process is for reacting compound of the formula (P) with compound of the formula: R-C(=O)-OH in the presence of a condensing agent to give compound of the formula (O). Y and Z are preferably protected in advance. The process can be conducted as well as Process C and Process N.

[0174] Examples of compound of the formula (P) include 2-hydrazinocarbonyl-3,4-dihydroxyquinoline. Protected types thereof include 2-hydrazinocarbonyl-3,4-dimethoxyquinoline.



(wherein, R^6 , R^7 , R^B , R^E , R^F , X and Y are the same as above ; L is a leaving group ; Q is a protecting group ; Y^A is O , S or NH_2 ; R^X is the formula : $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as above))

25 Process Q

[0175] This process is for reacting compound of the formula (Q-1) with compound of the formula (Q-2) to give compound of the formula (Q-3).

30 **[0176]** Examples of compound of the formula (Q-1) include cyclohexenon which can be prepared by the known method (Tetrahedron, 1997, 53, p8963).

[0177] Examples of compound of the formula (Q-2) include furan-2-carboxylic acid halides which can be prepared by the known method (Zhurnal Organicheskoi Khimii, Vol. 22, No. 8, pp. 1749-1756).

[0178] Examples of reaction solvent include aethers (e.g., tetrahydrofuran, dioxane) and N,N -dimethylformamide, which can be used by itself or in combination.

35 **[0179]** The process can be conducted in the presence of a base (e.g., lithium bistrimethylsilylamide) or an acid (e.g., $ZnCl_2$, $TiCl_4$, HCl).

Process R

40 **[0180]** This process is for deprotecting compound of the formula (Q-3) in the presence of an acid to give compound of the formula (R-1).


[0181] Examples of acid include hydrochloric acid and sulfuric acid.

[0182] Examples of reaction solvent include aethers (e.g., tetrahydrofuran, dioxane), alcohols (e.g., methanol, ethanol), which can be used by itself or in combination.

45

50

55



(wherein, $R^9, R^{10}, R^F, R^G, R^X$, and Y are the same as above; Y^A is O, S or NH_2 ; R^{N1} and R^{N2} are alkyl; Q is a protecting group)

Process S

[0183] This process is for reacting compound of the formula (S-1) with compound of the formula (S-2) to give compound of the formula (S-3).

[0184] Examples of compound of the formula (S-1) include pyridine carboxylic acid which can be prepared from picoline by oxidation with selenium dioxide and esterification.

[0185] Examples of compound of the formula (S-2) include protected 2-hydroxyacetic acid esters.

[0186] Examples of reaction solvent include aether (e.g., tetrahydrofuran, dioxane), N,N-dimethylformamide, which can be used by itself or in combination.

[0187] The process can be conducted in the presence of a base (e.g., lithium bistrimethylsililamide).

Process T

[0188] This process is for reacting compound of the formula (S-3) with compound of the formula (T-1) to give compound of the formula (T-2).

[0189] Examples of compound of the formula (T-1) include amidines.

[0190] Examples of reaction solvent include alcohol (e.g., methanol, ethanol).

[0191] The process can be conducted in the presence of a base (e.g., sodium methoxide).

Process U

[0192] This process is for deprotecting compound of the formula (T-2) to give compound of the formula (U-1).

[0193] Examples of reaction solvent include alcohol (e.g., methanol, ethanol), aether (e.g., tetrahydrofuran, dioxane), which can be used by itself or in combination.

[0194] The process can be conducted in the presence of an acid (e.g., hydrochloric acid, p-toluene sulfonic acid) or by adding hydrogen.


Process V

[0195] This process is for reacting compound of the formula (U-1) with a sulfurizing reagent or an amine to give compound of the formula (V-1).

[0196] Examples of sulfurizing reagent include Lawson's reagent and phosphorus pentasulfide.

[0197] Examples of amine include methylamine and morpholine.

[0198] Examples of reaction solvent include aromatic hydrocarbon (e.g., toluene, xylene), aether (e.g., tetrahydrofuran, dioxane) which can be used by itself or in combination.



(wherein, R⁵, R^{5'}, R⁶, R⁷, R^B, R^X, L, Q, X, Y and Y^A are the same as above)

Process W

[0199] This process is for reacting compound of the formula (W-1) with compound of the formula (W-2) to give compound of the formula (W-3).

[0200] Examples of compound of the formula (W-1) include pyrazolones.

[0201] Examples of compound of the formula (W-2) include those exemplified as compound of the formula (Q-2).

[0202] Examples of reaction solvent include aether (e.g., tetrahydrofuran, dioxane), N,N-dimethylformamide, which can be used by itself or in combination.

[0203] The process can be conducted in the presence of a base (e.g., n-butyllithium).

Process X


[0204] This process is for deprotecting compound of the formula (W-3) to give compound the formula (Y-1).

[0205] Examples of reaction solvent include alcohol (e.g., methanol, ethanol), aether (e.g., tetrahydrofuran, dioxane), which can be used by itself or in combination.

[0206] The process can be conducted in the presence of an acid (e.g., hydrochloric acid, -toluenesulfonic acid or by adding hydrogen).

[0207] The present invention compounds can also be prepared according to the general organic synthesis method of heterocyclyl compounds described in literatures e.g., (1) Alan R.Katriszly et al., Comprehensive Heterocyclic Chemistry, (2) Alan R.Katriszly et al., Comprehensive Heterocyclic Chemistry II, (3) RODD'S CHEMISTRY OF CARBON COMPOUNDS VOLUME IV HETEROCYCLIC COMPOUNDS.

[0208] Introduction of a group of the formula : $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as above) may be conducted before or after each of the the above processes, according to the method of WO 00/39086.



(wherein, R^6 , R^7 , R^B , R^F , R^G , R^X , L , Q , X , Y and Z are the same as above)

Process A A

[0209] This process is for reacting compound of the formula (AA-1) with compound of the formula (AA-2) in the presence of a base to give compound of the formula (AA-3).

[0210] Examples of compound of the formula (AA-1) include Boc-protected pyrrolidine 2-one which can be prepared by the known method (Tetrahedron Lett., 36, 8949-8952 (1995)).

[0211] The process can be conducted as well as Process H.


Process A B

[0212] This process is for cyclizing compound of the formula (A A- 3), optionally followed by Retroclaisen Reaction, to give compound of the formula (A B). The cyclization can be conducted as well as Process B.

[0213] The Retroclaisen Reaction can be conducted by treating with a base such as LiOH in a solvent such as tetrahydrofran.

Process AC

[0214] This process is for reacting compound of the formula (A B) with compound of the formula: R^5-L (wherein L is a leaving group) in the presence of a base to give compound of the formula (AC). The process can be conducted according to the conventional N-alkylation. For example, compound of the formula (A B) is reacted with bromoethane etc. in the presence of a base such as potassium bis(trimethylsili)amide in a solvent such as tetrahydrofran.



(wherein, R^6 , R^7 , R^B , R^F , R^G , R^{N1} , R^X , L , Q , X , Y , Y^A and Z are the same as above)

30 Process BA

[0215] This process is for dehydrating compound of the formula (B A - 1) to give compound of the formula (B A-2).

[0216] Examples of compound of the formula (B A-1) include 5-hydroxy - 6 -oxo- 1 , 2,3,6-tetrahydropyridine - 4-carboxylic acid ethyl ester, which can be prepared by the known method (Org. Prep. Proced. Int., 29, 330-335 (1997)).

35 [0217] The process can be conducted by treating compound of the formula (B A-1) with a catalytic amount of paradium carbon in a solvent such as oxylene.

Process BB

40 [0218] This process is for protecting a reactive substituent of compound of the formula (B A- 2) to give compound of the formula (B B).


[0219] Examples of a protecting group include alkyl and alkoxyalkyl, which can be introduced by the conventional protection reaction (Protective Groups in Organic Synthesis, Theodora W. Greene).

45 Process BC

[0220] This process is for converting compound of the formula (B B) into compound of the formula (B C), according to the method of Process H and Process AA.

50 Process BD and BE

[0221] These processes are for deprotecting compound of the formula (B C) to give compound of the formula (B D), followed by deprotection to give compound the formula (B E). Depending on the reaction conditions, both deprotections can be conducted at the same time. These deprotections can be conducted according to the conventional method (Protective Groups in Organic Synthesis, Theodora W. Greene).



(wherein, R, R^F, R^G, R^{N1}, L, Q, X, Y, Y^A and Z are the same as above)

Process CA

[0222] This process is for reacting compound of the formula (B B) with hydrazine to give compound of the formula (C A). The process can be conducted by reaction with hydrazine in a solvent such as ethanol.

Process CB


[0223] This process is for converting compound of the formula (C A) into compound of the formula (C B) according to the methods of Process N and Process P.

Process CC

[0224] This process is for converting compound of the formula (C B) into compound of the formula (C C) according to the method of Process M.

Process CD and CE

[0225] This process is for deprotecting compounds of the formula (CC) and (CD) according to the method of Process CD and CE.



(wherein, R^6 , R^7 , R^8 , R^E , R^F , R^{N1} , R^X , Q , X , Y , Y^A and Z are the same as above, Z^A is O, S or NH_2)

Process DA

[0226] This process is for esterifying compound of the formula (D A - 1) to give compound of the formula (D A - 2).

[0227] Examples of compound of the formula (D A - 1) include 3-hydroxy- 4-methoxypyridine - 2 -carboxylic acid which can be obtained by the known method (Tetrahedron, 54, 12745-12774 (1998)). The esterification can be conducted by the conventional method.

Process DB


[0228] This process is for protecting a reactive substituent of compound of the formula (D A - 2) to give compound of the formula (D B). The protecting group is preferably alkyl. The protection can be conducted according to the conventional method (Protective Groups in Organic Synthesis, Theodora W. Greene).

Process DC

[0229] This process is for converting compound of the formula (D B) into compound of the formula (D C) according to Process B C.

Process DD

[0230] This process is for deprotecting compound of the formula (DC) to give compound of the formula (DD), according to the conventional method (Protective Groups in Organic Synthesis, Theodora W. Greene).



(wherein, R⁵, R⁶, R⁷, R^B, R^G, R^{N1}, R^X, Q, L, X, Y, Y^A, Z and Z^A are the same as above, Hal is halogen)

Process E A

[0231] This process is for halogenating compound of the formula (E A - 1) to give compound of the formula (E A - 2). Examples of compound of the formula (E A - 1) include 5-methoxy-6-methyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid methyl ester which can be obtained by the known method (WO92/02523). The halogenation can be conventionally conducted, for example, compound of the formula (E A - 1) is heated in phosphorus oxychloride.

Process EB

[0232] This process is for substituting halogen of compound of the formula (E A - 2) with a group of Y^{AQ} to give compound of the formula (EB). Compound of the formula (E A - 2) is reacted with sodium methoxide in a solvent such as methanol.

Process EC

[0233] This process is for substituting OR^{N1} of compound of the formula (EB) with a leaving group L to give compound of the formula (EC).

Process ED

[0234] This process is for converting compound of the formula (EC) into compound of the formula (ED) according to Process B C.

Process E F

[0235] This process is for deprotecting compound of the formula (ED) to give compound of the formula (EF) according to the conventional method (Protective Groups in Organic Synthesis, Theodora W. Greene).

[0236] Use of the present invention compounds is explained below.

[0237] The present invention compound is useful for preparing a pharmaceutical composition such as antiviral agent. The present invention compound, possessing a remarkable inhibitory activity on integrase of virus, is expected to exhibit a preventing or treating effect for diseases caused by viruses which grow at least via production of integrase in infected animal cells, thus being useful as an integrase inhibitor against a retro-virus (e.g., HIV-1, HIV-2, HTLV-1, SIV, FIV) as well as an anti-HIV agent.

[0238] Further, the present invention compound can be used in combination with other anti-HIV agents having a different action of mechanism such as a reverse transcriptase inhibitor and/or a protease inhibitor. Since any of the integrase inhibitors have not been on sale, a combination therapy of the present invention compound with a reverse transcriptase inhibitor and/or a protease inhibitor is very useful.

[0239] Further, the present invention compound can be used as a combined agent for enhancing the anti-HIV activity of other HIV agents, as shown in the cocktail therapy.

[0240] Further, the present invention compound can be used in gene therapy in order to prevent a retrovirus vector derived from HIV or MLV from spreading over non-targeted tissues. In particular, in a case that cells infected with a vector in vitro is put back to a body, administration of the present invention compound in advance can prevent an unnecessary infection in the body.

[0241] The compounds of the present invention can be administered orally or parenterally. For oral administration, the compounds of the present invention can be used in any form of usual formulations, for example, solid formulations such as tablets, powders, granules, capsules; aqueous formulations; oleaginous suspensions; solutions such as syrup or elixir. For parenteral administration, the compounds of the present invention can be used as an aqueous or oleaginous suspension injection, or nose drops. In the preparation of such formulations, conventional excipients, binding agents, lubricants, aqueous solvents, oleaginous solvents, emulsifying agents, suspending agents, preservatives, stabilizers, and the like can be optionally used. Preferred is an oral agent as an HIV-agent.

[0242] A formulation according to the present invention may be manufactured by combining (for example, admixing) a curatively effective amount of a compound of the present invention with a pharmaceutically acceptable carrier or diluent. The formulation of the present invention may be manufactured with well-known and easily available ingredients in accordance with a known method.

[0243] In the case of manufacturing a pharmaceutical composition according to the present invention, an active ingredient is admixed or diluted with a carrier, or they are contained in a carrier in the form of capsule, sachet, paper, or another container. In the case of functioning a carrier as a diluent, the carrier is a solid, semi-solid, or liquid material which functions as a medium. Accordingly, a formulation according to the present invention may be produced in the form of tablet, pill, powder medicine, intraoral medicine, elixir agent, suspending agent, emulsifier, dissolving agent, syrup agent, aerosol agent (solid in liquid medium), and ointment. Such a formulation may contain up to 10% of an active compound. It is preferred to formulate a compound of the present invention prior to administration.

[0244] Any suitable carrier well known to those skilled in the art may be used for the formulation. In such formulation, a carrier is in the form of solid, liquid, or a mixture of solid and liquid. For instance, a compound of the present invention is dissolved into 4% dextrose / 0.5% sodium citrate aqueous solution so as to be 2 mg/ml concentration for intravenous injection. Solid formulation includes powder, tablet, and capsule. Solid carrier consists of one or more of material(s) for serving also as fragrant, lubricant, dissolving agent, suspension, binder, tablet disintegrator, capsule. A tablet for oral administration contains a suitable excipient such as calcium carbonate, sodium carbonate, lactose, calcium phosphate and the like together with a disintegrator such as corn starch, alginic acid and the like and/or a binder such as gelatin, acacia and the like, and a lubricant such as magnesium stearate, stearic acid, talc and the like.

[0245] In a powder medicine, a carrier is a finely pulverized solid which is blended with finely pulverized active ingredients. In a tablet, active ingredients are admixed with a carrier having required binding power in a suitable ratio, and it is solidified in a desired shape and size. Powder medicine and tablet contain about 1 to about 99% by weight of the active ingredients being novel compounds according to the present invention. Example of suitable solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth gum, methyl cellulose, sodium carboxymethylcellulose, low-melting wax, and cocoa butter.

[0246] A liquid formulation includes suspending agent, emulsifier, syrup agent, and elixir agent. Active ingredients may be dissolved or suspended into a pharmaceutically acceptable carrier such as sterile water, a sterile organic solvent, a mixture thereof and the like. Active ingredients may be dissolved frequently into a suitable organic solvent such as propylene glycol aqueous solution. When finely pulverized active ingredients are dispersed into aqueous starch, sodium carboxymethylcellulose solution, or suitable oil, the other compositions can be prepared.

[0247] Although an appropriate dosage of the compound of the present invention varies depending on the administration route, age, body weight, conditions of the patient, and kind of disease, in the case of oral administration, the daily dosage can be between approximately 0.05-3000 mg, preferably approximately 0.1-1000 mg, for an adult. The daily dosage can be administered in divisions. In the case of parenteral administration, the daily dosage for an adult can be between approximately 0.01-1000 mg, preferably approximately 0.05-500 mg.

Examples


[0248] The production method and physical data of the synthesized products are shown below. Reactions are usually carried out under nitrogen atmosphere, and reaction solvents are used as dried over molecular sieve and the like. Extracts are dried over sodium sulfate or magnesium sulfate and the like.

A group compounds

Compound A-7

4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

[0249]



(A-1) Dimethyl fumarate (30g, 0.21mol) was dissolved in acetonitrile (200ml) under heating and isopropylamine (25g, 0.42mol) was added thereto under ice cooling, then the mixture was stirred for 16 hours at room temperature. Evaporation of the solvent and the excess isopropylamine under reduced pressure gave dimethyl 2-isopropylaminosuccinate (42g, yield : 100%). NMR(CDCl₃) δ : 1.01(3H, d, J=6.0Hz), 1.05(3H, d, J=6.3Hz), 2.67(1H, t, J=9.9Hz), 2.79(1H, m), 3.69(3H, s), 3.74(3H, s), 3.68-3.75(2H, m).

(A-2) According to the method of the reference (J. Org. Chem., 1968, 33, p2051), the above-mentioned compound A-1 (42g, 0.21mol) was reacted with sodium methoxide (33g, 0.6mol) and dimethyl oxalate (25g, 0.21mol). After stirring for 16 hours at room temperature and further refluxing under heating for 2 hours, the solvent was evaporated. The dilute hydrochloric acid was added to the residue, then the precipitated crystal was filtered to give 4-hydroxyisopropyl-5-oxo-2,5-dihydro-1H-pyrrole-2,3-dicarboxylic acid dimethyl (33.6g, yield : 65%).

NMR(CDCl₃) δ : 1.20(3H, d, J=6.9Hz), 1.32(3H, d, J=6.9Hz), 3.77(3H, s), 3.85(3H, s), 4.39(1H, m), 4.78(1H, s).

(A-3) To a suspension of the above-mentioned compound A-2 (10g, 39mmol) in diethyl ether (200ml), a diethyl ether solution of diazomethane was added. After the reaction was stopped by adding acetic acid, the reaction mixture was washed and dried. The solvent was evaporated to give 1-isopropyl-4-methoxy-5-oxo-2,5-dihydro-1H-pyrrole-2,3-dicarboxylic acid dimethyl (10.2g, yield : 97%).

NMR(CDCl₃) δ : 1.18(3H, d, J=6.9Hz), 1.31(3H, d, J=6.9Hz), 3.77(3H, s), 3.78(3H, s), 4.36(3H, s), 4.30-4.40(1H, m), 4.76(1H, s).

(A-4) The above-mentioned compound A-3 (10.2g, 38mmol) was dissolved in methyl alcohol (50ml) and was added thereto the aqueous sodium hydroxide solution (sodium hydroxide 8g, water 50ml). The reaction mixture was refluxed for 1 hour. After the solvent was evaporated, water (50ml) was added to the residue. The solution was acidified with the concentrated hydrochloric acid and extracted with diethyl ether. The extract was washed and dried. The solvent was evaporated and the residue was crystallized with diisopropylether to give 1-isopropyl-4-methoxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3.9g, yield : 52%).

NMR(CDCl₃) δ : 1.24(6H, d, J=6.9Hz), 3.97(2H, s), 4.38(3H, s), 4.40-4.50(1H, m).

(A-5) The above-mentioned compound A-4 (1.6g, 8.0mmol) was dissolved in methylene chloride (30ml) and to

which was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1.5g, 9.8mmol), N,O-dimethylhydroxylamine hydrochloride (940mg, 9.6mmol), hydroxybenzimidazole (110mg, 0.8mmol) and triethylamine (1.0g, 9.9mmol). The mixture was stirred for 2 hours at room temperature. The solution was diluted with chloroform, washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate) to give 1-isopropyl-4-methoxy-5-oxo-2, dihydro-1*H*-pyrrole-3-carboxylic acid methoxymethylamide (1.5g, yield : 77%).

NMR(CDCl₃) δ : 1.22(6H, d, J=6.9Hz), 3.30(3H, s), 3.71(3H, s), 3.98(2H, s), 4.04(3H, s), 4.40-4.50(1H, m).

(A-6) Aluminum chloride (1.36g, 10mmol) was suspended in tetrahydrofuran (20ml), to which was added sodium borohydride (650mg, 17mmol) under ice cooling. After the mixture was stirred for 10 minutes, (5-bromofuran-2-yl)-(4-fluorophenyl)metanone (900mg, 3.4mmol) was added to the mixture and refluxed for 30 minutes under heating. After cooling, the reaction solution was poured into the ice water and extracted with diethyl ether. The extract was washed, dried, and evaporated to give 2-bromo-5-(4-fluorobenzyl)furan. This residue was dissolved in tetrahydrofuran, to which was added *n*-butyllithium (2.5ml, 4mmol) at -78°C. 10 Minutes later, the compound A-5 (820mg, 3.4mmol) was added to the mixture and stirred for 1 hour. Water was added to the solution and the mixture was extracted with ethyl acetate. After the ethyl acetate solution was washed and dried, the solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (*n*-hexane:ethyl acetate=2:1) to give 4-[5-(4-fluorobenzyl)furan-2-carbonyl]-1-isopropyl-3-methoxy-1,5-dihydropyrrole-2-one (80mg, yield: 7%).

NMR(CDCl₃) δ : 1.23(6H, d, J=6.9Hz), 4.05(2H, s), 4.08(2H, s), 4.15(3H, s), 4.40-4.50(1H, m), 6.17(1H, d, J=3.6Hz), 6.90-7.06(2H, m), 7.20-7.26(2H, m), 7.35(1H, d, J=3.6Hz).

(A-7) The above-mentioned compound A-6 (80mg, 0.22mmol) was dissolved in acetonitrile (5ml), to which was added chlorotrimethylsilane (200mg, 1.8mmol) and sodium iodide (270mg, 1.8mmol), and the mixture was stirred for 30 minutes at room temperature. Sodium sulfite was added to the solution, which was acidified with the 1 N hydrochloric acid aqueous solution and extracted with ethyl acetate. The extract was washed, dried and was evaporated and the residue was Crystallized with diethylether to give 4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one (50mg, yield : 68%).

Melting point: 155-157°C


Elementary analysis as as C ₁₉ H ₁₈ FNO ₄ 0.2H ₂ O				
Calcd. (%)	C, 65.77;	H, 5.35;	N, 4.04;	F, 5.48.
Found (%)	C, 65.72;	H, 5.27;	N, 3.97;	F, 5.26.

NMR(CDCl₃) δ : 1.23(6H, d, J=6.9Hz), 4.08(2H, s), 4.13(2H, s), 4.50-4.60(1H, m), 6.33(1H, d, J=3.6Hz), 7.02-7.10(2H, m), 7.20-7.26(2H, m), 7.33(1H, d, J=3.6Hz).

Compound A-12

4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0250]



(A-8) Acrylic acid ethyl ester (2.0g, 20mmol) was dissolved in ethanol(20ml),to which was added dropwise methylamine (20mmol, 20% ethanol solution) under ice cooling. Di-tert-butyl dicarbonate (4.4g, 20mmol) was added thereto and the mixture was warmed to room temperature. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=5:1-3:1) to give 3-(tert-butoxycarbonylmethylamino)propionic acid ethyl ester (3.1g, yield : 66%).

NMR(CDCl₃) δ: 1.26(3H, t, J=7.2Hz), 1.46(9H, s), 2.54(2H, t, J=7.0Hz), 2.87(3H, s), 3.50(2H, t, J=7.0Hz), 4.14(2H, q, J=7.2Hz).

(A-9) 1N Lithium hydroxide aqueous solution (17.5ml) was added to the above-mentioned compound A-8 (4.05g, 17.5mmol) in methyl alcohol (35ml) and the mixture was stirred for 5 hours. Methyl alcohol was evaporated under reduced pressure and the solution was acidified with citric acid and extracted with ethyl acetate. The extract was washed, dried and was evaporated to give 3-(tert-butoxycarbonylmethylamino)propionic acid (3.57g, yield : 100%).

NMR(CD₃OD) δ: 1.45(9H, s), 2.51(2H, t, J=7.0Hz), 2.87(3H, s), 3.50(2H, d, J=7.0Hz).

(A-10) The above-mentioned compound A-9 (3.82g, 18.8mmol) was dissolved in a chloroform (20ml) -acetonitrile (10ml) solution and to which was added O,N-dimethylhydroxylamine hydrochloride (2.02g, 20.7mmol), 1-hydroxybenzotriazole (254mg, 1.88mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (3.50g, 22.6mmol) and triethylamine (2.09g, 20.7mmol) and the mixture was stirred for 3 hours. Water was added to the solution and extracted with chloroform. The extract was washed, dried, and evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=1:1-2:1) to give [2-(methoxymethylcarbamoyl)ethyl]methylcarbamic acid tert-butyl ester (3.94g, yield : 85%).

NMR(CDCl₃) δ: 1.46(9H, s), 2.67(2H, t, J=7.0Hz), 2.89(3H, s), 3.19(3H, s), 3.52(2H, t, J=7.0Hz), 3.69(3H, s).

(A-11) N-butyllithium (5mmol) was added dropwise to 2-bromo-5-(4-fluorobenzyl)furan (1.30g, 5mmol) in THF (10ml) at -78°C. The above-mentioned compound A-10 (1.23g, 5mmol) in THF (5ml) was added to the mixture and stirred for 30 minutes, then an ammonium chloride aqueous solution was added to the solution and the solution was extracted with ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=3:1-2:1) to give {3-[5-(4-fluorobenzyl)furan-2-yl]-3-oxopropyl}methylcarbamic acid tert-butyl ester (1.02g, yield : 56%).

NMR(CDCl₃) δ: 1.42(9H, s), 2.87(3H, s), 3.00(2H, t, J=7.0Hz), 3.58(2H, t, J=7.0Hz), 4.01(2H, s), 6.10(1H, d, J=3.7Hz), 6.98-7.05(2H, m), 7.13(1H, d, J=4.0Hz), 7.19-7.26(2H, m). The following compound was synthesized by the same method as above using 3-(4-fluorobenzyl)-bromobenzene which was synthesized according to the

EP 1 422 218 A1

method of the reference (Journal of Medicinal Chemistry, 2000, 43, 26, p4923) . {3-[3-(4-Fluorobenzyl)phenyl]-3-oxopropyl)methylcarbamic acid tert-butyl ester

NMR(CDCl₃) δ: 1.43(9H, s), 2.89(3H, s), 3.18(2H, t, J=6.7Hz), 3.61(2H, t, J=6.7Hz), 4.01(2H, s), 6.95-7.01(2H, m), 7.11-7.16(2H, m), 7.37-7.40(2H, m), 7.81-7.82(2H, m).

(A-12) A 4Nhydrochloric acid dioxane solution (5ml) was added to the above-mentioned compound A-11 (1.00g, 2.77mmol) and the mixture was stirred for 30minutes. The excess hydrochloric acid and solvent were evaporated under reduced pressure, to which was added oxalic acid diethyl (485mg, 3.32mmol) in ethanol (5ml) After sodium ethoxide (8.31mmol, 20% ethanol solution) was added under ice cooling, the solution was warmed to room temperature and stirred for 1 hour. Water was added to the solution and extracted with ethyl acetate. The extract was washed, dried and evaporated. The precipitated crystal was washed with methyl alcohol and dried under reduced pressure to give 4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxyl-methyl-1,5-dihydropyrrole-2-one (641mg, yield :73%) .

Melting point: 141-143°C

Elementary analysis as as C ₁₇ H ₁₄ FNO ₄ 0.1H ₂ O				
Calcd. (%)	C, 64.39;	H, 4.51;	N, 4.42;	F, 5.99.
Found (%)	C, 64.24;	H, 4.29;	N, 4.43;	F, 5.92.

NMR(CDCl₃) δ: 3.14(3H, s), 4.07(2H, s), 4.19(2H, s), 6.29(1H, d, J=3.7Hz), 7.03-7.09(2H, m), 7.20-7.26(2H, m), 7.32(1H, d, J=3.7Hz).

[0251] The following compound was synthesized by the above-mentioned method.

(A-12-a) 4-[3-(4-Fluorobenzyl)benzoyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one Melting point:135-137°C


Elementary analysis as as C ₁₉ H ₁₆ FNO ₃ 0.2H ₂ O				
Calcd. (%)	C, 69.38;	H, 5.03;	N, 4.26;	F, 5.78.
Found (%)	C, 69.53;	H, 4.83;	N, 4.21;	F, 5.61.

NMR(CDCl₃) δ: 3.16(3H, s), 4.04(2H, s), 4.23(2H, s), 6.99-7.04(2H, m), 7.13-7.18(2H, m), 7.42-7.44(2H, m), 7.56(1H, s), 7.62-7.65(1H, m).

Compound A-17

1-Cyclopropyl-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one

[0252]



(A-13) Sodium hydrogen carbonate(54g, 0.64mol) was added to N,O-dimethylhydroxylamine hydrochloride(32g, 0.32mol)in methylene chloride(1L),and the mixture was stirred for 30 minutes at room temperature.Acryloyl chloride (30g, 0.32mol)in methylene chloride was added dropwise to the solution under ice cooling and stirred for 1 hour at room temperature.The solution was dried, filtered and evaporated to give N-methoxy-N-methylacrylamide(34g, yield:92%).

NMR(CDCl₃) δ : 3.27(3H, s), 3.72(3H, s), 5.75(1H, dd, J=10.2,1.8Hz), 6.43(1H, dd, J=17.1,1.8Hz), 6.73(1H, dd, J=17.1,10.2Hz).

(A-14) The above-mentioned compound A-13(2.0g, 17.4mmol)and cyclopropylamine(1.0g, 17.5mmol) were dissolved in ethanol(20ml),and the mixture was refluxed for 1 hour under heating.After di-tert-butylidicarbonate(4.5g, 20mmol) was added to the solution under ice cooling,and the mixture was stirred for 30 minutes at room temperature. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography(n-hexane:ethyl acetate=1:2)to give cyclopropyl[2-(methoxymethylcarbamoyl)ethyl]carbamate(2.9g, yield:60%).

NMR(CDCl₃) δ : 0.58-0.65(2H, m), 0.70-0.78(2H, m), 1.46(9H, s), 2.50-2.56(1H, m), 2.68(2H, t, J=7.4Hz), 3.18(3H, s), 3.52(2H, t, J=7.4Hz), 3.70(3H, s).

The following compounds were synthesized by the above-mentioned method.

Ethyl[2-(methoxymethylcarbamoyl)ethyl]carbamate tert-butyl ester

NMR(CDCl₃) δ : 1.09(3H, t, J=7.0Hz), 1.46(9H, s), 2.68(2H, t, J=6.8Hz), 3.18(3H, s), 3.26(2H, q, J=7.0Hz), 3.48(2H, t, J=6.8Hz), 3.69(3H, s).

[2-(Methoxymethylcarbamoyl)ethyl]propylcarbamate tert-butyl ester

NMR(CDCl₃) δ :0.87(3H, t, J=7.5Hz), 1.45-1.59(2H, m), 1.46(9H, s), 2.69(2H, s), 3.14-3.20(2H, m), 3.18(3H, s), 3.49(2H, t, J=7.1Hz), 3.69(3H, s).

Butyl[2-(methoxymethylcarbamoyl)ethyl]carbamate tert-butyl ester

NMR(CDCl₃) δ : 0.92(3H, t, J=7.4Hz), 1.23-1.34(2H, m), 1.44-1.53(2H, m), 1.46(9H, s), 2.69(2H, s), 3.18(3H, s), 3.20(2H, t, J=7.5Hz), 3.48(2H, t, J=7.1Hz), 3.69(3H, s).

(2-Methoxyethyl)-[2-(methoxymethylcarbamoyl)ethyl]carbamate tert-butyl ester

NMR(CDCl₃) δ : 1.46(9H, s), 2.71(2H, brs), 3.18(3H, s), 3.34(3H, s), 3.42(2H, brs), 3.45(2H, brs), 3.55(2H, t, J=6.7Hz), 3.69(3H, s).

(1-Ethylpropyl)-[2-(methoxymethylcarbamoyl)ethyl]carbamate tert-butyl ester

NMR(CDCl₃) δ : 0.85(6H, t, J=7.5Hz), 1.46(9H, s), 2.65-2.80(2H, m), 3.18(3H, s), 3.25-3.40(2H, m), 3.63(0.5H, brs), 3.69(3H, s), 3.88(0.5H, brs).

(A-15) N-butyllithium(1.55M solution, 3.3ml, 5.1mmol)was added to 2-bromo-5-(4-fluorobenzyl)furan(1.3g,

5.1mmol) in tetrahydrofuran (10ml) at -78°C. After the mixture was stirred for 5 minutes, the compound A-14 (1.36g, 5mmol) was added and stirred for 30 minutes. A saturated ammonium chloride aqueous solution was added to the solution and was extracted with ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure, then the residue was purified with silica gel column chromatography (ethyl acetate:n-hexane=4:1) to give cyclopropyl{3-[5-(4-fluorobenzyl)furan-2-yl]-3-oxopropyl}carbamic acid tert-butyl ester (1.12g, yield:58%).
 NMR(CDCl₃) δ: 0.55-0.62(2H, m), 0.66-0.7(2H, m), 1.44(9H, s), 2.45-2.52(1H, m), 3.00(2H, t, J=7.1Hz), 3.60(2H, t, J=7.1Hz), 4.01(2H, s), 6.10(1H, d, J=3.6Hz), 6.96-7.05(2H, m), 7.14(1H, d, J=3.6Hz), 7.16-7.23(2H, m).

The following compounds were synthesized by the above-mentioned method.

Ethyl{3-[5-(4-fluorobenzyl)furan-2-yl]-3-oxopropyl}carbamic acid tert-butyl ester
 NMR(CDCl₃) δ: 1.08(3H, t, J=7.1Hz), 1.43(9H, s), 3.01(2H, t, J=6.8Hz), 3.24(2H, q, J=7.1Hz), 3.54(2H, t, J=6.8Hz), 4.01(2H, s), 6.10(1H, d, J=3.6Hz), 7.00-7.04(2H, m), 7.14(1H, s), 7.18-7.24(2H, m).

{3-[5-(4-Fluorobenzyl)furan-2-yl]-3-oxopropyl}propylcarbamic acid tert-butyl ester
 NMR(CDCl₃) δ: 0.86(3H, t, J=7.4Hz), 1.42-1.58(2H, m), 1.43(9H, s), 3.01(2H, t, J=6.9Hz), 3.14(2H, t, J=7.4Hz), 3.54(2H, t, J=6.9Hz), 4.01(3H, s), 6.10(1H, d, J=3.3Hz), 6.97-7.04(2H, m), 7.14(1H, s), 7.18-7.24(2H, m).

Butyl{3-[5-(4-fluorobenzyl)furan-2-yl]-3-oxopropyl}carbamic acid tert-butyl ester
 NMR(CDCl₃) δ: 0.91(3H, t, J=7.4Hz), 1.21-1.35(2H, m), 1.42-1.52(2H, m), 1.43(9H, s), 3.01(2H, t, J=7.0Hz), 3.18(2H, t, J=7.5Hz), 3.54(2H, t, J=7.0Hz), 4.01(2H, s), 6.10(1H, d, J=3.3Hz), 6.97-7.04(2H, m), 7.15(1H, s), 7.18-7.23(2H, m).

{3-[5-(4-Fluorobenzyl)furan-2-yl]-3-oxopropyl}-(2-methoxyethyl)carbamic acid tert-butyl ester
 NMR(CDCl₃) δ: 1.42(9H, s), 3.02(2H, brs), 3.32(3H, s), 3.39(2H, brs), 3.46(2H, brs), 3.61(2H, t, J=6.9Hz), 4.00(2H, s), 6.09(1H, d, J=2.3Hz), 6.98-7.05(2H, m), 7.13(1H, brs), 7.18-7.28(2H, m).

(1-Ethylpropyl)-{3-[5-(4-fluorobenzyl)furan-2-yl]-3-oxopropyl}-carbamic acid tert-butyl ester
 NMR(CDCl₃) δ: 0.85(6H, brs), 1.45(9H, s), 3.02-3.11(2H, m), 3.32-3.43(2H, m), 3.63(0.5H, brs), 3.88(0.5H, brs), 4.01(2H, s), 6.08-6.11(1H, m), 6.98-7.03(2H, m), 7.11(1H, brs), 7.17-7.28(2H, m).

(A-16) The above-mentioned compound A-15 (1.12g, 2.9mmol) was dissolved in a 4N hydrochloric acid/dioxane solution (4ml) and the mixture was stirred for 30 minutes at room temperature. The solution was poured into a sodium hydrogen carbonate solution and extracted with ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure, then the residue was purified with silica gel column chromatography (chloroform:methyl alcohol=10:1) to give 3-cyclopropylamino-1-[5-(4-fluorobenzyl)furan-2-yl]propane-1-one (810mg, yield:98%).

NMR(CDCl₃) δ: 0.30-0.37(2H, m), 0.41-0.48(2H, m), 2.11-2.20(1H, m), 2.95-3.01(2H, m), 3.05-3.11(2H, m), 4.01(2H, s), 6.10(1H, d, J=3.6Hz), 6.96-7.05(2H, m), 7.12(1H, d, J=3.6Hz), 7.16-7.23(2H, m).

The following compounds were synthesized by the above-mentioned method.

3-Ethylamino 1-[5-(4-fluorobenzyl)furan-2-yl]propane-1-one
 NMR(CDCl₃) δ: 1.48(3H, t, J=7.2Hz), 3.04-3.18(2H, m), 3.33-3.41(2H, m), 3.53(2H, t, J=6.6Hz), 3.98(2H, s), 6.10(1H, d, J=3.6Hz), 6.97-7.04(2H, m), 7.15-7.21(2H, m), 7.23(1H, d, J=3.6Hz), 9.57(1H, s).

1-[5-(4-Fluorobenzyl)furan-2-yl]-3-propylaminopropane-1-one
 NMR(CDCl₃) δ: 1.05(3H, t, J=7.4Hz), 1.85-1.99(2H, m), 2.90-3.05(2H, m), 3.29-3.40(2H, m), 3.55(2H, t, J=6.5Hz), 3.99(2H, s), 6.12(1H, d, J=3.5Hz), 6.98-7.06(2H, m), 7.17-7.23(2H, m), 7.24(1H, d, J=3.5Hz), 9.50(1H, s).

3-Butylamino-1-[5-(4-fluorobenzyl)furan-2-yl]propane-1-one
 NMR(CDCl₃) δ: 0.95(3H, t, J=7.4Hz), 1.37-1.51(2H, m), 1.80-1.93(2H, m), 2.94-3.08(2H, m), 3.30-3.41(2H, m), 3.54(2H, t, J=7.1Hz), 3.98(2H, s), 6.10(1H, d, J=3.6Hz), 6.96-7.05(2H, m), 7.15-7.22(2H, m), 7.25(1H, d, J=3.6Hz), 9.51(1H, s).

1-[5-(4-Fluorobenzyl)furan-2-yl]-3-(2-methoxyethylamino)propane-1-one
 NMR(CDCl₃) δ: 2.86(2H, t, J=5.2Hz), 3.05(4H, dd, J=2.7, 2.7Hz), 3.36(3H, s), 3.52(2H, t, J=5.2Hz), 4.00(2H, s), 6.11(1H, d, J=3.6Hz), 6.98-7.04(2H, m), 7.13(1H, d, J=3.4Hz), 7.18-7.26(2H, m).

3-(1-Ethylpropylamino)-1-[5-(4-fluorobenzyl)furan-2-yl]propane-1-one
 NMR(CDCl₃) δ: 0.90(6H, brs), 1.45(4H, brs), 2.90-3.15(4H, m), 4.00(2H, s), 6.12(1H, d, J=3.7Hz), 6.95-7.08(2H, m), 7.15(1H, d, J=3.7Hz), 7.20-7.28(2H, m).

(A-17) The above-mentioned compound A-16 (300mg, 1mmol) and oxalic acid dimethyl (140mg, 1.2mmol) were dissolved in methyl alcohol (2ml), then 3N-sodium methoxide/methyl alcohol (0.7ml, 2mmol) was added to the mixture and stirred for 1 hour at room temperature. The solution was poured into an ammonium chloride aqueous solution and extracted with chloroform. The extract was washed, dried, and evaporated under reduced pressure. The residue was recrystallized from methyl alcohol to give 1-cyclopropyl-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one (110mg, yield:32%).

Melting point: 158-159°C

Elementary analysis as C₁₉H₁₆FNO₄

Calcd. (%)	C, 66.86;	H, 4.72;	N, 4.10;	F, 5.57.
Found (%)	C, 66.84;	H, 4.62;	N, 4.09;	F, 5.24.

NMR(CDCl₃)δ : 0.76-0.85(2H, m), 0.90-0.98(2H, m), 2.84-2.92(1H, m), 4.07(2H, s), 4.10(2H, d, J=0.6Hz), 6.31(1H, dt, J=3.6, 0.6Hz), 7.03-7.10(2H, m), 7.20-7.26(2H, m), 7.32(1H, d, J=3.6Hz).

[0253] The following compounds were synthesized by the above-mentioned method.

(A-17-a) 1-Ethyl-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one NMR(CDCl₃)δ: 1.23(3H, t, J=7.3Hz), 3.58(2H, q, J=7.3Hz), 4.08(2H, s), 4.18(2H, s), 6.31(1H, d, J=3.6Hz), 7.02-7.10(2H, m), 7.21-7.26(2H, m), 7.33(1H, d, J=3.6Hz).

(A-17-b) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-propyl-1,5-dihydropyrrole-2-one NMR(CDCl₃)δ: 0.96(3H, t, J=7.4Hz), 1.56-1.70(2H, m), 3.48(2H, t, J=7.4Hz), 4.08(2H, s), 6.31(1H, d, J=3.3Hz), 7.00-7.10(2H, m), 7.20-7.26(2H, m), 7.33(1H, d, J=3.3Hz). (A-17-c) 1-Butyl-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one NMR(CDCl₃)δ: 0.97(3H, t, J=7.2Hz), 1.30-1.44(2H, m), 1.53-1.64(2H, m), 3.52(2H, t, J=7.4Hz), 4.08(2H, s), 4.16(2H, s), 6.31(1H, d, J=3.5Hz), 7.01-7.10(2H, m), 7.20-7.26(2H, m), 7.33(1H, d, J=3.5Hz).

(A-17-d) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-(2-methoxyethyl)-1,5-dihydropyrrole-2-one

Melting point: 105-106°C

NMR(CDCl₃) δ : 3.35(3H, s), 3.60(2H, t, J=4.3Hz), 3.72(2H, t, J=4.6Hz), 4.06(2H, s), 4.40(2H, s), 6.29(1H, d, J=3.7Hz), 7.03-7.08(2H, m), 7.21-7.24(2H, m), 7.31(1H, d, J=3.7Hz). (A-17-e) 1-(1-Ethylpropyl)-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one


Melting point: 140-141°C

NMR(CDCl₃) δ : 0.86(6H, t, J=7.3Hz), 1.42-1.73(4H, m), 4.02(2H, s), 4.06-4.15(3H, m), 6.33(1H, d, J=3.7Hz), 7.02-7.08(2H, m), 7.20-7.27(2H, m) 7.34(1H, d, J=3.1Hz).

Compound A-19

1-Cyclohexyl-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one

[0254]



(A-18) 4-[5-(4-Fluorobenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-buten-1-yl methyl ester was synthesized according to the method of the reference(WO00/39086).

(A-19) The above-mentioned compound A-18(300mg, 1mmol) was dissolved in dioxane(3ml), to which were added cyclohexylamine(200mg, 2mmol) and paraformaldehyde(80mg) under ice cooling. After the mixture was stirred for 3 hours at room temperature, the solution was poured into a dilute hydrochloric acid-ice water and extracted with ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure. The residue was recrystallized from diethyl ether to give 1-cyclohexyl-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one(280mg, yield:73%).

Melting point: 41-42°C

EP 1 422 218 A1

Elementary analysis as C ₂₂ H ₂₂ FNO ₄				
Calcd. (%)	C, 68.92;	H, 5.78;	N, 3.65;	F, 4.96.
Found (%)	C, 68.73;	H, 5.77;	N, 3.60;	F, 4.80.

NMR(CDCl₃)δ : 1.15-1.51(5H, m), 1.70-1.91(5H, m), 4.08(2H, s), 4.12(2H, s), 4.10-4.20(1H, m), 6.33(1H, d, J=3.6Hz), 7.03-7.10(2H, m), 7.20-7.26(2H, m), 7.33(1H, d, J=3.6Hz).

[0255] The following compounds were synthesized by the above-mentioned method.

(A-19-a) 1-Cyclopentyl-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one
Melting point:157-159°C

Elementary analysis as C ₂₁ H ₂₀ FNO ₄				
Calcd. (%)	C, 68.28;	H, 5.46;	N, 3.79;	F, 5.14.
Found (%)	C, 67.94;	H, 5.48;	N, 3.72;	F, 5.13.

NMR(CDCl₃)δ : 1.44-1.60(2H, m), 1.60-1.82(4H, m), 1.90-2.02(2H, m), 4.07(2H, s), 4.15(2H, s), 4.56-4.68(1H, m), 6.33(1H, d, J=3.6Hz), 7.03-7.10(2H, m), 7.18-7.26(2H, m), 7.33(1H, d, J=3.6Hz).

(A-19-b) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxyl-(4-methoxyphenyl)-1,5-dihydropyrrole-2-one
Melting point:225-227°C

Elementary analysis as C ₂₃ H ₁₈ FNO ₅ ·0.1H ₂ O				
Calcd. (%)	C, 67.51;	H, 4.48;	N, 3.42;	F, 4.64.
Found (%)	C, 67.31;	H, 4.46;	N, 3.38;	F, 4.38.

NMR(CDCl₃)δ: 3.85(3H, s), 4.10(2H, s), 4.60(2H, s), 6.36(1H, d, J=3.6Hz), 6.97(2Hx2, Abq, J=9.0Hz), 7.02-7.10(2H, m), 7.20-7.26(2H, m), 7.38(1H, d, J=3.6Hz), 7.57(2Hx2, Abq, J=9.0Hz).

(A-19-c) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxyl-(2-hydroxyl-methylethyl)-1,5-dihydropyrrole-2-one
Melting point:168-169°C

Elementary analysis as C ₁₉ H ₁₈ FNO ₅				
Calcd. (%)	C, 63.50;	H, 5.05;	N, 3.90;	F, 5.29.
Found (%)	C, 63.17;	H, 4.99;	N, 3.83;	F, 5.13.

NMR(DMSO-*d*₆)δ : 1.07(3H, d, J=6.3Hz), 3.32-3.38(2H, m), 3.89-3.96(1H, m), 4.09(2H, s), 4.27(2H, s), 4.60(1H, bs), 6.41(1H, d, J=3.6Hz), 7.00-7.15(2H, m), 7.30-7.36(2H, m), 7.50(1H, d, J=3.6Hz).

(A-19-d) 1-Allyl-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one
Melting point:95-96.5°C

Elementary analysis as C ₁₉ H ₁₆ FNO ₄				
Calcd. (%)	C, 66.86;	H, 4.72;	N, 4.10;	F, 5.57.
Found (%)	C, 66.69;	H, 4.65;	N, 4.07;	F, 5.36.

NMR(CDCl₃)δ : 4.05(2H, s), 4.15(2H, d, J=6.1Hz), 4.18(2H, s), 5.24(1H, dd, J=16.7, 1.1Hz), 5.29(1H, dd, J=10.1, 1.1Hz), 5.81(1H, ddt, J=16.7, 10.1, 6.1Hz), 6.31(1H, d, J=3.5Hz), 7.00-7.08(2H, m), 7.17-7.25(2H, m), 7.32(1H, d, J=3.5Hz).

(A-19-e) 1-Benzyl-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one
Melting point:129-130°C

Elementary analysis as C ₂₃ H ₁₈ FNO ₄				
Calcd. (%)	C, 70.58;	H, 4.64;	N, 3.58;	F, 4.85.

EP 1 422 218 A1

(continued)

Elementary analysis as C ₂₃ H ₁₈ FNO ₄				
Found (%)	C, 70.42;	H, 4.56;	N, 3.60;	F, 4.74.

NMR(CDCl₃)δ : 3.99(2H, s), 4.13(2H, s), 4.71(2H, s), 6.27(1H, d, J=3.6Hz), 6.91-7.00(2H, m), 7.08-7.16(2H, m), 7.23-7.30(3H, m), 7.33-7.42(3H, m).

(A-19-f) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxyl-(2-hydroxyethyl)-1,5-dihydropyrrole-2-one

Melting point: 144-145.5°C

Elementary analysis as C ₁₈ H ₁₆ FNO ₅				
Calcd. (%)	C, 62.61;	H, 4.67;	N, 4.06;	F, 5.50.
Found (%)	C, 62.39;	H, 4.61;	N, 4.01;	F, 5.42.

NMR(CDCl₃)δ : 3.68(2H, t, J=4.9Hz), 3.89(2H, t, J=4.9Hz), 4.07(2H, s), 4.37(2H, s), 6.29(1H, d, J=3.6Hz), 7.01-7.10(2H, m), 7.20-7.28(2H, m), 7.32(1H, d, J=3.6Hz).

(A-19-g) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-(2-hydroxypropyl)-1,5-dihydropyrrole-2-one

Melting point: 172°C

Elementary analysis as C ₁₉ H ₁₈ NO ₅ F				
Calcd. (%)	C: 65.50	H: 5.05	N: 3.90	F: 5.29.
Found (%)	C: 63.32	H: 5.09	N: 3.88	F: 4.94.

NMR(CDCl₃)δ : 1.27(d, 3H, J=6.0Hz), 3.40-3.60(m, 3H), 4.07(s, 2H), 4.00-4.20(m, 1H), 4.25-4.50(m, 2H), 6.29(d, 1H, J=3.6Hz), 7.02-7.10(m, 2H), 7.20-7.26(m, 2H), 7.32(d, 1H, J=3.6Hz).

(A-19-h) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-(2-hydroxybutyl)-1,5-dihydropyrrole-2-one

Melting point: 132-133°C

Elementary analysis as C ₂₀ H ₂₀ NO ₅ F				
Calcd. (%)	C: 64.34	H: 5.40	N: 3.75	F: 5.09.
Found (%)	C: 64.18	H: 5.39	N: 3.74	F: 4.71.

NMR(CDCl₃)δ : 1.03(t, 3H, J=7.2Hz), 1.45-1.65(m, 2H), 3.48(dd, 1H, J=14.1Hz, 8.1Hz), 3.61(dd, 1H, J=14.4Hz, 2.7Hz), 3.75-3.90(m, 1H), 4.07(s, 2H), 4.33(d, 1H, J=18.0Hz), 4.43(d, 1H, J=18.0Hz), 6.29(d, 1H, J=3.6Hz), 7.02-7.10(m, 2H), 7.20-7.28(m, 2H), 7.32(d, 1H, J=3.6Hz).

(A-19-i) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-(2-hydroxypentyl)-1,5-dihydropyrrole-2-one

Melting point: 171°C

Elementary analysis as C ₂₁ H ₂₂ NO ₅ F				
Calcd. (%)	C: 65.11	H: 5.72	N: 3.62	F: 4.90.
Found (%)	C: 64.82	H: 5.68	N: 3.58	F: 4.42.

NMR(CDCl₃)δ : 0.95(t, 3H, J=7.2Hz), 1.20-1.40(m, 2H), 1.50-1.70(m, 2H), 3.65-3.76(m, 1H), 3.80-3.90(m, 1H), 4.07(s, 2H), 4.13(d, 1H, J=18.0Hz), 4.31(d, 1H, J=18.0Hz), 6.32(d, 1H, J=3.6Hz), 7.02-7.10(m, 2H), 7.20-7.28(m, 2H), 7.34(d, 1H, J=3.6Hz).

(A-19-j) 1-(2,3-Dihydroxypropyl)-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one

Melting point: 119-120°C

Elementary analysis as C ₁₉ H ₁₈ NO ₆ F				
Calcd. (%)	C: 60.80	H: 4.83	N: 3.73	F: 5.06.
Found (%)	C: 60.56	H: 4.81	N: 3.70	F: 4.66.

NMR(CDCl₃)δ : 3.54-3.72(m, 4H), 3.90-4.02(m, 1H), 4.07(s, 2H), 4.35(d, 1H, J=18.0Hz), 4.43(d, 1H, J=18.0Hz),

EP 1 422 218 A1

6.30(d, 1H, J=3.6Hz), 7.02-7.10(m, 2H), 7.20-7.28(m, 2H), 7.34(d, 1H, J=3.6Hz).

(A-19-k) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one Melting point:178-179°C

Elementary analysis as C ₁₆ H ₁₂ NO ₄ F				
Calcd. (%)	C: 63.79	H: 4.01	N: 4.65	F: 6.31.
Found (%)	C: 62.87	H: 4.29	N: 4.17	F: 5.92.

NMR(CDCl₃)δ : 4.05(s, 2H), 4.39(s, 2H), 6.31(d, 1H, J=3.6Hz), 7.00-7.10(m, 2H), 7.16-7.24(m, 2H), 7.26-7.32(m, 1H), 7.35(d, 1H, J=3.6Hz).

(A-19-l) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-(2-morpholine-4-ylethyl)-1,5-dihydropyrrole-2-one

Melting point:189-190°C (decomp.)

Elementary analysis as C ₂₂ H ₂₃ N ₂ O ₅ F·0.3H ₂ O				
Calcd. (%)	C: 62.94	H: 5.67	N: 6.67	F: 4.53.
Found (%)	C: 62.91	H: 5.61	N: 6.64	F: 4.25.

NMR(DMSO-d₆)δ : 2.58(m), 3.55(m), 4.08(s, 2H), 4.14(s, 2H), 6.37(d, 1H, J=3.6Hz), 7.13-7.20(m, 2H), 7.30-7.35(m, 2H), 7.85(bs, 1H).

(A-19-m) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-(2-piperidine-1-ylethyl)-1,5-dihydropyrrole-2-one

Melting point:228-232°C (decomp.)

Elementary analysis as C ₂₃ H ₂₅ N ₂ O ₄ F·0.1H ₂ O				
Calcd. (%)	C: 66.68	H: 6.13	N: 6.76	F: 4.59.
Found (%)	C: 66.55	H: 6.06	N: 6.76	F: 4.38.

NMR(DMSO-d₆)δ : 1.40-1.60(m, 6H), 2.40-2.80(m), 3.20-3.60(m), 3.93(s, 2H), 4.01(s, 2H), 6.19(bs, 1H), 7.11-7.20(m, 2H), 7.28-7.35(m, 2H), 8.58(bs, 1H).

(A-19-n) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-5H-furan-2-one

Melting point:178-179°C

Elementary analysis as C ₁₆ H ₁₂ NO ₄ F				
Calcd. (%)	C: 63.79	H: 4.01	N: 4.65	F: 6.31.
Found (%)	C: 62.87	H: 4.29	N: 4.17	F: 5.92.

NMR(CDCl₃)δ: 4.06(s, 2H), 5.18(d, 2H, J=0.6Hz), 6.35(dd, 1H, J=3.6Hz, 0.6Hz), 7.02-7.10(m, 2H), 7.18-7.24(m, 2H), 7.41(d, 1H, J=3.6Hz).

(A-19-o) 4-[5-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-isopropyl-5-methyl-1,5-dihydropyrrole-2-one was synthesized by using acetaldehyde instead of paraformaldehyde.

Melting point:120-122°C


NMR(CDCl₃)δ:1.25(3H, d, J=6.4Hz), 1.38(3H, d, J=6.9Hz), 1.41(3H, d, J=6.9Hz), 4.07(2H, d, J=2.1Hz), 4.12(1H, sep, J=6.9Hz), 4.55(1H, q, J=6.4Hz), 6.32(1H, d, J=3.6Hz), 7.01-7.10(2H, m), 7.19-7.28(2H, m), 7.36(1H, d, J=3.6Hz).

Compound A-29

4-[5-(4-Fluorobenzyl)oxazole-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one(A-29-a)

4-[5-(4-Fluorobenzyl)oxazole-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(A-29-b)

[0256]



(A-20) To a solution of benzyloxycarbonylaminoacetic acid(102.5g, 0.49mol), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloric acid(112.7g, 0.588mol), hydroxybenzotriazole(6.62g, 0.049mol) and N,O-dimethylhydroxylamine hydrochloric acid(57.35g, 0.588mol) in dichloromethane(1L), was added triethylamine(82ml, 0.588mol) and stirred for 10 minutes under water cooling, 10 minutes later, the mixture was stirred at room temperature for 1 hour. The solution was allowed to stand overnight at room temperature. The mixture was evaporated under reduced pressure, to which were added ethyl acetate(500ml), 2N hydrochloric acid(70ml) and water(300ml) and the solution was shaken and separated. The solution was washed with water(200ml), a saturated sodium bicarbonate aqueous solution(100ml) and water(100ml), and water(200ml) successively. The water solution was extracted with ethyl acetate(300ml), the ethyl acetate was collected, dried with magnesium sulfate and evaporated under reduced pressure to give [(methoxymethylcarbamoyl)methyl]carbamic acid benzyl ester(108.92g, yield: 88.1%).

Melting point: 77-78°C

NMR(CDCl₃) δ : 3.21(3H, s), 3.72(3H, s), 4.15(2H, d, J=4.2Hz), 5.13(2H, s), 5.55(1H, bs), 7.30-7.40(5H, m).

(A-21) A metal sheet of magnesium(21.89g, 900mmol) and diethyl ether(120ml) were added in 2L 3 necked flask under nitrogen atmosphere, to which was added a small amount of iodine. After a small portion of 4-fluorobenzyl bromide(112.2ml, 900mmol) in diethyl ether(150ml) was added dropwise and diluted with diethyl ether(930ml), the reaction mixture was cooled with ice-NaCl. When the reaction mixture was cooled to 1°C, the remaining 4-fluorobenzyl bromide was added dropwise for 3 hours 40 minutes and the reaction mixture was stirred for 40 minutes. The above-mentioned compound A-20(75.68g, 300mmol) in tetrahydrofuran(720ml) was added to 3L 3 necked flask under nitrogen atmosphere, then the reaction mixture was cooled with ice-NaCl, to which was added dropwise for 1.5 hours a diethyl ether solution of Grignard reagent which was previously prepared. The solution was kept from -1°C to 3°C, and further stirred for 1 hour. (the temperature of the end of the reaction was at 3°C). The reaction mixture was poured into an ice water, to which were added ethyl acetate(800ml) and 2N hydrochloric acid(600ml) and extracted. The water solution was reextracted with ethyl acetate(400ml). The ethyl acetate solution was washed one time with water(600ml), dried with magnesium sulfate and evaporated under reduced pressure. N-hexane and diethyl ether(2:1, 720ml) were added to a crystal residue(130.7g), to give crude crystal(71.15g, 78.7%) of A-21 which was recrystallized from dichloromethane and n-hexane to give A-21(47.82g, yield: 52.9%). The filtrate was purified with silica gel column chromatography(toluene:acetone=98:2) to give A-21(11.85g, 13.1%).

Melting point: 92-93°C

EP 1 422 218 A1

NMR(CDCl₃) δ: 3.71(2H, s), 4.13(2H, d, J=4.5Hz), 5.10(2H, s), 5.43(1H, bs), 7.00-7.05(2H, m), 7.15-7.19(2H, m), 7.35(5H, bs).

(A-22) The above-mentioned compound A-21(113.88g, 378mmol) was suspended in methyl alcohol(756ml), to which were added 10 % Pd-C(7.56g) , water(76ml) and 5N hydrochloric acid(114ml).The mixture was reduced under atmosphere pressure.3 Hours later,methyl alcohol(160ml),water(40ml) and 10% Pd-C(3.83g) were added to the mixture and further reduced for 4.7hours (6.05L,hydrogen).The catalyst was filtered, washed with methyl alcohol and then the solution was evaporated under reduced pressure. Diethyl ether(400ml) was added to a crystal residue and the crystal was Crushed to give 1-amino-3-(4-fluorophenyl)propane-2-one hydrochloride(74.67g, yield:97%).

Melting point:190-192°C

NMR(DMSO-d₆) δ: 3.91(2H, s), 4.01(2H, s), 7.13-7.21(2H, m), 7.22-7.28(2H, m), 8.24(2H, bs).

(A-23) The above-mentioned compound A-22(69.50g, 341.3mmol) was suspended to toluene(535ml),to which was added chloroglyoxylic acid ethyl(77ml, 689mmol), then the mixture was stirred and heated at 90°C for 2 hours. The reaction mixture was Cooled by ice,then ethyl acetate (500ml) and water were added to the mixture and shakend(the precipitated crystal was not dissolved).The water layer and the precipitate were extracted 3 times with chloroform(400ml)each chloroform solution was washed ,dried with sodium sulfate and evaporated under reduced pressure.Diethyl ether and n-hexane(1:1, 200ml) were added to a crystal residue and the crystal was Crushed to give N-[3-(4-fluorophenyl)-2-oxopropyl] oxamic acid ethyl ester(80.0g, yield:87.7%).

Melting point:126-127°C

NMR(CDCl₃) δ: 1.38(3H, t, J=7.2Hz), 3.76(2H, s), 4.25(2H, d, J=4.8Hz), 4.36(2H, q, J=7.2Hz), 7.01-7.08(2H, m), 7.17-7.22(2H, m), 7.70(1H, bs).

(A-24) The above-mentioned compound A-23(74.90g, 280mmol) was suspended to toluene(784ml),to which was added phosphorus oxychloride(144ml, 1.545mol),then the mixture was stirred and heated at 120°C for 2 hours. The solution was evaporated under reduced pressure and then the residue was dissolved in ethyl acetate .The solution was poured into ice water, then extracted one time with ethyl acetate and washed 2 times and dried with magnesium sulfate.The solution was evaporated under reduced pressure to give a crude product(70.15g).The crude product was purified with silica gel column chromatography(chloroform) to give 5-(4-fluorobenzyl)oxazole-2-carboxylic acid ethyl ester(66.70g, yield:95.6%) as a red oil.

NMR(CDCl₃) δ: 1.42(3H, t, J=7.2Hz), 4.05(2H, s), 4.45(2H, q, J=7.2Hz), 6.92(1H, s), 6.99-7.07(2H, m), 7.18-7.24(2H, m).

(A-25) The above-mentioned compound A-24(54.70g, 219.5mmol) was dissolved in ethanol(640ml) and the mixture was stirred under ice cooling, to which was added dropwise 4N lithium hydroxide(110ml, 440mmol)for 15 minutes and stirred for 1.5 hours.1N hydrochloric acid(444ml) was added dropwise for 30minutes and then water (500ml) was added.The mixture was stirred for 10 minutes and the precipitated crystal was separated to give 5-(4-fluorobenzyl)oxazole-2-carboxylic acid(43.74g, yield:90.1%).

Melting point:84-85°C

NMR(DMSO-d₆) δ: 4.13(2H, s), 7.12-7.21(3H, m), 7.27-7.35(2H, m).

(A-26) According to the method of the example A-20, 5-(4-fluorobenzyl)oxazole-2-carboxylic acid methoxymethylamide was synthesized from the above-mentioned compound A-25.

NMR(CDCl₃) δ: 3.46(3H, bs), 3.83(3H, s), 4.04(2H, s), 6.86(1H, s), 6.98-7.05(2H, m), 7.16-7.28(2H, m).

(A-27) According to the method of the example A-21, 1-[5-(4-fluorobenzyl)oxazole-2-yl]etanone was synthesized from the above-mentioned compound A-26.

Melting point:51-52°C

NMR(CDCl₃) δ: 2.63(3H, s), 4.05(2H, s), 6.91(1H, m), 7.00-7.06(2H, m), 7.19-7.24(2H, m).

(A-28) According to the method of the example A-18, 4-[5-(4-fluorobenzyl)oxazole-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester was synthesized from the above-mentioned compound A-27.

Melting point: 115-116°C

NMR(CDCl₃) δ: 3.94(3H, s), 4.09(2H, s), 7.00-7.07(3H, m), 7.24-7.27(3H, m).

(A-29-a) According to the method of the example A-19, 4-[5-(4-fluorobenzyl)oxazole-2-carbonyl]-3-hydroxyl-isopropyl-1,5-dihydropyrrole-2-one was synthesized from the above-mentioned compound A-28.

Melting point:217-219°C

Elementary analysis as C ₁₈ H ₁₇ FN ₂ O ₄				
Calcd. (%)	C, 62.79;	H, 4.98;	N, 8.14;	F, 5.52.
Found (%)	C, 62.31;	H, 4.89;	N, 8.00;	F, 5.51.

NMR(CDCl₃) δ: 1.27(6H, d, J=6.9Hz), 4.10(2H, s), 4.14(2H, s), 4.55(1H, m), 7.03-7.09(3H, m), 7.23-7.28(2H, m),

15.08(1H, bs).

According to the same method, A-29-b, 4-[5-(4-fluorobenzyl)oxazole-2-carbonyl]-3-hydroxyl-methyl-1,5-dihydro-pyrrole-2-one was synthesized.

Melting point: 218-220°C

Elementary analysis as $C_{16}H_{13}FN_2O_4$


Calcd. (%)	C, 60.76;	H, 4.14;	N, 8.86;	F, 6.01.
Found (%)	C, 60.46;	H, 4.08;	N, 8.78;	F, 5.97.

NMR($CDCl_3$) δ : 3.16(3H, s), 4.14(4H, s), 7.02-7.09(3H, m), 7.22-7.28(2H, m), 15.21(1H, bs).

Compound A-33

4-[5-(4-Fluorobenzyl)thiazole-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0257]



(A-30) formic acid(2ml) was added to acetic anhydride(4ml) under ice cooling and stirred at 50°C for 15 minutes. The solution was stirred for 3 minutes under ice cooling, to which was added sodium formate (0.91g, 13.4mmol) and then the mixture was stirred at room temperature for 5 minutes. 1-Amino-3-(4-fluorophenyl)propan-2-one hydrochloride A-22(2.04g, 10mmol) was added to the solution and stirred at room temperature for 40 minutes. Then water was added to the solution which was extracted with methylene chloride. The extract was washed, dried and evaporated under reduced pressure to give a crude crystal(1.85g) of *N*-[3-(4-fluorophenyl)-2-oxopropyl]formamide.

NMR($CDCl_3$) δ : 3.75 (2H, s), 4.24 (2H, d, $J=5.4$ Hz), 6.34 (1H, br.s), 7.04 (2H, t like, $J=8.7$ Hz), 7.16-7.22(2H, m), 8.23 (1H, s).

(A-31) A crude crystal(1.85g) of the above-mentioned compound A-30 was dissolved in toluene(40ml), to which was added Lawesson's reagent(4.05g, 10mmol) and the mixture stirred at room temperature for 15 minutes, 60°C for 15 minutes and 100°C for 1.5 hours. The solution was cooled to room temperature, then the insoluble matter was separated and washed with toluene. The filtrate and the toluene solution were concentrated under reduced pressure. The residue was purified with silica gel column chromatography(chloroform:methyl alcohol=1:0-49:1, n-hexane:ethyl acetate=2:1) to give 5-(4-fluorobenzyl)thiazole(1.47g, 2step yield:76%).

NMR($CDCl_3$) δ : 4.14 (2H, s), 7.00 (2H, t like, $J=8.7$ Hz), 7.14-7.20 (2H, m), 7.72 (1H, s), 8.86 (1H, s).

(A-32) A *n*-butyllithium-hexane solution(1.5mmol) was added dropwise to the above-mentioned compound A-31 (290mg, 1.5 mmol) in tetrahydrofuran(8ml) at -78°C and the mixture was stirred for 20 minutes, to which was added dropwise 4-methoxy-1-methyl-5-oxo-2,5-dihydro-1*H*-pyrrole-3-carboxylic acid methoxymethylamide(321mg, 1.5 mmol) in tetrahydrofuran(1.5ml) which was synthesized according to the method of A-5 and stirred for 55 minutes. A saturated ammonium chloride aqueous solution was added to the solution, then extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure. The residue was crystallized from ethyl ace-

EP 1 422 218 A1

tate-diisopropylether to give 4-[5-(4-fluorobenzyl)thiazole-2-carbonyl]-3-methoxy-1-methyl-1,5-dihydropyrrole-2-one(226mg, yield:44%).

NMR(CDCl₃)δ:3.12 (3H, s), 4.19 (2H, s), 4.31 (3H, s), 4.60 (2H, s), 7.03 (2H, t, like, J=8.7Hz), 7.17-7.23 (2H, m), 7.66 (1H, t, J=0.9Hz).

The following compounds were synthesized by the above-mentioned method using 1-isopropyl-4-methoxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid methoxymethylamide. 4-[5-(4-Fluorobenzyl)thiazole-2-carbonyl]-1-isopropyl-3-methoxy-1,5-dihydropyrrole-2-one NMR(CDCl₃) δ:1.28 (6H, d, J=6.6Hz), 4.19 (2H, s), 4.29 (3H, s), 4.52 (2H, s), 4.45-4.54 (1H, m), 7.26 (2H, t, like, J=8.7Hz), 7.18-7.23 (2H, m), 7.68 (1H, s).

(A-33) 5N hydrochloric acid(2ml) was added to the above-mentioned compound A-32(219mg, 0.63mmol) in methyl alcohol(10ml), and the mixture was stirred at 50°C for 14 hours, then stirred for 30 minutes under ice cooling. The precipitated crystal was filtered out, then washed with methyl alcohol to give 164mg of the crystal which was recrystallized from methyl alcohol-ethyl acetate to give 4-[5-(4-fluorobenzyl)thiazole-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(145mg, yield:69%).

Melting point:230-231°C

Elementary analysis as C ₁₆ H ₁₃ FN ₂ O ₃ S					
Calcd. (%)	C, 57.82;	H, 3.94;	N, 8.43;	F, 5.72;	S, 9.65.
Found (%)	C, 57.91;	H, 3.89;	N, 8.34;	F, 5.71;	S, 9.47.

NMR(CDCl₃)δ :3.16 (3H, s), 4.11 (2H, s), 4.23 (2H, s), 7.06 (2H, t like, J=8.7Hz), 7.20-7.25 (2H, m), 7.76 (1H, s).

[0258] The following compound was synthesized by the above-mentioned method.

4-[5-(4-Fluorobenzyl)thiazole-2-carbonyl]-1-isopropyl-3-hydroxy-1,5-dihydropyrrole-2-one

Melting point:201-202°C


Elementary analysis as C ₁₈ H ₁₇ FN ₂ O ₃ S					
Calcd. (%)	C, 59.99;	H, 4.75;	N, 7.77;	F, 5.27;	S, 8.90.
Found (%)	C, 60.04;	H, 4.70;	N, 7.70;	F, 5.30;	S, 8.84.

NMR(CDCl₃)δ:1.26 (6H, d, J=6.6Hz), 4.08 (2H, s), 4.24 (2H, s), 4.50-4.62 (1H, m), 7.06 (2H, t like, J=8.7Hz), 7.20-7.26 (2H, m), 7.56 (1H, s).

Compound A-39

4-[2-(4-Fluorobenzyl)furan-3-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0259]



(A-34) To a lithium diisopropylamide solution prepared from diisopropylamine (22.0 ml, 157 mmol) and *n*-butyllithium (157 mmol) in tetrahydrofuran (150 ml), was added dropwise 3-furancarboxylic acid (8.79 g, 78.5 mmol) in tetrahydrofuran (80 ml) at -78°C . The mixture was stirred at the same temperature for 1 hour 10 minutes, to which was added 4-fluorobenzaldehyde (10.7 g, 86.4 mmol) in tetrahydrofuran (30 ml). The temperature was warmed to 0°C for 30 minutes, then water (100 ml) was added to the solution and the organic layer was extracted with 1N sodium hydroxide aqueous solution. The water solution was acidified with concentrated hydrochloric acid, then extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure to give the residue which was crystallized from diisopropylether-*n*-hexane to afford 2-[(4-fluorophenyl)hydroxymethyl]furan-3-carboxylic acid (13.5 g, yield: 73%).

(A-35) The above-mentioned compound A-34 (13.5 g, 57.2 mmol) in acetonitrile (75 ml) was added dropwise to sodium iodide (34.3 g) and chlorotrimethylsilane (29.1 ml) in acetonitrile (60 ml) under ice cooling, then stirred for 15 minutes, to which was added 10% sodium hydrogen sulfite aqueous solution (200 ml) and stirred for 15 minutes. The solution was extracted with ethyl acetate, washed and dried, then evaporated under reduced pressure to give the residue which was crystallized from isopropylether-*n*-hexane to afford 2-(4-fluorobenzyl)furan-3-carboxylic acid (9.73 g, yield: 77%).
NMR(CDCl_3) δ : 4.35 (2H, s), 6.72 (1H, d, $J=2.1\text{ Hz}$), 6.98 (2H, t like, $J=8.7\text{ Hz}$), 7.22-7.28 (2H, m), 7.30 (1H, d, $J=2.1\text{ Hz}$).

(A-36) To a mixture of the above-mentioned compound A-35 (3.00 g, 13.6 mmol), *N,O*-dimethylhydroxylamine hydrochloride (1.60 g, 16.4 mmol) and 1-hydroxy-1H-benzotriazole hydrate (0.21 g, 1.4 mmol) in tetrahydrofuran (40 ml), was added triethylamine (2.27 ml, 16.4 mmol) and stirred for 10 minutes, to which was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (3.14 g, 16.4 mmol) and stirred overnight. Water and 2N hydrochloric acid (10 ml) were added to the solution and extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure, then the residue was purified with silica gel column chromatography (*n*-hexane:ethyl acetate=3:1) to give 2-(4-fluorobenzyl)furan-3-carboxylic acid methoxymethylamide (2.29 g, yield: 64%).

NMR(CDCl_3) δ : 3.33 (3H, s), 3.61 (3H, s), 4.27 (2H, s), 6.70 (1H, d, $J=1.8\text{ Hz}$), 6.96 (2H, t like, $J=8.7\text{ Hz}$), 7.24-7.31 (3H, m).

(A-37) To the above-mentioned compound A-36 (2.29 g, 8.71 mmol) in tetrahydrofuran (40 ml), was added dropwise

EP 1 422 218 A1

a tetrahydrofuran solution of methyl magnesium bromide (26.1 mmol) under ice cooling, and the mixture was stirred for 1 hour 10 minutes, to which was added a saturated ammonium chloride aqueous solution and extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography(n-hexane:ethyl acetate=5:1) to give 1-[2-(4-fluorobenzyl)furan-3-yl]etanone (1.83 g, yield:97%).

NMR(CDCl₃)δ:2.43 (3H, s), 4.32 (2H, s), 6.63 (1H, d, J=1.8Hz), 6.96 (2H, t like, J=8.7Hz), 7.24-7.39 (3H, m).

(A-38) According to the method of the example A-18, 4-[2-(4-fluorobenzyl)furan-3-yl]-2-hydroxy-4-oxo-2-butenic acid methyl(557 mg, yield:79%) was synthesized by using the above-mentioned compound A-37 (504 mg, 2.31 mmol).

Melting point:61-62°C (diisopropylether)

NMR(CDCl₃) δ:3.93 (3H, s), 4.38 (2H, s), 6.67 (1H, d, J=2.1Hz), 6.70 (1H, s), 6.98 (2H, t like, J=8.7Hz), 7.23-7.29 (2H, m), 7.34 (1H, J=2.1Hz), 15.23 (1H, br.s).

(A-39) According to the method of the example A-19, 4-[2-(4-fluorobenzyl)furan-3-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(85mg, yield:40%) was synthesized by using the above-mentioned compound 21(203 mg, 0.67 mmol).

Melting point:171-172°C

Elementary analysis as C ₁₇ H ₁₄ FNO ₄				
Calcd. (%)	C, 64.76;	H, 4.48;	N, 4.44;	F, 6.03.
Found (%)	C, 64.74;	H, 4.43;	N, 4.41;	F, 5.88.

NMR(CDCl₃)δ:3.18 (3H, s), 4.30 (2H, s), 4.38 (2H, s), 6.56 (1H, d, J=2.1Hz), 6.98 (2H, tlike, J=8.7Hz), 7.26-7.31 (2H, m), 7.38 (1H, d, J=2.1Hz).

[0260] According to the same method, 4-[2-(4-fluorobenzyl)furan-3-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one was synthesized.

Melting point:180-182°C


Elementary analysis as C ₁₉ H ₁₈ FNO ₄				
Calcd. (%)	C, 66.46;	H, 5.28;	N, 4.08;	F, 5.53.
Found (%)	C, 66.45;	H, 5.26;	N, 4.08;	F, 5.46.

NMR(CDCl₃)δ:1.29 (6H, d, J=6.6Hz), 4.23 (2H, s), 4.38 (2H, s), 4.54-4.63 (1H, m), 6.61 (1H, d, J=2.1Hz), 6.98 (2H, t like, J=9Hz), 7.26-7.31 (2H, m), 7.39 (1H, d, J=2.1Hz).

Compound A-50

4-[3-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

5 [0261]



(A-40) To a toluene(60 ml) solution of 2-furancarboxylic acid(11.2 g, 100 mmol), were added thionyl chloride(8.76 ml, 120 mmol) and two drops of *N,N*-dimethylformamide, and stirred at 80°C for 4 hours. The solution was concentrated to give a crude product of 2-furancarboxylic acid chloride, which was used without purification to the following reaction.

(A-41) The above-mentioned A-40 was added to 2-amino-2-methyl-1-propylalcohol(22.3 g, 250 mmol) in methylene chloride(100 ml) under ice cooling, the mixture was stirred for 21 minutes, then water was added and the solution was extracted with methylene chloride after salting-out. The extract was dried, then evaporated under reduced pressure to give a crude product(18 g) of 2-furancarboxylic acid(2-hydroxy-1,1-dimethylethyl)amide. The crude product was used without purification to the following reaction.

(A-42) To a toluene(150 ml) solution of the above-mentioned crude product A-41, was added thionyl chloride(9.48 ml, 130 mmol) under ice cooling and stirred at room temperature for 1 hour 20 minutes, to which was carefully added water(50 ml) and sodium hydroxide(26 g) aqueous solution(100 ml) under ice cooling. The solution was extracted with toluene, washed and dried, then evaporated under reduced pressure. The residue was distilled under reduced pressure to give 2-furan-2-yl-4,4-dimethyl-4,5-dihydroxazole(12.6 g, total yield of 3 steps: 76%). Boiling point: 67-70°C (3 mmHg)

EP 1 422 218 A1

NMR(CDCl₃) δ: 1.39 (6H, s), 4.10 (2H, s), 6.47-6.50 (1H, m), 6.94 (1H, d; J=3.3Hz), 7.53 (1H, br. s).

(A-43) To the above-mentioned compound A-42 (11.6 g, 70.3 mmol) in 1,2-dimethoxyethane(290 ml) at -60°C, was added dropwise n-butyllithium(73.8 mmol) in n-hexane and stirred for 15 minutes, to which was added dropwise 4-fluorobenzaldehyde(9.15 g, 73.8 mmol) in 1,2-dimethoxyethane(20ml). The mixture was stirred for 1 hour 10 minutes, then added 1N hydrochloric acid(200ml) evaporated under reduced pressure and washed with toluene. The water layer was alkalized with 2N sodium hydroxide aqueous solution(100 ml) and extracted with toluene. The extract was washed, dried and evaporated under reduced pressure to give the residue, purified with silica gel column chromatography(toluene:acetone=9:1) to give [2-(4,4-dimethyl-4,5-dihydroxazole-2-yl)furan-3-yl]-(4-fluorophenyl)methyl alcohol(15.1 g, yield:74%).

NMR(CDCl₃) δ: 1.35 (3H, s), 1.40 (3H, s), 4.17 (2H, s), 5.88 (1H, s) 6.13 (1H, d, J=1.8Hz), 7.03 (2H, t like, J=8.7Hz), 7.37-7.43 (3H, m).

(A-44) To the above-mentioned compound A-43 (14.6 g, 50.5 mmol) in nitromethane(100 ml), added iodomethane (15.7 ml) and the mixture was stirred at 50°C for 50 hours, to which was added diethyl ether(400 ml) at room temperature. The solution was stirred under ice cooling, then the precipitated crystal was filtered to give iodo [2-[3-[(4-fluorophenyl)hydroxy]furan-2-yl]-3,4,4-trimethyl-4,5-dihydroxazole-3-ium].

Immediately, this crystal was used to the following reaction.

(A-45) To the above-mentioned compound A-44 in methyl alcohol(200 ml), was added 2N sodium hydroxide aqueous solution(101ml), and the mixture was stirred at room temperature for 1 hour and evaporated under reduced pressure. Water(150 ml) was added to the residue, then washed with toluene. The water layer was acidified with 2N hydrochloric acid(130 ml), and extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure to give a crude product(15.0 g) of 3-[(4-fluorophenyl)hydroxymethyl]furan-2-carboxylic acid.

NMR(CDCl₃) δ: 5.6 (2H, br, s), 6.23 (1H, s) 6.42 (1H, d, J=1.8Hz), 7.04 (2H, t like, J=8.7Hz), 7.37-7.43 (2H, m), 7.53 (1H, d, J=1.8Hz).

(A-46) According to the method of A-35, 3-(4-fluorobenzyl)-2-furancarboxylic acid (7.72 g: total yield of 3 steps 70%) was synthesized by using the above-mentioned crude product A-45(15.0 g).

Melting point:144°C

NMR(CDCl₃) δ : 4.18 (2H, s), 6.31 (1H, d, J=1.8Hz), 6.99 (2H, t like, J=8.7Hz), 7.18-7.23 (2H, m), 7.53 (1H, d, J=1.8Hz).

(A-47) According to the method of A-36, 3-(4-fluorobenzyl)-2-furancarboxylic acid methoxymethylamide(1.87 g: 71%) was synthesized by using the above-mentioned compound A-46(2.20 g).

NMR(CDCl₃) δ : 3.33 (3H, s), 3.82 (3H, s), 4.11 (2H, s), 6.24 (1H, d, J=1.8Hz), 6.96 (2H, t like, J=8.7Hz), 7.20-7.25 (2H, m), 7.37 (1H, d, J=1.8Hz).

(A-48) According to the method of A-37, 1-[3-(4-fluorobenzyl)furan-2-yl]etanone(1.99 g:96%) was synthesized by using the above-mentioned compound A-47(2.50 g).

NMR(CDCl₃) δ : 2.51 (3H, s), 4.17 (2H, s), 6.29 (1H, d, J=1.8Hz), 6.96 (2H, t like, J=8.7Hz), 7.17-7.23 (2H, m), 7.39 (1H, d, J=1.8Hz).

(A-49) According to the method of A-18, 4-[3-(4-fluorobenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl (2.48 g, yield:90%) was synthesized by using the above-mentioned compound A-48(1.98 g, 9.08 mmol).

Melting point:100-101°C

NMR(CDCl₃) δ : 3.94 (3H, s), 4.24 (2H, s), 6.36 (1H, d, J=1.5Hz), 6.98 (2H, t like, J=8.7Hz), 7.05 (1H, s), 7.18-7.24 (2H, m), 7.51 (1H, d, J=1.5Hz), 14.73 (1H, br.s).

(A-50) According to the method of A-19, 4-[3-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(112 mg, yield:54%) was synthesized by using above-mentioned compound 32(200 mg, 0.66 mmol).

Melting point:208-210°C

Elementary analysis as C ₁₇ H ₁₄ FNO ₄				
Calcd. (%)	C, 64.76;	H, 4.48;	N, 4.44;	F, 6.03.
Found (%)	C, 64.67;	H, 4.38;	N, 4.33;	F, 5.96.

NMR(CDCl₃)δ:3.18 (3H, s), 4.27 (2H, s), 4.47 (2H, s), 6.40 (1H, d, J=1.8Hz), 6.99 (2H, t like, J=8.7Hz), 7.20-7.26 (2H, m), 7.58 (1H, d, J=1.8Hz).

[0262] The following compounds were synthesized by the above-mentioned method.

(A-50-a) 4-[3-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point:197-199°C

EP 1 422 218 A1

Elementary analysis as C₁₉H₁₈FNO₄

Calcd. (%)	C, 66.46;	H, 5.28;	N, 4.08;	F, 5.53.
Found (%)	C, 66.40;	H, 5.24;	N, 4.04;	F, 5.52.

NMR(CDCl₃)δ: 1.30 (6H, d, J=7.2Hz), 4.27 (2H, s), 4.41 (2H, s), 4.55-4.66 (1H, m), 6.41 (1H, d, J=1.5Hz), 6.99 (2H, t like, J=8.7Hz), 7.20-7.26 (2H, m), 7.56 (1H, d, J=1.5Hz).

(A-50-b) 4-[3-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-(2-hydroxyethyl)-1,5-dihydropyrrole-2-one

Melting point: 195-196°C

Elementary analysis as C₁₈H₁₆NO₅F

Calcd. (%)	C: 62.61	H: 4.67	N: 4.06	F: 5.50
Found (%)	C: 62.48	H: 4.52	N: 4.05	F: 5.45

NMR(DMSO-d₆)δ: 3.52(m,2H), 3.58(m,2H), 4.19(s,2H), 4.47(s,2H), 6.62(d,1H, J=1.2Hz), 7.05-7.15(m, 2H), 7.28-7.35(m,2H), 7.91(d, 1H, J=1.2Hz).

(A-50-c) 4-[3-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-(2-methoxyethyl)-1,5-dihydropyrrole-2-one

Melting point: 170°C

Elementary analysis as C₁₉H₁₈NO₅F

Calcd. (%)	C: 63.50	H: 5.05	N: 3.90	F: 5.29
Found (%)	C: 63.35	H: 4.93	N: 3.91	F: 5.21

NMR(DMSO-d₆)δ: 3.26(s,2H), 3.52(m,2H), 3.60 (m,2H), 4.18(s,2H), 4.43(s,2H), 6.62(d,1H, J=1.2Hz), 7.05-7.14 (m, 2H), 7.28-7.35(m,2H), 7.91(d, 1H, J=1.2Hz).

(A-50-d) 1-Ethyl-4-[3-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one

Melting point: 167°C

Elementary analysis as C₁₈H₁₆NO₄F

Calcd. (%)	C: 65.65	H: 4.90	N: 4.25	F: 5.77
Found (%)	C: 65.65	H: 4.77	N: 4.25	F: 5.69

NMR(DMSO-d₆)δ: 1.15(t,3H,J=7.2Hz), 3.48(q,2H,J=7.2Hz), 4.18(s,2H), 4.40(s,2H), 6.62(d,1H, J=1.2Hz), 7.05-7.14(m, 2H), 7.28-7.35(m,2H), 7.90(d, 1H, J=1.2Hz).

(A-50-e) 1-(2,3-Dihydroxypropyl)-4-[3-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one

Melting point: 208-210°C

Elementary analysis as C₁₉H₁₈NO₆F·0.1H₂O


Calcd. (%)	C: 60.51	H: 4.86	N: 3.71	F: 5.04
Found (%)	C: 60.36	H: 4.64	N: 3.67	F: 4.95

NMR(DMSO-d₆)δ: 3.29-3.36(m, 3H), 3.60(dd,1H,J=14.1Hz, 3.6Hz), 3.72 (m, 1H), 4.19(s,2H), 4.45(d,1H, J=18.6Hz), 4.55(d,1H,J=18.6Hz), 4.68(m, 1H), 4.98(m, 1H), 6.62(d, 1H, J=1.2Hz), 7.05-7.14(m, 2H), 7.28-7.35(m, 2H), 7.91(d, 1H, J=1.2Hz).

Compound A-56

4-[3-(4-Fluorobenzyl)-5-methylfuran-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0263]



(A-51) According to the method of the reference (Tetrahedron Lett. 1985, 26, p1777), 5-methyl-2-furoic acid (2.64g, 20.9mmol) was reacted with 4-fluorobenzaldehyde (2.7ml, 25mmol).

(A-52) According to the method of the reference (Tetrahedron 1995, 51, p11043), the above-mentioned crude product was reacted with trimethylsilyl chloride (10.2ml, 80mmol) and sodium iodide (12.0g, 80mmol).

(A-53) According to the method of the example A-36, the above-mentioned crude product was reacted with N,O-dimethylhydroxylamine hydrochloride (2.05g, 21mmol) to give 3-(4-fluorobenzyl)-5-methyl-2-furoic acid methoxymethylamide (3.38g, yield:58%).

(A-54) According to the method of the example A-37, the above-mentioned compound A-53 (3.35g, 12.1mmol) was reacted with 1M methylmagnesium bromide (24ml, 24mmol) to give 1-[3-(4-fluorobenzyl)-5-methylfuran-2-yl]etanone (2.44g, yield:87%).

NMR(CDCl₃) δ : 2.30(3H, d, J=0.6Hz), 2.46(3H, s), 4.12(2H, s), 5.92(1H, s), 6.93-6.99(2H, m), 7.17-7.22(2H, m).

The following compounds were synthesized by the above-mentioned method.

1-[3,5-Bis(4-fluorobenzyl)-5-methylfuran-2-yl]etanone

NMR(CDCl₃) δ : 2.45(3H, s), 3.92(2H, s), 4.11(2H, s), 5.90(1H, s), 6.92-7.03(4H, m), 7.15-7.20(4H, m).

1-[5-Tert-butyl-3-(4-fluorobenzyl)furan-2-yl]etanone

NMR(CDCl₃) δ : 1.28(9H, s), 2.47(3H, s), 4.13(2H, s), 5.90(1H, s), 6.93-6.99(2H, m), 7.19-7.24(2H, m).

1-[3-(4-Fluorobenzyl)-5-p-tolylfuran-2-yl]etanone

NMR(CDCl₃) δ : 2.37(3H, s), 2.58(3H, s), 4.21(2H, s), 6.47(1H, s), 6.95-7.01(2H, m), 7.20-7.27(4H, m), 7.60(2H, d, J=8.1Hz).

1-[3-(4-Fluorobenzyl)-4,5-dimethylfuran-2-yl]etanone

NMR(CDCl₃) δ : 1.82(3H, s), 2.26(3H, s), 2.45(3H, s), 4.13(2H, s), 6.89-6.95(2H, m), 7.15-7.20(2H, m).

(A-55) According to the method of the example A-38, the above-mentioned compound A-54 was reacted to give 4-[3-(4-fluorobenzyl)-5-methylfuran-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester.

NMR(CDCl₃) δ : 2.35(3H, d, J=0.6Hz), 3.94(3H, s), 4.19(2H, s), 6.01(1H, s), 6.95-7.01(2H, m), 7.00(1H, s), 7.19-7.23(2H, m).

EP 1 422 218 A1

The following compounds were synthesized by the above-mentioned method.

4-[3,5-Bis(4-fluorobenzyl)-5-methylfuran-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester

NMR(CDCl₃)δ : 3.93(3H, s), 3.95(2H, s), 4.17(2H, s), 5.96(1H, s), 6.93-7.04(4H, m), 6.97(1H, s), 7.15-7.21(4H, m), 14.84(1H, brs).

4-[5-Tert-butyl-3-(4-fluorobenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester

NMR(CDCl₃)δ : 1.30(9H, s), 3.94(3H, s), 4.20(2H, s), 5.99(1H, s), 6.96-7.02(2H, m), 6.96(1H, s), 7.20-7.25(2H, m).

4-[3-(4-Fluorobenzyl)-5-p-tolylfuran-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester

NMR(CDCl₃)δ : 2.39(3H, s), 3.96(3H, s), 4.27(2H, s), 6.54(1H, s), 6.98-7.03(2H, m), 7.11(1H, s), 7.22-7.28(4H, m), 7.63(2H, d, J=8.1Hz).

4-[3-(4-Fluorobenzyl)-4,5-dimethylfuran-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester NMR(CDCl₃)δ : 1.84(3H, s), 2.31(3H, s), 3.93(3H, s), 4.20(2H, s), 6.91-6.97(2H, m), 7.01(1H, s), 7.15-7.20(2H, m), 14.88(1H, brs).

(A-56) According to the method of the example A-39, the above-mentioned compound A-55 was reacted to give 4-[3-(4-fluorobenzyl)-5-methylfuran-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one.

Melting point: 154-156°C

Elementary analysis as C ₁₈ H ₁₆ FNO ₄				
Calcd. (%)	C, 65.65;	H, 4.90;	N, 4.25;	F, 5.77.
Found (%)	C, 65.30;	H, 4.83;	N, 4.05;	F, 5.59.

NMR(CDCl₃)δ : 2.37(3H, s), 3.18(3H, s), 4.22(2H, s), 4.43(2H, s), 6.05(1H, s), 6.96-7.01(2H, m), 7.20-7.26(2H, m).

[0264] The following compounds were synthesized by the above-mentioned method.

(A-56-a) 4-[3-(4-Fluorobenzyl)-5-methylfuran-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 125-127°C

Elementary analysis as C ₂₀ H ₂₀ FNO ₄				
Calcd. (%)	C, 67.22;	H, 5.64;	N, 3.92;	F, 5.32.
Found (%)	C, 67.95;	H, 5.64;	N, 3.86;	F, 5.64.

NMR(CDCl₃)δ : 1.30(6H, d, J=6.7Hz), 2.38(3H, d, J=0.9Hz), 4.22(2H, s), 4.38(2H, s), 4.59(1H, sec, J=6.7Hz), 6.05(1H, d, J=0.9Hz), 6.95-7.01(2H, m), 7.20-7.24(2H, m).

(A-56-b) 4-[3,5-Bis(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point: 157-160°C

Elementary analysis as C ₂₄ H ₁₉ F ₂ NO ₄ 0.2H ₂ O				
Calcd. (%)	C, 67.51;	H, 4.55;	N, 3.28;	F, 8.90.
Found (%)	C, 67.45;	H, 4.52;	N, 3.21;	F, 8.61.

NMR(CDCl₃)δ : 3.10(3H, s), 3.98(2H, s), 4.09(2H, s), 4.20(2H, s), 6.08(1H, s), 6.95-7.08(4H, m), 7.17-7.24(4H, m).

(A-56-c) 4-[3,5-Bis(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 159-161°C

Elementary analysis as C ₂₆ H ₂₃ F ₂ NO ₄				
Calcd. (%)	C, 69.17;	H, 5.14;	N, 3.10;	F, 8.42.
Found (%)	C, 68.94;	H, 5.22;	N, 3.06;	F, 8.07.

NMR(CDCl₃)δ : 1.20(6H, d, J=6.7Hz), 3.98(2H, s), 4.07(2H, s), 4.21(2H, s), 4.54(1H, sec, J=6.7Hz), 6.18(1H, d, J=0.9Hz), 6.96-7.08(4H, m), 7.18-7.24(4H, m).

(A-56-d) 4-[5-Tert-butyl-3-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point: 179-181°C

EP 1 422 218 A1

Elementary analysis as C ₂₁ H ₂₂ FNO ₄				
Calcd. (%)	C, 67.91;	H, 5.97;	N, 3.77;	F, 5.12.
Found (%)	C, 67.51;	H, 5.88;	N, 3.62;	F, 4.96.

NMR(CDCl₃)δ: 1.31(9H, s), 3.19(3H, s), 4.22(2H, s), 4.43(2H, s), 6.02(1H, s), 6.96-7.02(2H, m), 7.21-7.26(2H, m).
(A-56-e) 4-[3-(4-Fluorobenzyl)-5-p-tolylfuran-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one
Melting point:242-245°C

Elementary analysis as C ₂₄ H ₂₀ FNO ₄ 0.1H ₂ O				
Calcd. (%)	C, 70.79;	H, 5.00;	N, 3.44;	F, 4.67.
Found (%)	C, 70.50;	H, 5.17;	N, 3.41;	F, 4.58.

NMR(CDCl₃)δ: 2.41(3H, s), 3.23(3H, s), 4.30(2H, s), 4.57(2H, s), 6.58(1H, s), 6.98-7.04(2H, m), 7.25-7.30(4H, m), 7.54(2H, d, J=8.1Hz).
(A-56-f) 4-[3-(4-Fluorobenzyl)-4,5-dimethylfuran-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one
Melting point:202-204°C

Elementary analysis as C ₁₉ H ₁₈ FNO ₄ 0.2H ₂ O				
Calcd. (%)	C, 66.46;	H, 5.28;	N, 4.08;	F, 5.53.
Found (%)	C, 66.46;	H, 5.20;	N, 4.00;	F, 5.44.

NMR(CDCl₃)δ:1.87(3H, s), 2.32(3H, s), 3.18(3H, s), 4.22(2H, s), 4.43(2H, s), 6.91-6.97(2H, m); 7.17-7.22(2H, m).
(A-56-g) 4-[5-Tert-butyl-3-(4-fluorobenzyl)furan-2-carbonyl]-1-ethyl-3-hydroxy-1,5-dihydropyrrole-2-one
Melting point:141-143°C

Elementary analysis as C ₂₂ H ₂₄ FNO ₄				
Calcd. (%)	C, 68.56;	H, 6.28;	N, 3.63;	F, 4.93.
Found (%)	C, 68.54;	H, 6.36;	N, 3.63;	F, 4.87.

NMR(CDCl₃)δ: 1.21(3H, t, J=7.4Hz), 1.31(9H, s), 3.65(2H, q, J=7.2Hz), 4.22(2H, s), 4.44(2H, s), 6.02(1H, s), 6.96-7.02(2H, m), 7.21-7.26(2H, m).
(A-56-h) 4-[5-Tert-butyl-3-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one
Melting point:146-147°C

Elementary analysis as C ₂₃ H ₂₆ FNO ₄				
Calcd. (%)	C, 69.16;	H, 6.56;	N, 3.51;	F, 4.76.
Found (%)	C, 69.11;	H, 6.62;	N, 3.50;	F, 4.77.

NMR(CDCl₃)δ: 1.30(6H, d, J=6.6Hz), 1.32(9H, s), 4.22(2H, s), 4.40(2H, s), 4.59(1H, seq, J=6.6Hz), 6.03(1H, s), 6.96-7.02(2H, m), 7.21-7.26(2H, m).
(A-56-i) 4-[5-Tert-butyl-3-(4-fluorobenzyl)furan-2-carbonyl]-1-cyclopropyl-3-hydroxy-1,5-dihydropyrrole-2-one
Melting point:148-150°C


Elementary analysis as C ₂₃ H ₂₄ FNO ₄ 0.1H ₂ O				
Calcd. (%)	C, 69.19;	H, 6.11;	N, 3.51;	F, 4.76.
Found (%)	C, 68.82;	H, 6.17;	N, 3.73;	F, 4.61.

NMR(CDCl₃)δ: 0.83-0.99(4H, m), 1.32(9H, s), 2.92-3.00(1H, m), 4.21(2H, s), 4.36(2H, s), 6.02(1H, s), 6.96-7.02(2H, m), 7.21-7.25(2H, m).

Compound A-61

4-[3-(4-Fluorobenzyl)thiophene-2-carbonyl]-3-hydroxy-1-methyl-1, 5-dihydropyrrole-2-one

[0265]



(A-57) According to the method of the reference (Tetrahedron Lett. 1985, 26, p1777), 2-thiophenecarboxylic acid (3.84g, 30mmol) was reacted with 4-fluorobenzylbromide (5.6ml, 45mmol).

(A-58) According to the example A-36, the above-mentioned crude product A-57 was reacted with N,O-dimethylhydroxylamine hydrochloride (2.93g, 30mmol).

(A-59) According to the example A-37, the above-mentioned crude product A-58 was reacted with 1M methylmagnesium bromide (30ml, 30mmol) to give 1-[3-(4-fluorobenzyl)thiophene-2-yl]etanone (3.47g, yield:49%).

NMR(CDCl₃)δ: 2.55(3H, s), 4.36(2H, s), 6.86(1H, d, J=4.9Hz), 6.93-6.99(2H, m), 7.15-7.20(2H, m), 7.41(1H, d, J=5.2Hz).

(A-60) According to the example A-38, the above-mentioned crude product A-59 was reacted to give 4-[3-(4-fluorobenzyl)thiophene-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester.

NMR(CDCl₃)δ: 3.93(3H, s), 4.42(2H, s), 6.83(1H, s), 6.91(1H, d, J=4.9Hz), 6.95-7.01(2H, m), 7.16-7.21(2H, m), 7.55(1H, d, J=5.2Hz).

(A-61) According to the example A-39, the above-mentioned crude product A-60 was reacted to give 4-[3-(4-fluorobenzyl)thiophene-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one.

Melting point: 181-183°C

Elementary analysis as C₁₇H₁₄FN₁O₃S

Calcd. (%)	C, 61.62;	H, 4.26;	N, 4.23;	F, 5.73.
Found (%)	C, 61.34;	H, 4.35;	N, 3.99;	F, 5.59.

NMR(CDCl₃)δ: 3.19(3H, s), 4.42(4H, s), 6.96(1H, d, J=5.1Hz), 6.95-7.01(2H, m), 7.18-7.22(2H, m), 7.58(1H, d, J=4.8Hz).

[0266] The following compound was synthesized by the above-mentioned method.

4-[3-(4-Fluorobenzyl)thiophene-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one Melting point: 174-175°C


Elementary analysis as C ₁₉ H ₁₈ FNO ₃ S 0.1H ₂ O				
Calcd. (%)	C, 63.18;	H, 5.08;	N, 3.88;	F, 5.26.
Found (%)	C, 62.93;	H, 5.03;	N, 3.78;	F, 5.08.

NMR(CDCl₃)δ: 1.31(6H, d, J=6.7Hz), 4.34(2H, s), 4.42(2H, s), 4.60(1H, sec, J=6.7Hz), 6.96(1H, d, J=5.2Hz), 6.95-7.01 (2H, m), 7.18-7.22(2H, m), 7.58(1H, d, H=4.9Hz).

Compound A-69

4-[5-(4-Fluorobenzyl)-2-methyloxazole-4-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0267]



(A-62) According to the method of the reference (Org. Synth. Col. VII, 1990, p359), 4-fluorophenylacetyl chloride (27.6g, 160mmol) was reacted with Meldrum's acid in the presence of pyridine, then reacted with methyl alcohol to give 4-(4-fluorophenyl)-3-oxobutanoic acid methyl ester (28.9g, yield:86%).

NMR(CDCl₃)δ: 3.47(2H, s), 3.72(3H, s), 3.81(2H, s), 7.00-7.06(2H, m), 7.15-7.20(2H, m).

(A-63) According to the method of the reference (Org. Synth. 1992, 70, p93), the above-mentioned compound A-62 (4.20g, 20mmol) was reacted with 4-acetamidobenzenesulfonyl azide in the presence of triethylamine to give 2-diazo-4-(4-fluorophenyl)-3-oxobutanoic acid methyl ester 2a (3.67g, yield:78%). NMR(CDCl₃)δ: 3.85(3H, s), 4.16(2H, s), 6.97-7.03(2H, m), 7.23-7.28(2H, m).

According to the method of the reference (J. Org. Chem. 1962, 27, p1717), 2-diazo-5-(4-fluorophenyl)-3-oxopentanoic acid methyl ester was prepared from the known compound 5-(4-fluorophenyl)-3-oxopentanoic acid methyl ester.

NMR(CDCl₃)δ: 2.93(2H, t, J=7.5Hz), 3.13-3.18(2H, m), 3.83(3H, s), 6.93-6.99(2H, m), 7.17-7.21(2H, m).

(A-64) According to the method of the reference (Synthesis, 1993, p793), the above-mentioned compound A-63 (2.92g, 12.4mmol) was reacted with acetonitrile in the presence of boron trifluoride to give 5-(4-fluorobenzyl)-2-methyloxazole-4-carboxylic acid methyl ester (1.72g, yield:56%).

NMR(CDCl₃)δ: 2.43(3H, s), 3.93(3H, s), 4.31(2H, s), 6.97-7.02(2H, m), 7.23-7.28(2H, m).

The following compound was synthesized by the above-mentioned method.

EP 1 422 218 A1

5-[2-(4-Fluorophenyl)ethyl]-2-methyloxazole-4-carboxylic acid methyl ester

NMR(CDCl₃)δ: 2.44(3H,s), 2.95(2H, t, J=7.8Hz), 3.27(2H, dd, J=6.9, 8.7Hz), 3.87(3H, s), 6.94-6.99(2H, m), 7.12-7.17(2H, m).

(A-65) The above-mentioned compound A-64(1.70g, 6.82mmol) washed hydrolyzed to give 5-(4-fluorobenzyl)-2-methyloxazole-4-carboxylic acid(1.27g, yield:79%).

NMR(CDCl₃)δ: 2.31(3H, s), 4.29(2H, s), 6.90-6.96(2H, m), 7.22-7.26(2H, m).

The following compound was synthesized by the above-mentioned method.

5-[2-(4-Fluorophenyl)ethyl]-2-methyloxazole-4-carboxylic acid

NMR(CDCl₃)δ: 2.49(3H,s), 2.97(2H, t, J=8.0Hz), 3.30(2H, dd, J=6.9, 8.7Hz), 6.94-7.00(2H, m), 7.12-7.17(2H, m).

(A-66) According to the method of the example A-36, the above-mentioned compound A-65(1.25g, 5.31mmol) was reacted with N,O-dimethylhydroxylamine hydrochloride(1.53g, 8.0mmol) to give 5-(4-fluorobenzyl)-2-methyloxazole-4-carboxylic acid methoxymethylamide(1.30g, yield:88%).

NMR(CDCl₃)δ: 2.40(3H, s), 3.43(3H, s), 3.80(3H, s), 4.22(2H, s), 6.95-7.01(2H, m), 7.28-7.33(2H, m).

The following compound was synthesized by the above-mentioned method.

5-[2-(4-Fluorophenyl)ethyl]-2-methyloxazole-4-carboxylic acid methoxymethylamide 5b

NMR(CDCl₃)δ: 2.42(3H,s), 2.94(2H, t, J=8.1Hz), 3.20(2H, dd, J=6.8, 8.9Hz), 3.37(3H, s), 3.76(3H, s), 6.92-6.98(2H, m), 7.13-7.18(2H, m).

(A-67) According to the method of the example A-37, the above-mentioned compound A-66(1.28g, 4.6mmol) was reacted with 1M methylmagnesium bromide(9.2ml, 9.2mmol) to give 1-[5-(4-fluorobenzyl)-2-methyloxazole-4-yl] ethanone A-7(0.89g, yield:83%).

NMR(CDCl₃)δ: 2.42(3H, s), 2.54(3H, s), 4.30(2H, s), 6.95-7.01(2H, m), 7.24-7.29(2H, m).

The following compound was synthesized by the above-mentioned method.

1-[5-[2-(4-Fluorophenyl)ethyl]-2-methyloxazole-4-yl]ethanone

NMR(CDCl₃)δ: 2.43(3H,s), 2.49(3H, s), 2.93(2H, t, J=8.0Hz), 3.27(2H, dd, J=7.1, 8.9Hz), 6.93-6.99(2H, m), 7.12-7.17(2H, m).

(A-68) According to the method of the example A-38, the above-mentioned compound A-67 was reacted to give 4-[5-(4-fluorobenzyl)-2-methyloxazole-4-carbonyl]-2-hydroxy-4-oxo-2-butenic acid methyl ester.

NMR(CDCl₃)δ: 2.44(3H, s), 3.92(3H, s), 4.36(2H, s), 6.97-7.03(2H, m), 7.19(1H, s), 7.25-7.30(2H, m), 14.82(1H, brs).

The following compound was synthesized by the above-mentioned method. 4-[5-[2-(4-Fluorophenyl)ethyl]-2-methyloxazole-4-carbonyl]-2-hydroxy-4-oxo-2-butenic acid methyl ester

NMR(CDCl₃)δ: 2.45(3H,s), 2.97(2H, t, J=7.8Hz), 3.33(2H, dd, J=6.8, 8.9Hz), 3.91(3H, s), 6.94-7.00(2H, m), 7.13-7.19(2H, m), 7.14(1H,s), 14.70(1H, brs).

(A-69) According to the method of the example A-39, the above-mentioned compound A-68 was reacted to give 4-[5-(4-fluorobenzyl)-2-methyloxazole-4-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one.

Melting point: 170°C

Elementary analysis as C ₁₇ H ₁₅ FN ₂ O ₄				
Calcd. (%)	C, 61.82;	H, 4.58;	N, 8.48;	F, 5.75.
Found (%)	C, 61.66;	H, 4.57;	N, 8.45;	F, 5.64.

NMR(CDCl₃)δ: 2.56(3H, s), 3.15(3H, s), 4.15(2H, d, J=0.6Hz), 4.41(2H, s), 6.97-7.03(2H, m), 7.26-7.31(2H, m), 15.08(1H, brs).

[0268] The following compound was synthesized by the above-mentioned method.

4-[5-(4-Fluorobenzyl)-2-methyloxazole-4-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Negative ESIMS m/z 357 (M-H)⁻

Positive ESIMS m/z 359 (M+H)⁺

NMR(CDCl₃)δ: 1.27(6H, d, J=5.3Hz), 2.57(3H, s), 4.08(2H, s), 4.14(2H, s), 4.54(1H, sec, J=6.6Hz), 6.97-7.02(2H, m), 7.27-7.32(2H, m), 15.03(1H, brs).

4-[5-[2-(4-Fluorophenyl)ethyl]-2-methyloxazole-4-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point: 184-185°C

Elementary analysis as C ₁₈ H ₁₇ FN ₂ O ₄				
Calcd. (%)	C, 62.79;	H, 4.98;	N, 8.14;	F, 5.52.
Found (%)	C, 62.57;	H, 4.91;	N, 8.03;	F, 5.37.


EP 1 422 218 A1

NMR(CDCl₃)δ: 2.56(3H, s), 2.98(2H, t, J=7.2Hz), 3.14(3H, s), 3.38(2H, dd, J=6.9, 8.7Hz), 4.07(2H, s), 6.94-7.00(2H, m), 7.15-7.19(2H, m), 15.11(1H, brs).

Compound A-73

4-[2-(4-Fluorobenzyl)-1H-imidazole-4-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

[0269]



(A-70) According to the method of the reference(J. Org. Chem. 1987, 52, p2714), (5-methylisoxazole-4-yl)amine hydrochloride(16.15g, 120mmol) was reacted with 4-fluorophenylacetyl chloride(20.8g, 120mmol) in the presence of triethylamine to give 2-(4-fluorophenyl)-N-(5-methylisoxazole-4-yl)acetamide(22.55g, yield:80%).

NMR(CDCl₃)δ : 2.28(3H, s), 3.69(3H, s), 6.71(1H, brs), 7.06-7.20(2H, m), 7.26-7.32(2H, m), 8.46(1H, s).

(A-71) The above-mentioned compound A-70 was reduced by hydrogenation, then treated with sodium hydroxide to give 1-[2-(4-fluorobenzyl)-1H-imidazole-4-yl]ethanone(yield:82%). NMR(CDCl₃)δ : 2.45(3H, s), 4.12(2H, s), 6.96-7.01(2H, m), 7.19-7.23(2H, m), 7.64(1H, s).

(A-72) The above-mentioned compound A-71 was protected with a BOC group, then according to the method of the example A-38, 2-(4-fluorobenzyl)-4-(3-hydroxy-3-methoxycarbonylacryloyl)imidazole-4-carboxylic acid tert-butyl ester was synthesized.

NMR(CDCl₃)δ: 1.55(9H, s), 3.93(3H, s), 4.41(2H, s), 6.94-7.00(2H, m), 7.17(1H, s), 7.19-7.23(2H, m), 8.06(1H, s).

(A-73) A-72 was reacted according to the method of example A-39 to give a mixture comprising a de-protected product. The mixture was deprotected by using trifluoroacetic acid to give 4-[2-(4-fluorobenzyl)-1H-imidazole-4-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one.


Melting point:220°C

Elementary analysis as C ₁₈ H ₁₈ FN ₃ O ₃ 0.2H ₂ O				
Calcd. (%)	C, 62.31;	H, 5.35;	N, 12.11;	F, 5.48.
Found (%)	C, 62.13;	H, 5.07;	N, 11.94;	F, 5.57.

NMR(CDCl₃)δ: 1.24(6H, d, J=6.7Hz), 4.05(2H, s), 4.12(2H, s), 4.52(1H, sec, J=6.7Hz), 6.98-7.03(2H, m), 7.24-7.29(2H, m), 7.64(1H, s).

Compound A-78-a

[0270]



(A-74-a, A-74-b) To a dimethylformamide solution (30ml) of 1H-imidazole-4-carbaldehyde (2.88g, 30mmol), potassium tert-butoxide (3.7g, 33mmol) and 4-fluorobenzyl bromide (3.74ml, 30mmol) were added under ice cooling, then, the mixture was stirred for 1 hour. The solution was added a saturated ammonium chloride aqueous solution and extracted with ethyl acetate, washed with water and brine, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography to give 1-(4-fluorobenzyl)-1H-imidazole-4-carbaldehyde A-74-a (2.7g, yield: 44%); NMR(CDCl₃) δ : 5.18(2H, s), 7.06-7.18(2H, m), 7.20-7.23(2H, m), 7.60(1H, d, J=1.1Hz), 7.62(1H, s), 9.87(1H, s) and 3-(4-fluorobenzyl)-3H-imidazole-4-carbaldehyde A-74-b (2.95g, yield: 48%);

NMR(CDCl₃) δ : 5.49(2H, s), 7.00-7.06(2H, m), 7.21-7.24(2H, m), 7.72(1H, s), 7.84(1H, s), 9.75(1H, d, J=0.9Hz).

(A-75-a) To a tetrahydrofuran solution (30ml) of the above-mentioned compound A-74-a (2.7g, 13.2mmol), was added dropwise 1M methylmagnesium bromide (16ml, 16mmol) under ice cooling at room temperature, the mixture was stirred for 1.5 hours, then was added dropwise 1M methylmagnesium bromide (16ml, 16mmol). The solution was stirred for 1.5 hours, then was added a saturated ammonium chloride aqueous solution and extracted with ethyl acetate, washed with water and brine. The solution was dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography to give 1-[1-(4-fluorobenzyl)-1H-imidazole-4-yl]ethanol (2.75g, yield: 95%).

NMR(CDCl₃) δ : 1.50(3H, d, J=6.4Hz), 3.04(1H, brs), 4.86(1H, q, J=6.6Hz), 5.03(2H, s), 6.76(1H, s), 7.01-7.08(2H, m), 7.13-7.17(2H, m), 7.47(1H, d, J=1.3Hz).

(A-75-b) The following compound was synthesized by the above-mentioned method from the compound A-74-b.

1-[3-(4-Fluorobenzyl)-3H-imidazole-4-yl]ethanol.

NMR(DMSO-d₆) δ : 1.36(3H, d, J=6.7Hz), 4.55(1H, m), 5.18(1H, q, J=6.1Hz), 5.25(2H, s), 6.81(1H, t, J=0.9Hz), 7.17-7.22(4H, m), 7.65(1H, d, J=1.2Hz).

(A-76-a) To a tetrahydrofuran solution (60ml) of the above-mentioned compound A-75-a (2.48g, 11.3mmol), was added manganese dioxide (9.56g, 110mmol) at room temperature, then the mixture was stirred for 2.5 hours. The solution was filtered by celite, then evaporated under reduced pressure and the residue was recrystallized with diisopropylether-ethyl acetate to give 1-[1-(4-fluorobenzyl)-1H-imidazole-4-yl]etanone (1.77g, yield: 72%).

NMR(CDCl₃) δ : 2.55(3H, s), 5.12(2H, s), 7.05-7.10(2H, m), 7.16-7.21(2H, m), 7.54-7.56(2H, m).

(A-76-b) The following compound was synthesized by the above-mentioned method from the compound A-75-b.

1-[3-(4-Fluorobenzyl)-3H-imidazole-4-yl]etanone.

NMR(CDCl₃) δ : 2.55(3H, s), 5.49(2H, s), 6.99-7.04(2H, m), 7.15-7.20(2H, m), 7.64(1H, s), 7.82(1H, s).

(A-77-a) According to the method of the above-mentioned example A-39, 4-[1-(4-fluorobenzyl)-1H-imidazole-4-carbonyl]-2-hydroxy-4-oxo-2-butenic acid methyl ester was synthesized from the compound A-76-a.

NMR(DMSO-d₆) δ : 3.65(3H, s), 5.18(2H, s), 7.12-7.18(2H, m), 7.32-7.37(2H, m), 7.54(1H, brs), 7.67(1H, brs).

(A-77-b) The following compound was synthesized by the above-mentioned method from the compound A-76-b.
4-[3-(4-Fluorobenzyl)-3H-imidazole-4-carbonyl]-2-hydroxy-4-oxo-2-butenic acid methyl ester

NMR(CDCl₃) δ : 3.71(3H, s), 5.43(2H, s), 6.46(1H, s), 6.81-6.87(2H, m), 7.06-7.10(2H, m), 7.52(1H, s), 7.65(1H, s).

(A-78-a) According to the method of the above-mentioned example A-39, 4-[1-(4-fluorobenzyl)-1H-imidazole-4-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one was synthesized from the compound A-77-a.

Melting point: 224-226°C

Elementary analysis as C₁₈H₁₈FN₃O₃

Calcd. (%)	C, 62.97;	H, 5.28;	N, 12.24;	F, 5.53.
Found (%)	C, 62.57;	H, 5.15;	N, 12.02;	F, 5.27.

NMR(DMSO-d₆) δ : 1.18(6H, d, J=6.7Hz), 3.97(2H, s), 4.25(1H, sec, J=6.7Hz), 5.37(2H, s), 7.21-7.27(2H, m), 7.47-7.52(2H, m), 8.17(1H, s), 8.48(1H, s).

(A-78-b) The following compound was synthesized by the above-mentioned method from the compound A-77-b.
4-[3-(4-Fluorobenzyl)-3H-imidazole-4-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 156-159°C

Negative ESIMS m/z 342 (M-H)⁻


Positive ESIMS m/z 344 (M+H)⁺

NMR(DMSO-d₆) δ : 1.17(6H, d, J=6.7Hz), 4.02(2H, s), 4.21(1H, sec, J=6.7Hz), 5.55(2H, s), 7.03(2H, brt), 7.21-7.25(2H, m), 7.90(1H, brs), 8.11(1H, brs).

Compound A-84

4-[5-(4-Fluorobenzyl)-1H-pyrrole-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0271]



(A-79) According to the method of the reference(J. Org. Chem., 1983, 48, p3214), 1-benzenesulfonyl 1H-pyrrole (J. Org. Chem., 1999, 64, p3379)(45.0 g, 217 mmol) was reacted with 4-fluorobenzoyl chloride(103 g, 651 mmol) in the presence of boron trifluoride-diethyl ether complex(80.1 ml, 651 mmol) in methylene chloride(360 ml) to give 2-(4-fluorophenyl)-N-(5-methylisoxazole-4-yl)acetamide(22.55g, yield:80%).

The residue was Crystallized(diisopropylether-n-hexane) to give (1-benzenesulfonyl1H-pyrrole-2-yl)-(4-fluorophenyl)metanone(33 g, yield :46%).

NMR(CDCl₃) δ : 6.36(1H, dd, J=3.3, 3.6Hz), 6.70(1H, dd, J=1.5, 3.6Hz), 7.08-7.15(2H, m), 7.55-7.70(3H, m), 7.78

(1H, dd, J=1.5, 3.3Hz), 7.80-7.89(2H, m), 8.00-8.14(2H, m).

(A-80) According to the method of the reference(Synth. Comm., 1990, 20, p1647), the above-mentioned compound A-79(32.5 g, 98.7 mmol) was reduced by borane tert-butylamine complex(51.5 g, 0.59 mol) in the presence of aluminum chloride(39.5 g, 0.30 mol) in methylene chloride(150 ml). The residue was purified with column chromatography(ethyl acetate:n-hexane=1:4-1:3) to give 1-benzenesulfonyl-2-(4-fluorobenzyl)-1H-pyrrole(26.9 g, yield :86%).

NMR(CDCl₃)δ: 4.05(2H, s), 5.81(1H, dd, J=1.5, 3.3Hz), 6.21(1H, t, J=1.5Hz), 6.81-7.01(4H, m), 7.34(1H, dd, J=1.5, 3.3Hz), 7.37-7.44(2H, m), 7.52-7.61(3H, m).

(A-81) To a methyl alcohol(400 ml) solution of the above-mentioned compound A-80(26.9 g, 86.5 mmol), was added 5N sodium hydroxide aqueous solution 85 ml, and the reaction mixture was stirred for 6 hours under refluxing. The solution was Cooled at room temperature, to which was added 2N hydrochloric acid 185 ml, then extracted with ethyl acetate. The extract was washed with saturated NaCl aqueous solution, dried, then evaporated under reduced pressure. The residue was purified with column chromatography(ethyl acetate:n-hexane=1:3)to give 2-(4-fluorobenzyl)-1H-pyrrole(14.5 g, yield :97%).

NMR(CDCl₃)δ: 3.95(2H, s), 5.97(1H, s), 6.15(1H, dd, J=2.7, 5.7Hz), 6.68(1H, dd, J=2.7, 4.2Hz), 6.94-7.02(2H, m), 7.12-7.19(2H, m), 7.82(1H, brs).

(A-82) To phosphorus oxychloride(7.33 ml, 78.6 mmol) at room temperature, was added dropwise DMA(12.5 ml) for 20 minutes under stirring, to which was added dropwise a DMA(12.5 ml) solution of the above-mentioned compound A-81(12.5 g, 71.3 mmol) at room temperature. The solution was stirred at 50°C for 3 hours, to which was added 5N sodium hydroxide aqueous solution 86 ml under ice-water cooling, to which was added 6N hydrochloric acid 30 ml and extracted with ethyl acetate. The extract was washed with water, and saturated NaCl aqueous solution, dried, then evaporated under reduced pressure. The residue was Crystallized with diisopropylether 40 ml and filtered out, then washed with diisopropylether, dried to give 1-[5-(4-fluorobenzyl)-1H-pyrrole-2-yl]etanone (5.65 g, yield :36%). The filtrate was Concentrated under reduced pressure, then the residue was purified with column chromatography(ethyl acetate:n-hexane=1:3-1:2)and recrystallized(diisopropylether) to give 1-[5-(4-fluorobenzyl)-1H-pyrrole-2-yl]etanone(3.85 g, yield :25%).

NMR(CDCl₃)δ: 3.37(3H, s), 3.96(2H, s), 6.00-6.04(1H, m), 6.82-6.86(1H, m), 6.96-7.05(2H, m), 7.12-7.18(2H, m), 9.11(1H, brs).

(A-83) According to the method of the above-mentioned example A-18, 4-[5-(4-fluorobenzyl)-1H-pyrrole-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester was synthesized from the above-mentioned compound A-82.

NMR(CDCl₃)δ: 3.92(3H, s), 4.00(2H, s), 6.10-6.13(1H, m), 6.75(1H, s), 6.97-7.06(3H, m), 7.12-7.19(2H, m), 9.09(1H, brs).

(A-84) According to the method of the above-mentioned example A-19, 4-[5-(4-fluorobenzyl)-1H-pyrrole-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one was synthesized from the above-mentioned compound A-83. NMR(DMSO-d₆)δ: 3.00(3H, s), 3.95(2H, s), 4.22(2H, s), 5.97-6.03(1H, m), 7.06-7.16(3H, m), 7.26-7.34(2H, m), 12.00(1H, brs).

Melting point:221-223°C

Elementary analysis as C ₁₇ H ₁₅ FN ₂ O ₃				
Calcd. (%)	C, 64.96;	H, 4.81;	N, 8.91;	F, 6.04.
Found (%)	C, 64.87;	H, 4.68;	N, 8.80;	F, 6.10.

Calcd. (%)	C, 64.96;	H, 4.81;	N, 8.91;	F, 6.04.
Found (%)	C, 64.87;	H, 4.68;	N, 8.80;	F, 6.10.

[0272] The following compound was synthesized by the above-mentioned method.

4-[5-(4-Fluorobenzyl)-1H-pyrrole-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

NMR(DMSO-d₆)δ: 1.20(6H, d, J=6.9Hz), 3.95(2H, s), 4.17(2H, s), 4.19-4.31(1H, m), 5.99-6.03(1H, m), 7.07-7.18(3H, m), 7.27-7.35(2H, m), 11.96(1H, brs).

Melting point:222-224°C


Elementary analysis as C ₁₉ H ₁₉ FN ₂ O ₃				
Calcd. (%)	C, 66.66;	H, 5.59;	N, 8.18;	F, 5.55
Found (%)	C, 66.66;	H, 5.49;	N, 8.12;	F, 5.62

Calcd. (%)	C, 66.66;	H, 5.59;	N, 8.18;	F, 5.55
Found (%)	C, 66.66;	H, 5.49;	N, 8.12;	F, 5.62

Compound A-89

4-[4-(4-Fluorobenzyl)-1H-pyrrole-3-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0273]



(A-85) According to the method of the reference(J. Org. Chem., 1983, 48, p3214), 1-benzenesulfonyl-1H-pyrrole (J. Org. Chem., 1999, 64, p3379) was reacted with 4-fluorobenzoyl chloride(2.88 ml, 26.5 mmol) in the presence of aluminum chloride(3.25 g, 26.5 mmol) in methylene chloride(40 ml) to give a crude ketone(9.15 g) which was reduced by borane tert-butylamine complex(11.6 g, 133 mmol) in the presence of aluminum chloride(8.88 g, 66.6 mmol) in methylene chloride(200 ml) according to the method of the reference(Synth. Comm., 1990, 20, p1647). The residue was purified with column chromatography(ethyl acetate:n-hexane=1:4-1:3) to give 1-benzenesulfonyl-3-(4-fluorobenzyl)-1H-pyrrole(4.66 g, yield :61%).

NMR(CDCl₃)δ: 3.70(2H, s), 6.10(1H, dd, J=1.5, 3.0Hz), 6.86-7.12(6H, m), 7.46-7.64(3H, m), 7.80-7.85(2H, m).

(A-86) To a methylene chloride(35 ml) suspension of aluminum chloride(4.33 g, 32.5 mmol) at room temperature, was added dropwise a methylene chloride(5 ml) solution of acetic anhydride(1.66 g, 16.3 mmol)for 15minutes under stirring, to which a methylene chloride(10 ml) solution of the above-mentioned compound A-85(4.66 g, 14.8 mmol) was added dropwise under ice cooling. The solution was stirred for 1 hour under ice cooling, then for 30 minutes at room temperature, to which was added ice water and extracted with ethyl acetate. The extract was washed with a saturated sodium hydrogen carbonate aqueous solution and a saturated NaCl aqueous solution, then dried and evaporated under reduced pressure. The residue was Crystallized by diisopropyl ether and n-hexane and filtered out. The filtrate was evaporated under reduced pressure, then the residue was purified with column chromatography(ethyl acetate:n-hexane=1:3-1:2) and crystallized with(diisopropyl ether-n-hexane) to give 1-[1-benzenesulfonyl-4-(4-fluorobenzyl)-1H-pyrrole-3-yl]etanone(3.57 g, yield :68%).

NMR(CDCl₃)δ: 2.39(3H, s), 3.98(2H, s), 6.66-6.89 (1H, m), 6.91-7.15(4H, m), 7.52-7.89(6H, m).

(A-87) According to the method of the above-mentioned example A-18, 4-[1-benzenesulfonyl-4-(4-fluorobenzyl)-1H-pyrrole-3-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester was synthesized from the above-mentioned compound A-86.

NMR(CDCl₃)δ:3.93(3H, s), 4.03(2H, s), 6.72-6.74(1H, m), 6.93-7.15(4H, m), 7.53-7.92(6H, m).

(A-88) According to the method of the above-mentioned example A-19, 4-[1-benzenesulfonyl-4-(4-fluorobenzyl)-1H-pyrrole-3-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one was synthesized from the above-mentioned

compound A-87.

NMR(DMSO- d_6) δ : 2.99(3H, s), 3.90(2H, s), 4.02(2H, s), 7.00-7.21(6H, m), 7.63-7.82(3H, m), 7.97-8.14 (3H, m).

The following compound was synthesized by the above-mentioned method.

4-[1-Benzenesulfonyl-4-(4-fluorobenzyl)-1*H*-pyrrole-3-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one
 5 NMR(DMSO- d_6) δ : 1.18(6H, d, $J=6.7$ Hz), 3.90(2H, s), 3.97(2H, s), 4.16-4.31(1H, m), 7.05-7.15(6H, m), 7.63-7.82 (5H, m), 8.13(2H, brs).

(A-89) According to the method of the reference(J. Org. Chem., 1983, 48, p3214), the protected NH group of the pyrrole ring of the above-mentioned compound A-88 was deprotected by hydrolysis to give 4-[4-(4-fluorobenzyl)-1*H*-pyrrole-3-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one.

10 NMR(DMSO- d_6) δ : 2.99(3H, s), 4.02(2H, s), 4.19(2H, s), 6.54(1H, s), 7.00-7.27(4H, m), 7.62(1H, s), 11.41(1H, brs).
 Melting point:265-267°C

Elementary analysis as $C_{17}H_{15}FN_2O_3 \cdot 0.1H_2O$				
Calcd. (%)	C, 64.59;	H, 4.85;	N, 8.86;	F, 6.01.
Found (%)	C, 64.54;	H, 4.72;	N, 8.82;	F, 5.89.

The following compound was synthesized by the above-mentioned method. 4-[4-(4-Fluorobenzyl)-1*H*-pyrrole-3-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

20 NMR(DMSO- d_6) δ : 1.20(6H, d, $J=6.7$ Hz), 4.02(2H, s), 4.14(2H, s), 4.18-4.32(1H, m), 6.56(1H, s), 7.00-7.26(4H, m), 7.68(1H, s), 11.39(1H, brs).


Melting point:255-258°C

Elementary analysis as $C_{19}H_{19}FN_2O_3 \cdot 0.2H_2O$				
Calcd. (%)	C, 65.96;	H, 5.65;	N, 8.10;	F, 5.49.
Found (%)	C, 66.06;	H, 5.45;	N, 8.01;	F, 5.42.

Compound A-92

4-[1-(4-Fluorobenzyl)-1*H*-pyrrole-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0274]



(A-90) Sodium hydride(5g, 12.5mmol) was washed with n-hexane, then dried and suspend in dimethylformamide 100ml, to which were added 2-acetylpyrrole(10.9g, 10mmol) and 4-fluorobenzyl bromide(20g, 10.6mmol) under ice cooling. Then the mixture was stirred at room temperature for 1 hour and added to an ammonium chloride solution. The solution was extracted with ethyl ether, then washed, dried and evaporated under reduced pressure. The residue was purified with column chromatography(ethyl acetate:n-hexane=1:10) to give the objective compound 21.4g(yield 99%).

55 NMR($CDCl_3$) δ : 2.41(s, 3H), 5.53(s, 2H), 6.20(dd, 1H, $J=3.9$ Hz, 2.4Hz), 6.90(m, 1H), 6.92-7.02(m, 3H), 7.07-7.12 (m, 2H).

EP 1 422 218 A1

(A-91) To a tetrahydrofuran 40ml solution of the above-mentioned compound A-90(4.35g, 20mmol), lithium hexamethyl disilazide(1N tetrahydrofuran solution, 24ml) was added dropwise at -78°C. 10 Minutes later, oxalic acid dimethyl(2.83g, 24mmol) was added thereto and stirred at 0°C for 30minutes. The solution was added to ice water and acidified with hydrochloric acid, then extracted with ethyl acetate, washed, dried and evaporated under reduced pressure. The residue was Crystallized with n-hexane to give the objective compound 5.7g(yield 94%).

NMR(CDCl₃)δ: 3.90(s, 3H), 5.60(s, 2H), 6.28(dd, 1H, J=3.9Hz, 2.4Hz), 6.84(s, 1H), 6.95-6.99(m, 3H), 7.07-7.16(m, 3H).

(A-92) To a dioxane 50ml solution of the above-mentioned compound A-91(1.0g, 3.3mmol), methylamine(40% methyl alcohol solution) and paraformaldehyde 300 mg were added at room temperature for 1 hour under stirring. The solvent was evaporated under reduced pressure, to which was added an ammonium chloride solution and extracted with chloroform, washed, dried and evaporated under reduced pressure. The residue was Crystallized by isopropyl alcohol to give 4-[1-(4-fluorobenzyl)-1H-pyrrole-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one 720mg(yield 69%).

Melting point:150-151°C

Elementary analysis as C ₁₇ H ₁₅ N ₂ O ₃ F				
Calcd. (%)	C: 64.96	H: 4.81	N: 8.91	F: 6.04
Found (%)	C: 65.81	H: 4.68	N: 8.74	F: 5.85

NMR(CDCl₃)δ: 3.15(s,3H), 4.32(s,2H), 5.60(s,2H), 6.31(dd,1H,J=4.2Hz, 2.4Hz), 6.91(dd,1H,J=4.2Hz, 1.5Hz), 6.96-7.16(m,5H).

[0275] The following compound was synthesized by the above-mentioned method.

4-[1-(4-Fluorobenzyl)-1H-pyrrole-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point:132°C


Elementary analysis as C ₁₉ H ₁₉ N ₂ O ₃ F				
Calcd. (%) C	66.66	H: 5.59	N: 8.18	F: 5.55
Found (%) C	66.46	H: 5.48	N: 8.14	F: 5.47

NMR(CDCl₃)δ:1.28(d,6H,J=6.6Hz), 4.25(s,2H), 4.57(m,1H), 5.61(s,2H), 6.32(dd,1H,J=4.2Hz, 2.4Hz), 6.95-7.14(m, 6H).

Compound A-98

4-[5-(4-Fluorobenzyl)oxazole-4-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0276]



(A-93) To a tetrahydrofuran solution (20ml) of potassium t-butoxide (3.4g, 30mmol), isocyanoacetic acid ethylester (3.4g, 30mmol) was added dropwise thereto under ice cooling. 10 minutes later, 4-phenylacetic acid chloride (5g, 29mmol) was added dropwise under ice cooling and stirred for 1 hour. The solution was added to the ammonium chloride solution and extracted with ethyl acetate, then washed, dried and evaporated under reduced pressure. The residue was purified with column chromatography (ethyl acetate:n-hexane=1:2) to give the objective compound 4.8g (yield 65%).

NMR(CDCl₃) δ : 1.42(t, 3H, J=7.1Hz), 4.37(s, 2H), 3.92(q, 2H, J=7.1Hz), 6.95-7.03(m, 2H), 7.23-7.29(m, 2H), 7.76(s, 1H).

(A-94) To an ethanol 30ml solution of the above-mentioned compound A-93 (4.8g, 19.3mmol), 1N lithium hydroxide solution 20ml was added at room temperature for 1 hour under stirring, then the mixture was evaporated under reduced pressure and acidified with 1N hydrochloric acid. The solution was extracted with ethyl acetate, then washed, dried and evaporated under reduced pressure. The residue was Crystallized with isopropyl alcohol to give the objective compound 3.9g (yield 91%).

NMR(DMSO-d₆) δ : 4.38(s, 2H), 7.11-7.18(m, 2H), 7.28-7.31(m, 2H), 8.34(s, 1H), 13.20(bs, 1H).

(A-95) According to the method of the above-mentioned example A-20, 5-(4-fluorobenzyl) oxazole-4-carboxylic acid methoxymethylamide 4.4g (yield 95%) was synthesized from the above-mentioned compound A-94 (3.9g, 17.6mmol).

NMR(CDCl₃) δ : 3.42(s, 3H), 3.83(s, 3H), 4.28(s, 2H), 6.95-7.01(m, 2H), 7.25-7.34(m, 2H), 7.72(s, 1H).

(A-96) According to the method of the above-mentioned example A-21, 1-[5-(4-fluorobenzyl)oxazole-4-yl] etanone 3.5g (yield 96%) was synthesized from the above-mentioned compound A-95 (4.4g, 16.7mmol).

NMR(CDCl₃) δ : 2.59(s, 3H), 4.36(s, 2H), 6.95-7.01(m, 2H), 7.25-7.34(m, 2H), 7.71(s, 1H).

(A-97) According to the method of the above-mentioned example A-18, 4-[5-(4-fluorobenzyl)oxazole-4-yl]-2-hydroxy-4-oxo-2-butenic acid methylester 5.37g (yield 90%) was synthesized from the above-mentioned compound A-96 (4.3g, 19.6mmol).

NMR(CDCl₃) δ : 3.93(s, 3H), 4.43(s, 2H), 6.95-7.04(m, 2H), 7.26(s, 1H), 7.25-7.31(m, 2H), 7.77(s, 1H).

(A-98) According to the method of the above-mentioned example A-19, 4-[5-(4-fluorobenzyl)oxazole-4-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one 760mg (yield 67%) was synthesized from the above-mentioned compound A-97 (1g, 3.3mmol).

NMR(CDCl₃) δ : 3.93(s, 3H), 4.14(s, 2H), 4.49(s, 2H), 6.95-7.04(m, 2H), 7.25-7.31(m, 2H), 8.14(s, 1H).

Melting point: 257°C

Elementary analysis as $C_{16}H_{13}N_2O_4F \cdot 0.2HCl$

Calcd. (%)	C: 59.39	H: 4.11	N: 8.66	F: 5.87	Cl: 2.19
Found (%)	C: 59.51	H: 4.01	N: 8.65	F: 5.69	Cl: 2.12

[0277] The following compound was synthesized by the above-mentioned method.

4-[5-(4-Fluorobenzyl)oxazole-4-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

NMR($CDCl_3$) δ : 3.93(s,3H), 4.14(s,2H), 4.49(s,2H), 6.95-7.04(m,2H), 7.25-7.31(m,2H), 8.14(s,1H).

Melting point: 193°C


Elementary analysis as $C_{18}H_{17}N_2O_4F$

Calcd. (%)	C: 62.79	H: 4.98	N: 8.14	F: 5.52
Found (%)	C: 62.73	H: 4.91	N: 8.14	F: 5.42

Compound A-102

4-[1-(4-Fluorobenzyl)-1H-pyrazole-4-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

[0278]



(A-99) To a N,N-dimethylformamide solution (20ml) of 4-bromopyrazole (5.0g, 34.0mmol) at 0°C, sodium hydride (60%) (2.04g, 51.0mmol) was added, then the mixture was stirred for 20 minutes, to which was added 4-fluorobenzyl bromide (5.1ml, 40.8mmol) at room temperature for 1 hour. The solution was poured into ice water, then extracted with ether, washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexane/ethyl acetate=8/1) to give 4-bromo-1-(4-fluorobenzyl)-1H-pyrazole (7.42g, yield: 86%).

(A-100) A mixture of the above-mentioned compound A-99 (1.28g, 5.00mmol), acetic acid palladium (34mg, 0.150mmol), 1,3-diphenylphosphinopropane (136mg, 0.330mmol), butylvinylether (3.24ml, 25.0mmol) and potassium carbonate (829mg, 6.00mmol) in a solution of N,N-dimethylformamide (12.5ml) and water (3ml) was reacted in a shield tube at 100°C for 24 hours. The solution was cooled, then poured into 5% hydrochloric acid and stirred for 30 minutes, to which was added a saturated sodium bicarbonate aqueous solution, extracted with ethyl acetate, washed, dried, and evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexane/ethyl acetate=2/1) to give 1-[1-(4-fluorobenzyl)-1H-pyrazole-4-yl]etanone (555mg, yield: 51%). NMR($CDCl_3$) δ : 2.41(3H, s), 5.28(2H, s), 7.01-7.09(2H, m), 7.21-7.28(2H, m), 7.85(1H, s), 7.93(1H, s).

(A-101) According to the method of the above-mentioned example A-18, 4-[1-(4-fluorobenzyl)-1H-pyrazole-4-yl]-2-hydroxy-4-oxo-2-butenic acid methyl (1.08g, yield: 77%) was synthesized from the above-mentioned compound A-100 (1.00g, 4.59mmol).

NMR($CDCl_3$) δ : 3.92(3H, s), 5.31(2H, s), 6.67(1H, s), 7.03-7.12(2H, m), 7.23-7.28(2H, m), 7.94(1H, s), 8.02(1H, s). (A-102) According to the method of the above-mentioned example A-19, 4-[1-(4-fluorobenzyl)-1H-pyrazole-4-car-

bonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one(122mg, yield:36%) was synthesized from the above-mentioned compound A-101(304mg, 1.00mmol).

Melting point:129.5-131°C

Elementary analysis as $C_{18}H_{18}FN_3O_3$

Calcd. (%)	C, 62.97;	H, 5.28;	N, 12.24;	F, 5.53.
Found (%)	C, 62.96;	H, 5.22;	N, 12.22;	F, 5.49.

NMR($CDCl_3$) δ :1.30(6H, d, J=6.7Hz), 4.22(2H, s), 4.56(1H, sep, J=6.7Hz), 5.33(2H, s), 7.03-7.12(2H, m), 7.23-7.31(2H, m), 7.97(1H, s), 8.05(1H, s).

[0279] The following compound was synthesized by the above-mentioned method.

(4-1) 4-[1-(4-Fluorobenzyl)-1H-pyrazole-4-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point:150-151°C

Elementary analysis as $C_{16}H_{14}FN_3O_3$


Calcd. (%)	C, 60.95;	H, 4.48;	N, 13.33;	F, 6.03.
Found (%)	C, 60.73;	H, 4.38;	N, 13.25;	F, 6.00.

NMR($CDCl_3$) δ :3.18(3H, s), 4.29(2H, s), 5.33(2H, s), 7.03-7.13(2H, m), 7.24-7.31(2H, m), 7.92(1H, s), 8.01(1H, s).

Compound A-107

4-[2-(4-Fluorobenzyl)oxazole-5-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

[0280]



(A-103) To a dioxane solution(30ml) of 2-(4-fluorobenzyl)oxazole-5-carboxylic acid ethyl(10g,40.1mmol) which was prepared according to the method of the reference(J. Chem. Soc.,Perkin Trans. 1, 1997, p2673), 1N lithium hydroxide aqueous solution(48ml, 48.0mmol) was added for 3 minutes at 0°C. The mixture was stirred at room temperature for 30 minutes, then 1N hydrochloric acid(55ml, 55.0mmol) was added and extracted with ethyl acetate, washed, dried and evaporated under reduced pressure. The residue was Crystallized using diisopropyl ether and hexane to give 2-(4-fluorobenzyl)oxazole-5-carboxylic acid(8.50g, yield:95%).

NMR($CDCl_3$) δ :4.19(2H, s), 7.00-7.08(2H, m), 7.25-7.34(2H, m), 7.80(1H, s).

The following compound was synthesized by the above-mentioned method using 2-(4-fluorobenzyl)oxazole-4-carboxylic acid ethyl which was prepared according to the method of the reference(J. Org. Chem., 1996, 61, p1761).

NMR(CDCl₃) δ : 4.21(2H, s), 6.97-7.06(2H, m), 7.25-7.33(2H, m), 8.24(1H, s).

(A-104) According to the method of the above-mentioned example A-20, 2-(4-fluorobenzyl)oxazole-5-carboxylic acid methoxymethylamide (955mg, yield: 76%) was synthesized from the above-mentioned compound A-103 (1.0g, 4.70mmol).

NMR(CDCl₃) δ : 3.33(3H, s), 3.74(3H, s), 4.16(2H, s), 6.97-7.06(2H, m), 7.25-7.34(2H, m), 7.60(1H, s).

The following compound was synthesized by the above-mentioned method.

2-(4-Fluorobenzyl)oxazole-4-carboxylic acid methoxymethylamide

NMR(CDCl₃) δ : 3.37(3H, s), 3.73(3H, s), 4.14(2H, s), 6.96-7.05(2H, m), 7.25-7.33(2H, m), 8.08(1H, s).

(A-105) According to the method of the above-mentioned example A-21, 1-[2-(4-fluorobenzyl)oxazole-5-yl]etanone (7)(730mg, yield: 92%) was synthesized from the above-mentioned compound A-104 (950mg, 3.60mmol).

NMR(CDCl₃) δ : 2.46(3H, s), 4.16(2H, s), 6.69-7.08(2H, m), 7.25-7.33(2H, m), 7.68(1H, s).

The following compound was synthesized by the above-mentioned method.

1-[2-(4-Fluorobenzyl)oxazole-4-yl]etanone

NMR(CDCl₃) δ : 2.51(3H, s), 4.12(2H, s), 6.98-7.06(2H, m), 7.24-7.31(2H, m), 8.11(1H, s). (A-106) According to the method of the above-mentioned example A-18, 4-[2-(4-fluorobenzyl)oxazole-5-yl]-2-hydroxy-4-oxo-2-butenic acid methyl (1.43g, yield: 86%) was synthesized from the above-mentioned compound A-105 (1.20g, 5.48mmol).

NMR(CDCl₃) δ : 3.94(3H, s), 4.19(2H, s), 6.80(1H, s), 7.00-7.09(2H, m), 7.26-7.34(2H, m), 7.83(1H, s).

The following compound was synthesized by the above-mentioned method.

4-[2-(4-Fluorobenzyl)oxazole-4-yl]-2-hydroxy-4-oxo-2-butenic acid methyl

(A-107) According to the method of the above-mentioned example A-19, 4-[2-(4-fluorobenzyl)oxazole-5-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one (256mg, yield: 75%) was synthesized from the above-mentioned compound (8) (305mg, 1.00mmol).

Melting point: 174-178°C

Elementary analysis as C ₁₈ H ₁₇ FN ₂ O ₄				
Calcd. (%)	C, 62.79;	H, 4.98;	N, 8.14;	F, 5.52.
Found (%)	C, 62.41;	H, 4.89;	N, 7.98;	F, 5.33.

NMR(CDCl₃) δ : 1.25(6H, d, J=6.8Hz), 4.10(2H, s), 4.23(2H, s), 4.54(1H, sep, J=6.8Hz), 7.03-7.12(2H, m), 7.28-7.35(2H, m), 7.95(1H, s).

[0281] The following compound was synthesized by the above-mentioned method.

4-[2-(4-Fluorobenzyl)oxazole-4-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one


Melting point: 154-155°C

NMR(CDCl₃) δ : 1.26(6H, d, J=6.8Hz), 4.05(2H, s), 4.22(2H, s), 4.54(1H, sep, J=6.8Hz), 7.03-7.12(2H, m), 7.25-7.32(2H, m), 8.27(1H, s).

Compound A-111

4-[5-(4-Fluorobenzyl)thiophene-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

[0282]



(A-108) To a tetrahydrofuran solution(25ml) of 2-(2-methyl[1,3]dioxolane-2-yl)thiophene(2.0g, 11.8mmol) at -78°C, 1.55M n-butyllithium-hexane solution(9.1ml, 14.1mmol) was added dropwise for 10 minutes. The mixture was stirred at -78°C for 1 hour, then a tetrahydrofuran solution(5ml) of p-fluorobenzaldehyde(2.2g, 17.7mmol) was added and stirred for 15 minutes, to which was added a saturated ammonium chloride aqueous solution. The solution was extracted with ethyl acetate, washed, dried and evaporated. The residue was purified with silica gel column chromatography(n-hexane/ethyl acetate=3/1) to give (4-fluorophenyl)-[5-(2-methyl[1,3]dioxolane-2-yl)thiophene-2-yl]methyl alcohol(3.20g, yield:92%).

(A-109) To an acetonitrile solution(30ml) of sodium iodide(7.85g, 52.4mmol), chlorotrimethylsilane(6.7ml, 52.4mmol) was added at 0°C, to which an acetonitrile solution(10ml) of the above-mentioned compound A-108 (3.08g, 10.5mmol) was added and stirred for 1 hour. The saturated sodium bicarbonate and 0.5 M sodium thiosulfate aqueous solution were added to the reaction mixture and extracted with ethyl acetate, washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography(n-hexane/ethyl acetate=3/1) to give 1-[5-(4-fluorobenzyl)thiophene-2-yl]etanone (1.34g, yield:55%).

NMR(CDCl₃)δ: 2.50(3H, s), 4.13(2H, s), 6.81(1H, d, J=3.8Hz), 6.97-7.05(2H, m), 7.16-7.24(2H, m), 7.53(1H, d, J=3.8Hz).

(A-110) According to the method of the above-mentioned example A-18, (4-[5-(4-fluorobenzyl)thiophene-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl(1.27g, yield:76%) was synthesized from the above-mentioned compound A-109(1.23g, 5.26mmol).

NMR(CDCl₃)δ: 3.93(3H, s), 4.17(2H, s), 6.85(1H, s), 6.88(1H, d, J=3.9Hz), 6.98-7.07(2H, m), 7.17-7.24(2H, m), 7.69(1H, d, J=3.9Hz).

(A-111) According to the method of the above-mentioned example A-19, 4-[5-(4-fluorobenzyl)thiophene-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one(181mg, yield:50%) was synthesized from the above-mentioned compound A-110(320mg, 1.00mmol).


Melting point: 138-139°C

NMR(CDCl₃)δ: 1.30(6H, d, J=6.8Hz), 4.19(2H, s), 4.28(2H, s), 4.58(1H, sep, J=6.8Hz), 6.91(1H, d, J=3.9Hz), 7.00-7.07(2H, m), 7.19-7.25(2H, m), 7.64(1H, d, J=3.9Hz).

Compound A-115

4-[2-(4-Fluorobenzyl)-2H-pyrazole-3-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0283]



(A-112) To a dimethylformamide (57ml) suspension of sodium hydride(purity 60%, 3.23g, 80.7mmol), the dimethylformamide(5ml) solution of pyrazole(5.00g, 73.4mmol) was added dropwise. The mixture was stirred at room temperature for 1 hour, then to which was added a dimethylformamide(5ml) solution of 4-fluorobenzylbromide (14.6g, 77.1mmol) and stirred for 1 hour. The mixture was poured into ice water, extracted with ethyl acetate, washed, dried and evaporated under reduced pressure to give a crude product of 1-(4-fluorobenzyl)-1H-pyrazole (14.2g, yield: 100%).

NMR(CDCl₃)δ: 5.29(2H, s), 6.29(1H, dd, J=1.8Hz, 2.1Hz), 7.00-7.05(2H, m), 7.17-7.21(2H, m), 7.38(1H, d,

J=2.1Hz), 7.55(1H, d, J=1.8Hz).

(A-113) To a solution of tetrahydrofuran(35ml)-diethyl ether(23ml) of the above-mentioned compound A-112(2.00g, 11.4mmol), n-butyllithium(7.90ml, 12.5mmol, 1.59M hexane solution) was added at -78°C, then the mixture was stirred for 1.5 hours, to which was added acetic anhydride(2.32g, 22.7mmol). The mixture was stirred for 1 hour under ice cooling, then sodium hydrogen carbonate aqueous solution was added and extracted with ethyl acetate, washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography(n-hexane:ethyl acetate=4:1) to give 1-[2-(4-fluorobenzyl)-2H-pyrazole-3-yl]ethanone(700mg, yield:28%). NMR(CDCl₃)δ:4.50(3H, s), 5.71(2H, s), 6.87(1H, d, J=2.1Hz), 6.95-7.00(2H, m), 7.24-7.29(2H, m), 7.55(1H, d, J=2.1Hz).

(A-114) To a tetrahydrofuran solution(8ml) of the above-mentioned compound A-113(1.00g, 4.58mmol), lithium hexamethyldisilazane(5.50ml, 5.50mmol, 1.0M tetrahydrofuran solution) was added dropwise at -78°C for 10 minutes under stirring, to which was added oxalic acid diethyl(804mg, 5.50mmol). The mixture was stirred at 0°C for 1 hour, then ammonium chloride aqueous solution was added, then extracted with ethyl acetate, washed, dried and evaporated under reduced pressure. The crystal was washed with isopropyl ether to give 4-[2-(4-fluorobenzyl)-2H-pyrazole-3-yl]-2-hydroxy-4-oxo-2-butenic acid ethyl ester(754mg, yield:52%). NMR(CDCl₃)δ: 1.40(3H, q, J=6.9Hz), 4.39(2H, q, J=6.9Hz), 5.78(2H, s), 6.82(1H, s), 6.96-7.01(3H, m), 7.24-7.29(2H, m), 7.61(1H, d, J=2.1Hz), 14.24(1H, br).

(A-115) To a dioxane(13ml) solution of the above-mentioned compound A-114(318mg, 1.00mmol), methylamine (2.20 mmol, 40% ethanol solution) and paraformaldehyde(90mg) were added. The mixture was stirred for 1 hour at room temperature and diluted with ammonium chloride aqueous solution and chloroform. An insoluble product was filtered out, then the filtrate was extracted with chloroform, washed, dried and evaporated under reduced pressure. The crude crystal was recrystallized by acetone-isopropylether to give 4-[2-(4-fluorobenzyl)-2H-pyrazole-3-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(161mg, yield:51%).

Melting point:179-181°C

Elementary analysis as C ₁₆ H ₁₄ FN ₂ O ₃				
Calcd. (%)	C, 60.95;	H, 4.48;	N, 13.33;	F, 6.03.
Found (%)	C, 60.86;	H, 4.24;	N, 13.28;	F, 5.78.

NMR(CDCl₃) δ: 3.17(3H, s), 4.28(2H, s), 5.77(2H, s), 6.82(1H, d, J=2.2Hz), 6.98(2H, t, J=8.7Hz), 7.24-7.29(2H, m), 7.63(1H, d, J=2.2Hz).

[0284] The following compound was synthesized by the above-mentioned method.

4-[2-(4-Fluorobenzyl)-2H-pyrazole-3-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one (199mg, yield:58%)
Melting point:170-171°C


Elementary analysis as C ₁₈ H ₁₈ FN ₃ O ₃				
Calcd. (%)	C, 62.97;	H, 5.28;	N, 12.24;	F, 5.58.
Found (%)	C, 62.95;	H, 5.00;	N, 12.25;	F, 5.59.

NMR(CDCl₃)δ:1.29(6H, d, J=6.9Hz), 4.20(2H, s), 4.51-4.60(1H, m), 5.77(2H, s), 6.88(1H, d, J=2.1Hz), 6.96-7.02(2H, m), 7.25-7.30(2H, m), 7.65(1H, d, J=2.1Hz)

Compound A-124

4-[5-(4-Fluorobenzyl)furan-3-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0285]



(A-116) To a diethylformamide(0.5ml)-methylene chloride(200ml) solution of furan-3-carboxylic acid(20.0g, 178mmol), oxalyl chloride(24.9g, 196mmol) was added dropwise. The mixture was stirred at room temperature for 1 hour and was evaporated under reduced pressure. The residue was dissolved into methylene chloride(200ml), to which were added N,O-dimethylhydroxylamine hydrochloride(20.8g, 214mmol) and triethylamine(43.2g, 427mmol) at 0°C. The mixture was stirred at room temperature for 30 minutes, then was added water, which was extracted with chloroform, washed, dried and evaporated under reduced pressure to give a crude product of furan-3-carboxylic acid methoxymethylamide(31.3g).

NMR(CDCl₃) δ : 3.34(3H, s), 3.72(3H, s), 6.87-6.88(1H, m), 7.42-7.43(1H, m), 8.03-8.04(1H, m).

(A-117) To a tetrahydrofuran(300ml) solution of the above-mentioned crude product A-116(31.3g), methyl magnesiumbromide(214ml, 214mmol, 1M tetrahydrofuran solution) was added at -50°C. The mixture was stirred at 0°C for 2 hours, to which was added methyl magnesiumbromide(70ml, 70mmol, 1M tetrahydrofuran solution) and was stirred for 2 hours. 2N Hydrochloric acid(200ml) was added to the mixture, which was extracted with diethyl ether and washed, dried and evaporated under reduced pressure to give 3-acetylfuran (15.9g, yield:81%).

NMR(CDCl₃) δ : 2.45(3H, s), 6.77-6.78(1H, m), 7.44-7.45(1H, m), 8.02-8.03(1H, m).

(A-118) A mixture of the above-mentioned compound A-117(15.9g, 144mmol), p-toluenesulfonic acid mono hydrate(1.69g, 8.90mmol) and ethylene glycol(55.2g, 890 mmol) was refluxed in benzene(500ml)for 16 hours removing the produced water. Then, sodium hydrogen carbonate aqueous solution was added to the mixture, which was extracted with ethyl acetate, washed, dried and evaporated under reduced pressure to give 2-furan-3-yl-

EP 1 422 218 A1

2-methyl[1,3]-dioxolane(20.9g, yield:94%).

NMR(CDCl₃)δ: 1.67(3H, s), 3.89-4.05(4H, m), 6.36-6.37(1H, m), 7.36-7.37(1H, m), 7.41-7.42(1H, m).

(A-119) To a tetrahydrofuran(200ml) solution of the above-mentioned compound A-118(19.8g, 128mmol), n-butyl-lithium(90.0ml, 141mmol, 1.59M hexane solution) was added at -78°C and the mixture was stirred at 0°C for 30 minutes. Then chloro trimethylsilane(15.3g, 141mmol) was added at -78°C, which was stirred at 0°C for 30 minutes, to which was added ammonium chloride aqueous solution and extracted with diethyl ether, washed, dried and evaporated under reduced pressure to give trimethyl[3-(2-methyl[1,3]dioxolane-2-yl)furan-2-yl]silane(26.7g, yield:92%).

NMR(CDCl₃)δ: 0.30(9H, s), 1.63(3H, s), 3.81-4.02(4H, m), 6.39(1H, d, J=1.8Hz), 7.51(1H, d, J=1.8Hz).

(A-120) To a tetrahydrofuran(130ml) solution of the above-mentioned compound A-119(26.7g, 118mmol), n-butyl-lithium(89ml, 142mmol, 1.59M hexanesolution) was added at -78°C and the mixture was stirred at 0°C for 30minutes, to which was added a tetrahydrofuran(60ml) solution of p-fluorobenzaldehyde(17.6g, 142mmol) at -78°C. To the mixture was added ammonium chloride aqueous solution at room temperature, then extracted with diethyl ether, washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography(n-hexane:ethyl acetate=4:1) to give (4-fluorophenyl)-[4-(2-methyl[1,3]dioxolane-2-yl)-5-trimethylsilylfuran-2-yl]methyl alcohol(18.3g, yield:49%).

NMR(CDCl₃)δ: 0.29(9H, S), 1.57(3H, s), 3.78-3.99(4H, m), 5.76(1H, m), 6.02(1H, s), 7.03-7.09(2H, m), 7.41-7.46(2H, m).

(A-121) Tetrabutylammonium fluoride(8ml, 8mmol, 1M tetrahydrofuran solution) was added to the above-mentioned compound A-120(762mg, 2.17mmol) in tetrahydrofuran(8ml) then the mixture was stirred at 60°C for 30minutes. The solution was diluted with diethyl ether, which was washed with 1N hydrochloric acid, water and saturated NaCl aqueous solution, successively, then dried and evaporated under reduced pressure to give (4-fluorophenyl)-[4-(2-methyl[1,3]dioxolane-2-yl)furan-2-yl]methyl alcohol(561mg, yield:93%).

NMR(CDCl₃)δ: 1.61(3H, s), 3.86-4.03(4H, m), 5.76(1H, s), 6.06-6.07(1H, m), 7.04-7.09(2H, m), 7.37-7.44(3H, m).

(A-122) A mixture of sodium iodide(1.90g, 12.7mmol) and chlorotrimethylsilane(1.39g, 12.7mmol) in acetonitrile(7ml) was stirred at room temperature for 15 minutes, to which was added the above-mentioned compound A-121(709mg, 2.55mmol) at 0°C, then the mixture was stirred at room temperature for 30 minutes. Water and 1N sodium hydroxide aqueous solution were added thereto successively, which was extracted with diethyl ether, washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give 3-acetyl-5-(4-fluorobenzyl)furan(307mg, yield:55%).

NMR(CDCl₃)δ: 2.39(3H, s), 3.93(2H, s), 6.36(1H, d, J=0.9Hz), 6.79-7.03(2H, m), 7.16-7.21(2H, m), 7.26(1H, d, J=0.9Hz).

(A-123) Lithium hexamethyldisilazane(4.30ml, 4.30mmol, 1M tetrahydrofuran solution) was added to the above-mentioned compound A-122(773mg, 3.54mmol) in tetrahydrofuran(15ml) at -78°C, then the mixture was stirred for 10 minutes. Oxalic acid diethyl(621mg, 4.25mmol) was added at -30°C, which was stirred for 30 minutes, to which was added water and 1N hydrochloric acid. The mixture was extracted with ethyl acetate, washed, dried and evaporated under reduced pressure. The crude crystal was washed with diisopropyl ether to give 4-[5-(4-fluorobenzyl)furan-3-yl]-2-hydroxy-4-oxo-2-butenic acid ethyl ester(689mg, yield:61%).

NMR(CDCl₃)δ: 1.39(3H, t, J=7.2Hz), 3.96(2H, s), 4.37(2H, q, J=7.2Hz), 6.40(1H, d, J=0.9Hz), 6.62(1H, s), 6.99-7.04(2H, m), 7.17-7.22(2H, m), 8.03(1H, d, J=0.9Hz).

(A-124) To a dioxane(8ml) solution of the above-mentioned compound A-123(200mg, 0.628mmol), methylamine(1.38mmol, 30% ethanol solution) and paraformaldehyde(57mg) were added successively. The mixture was stirred at room temperature for 30minutes, then diluted with ammonium chloride aqueous solution and chloroform. The insoluble product was filtered off, then the filtrate was extracted with chloroform, washed with 1N hydrochloric acid, water and saturated NaCl aqueous solution successively. The mixture was evaporated under reduced pressure, then the residue was Crystallized by acetone-diisopropyl ether to give 4-[5-(4-fluorobenzyl)furan-3-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(56mg, yield:28%).

Melting point:158-160°C

Elementary analysis as C ₁₇ H ₁₄ FNO ₄				
Calcd. (%)	C, 64.76;	H, 4.48;	N, 4.44;	F, 6.03.
Found (%)	C, 64.54;	H, 4.48;	N, 4.41;	F, 6.03.

NMR(CDCl₃)δ: 3.17(3H, s), 3.98(2H, s), 4.24(2H, s), 6.43(1H, s), 6.99-7.05(2H, m), 7.18-7.23(2H, m), 7.98(1H, s).

[0286] The following compound was synthesized by the above-mentioned method.

4-[5-(4-Fluorobenzyl)furan-3-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one(87mg, yield:43%)

Melting point: 162-164°C

Elementary analysis as C₁₉H₁₈FNO₄


Calcd. (%)	C, 66.46;	H, 5.28;	N, 4.08;	F, 5.53.
Found (%)	C, 66.42;	H, 5.30;	N, 3.96;	F, 5.53.

NMR(CDCl₃)δ: 1.29(6H, d, J=6.9Hz), 3.98(2H, s), 4.17(2H, s), 4.51-4.60(1H, m), 6.46(1H, d, J=0.9Hz), 6.98-7.04(2H, m), 7.18-7.23(2H, m), 8.03(1H, d, J=0.9Hz).

Compound A-130

4-[4-(4-Fluorobenzyl)oxazole-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0287]



(A-125) To a methylene chloride(100ml) solution of 4-fluorophenylacetic acid(10.0g, 64.9mmol) and dimethylformamide(0.5ml), oxalyl chloride(9.06g, 71.4mmol) was added dropwise at room temperature and the mixture was stirred for 1 hour, which was evaporated under reduced pressure. The residue was distilled to give (4-fluorophenyl) acetyl chloride(8.44g, yield:75%).

Boiling point: 80°C/15mmHg

(A-126) N,N-Nitrosomethylurea(10.1g, 97.8mmol) was added to 50% potassium hydroxide aqueous solution (40ml)-diethyl ether(250ml), then the yellow ether layer was added to the above-mentioned compound A-125 (8.44g, 48.9mmol) in diethyl ether(80ml) under ice cooling. The mixture was stirred at 0°C for 15 minutes and at room temperature for 15 minutes. The solution was cooled at -30°C, to which was added 48% hydrogen bromide (50ml), then which was stirred at -30°C for 30 minutes and at room temperature for 30 minutes. To the solution was added water, then which was extracted with diethyl ether, washed, dried and evaporated under reduced pressure to give 1-bromo-3-(4-fluorophenyl)propane-2-one(6.52g, yield:58%).

NMR(CDCl₃)δ: 3.91(2H, s), 3.94(2H, s), 7.01-7.07(2H, m), 7.18-7.22(2H, m).

(A-127) A solution mixture of the above-mentioned compound A-126(6.52g, 28.2mmol) and 2-methylacrylamide (5.28g, 62.1mmol) in tetrahydrofuran(100ml) was stirred for 3 days at 100°C. To the solution was added water and extracted with ethyl acetate, washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography(chloroform) to give 4-(4-fluorobenzyl)-2-isopropenyloxazole(5.68g, yield:93%).

NMR(CDCl₃)δ: 2.15-2.16(3H, m), 3.86(2H, s), 5.35-5.36(1H, m), 5.91-5.92(1H, m), 6.97-7.03(2H, m), 7.15-7.16(1H, m), 7.22-7.24(2H, m).

(A-128) To a dioxane(110ml)-water(110ml) solution of the above-mentioned compound A-127(5.68g, 26.1mmol),

EP 1 422 218 A1

5% osmium tetroxide(0.44ml) and sodium periodic acid(11.2g, 52.5mmol) were added at room temperature for 20 minutes under stirring. The solution was diluted with water, then extracted with ethyl acetate, washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography(n-hexane: ethyl acetate=4:1) to give 1-[4-(4-fluorobenzyl)oxazole-2-yl]etanone(2.26g, yield:40%).

NMR(CDCl₃)δ : 2.65(3H, m), 3.92(2H, s), 6.99-7.05(2H, m), 7.22-7.24(2H, m), 7.43(1H, m).

(A-129) To a tetrahydrofuran(2.5ml) solution of the above-mentioned compound A-128(110mg, 0.50mmol), lithium hexamethyldisilazane(0.60mmol, 1M tetrahydrofuran solution) was added dropwise at -78°C, then the mixture was stirred for 30 minutes, to which was added a tetrahydrofuran(1ml) solution of imidazole-1-yloxoethyl acetate ester (101mg, 0.60mmol) which was synthesized according to the method of the reference (J. Org. Chem., 1981, 46, 211-213). The mixture was stirred at -78°C for 1 hour, to which was added 2N hydrochloric acid-ice water, which was extracted with diethyl ether, washed, dried and evaporated under reduced pressure to give 4-[4-(4-fluorobenzyl)oxazole-2-yl]-2-hydroxy-4-oxo-2-butenic acid ethyl ester(152mg, yield:95%).

NMR(CDCl₃)δ :1.41(3H, t, J=7.2Hz), 3.95(2H, s), 4.40(2H, q, J=7.2Hz), 6.99-7.05(2H, m), 7.22-7.26(3H, m), 7.51-7.52(1H, m).

(A-130) To a dioxane(8ml) solution of the above-mentioned compound A-129(199mg, 0.623mmol), methylamine (1.37mmol, 40%ethanol solution) and paraformaldehyde(56mg) were added, then the mixture was stirred at room temperature for 1 hour. The solution was diluted with ammonium chloride aqueous solution and chloroform, successively. The insoluble product was filtered out, then the filtrate was extracted with chloroform. The extract was washed with 1Nhydrochloric acid, water and saturated NaCl aqueous solution, successively. The solvent was evaporated under reduced pressure, then the residue was Crystallized by isopropyl alcohol to give 4-[4-(4-fluorobenzyl)oxazole-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(36mg, yield: 18%).

Melting point:209-210°C

Elementary analysis as C ₁₆ H ₁₃ FN ₂ O ₄				
Calcd. (%)	C, 60.76;	H, 4.14;	N, 8.86;	F, 6.01.
Found (%)	C, 60.63;	H, 4.13;	N, 8.64;	F, 5.91.

NMR(CDCl₃)δ: 3.16(3H, s), 3.99(2H, s), 4.14(2H, s), 7.02-7.08(2H, m), 7.23-7.27(2H, m), 7.67(1H, s).

[0288] The following compound was synthesized by the above-mentioned method. 4-[4-(4-Fluorobenzyl)oxazole-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one(48mg, yield:29%)

Melting point:184.5-185.5°C


Elementary analysis as C ₁₈ H ₁₇ FN ₂ O ₄				
Calcd. (%)	C, 62.79;	H, 4.98;	N, 8.14;	F, 5.52.
Found (%)	C, 62.70;	H, 4.78;	N, 8.26;	F, 5.43.

NMR(CDCl₃)δ : 1.27(6H, d, J=6.6Hz), 3.99(2H, s), 4.10(2H, s), 4.51-4.60(1H, m), 7.02-7.08(2H, m), 7.22-7.27(2H, m), 7.68(1H, m).

Compound A-137

4-[4-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

5 [0289]



(A-131) 2-Acetylfuran(11.0g, 100mmol) and bromine(32.0g, 200mmol) were successively added dropwise to aluminum chloride(33.3g, 250mmol) at room temperature, then the mixture was stirred for 10 minutes. The solution was poured into ice-37% hydrochloric acid, then which was extracted with diethyl ether, washed, dried and evaporated under reduced pressure. The residue was purified with silica gel chromatography(n-hexane:ethyl acetate=4:1) to give 2-acetyl-4,5-dibromofuran(20.9g, yield:78%).

NMR(CDCl₃)δ: 2.46(3H, s), 7.17(1H, s).

(A-132) The above-mentioned compound A-131(7.00g, 26.1mmol) in diethyl ether(3.5L) was irradiated at 0°C for 2 hours, then which was evaporated under reduced pressure. The residue was purified with silica gel chromatography(n-hexane:ethyl acetate=9:1) to give 2-acetyl-4-bromofuran(2.03g, yield:41%).

NMR(CDCl₃)δ: 2.47(3H, s), 7.18(1H, d, J=0.6Hz), 7.59(1H, d, J=0.6Hz).

(A-133) A mixture of the above-mentioned compound A-132(1.80g, 9.52mmol)ethylene glycol(3.00g, 47.6mmol) and p-toluenesulfonic acid(91mg, 0.475mmol) in benzene(100ml) was refluxed for 5 hours removing the produced water. The solution was diluted with diethyl ether, then washed with water, saturated NaCl aqueous solution, successively. The mixture was dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography(n-hexane:ethyl acetate=9:1) to give 2-(4-bromofuran-2-yl)-2-methyl[1,3]dioxolane(1.96g, yield:88%).

NMR(CDCl₃)δ: 1.70(3H, s), 3.95-4.08(4H, m), 6.38(1H, d, J=0.9Hz), 7.37(1H, d, J=0.9Hz).

(A-134) To a tetrahydrofuran(30ml) solution of the above-mentioned compound A-133(1.50g, 6.44mmol), n-butyllithium(4.45ml, 7.08mmol, 1.59M hexane solution) was added dropwise at -78°C. The mixture was stirred at -78°C for 10 minutes, then to which was added a tetrahydrofuran(8ml) solution of p-fluorobenzaldehyde(959mg, 7.73mmol) and stirred for 1.5 hours. To the solution was added ammonium chloride aqueous solution, then ex-

tracted with ethyl acetate, washed, dried and evaporated under reduced pressure. The residue was purified with silica gel chromatography(n-hexane:ethyl acetate=2:1) to give (4-fluorophenyl)-[5-(2-methyl[1,3]dioxolane-2-yl)furan-3-yl]methyl alcohol(939mg, yield:53%). NMR(CDCl₃)δ: 1.69(3H, s), 3.98-4.04(4H, m), 5.72(1H, s), 6.25(1H, d, J=0.9Hz), 7.02-7.05(2H, m), 7.22(1H, d, J=0.9Hz), 7.35-7.40(2H, m).

(A-135) To an acetonitrile(20ml) solution of sodium iodide(2.35g, 15.7mmol) and chlorotrimethylsilane(1.71g, 15.7mmol) was added, then which was stirred at room temperature for 15 minutes. To the mixture was added an acetonitrile(20ml) solution of the above-mentioned compound A-134(876mg, 3.15mmol) under ice cooling, which was stirred for 30 minutes, to which was added 1N sodium hydroxide aqueous solution, then extracted with diethyl ether. The extract was washed, dried and evaporated under reduced pressure. The residue was purified with silica gel chromatography(n-hexane:ethyl acetate=4:1) to give 1-[4-(4-fluorobenzyl)furan-2-yl]etanone(299mg, yield: 44%).

NMR(CDCl₃)δ: 2.43(3H, s), 3.77(2H, s), 6.97-7.02(3H, m), 7.13-7.18(2H, m), 7.35(1H, d, J=0.9Hz).

(A-136) To a tetrahydrofuran(10ml) solution of the above-mentioned compound A-135(299mg, 1.37mmol), lithium hexamethyldisilazane(1.64ml, 1.64mmol, 1M tetrahydrofuran solution) was added dropwise at -78°C, then the mixture was stirred at -78°C for 10 minutes. Oxalic acid diethyl(240mg, 1.64mmol) was added at -30°C and was stirred for 1 hour, to which was added ammonium chloride aqueous solution and extracted with ethyl acetate. The extract was washed, dried and evaporated with reduced pressure to give 4-[4-(4-fluorobenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenic acid ethyl ester(436mg, yield:100%).

NMR(CDCl₃)δ: 1.40(3H, t, J=6.9Hz), 3.80(2H, s), 4.38(2H, q, J=6.9Hz), 6.88(1H, d, J=1.4Hz), 6.99-7.04(2H, m), 7.14-7.19(3H, m), 7.44(1H, br).

(A-137) To a dioxane(8ml) solution of the above-mentioned compound A-136(200mg, 0.628mmol), methylamine (1.38mmol, 40% ethanol solution) and paraformaldehyde(57mg) were added successively at room temperature and the mixture was stirred for 1 hour. The solution was diluted with ammonium chloride aqueous solution and chloroform, then insoluble product was filtered out, and the filtrate was extracted with chloroform. The extract was washed with 1N hydrochloric acid, water, saturated NaCl aqueous solution, successively, which was evaporated under reduced pressure. The residue was Crystallized with isopropyl alcohol to give 4-[4-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(72mg, yield:36%).

Melting point:143-145°C

Elementary analysis as C ₁₇ H ₁₄ FNO ₄				
Calcd. (%)	C, 64.76;	H, 4.48;	N, 4.44;	F, 6.03.
Found (%)	C, 64.56;	H, 4.59;	N, 4.35;	F, 5.95.

NMR(CDCl₃)δ:3.17(3H, s), 3.81(2H, s), 4.42(2H, s), 6.99-7.04(2H, m), 7.14-7.19(2H, m), 7.22(1H, s), 7.43(1H, s).

[0290] The following compound was synthesized by the above-mentioned method. 4-[4-(4-Fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one(26mg yield:36%)

Melting point:148-150°C


Elementary analysis as C ₁₉ H ₁₈ FNO ₄				
Calcd. (%)	C, 66.46;	H, 5.28;	N, 4.08;	F, 5.53.
Found (%)	C, 66.11;	H, 5.23;	N, 4.10;	F, 5.37.

NMR(CDCl₃)δ: 1.29(6H, d, J=6.6Hz), 3.81(2H, s), 4.36(2H, s), 4.54-4.63(1H, m), 6.98-7.04(2H, m), 7.14-7.19(2H, m), 7.23(1H, br), 7.44(1H, d, J=0.9Hz).

Compound A-141

3-Hydroxy-1-isopropyl-4-[5-(2-methoxybenzyl)furan-2-carbonyl]-1,5-dihydropyrrole-2-one

[0291]



(A-138) To a tetrahydrofuran solution (25ml) of 2-(2-methyl[1,3]dioxolane-2-yl)furan (2.50g, 16.2mmol), 1.58M *n*-butyllithium-hexane solution (11.3ml, 17.9mmol) was added dropwise for 10 minutes at -78°C , then the solution was stirred for 1 hour at -30°C . A tetrahydrofuran solution (20ml) of *o*-isopropoxybenzaldehyde (2.06g, 18.7mmol) was added at -78°C and the reaction mixture was stirred at 0°C for 20 minutes, to which was added saturated ammonium chloride aqueous solution, which was extracted with ethyl acetate. The extract was washed, dried and evaporated, then the residue was purified with silica gel column chromatography (*n*-hexane/ethyl acetate=3/1) to give (2-methoxyphenyl)-[5-(2-methyl[1,3]dioxolane-2-yl)furan-2-yl]methyl alcohol (3.97g, yield:77%).

(A-139) To an acetonitrile solution (40ml) of sodium iodide (4.65g, 31.1mmol), chlorotrimethylsilane (3.90ml, 31.1mmol) was added at 0°C , to which was added an acetonitrile solution (20ml) of the above-mentioned compound A-138 (3.95g, 12.5mmol). To the reaction mixture were added saturated sodium bicarbonate and 0.5M sodium thiosulfate aqueous solution, then which was extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography (*n*-hexane/ethyl acetate=8/1) to give 1-[5-(2-methoxybenzyl)furan-2-yl]etanone (1.82g, yield:57%).

NMR(CDCl_3) δ : 2.43(3H, s), 3.82(3H, s), 4.04(2H, s), 6.05(1H, d, $J=3.6\text{Hz}$), 6.87-6.94(2H, m), 7.08(1H, d, $J=3.6\text{Hz}$), 7.15(1H, dd, $J=7.4, 1.7\text{Hz}$), 7.25(1H, td, $J=7.8, 1.4\text{Hz}$).

The following compounds were synthesized by the above-mentioned method.

1-(5-Benzo[1,3]dioxol-4-ylmethylfuran-2-yl)etanone

NMR(CDCl_3) δ : 2.43(3H, s), 4.01(2H, s), 5.96(2H, s), 6.15(1H, d, $J=3.6\text{Hz}$), 6.68-6.81(3H, m), 7.10(1H, d, $J=3.6\text{Hz}$).

1-(5-Naphthalene-1-ylmethylfuran-2-yl)etanone

NMR(CDCl_3) δ : 2.43(3H, s), 4.49(2H, s), 5.94(1H, d, $J=3.5\text{Hz}$), 7.05(1H, d, $J=3.5\text{Hz}$), 7.36-7.53(4H, m), 7.81(1H, d, $J=8.1\text{Hz}$), 7.85-7.90(1H, m), 7.93-7.98(1H, m).

1-[5-(2-Isopropoxybenzyl)furan-2-yl]etanone

NMR(CDCl_3) δ : 1.29(6H, d, $J=6.1\text{Hz}$), 2.42(3H, s), 4.02(2H, s), 4.55(1H, sep, $J=6.1\text{Hz}$), 6.07(1H, d, $J=3.5\text{Hz}$), 6.84-6.91(2H, m), 7.09(1H, d, $J=3.5\text{Hz}$), 7.14-7.25(2H, m).

1-[5-(3-Isopropoxybenzyl)furan-2-yl]etanone

NMR(CDCl_3) δ : 1.32(6H, d, $J=6.0\text{Hz}$), 2.43(3H, s), 4.00(2H, s), 4.53(1H, sep, $J=6.0\text{Hz}$), 6.12(1H, dd, $J=4.0, 0.9\text{Hz}$), 6.75-6.83(3H, m), 7.10(1H, d, $J=4.0\text{Hz}$), 7.17-7.24(1H, m).

1-[5-(4-Fluoro-2-methoxybenzyl)furan-2-yl]etanone

NMR(CDCl_3) δ : 2.42(3H, s), 3.80(3H, s), 3.98(2H, s), 6.04(1H, d, $J=3.6\text{Hz}$), 6.58-6.64(2H, m), 7.06-7.12(2H, m).

1-[5-(4-Fluoro-3-methoxybenzyl)furan-2-yl]etanone

NMR(CDCl_3) δ : 2.44(3H, s), 3.87(3H, s), 4.00(2H, s), 6.12(1H, d, $J=3.6\text{Hz}$), 6.76(1H, ddd, $J=8.1, 4.1, 2.1\text{Hz}$), 6.85(1H, dd, $J=8.3, 2.1\text{Hz}$), 7.02(1H, dd, $J=11.0, 8.1\text{Hz}$), 7.11(1H, d, $J=3.6\text{Hz}$).

1-[5-(4-Fluoro-2-isopropoxybenzyl)furan-2-yl]etanone

NMR(CDCl_3) δ : 1.29(6H, d, $J=6.0\text{Hz}$), 2.42(3H, s), 3.96(2H, s), 4.49(1H, sep, $J=6.0\text{Hz}$), 6.04-6.06(1H, m), 6.54-6.62(2H, m), 7.07-7.13(2H, m).

1-(5-Benzylfuran-2-yl)etanone

NMR(CDCl_3) δ : 2.43(3H, s), 4.04(2H, s), 6.10(1H, d, $J=3.5\text{Hz}$), 7.09(1H, d, $J=3.5\text{Hz}$), 7.23-7.36(4H, m).

1-[5-(2-[1,3]Dioxolane-2-yl-4-fluorobenzyl)furan-2-yl]etanone

NMR(CDCl₃)δ: 2.43(3H, s), 3.98-4.16(4H, m), 4.17(2H, s), 5.91(1H, s), 6.02(1H, d, J=3.5Hz), 7.01(1H, td, J=8.4, 2.9Hz), 7.08(1H, d, J=3.5Hz), 7.17(1H, dd, J=5.6, 2.9Hz), 7.33(1H, dd, J=9.6, 2.9Hz).

1-[5-(2-[1,3]Dioxolane-2-ylbenzyl)furan-2-yl]etanone

NMR(CDCl₃)δ: 2.43(3H, s), 3.99-4.16(2H, m), 4.22(2H, s), 5.93(1H, s), 6.01(1H, d, J=3.4Hz), 7.08(1H, d, J=3.4Hz), 7.18-7.22(1H, m), 7.29-7.34(2H, m), 7.58-7.62(1H, m) (A-140) According to the method of the above-mentioned example A-18, 2-hydroxy-4-[5-(2-methoxybenzyl)furan-2-yl]-4-oxo-2-butenic acid methyl(977mg, yield:88%) was synthesized from the above-mentioned compound A-139(810mg, 3.52mmol).

NMR(CDCl₃)δ: 3.83(3H, s), 3.93(3H, s), 4.07(2H, s), 6.15(1H, d, J=3.6Hz), 6.88(1H, s), 6.89-6.95(2H, m), 7.16(1H, dd, J=7.5, 1.8Hz) 7.23-7.30(2H, m).

The following compounds were synthesized by the above-mentioned method.

4-(5-Benzo[1,3]dioxol-4-ylmethylfuran-2-yl)-2-hydroxy-4-oxo-2-butenic acid methyl

NMR(CDCl₃)δ: 3.93(3H, s), 4.04(2H, s), 5.97(2H, s), 6.25(1H, d, J=3.6Hz), 6.67-6.84(3H, m), 6.89(1H, s), 7.27(1H, d, J=3.6Hz).

2-Hydroxy-4-(5-naphthalene-1-ylmethylfuran-2-yl)-4-oxo-2-butenic acid methyl

NMR(CDCl₃)δ: 3.93(3H, s), 4.53(2H, s), 6.05(1H, d, J=3.6Hz), 6.88(1H, s), 7.22(1H, d, J=3.6Hz), 7.36-7.55(1H, m), 7.80-7.97(3H, m).

2-Hydroxy-4-[5-(2-isopropoxybenzyl)furan-2-yl]-4-oxo-2-butenic acid methyl

NMR(CDCl₃)δ: 1.29(6H, d, J=6.1Hz), 3.93(3H, s), 4.06(2H, s), 4.57(1H, sep, J=6.1Hz), 6.17(1H, d, J=3.9Hz), 6.85-6.92(3H, m), 7.15-7.28(3H, m).

2-Hydroxy-4-[5-(3-isopropoxybenzyl)furan-2-yl]-4-oxo-2-butenic acid methyl

NMR(CDCl₃)δ: 1.33(6H, d, J=6.0Hz), 3.93(3H, s), 4.03(2H, s), 4.54(1H, sep, J=6.0Hz), 6.22(1H, d, J=3.6Hz), 6.76-6.82(3H, m), 6.88(1H, s), 7.20-7.26(1H, m), 7.27(1H, d, J=3.6Hz).

4-[5-(4-Fluoro-2-methoxybenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl

NMR(CDCl₃)δ: 3.82(3H, s), 3.93(3H, s), 4.02(2H, s), 6.14(1H, d, J=3.3Hz), 6.60-6.66(2H, m), 6.88(1H, s), 7.07-7.14(1H, m), 7.26(1H, d, J=3.3Hz).

4-[5-(4-Fluoro-3-methoxybenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl

NMR(CDCl₃)δ: 3.88(3H, s), 3.93(3H, s), 4.03(2H, s), 6.22(1H, d, J=3.5Hz), 6.77(1H, ddd, J=8.3, 4.1, 1.9Hz), 6.84-6.88(1H, m), 6.87(1H, s), 7.03(1H, dd, J=11.1, 8.3Hz), 7.28(1H, d, J=3.5Hz).

4-[5-(4-Fluoro-2-isopropoxybenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl

NMR(CDCl₃)δ: 1.30(6H, d, J=6.0Hz), 3.93(3H, s), 4.00(2H, s), 4.50(1H, sep, J=6.0Hz), 6.15(1H, d, J=3.5Hz), 6.55-6.62(2H, m), 6.87(1H, s), 7.08-7.14(1H, m), 7.26(1H, d, J=3.5Hz).

4-(5-Benzylfuran-2-yl)-2-hydroxy-4-oxo-2-butenic acid methyl

NMR(CDCl₃)δ: 3.93(3H, s), 4.08(2H, s), 6.20(1H, d, J=3.6Hz), 6.88(1H, s), 7.23-7.37(5H, m).

(A-141) According to the method of the above-mentioned example A-19, 3-hydroxy-1-isopropyl-4-[5-(2-methoxybenzyl)furan-2-carbonyl]-1,5-dihydropyrrole-2-one (168mg, yield:47%) was synthesized from the above-mentioned compound A-140(316mg, 1.00mmol).

Melting point: 123-124°C

Elementary analysis as C ₂₀ H ₂₁ NO ₅			
Calcd. (%)	C, 67.59;	H, 5.96;	N, 3.94.
Found (%)	C, 67.36;	H, 5.94;	N, 3.88.

NMR(CDCl₃)δ: 1.24(6H, d, J=6.8Hz), 3.81(3H, s), 4.09(2H, s), 4.15(2H, s), 4.55(1H, sep, J=6.8Hz), 6.30(1H, d, J=3.6Hz), 6.89-6.98(2H, m), 7.19-7.34(3H, m).

[0292] The following compounds were synthesized by the above-mentioned method.

(A-141-a) 4-(5-Benzo[1,3]dioxyl-4-ylmethylfuran-2-carbonyl)-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 130-132°C

NMR(CDCl₃)δ: 1.25(6H, d, J=6.8Hz), 4.06(2H, s), 4.20(2H, s), 4.56(1H, sep, J=6.8Hz), 5.96(2H, s), 6.36(1H, d, J=3.6Hz), 6.72-6.87(3H, m), 7.34(1H, d, J=3.6Hz).

(A-141-b) 4-(5-Benzo[1,3]dioxyl-4-ylmethylfuran-2-carbonyl)-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point: 169-170°C

NMR(CDCl₃)δ: 3.14(3H, s), 4.06(2H, s), 4.23(2H, s), 5.97(2H, s), 6.34(1H, d, J=3.6Hz), 6.68-6.74(1H, m), 6.77-6.87(2H, m), 7.33(1H, d, J=3.6Hz).

(A-141-c) 3-Hydroxy-1-isopropyl-4-(5-naphthalene-1-ylmethylfuran-2-carbonyl)-1,5-dihydropyrrole-2-one

EP 1 422 218 A1

Melting point: 165-166.5°C

NMR(CDCl₃)δ: 1.14(6H, d, J=6.8Hz), 3.92(2H, s), 4.47(1H, sep, J=6.8Hz), 4.55(2H, s), 6.37(1H, d, J=3.8Hz), 7.33(1H, d, J=3.8Hz), 7.43-7.56(4H, m), 7.83-7.96(3H, m). (A-141-d) 3-Hydroxy-4-[5-(2-isopropoxybenzyl)furan-2-carbonyl]-1-isopropyl-1,5-dihydropyrrole-2-one

NMR(CDCl₃)δ: 1.22(6H, d, J=3.6Hz), 1.24(6H, d, J=3.3Hz), 4.06(2H, s), 4.11(2H, s), 4.50-4.61(2H, m), 6.32(1H, d, J=3.5Hz), 6.87-6.95(2H, m), 7.21-7.30(2H, m), 7.34(1H, d, J=3.5Hz).

(A-141-e) 3-Hydroxy-4-[5-(3-isopropoxybenzyl)furan-2-carbonyl]-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 98-99°C

Elementary analysis as C₂₂H₂₅NO₅

Calcd. (%) C, 68.91; H, 6.57; N, 3.65.

Found (%) C, 68.74; H, 6.49; N, 3.65.

NMR(CDCl₃)δ: 1.24(6H, d, J=6.9Hz), 1.32(6H, d, J=6.0Hz), 4.04(2H, s), 4.18(2H, s), 4.48-4.63(2H, m), 6.35(1H, d, J=3.8Hz), 6.77-6.84(3H, m), 7.22-7.29(1H, m), 7.33(1H, d, J=3.8Hz).

(A-141-f) 4-[5-(4-Fluoro-2-methoxybenzyl)furan-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 112-113°C

Elementary analysis as C₂₀H₂₀FNO₅

Calcd. (%) C, 64.34; H, 5.40; N, 3.75; F, 5.09.

Found (%) C, 64.24; H, 5.45; N, 3.69; F, 4.97.

NMR(CDCl₃)δ: 1.25(6H, d, J=6.8Hz), 3.80(3H, s), 4.04(2H, s), 4.15(2H, s), 4.56(1H, sep, J=6.8Hz), 6.28(1H, d, J=3.8Hz), 6.62-6.70(2H, m), 7.13-7.19(1H, m), 7.33(1H, d, J=3.8Hz).

(A-141-g) 4-[5-(4-Fluoro-2-methoxybenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point: 134-135°C

Elementary analysis as C₁₈H₁₆FNO₅

Calcd. (%) C, 62.61; H, 4.67; N, 4.06; F, 5.50.

Found (%) C, 62.36; H, 4.64; N, 3.73; F, 5.43.

NMR(CDCl₃)δ: 3.13(3H, s), 3.82(3H, s), 4.04(2H, s), 4.18(2H, s), 6.25(1H, d, J=3.6Hz), 6.63-6.70(2H, m), 7.10-7.16(1H, m), 7.32(1H, d, J=3.6Hz).

(A-141-h) 4-[5-(4-Fluoro-3-methoxybenzyl)furan-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 160-161°C

Elementary analysis as C₂₀H₂₀FNO₅

Calcd. (%) C, 64.34; H, 5.40; N, 3.75; F, 5.09.

Found (%) C, 64.12; H, 5.42; N, 3.68; F, 5.04.

NMR(CDCl₃)δ: 1.24(6H, d, J=6.7Hz), 3.87(3H, s), 4.06(2H, s), 4.15(2H, s), 4.55(1H, sep, J=6.7Hz), 6.33(1H, d, J=3.6Hz), 6.77-6.85(2H, m), 7.06(1H, dd, J=11.1, 8.1Hz), 7.33(1H, d, J=3.6Hz).

(A-141-i) 4-[5-(4-Fluoro-3-methoxybenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point: 164-166°C

Elementary analysis as C₁₈H₁₆FNO₅

Calcd. (%) C, 62.61; H, 4.67; N, 4.06; F, 5.50.

Found (%) C, 62.36; H, 4.61; N, 3.87; F, 5.38.

NMR(CDCl₃)δ: 3.13(3H, s), 3.89(3H, s), 4.05(2H, s), 4.21(2H, s), 6.30(1H, d, J=3.6Hz), 6.78(1H, ddd, J=8.2, 4.1, 2.2Hz), 6.84(1H, dd, J=8.0, 2.2Hz), 7.06(1H, dd, J=11.1, 8.2Hz), 7.32(1H, d, J=3.6Hz).

(A-141-j) 4-[5-(4-Fluoro-2-isopropoxybenzyl)furan-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 98-100°C

Elementary analysis as C₂₂H₂₄FNO₅

Calcd. (%)	C, 65.82;	H, 6.03;	N, 3.49;	F, 4.73.
Found (%)	C, 65.68;	H, 5.98;	N, 3.49;	F, 4.65.

NMR(CDCl₃)δ: 1.23(6H, d, J=6.9Hz), 1.25(6H, d, J=6.3Hz), 4.02(2H, s), 4.11(2H, s), 4.42-4.62(2H, m), 6.29(1H, d, J=3.6Hz), 6.60-6.67(2H, m), 7.14-7.20(1H, m), 7.34(1H, d, J=3.6Hz).

(A-141-k) 4-[5-(4-Fluoro-2-isopropoxybenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point: 126-129°C

NMR(CDCl₃)δ: 1.26(6H, d, J=6.1Hz), 3.12(3H, s), 4.01(2H, s), 4.15(2H, s), 4.49(1H, sep, J=6.1Hz), 6.26(1H, d, J=3.3Hz), 6.60-6.67(2H, m), 7.11-7.17(1H, m), 7.32(1H, d, J=3.3Hz).

(A-141-l) 4-[5-(4-Fluoro-2-isopropoxybenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point: 162.163°C

Elementary analysis as C₁₉H₁₉NO₄

Calcd. (%)	C, 70.14;	H, 5.89;	N, 4.31.
Found (%)	C, 70.11;	H, 5.81;	N, 4.31.

NMR(CDCl₃)δ: 1.23(6H, d, J=6.8Hz), 4.10(2H, s), 4.14(2H, s), 4.55(1H, sep, J=6.8Hz), 6.34-6.36(1H, m), 7.25-7.31(2H, m), 7.32-7.40(3H, m).

(A-141-m) 4-[5-(4-Fluoro-2-isopropoxybenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one


Melting point: 116-118°C

NMR(CDCl₃)δ: 3.12(3H, s), 4.10(2H, s), 4.18(2H, s), 6.32(1H, d, J=3.6Hz), 7.24-7.29(2H, m), 7.31-7.41(3H, m).

Compound A-145

5-Fluoro-2-[5-(4-hydroxy-1-isopropyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-2-ylmethyl]benzamide

[0293]



(A-142) According to the method of the above-mentioned example A-18, a crude product (2.78g) of 4-[5-(2-[1,3]dioxolane-2-yl-4-fluorobenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl was synthesized from the above-mentioned compound; 1-[5-(2-[1,3]dioxolane-2-yl-4-fluorobenzyl)furan-2-yl]ethane (2.03g, 7.00mmol).

NMR(CDCl₃)δ: 3.93(3H, s), 4.02-4.15(4H, m), 4.21(2H, s), 5.92(1H, s), 6.12(1H, d, J=3.6Hz), 6.88(1H, s), 7.03(1H, td, J=8.3, 2.8Hz), 7.18(1H, dd, J=8.3, 5.6Hz), 7.26(1H, d, J=3.6Hz), 7.34(1H, dd, J=9.8, 2.8Hz).

The following compound was synthesized by the above-mentioned method.

4-[5-(2-[1,3]Dioxolane-2-ylbenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl

NMR(CDCl₃)δ: 3.93(3H, s), 4.00-4.17(4H, m), 4.26(2H, s), 5.94(1H, s), 6.12(1H, d, J=3.8Hz), 6.89(1H, s), 7.18-7.22(1H, m), 7.26(1H, d, J=3.8Hz), 7.31-7.35(2H, m), 7.58-7.62(1H, m).

(A-143) To a methyl alcohol (3ml)-ether (10ml) solution of a crude product (1.51g) of 4-[5-(2-[1,3]dioxolane-2-yl-4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one which was produced from the

above-mentioned compound A-142(1.39g), an ether solution of diazomethane was added at 0°C until the foam disappeared. According to the method of the above-mentioned example A-19, the reaction mixture was stirred for 10 minutes, then which was evaporated under reduced pressure. The residue was purified with silica gel column chromatography(n-hexane/ethyl acetate=1/1) to give 4-[5-(2-[1,3]dioxolane-2-yl-4-fluorobenzyl)furan-2-carbonyl]-1-isopropyl-3-methoxy-1,5-dihydropyrrole-2-one(880mg, yield:59%(from 2-9)).

NMR(CDCl₃)δ:1.23(6H, d, J=6.8Hz), 4.00-4.15(4H, m), 4.07(2H, s), 4.16(3H, s), 4.21(2H, s), 4.45(1H, sep, J=6.8Hz), 5.91(1H, s), 6.09(1H, dd, J=3.6, 0.9Hz), 7.02(1H, td, J=8.3, 2.7Hz), 7.20(1H, dd, J=8.3, 5.4Hz), 7.30-7.37(1H, m), 7.33(1H, d, J=3.6Hz).

The following compound was synthesized by the above-mentioned method. 4-[5-(2-[1,3]Dioxolane-2-ylbenzyl)furan-2-carbonyl]-1-isopropyl-3-methoxy-1,5-dihydropyrrole-2-one

NMR(CDCl₃)δ:1.22(6H, d, J=6.7Hz), 3.99-4.16(4H, m), 4.08(2H, s), 4.15(3H, s), 4.26(2H, s), 4.45(1H, sep, J=6.7Hz), 5.93(1H, s), 6.10(1H, d, J=3.9Hz), 7.22-7.27(1H, m), 7.31-7.36(3H, m), 7.59-7.63(1H, m)

(A-144) To a tetrahydrofuran(10ml)-methyl alcohol(10ml) solution of the above-mentioned compound A-143(880mg, 2.05mmol), 2N hydrochloric acid(1.0ml) was added at 50°C, then the reaction mixture was stirred for 3 hours, to which was added a saturated sodium bicarbonate aqueous solution under cooling. The mixture was extracted with ethyl acetate, washed, dried and evaporated under reduced pressure to give a crude product(764mg, yield:97%) of 5-fluoro-2-[5-(1-isopropyl-4-methoxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-2-ylmethyl]benzaldehyde, which was dissolved into dioxane(10ml)-methyl alcohol(5ml), then 2-methyl-2-butene(2.1ml, 19.8mmol) was added thereto. Sodium chlorite(538mg, 5.94mmol) was added to the reaction mixture at 0°C, to which was added a sodium dihydrogen phosphate dihydrate(929mg, 5.94mmol) aqueous solution(10ml) for 5 minutes. The reaction mixture was stirred at the same temperature for 1 hour, then 2N hydrochloric acid was added and the mixture was extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure to give 5-fluoro-2-[5-(1-isopropyl-4-methoxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-2-ylmethyl]benzoic acid (609mg, yield:77%).

NMR(CDCl₃)δ:1.23(6H, d, J=6.7Hz), 4.08(2H, s), 4.11(3H, s), 4.46(1H, sep, J=6.7Hz), 4.52(2H, s), 6.15(1H, d, J=3.3Hz), 7.20-7.27(1H, m), 7.30-7.36(2H, m), 7.78(1H, dd, J=9.3, 2.7Hz).

The following compound was synthesized by the above-mentioned method. 2-[5-(1-Isopropyl-4-methoxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-2-ylmethyl]benzoic acid

NMR(CDCl₃)δ:1.23(6H, d, J=6.8Hz), 4.03-4.16(4H, m), 4.08(2H, s), 4.10(3H, s), 4.45(1H, sep, J=6.8Hz), 4.56(2H, s), 6.15(1H, d, J=3.6Hz), 7.32(1H, d, J=3.6Hz), 7.34-7.42(2H, m), 7.54(1H, td, J=7.5, 1.5Hz), 8.11(1H, dd, J=7.2, 1.2Hz).

(A-145) To a N,N-dimethylformamide solution(5ml) of the above-mentioned compound A-144(300mg, 0.748mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride(215mg, 1.12mmol), 1-hydroxy-1H-benzotriazole monohydrate(127mg, 0.898mmol) and ammonium chloride(60mg, 1.12mmol), triethylamine(0.16ml, 1.12mmol) was added at 0°C, then the reaction mixture was stirred for overnight at room temperature. 2N Hydrochloric acid was added to the solution, which was extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography(chloroform/methyl alcohol=40/1) to give 5-fluoro-2-[5-(1-isopropyl-4-methoxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-2-ylmethyl]benzamide(82mg, yield:27%) from which compound(82mg, 0.205mmol), 5-fluoro-2-[5-(4-hydroxy-1-isopropyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-2-ylmethyl]benzamide(39mg, yield:49%) was produced according to the synthetic method of compound(16).

Melting point:215-218°C

Elementary analysis as C ₂₀ H ₁₉ FN ₂ O ₅				
Calcd. (%)	C, 62.17;	H, 4.96;	N, 7.25;	F, 4.92.
Found (%)	C, 62.14;	H, 5.03;	N, 7.18;	F, 4.92.

NMR(DMSO)δ:1.19(6H, d, J=6.6Hz), 4.10(2H, s), 4.25(1H, sep, J=6.6Hz), 4.31(2H, s), 6.29(1H, d, J=3.5Hz), 7.23-7.31(2H, m), 7.35-7.40(2H, m), 7.52(1H, s), 7.55(1H, d, J=3.5Hz), 7.90(1H, s).

[0294] The following compound was synthesized by the above-mentioned method. 2-[5-(4-Hydroxy-1-isopropyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-2-ylmethyl]benzamide


Melting point:195-197°C

NMR(CDCl₃)δ:1.26(6H, d, J=7.0Hz), 4.20(2H, s), 4.41(2H, s), 4.56(1H, sep, J=7.0Hz), 5.60(1H, br s), 5.83(1H, br s), 6.35(1H, d, J=3.9Hz), 7.31-7.39(3H, m), 7.43-7.50(1H, m), 7.53-7.58(1H, m).

Compound A-146

5-Fluoro-2-[5-(4-hydroxy-1-isopropyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-2-ylmethyl]benzoic acid methyl

[0295]



(A-146) To a methyl alcohol(2ml)-ether(4ml) solution of the above-mentioned compound, 5-fluoro-2-[5-(1-isopropyl-4-methoxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxy)furan-2-ylmethyl]benzoic acid, an ether solution of diazomethane was added at 0°C, until the foam disappeared. The reaction mixture was stirred for 10 minutes, then which was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexane/ethyl acetate=2/1-1/1) to give 5-fluoro-2-[5-(1-isopropyl-4-methoxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-2-ylmethyl]benzoic acid methyl(187mg, yield:60%) from which compound(187mg, 0.451mmol), 5-fluoro-2-[5-(4-hydroxy-1-isopropyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-2-ylmethyl]benzoic acid methyl(121mg, yield:70%) was produced according to the synthetic method of the compound(16).

Melting point:110-111°C


Elementary analysis as C ₂₁ H ₂₀ FNO ₆				
Calcd. (%)	C, 62.84;	H, 5.02;	N, 3.49;	F, 4.73.
Found (%)	C, 62.99;	H, 5.15;	N, 3.43;	F, 4.66.

NMR(CDCl₃)δ:1.25(6H, d, J=6.8Hz), 3.87(3H, s), 4.14(2H, s), 4.50(2H, s), 4.56(1H, sep, J=6.8Hz), 6.30(1H, d, J=3.4Hz), 7.20-7.29(1H, m), 7.31-7.37(1H, m), 7.33(1H, d, J=3.4Hz), 7.72(1H, dd, J=9.1, 2.7Hz).

Compound A-152

4-[5-Cyclohexyl-3-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

5 [0296]



(A-147) To a tetrahydrofuran solution(14ml) of diisopropylamine(1.54ml, 11mmol) under dry ice cooling, 1.58M n-butyllithium(7.0ml, 11mmol) was added, then the reaction mixture was stirred for 30 minutes, to which was added dropwise a tetrahydrofuran solution(7ml) of the above-mentioned compound A-46(1.10g, 5.0mmol) for 10 minutes. The reaction mixture was stirred for 1hour, then to which was added cyclohexanone(0.62ml, 6.0mmol) and stirred for 30 minutes. 2N Hydrochloric acid was added to the reaction mixture, then which was extracted 2 times with ethyl acetate. The organic layer was washed with 2N hydrochloric acid and brine, successively, then dried with anhydrous sodium sulfate, which was evaporated to give a crude product(1.8g) of 3-(4-fluorobenzyl)-5-(1-hydroxycyclohexyl)-2-furoin acid.

(A-148) According to the method of A-35, a crude product(1.6g) of 5-cyclohexyl-3-(4-fluorobenzyl)-2-furoin acid was synthesized from the above-mentioned crude product A-147.

(A-149) According to the method of A-36, 5-cyclohexyl-3-(4-fluorobenzyl)-2-furoin acid methoxymethylamide (1.05g, total yield of 3 process:61%) was synthesized from the above-mentioned product A-148.

NMR(CDCl₃) δ : 1.1-2.1(10H, m), 2.5-2.6(1H, m), 3.32(3H, s), 3.84(3H, s), 4.08(2H, s), 5.83(1H, d, J=0.9Hz), 6.93-6.98(2H, m), 7.21-7.25(2H, m).

(A-150) According to the method of A-37, 1-[5-cyclohexyl-3-(4-fluorobenzyl)furan-2-yl]etanone(860mg, yield:99%) was synthesized from the above-mentioned compound A-149(1.0g, 2.9mmol).

NMR(CDCl₃) δ : 1.2-2.1(10H, m), 2.46(3H, s), 2.5-2.7(1H, m), 4.13(2H, s), 5.89(1H, s), 6.93-6.98(2H, m), 7.18-7.22(2H, m).

(A-151) According to the method of A-18, 4-[5-cyclohexyl-3-(4-fluorobenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester(709mg, yield:65%) was synthesized from the above-mentioned compound A-150(850mg, 2.83mmol).

NMR(CDCl₃) δ : 1.1-2.1(10H, m), 2.64(1H, m), 3.94(3H, s), 4.20(2H, s), 5.97(1H, s), 6.95-7.01(2H, m), 6.98(1H, s), 7.19-7.24(2H, m).

(A-152) According to the method of A-19, 4-[5-cyclohexyl-3-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(102mg, yield:34%) was synthesized from the above-mentioned compound A-151 (290mg, 0.75mmol).

Melting point:175-176°C

Elementary analysis as $C_{23}H_{24}FNO_4$


Calcd. (%)	C, 69.51; H, 6.09; N, 3.52; F, 4.78.
Found (%)	C, 69.45; H, 6.11; N, 3.57; F, 4.69.

NMR($CDCl_3$) δ : 1.20-2.05(10H, m), 2.65(1H, m), 3.20(3H, s), 4.22(2H, s), 4.42(2H, s), 6.02(1H, s), 6.96-7.02(2H, m), 7.21-7.25(2H, m).

Compound A-158

4-[3-(4-Fluorobenzyl)-5-(1-methoxy-1-methylethyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0297]



(A-153) To a tetrahydrofuran solution(28ml) of diisopropylamine(3.1ml, 22mmol) under dry ice cooling, 1.58M n-butyllithium(14ml, 22mmol) was added, then the reaction mixture was stirred for 30 minutes, to which was added dropwise a tetrahydrofuran solution(7ml) of the above-mentioned compound A-46(2.2g, 10mmol)for 10 minutes. The reaction mixture was stirred for 1hour, then to which was added acetone(1ml) and stirred for 30 minutes. 2N Hydrochloric acid was added to the reaction mixture, then which was extracted 2 times with ethyl acetate. The organic layer was washed with 2N hydrochloric acid and brine, successively, then dried with anhydrous sodium sulfate, which was evaporated to give a crude product(3.07g) of 3-(4-fluorobenzyl)-5-(1-hydroxy-1-methylethyl)-2-furoic acid.

(A-154) According to the method of A-36, 3-(4-fluorobenzyl)-5-(1-hydroxy-1-methyl ethyl)-2-furoic acid meth-

oxymethylamide(1.97g, total yield of 2 process:61%)was synthesized from the above-mentioned crude product A-153.

NMR(CDCl₃)δ : 1.56(6H, s), 3.31(3H, s), 3.84(3H, s), 4.07(2H, s), 6.06(1H, s), 6.93-6.99(2H, m), 7.21-7.25(2H, m).

(A-155) To a N,N-dimethylformamide solution(8ml) of the above-mentioned compound A-154(964mg, 3.0mmol), 60% sodium hydride(144mg, 3.6mmol) and iodomethane(0.28ml, 4.5mmol) were successively added under ice cooling, then the reaction mixture was stirred at room temperature for 3 hours, to which was added water and 2N hydrochloric acid, successively. The reaction mixture was extracted 2 times with ethyl acetate, then the organic layer was washed with water and brine, successively, which was dried with anhydro magnesium sulfate. The reaction mixture was evaporated, then the crude product was treated with silica gel column chromatography to give 3-(4-fluorobenzyl)-5-(1-methoxy-1-methylethyl)-2-furoin acid methoxymethylamide(774mg, yield:77%).

NMR(CDCl₃)δ : 1.50(6H, s), 3.07 (3H, s), 3.32(3H, s), 3.87(3H, s), 4.09(2H, s), 6.09(1H, s), 6.94-7.00(2H, m), 7.21-7.26(2H, m).

(A-156) According to the method of A-37, 1-[3-(4-fluorobenzyl)-5-(1-methoxy-1-methylethyl)furan-2-yl]etanone (624mg, yield:95%) was synthesized from the above-mentioned A-155(760mg, 2.27mmol).

NMR(CDCl₃)δ : 1.52(6H, s), 2.51(3H, s), 3.10(3H, s), 4.15(2H, s), 6.15(1H, s), 6.94-7.00(2H, m), 7.18-7.23(2H, m).

(A-157) According to the method of A-18, a crude product(822mg) of 4-[3-(4-fluorobenzyl)-5-(1-methoxy-1-methylethyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester was synthesized from the above-mentioned compound A-156(620mg, 2.10mmol).

NMR(CDCl₃)δ: 1.54(6H, s), 3.11(3H, s), 3.94(3H, s), 4.22(2H, s), 6.22(1H, s), 6.97-7.02(2H, m), 7.01(1H, s), 7.20-7.24(2H, m).

(A-158) According to the method of A-19, 4-[3-(4-fluorobenzyl)-5-(1-methoxy-1-methylethyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(143mg, yield:34%) was synthesized from the above-mentioned crude product A-157(410mg, 1.09mmol).

Melting point:144-145°C

Elementary analysis as C ₂₁ H ₂₂ FNO ₅				
Calcd. (%)	C, 65.11;	H, 5.72;	N, 3.62;	F, 4.90.
Found (%)	C, 65.00;	H, 5.63;	N, 3.62;	F, 4.67.

NMR(CDCl₃)δ: 1.54(6H, s), 3.09(3H, s), 3.19(3H, s), 4.24(2H, s), 4.45(2H, d, J=0.6Hz), 6.25(1H, s), 6.97-7.03(2H, m), 7.21-7.26(2H, m).

1-Ethyl-4-[3-(4-fluorobenzyl)-5-(1-methoxy-1-methylethyl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one (187mg, yield:47%) was synthesized from the above-mentioned crude product A-157(376mg, 1.0mmol).

Melting point:146-148°C


Elementary analysis as C ₂₂ H ₂₄ FNO ₅				
Calcd. (%)	C, 65.82;	H, 6.03;	N, 3.49;	F, 4.73.
Found (%)	C, 65.78;	H, 6.00;	N, 3.45;	F, 4.55.

NMR(CDCl₃)δ: 1.27(3H, t, J=7.2Hz), 1.54(6H, s), 3.09(3H, s), 3.65(2H, q, J=7.2Hz), 4.24(2H, s), 4.45(2H, s), 6.24(1H, s), 6.97-7.02(2H, m), 7.21-7.25(2H, m).

Compound A-164

1-Ethyl-4-[3-(4-fluorobenzyl)-5-methanesulfonylfuran-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one

[0298]



(A-159) To a tetrahydrofuran solution(30ml) of diisopropylamine(3.4ml, 24mmol) under dry ice cooling, 1.58M n-butyllithium(15ml, 24mmol) was added, then the reaction mixture was stirred for 30 minutes, to which was added dropwise a tetrahydrofuran solution(10ml) of the above-mentioned compound A-46(2.2g, 10mmol)for 10 minutes. The reaction mixture was stirred for 1 hour, then to which was added dimethyl disulfide(0.9ml, 10mmol) and stirred for 30 minutes. 2N Hydrochloric acid was added to the reaction mixture, then which was extracted 2 times with ethyl acetate. The organic layer was washed with 2N hydrochloric acid and brine, successively, then dried with anhydrous sodium sulfate, which was evaporated to give a crude product(2.82g) of 3-(4-fluorobenzyl)-5-methylsulfonylfuran-2-carboxylic acid.

(A-160) According to the method of A-36, 3-(4-fluorobenzyl)-5-methylsulfonylfuran-2-carboxylic acid methoxymethylamide (3.14g) was synthesized from the above-mentioned crude product A-159.

(A-161) According to the method of A-37, 1-[3-(4-fluorobenzyl)-5-methylsulfonylfuran-2-yl]etanone(2.44g) was synthesized from the above-mentioned crude product A-160.

(A-162) To a methylene chloride solution(6ml) of the above-mentioned crude product A-161(1.06g, 4mmol) under ice cooling, a methylene chloride solution(8ml) of 80% m-chloroperbenzoic acid(1.73g, 8mmol) was added dropwise for 10 minutes, then the reaction mixture was stirred for 30 minutes, to which was added 80% m-chloroperbenzoic acid(863mg, 4mmol). The reaction mixture was stirred for 2 hours, then the crystal was filtered out. The filtrate was evaporated, then the residue was dissolved in ethyl acetate, which was washed 3 times with saturated sodium hydrogen carbonate aqueous solution and 1 time with brine, which was then dried with anhydrous magnesium sulfate. The reaction mixture was evaporated to give a crude product, which was treated with silica gel column chromatography to give 1-[3-(4-fluorobenzyl)-5-methanesulfonylfuran-2-yl]etanone(942mg, total yield of 4 processes:64%).

NMR(CDCl₃)δ: 2.59(3H, s), 3.19(3H, s), 4.17(2H, s), 6.95(1H, s), 6.97-7.03(2H, m), 7.17-7.21(2H, m).

(A-163) According to the method of A-18, a crude product(213mg) of 4-[3-(4-fluorobenzyl)-5-methanesulfonylfuran-2-yl]-2-hydroxy-4-oxo-2-butenic acid ethyl ester was synthesized from the above-mentioned compound A-162 (148mg, 0.5mmol).

NMR(CDCl₃) δ : 1.42(3H, t, J=7.1Hz), 3.21(3H, s), 4.25(2H, s), 4.43(2H, q, J=7.2Hz), 6.99-7.05(2H, m), 6.99(1H, s), 7.05(1H, s), 7.18-7.23(2H, m).

(A-164) According to the method of A-19, 1-ethyl-4-[3-(4-fluorobenzyl)-5-methanesulfonylfuran-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one(69mg yield:34%) was synthesized from the above-mentioned crude product 15 (213mg, 0.5mmol).

Melting point:154-157°C

Elementary analysis as C₁₉H₁₈FNO₆S


Calcd. (%)	C, 56.01; H, 4.45; N, 3.44; F, 4.66; S, 7.87.
Found (%)	C, 55.77; H, 4.36; N, 3.39; F, 4.43; S, 7.69.

NMR(CDCl₃) δ : 1.28(3H, t, J=7.1Hz), 3.19(3H, s), 3.65(2H, q, J=7.2Hz), 4.27(2H, s), 4.48(2H, s), 7.00-7.05(2H, m), 7.02(1H, s), 7.20-7.25(2H, m).

Compound A-171

4-[3-(4-Fluorobenzyl)-5-(1,1-dioxotetrahydrothiopyran-4-yl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0299]



(A-165) To a tetrahydrofuran solution(30ml) of diisopropylamine(3.08ml, 22mmol) under dry ice cooling, 1.57M n-butyllithium(14ml, 22mmol) was added, then the reaction mixture was stirred for 30 minutes, to which was added dropwise a tetrahydrofuran solution(10ml) of the above-mentioned compound A-46(2.2g, 10mmol)for 10 minutes. The reaction mixture was stirred for 1hour, then to which was added tetrahydrothiopyran-4-one(1.39g, 12mmol) and stirred for 30 minutes. 2N Hydrochloric acid was added to the reaction mixture, then which was extracted 2 times with ethyl acetate. The organic layer was washed with 2N hydrochloric acid and brine, successively, then dried with anhydrous sodium sulfate, which was evaporated to give a crude product(3.95g) of 3-(4-fluorobenzyl)-5-(4-hydroxytetrahydrothiopyran-4-yl)-2-furoin acid.

(A-166) According to the method of A-36, 3-(4-fluorobenzyl)-5-(4-hydroxytetrahydrothiopyran-4-yl)-2-furoin acid

methoxymethylamide(2.97g, total yield of 2process:78%) was synthesized from the above-mentioned compound A-165.

NMR(CDCl₃) δ: 2.15-2.19(4H, m), 2.43-2.51(2H, m), 3.00-3.09(2H, m), 3.31(3H, s), 3.83(3H, s), 4.07(2H, s), 6.07(1H, s), 6.93-6.99(2H, m), 7.19-7.24(2H, m).

(A-167) To a methylene chloride solution(20ml) of the above-mentioned crude product A-166(2.86g, 7.54mmol) under ice cooling, a methylene chloride solution(20ml) of 80% m-chloroperbenzoic acid(3.11g, 18mmol) was added dropwise for 15 minutes, then the reaction mixture was stirred for 2 hours, to which was added 80% m-chloroperbenzoic acid(650mg, 3.77mmol). The reaction mixture was stirred for 1 hour, then the crystal was filtered out. The filtrate was evaporated, then the residue was dissolved in ethyl acetate, which was washed 3 times with saturated sodium hydrogen carbonate aqueous solution and 1 time with brine, which was then dried with anhydrous magnesium sulfate. The reaction mixture was evaporated to give a crude product, which was crystallized with diisopropyl ether-acetone to give 3-(4-fluorobenzyl)-5-(4-hydroxy-1,1-dioxotetrahydrothiopyran-4-yl)-2-furoin acid methoxymethylamide (2.63g, yield:85%).

NMR(CDCl₃) δ: 2.30-2.37(2H, m), 2.51-2.61(2H, m), 2.88-2.94(2H, m), 3.30(3H, s), 3.46(2H, dt, J=3.3, 13.5Hz), 3.81(3H, s), 4.03(2H, s), 6.12(1H, s), 6.94-6.99(2H, m), 7.17-7.22(2H, m).

(A-168) According to the method of A-35, 3-(4-fluorobenzyl)-5-(1,1-dioxotetrahydrothiopyran-4-yl)-2-furoin acid methoxymethylamide(1.53g, yield:97%) was synthesized from the above-mentioned compound A-167(1.65g, 4.0mmol).

NMR(CDCl₃)δ : 2.29-2.43(4H, m), 2.90-3.16(5H, m), 3.32(3H, s), 3.81(3H, s), 4.07(2H, s), 5.95(1H, s), 6.94-7.00(2H, m), 7.19-7.24(2H, m).

(A-169) According to the method of A-37, 1-[3-(4-fluorobenzyl)-5-(1,1-dioxotetrahydrothiopyran-4-yl)furan-2-yl] ethanone(1.14g, yield:92%) was synthesized from the above-mentioned compound A-168(1.40g, 3.54mmol).

NMR(CDCl₃)δ : 2.31-2.43(4H, m), 2.47(3H, s), 2.91-3.17(5H, m), 4.13(2H, s), 6.00(1H, s), 6.94-7.00(2H, m), 7.16-7.21(2H, m).

(A-170) According to the method of A-18, 4-[3-(4-fluorobenzyl)-5-(1,1-dioxotetrahydrothiopyran-4-yl)furan-2-yl]-2-hydroxy-4-oxo-2-butenoic acid ethyl ester(286mg, yield:66%) was synthesized from the above-mentioned compound A-169(350mg, 1.0mmol).

NMR(CDCl₃)δ : 2.28-2.48(4H, m), 2.94-3.18(5H, m), 3.95(3H, s), 4.20(2H, s), 6.07(1H, s), 6.94(1H, s), 6.97-7.02(2H, m), 7.18-7.23(2H, m).

(A-171) According to the method of A-19, 4-[3-(4-fluorobenzyl)-5-(1,1-dioxotetrahydrothiopyran-4-yl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(69mg, yield:34%) was synthesized from the above-mentioned compound A-170(175mg, 0.4mmol).

Melting point:200-203°C

Elementary analysis as C ₂₂ H ₂₂ FNO ₆ S					
Calcd. (%)	C, 59.05;	H, 4.96;	N, 3.13;	F, 4.25;	S, 7.17.
Found (%)	C, 58.67;	H, 4.85;	N, 2.95;	F, 4.06;	S, 7.05.

Calcd. (%)	C, 59.05;	H, 4.96;	N, 3.13;	F, 4.25;	S, 7.17.
Found (%)	C, 58.67;	H, 4.85;	N, 2.95;	F, 4.06;	S, 7.05.

NMR(CDCl₃)δ: 2.29-2.45(4H, m), 2.93-3.15(5H, m), 3.20(3H, s), 4.23(2H, s), 4.40(2H, s), 6.12(1H, s), 6.97-7.03(2H, m), 7.19-7.24(2H, m).

According to the same method, 1-ethyl-4-[3-(4-fluorobenzyl)-5-(1,1-dioxotetrahydrothiopyran-4-yl)furan-2-carbonyl]-3-hydroxy-1,5-dihydropyrrole-2-one(55mg, yield:52%) was synthesized from the above-mentioned compound A-170(100mg, 0.23mmol).

Melting point:213-216°C

Elementary analysis as C ₂₃ H ₂₄ FNO ₆ S 0.2H ₂ O					
Calcd. (%)	C, 59.39;	H, 5.29;	N, 3.01;	F, 4.08;	S, 6.89.
Found (%)	C, 59.22;	H, 5.20;	N, 2.91;	F, 3.95;	S, 6.76.


Calcd. (%)	C, 59.39;	H, 5.29;	N, 3.01;	F, 4.08;	S, 6.89.
Found (%)	C, 59.22;	H, 5.20;	N, 2.91;	F, 3.95;	S, 6.76.

NMR(CDCl₃)δ : 1.29(3H, t, J=7.2Hz), 2.35-2.43(4H, m), 2.95-3.19(5H, m), 3.65(2H, q, J=7.2Hz), 4.23(2H, s), 4.40(2H, s), 6.12(1H, s), 6.97-7.03(2H, m), 7.19-7.24(2H, m).

Compound A-178

4-[3-(4-Fluorobenzyl)-5-(morpholine-4-carbonyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1, 5-dihydropyrrole-2-one

[0300]



(A-172) To a tetrahydrofuran(75ml) solution of diisopropylamine(8.41ml, 60mmol) in nitrogen gas under dry ice acetone cooling (-70°C), *n*-butyllithium-hexane solution(1.58M)(38ml, 60mmol) was added dropwise(LDA preparation)for 20 minutes, then the reaction mixture was stirred for 30 minutes, to which was added dropwise a tetrahydrofuran(35ml) solution of 3-(4-fluorobenzyl)furan-2-carboxylic acid(A-46)(5.505g, 25mmol)for 20 minutes. The reaction mixture was stirred for 1 hour, then a tetrahydrofuran(25ml) solution of carbonic acid di-*t*-butyl ester (19.3g, 88.4mmol) was added dropwise for 15 minutes, which was stirred for 1.5 hours. The reaction mixture was stirred for 15 minutes under ice cooling, then water(100ml) was added dropwise and stirred for 20 minutes. The reaction mixture was extracted with diethyl ether(300ml)-water(200ml), then the ether layer was extracted 4 times with 2N sodium hydroxide(15ml) and water(50ml). The alkali layer was cooled with ice, to which was added 2N hydrochloric acid(105ml), then which was extracted with ethyl acetate(300ml), washed with water(100ml) and dried with magnesium sulfate. The reaction mixture was evaporated under reduced pressure to give a crude product of 3-(4-fluorobenzyl)furan-2,5-dicarboxylic acid-5-*t*-butyl ester(A-172)(7.70g, yield:96.1%).

(A-173) A mixture of 3-(4-fluorobenzyl)furan-2,5-dicarboxylic acid 5-*t*-butyl ester(A-172)(7.70g, 24.04mmol), *N*, *O*-dimethylhydroxylamine hydrochloric acid(2.93g, 30mmol) and hydroxybenzotriazole(4.05g, 30mmol) was suspended in dichloromethane(250ml) at room temperature, to which were added triethylamine(4.25ml, 30.5mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloric acid(5.75g, 30mmol), successively. The reaction mixture was stirred, then allowed to stand overnight at room temperature, to which was added ethyl acetate, then dichloromethane was evaporated under reduced pressure. To the ethyl acetate solution, ice water and saturated sodium bicarbonate aqueous solution(80ml) were added, and the mixture was extracted, washed and dried with magnesium sulfate. The reaction mixture was evaporated under reduced pressure, then the residue was purified with silica gel column chromatography(*n*-hexane:acetone=19:1) to give 4-(4-fluorobenzyl)-5-(methoxymethylcarbonyl)furan-2-carboxylic acid *t*-butyl ester(3.901g, yield:44.6%)from the *n*-hexane eluent.

Melting point: 103-107°C

NMR(CDCl₃) δ: 1.55(9H, s), 3.33(3H, s), 3.93(3H, s), 4.09(2H, s), 6.83(1H, s), 6.94-7.01(2H, m), 7.20-7.25(2H, m).
 (A-174) To a tetrahydrofuran(40ml) solution of the above-mentioned compound A-173(3.80g, 10.46mmol) in nitrogen gas under dry ice acetone cooling(-30°C), methylmagnesium bromide tetrahydrofuran solution(1M)(15.7ml, 15.7mmol) was added dropwise for 10 minutes, then the reaction mixture was stirred for 40 minutes, to which was added dropwise methylmagnesium bromide tetrahydrofuran solution(1M)(18.8ml, 18.8mmol). The reaction mixture was stirred for 1.5 hours, then the reaction mixture was poured into ice water, to which was added ethyl acetate and 2N hydrochloric acid(17.3ml, 34.5mmol), then extracted. The extract was washed with water, then dried with magnesium sulfate, which was evaporated under reduced pressure. N-hexane(8ml) was added to the crystalline residue(3.375g) under ice cooling to give a crystalline colorless powder of 5-acetyl-4-(4-fluorobenzyl)furan-2-carboxylic acid tert-butyl ester(2.906g, yield:87.3%). The filtrate was purified with silica gel column chromatography (n-hexane:acetone=24:1) to give A-174(200mg, yield:6.0%) which was similarly treated with n-hexane.

Melting point: 102-103°C

NMR(CDCl₃) δ: 1.56(9H, s), 2.58(3H, s), 4.16(2H, s), 6.83(1H, s), 6.95-7.01(2H, m), 7.16-7.21(2H, m).
 (A-175) To a dichloromethane(20ml) solution of the above-mentioned compound A-174(1.273g, 4.0mmol) at room temperature, trifluoroacetic acid(12ml) was added. The reaction mixture was stirred for 1.5 hours, then evaporated under reduced pressure. Toluene was added to the residue and evaporated. This operation was done for 2 times. N-hexane was added to the crystalline residue to give a colorless powder of 5-acetyl-4-(4-fluorobenzyl)furan-2-carboxylic acid(1.004g, yield:95.7%).

Melting point: 143-144°C

NMR(CDCl₃) δ: 2.61(3H, s), 4.18(2H, s), 6.96-7.02(2H, m), 7.07(1H, s), 7.17-7.22(2H, m).
 (A-176) To a dichloromethane(10ml) suspension of the above-mentioned compound A-175(262mg, 1.0mmol) and hydroxybenzotriazole(162mg, 1.2mmol) at room temperature, morpholine(0.105ml, 1.2mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloric acid(230mg, 1.2mmol) were added. The reaction mixture was stirred for 3 hours, then evaporated under reduced pressure. Ice water and ethyl acetate were added to the residue (776mg), which was washed with 2N hydrochloric acid(0.5ml, 1mmol), saturated sodium bicarbonate aqueous solution and water, successively. The reaction mixture was dried with magnesium sulfate, then evaporated under reduced pressure to give a yellow green oil of 1-[3-(4-fluorobenzyl)-5-(morpholine-4-carbonyl)furan-2-yl]etanone (343mg, 103%).

NMR(CDCl₃) δ: 2.53(3H, s), 3.70-3.85(8H, m), 4.16(2H, s), 6.81(1H, s), 6.94-7.00(2H, m), 7.17-7.22(2H, m).
 5-Acetyl-4-(4-fluorobenzyl)furan-2-carboxylic acid diethylamide(yield:91.8%) was synthesized, by the above-mentioned method.

Melting point: 74-75°C

NMR(CDCl₃) δ: 1.15-1.40(6H, m), 2.53(3H, s), 3.40-3.65(4H, m), 4.16(2H, s), 6.85(1H, s), 6.94-6.99(2H, m), 7.18-7.22(2H, m).

(A-177) According to the method of A-18, a yellow crystal of 4-[3-(4-fluorobenzyl)-5-(morpholine-4-carbonyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester(407mg, yield:97.6%) was synthesized from the above-mentioned compound A-176(343mg, 1.0mmol).

Melting point: 143-146°C

NMR(CDCl₃) δ: 3.73-3.83(8H, m), 3.95(3H, s), 4.23(2H, s), 6.84(1H, s), 6.97-7.03(3H, m), 7.18-7.25(2H, m).
 A yellow powder crystal of 4-[5-diethylcarbamoyl-3-(4-fluorobenzyl)furan-2-yl]-2-hydroxy-4-oxo-2-butenic acid methyl ester(yield:93.1%) was synthesized, by the above-mentioned method.

Melting point: 128-130°C

NMR(CDCl₃) δ: 1.15-1.45(6H, m), 3.45-3.65(4H, m), 3.94(3H, s), 4.23(2H, s), 6.91(1H, s), 6.96-7.03(3H, m), 7.19-7.24(2H, m).

(A-178) According to the method of A-19, a yellow crystal of 4-[3-(4-fluorobenzyl)-5-(morpholine-4-carbonyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(237mg, yield:57.5%) was synthesized from the above-mentioned compound A-177(401mg, 0.961mmol).

Melting point: 209-211°C(dec)

Elementary analysis as C ₂₂ H ₂₁ FN ₂ O ₆				
Calcd. (%)	C, 61.68;	H, 4.94;	N, 6.54;	F, 4.43.
Found (%)	C, 61.33;	H, 4.92;	N, 6.36;	F, 4.34.

NMR(CDCl₃) δ: 3.19(3H, s), 3.75(8H, bs), 4.27(2H, s), 4.47(2H, s), 6.69(1H, s), 6.98-7.03(2H, m), 7.20-7.25(2H, m).
 (A-178-a) An other prism crystal of 4-(4-fluorobenzyl)-5-(4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-2-carboxylic acid diethylamide(yield:36.5%) was synthesized, by the above-mentioned method.

Melting point: 122-123°C


Elementary analysis as C ₂₂ H ₂₃ FN ₂ O ₅				
Calcd. (%)	C, 63.76;	H, 5.59;	N, 6.76;	F, 4.58.
Found (%)	C, 63.63;	H, 5.58;	N, 6.61;	F, 4.44.

NMR(CDCl₃) δ: 1.25(6H, t, J=6.9Hz), 3.18(3H, s), 3.53(4H, q, J=6.9Hz), 4.27(2H, s), 4.51(2H, s), 6.64(1H, s), 6.97-7.03(2H, m), 7.20-7.27(2H, m).

Compound A-184

2-(4-Fluorobenzyl)-5-(4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-3-carboxylic acid ethylamide

[0301]



(A-179) To an ethanol(40ml) solution of the above-mentioned compound A-35(3.55g, 16.1mmol), conc-sulfuric acid(0.1ml) was added, then dehydration was performed for 9 hours under refluxing. The reaction mixture was allowed to stand overnight at room temperature, then evaporated. The residue was dissolved to ethyl acetate, which was washed with saturated sodium hydrogen carbonate solution, dried and evaporated under reduced pressure to give a crude product of 2-(4-fluorobenzyl)furan-3-carboxylic acid ethyl ester(4.18g, yield: 100%). NMR(CDCl₃) δ: 1.35(3H, t, J=7.2Hz), 4.31(2H, q, J=7.2Hz), 4.32(2H, s), 6.67(1H, d, J=2.1Hz), 6.94-7.00(2H, m), 7.22-7.27(3H, m).

(A-180) Aluminum chloride(11.2g, 84mmol) was added to methylene chloride(30ml), then a methylene chloride solution(5ml) of the above-mentioned compound A-179(4.18g, 16.8mmol) was added thereto under ice cooling. The reaction mixture was stirred for 30 minutes, to which was added acetyl chloride(6.6g, 84mmol), then which was stirred at room temperature for 15 minutes. The reaction mixture was poured into ice water, which was extracted with methylene chloride, washed with 1N hydrochloric acid and saturated sodium hydrogen carbonate aqueous solution, successively. The reaction mixture was dried, then which was evaporated under reduced pressure to give a crude product of 5-acetyl-2-(4-fluorobenzyl)furan-3-carboxylic acid ethyl ester(4.54g, yield:93%). NMR(CDCl₃) δ: 1.37(3H, t, J=7.2Hz), 2.44(3H, s), 4.35(2H, q, J=7.2Hz), 4.38(2H, s), 6.94-7.00(2H, m), 7.26-7.31(2H, m), 7.41(1H, s).

(A-181) According to the method of the example A-18, 5-(3-ethoxycarbonyl-3-hydroxyacryloyl)-2-(4-fluorobenzyl)furan-3-carboxylic acid ethyl ester(1.1g, yield:82%) was synthesized from the above-mentioned compound A-180 (1.0g, 3.44mmol).

NMR(CDCl₃) δ: 1.38(3H, t, J=7.2Hz), 1.41(3H, t, J=7.2Hz), 4.35(2H, q, J=7.2Hz), 4.39(2H, q, J=7.2Hz), 4.41(2H, s), 6.84(1H, s), 6.97-7.03(2H, m), 7.26-7.31(2H, m), 7.57(1H, s).

EP 1 422 218 A1

(A-182) According to the method of the example A-19, 2-(4-fluorobenzyl)-5-(4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-3-carboxylic acid ethyl ester(850mg, yield:86%) was synthesized from the above-mentioned compound A-181(1.0g, 2.56mmol).

Melting point:172-173°C

Elementary analysis as C ₂₀ H ₁₈ FNO ₆				
Calcd. (%)	C, 62.01;	H, 4.68;	N, 3.62;	F, 4.90.
Found (%)	C, 61.95;	H, 4.45;	N, 3.60;	F, 4.73.

NMR(CDCl₃) δ: 1.40(3H, t, J=7.2Hz), 3.10(3H, s), 4.02(2H, s), 4.38(2H, q, J=7.2Hz), 4.45(2H, s), 7.03-7.10(2H, m), 7.26-7.31(2H, m), 7.61(1H, s).

(A-183) To a dioxane(20ml) solution of the above-mentioned compound A-182(500mg, 1.29mmol), 1N lithium hydroxide solution(3ml) was added at 50°C for 30 minutes, then the reaction mixture was concentrated, diluted with water, which was acidified with hydrochloric acid. The reaction mixture was extracted with chloroform, washed, dried and evaporated under reduced pressure to give a crude product(420mg, yield:91%), which was crystallized from methyl alcohol to give 2-(4-fluorobenzyl)-5-(4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-3-carboxylic acid.

Melting point:255-258°C(decomp.)

Elementary analysis as C ₁₈ H ₁₄ FNO ₆				
Calcd. (%)	C, 60.17;	H, 3.93;	N, 3.90;	F, 5.29.
Found (%)	C, 59.86;	H, 3.86;	N, 3.80;	F, 5.04.

NMR(DMSO-d₆) δ : 2.99(3H, s), 4.09(2H, s), 4.42(2H, s), 7.13-7.19(2H, m), 7.29-7.34(2H, m), 7.85(1H, s), 13.22(1H, bs).

(A-184) To a DMF(5ml) solution of the above-mentioned compound A-183(359mg, 1mmol), HOBT(13.5mg, 0.1mmol) and WSCD(575mg, 3mmol) in ethylamine(2mol/l in THF, 1.5ml, 3mmol) was added under ice cooling. The reaction mixture was stirred at room temperature for 20 hours, then water was added to stop the reaction, which was extracted with chloroform, washed with water, dried and evaporated under reduced pressure. The crystalline residue was recrystallized from isopropyl alcohol to give 2-(4-fluorobenzyl)-5-(4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-3-carboxylic acid ethylamide(91mg, yield:24%).

Melting point:169-170°C

Elementary analysis as C ₂₀ H ₁₉ O ₅ FN ₂				
Calcd. (%)	C: 62.17	H: 4.96	F: 4.92	N: 7.25
Found (%)	C: 62.05	H: 4.89	F: 4.75	N: 7.22

¹H-NMR(CDCl₃)δ: 1.26(3H, t, J=7.2Hz), 3.10(3H, s), 3.40-3.53(2H, m), 4.01(2H, s), 4.49(2H, s), 5.93(1H, bs), 7.03-7.08(2H, m), 7.25-7.33(2H, m), 7.41(1H, s).

[0302] The following compound was synthesized by the above-mentioned method.

(A-184-a) 2-(4-Fluorobenzyl)-5-(4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carbonyl)furan-3-carboxylic acid benzylamide

Melting point:181-184°C

Elementary analysis as C ₂₅ H ₂₁ O ₅ FN ₂				
Calcd. (%)	C: 66.96	H: 4.72	F: 4.24	N: 6.25
Found (%)	C: 66.63	H: 4.64	F: 4.06	N: 6.12


¹H-NMR(CDCl₃)δ: 3.9(3H, s), 4.00(2H, s), 4.51(2H, s), 4.62(2H, d, J=5.5Hz), 6.28(1H, bs), 7.02-7.08(2H, m), 7.26-7.42(8H, m).

B group compound

Compound B-6

3-Hydroxy-1-isopropyl-4-(6-phenethylpyrimidine-4-yl)-1,5-dihydropyrrole-2-one

[0303]



(B-1) According to the method of the reference (WO01/17968), 4-methyl-6-phenethylpyrimidine was synthesized.

(B-2) To a THF(100ml) solution of the above-mentioned compound B-1(19.8g, 100mmol) at -78°C , *n*-butyllithium solution(100mmol) was added dropwise, then a THF(50ml) solution of 2-(trimethylsilyl)ethoxymethyl chloride (16.7g, 100mmol) was added thereto. The reaction mixture was stirred at 0°C for 30 minutes, to which was added ammonium chloride aqueous solution, then extracted with ethyl acetate. The extract was washed, dried and evaporated to give a 9:1 mixture(32.7g, yield:100%) of 4-phenethyl-6-[2-(2-trimethylsilyl)ethoxy]ethylpyrimidine and 4-methyl-6-[2-phenyl-1-(2-trimethylsilyl)ethoxymethyl]ethylpyrimidine.

(4-phenethyl-6-[2-(2-trimethylsilyl)ethoxy]ethylpyrimidine)

NMR(CDCl_3) δ : -0.03(9H, s), 0.89(2H, dd, $J=8.0$, 8.0Hz), 2.95(2H, t, $J=6.5$ Hz), 3.04(4H, s), 3.50(2H, dd, $J=8.0$, 8.0Hz), 3.75(2H, t, $J=6.5$ Hz), 7.03(1H, d, $J=1.2$ Hz), 7.18-7.31(5H, m), 9.05(1H, d, $J=1.2$ Hz).

(B-3) To a 1,4-dioxane(50ml) solution of the above-mentioned compound B-2(32.7g, 100mmol), 5N-hydrochloric acid aqueous solution(100ml) was added, then the reaction mixture was stirred at 60°C for 1 hour, to which was added sodium carbonate until the solution became alkali, then extracted with ethyl acetate. The extract was washed, dried, and evaporated to give a crude mixture product(23.6g) of 2-(6-phenethylpyrimidine-4-yl)ethanol and 2-(6-methylpyrimidine-4-yl)-3-phenylpropane-1-ol.

NMR(CDCl_3) δ : 2.94(2H, t, $J=5.5$ Hz), 3.06(4H, s), 4.00(2H, t, $J=5.5$ Hz), 6.97(1H, d, $J=1.2$ Hz), 7.16-7.31(5H, m), 9.05(1H, d, $J=1.2$ Hz).

(B-4) To a chloroform(100ml) solution of the above-mentioned crude product B-3(23.6g), pyridine(15.8g, 200mmol) was added, to which was added trifluoromethanesulfonic acid anhydride(28.2g, 100mmol) under ice cooling. The reaction mixture was stirred for 10 minutes, then sodium hydrogen carbonate aqueous solution(100ml) was added thereto and chloroform was evaporated under reduced pressure. 1,4-Dioxane(50ml) was added to the residue, then was added 5N-sodium hydroxide aqueous solution(50ml) under ice cooling. The reaction mixture was stirred for 30 minutes, which was extracted with diethyl ether. The extract was washed, dried and evaporated under reduced pressure, then the residue was purified with silica gel column chromatography(*n*-hexane ethyl acetate=5:

1-1:1) to give 4-phenethyl-6-vinylpyrimidine(3.7g, yield:18%).

NMR(CDCl₃) δ: 3.07(4H, s), 5.67(1H, dd, J=10.7, 1.2Hz), 6.42(1H, dd, J=17.4, 1.2Hz), 6.68(1H, dd, J=10.4, 17.4Hz), 7.03(1H, d, J=1.2Hz), 7.17-7.32(5H, m), 9.09(1H, d, J=1.2Hz). (B-5) To an ethanol(3ml) solution of the above-mentioned compound B-4(316mg, 1.5mmol), acetic acid(90mg, 1.5mmol) and isopropylamine(266mg, 4.5mmol) were added, then the reaction mixture was refluxed for 3 hours. Sodium hydrogen carbonate aqueous solution was added thereto, then extracted with chloroform. The extract was washed, dried and evaporated under reduced pressure, then the residue was purified with silica gel column chromatography(chloroform:methyl alcohol=9:1) to give isopropyl[2-(6-phenethylpyrimidine-4-yl)ethyl]amine(309mg, yield:76%).

NMR(CDCl₃) δ: 1.07(6H, d, J=6.3Hz), 2.85-3.06(9H, m), 6.96(1H, d, J=1.2Hz), 7.16-7.31(5H, m), 9.05(1H, d, J=1.2Hz).

The following compounds were synthesized by the above-mentioned method.

Methyl[2-(6-phenethylpyrimidine-4-yl)ethyl]amine

NMR(CDCl₃) δ: 2.45(3H, s), 2.86-3.04(4H, m), 3.06(4H, s), 6.94(1H, d, J=1.2Hz), 7.16-7.31(5H, m), 9.05(1H, d, J=1.2Hz).

Benzyl[2-(6-phenethylpyrimidine-4-yl)ethyl]amine

NMR(CDCl₃) δ: 2.90-3.05(8H, m), 3.84(2H, s), 6.93(1H, d, J=0.9Hz), 7.15-7.33(5H, m), 9.03(1H, d, J=1.3Hz).

(1-Ethylpropyl)-[2-(6-phenethylpyrimidine-4-yl)ethyl]amine

NMR(CDCl₃) δ: 0.87(6H, t, J=7.5Hz), 1.45(4H, dq, J=7.6, 7.0Hz), 2.44(1H, tt, J=6.1, 5.8Hz), 2.89-3.06(8H, m), 6.99(1H, d, J=1.2Hz), 7.17-7.31(5H, m), 9.04(1H, d, J=1.2Hz).

Cyclohexyl[2-(6-phenethylpyrimidine-4-yl)ethyl]amine

NMR(CDCl₃) δ: 1.07-1.28(6H, m), 1.60-1.91(4H, m), 2.48(1H, m), 2.90(2H, t, J=6.7Hz), 3.01-3.06(6H, m), 6.96(1H, d, J=1.2Hz), 7.16-7.31(5H, m), 9.05(1H, d, J=1.2Hz).

[2-(6-Phenethylpyrimidine-4-yl)ethyl]phenylamine

NMR(CDCl₃) δ: 2.97-3.05(6H, m), 3.53(2H, t, J=6.4Hz), 6.65(2H, d, J=7.3Hz), 6.75(1H, t, J=7.3Hz), 6.92(1H, d, J=0.9Hz), 7.14-7.30(7H, m), 9.08(1H, d, J=1.2Hz).

Tert-butyl[2-(6-phenethylpyrimidine-4-yl)ethyl]amine

NMR(CDCl₃) δ: 1.19(9H, s), 2.99-3.06(8H, m), 6.97(1H, d, J=1.2Hz), 7.16-7.31(5H, m), 9.04(1H, d, J=1.2Hz).

O-tert-butyl N-[2-(6-phenethylpyrimidine-4-yl)ethyl]hydroxylamine

NMR(CDCl₃) δ: 1.20(9H, s), 2.95(2H, brs), 3.04(4H, s), 3.27(2H, brs), 6.99(1H, d, J=1.2Hz), 7.16-7.31(5H, m), 9.04(1H, d, J=1.2Hz).

(B-6) To an ethanol(1.5ml) solution of the above-mentioned compound B-5(269mg, 1mmol), oxalic acid diethyl (175mg, 1.2mmol) and sodium ethoxide(4.5mmol, 20% ethanol solution) were added, then the reaction mixture was heated at 60°C for 5 hours. Ammonium chloride aqueous solution was added to the solution, which was extracted with chloroform. The extract was washed, dried and evaporated under reduced pressure. The precipitated crystal was washed with methyl alcohol, which was dried with reduced pressure to give 3-hydroxy-1-isopropyl-4-(6-phenethylpyrimidine-4-yl)-1,5-dihydropyrrole-2-one(209mg, yield:65%).

Melting point:229-231°C

Elementary analysis as C ₁₉ H ₂₁ N ₃ O ₂ 0.2H ₂ O			
Calcd. (%)	C, 69.79;	H, 6.60;	N, 12.85.
Found (%)	C, 69.85;	H, 6.46;	N, 12.83.

NMR(CDCl₃) δ: 1.28(6H, d, J=6.7Hz), 3.09(4H, s), 4.05(2H, s), 4.57(1H, qq, J=6.9, 6.7Hz), 6.93(1H, s), 7.18-7.32(5H, m), 9.02(1H, s).

[0304] The following compounds were synthesized by the above-mentioned method.

(B-6-a) 3-Hydroxy-1-methyl-4-(6-phenethylpyrimidine-4-yl)-1,5-dihydropyrrole-2-one

Melting point:211-213°C

Elementary analysis as C ₁₇ H ₁₇ N ₃ O ₂			
Calcd. (%)	C, 69.14;	H, 5.80;	N, 14.23.
Found (%)	C, 69.09;	H, 5.61;	N, 14.23.

NMR(CDCl₃) δ: 3.09(4H, s), 3.16(3H, s), 4.07(2H, s), 6.79(1H, s), 7.16-7.29(5H, m), 9.01(1H, s).

(B-6-b) 1-Benzyl-3-hydroxy-4-(6-phenethylpyrimidine-4-yl)-1,5-dihydropyrrole-2-one Melting point:222-223°C

EP 1 422 218 A1

Elementary analysis as C ₂₃ H ₂₁ N ₃ O ₂ 0.3H ₂ O			
Calcd. (%)	C, 73.31;	H, 5.78;	N, 11.15.
Found (%)	C, 73.37;	H, 5.49;	N, 11.19.

NMR(CDCl₃) δ: 3.05(4H, s), 3.93(3H, s), 4.73(2H, s), 6.70(1H, s), 7.13-7.39(10H, m), 9.00(1H, s).
(B-6-c) 1-(1-Ethylpropyl)-3-hydroxy-4-(6-phenethylpyrimidine-4-yl)-1,5-dihydropyrrole-2-one
Melting point: 182-183°C

Elementary analysis as C ₂₁ H ₂₅ N ₃ O ₂			
Calcd. (%)	C, 71.77;	H, 7.17;	N, 11.96.
Found (%)	C, 71.69;	H, 7.13;	N, 11.90.

NMR(CDCl₃) δ: 0.88(6H, t, J=7.3Hz), 1.48-1.74(4H, m), 3.10(4H, s), 3.96(2H, s), 4.10(1H, m), 6.94(1H, s), 7.19-7.33(5H, m), 9.06(1H, s).
(B-6-d) 1-Cyclohexyl-3-hydroxy-4-(6-phenethylpyrimidine-4-yl)-1,5-dihydropyrrole-2-one
Melting point: 248-250°C

Elementary analysis as C ₂₂ H ₂₅ N ₃ O ₂ 0.1H ₂ O			
Calcd. (%)	C, 72.34;	H, 6.95;	N, 11.50.
Found (%)	C, 72.28;	H, 6.92;	N, 11.55.

NMR(CDCl₃) δ: 1.41-1.51(4H, m), 1.71-1.88(6H, m), 3.10(4H, s), 4.07(2H, s), 4.15(1H, m), 6.92(1H, s), 7.18-7.32(5H, m), 9.03(1H, s).
(B-6-e) 1-Hydroxy-4-(6-phenethylpyrimidine-4-yl)-1-phenyl-1,5-dihydropyrrole-2-one
Melting point: 253-255°C

Elementary analysis as C ₂₂ H ₁₉ N ₃ O ₂ 0.1H ₂ O			
Calcd. (%)	C, 73.56;	H, 5.39;	N, 11.70.
Found (%)	C, 73.37;	H, 5.16;	N, 11.65.

NMR(CDCl₃) δ: 3.13(4H, s), 4.56(2H, s), 6.98(1H, s), 7.18-7.33(6H, m), 7.44(2H, t, J=7.6Hz), 7.81(2H, d, J=7.6Hz), 9.08(1H, s).
(B-6-f) 1-Tert-butyl-3-hydroxy-4-(6-phenethylpyrimidine-4-yl)-1,5-dihydropyrrole-2-one
Melting point: 199-200°C

Elementary analysis as C ₂₀ H ₂₃ N ₃ O ₂			
Calcd. (%)	C, 71.19;	H, 6.87;	N, 12.45.
Found (%)	C, 70.84;	H, 6.81;	N, 12.30.

NMR(CDCl₃) δ: 1.53(9H, s), 3.09(4H, s), 4.16(2H, s), 7.03(1H, s), 7.19-7.32(5H, m), 9.03(1H, s).
(B-6-g) 1-Tert-butoxy-3-hydroxy-4-(6-phenethylpyrimidine-4-yl)-1,5-dihydropyrrole-2-one
Melting point: 230-232°C


Elementary analysis as C ₂₀ H ₂₃ N ₃ O ₂ 0.1H ₂ O			
Calcd. (%)	C, 67.62;	H, 6.58;	N, 11.83.
Found (%)	C, 67.51;	H, 6.42;	N, 11.83.

NMR(CDCl₃) δ: 1.39(9H, s), 3.10(4H, s), 4.27(2H, s), 6.76(1H, s), 7.17-7.32(5H, m), 9.02(1H, s).

Compound B-9

4-[5-(4-Fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

[0305]



(B-7) To a THF(10ml) solution of 4-hydroxy-1-isopropyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid A-4 (995mg, 5mmol), (4-fluorophenyl) acetic acid hydrazide (924mg, 5.5mmol), 1-hydroxybenzotriazole(67mg, 0.5mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide(931mg, 6mmol) were added, then the reaction mixture was stirred for 2 hours. The reaction was stopped with water, which was extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography(n-hexane:ethyl acetate=1:4-0:1) to give 1-isopropyl-4-methoxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid N'-[2-(4-fluorophenyl)acetyl]hydrazide(1.46g, yield:84%).

Melting point: 157-158°C

NMR(CDCl₃) δ: 1.21(6H, d, J=6.9Hz), 3.63(2H, s), 3.94(2H, s), 4.36-4.45(4H, m), 7.00-7.08(2H, m), 7.26-7.32(2H, m), 8.38(1H, s), 9.26(1H, s).

(B-8) To a methylene chloride(3ml) solution of triphenylphosphine (629mg, 2.4mmol), bromine(2.4mmol, 1M methylene chloride solution) was added dropwise under ice cooling, then the reaction mixture was stirred at room temperature for 30 minutes, to which triethylamine(506mg, 5mmol) and the above-mentioned compound B-7 (699mg, 2mmol) were added at room temperature, successively. The reaction mixture was warmed, then the reaction was stopped with water, which was extracted with chloroform. The extract was washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography(n-hexane:ethyl acetate=1:1-1:3) to give 4-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-1-isopropyl-3-methoxy-1,5-dihydropyrrole-2-one(595mg, yield:90%).

NMR(CDCl₃) δ: 1.24(6H, d, J=6.7Hz), 4.16(2H, s), 4.22(2H, s), 4.30(3H, s), 4.46(1H, qq, J=6.7Hz), 7.00-7.08(2H, m), 7.27-7.34(2H, m).

(B-9) To an acetonitrile solution(5ml) of the above-mentioned compound B-8(550mg, 1.66mmol), sodium iodide (1.99g, 13.3mmol) was added, to which was added chlorotrimethylsilane(1.44g, 13.3mmol) under ice cooling. The reaction mixture was stirred at 50°C for 2 hours, to which were added water and 10% sodium sulfite aqueous solution(2ml), successively. The precipitated crystal was washed with water and ethyl acetate, successively, then dried under reduced pressure to give 4-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one(441mg, yield:84%).

Melting point: 204-206°C

Elementary analysis as C ₁₆ H ₁₆ N ₃ O ₃				
Calcd. (%)	C, 60.56;	H, 5.08;	N, 13.24;	F, 5.99.
Found (%)	C, 60.43;	H, 4.93;	N, 13.14;	F, 5.93.


NMR(CDCl₃) δ: 1.28(6H, d, J=6.7Hz), 4.22(2H, s), 4.24(2H, s), 4.50(1H, qq, J=6.7Hz), 6.99-7.07(2H, m), 7.26-7.34

(2H, m).

Compound B-12

4-(6-Benzyloxypyrimidine-4-yl)-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0306]



(B-10) To a dimethylformamide(5ml) solution of sodium hydride(192mg, 8mmol), a dimethylformamide(3ml) solution of benzyl alcohol was added for 30 minutes, to which was added for 10 minutes 4-chloro-6-methylpyrimidine (1.03g, 8mmol) which was synthesized according to the method of the reference(WO01/17968). The reaction was quenched by adding ammonium chloride aqueous solution, then the reaction mixture was extracted with diethyl ether. The extract was washed, dried and evaporated under reduced pressure. The residue was purified with silica gel column chromatography(n-hexane:ethyl acetate=3:1-2:1) to give 4-benzyloxy-6-methylpyrimidine(1.49g, yield: 93%).

NMR(CDCl₃) δ: 2.45(3H, s), 5.42(2H, s), 6.64(1H, s), 7.36-7.43(5H, m), 8.69(1H, s).

(B-11) To a tetrahydrofuran(10ml) solution of the above-mentioned compound B-10(601mg, 3mmol), oxalic acid diethyl(2.2g, 15mmol) and potassium tert-butoxide(672mg, 6mmol) were added at 60°C for 30 minutes, successively. The reaction was quenched by adding ammonium chloride aqueous solution, then extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure. The precipitated crystal was washed with n-hexane, then dried under reduced pressure to give 3-(6-benzyloxypyrimidine-4-yl)-2-hydroxyacrylic acid ethyl ester(694mg, yield:77%).

Melting point: 136-137°C

NMR(CDCl₃) δ: 1.39(3H, t, J=7.2Hz), 4.36(2H, q, J=7.2Hz), 5.46(2H, s), 6.42(1H, s), 6.57(1H, s), 7.35-7.46(5H, m), 8.69(1H, s).

(B-12) To a dioxane(1ml) solution of the above-mentioned compound B-11(100mg, 0.33mmol), paraformaldehyde (50mg, 1.65mmol) and methylamine(0.66mmol, 30%ethanol solution) were added at room temperature for 1 hour, successively. The reaction was quenched by adding ammonium chloride aqueous solution, then the reaction mixture was extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure. The precipitated crystal was washed with diethyl ether, then dried under reduced pressure to give 4-(6-benzyloxypyrimidine-4-yl)-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(83mg, yield:85%).

Melting point:203-204°C

Elementary analysis as C ₁₆ H ₁₅ N ₃ O ₃ 0.1H ₂ O				
Calcd. (%)	C, 64.25;	H, 5.12;	N, 14.05.	

EP 1 422 218 A1

(continued)

Elementary analysis as C ₁₆ H ₁₅ N ₃ O ₃ 0.1H ₂ O				
Found (%)	C, 64.09;	H, 4.94;	N, 13.99.	

NMR(CDCl₃) δ : 1.15(3H, s), 4.07(2H, s), 5.47(2H, s), 6.47(1H, s), 7.30-7.48(5H, m), 8.72(1H, s).

[0307] The following compounds were synthesized by the above-mentioned method.

(B-12-a) 4-[6-(4-Benzoyloxypyrimidine-4-yl)-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one
Melting point:177-178°C

Elementary analysis as C ₁₈ H ₁₉ N ₃ O ₃ 0.1H ₂ O				
Calcd. (%)	C, 66.08;	H, 5.92;	N, 12.84.	
Found (%)	C, 65.99;	H, 5.80;	N, 12.68.	

NMR(CDCl₃) δ : 1.26(6H, d, J=6.7Hz), 4.04(2H, s), 4.56(1H, sept), 5.47(2H, s), 6.55(1H, s), 7.30-7.47(5H, m), 8.72(1H, s).

(B-12-b) 4-[6-(4-Fluorobenzyloxy)pyrimidine-4-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one
H-NMR(CDCl₃)δ : 3.15(s,3H), 4.08(s,2H), 5.43(s,2H), 6.47(d,1H, J=1.2Hz), 7.05-7.15(m, 2H), 7.40-7.50(m,2H), 8.71(d, 1H, J=1.2Hz).
Melting point:232-234°C

Elementary analysis as C ₁₆ H ₁₄ N ₃ O ₃ F				
Calcd. (%)	C: 60.95	H: 4.48	N: 13.33	F: 6.03
Found (%)	C: 60.89	H: 4.36	N: 13.27	F: 6.14

(B-12-c) 4-[6-(4-Fluorobenzyloxy)pyrimidine-4-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one
H-NMR(CDCl₃)δ: 1.26(d,6H,J=6.9Hz), 4.05(s,2H), 4.55(m, 1H), 5.43(s,2H), 6.50(d, 1H, J=1.2Hz), 7.05-7.15(m, 2H), 7.40-7.50(m,2H), 8.71(d, 1H, J=1.2Hz).
Melting point: 191°C

Elementary analysis as C ₁₈ H ₁₈ N ₃ O ₃ F 0.3H ₂ O				
Calcd. (%)	C: 61.99	H: 5.38	N: 12.05	F: 5.45
Found (%)	C: 61.87	H: 5.11	N: 12.05	F: 5.35

(B-12-d) 4-[6-(2-Fluorobenzyloxy)pyrimidine-4-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one
H-NMR(CDCl₃)δ: 3.15(s,3H), 4.07(s,2H), 5.53(s,2H), 6.48(d,1H, J=1.2Hz), 7.10-7.20(m, 2H), 7.34(m,1H), 7.48(m, 1H), 8.72(d, 1H, J=1.2Hz).
Melting point:215-217°C

Elementary analysis as C ₁₆ H ₁₄ N ₃ O ₃ F 0.3H ₂ O				
Calcd. (%)	C: 59.92	H: 4.59	N: 13.10	F: 5.92
Found (%)	C: 60.10	H: 4.51	N: 13.05	F: 5.64

(B-12-e) 4-[6-(2-Fluorobenzyloxy)pyrimidine-4-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one
H-NMR(CDCl₃)δ: 1.26(d,6H,J=6.9Hz), 4.06(s,2H), 4.55(m,1H), 5.54(s,2H), 6.63(d,1H, J=1.2Hz), 7.05-7.20(m, 2H), 7.35(m,1H), 7.48(m,1H), 8.72(d, 1H, J=1.2Hz).
Melting point:170-171°C

Elementary analysis as C ₁₈ H ₁₈ N ₃ O ₃ F				
Calcd. (%)	C: 62.97	H: 5.28	N: 12.24	F: 5.53
Found (%)	C: 62.94	H: 5.33	N: 12.21	F: 5.31

EP 1 422 218 A1

(B-12-f) 3-Hydroxy-4-[6-(3-isopropylbenzyloxy)pyrimidine-4-yl]-1-methyl-1,5-dihydropyrrole-2-one
H-NMR(CDCl₃) δ : 1.27(d,6H,J=6.6Hz), 2.93(m,1H), 3.15(s,3H), 4.08(s,2H), 5.45(s,2H), 6.48(d,1H, J=1.2Hz), 7.20-7.36(m, 4H), 8.73(d, 1H, J=1.2Hz).
Melting point: 149-150°C

Elementary analysis as C ₁₉ H ₂₁ N ₃ O ₃			
Calcd. (%)	C: 67.24	H: 6.24	N: 12.38
Found (%)	C: 67.17	H: 6.08	N: 12.38

(B-12-g) 3-Hydroxy-4-[6-(3-isopropylbenzyloxy)pyrimidine-4-yl]-1-isopropyl-1,5-dihydropyrrole-2-one
H-NMR(CDCl₃) δ : 1.26(d,6H,J=6.6Hz), 1.27(d,6H,J=6.9Hz), 2.93(m,1H), 4.05(s,3H), 4.56(m,1H), 5.45(s,2H), 6.58(d,1H, J=1.2Hz), 7.20-7.36(m, 4H), 8.73(d, 1H, J=1.2Hz).
Melting point: 191°C

Elementary analysis as C ₂₁ H ₂₅ N ₃ O ₃			
Calcd. (%)	C: 68.64	H: 6.86	N: 11.44
Found (%)	C: 68.63	H: 6.64	N: 11.38

(B-12-h) 1-Ethyl-4-[6-(4-fluorobenzyloxy)pyrimidine-4-yl]-3-hydroxy-1,5-dihydropyrrole-2-one
H-NMR(CDCl₃) δ : 1.24(t,3H,J=7.2Hz), 3.61(q,2H,J=7.2Hz), 4.10(s,2H), 5.43(s,2H), 6.57(d,1H, J=1.2Hz), 7.05-7.11(m, 2H), 7.40-7.46(m,2H), 8.70(d, 1H, J=1.2Hz).
Melting point: 171-173°C

Elementary analysis as C ₁₇ H ₁₆ N ₃ O ₃ F				
Calcd. (%)	C: 62.00	H: 4.90	N: 12.76	F: 5.77
Found (%)	C: 61.97	H: 4.83	N: 12.69	F: 5.77

(B-12-i) 4-[6-(4-Fluorobenzyloxy)pyrimidine-4-yl]-3-hydroxy-1-propyl-1,5-dihydropyrrole-2-one
H-NMR(CDCl₃) δ : 0.95(t,3H,J=7.5Hz), 1.65(m,2H), 3.51(t,2H,J=7.5Hz), 4.08(s,2H), 5.43(s,2H), 6.52(d,1H, J=1.2Hz), 7.05-7.11(m, 2H), 7.40-7.45(m,2H), 8.71(d, 1H, J=1.2Hz).
Melting point: 159-160°C

Elementary analysis as C ₁₈ H ₁₈ N ₃ O ₃ F				
Calcd. (%)	C: 62.97	H: 5.28	N: 12.24	F: 5.53
Found (%)	C: 63.00	H: 5.24	N: 12.21	F: 5.65

(B-12-j) 4-[6-(4-Fluorobenzyloxy)pyrimidine-4-yl]-3-hydroxy-1-(2-hydroxyethyl)-1,5-dihydropyrrole-2-one
H-NMR(DMSO-d₆) δ : 3.50(m,2H), 3.59(m,2H), 4.29(s,2H), 4.85(bs,2H), 5.42(s,2H), 7.19-7.28(m, 3H), 7.50-7.58(m,2H), 8.75(m, 1H).
Melting point: 178-180°C

Elementary analysis as C ₁₇ H ₁₆ N ₃ O ₄ F				
Calcd. (%)	C: 59.13	H: 4.67	N: 12.17	F: 5.50
Found (%)	C: 59.07	H: 4.64	N: 12.07	F: 5.55

(B-12-k) 4-[6-(4-Fluorobenzyloxy)pyrimidine-4-yl]-3-hydroxy-1-(2-methoxyethyl)-1,5-dihydropyrrole-2-one
H-NMR(CDCl₃) δ : 3.35(s,3H), 3.59(t,2H,J=4.8Hz), 3.72(t,2H,J=4.8Hz), 4.23(s,2H), 5.43(s,2H), 6.48(d,1H, J=1.2Hz), 7.05-7.11(m, 2H), 7.40-7.46(m,2H), 8.71(d, 1H, J=1.2Hz).
Melting point: 153-154°C

Elementary analysis as C ₁₈ H ₁₈ N ₃ O ₄ F				
Calcd. (%)	C: 60.16	H: 5.05	N: 11.69	F: 5.29

EP 1 422 218 A1

(continued)

Elementary analysis as C ₁₈ H ₁₈ N ₃ O ₄ F				
Found (%)	C: 60.17	H: 5.01	N: 11.64	F: 5.37

(B-12-l)

4-[6-(4-Fluorobenzyloxy)pyrimidine-4-yl]-3-hydroxy-1,5-dihydropyrrole-2-one

H-NMR(DMSO-d₆) δ : 4.11(s,2H), 5.42(s,2H), 7.18-7.28(m, 3H), 7.50-7.56(m, 2H), 8.73(s,1H), 8.76(m, 1H).

Melting point:194-196°C

Elementary analysis as C ₁₅ H ₁₂ N ₃ O ₃ F				
Calcd. (%)	C: 59.80	H: 4.01	N: 13.95	F: 6.31
Found (%)	C: 59.53	H: 4.00	N: 13.83	F: 6.21

(B-12-m) 4-[6-(4-Fluorobenzyloxy)pyrimidine-4-yl]-3-hydroxy-1-(4-methoxybenzyl)-1,5-dihydropyrrole-2-one

H-NMR(CDCl₃)δ: 3.80(s,3H), 3.91(s,2H), 4.66(s,2H), 5.40(s,2H), 6.38(d,1H, J=1.2Hz), 6.87 and 7.20(ABq, 2Hx2,J=8.4Hz), 7.02-7.09(m, 2H), 7.37-7.41(m,2H), 8.69(d, 1H, J=1.2Hz).

Melting point:227-228°C

Elementary analysis as C ₂₃ H ₂₀ N ₃ O ₄ F·0.1H ₂ O				
Calcd. (%)	C: 65.27	H: 4.81	N: 9.93	F: 4.49
Found (%)	C: 65.06	H: 4.52	N: 9.94	F: 4.43

(B-12-n) 1-Allyl-4-[6-(4-fluorobenzyloxy)pyrimidine-4-yl]-3-hydroxy-1,5-dihydropyrrole-2-one

H-NMR(CDCl₃)δ : 4.05(s,2H), 4.16(m,2H), 5.20-5.23(m,1H), 5.26(m,1H), 5.43(s,2H), 5.75-5.90(m,1H), 6.48(d,1H, J=1.2Hz), 7.04-7.10(m, 2H), 7.37-7.44(m,2H), 8.71(d, 1H, J=1.2Hz).

Melting point:167-168°C

Elementary analysis as C ₁₈ H ₁₆ N ₃ O ₃ F				
Calcd. (%)	C: 63.34	H: 4.72	N: 12.31	F: 5.57
Found (%)	C: 63.43	H: 4.59	N: 12.37	F: 5.62

(B-12-o)

3-Hydroxy-4-[6-(2-isopropylbenzyloxy)-pyrimidine-4-yl]-l-methyl-1,5-dihydropyrrole-2-one

Melting point:240-241°C


Elementary analysis as C ₁₉ H ₂₁ N ₃ O ₃			
Calcd. (%)	C, 67.24;	H, 6.24;	N, 12.38.
Found (%)	C, 67.03;	H, 6.07;	N, 12.31.

NMR(CDCl₃) δ:1.28(6H, d, J=6.7Hz), 3.15(3H, s), 3.22(1H, m), 4.08(2H, s), 5.52(2H, s), 6.42(1H, s), 7.19-7.23 (1H, m), 7.37-7.42(3H, m), 8.73(1H, s).

Compound B-14

4-{6-[2-(4-Fluorophenyl)ethyl]pyrimidine-4-yl}-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0308]



(B-13) According to the method of the reference (WO01/17968), 3-{6-[2-(4-fluorophenyl)ethyl]pyrimidine-4-yl}-2-hydroxyacrylic acid ethyl ester was synthesized. Melting point: 139-141°C

NMR(CDCl₃) δ: 1.39(3H, t, J=7.3Hz), 3.04(4H, s), 4.37(2H, q, J=7.3Hz), 6.39(1H, s), 6.86(1H, s), 6.93-6.99(2H, m), 7.10-7.18(2H, m), 8.95(1H, s).

(B-14) To a dioxane(2ml) solution of the above-mentioned compound B-13(100mg, 0.33mmol), paraformaldehyde (20mg, 0.66mmol) and methylamine(0.66mmol, 30% ethanol solution) were added, successively at room temperature for 2 hours. The reaction was quenched with ammonium chloride aqueous solution, then the reaction mixture was extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure. The precipitated crystal was washed with methyl alcohol and dried under reduced pressure to give 4-{6-[2-(4-fluorophenyl)ethyl]pyrimidine-4-yl}-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(72mg, yield:72%).

Melting point:225-228°C

Elementary analysis as C ₁₇ H ₁₆ FN ₃ O ₂				
Calcd. (%)	C, 65.17;	H, 5.15;	N, 13.41;	F, 6.06.
Found (%)	C, 65.03;	H, 5.31;	N, 13.37;	F, 5.93.

NMR(CDCl₃) δ: 3.06(3H, s), 3.16(2H, s), 4.08(2H, s), 6.78(1H, s), 6.94-7.00(2H, m), 7.10-7.15(2H, m), 9.01(1H, d, J=1.2Hz).

[0309] The following compound was synthesized by the above-mentioned method.

(B-14-a) 4-{6-[2-(4-Fluorophenyl)ethyl]pyrimidine-4-yl}-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point:225-228°C


Elementary analysis as C ₁₉ H ₂₀ FN ₃ O ₂				
Calcd. (%)	C, 66.85;	H, 5.91;	N, 12.31;	F, 5.57.
Found (%)	C, 66.61;	H, 6.10;	N, 12.25;	F, 5.43.

NMR(CDCl₃) δ: 1.28(6H, d, J=6.7Hz), 3.06(4H, s), 4.05(2H, s), 4.57(1H, sept), 6.89(1H, d, J=1.2Hz), 6.91-6.99(2H, m), 7.00-7.16(2H, m), 9.02(1H, d, H=1.2Hz).

Compound 16

4-{6-[1-(4-Fluorobenzyl)-2-(4-fluorophenyl)ethyl]pyrimidine-4-yl}-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0310]



(B-15) According to the method of the reference (WO01/17968), 3-{6-[1-(4-fluorobenzyl)-2-(4-fluorophenyl)ethyl]pyrimidine-4-yl}-2-hydroxyacrylic acid ethyl ester was synthesized.

Melting point: 132-133°C

NMR(CDCl₃) δ: 1.36(3H, t, J=7.0Hz), 2.95-3.15(5H, m), 4.33(2H, q, J=7.0Hz), 6.22(1H, s), 6.42(1H, d, J=1.4Hz), 6.85-7.00(8H, m), 8.97(1H, s).

(B-16) To a dioxane(2ml) solution of the above-mentioned compound B-15(100mg, 0.24mmol), paraformaldehyde (14mg, 0.48mmol) and methylamine(0.48mmol, 30% ethanol solution) were added successively at room temperature for 2 hours. The reaction was quenched with ammonium chloride aqueous solution, then the reaction mixture was extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure. The precipitated crystal was washed with diethyl ether, which was dried to give 4-{6-[1-(4-fluorobenzyl)-2-(4-fluorophenyl)ethyl]pyrimidine-4-yl}-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one(60mg, yield:59%).

Melting point: 162-164°C

Elementary analysis as C ₂₄ H ₂₁ F ₂ N ₃ O ₂ 0.2H ₂ O				
Calcd. (%)	C, 67.82;	H, 5.07;	N, 9.89;	F, 8.94.
Found (%)	C, 67.82;	H, 5.09;	N, 9.87;	F, 8.79.

NMR(CDCl₃) δ : 2.99-3.15(8H, m), 3.89(2H, s), 6.28(1H, s), 6.85-6.99(8H, m), 9.04(1H, s).

[0311] The following compound was synthesized by the above-mentioned method.

(B-16-a) 4-{6-[1-(4-Fluorobenzyl)-2-(4-fluorophenyl)ethyl]pyrimidine-4-yl}-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 181-183°C


Elementary analysis as C ₂₆ H ₂₅ F ₂ N ₃ O ₂				
Calcd. (%)	C, 69.47;	H, 5.61;	N, 9.35;	F, 8.45.
Found (%)	C, 69.49;	H, 5.65;	N, 9.32;	F, 8.32.

NMR(CDCl₃) δ: 1.23(6H, d, J=6.7Hz), 3.00-3.20(5H, m), 3.87(2H, s), 4.53(1H, sept), 6.42(1H, s), 6.86-7.00(8H, m), 9.05(1H, s).

Compound B-19

3-Hydroxy-1-methyl-4-(6-phenoxy pyrimidine-4-yl)-1,5-dihydropyrrole-2-one

[0312]



(B-17) According to the synthetic method of (B-10), 4-methyl-6-phenoxy pyrimidine was synthesized.

NMR(CDCl₃) δ : 2.50(3H, s), 6.72(1H, s), 7.13-7.17(2H, m), 7.25-7.31(1H, m), 7.42-7.47(2H, m), 8.68(1H, s).

(B-18) According to the synthetic method of (B-11), 2-hydroxy-3-(6-phenoxy pyrimidine-4-yl)acrylic acid ethyl ester was synthesized from the above-mentioned compound (B-17).

NMR(CDCl₃) δ : 1.40(3H, t, J=7.0Hz), 4.37(2H, q, J=7.0Hz), 6.46(1H, s), 6.64(1H, s), 7.14-7.18(2H, m), 7.29-7.34(1H, m), 7.44-7.49(2H, m), 8.69(1H, s).

(B-19) According to the synthetic method of (B-12), 3-hydroxy-1-methyl-4-(6-phenoxy pyrimidine-4-yl)-1,5-dihydropyrrole-2-one was synthesized from the above-mentioned compound (B-18).

Melting point: 235-236°C


Elementary analysis as C ₁₅ H ₁₃ N ₃ O ₃ 0.3H ₂ O			
Calcd. (%)	C, 62.41;	H, 4.75;	N, 14.56.
Found (%)	C, 62.48;	H, 4.41;	N, 14.49.

NMR(DMSO-d₆) δ : 3.02(3H, s), 4.20(2H, s), 7.21-7.32(3H, m), 7.39(1H, d, J=1.0Hz), 7.44-7.49(2H, m), 8.67(1H, d, J=1.0Hz).

Compound B-22

N-[6-(4-Hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-yl)pyrimidine-4-yl]-benzenesulfoneamide

[0313]



(B-20) To a DMSO(2ml) solution of 4-chloro-6-methylpyrimidine(128mg, 1mmol) which was synthesized according to the method of the reference (WO01/17968), benzenesulfone amide(236mg, 1.5mmol) and potassium carbonate (207mg, 1.5mmol) were added, successively. The reaction mixture was heated at 120°C for 3 hours. The reaction was quenched with ammonium chloride aqueous solution, then the reaction mixture was extracted with chloroform. The extract was dried and evaporated under reduced pressure. The precipitated crystal was washed with ethyl acetate and diethyl ether, successively, which was dried to give N-(6-methylpyrimidine-4-yl)benzenesulfoneamide (151mg, yield:61%).

Melting point:188-189°C

NMR(CDCl₃) δ : 2.45(3H, s), 7.11(1H, s), 7.45-7.63(3H, m), 7.92-7.95(2H, m), 8.71(1H, s).

(B-21) According to the synthetic method of (B-11), 3-(6-benzenesulfonylamino-4-pyrimidinyl)-2-hydroxyacrylic acid ethyl ester was synthesized from the above-mentioned compound (B-20).

Melting point: 205-208°C

NMR(CDCl₃) δ: 1.40(3H, t, J=7.0Hz), 4.37(2H, q, J=7.0Hz), 6.44(1H, s), 7.08(1H, s), 7.52-7.67(3H, m), 7.93-8.00(2H, m), 8.84(1H, s), 10.82(1H, bs), 13.81(1H, bs), 8.69(1H, s).

(B-22) According to the synthetic method of (B-12), N-[6-(4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-yl)pyrimidine-4-yl]-benzenesulfoneamide was synthesized from the above-mentioned compound (B-21).

Melting point:>300°C

Elementary analysis as C₁₅H₁₄N₄O₄S 0.9H₂O

Calcd. (%)	C, 49.69;	H, 4.39;	N, 15.45;	S, 8.84.
------------	-----------	----------	-----------	----------

Found (%)	C, 49.67;	H, 4.17;	N, 15.32;	S, 8.82.
-----------	-----------	----------	-----------	----------

NMR(DMSO-d₆) δ: 3.00(3H, s), 4.12(2H, s), 7.54-7.65(3H, m), 7.69(1H, s), 7.90(2H, m), 8.53(1H, s).

[0314] The following compound was synthesized by the above-mentioned method.

(B-22-a) N-[6-(4-Hydroxy-1-isopropyl-5-oxo-2,5-dihydro-1H-pyrrole-3-yl)pyrimidine-4-yl]benzenesulfoneamide

Melting point:255-260°C

Elementary analysis as C₁₇H₁₈N₄O₄S 0.5H₂O

Calcd. (%)	C, 53.25;	H, 4.99;	N, 14.61;	S, 8.36.
------------	-----------	----------	-----------	----------


Found (%)	C, 53.55;	H, 4.72;	N, 14.61;	S, 8.09.
-----------	-----------	----------	-----------	----------

NMR(DMSO-d₆) δ:1.18(6H, d, J=6.7Hz), 4.05(2H, s), 4.25(1H, m), 7.52-7.62(4H, m), 7.89-7.92(2H, m), 8.48(1H, s).

Compound B-25

3-Hydroxy-1-methyl-4-(5-phenoxy-2-methylpyridine-2-yl)-1,5-dihydropyrrole-2-one

[0315]



(B-23) According to the method of the reference (J. Am. Chem. Soc. 1997, 119(43), 10539-10540), 2-methyl-5-phenoxy-2-methylpyridine was synthesized using 6-methylpyridine-3-ol and iodobenzene.
NMR(CDCl₃) δ : 2.54(3H, s), 6.67-7.01(2H, m), 7.09-7.15(2H, m), 7.21-7.24(1H, m), 7.31-7.38(2H, m), 8.30(1H, d, J=2.7Hz).

The following compound was synthesized by the above-mentioned method.

5-(4-Fluorophenoxy)-2-methylpyridine

NMR(CDCl₃) δ : 2.54(3H, s), 6.94-7.07(4H, m), 7.11(1H, d, J=8.4Hz), 7.18(1H, dd, J=2.8, 5.6Hz), 8.26(1H, d, J=2.8Hz).

(B-24) According to the method of the reference (WO01/17968), 2-hydroxy-3-(5-phenoxy-2-methylpyridine-2-yl)acrylic acid ethyl ester was synthesized using the above-mentioned compound B-23.

Melting point: 73-75°C

NMR(CDCl₃) δ : 1.39(3H, t, J=7.0Hz), 4.36(2H, q, J=7.0Hz), 6.58(1H, s), 7.04-7.08(2H, m), 7.17-7.22(2H, m), 7.35-7.43(3H, m), 8.24(1H, d, J=2.7Hz).

The following compound was synthesized by the above-mentioned method.

3-[5-(4-Fluorophenoxy)pyridine-2-yl]-2-hydroxyacrylic acid ethyl ester

Melting point: 99-101°C

NMR(CDCl₃) δ : 1.39(3H, t, J=7.0Hz), 4.36(2H, q, J=7.0Hz), 6.58(1H, s), 7.01-7.13(4H, m), 7.21(1H, d, J=8.9Hz), 7.33(1H, dd, J=2.7, 8.5Hz), 8.22(1H, d, J=2.7Hz).

(B-25) According to the synthetic method of (B-12), 3-hydroxy-1-methyl-4-(5-phenoxy-2-methylpyridine-2-yl)-1,5-dihydropyrrole-2-one was synthesized from the above-mentioned compound (B-24).

Melting point: 200-202°C

Elementary analysis as C ₁₆ H ₁₄ N ₂ O ₃ · 0.2H ₂ O			
Calcd. (%)	C, 67.22;	H, 5.08;	N, 9.80.
Found (%)	C, 67.22;	H, 4.97;	N, 9.74.

NMR(CDCl₃) δ : 3.15(3H, s), 4.15(2H, s), 7.03-7.07(2H, m), 7.15-7.22(2H, m), 7.36-7.43(3H, m), 8.32(1H, d, J=2.3Hz).

[0316] The following compounds were synthesized by the above-mentioned method.

(B-25-a) 3-Hydroxy-1-isopropyl-4-(5-phenoxy-2-methylpyridine-2-yl)-1,5-dihydropyrrole-2-one

Melting point: 181-183°C

Elementary analysis as $C_{18}H_{18}N_2O_3 \cdot 0.2H_2O$

Calcd. (%)	C, 68.86;	H, 5.91;	N, 8.92.
Found (%)	C, 68.65;	H, 5.65;	N, 8.89.

NMR($CDCl_3$) δ : 1.27(6H, d, $J=6.7$ Hz), 4.12(2H, s), 4.57(1H, sept), 7.02-7.07(2H, m), 7.17-7.28(2H, m), 7.37-7.43(3H, m), 8.32(1H, dd, $J=0.6, 2.7$ Hz).

(B-25-b) 4-[5-(4-Fluorophenoxy)pyridine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one Melting point: 229-230°C

Elementary analysis as $C_{16}H_{13}FN_2O_3$

Calcd. (%)	C, 64.00;	H, 4.36;	N, 9.33;	F, 6.33.
Found (%)	C, 63.90;	H, 4.27;	N, 9.32;	F, 6.13.

NMR($CDCl_3$) δ : 3.15(3H, s), 4.16(2H, s), 7.01-7.13(4H, m), 7.19(1H, d, $J=8.9$ Hz), 7.35(1H, dd, $J=2.7, 8.5$ Hz), 8.30(1H, d, $J=2.7$ Hz).

(B-25-c) 4-[5-(4-Fluorophenoxy)pyridine-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one
Melting point: 178-179°C

Elementary analysis as $C_{18}H_{17}FN_2O_3$


Calcd. (%)	C, 65.84;	H, 5.22;	N, 8.49;	F, 5.79.
Found (%)	C, 65.63;	H, 5.14;	N, 8.49;	F, 5.58.

NMR($CDCl_3$) δ : 1.28(6H, d, $J=7.0$ Hz), 4.12(2H, s), 4.56(1H, sept), 7.00-7.13(4H, m), 7.27(1H, d, $J=8.9$ Hz), 7.35(1H, dd, $J=2.7, 8.8$ Hz), 8.30(1H, dd, $J=0.6, 2.7$ Hz).

Compound B-29

4-[5-(4-Fluorobenzyl)-pyridine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0317]



(B-26) To a methylene chloride(100ml) solution of 5-hydroxy-2-methylpyridine(10.9g, 100mmol) and pyridine (12.2ml, 150 mmol), trifluoromethanesulfonic acid anhydride(18.5ml, 120mmol) was added dropwise under ice cooling, then the reaction mixture was stirred for 1.5 hours, to which were added methyl alcohol(2ml) and saturated sodium hydrogen carbonate aqueous solution(150ml), successively. Then the reaction mixture was extracted with methylene chloride. The extract was washed, dried and evaporated under reduced pressure. The residue was

purified with silica gel column chromatography(n-hexane:ethyl acetate=9:1-4:1) to give 2-methyl-5-(trifluoromethanesulfonyloxy)pyridine(23.0g, yield:95%).

(B-27) To a tetrahydrofuran(130ml) solution of the above-mentioned compound B-26(10.4g, 43.2 mmol), 4-fluorobenzylzinc bromide in tetrahydrofuran (65 mmol) synthesized according to the method of the reference(J. Org. Chem., 1994, 59, p2671) and tetrakis(triphenylphosphine)palladium(2.4g) were added, then the reaction mixture was refluxed for 5 hours. The reaction mixture was evaporated under reduced pressure, to which were added water and ethyl acetate, then insoluble product was filtered with celite. The filtrate was extracted with ethyl acetate, then washed with water. The ethyl acetate solution was extracted with 1N hydrochloric acid, then the hydrochloric acid extract was alkalinized with 2N sodium hydroxide aqueous solution. The alkali solution was extracted with ethyl acetate, then washed, dried and evaporated. The residue was purified with silica gel column chromatography(n-hexane:ethyl acetate=2:1) to give 5-(4-fluorobenzyl)-2-methylpyridine(5.42g, yield:62%).

NMR(CDCl₃) δ:2.53 (3H, s), 3.91 (2H, s), 6.96 (2H, t like, J=8.7Hz), 7.06-7.15 (3H, m), 7.34 (1H, dd, J=8.1Hz, 1.5Hz), 7.36 (1H, d, J=1.5Hz).

(B-28) To a tetrahydrofuran(30ml) solution of the above-mentioned compound B-27(2.88g, 14.3 mmol), n-butyllithium solution(15.7mmol) was added dropwise at -78°C, and oxalic acid diethyl(6.27g, 42.9mmol) was added thereto, then the reaction mixture was stirred for 30 minutes, then stirred at 0°C for 30 minutes. The reaction was quenched with ammonium chloride aqueous solution, extracted with ethyl acetate. The extract was washed, dried and evaporated under reduced pressure. The precipitated crystal was washed with n-hexane, which was dried to give 3-[5-(4-fluorobenzyl)pyridine-2-yl]-2-hydroxyacrylic acid ethyl ester(2.72g, yield:63%).

Melting point: 94-96°C

Elementary analysis as C ₁₇ H ₁₆ FNO ₃				
Calcd. (%)	C, 67.76;	H, 5.35;	N, 4.65;	F, 6.31.
Found (%)	C, 67.83;	H, 5.21;	N, 4.63;	F, 6.13.

Calcd. (%)	C, 67.76;	H, 5.35;	N, 4.65;	F, 6.31.
Found (%)	C, 67.83;	H, 5.21;	N, 4.63;	F, 6.13.

NMR(CDCl₃) δ : 1.39(3H, t, J=7.1Hz), 3.96(2H, s), 4.36(2H, q, J=7.1Hz), 6.56(1H, s), 6.98-7.04(2H, m), 7.11-7.18 (3H, m), 7.51(1H, dd, J=2.0, 8.3Hz), 8.29(1H, d, J=2.0Hz).

(B-29) To a dioxane (7.5ml) solution of the above-mentioned compound B-28 (151mg, 0.50mmol), paraformaldehyde (40mg, 1.0mmol) and methylamine (1.0mmol, 40% methyl alcohol solution) were added successively, then the reaction mixture was stirred at room temperature for 2 hours. The solvent was evaporated in vacuum and an ammonium chloride aqueous solution, water and chloroform were added thereto, followed by filtration. The filtrate was washed, dried and evaporated in vacuum. The precipitated crystal was recrystallized from 2-propyl alcohol and dried in vacuum to give 4-[5-(4-fluorobenzyl)-pyridine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one (55mg, yield : 37%).

Melting point: 204-206°C

Elementary analysis as C ₁₇ H ₁₅ FN ₂ O ₂				
Calcd. (%)	C, 68.45;	H, 5.07;	N, 9.39;	F, 6.37.
Found (%)	C, 68.14;	H, 5.14;	N, 9.09;	F, 6.00.

Calcd. (%)	C, 68.45;	H, 5.07;	N, 9.39;	F, 6.37.
Found (%)	C, 68.14;	H, 5.14;	N, 9.09;	F, 6.00.

NMR(CDCl₃) δ: 3.14(3H, s), 3.97(2H, s), 4.12(2H, s), 6.98-7.16(5H, m), 7.53(1H, dd, J=2.1, 8.2Hz), 8.37(1H, d, J=1.5Hz).

[0318] The following compounds were prepared as well as above.

(B-29-a) 4-[5-(4-fluorobenzyl)-pyridine-2-yl]-3-hydroxyl-isopropyl-1,5-dihydro-pyrrole-2-one Melting point: 162-164°C

Elementary analysis as C ₁₉ H ₁₉ FN ₂ O ₂				
Calcd. (%)	C, 69.92;	H, 5.87;	N, 8.58;	F, 5.82.
Found (%)	C, 69.77;	H, 5.81;	N, 8.57;	F, 5.58.

Calcd. (%)	C, 69.92;	H, 5.87;	N, 8.58;	F, 5.82.
Found (%)	C, 69.77;	H, 5.81;	N, 8.57;	F, 5.58.

NMR(CDCl₃) δ: 1.27(6H, d, J=6.7Hz), 3.98(2H, s), 4.08(2H, s), 4.57(1H, sept, J=6.7Hz), 6.98-7.16(5H, m), 7.53 (1H, dd, J=2.4, 8.2Hz), 8.37-8.38 (1H, m).

(B-29-b) 4-[5-(4-fluorobenzyl)-pyridine-2-yl]-3-hydroxyl-(2-hydroxyethyl)-1,5-dihydropyrrole-2-one

Melting point : 202-204°C

Elementary analysis as $C_{18}H_{17}FN_2O_3$

Calcd. (%)	C, 65.84;	H, 5.22;	N, 8.53;	F, 5.79.
Found (%)	C, 60.49;	H, 4.89;	N, 7.66;	F, 5.09.

NMR($CDCl_3$) δ : 3.70(2H, t, $J=5.1$ Hz), 3.90(2H, t, $J=5.0$ Hz), 3.98(2H, s), 4.27(2H, s), 6.98-7.04(3H, m), 7.11-7.16(2H, m), 7.53(1H, dd, $J=1.9, 8.9$ Hz), 8.37(1H, d, $J=1.9$ Hz). (B-29-c) 4-[5-(4-fluorobenzyl)-pyridine2-yl]-3-hydroxyl-(2-methoxyethyl)-1,5-dihydropyrrole2-one

Melting point: 202-204°C

Elementary analysis as $C_{20}H_{23}FN_2O_3$

Calcd. (%)	C, 67.02;	H, 6.47;	N, 7.82;	F, 5.30.
Found (%)	C, 66.23;	H, 5.52;	N, 8.02;	F, 5.33.

NMR($CDCl_3$) δ : 3.35(3H, s), 3.60(2H, t, $J=4.9$ Hz), 3.73(2H, t, $J=4.9$ Hz), 3.97(2H, s), 4.26(2H, s), 6.98-7.05(3H, m), 7.11-7.15(2H, m), 7.52(1H, dd, $J=2.3, 8.1$ Hz), 8.37(1H, d, $J=1.4$ Hz).

(B-29-d) 4-[5-(4-fluorobenzyl)-pyridine-2-yl]-3-hydroxy-1-(4-methoxybenzyl)-1,5-dihydropyrrole-2-one

Melting point : 164-166°C

Elementary analysis as $C_{24}H_{21}FN_2O_3$


Calcd. (%)	C, 71.27;	H, 5.23;	N, 6.93;	F, 4.70.
Found (%)	C, 70.28;	H, 5.15;	N, 6.93;	F, 4.38.

NMR($CDCl_3$) δ : 3.79(3H, s), 3.94(2H, s), 3.96(2H, s), 4.66(2H, s), 6.85-6.89(2H, m), 6.96-7.02(3H, m), 7.08-7.13(2H, m), 7.20-7.25(2H, m), 7.46(1H, dd, $J=2.2, 8.0$ Hz), 8.34(1H, d, $J=2.3$ Hz).

Compound B-34

4-[4-[2-(4-fluorophenyl)ethyl]pyridine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0319]



(B-30) To a solution of diisopropylamine (5.06g, 50mmol) in THF (20ml), was added a n-butyllithium solution (50mmol) at 0°C. After stirring for 5 minutes, a solution of 2,4-dimethylpyridine (5.35g, 50mmol) in THF (10ml) was added dropwise thereto at -78°C. The mixture was stirred at -78°C for 30 minutes, warmed to 10°C, and 4-fluorobenzaldehyde (6.8g, 55mmol) was added thereto, whereby the temperature rose to 35°C. After stirring for 10 minutes, an ammonium chloride aqueous solution was added to terminate the reaction, followed by extraction with

ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure. The residue was purified with silica gel column chromatography using ethyl acetate to give 1-(4-fluorophenyl)-2-(2-methylpyridine-4-yl)ethanol (6.2g, yield : 54%).

(B-31) To a solution of the above-mentioned compound B-30 (6.15g, 26.6mmol), triethylamine (4.03g, 39.9mmol), and dimethylaminopyridine (200mg, 1.6mmol) in THF (20ml), was added dropwise acetic anhydride (4.07g, 36mmol) under ice cooling. After stirring for 45 minutes, ice water was added to terminate the reaction, followed by extraction with ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure, to give acetic acid 1-(4-fluorophenyl)-2-(2-methylpyridine-4-yl)ethylester (7.25g, yield : 99%).

(B-32) To a solution of the above-mentioned compound B-31 (7.25g, 26.5mmol) in ethanol (250ml), were added triethylamine (5.37g, 53mmol) and 10% palladium carbon (1g) and the mixture was stirred under hydrogen atmosphere at room temperature. After removing palladium carbon, the solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate) to give 4-[2-(4-fluorophenyl)ethyl]-2-methylpyridine (5.23g, yield : 92%).

NMR(CDCl₃) δ : 2.52(3H, s), 2.90-3.00(4H, m), 6.88(1H, dd, J=5.5, 1.2Hz), 6.90-7.00(3H, m), 7.04-7.14(2H, m), 8.37(1H, d, J=5.1Hz).

(B-33) To a solution of isopropylamine (1.01g, 10mmol) in THF (10ml), was added a n-butyllithium solution (10mmol) under ice-cooling. After stirring the mixture for 5 minutes, a solution of B-32 (2.15g, 10mmol) in THF (5ml) was added dropwise at -78°C, then the mixture was stirred for 20 minutes and oxalic acid diethyl (5.84g, 40mmol) was added dropwise with stirring for 45 minutes. The mixture was further stirred at room temperature for 1 hour, then an ammonium chloride aqueous solution was added to terminate the reaction, followed by extraction with ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate) to give 3-{4-[2-(4-fluorophenyl)ethyl]pyridine-2-yl}-2-hydroxyacrylic acid ethylester (224mg, yield : 11%). Melting point: 129-130°C

NMR(CDCl₃) δ : 1.39(3H, t, J=6.9Hz), 2.92(4H, s), 4.36(2H, q, J=6.9), 6.48(1H, s), 5.47(2H, s), 6.90-7.04(3H, m), 7.04-7.14(2H, m), 8.25(1H, d, J=5.1Hz).

Elementary analysis as C ₁₈ H ₁₈ NFO ₃				
Calcd. (%)	C, 68.56;	H, 5.75;	N, 4.44;	F, 6.02.
Found (%)	C, 68.85;	H, 5.55;	N, 4.57;	F, 5.93.

Calcd. (%)	C, 68.56;	H, 5.75;	N, 4.44;	F, 6.02.
Found (%)	C, 68.85;	H, 5.55;	N, 4.57;	F, 5.93.

(B-34) To a solution of the above-mentioned compound B-33 (200mg, 0.635mmol) and 95% paraformaldehyde (52mg, 1.73mmol) in dioxane (3ml), was added a 30% methylamine ethanol solution (250μl) at room temperature and the mixture was stirred for 2 hours 30 minutes. An ammonium chloride aqueous solution was added thereto to terminate the reaction, which was extracted with ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure. The precipitated crystal was washed with diethyl ether to give 4-{4-[2-(4-fluorophenyl)ethyl]pyridine-2-yl}-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one (108mg, yield : 55%).

Melting point : 167-168°C

NMR(CDCl₃) δ : 2.92(4H, s), 3.15(3H, s), 4.07(2H, s), 6.74(1H, s), 6.93(1H, dd, J=5.7, 2.1Hz), 6.98(2H, t, J=8.4Hz), 7.08-7.14(2H, m), 8.33(1H, d, J=6.7Hz).

Elementary analysis as C ₁₈ H ₁₇ N ₂ FO ₂				
Calcd. (%)	C, 69.22;	H, 5.49;	N, 8.97;	F, 6.08.
Found (%)	C, 69.08;	H, 5.39;	N, 8.58;	F, 6.00.

Calcd. (%)	C, 69.22;	H, 5.49;	N, 8.97;	F, 6.08.
Found (%)	C, 69.08;	H, 5.39;	N, 8.58;	F, 6.00.

[0320] The following compound was prepared as well as above.

(B-34-a) 4-{4-[2-(4-fluorophenyl)ethyl]pyridine-2-yl}-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 167-168°C

NMR(CDCl₃) δ : 1.27(6H, d, J=6.6Hz), 2.93(4H, s), 4.03(2H, s), 4.58(1H, m), 6.82(1H, s), 6.93(1H, dd, J=6.0, 1.5Hz), 6.98(2H, t, J=8.7Hz), 7.05-7.14(2H, m), 8.35(1H, d, J=6.0Hz).


Elementary analysis as C ₂₀ H ₂₁ N ₂ FO ₂				
Calcd. (%)	C, 70.57;	H, 6.22;	N, 8.23;	F, 5.58.
Found (%)	C, 70.10;	H, 6.10;	N, 8.11;	F, 5.50.

Calcd. (%)	C, 70.57;	H, 6.22;	N, 8.23;	F, 5.58.
Found (%)	C, 70.10;	H, 6.10;	N, 8.11;	F, 5.50.

Compound B-38

4-[5-(4-fluorobenzoyloxy)-pyridine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0321]



(B-35) According to the reference (J. Med. Chem.20,1258,1977) , 5-(4-fluorobenzoyloxy)-pyridine-2-carbaldehyde was synthesized.

(B-36) To a THF (50ml) solution containing (dimethoxyphosphoryl) - (2,2,2-trichloro-1,1-dimethylethoxycarbonyloxy) -acetic acid methyl ester (1.91g, 4.76mmol) prepared according to the reference (Tetrahedron Lett. 25, 3529, 1984) , lithium bistrimethylsilylamine (1M-THF solution, 5.62mmol) was added at -78°C and the mixture was stirred for 30 minutes. The above-mentioned compound B-35 (1g, 4.3mmol) was slowly added thereto and the mixture was stirred for 15 minutes, warmed to 0°C , and further stirred for 30 minutes. An ammonium chloride aqueous solution was added to terminate the reaction, which was extracted with ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate:hexane=1:1) to give 3-[5-(4-fluorobenzoyloxy)-pyridine-2-yl]-2-(2,2,2-trichloro-1,1-dimethylethoxycarbonyloxy)-acrylic acid methyl ester (1.096g, 50%).

(B-37) To a solution of the above-mentioned compound B-36 (1.2g, 2.36mmol) in methyl alcohol (25ml) , 28% sodium methoxide (910mg, 4.72mmol) was added at 0°C and the mixture was at room temperature for 1 hour. An ammonium chloride aqueous solution was added to terminate the reaction, which was extracted with ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate) to give 3-[5-(4-fluorobenzoyloxy)-pyridine-2-yl]-2-hydroxyacrylic acid methyl ester (233mg, yield : 32%) .

Melting point: $131-132^{\circ}\text{C}$

NMR(CDCl_3) δ : 3.89(3H, s), 5.10(2H, s), 6.56(1H, s), 7.10(2H, t, $J=8.4\text{Hz}$), 7.18(1H, d, $J=8.4\text{Hz}$), 7.33(1H, dd, $J=8.4, 2.7\text{Hz}$), 7.36-7.45(2H, m), 8.13(1H, d, $J=2.7\text{Hz}$).

Elementary analysis as $\text{C}_{16}\text{H}_{14}\text{NFO}_4$				
Calcd. (%)	C, 60.36;	H, 4.65;	N, 4.62;	F, 6.26.
Found (%)	C, 60.63;	H, 4.57;	N, 4.66;	F, 6.06.

(B-38) To a solution of the above-mentioned compound B-37 (150mg, 0.495mmol) and 95% paraformaldehyde (40mg, 1.33mmol) in dioxane (5ml) , was added a 30% methylamine — ethanol solution (150 μl) and the mixture was stirred at room temperature for 5 hours. An ammonium chloride aqueous solution was added to terminate the reaction, followed by extraction with ethyl acetate stirred. The extract was washed, dried, and evaporated under reduced pressure. The precipitated crystal was washed with diethyl ether to give 4-[5-(4-fluorobenzoyloxy)-pyridine-2-yl]-3-hydroxymethyl-1,5-dihydropyrrole-2-one (70mg, yield : 45%).

Melting point: $210-211^{\circ}\text{C}$

NMR(CDCl_3) δ : 3.14(3H, s), 4.11(2H, s), 5.10(2H, s), 7.10(2H, t, $J=8.7\text{Hz}$), 7.11(1H, d, $J=8.4\text{Hz}$), 7.32(1H, dd, $J=9.0, 3.0\text{Hz}$), 7.41(2H, dd, $J=8.7, 5.4\text{Hz}$), 8.29(1H, d, $J=3.0\text{Hz}$).

Elementary analysis as $C_{17}H_{15}N_2FO_3$

Calcd. (%)	C, 64.96; H, 4.81; N, 8.91; F, 6.04.
Found (%)	C, 64.68; H, 4.77; N, 8.78; F, 5.81.

[0322] The following compound was prepared as well as above.

(B-38-a) 4-[5-(4-fluorobenzyloxy)-pyridine-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 195-196°C

NMR($CDCl_3$) δ : 1.26(6H, d, $J=6.6$), 4.09(2H, s), 4.56(1H, m), 5.10(2H, s), 7.10(2H, t, $J=8.7$ Hz), 7.20(1H, d, $J=8.7$ Hz), 7.32(1H, dd, $J=8.7, 3.0$ Hz), 7.41(2H, dd, $J=8.4, 5.4$ Hz), 8.30(1H, d, $J=3.0$ Hz).


Elementary analysis as $C_{19}H_{19}N_2FO_3$

Calcd. (%)	C, 66.66; H, 5.59; N, 8.18; F, 5.55.
Found (%)	C, 66.46; H, 5.61; N, 8.20; F, 5.54.

Compound B-42

4-[5-(4-fluorophenylsulfanyl)-pyridine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrol-2-one

[0323]



(B-39) Using 6-methylpyridine-3-ol, with reference to J. Org. Chem. 1967,32,1607, 5-bromo-2-methylpyridine was synthesized.

NMR($CDCl_3$) δ : 2.51(3H, s), 7.05(1H, d, $J=8.3$ Hz), 7.68(1H, d, $J=2.5, 8.3$ Hz), 8.55(1H, d, $J=2.3$ Hz).

(B-40) To a solution of the above-mentioned compound B-39 (6.0g, 35mmol) in tetrahydrofuran (100ml), was added *n*-butyllithium (35mmol) at $-78^\circ C$, then 4-fluorophenyldisulphide (8.9g, 35mmol) synthesized according to Tetrahedron Lett. 1990,31,5007 was added thereto and the mixture was stirred for 30 minutes. Water was added to terminate the reaction, followed by extraction with ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure. The residue was purified with silica gel column chromatography (*n*-hexane:ethyl acetate=6:1) to give 5-(4-fluorophenylsulfanyl)-2-methylpyridine (2.8g, yield: 34%).

NMR($CDCl_3$) δ : 2.54(3H, s), 6.98-7.04(2H, m), 7.09(1H, d, $J=8.1$ Hz), 7.31-7.36(2H, m), 7.49(1H, dd, $J=2.3, 8.1$ Hz), 8.46(1H, d, 2.3Hz).

(B-41) Using the above-mentioned compound B-40, according to the method of (B-11), 3-[5-(4-fluorophenylsulfanyl)-pyridine-2-yl]-2-hydroxyacrylic acid ethyl ester was synthesized.

Melting point: 96-98°C

EP 1 422 218 A1

NMR(CDCl₃) δ: 1.39(3H, t, J=7.0Hz), 4.36(2H, q, J=7.0Hz), 6.54(1H, s), 7.06-7.13(3H, m), 7.42-7.46(2H, m), 7.55(1H, dd, J=2.4, 8.5Hz), 8.32(1H, d, J=2.4Hz).

(B-42) Using the above-mentioned compound B-41, according to the method of (B-12), 4-[5-(4-fluorophenylsulfinyl)-pyridine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one was synthesized.

Melting point: 210-212°C

Elementary analysis as C ₁₆ H ₁₃ FN ₂ O ₂ S					
Calcd. (%)	C, 60.75;	H, 4.14;	N, 8.86;	F, 6.01;	S, 10.14.
Found (%)	C, 60.44;	H, 4.01;	N, 8.66;	F, 5.75;	S, 9.97.

NMR(CDCl₃) δ: 1.14(3H, s), 4.11(2H, s), 7.02-7.11(3H, m), 7.41-7.46(2H, m), 7.58(1H, dd, J=2.3, 8.2Hz), 8.38(1H, d, J=1.6Hz).

[0324] The following compound was prepared as well as above.

(B-42-a) 4-[5-(4-fluorophenylsulfinyl)-pyridine-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point : 163-164°C


Elementary analysis as C ₁₈ H ₁₇ FN ₂ O ₂ S					
Calcd. (%)	C, 62.77;	H, 4.98;	N, 8.13;	F, 5.52;	S, 9.31.
Found (%)	C, 62.62;	H, 4.74;	N, 7.98;	F, 5.28;	S, 9.10.

NMR(CDCl₃) δ: 1.27(6H, d, J=6.9Hz), 4.08(2H, s), 4.56(1H, sept), 7.05-7.11(2H, m), 7.13(1H, dd, J=0.6, 8.3Hz), 7.39-7.45(2H, m), 7.59(1H, dd, J=2.3, 8.4Hz), 8.38(1H, dd, J=0.6, 2.3Hz).

Compound B-44

4-[5-(4-fluorobenzenesulfinyl)-pyridine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0325]



(B-43) To a solution of B-41 (640mg, 2mmol) in chloroform (6ml) , was added mCPBA (690mg, 4mmol) under ice-cooling. After 30 minutes stirring, a saturated sodium hydrogen carbonate aqueous solution was added to terminate the reaction, which was extracted with chloroform. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexaneethyl acetate=4:1) to give 3-[5-(4-fluorobenzenesulfinyl)-pyridine-2-yl]-2-hydroxyacrylic acid ethyl ester (400mg, yield : 60%) .

Melting point: 148-150°C

NMR(CDCl₃) δ : 1.39(3H, t, J=7.2Hz), 4.36(2H, q, J=7.2Hz), 6.58(1H, s), 7.20-7.26(2H, m), 7.29(1H, d, J=8.4Hz), 7.66-7.71(2H, m), 7.93(1H, dd, J=2.3, 8.4Hz), 8.64(1H, d, J=2.3Hz).

(B-44) Using the above-mentioned compound B-43, according to the method of B-12, 4-[5-(4-fluorobenzenesulfinyl)-pyridine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one was synthesized.

Melting point : 228-230°C

Elementary analysis as C ₁₆ H ₁₃ FN ₂ O ₃ S					
Calcd. (%)	C, 57.82;	H, 3.94;	N, 8.43;	F, 5.72;	S, 9.65.
Found (%)	C, 57.56;	H, 3.74;	N, 8.20;	F, 5.52;	S, 9.49.

NMR(CDCl₃) δ: 3.16(3H, s), 4.16(2H, s), 7.19-7.26(2H, m), 7.30(1H, dd, J=0.9, 8.5Hz), 7.66-7.71(2H, m), 8.02(1H, dd, J=2.4, 8.5Hz), 8.67(1H, dd, J=0.9, 2.4Hz).

[0326] The following compound was prepared as well as above..

(B-44-a) 4-[5-(4-fluorobenzenesulfinyl)-pyridine-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one
Melting point: 205-207°C


Elementary analysis as C ₁₈ H ₁₇ FN ₂ O ₃ S					
Calcd. (%)	C, 59.99;	H, 4.75;	N, 7.77;	F, 5.27;	S, 8.90.
Found (%)	C, 59.75;	H, 4.57;	N, 7.58;	F, 5.08;	S, 8.84.

NMR(CDCl₃) δ: 1.27(6H, d, J=7.0Hz), 4.12(2H, s), 4.56(1H, sept), 7.19-7.26(2H, m), 7.38(1H, d, J=8.5Hz), 7.65-7.71(2H, m), 8.01(1H, dd, J=2.4, 8.5Hz), 8.67(1H, dd, J=0.9, 2.4Hz).

Compound B-55

4-[5-(4-fluorobenzyl)-pyrimidine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0327]



(B-45) According to J.Org.Chem. vol. 64, No.3, (1999), p992, experimental(25), using 4-fluorobenzylbromide and di-*t*-butyl malonate, 2-(4-fluorobenzyl)-malonic acid *t*-butyl ester was synthesized.

NMR(CDCl₃) δ : 1.41(18H, s), 3.09(2H, d, J=7.9Hz), 3.42(1H, t, J=7.9Hz), 6.93-6.98(2H, m), 7.15-7.19(2H, m).

(B-46) To a solution of the above-mentioned compound B-45 (16.4g, 50.6 mmol) in dichloromethane(15ml), trifluoroacetic acid(15ml) was added and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure and the residue was recrystallized with ethylether and n-hexane to give 2-(4-fluorobenzyl)malonic acid (8.90g, yield : 83%).

NMR(CDCl₃) δ : 3.13(2H, d, J=7.6Hz), 3.60(1H, t, J=7.8Hz), 6.95-7.01(2H, m), 7.22-7.27(2H, m).

(B-47) According to Collection Czechoslov.Chem.Comm. vol.32 (1967), p3792-3793, using the above-mentioned compound B-46, 3-dimethylamino-2-(4-fluorobenzyl)-propenal was synthesized.

(B-48) To a solution of the above-mentioned compound B-47 (1.42g, 7.5 mmol) and actoamide hydrochloride (1.42g, 15mmol) in methyl alcohol (5ml), was added a solution of sodium methylate in methyl alcohol (15ml) and the mixture was refluxed for 4 hours. An ammonium chloride aqueous solution was added thereto, which was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated. The residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=1:2-1:3) to give 5-(4-fluorobenzyl)-2-methylpyrimidine (956mg, yield : 69%).

NMR(CDCl₃) δ : 2.71(3H, s), 3.90(2H, s), 6.97-7.03(2H, m), 7.12-7.15(2H, m), 8.46(2H, s).

(B-49) To a solution of the above-mentioned compound B-48 (3.01g, 15 mmol) in pyridine (22ml), was added selenium dioxide (11.0g, 99 mmol) and the mixture was refluxed for 17.5 hours. Chloroform and water were added thereto, followed by celite-filtration. The filtrate was washed and dried, then the solvent was evaporated to give crude 5-(4-fluorobenzyl)-pyrimidine-2-carboxylic acid (3.57g).

NMR(CDCl₃) δ : 4.07(2H, s), 6.99-7.06(2H, m), 7.13-7.18(2H, m), 8.83(2H, s).

(B-50) To a solution of the above-mentioned crude product B-49 (3.57g) in tetrahydrofuran (43ml), was added a solution of diazomethane in ethylether (30mmol) and the mixture was stirred at 0°C for 10 minutes. The solution was warmed to room temperature and stirred for 10 minutes. Acetic acid was added thereto under ice-cooling, which was neutralized with a sodium hydrogen carbonate aqueous solution, then extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated. The residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=2:3) to give 5-(4-fluorobenzyl)-pyrimidine-2-carboxylic acid methyl ester (1.98g, yield : 54%).

NMR(CDCl₃) δ : 4.05(2H, s), 4.07(3H, s), 7.01-7.06(2H, m), 7.12-7.17(2H, m), 8.75(2H, s).

(B-51) To a solution of the above-mentioned compound B-50 (1.98g, 8.04mmol) in tetrahydrofuran (26ml) and t-butanol (13ml), was added at -30°C sodium borohydride (338mg, 8.04mmol), then the mixture was warmed to room temperature and stirred for 4 hours. An ammonium chloride aqueous solution was added to terminate the reaction, followed by extraction with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=1:2) to give [5-(4-fluorobenzyl)-pyrimidine-2-yl]-methyl alcohol (470mg, yield : 27%).

NMR(CDCl₃) δ : 4.05(2H, s), 4.07(3H, s), 7.01-7.06(2H, m), 7.12-7.17(2H, m), 8.75(2H, s).

(B-52) To a solution of oxalyl chloride (281ul, 3.23mmol) in methylene chloride (5ml), was added dropwise a solution of dimethylsulfoxide (457ul, 6.45mmol) in methylene chloride (1ml) at -78°C with stirring for 10 minutes. A solution of the above-mentioned compound B-51 (470mg, 2.15mmol) in methylene chloride (1.5ml) was added dropwise thereto with stirring for 30 minutes. Triethylamine (1.79ml, 12.9mmol) was added dropwise to the mixture, which was warmed to 0°C and stirred for 30 minutes. The solution was diluted with chloroform, washed, and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=1:2) to give 5-(4-fluorobenzyl)-pyrimidine-2-carbaldehyde (337mg, yield : 72%).

NMR(CDCl₃) δ : 4.08(2H, s), 7.01-7.07(2H, m), 7.15-7.20(2H, m), 8.81(2H, s), 10.09(1H, s) (B-53) To a solution

of lithiumbis(trimethylsilyl)amide solution (1.87ml), was added dropwise at -78°C a tetrahydrofuran (2ml) solution containing (dimethoxyphosphoryl)-(2,2,2-trichloro-1,1-dimethylethoxycarbonyloxy)-acetic acid methyl ester (688mg, 1.71mmol) prepared according to Tetrahedron Lett.25,3529,1984, and the mixture was stirred for 10 minutes. A solution of the above-mentioned compound B-52 (337mg, 1.56mmol) in tetrahydrofuran (2ml) was added thereto and the mixture was stirred for 5 minutes, which was warmed to 0°C and stirred for 30 minutes. An ammonium chloride aqueous solution was added to terminate the reaction, followed by extraction with ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=2:1) to give 3-[5-(4-fluorobenzyl)-pyrimidine-2-yl]-2-(2,2,2-trichloro-1,1-dimethylethoxycarbonyloxy)-acrylic acid methyl ester (500mg, yield : 66%).

NMR(CDCl₃) δ : 1.98(6H, s), 3.76(2H, s), 3.94(3H, s), 6.88(1H, s), 6.99-7.04(2H, m), 7.10-7.16(2H, m), 8.52(2H, s).

(B-54) To a solution of the above-mentioned compound B-53 (380mg, 0.77mmol) in methyl alcohol (12ml), a solution of sodium methylate in methanol (376ul) was added under ice-cooling, which was warmed to room temperature and stirred for 30 minutes. Triethylamine (1.79ml, 12.9mmol) was added dropwise and the mixture was warmed to 0°C and stirred for 30 minutes. An ammonium chloride aqueous solution was added to terminate the reaction, followed by extraction with ethyl acetate. The extract was washed, dried, and the solvent was evaporated under reduced pressure. The precipitated crystal was washed with diisopropylether and dried under reduced pres-

EP 1 422 218 A1

sure to give 3-[5-(4-fluorobenzyl)-pyrimidine-2-yl]-2-hydroxyacrylic acid methylester (129mg, yield : 58%) .
Melting point: 132-134°C

Elementary analysis as C ₁₅ H ₁₃ FN ₂ O ₃				
Calcd. (%)	C, 62.50;	H, 4.55;	N, 9.72;	F, 6.59.
Found (%)	C, 60.81;	H, 4.55;	N, 9.69;	F, 6.42.

NMR(CDCl₃) δ: 3.91(3H, s), 3.97(2H, s), 6.75(1H, s), 7.01-7.06(2H, m), 7.13-7.18(2H, m), 8.54(2H, s).

[0328] According to the method of (B-55) (B-12), 4-[5-(4-fluorobenzyl)-pyrimidine-2-yl]-3-hydroxyl-methyl-1,5-dihydropyrrole-2-one was obtained.

Melting point: 163-165°C

Elementary analysis as C ₁₆ H ₁₄ FN ₃ O ₂				
Calcd. (%)	C, 64.21;	H, 4.71;	N, 14.04;	F, 6.35.
Found (%)	C, 63.05;	H, 4.82;	N, 13.48;	F, 6.07.

NMR(CDCl₃) δ: 3.16(3H, s), 3.97(2H, s), 4.22(2H, s), 7.01-7.06(2H, m), 7.13-7.18(2H, m), 8.53(2H, s).

[0329] The following compound was prepared as well as above.

(B-55-a) 4-[5-(4-fluorobenzyl)-pyrimidine-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point : 155-157°C


Elementary analysis as C ₁₈ H ₁₈ FN ₃ O ₂				
Calcd. (%)	C, 66.04;	H, 5.54;	N, 12.84;	F, 5.80.
Found (%)	C, 65.09;	H, 5.44;	N, 12.35;	F, 5.67.

NMR(CDCl₃) δ: 1.27(6H, d, J=6.7Hz), 3.97(2H, s), 4.19(2H, s), 4.58(1H, sept, J=6.9Hz), 7.01-7.06(2H, m), 7.13-7.17(2H, m), 8.53(2H, s).

Compound B-59

3-hydroxy-1-methyl-4-(5-phenoxy-pyrimidine-2-yl)-1,5-dihydropyrrole-2-one

[0330]



(B-56) According to J. Med. Chem. 1980,23,1016, 3-dimethylamino-2-phenoxypropenal was synthesized.

NMR(CDCl₃) δ : 3.10(6H, s), 6.57(1H, s), 6.93-6.99(3H, m), 7.24-7.30(2H, m), 8.83(1H, s).

The following compound was prepared as well as above..

3-dimethylamino-2-(4-fluorophenoxy)-propenal

NMR(CDCl₃) δ: 3.11(6H, s), 6.57(1H, s), 6.86-6.98(4H, m), 8.81(1H, s).

EP 1 422 218 A1

(B-57) To a solution of the above-mentioned compound B-56 (17.9g, 97mmol) and acetoamidinium hydrochloride (17.7g, 187mmol) in methyl alcohol (200ml), was added sodium methoxide (562mmol) and the mixture was refluxed for 3 hours. Ammonium chloride (20g) was added thereto at room temperature the mixture was stirred 1 for hours. The solvent was evaporated under reduced pressure and to the residue was added chloroform (200ml), then insoluble products were filtered off. The solvent was evaporated and the residue was purified with silica gel column chromatography (ethyl acetate) to give 2-methyl-5-phenoxy-pyrimidine (13.2g, yield : 76%) .

NMR(CDCl₃) δ: 2.73(3H, s), 7.01-7.05(2H, m), 7.16-7.21(1H, m), 7.36-7.42(2H, m), 8.40(2H, s).

The following compound was prepared as well as above.

5-(4-fluorophenoxy)-2-methylpyrimidine

NMR(CDCl₃) δ: 2.72(3H, s), 6.99-7.12(4H, m), 8.37(2H, s).

(B-58) Using the above-mentioned compound B-57, according to the method of (B-11), 2-hydroxy-3-(5-phenoxy-pyrimidine-2-yl)-acrylic acid ethyl ester was synthesized.

Melting point: 52-53°C

NMR(CDCl₃) δ: 1.39(3H, t, J=7.3Hz), 4.37(2H, q, J=7.3Hz), 6.78(1H, s), 7.07-7.11(2H, m), 7.24-7.28(1H, m), 7.41-7.46(2H, m), 8.47(2H, s).

The following compound was prepared as well as above..

3-[5-(4-fluorophenoxy)-pyrimidine-2-yl]-2-hydroxy-acrylic acid ethyl ester

Melting point: 92-93°C

NMR(CDCl₃) δ: 1.39(3H, t, J=7.3Hz), 4.37(2H, q, J=7.3Hz), 6.78(1H, s), 7.05-7.16(4H, m), 8.44(2H, s).

(B-59) Using the above-mentioned compound B-58, according to (B-12), 3-hydroxy-1-methyl-4-(5-phenoxy-pyrimidine-2-yl)-1,5-dihydropyrrole-2-one was synthesized.

Melting point: 207-208°C

Elementary analysis as C ₁₅ H ₁₃ N ₃ O ₃			
Calcd. (%)	C, 63.60;	H, 4.63;	N, 14.83.
Found (%)	C, 63.53;	H, 4.47;	N, 14.82.

NMR(CDCl₃) δ: 3.17(3H, s), 4.23(2H, s), 7.07-7.10(2H, m), 7.22-7.27(1H, m), 7.41-7.46(2H, m), 8.47(2H, s).

[0331] The following compound was prepared as well as above..

(B-59-a) 3-hydroxy-1-isopropyl-4-(5-phenoxy-pyrimidine-2-yl)-1,5-dihydropyrrole-2-one

Melting point: 164-165°C

Elementary analysis as C ₁₇ H ₁₇ N ₃ O ₃ 0.2H ₂ O			
Calcd. (%)	C, 64.83;	H, 5.57;	N, 13.34.
Found (%)	C, 64.98;	H, 5.48;	N, 13.22.

NMR(CDCl₃) δ: 1.28(6H, d, J=7.0Hz), 4.20(2H, s), 4.59(1H, sept), 7.05-7.10(2H, m), 7.22-7.27(1H, m), 7.40-7.47(2H, m), 8.47(2H, s).

(B-59-b) 4-[5-(4-fluorophenoxy)-pyrimidine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point : 230-232°C

Elementary analysis as C ₁₅ H ₁₂ FN ₃ O ₃				
Calcd. (%)	C, 59.80;	H, 4.01;	N, 13.95;	F, 6.31.
Found (%)	C, 59.60;	H, 3.89;	N, 13.81;	F, 6.05.

NMR(CDCl₃) δ: 3.17(3H, s), 4.22(2H, s), 7.04-7.16(4H, m), 8.44(2H, s).

(B-59-c) 4-[5-(4-fluorophenoxy)-pyrimidine-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 165-166°C


Elementary analysis as C ₁₇ H ₁₆ FN ₃ O ₃				
Calcd. (%)	C, 62.00;	H, 4.90;	N, 12.76;	F, 5.77.
Found (%)	C, 62.00;	H, 4.91;	N, 12.71;	F, 5.51.

NMR(CDCl₃) δ : 1.28(6H, d, J=7.0Hz), 4.19(2H, s), 4.59(1H, m), 7.04-7.16(4H, m), 8.45(2H, s).

Compound B-64

4-(4-benzyloxypyrimidine-2-yl)-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0332]



(B-60) To a solution of 3-ethoxyacrylic acid ethyl ester (12.95g, 89.82mmol) and acetoamidinium hydrochloride (25.44g, 269.1mmol) in ethanol(130ml), was added potassium carbonate (37.23g, 269.4mmol) and the mixture was refluxed for 2.5 hours. After filtrating, the solvent was evaporated under reduced pressure and the precipitated crystals were washed with chloroform and dried under reduced pressure to give crude 2-methyl-3H-pyrimidine-4-one.

(B-61) To the crude above-mentioned compound B-60, was added phosphorus oxychloride (60ml) and the mixture was stirred at 80°C for 1.5 hours. The solvent was evaporated under reduced pressure and to the residue was added ice (120g), then the mixture was neutralized with a 5N sodium hydroxide aqueous solution and extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was diluted with ethyl acetate and diethyl ether, and a 4N hydrochloric acid ethyl acetate solution (20ml) was added thereto. The precipitated crystals were washed with ethyl acetate and dried under reduced pressure to give 4-chloro-2-methylpyrimidine hydrochloride (8.08g, yield : 55%).
NMR(DMSO-d₆) δ: 2.62(3H, s), 7.55(1H, d, J=5.7Hz), 8.69(1H, d, J=5.7Hz).

(B-62) To a solution of sodium hydride (973mg, 24.3mmol) in dimethylformamide (10ml), was added benzylalcohol (2.50ml, 24.2mmol) under ice-cooling and the mixture was stirred at room temperature for 30 minutes. The above-mentioned compound B-xx (2.02g, 12.2mmol) was added thereto under ice-cooling, and the mixture was stirred at room temperature for 1 hour. Water was added to terminate the reaction, and the mixture was extracted with ethyl acetate. The extract was washed, dried, and evaporated under reduced pressure, then the residue was purified with silica gel column chromatography (n-hexane: ethyl acetate=5:1) to give 4-benzyloxy-2-methylpyrimidine (2.45g, yield:100%).

NMR(CDCl₃) δ: 2.64(3H, s), 5.42(2H, s), 6.58(1H, d, J=5.9Hz), 7.29-7.48(5H, m), 8.33(1H, d, J=5.9Hz).

The following compound was prepared as well as above.

4-(4-fluorobenzyloxy)-2-methylpyrimidine

NMR(CDCl₃) δ: 2.63(3H, s), 5.38(2H, s), 6.57(1H, d, J=5.7Hz), 7.07(2H, m), 7.43(2H, m), 8.34(1H, d, J=5.7Hz).

(B-63) To a solution of the above-mentioned compound B-62 (1.00g, 4.99mmol) in tetrahydrofuran (20ml), were added oxalic acid diethyl (3.40ml, 25.0mmol) and potassium tert-butoxide (1.12g, 9.98mmol) under ice-cooling and the mixture was stirred at 50°C for 45 minutes. An ammonium chloride aqueous solution was added to terminate the reaction, followed by extraction with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The precipitated crystals were recrystallized from ethyl acetate / n-hexane to give 3-(4-benzyloxypyrimidine-2-yl)-2-hydroxyacrylic acid ethyl ester (911mg, yield : 61%).

Melting point: 124-126°C

Elementary analysis as C ₁₆ H ₁₆ N ₂ O ₄ 0.1H ₂ O			
Calcd. (%)	C, 63.61;	H, 5.40;	N, 9.27.
Found (%)	C, 63.51;	H, 5.21;	N, 9.13.

NMR(CDCl₃) δ: 1.40(3H, t, J=7.2Hz), 4.38(2H, q, J=7.2Hz), 5.45(2H, s), 6.57(1H, d, J=6.0Hz), 6.60(1H, s), 7.34-7.48(5H, m), 8.29(1H, d, J=6.0Hz).

The following compound was prepared as well as above..

3-[4-(4-fluorobenzyloxy)pyrimidine-2-yl]-2-hydroxyacrylic acid ethyl ester

Melting point : 150-151°C

Elementary analysis as C ₁₆ H ₁₅ FN ₂ O ₄			
Calcd. (%)	C, 60.37;	H, 4.75;	N, 8.80; F, 5.97.
Found (%)	C, 60.28;	H, 4.61;	N, 8.78; F, 5.81.

NMR(CDCl₃) δ: 1.41(3H, t, J=7.5Hz), 4.38(2H, q, J=7.5Hz), 5.42(2H, s), 6.57(1H, d, J=5.9Hz), 6.60(1H, s), 7.08(2H, m), 7.43(2H, m), 8.29(1H, d, J=5.9Hz).

(B-64) To a solution of the above-mentioned compound B-63 (150mg, 0.50mmol) in dioxane (7.5ml), were added paraformaldehyde (80.5mg, 2.01mmol) and methylamine (2.00mmol, 40% methyl alcohol solution) and the mixture was stirred at room temperature for 18 hours. An ammonium chloride aqueous solution was added to terminate the reaction, followed by extraction with chloroform. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The precipitated crystals were recrystallized from methyl alcohol to give 4-(4-benzyloxypyrimidine-2-yl)-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one (86.0mg, yield : 58%). Melting point : 222-224°C

Elementary analysis as C ₁₆ H ₁₅ N ₃ O ₃ 0.1CH ₃ OH 0.2H ₂ O			
Calcd. (%)	C, 63.59;	H, 5.24;	N, 13.82.
Found (%)	C, 63.58;	H, 5.03;	N, 13.75.

NMR(CDCl₃) δ: 3.17(3H, s), 4.21(2H, s), 5.44(2H, s), 6.59(1H, d, J=5.9Hz), 7.33-7.47(5H, m), 8.34(1H, d, J=5.9Hz).

[0333] The following compound was prepared as well as above.

(B-64-a) 4-(4-benzyloxypyrimidine-2-yl)-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 155-157°C

Elementary analysis as C ₁₈ H ₁₉ N ₃ O ₃ 0.3H ₂ O			
Calcd. (%)	C, 65.36;	H, 5.97;	N, 12.70.
Found (%)	C, 65.31;	H, 5.84;	N, 12.62.

NMR(CDCl₃) δ: 1.29(6H, d, J=6.6Hz), 4.15(2H, s), 4.60(1H, sept), 5.45(2H, s), 6.60(1H, d, J=6.0Hz), 7.35-7.48(5H, m), 8.36(1H, d, J=6.0Hz).

(B-64-b) 4-[4-(4-fluorobenzyloxy)pyrimidine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point: 227-230°C

Elementary analysis as C ₁₆ H ₁₄ FN ₃ O ₃			
Calcd. (%)	C, 60.95;	H, 4.48;	N, 13.33; F, 6.03.
Found (%)	C, 60.82;	H, 4.30;	N, 13.12; F, 5.78.

NMR(CDCl₃) δ: 3.18(3H, s), 4.21(2H, s), 5.40(2H, s), 6.58(1H, d, J=6.2Hz), 7.09(2H, m), 7.42(2H, m), 8.35(1H, d, J=6.2Hz).

(B-64-c) 4-[4-(4-fluorobenzyloxy)pyrimidine-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point : 148-149°C

Elementary analysis as $C_{18}H_{18}FN_3O_3 \cdot 0.3H_2O$


Calcd. (%)	C, 61.99;	H, 5.38;	N, 12.05;	F, 5.45.
Found (%)	C, 61.95;	H, 5.17;	N, 11.78;	F, 5.23.

NMR($CDCl_3$) δ : 1.29(6H, d, $J=6.6$ Hz), 4.16(2H, s), 4.60(1H, sept), 5.41(2H, s), 6.59(1H, d, $J=6.0$ Hz), 7.09(2H, m), 7.43(2H, m), 8.37(1H, d, $J=6.0$ Hz).

Compound B-68

4-[5-(4-fluorobenzoyloxy)pyrimidine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0334]



(B-65) According to the method described in US 5010193, 2-methylpyrimidine-5-ol was synthesized.

(B-66) To a solution of the above-mentioned compound B-65 (640mg, 5.81mmol) and potassium carbonate (1.20g, 8.68mmol) in acetone (20ml), was added 4-fluorobenzyl bromide (1.10ml, 8.83mmol) and the mixture was stirred at room temperature for 15 hours. After filtrating, the solvent was evaporated under reduced pressure, then the residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=1:1) to give 5-(4-fluorobenzoyloxy)-2-methylpyrimidine (758mg, yield : 60%).

NMR($CDCl_3$) δ : 2.68(3H, s), 5.09(2H, s), 7.10(2H, m), 7.40(2H, m), 8.36(2H, s).

(B-67) To a solution of the above-mentioned compound B-66 (699mg, 3.20mmol) and 18-crown-6 (94.0mg, 0.355mmol) in tetrahydrofuran (15ml), were added oxalic acid diethyl (4.35ml, 32.0mmol) and potassium tert-butoxide (1.44g, 12.8mmol) and the mixture was stirred at 60°C for 1 hour. An ammonium chloride aqueous solution was added to terminate the reaction, followed by extraction with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography with ethyl acetate, giving the elution comprising the objective compound, from which the solvent was evaporated under reduced pressure. The precipitated crystals were recrystallized from isopropyl alcohol to give 3-[5-(4-fluorobenzoyloxy)pyrimidine-2-yl]-2-hydroxyacrylic acid ethyl ester (530mg, yield : 52%).

Melting point: 134-135°C

Elementary analysis as $C_{16}H_{15}FN_2O_4$

Calcd. (%)	C, 60.37;	H, 4.75;	N, 8.80;	F, 5.97.
Found (%)	C, 59.95;	H, 4.66;	N, 8.68;	F, 5.70.

NMR($CDCl_3$) δ : 1.39(3H, t, $J=7.1$ Hz), 4.36(2H, q, $J=7.1$ Hz), 5.15(2H, s), 6.75(1H, s), 7.12(2H, m), 7.41(2H, m), 8.45(2H, s), 12.74(1H, brs).

(B-68) To a solution of the above-mentioned compound B-67 (151mg, 0.474mmol) in dioxane (7.5ml), were added paraformaldehyde (75.7mg, 1.89mmol) and methylamine (3.86mmol, 30% ethanol solution) and the mixture was stirred at room temperature for 22 hours. An ammonium chloride aqueous solution was added to terminate the reaction, followed by extraction with chloroform. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The precipitated crystals were recrystallized from isopropyl alcohol to give

4-[5-(4-fluorobenzoyloxy)pyrimidine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one (104mg, yield : 70%).
Melting point: 185-187°C

Elementary analysis as C ₁₆ H ₁₄ FN ₃ O ₃				
Calcd. (%)	C, 60.95;	H, 4.48;	N, 13.33;	F, 6.03.
Found (%)	C, 60.82;	H, 4.44;	N, 13.20;	F, 5.78.

NMR(CDCl₃) δ: 3.15(3H, s), 4.20(2H, s), 5.16(2H, s), 7.12(2H, m), 7.42(2H, m), 8.44(2H, s), 10.53(1H, brs).

[0335] The following compound was prepared as well as above.

(B-68-a) 4-[5-(4-fluorobenzoyloxy)pyrimidine-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one
Melting point: 219-221°C


Elementary analysis as C ₁₈ H ₁₈ FN ₃ O ₃				
Calcd. (%)	C, 62.97;	H, 5.28;	N, 12.24;	F, 5.53.
Found (%)	C, 62.71;	H, 4.85;	N, 12.10;	F, 5.36.

NMR(CDCl₃) δ: 1.27(6H, d, J=6.9Hz), 4.17(2H, s), 4.58(1H, m), 5.16(2H, s), 7.12(2H, m), 7.42(2H, m), 8.44(2H, s), 10.43(1H, brs).

Compound B-73

4-[5-[2-(4-fluorophenyl)ethyl]pyrimidine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0336]



(B-69) According to J. Org. Chem. 1993, 58, 1696-1701, 1-fluoro-4-(4-methoxy-3-butenyl)benzene was synthesized.

(B-70) To dimethylformamide (3.35ml, 43.3mmol), was added dropwise phosphorus oxychloride (4.00ml, 42.9mmol) under ice-cooling and the mixture was stirred at 50°C for 45 minutes. The mixture was diluted with chloroform (6ml), to which was added at 75°C a solution of the above-mentioned compound B-69 (2.60g, 14.4mmol) in chloroform (3ml) and the mixture was refluxed for 5 hours. The reaction mixture was added dropwise to a solution of potassium carbonate (40g) in water-toluene-ethanol (10:9:1, 80ml), and the mixture was stirred for 1 hour. After filtrating, the filtrate was extracted with chloroform, washed, and dried, then the solvent was evaporated under reduced pressure to give crude 2-(4-fluorophenyl)but-3-enal.

(B-71) To a solution of the above-mentioned crude compound B-70 in methyl alcohol (15ml), were added acetoamide hydrochloride (2.61g, 27.6mmol) and sodium methoxide (83mmol, 28% methyl alcohol solution) and the mixture was refluxed for 3 hours. An ammonium chloride aqueous solution was added to terminate the reaction,

followed by extraction with chloroform. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=5:1) to give 5-[2-(4-fluorophenyl)ethyl]-2-methylpyrimidine (764mg, yield : 25%) .

NMR(CDCl₃) δ: 2.70(3H, s), 2.88(4H, m), 6.97(2H, m), 7.06(2H, m), 8.37(2H, s).

(B-72) To a solution of the above-mentioned compound B-71 (759mg, 3.51mmol) in tetrahydrofuran (15ml) , were added oxalic acid diethyl (2.40ml, 17.7mmol) and potassium tert-butoxide (787mg, 7.01mmol) under ice-cooling, and the mixture was stirred at 50°C for 2.5 hours and refluxed for 1.5 hours. An ammonium chloride aqueous solution was added to terminate the reaction, followed by extraction with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The precipitated crystals were recrystallized from ethyl acetate — isopropyl ether to 3-{5-[2-(4-fluorophenyl)ethyl]pyrimidine-2-yl}-2-hydroxyacrylic acid ethyl ester (704mg, yield : 63%) . Melting point : 133-134°C

Elementary analysis as C ₁₇ H ₁₇ FN ₂ O ₃				
Calcd. (%)	C, 64.55;	H, 5.42;	N, 8.86;	F, 6.01.
Found (%)	C, 64.38;	H, 5.35;	N, 8.73;	F, 6.06.

NMR(CDCl₃) δ : 1.39(3H, t, J=7.2Hz), 2.93(4H, s), 4.37(2H, q, J=7.2Hz), 6.74(1H, s), 6.98(2H, m), 7.07(2H, m), 8.44(2H, s), 13.25(1H, brs).

(B-73) To a solution of the above-mentioned compound B-72 (152mg, 0.481mmol) in dioxane (7.5ml), were added paraformaldehyde(76.9mg, 1.92mmol) and methylamine(1.93mmol, 30% ethanol solution) and the mixture was stirred at room temperature for 14 hours. An ammonium chloride aqueous solution was added to terminate the reaction, followed by extraction with chloroform. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The precipitated crystals were recrystallized from isopropyl alcohol to give 4-{5-[2-(4-fluorophenyl)ethyl]pyrimidine-2-yl}-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one (86.9mg, yield : 58%) . Melting point: 158-160°C

Elementary analysis as C ₁₇ H ₁₆ FN ₃ O ₂				
Calcd. (%)	C, 65.17;	H, 5.15;	N, 13.41;	F, 6.06.
Found (%)	C, 65.10;	H, 5.17;	N, 13.19;	F, 6.06.

NMR(CDCl₃) δ: 2.93(4H, s), 3.16(3H, s), 4.21(2H, s), 6.98(2H, m), 7.07(2H, m), 8.41(2H, s).

[0337] The following compound was prepared as well as above..

(B-73-a) 4-{5-[2-(4-fluorophenyl)ethyl]pyrimidine-2-yl}-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one
Melting point : 143-144°C


Elementary analysis as C ₁₉ H ₂₀ FN ₃ O ₂				
Calcd. (%)	C, 66.85;	H, 5.91;	N, 12.31;	F, 5.57.
Found (%)	C, 66.71;	H, 5.87;	N, 12.18;	F, 5.57.

NMR(CDCl₃) δ: 1.27(6H, d, J=6.9Hz), 2.93(4H, s), 4.18(2H, s), 4.58(1H, sept), 6.98(2H, m), 7.07(2H, m), 8.41(2H, s).

Compound B-79

3-hydroxy-1-methyl-4-(4-phenethylpyrimidine-2-yl)-1,5-dihydropyrrole-2-one

[0338]



(B-74) A solution of 4-phenylbutan-2-one (74g, 500mmol) and N,N-dimethylformamidedimethylacetal (60g, 500mmol) in DMF (50ml) was refluxed for 3 hours. The solvent was evaporated under reduced pressure and the oily residue was purified with silica gel column chromatography (ethyl acetate/hexane= 1:1) to give 1-dimethylamino-5-phenylpent-1-en-3-one (23.11g, yield:27.6%).

(B-75) To a solution of the above-mentioned compound B-74 (23.11g, 113.7mmol) and acetoamidinium hydrochloride (12.89g, 227.4mmol) in methyl alcohol (50ml), was added sodium methoxide (3N-methyl alcohol solution, 564mmol) and the mixture was refluxed for 6 hours. The methyl alcohol was evaporated under reduced pressure, to which was added water to terminate the reaction. After adding hydrochloric acid and an ammonium chloride aqueous solution for neutralization, the mixture was extracted with ethyl acetate, which was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate) to give 2-methyl-4-phenethylpyrimidine.

NMR(CDCl₃) δ : 2.73(3H, s), 3.03(4H, s), 6.87(1H, d, J=5.1Hz), 7.14-7.32(5H, m), 8.47(1H, d, J=5.1Hz).

(B-76) To a solution of the above-mentioned compound B-75 (1g, 5mmol) and oxalic acid diethyl (3.68g, 25mmol) in THF (15ml), was added at room temperature potassium tert-butoxide (2.24g, 20mmol) and the mixture was stirred at 80°C for 2 hours 30 minutes. An ammonium chloride aqueous solution was added to terminate the reaction, then the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (hexane/ethyl acetate=1:1) to give 3-{2-(2-ethoxycarbonyl-2-hydroxyvinyl)-3-methyl-2,3-dihydropyridine-4-yl}-2-hydroxy-4-phenyl-2-buten-1-ol (520mg, 26%).

(B-77) To a solution of the above-mentioned compound B-76 (628mg, 1.58mmol) in methylalcohol (20ml) and water (5ml), was added lithium hydroxide (1N-aqueous solution, 1.6mmol) and the mixture was stirred at 60°C for 1.5 hours. Methylalcohol was evaporated under reduced pressure and water was added thereto, then the mixture was washed with chloroform. Citric acid was added to the aqueous layer, which was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure to give 2-hydroxy-3-(4-phenethylpyrimidine-2-yl)-acrylic acid (510mg, 99%).

(B-78) To the above-mentioned compound B-77 (510mg, 1.9mmol) was added a hydrochloric acid / methyl alcohol solution (8ml) and the mixture was stirred at room temperature for 2.5 hours. The solvent was evaporated under

reduced pressure and the residue was added to a sodium hydrogen carbonate aqueous solution, which was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure to give 2-hydroxy-3-(4-phenethylpyrimidine-2-yl)-acrylic acid methyl ester (511mg, 94%).

NMR(CDCl₃) δ: 3.09(4H, s), 3.93(3H, s), 6.76(1H, s), 6.90(1H, d, J=5.4Hz), 7.15-7.35(5H, m), 8.55(1H, d, J=5.4Hz), 13.8(1H, bs).

(B-79) To a solution of the above-mentioned compound B-78 (230mg, 0.8195mmol) and 95% paraformaldehyde (51mg, 1.7mmol) in dioxane (5ml), was added a 30% methylamine / ethanol solution (170μl), and the mixture was stirred at room temperature for 2.5 hours. An ammonium chloride aqueous solution was added to terminate the reaction, then the mixture was extracted with ethyl. The extract was washed and dried, and the solvent was evaporated under reduced pressure. The precipitated crystals were recrystallized from ethanol to give 3-hydroxy-1-methyl-4-(4-phenethylpyrimidine-2-yl)-1,5-dihydropyrrole-2-one (120mg, yield : 50%).

Melting point : 118-119°C

NMR(CDCl₃) δ: 3.10(4H, s), 3.17(3H, s), 4.24(2H, s), 6.90(1H, d, J=6.0Hz), 7.20-7.35(5H, m), 8.52(1H, d, J=5.2Hz).

Elementary analysis as C ₁₇ H ₁₇ N ₃ O ₂			
Calcd. (%)	C, 69.14;	H, 5.80;	N, 14.32.
Found (%)	C, 69.04;	H, 5.54;	N, 14.18.

[0339] The following compound was prepared as well as above.

(B-79-a) 3-hydroxy-1-isopropyl-4-(4-phenethylpyrimidine-2-yl)-1,5-dihydropyrrole-2-one

Melting point: 126-127°C


NMR(CDCl₃) δ: 1.29(6H, d, J=6.6Hz), 3.00-3.15(4H, m), 4.20(2H, s), 4.60(1H, sept), 6.90(1H, d, J=5.4Hz), 7.15-7.35(5H, m), 8.53(1H, d, J=5.1Hz).

Elementary analysis as C ₁₉ H ₂₁ N ₃ O ₃			
Calcd. (%)	C, 70.57;	H, 6.55;	N, 12.99.
Found (%)	C, 70.39;	H, 6.55;	N, 12.93.

Compound B-84

3-hydroxy-1-methyl-4-(6-phenoxy-3-methylpyridazine-3-yl)-1,5-dihydropyrrole-2-one

[0340]



(B-80) According to the method of J. Chem. Soc. 1947,239, 6-methyl-2H-pyridazine-3-one was synthesized.

NMR(CDCl₃) δ : 2.34(3H, s), 6.92(1H, d, J=9.7Hz), 7.16(1H, d, J=9.5Hz), 11.97(1H, bs).

(B-81) Using the above-mentioned compound (B-80), according to the method of WO 01/17968, 3-chloro-6-methylpyridazine was synthesized.

NMR(CDCl₃) δ: 2.72(3H, s), 7.32(1H, d, J=8.9Hz), 7.42(1H, d, J=8.9Hz).

(B-82) Using the above-mentioned compound B-81, according to the method of (B-10), 3-methyl-6-phenoxy-3-methylpyridazine was synthesized.

dazine was synthesized.

NMR(CDCl₃) δ: 2.66(3H, s), 7.07(1H, d, J=8.9Hz), 7.17-7.25(3H, m), 7.34(1H, d, J=8.9Hz), 7.37-7.43(2H, m).

The following compound was prepared as well as above.

3-(4-fluorophenoxy)-6-methylpyridazine

NMR(CDCl₃) δ: 2.65(3H, s), 7.05-7.19(5H, m), 7.34(1H, d, J=8.9Hz).

(B-83) Using the above-mentioned compound B-82, according to the method of (B-11), 2-hydroxy-3-(6-phenoxy-pyridazine-3-yl)-acrylic acid ethyl ester was synthesized.

Melting point: 127-128°C

NMR(CDCl₃) δ: 1.39(3H, t, J=7.2Hz), 4.36(2H, q, J=7.2Hz), 6.47(1H, s), 7.19-7.32(4H, m), 7.41-7.49(3H, m).

The following compound was prepared as well as above.

3-[6-(4-fluorophenoxy)-pyridazine-3-yl]-2-hydroxyacrylic acid ethyl ester

Melting point: 164-165°C

NMR(CDCl₃) δ: 1.39(3H, t, J=7.0Hz), 4.36(2H, q, J=7.0Hz), 6.48(1H, s), 7.11-7.26(5H, m), 7.44(1H, dd, J=0.6, 9.1Hz).

(B-84) Using the above-mentioned compound B-83, according to the method of (B-12), 3-hydroxy-1-methyl-4-(6-phenoxy-pyridazine-3-yl)-1,5-dihydropyrrole-2-one was synthesized.

Melting point: 220-225°C

Elementary analysis as C ₁₅ H ₁₃ N ₃ O ₃				
Calcd. (%)	C, 63.60;	H, 4.63;	N, 14.83.	
Found (%)	C, 63.49;	H, 4.36;	N, 14.54.	

NMR(CDCl₃) δ: 3.17(3H, s), 4.29(2H, s), 7.20-7.30(4H, m), 7.42-7.48(2H, m), 7.85(1H, d, J=9.5Hz).

[0341] The following compound was prepared as well as above.

(B-84-a) 3-hydroxy-1-isopropyl-4-(6-phenoxy-pyridazine-3-yl)-1,5-dihydropyrrole-2-one

Melting point: 203-205°C

Elementary analysis as C ₁₇ H ₁₇ N ₃ O ₃ 0.1H ₂ O				
Calcd. (%)	C, 65.21;	H, 5.54;	N, 13.42.	
Found (%)	C, 65.17;	H, 5.22;	N, 13.17.	

NMR(CDCl₃) δ: 1.28(6H, d, J=6.7Hz), 4.31(2H, s), 4.53(1H, sept), 7.20-7.29(4H, m), 7.41-7.47(2H, m), 8.03(1H, d, J=9.2Hz).

(B-84-b) 4-[6-(4-fluorophenoxy)-pyridazine-3-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point: 240-243°C

Elementary analysis as C ₁₅ H ₁₂ FN ₃ O ₃ 0.2H ₂ O				
Calcd. (%)	C, 59.09;	H, 4.10;	N, 13.78;	F, 6.23.
Found (%)	C, 59.06;	H, 3.70;	N, 13.72;	F, 6.02.

NMR(CDCl₃) δ: 3.17(3H, s), 4.30(2H, s), 7.09-7.27(5H, m), 7.94(1H, d, J=9.2Hz).

(B-84-c) 4-[6-(4-fluorophenoxy)-pyridazine-3-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 204-206°C


Elementary analysis as C ₁₇ H ₁₆ FN ₃ O ₃				
Calcd. (%)	C, 62.00;	H, 4.90;	N, 12.76;	F, 5.77.
Found (%)	C, 61.95;	H, 4.61;	N, 12.67;	F, 5.58.

NMR(CDCl₃) δ: 1.28(6H, d, J=6.7Hz), 4.31(2H, s), 4.50(1H, m), 7.09-7.23(5H, m), 8.06(1H, d, J=9.2Hz).

Compound B-90

3-hydroxy-1-methyl-4-(5-phenethylpyridazine-3-yl)-1,5-dihydropyrrole-2-one

[0342]



(B-85) To a solution of diisopropylamine (11.5ml, 82.1mmol) in tetrahydrofuran (100ml), was added dropwise a *n*-butyl lithium solution (79.5mmol) under ice-cooling and the mixture was stirred for 20 minutes. Acetone (5.85ml, 79.7mmol) was added dropwise thereto at -78°C and the mixture was stirred for 30 minutes. A solution of 2-oxo-4-phenylbutanoic acid ethyl ester (15.0g, 72.7mmol) in tetrahydrofuran (50ml) was added dropwise thereto and the mixture was stirred for 1 hour. An ammonium chloride aqueous solution was added to terminate the reaction, then the mixture was extracted with ethyl acetate. The extract was washed and dried, and the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (*n*-hexane : ethyl acetate=5:1-2:1) to give 2-hydroxy-4-oxo-2-phenethylpentanoic acid ethyl ester (16.7g, yield : 87%).

NMR(CDCl_3) δ : 1.29(3H, t, $J=7.2\text{Hz}$), 1.96(2H, m), 2.16(3H, s), 2.49(1H, m), 2.79(1H, m), 2.88(1H, d, $J=17.4\text{Hz}$), 3.07(1H, d, $J=17.4\text{Hz}$), 3.81(1H, brs), 4.23(2H, q, $J=7.2\text{Hz}$), 7.13-7.31(5H, m).

(B-86) To a solution of the above-mentioned compound B-85 (16.7g, 63.2mmol) in 95% ethanol (35ml) was added hydrazine hydrate (4.70ml, 95.0mmol) and the mixture was refluxed for 2 hours. The solvent was evaporated under reduced pressure, then the precipitated crystals were washed with water and dried under reduced pressure to give 6-methyl-4-phenethyl-2H-pyridazine-3-one (8.71g, yield : 64%).

NMR(CDCl_3) δ : 2.25(3H, s), 2.92(4H, m), 6.82(1H, s), 7.16-7.33(5H, m), 11.03(1H, brs).

(B-87) To a solution of the above-mentioned compound B-86 (4.29g, 20.0mmol), was added phosphorus oxychloride (10ml) and the mixture was stirred at 80°C for 30 minutes. The solvent was evaporated and to the residue was added ice (40g), then the mixture was neutralized with a 5N sodium hydroxide aqueous solution and extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure to give crude 3-chloro-6-methyl-4-phenethylpyridazine.

(B-88) A suspension of the above-mentioned crude compound B-87, 28% aqueous ammonia (4g), and 10% palladium-carbon (0.80g) in 95% ethanol (400ml) was stirred in hydrogen atmosphere at 4 atm at room temperature for 30 minutes. The reaction mixture was filtered and the solvent was evaporated under reduced pressure. The residue was extracted with ethyl acetate and the extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate) to give 3-methyl-5-phenethylpyridazine (3.49g, yield: 88%). NMR(CDCl_3) δ : 2.66(3H, s), 2.93(4H, m), 7.05(1H, d, $J=2.3\text{Hz}$), 7.10-7.33(5H, m), 8.84(1H, d, $J=2.3\text{Hz}$).

(B-89) To a solution of the above-mentioned compound B-88 (3.00g, 15.1mmol) in tetrahydrofuran (60ml), was added dropwise a *n*-butyl lithium solution (16.7mmol) at -78°C . Oxalic acid diethyl (6.20ml, 45.6mmol) was added thereto and the mixture was stirred for 1 hour, to which was added an ammonium chloride aqueous solution under ice-cooling to terminate the reaction, followed by extraction with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography and the portion eluted with ethyl acetate was evaporated under reduced pressure. The precipitated crystals were recrystallized from ethyl acetate-isopropylether-*n*-hexane to give 2-hydroxy-3-(5-phenethylpyridazine-3-yl)-acrylic acid ethylester (954mg, yield : 21%).

Melting point : $94-95^{\circ}\text{C}$

Elementary analysis as $C_{17}H_{18}N_2O_3$

Calcd. (%)	C, 68.44;	H, 6.08;	N, 9.39.
Found (%)	C, 68.35;	H, 5.88;	N, 9.36.

NMR($CDCl_3$) δ : 1.39(3H, t, $J=7.1$ Hz), 2.88-3.02(4H, m), 4.35(2H, q, $J=7.1$ Hz), 6.02(1H, s), 7.00(1H, s), 7.10-7.16(2H, m), 7.21-7.35(3H, m), 8.31(1H, s).

(B-90) To a solution of the above-mentioned compound B-89 (149mg, 0.50mmol) in dioxane (7.5ml), were added paraformaldehyde (79.8mg, 2.00mmol) and methylamine (2.01mmol, 40% methyl alcohol solution) and the mixture was stirred at room temperature for 3.5 hours. An ammonium chloride aqueous solution was added thereto to terminate the reaction, and the mixture was extracted with chloroform. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The precipitated crystals were recrystallized from ethanol to give 3-hydroxy-1-methyl-4-(5-phenethylpyridazine-3-yl)-1,5-dihydropyrrole-2-one (119mg, yield: 81%).

Melting point: 203-205°C

Elementary analysis as $C_{17}H_{17}N_3O_2$

Calcd. (%)	C, 69.14;	H, 5.80;	N, 14.23.
Found (%)	C, 68.76;	H, 5.68;	N, 14.04.

NMR($CDCl_3$) δ : 2.99(4H, s), 3.17(3H, s), 4.15(2H, s), 7.11-7.18(3H, m), 7.21-7.37(3H, m), 8.62(1H, d, $J=1.5$ Hz).

[0343] The following compound was prepared as well as above.

(B-90-a) 3-hydroxy-1-isopropyl-4-(5-phenethylpyridazine-3-yl)-1,5-dihydropyrrole-2-one

Melting point: 182-184°C

Elementary analysis as $C_{19}H_{21}N_3O_2 \cdot 0.1C_3H_7OH$


Calcd. (%)	C, 70.37;	H, 6.67;	N, 12.76.
Found (%)	C, 70.06;	H, 6.40;	N, 12.64.

NMR($CDCl_3$) δ : 1.29(6H, d, $J=6.9$ Hz), 3.00(4H, s), 4.17(2H, s), 4.57(1H, m), 7.12-7.17(2H, m), 7.21-7.37(5H, m), 8.67(1H, d, $J=2.1$ Hz).

Compound B-95

3-hydroxy-1-methyl-4-(5-phenoxy-pyrazine-2-yl)-1,5-dihydropyrrole-2-one

[0344]



EP 1 422 218 A1

(B-91) According to the method of J. Am. Chem. Soc. 1952,74,1580, 5-methyl-1H-pyrazine-2-one was synthesized. NMR(CDCl₃) δ: 2.34(3H, s), 7.08(1H, s), 8.21(1H, s).

(B-92) Using the above-mentioned compound B-91, according to WO 01/17968, 2-chloro-5-methyl pyrazine was synthesized.

NMR(CDCl₃) δ: 2.56(3H, s), 8.24(1H, s), 8.49(1H, s).

(B-93) Using the above-mentioned compound B-92, according to the method of (B-10), 2-methyl-5-phenoxy pyrazine was synthesized.

NMR(CDCl₃) δ: 2.51(3H, s), 7.12-7.26(3H, m), 7.39-7.44(2H, m), 7.98(1H, s), 8.31(1H, s).

The following compound was prepared as well as above.

2-(4-fluorophenoxy)-5-methylpyrazine

NMR(CDCl₃) δ: 2.51(3H, s), 7.09-7.12(4H, m), 7.95(1H, s), 8.32(1H, s).

(B-94) Using the above-mentioned compound B-93, according to the method of (B-11), 2-hydroxy-3-(5-phenoxy pyrazine-2-yl)-acrylic acid ethyl ester was synthesized.

Melting point: 128-129°C

NMR(CDCl₃) δ: 1.40(3H, t, J=7.0Hz), 4.37(2H, q, J=7.0Hz), 6.63(1H, s), 7.16-7.19(2H, m), 7.26-7.31(1H, m), 7.43-7.48(2H, m), 8.13(1H, d, J=1.5Hz), 8.29(1H, d, J=1.2Hz).

The following compound was prepared as well as above..

3-[5-(4-fluorophenoxy)-pyrazine-2-yl]-2-hydroxyacrylic acid ethyl ester

Melting point: 139-140°C

NMR(CDCl₃) δ: 1.40(3H, t, J=7.0Hz), 4.37(2H, q, J=7.0Hz), 6.63(1H, s), 7.12-7.14(4H, m), 8.11(1H, d, J=1.1Hz), 8.30(1H, d, J=0.9Hz).

(B-95) Using the above-mentioned compound B-94, according to the method of (B-12), 3-hydroxy-1-methyl-4-(5-phenoxy pyrazine-2-yl)-1,5-dihydropyrrole-2-one was synthesized. Melting point: 233-235°C

Elementary analysis as C ₁₅ H ₁₃ N ₃ O ₃ 0.3H ₂ O			
Calcd. (%)	C, 62.41;	H, 4.75;	N, 14.56.
Found (%)	C, 62.52;	H, 4.48;	N, 14.61.

NMR(CDCl₃) δ: 3.16(3H, s), 4.19(2H, s), 7.16-7.18(2H, m), 7.25-7.31(1H, m), 7.42-7.48(2H, m), 8.27(1H, d, J=1.2Hz), 8.35(1H, d, J=1.5Hz).

[0345] The following compound was prepared as well as above.

(B-95-a) 3-hydroxy-1-isopropyl-4-(5-phenoxy pyrazine-2-yl)-1,5-dihydropyrrole-2-one

Melting point: 216-217°C

Elementary analysis as C ₁₇ H ₁₇ N ₃ O ₃			
Calcd. (%)	C, 65.58;	H, 5.50;	N, 13.50.
Found (%)	C, 65.27;	H, 5.35;	N, 13.47.

NMR(CDCl₃) δ: 1.29(6H, d, J=7.0Hz), 4.17(2H, s), 4.51(1H, sept), 7.15-7.20(2H, m), 7.24-7.30(1H, m), 7.41-7.47(2H, m), 8.34(1H, d, J=1.5Hz), 8.40(1H, d, J=1.2Hz), 8.78(1H, bs).

(B-95-b) 4-[5-(4-fluorophenoxy)-pyrazine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

Melting point: 237-238°C

Elementary analysis as C ₁₅ H ₁₂ FN ₃ O ₃ 0.1H ₂ O				
Calcd. (%)	C, 59.44;	H, 4.06;	N, 13.86;	F, 6.27.
Found (%)	C, 59.34;	H, 4.01;	N, 13.95;	F, 6.31.

NMR(CDCl₃) δ: 3.16(3H, s), 4.19(2H, s), 7.11-7.15(4H, m), 8.26(1H, d, J=0.9Hz), 8.36(1H, d, J=0.9Hz), 8.93(1H, bs).

(B-95-c) 4-[5-(4-fluorophenoxy)-pyrazine-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 227-229°C

Elementary analysis as C₁₇H₁₆FN₃O₃


Calcd. (%)	C, 62.00;	H, 4.90;	N, 12.76;	F, 5.77.
Found (%)	C, 62.05;	H, 4.81;	N, 12.75;	F, 5.72.

NMR(CDCl₃) δ: 1.29(6H, d, J=6.7Hz), 4.17(2H, s), 4.51(1H, sept), 7.09-7.16(4H, m), 8.35(1H, s), 8.40(1H, s), 8.69(1H, bs).

Compound B-106

4-[5-(4-fluorobenzyl)-pyrazine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0346]



(B-96) To a solution of 5-methyl-2-pyrazine carboxylic acid (25g, 180mmol), HOBt (4.9g, 36mmol), and N,O-dimethylhydroxyamine hydrochloride (21g, 220mmol) in methylene chloride (100ml) and chloroform (400ml), were added triethylamine (30ml, 220mmol) and WSCD (41g, 220mmol) and the mixture was stirred at room temperature for 2 hours. The solution was washed and dried, then the solvent was evaporated under reduced pressure to give crude 5-methylpyrazine-2-carboxylic acid methoxymethylamide (30.5g).

NMR(CDCl₃) δ: 2.63(3H, s), 3.41(3H, s), 3.75(3H, s), 8.47(1H, s), 8.82(1H, s).

(B-97) To a solution of the above-mentioned crude product B-96 (16.3g, 90mmol) in tetrahydrofuran (220ml), was added dropwise 4-fluorophenylmagnesium bromide (99ml) at -40°C and the mixture was stirred at -20°C for 30 minutes. An ammonium chloride aqueous solution was added to terminate the reaction, which was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The precipitated crystals were washed with n-hexane and dried to give 4-fluorophenyl-5-methylpyrazine-2-yl-metanone (16.8g, yield : 86%).

NMR(CDCl₃) δ: 2.70(3H, s), 7.15-7.21(2H, m), 8.16-8.20(2H, m), 8.54(1H, s), 9.17(1H, s).

(B-98) To a solution of the above-mentioned compound B-97 (16.8g, 78mmol) in chloroform (250ml), was added m-chloroperbenzoic acid (22.7g, 86mmol) and the mixture was stirred at room temperature overnight. Sodium hydrogen carbonate was added thereto to alkaliify the solution and the mixture washed and dried, then the solvent

was evaporated under reduced pressure. The precipitated crystals were washed with diisopropylether and dried under reduced pressure to give (4-fluorophenyl)-(5-methyl-4-oxypyrazine-2-yl)-metanone (15.8g, yield : 88%).

NMR(CDCI₃) δ: 2.56(3H, s), 7.14-7.22(2H, m), 8.18-8.24(2H, m), 8.53(1H, s), 8.77(1H, s).

(B-99) A solution of the above-mentioned compound B-98 (15.8g, 78mmol) in acetic anhydride (160ml) was stirred at 135°C for 3 hours, which was cooled to room temperature, then water (500ml) was added thereto with stirring overnight. The reaction solution was extracted with ethyl acetate, then the extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=3:1) to give acetic acid 5-(4-fluorobenzoyl)-pyrazine-2-ylmethyl ester (8.0g, yield : 43%).

NMR(CDCI₃) δ: 2.22(3H, s), 5.37(2H, s), 7.16-7.22(2H, m), 8.17-8.22(2H, m), 8.72(1H, s), 9.24(1H, s).

(B-100) To a solution of the above-mentioned compound B-99 (8.0g, 29mmol) in methyl alcohol (60ml), was added sodium borohydride (491mg, 11.7mmol) under ice-cooling and the mixture was stirred for 2 hours, which was warmed to room temperature, followed by stirring for 30 minutes. An ammonium chloride aqueous solution was added to terminate the reaction, and the mixture was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure to give crude acetic acid 5-[(4-fluorophenyl)-hydroxymethyl]-pyrazine-2-ylmethyl ester (8.0g) .

NMR(CDCI₃) δ: 2.15(3H, s), 5.25(2H, s), 5.87(1H, s), 7.02-7.08(2H, m), 8.34-8.39(2H, m), 8.53(1H, s), 8.58(1H, s).

(B-101) To a solution of the above-mentioned crude product B-100 (8.0g) in trifluoroacetic acid(200ml), was added triethylsilane(40ml, 250mmol)under ice-cooling and the mixture was stirred at room temperature for 4 days. The solvent was evaporated under reduced pressure and an aqueous solution of sodium hydrogen carbonate was added to neutrize the solution, which was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=1:1) to give acetic acid 5-(4-fluorobenzyl)-pyrazine-2-ylmethyl ester (4.5g, yield : 60%).

NMR(CDCI₃) δ: 2.15(3H, s), 4.14(2H, s), 5.22(2H, s), 6.97-7.03(2H, m), 7.20-7.25(2H, m), 8.43(1H, s), 8.57(1H, s).

(B-102) To a solution of the above-mentioned compound B-101 (4.5g, 17.3mmol) in methyl alcohol (50ml), was added a 2N sodium hydroxide aqueous solution (26ml) and the mixture was stirred at room temperature for 1 hour. Hydrochloric acid and an ammonium chloride aqueous solution were added to neutrize the reaction solution, which was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=1:2) to give [5-(4-fluorobenzyl)-pyrazine-2-yl]-methyl alcohol (3.1g, yield : 82%).

NMR(CDCI₃) δ: 3.15(1H, brs), 4.14(2H, s), 4.79(2H, s), 6.97-7.02(2H, m), 7.19-7.24(2H, m), 8.39(1H, s), 8.55(1H, s).

(B-103) To a solution of the above-mentioned compound B-102 (3.0g, 13.7mmol) in chloroform (90ml) , was added manganese dioxide (12.0g, 137mmol) and the mixture was refluxed for 3 hours. The reaction mixture was filtered with celite and the solvent was evaporated under reduced pressure to give crude 5-(4-fluorobenzyl)-pyrazine-2-carbaldehyde (2.46g) .

NMR(CDCI₃) δ: 4.25(2H, s), 7.00-7.06(2H, m), 7.23-7.28(2H, m), 8.60(1H, s), 9.09(1H, s), 10.11(1H, s).

(B-104) (B-105) -78°C, cool 下 To a lithium bis(trimethylsilyl)amide solution(13.6ml), was added dropwise a tetrahydrofuran (15ml) solution containing (dimethoxyphosphoryl) - (2,2,2-trichloro-1,1-dimethylethoxycarbonyloxy) - acetic acid methyl ester (5.03g, 12.5mmol) synthesized according to Tetrahedron Lett.25, 3529, 1984) and the mixture was stirred for 10 minutes. A solution of the above-mentioned compound B-103 (337mg, 1.56mmol) in tetrahydrofuran (2ml) was added thereto and the mixture was stirred for 10 minutes, which was warmed to 0°C and stirred for 20 minutes. An ammonium chloride aqueous solution was added to terminate the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=2:1-1:2) to give 3-[5-(4-fluorobenzyl)-pyrazine-2-yl]-2-(2,2,2-trichloro-1,1-dimethylethoxycarbonyloxy)-acrylic acid methyl ester (3.46g, yield : 62%) and 3-[5-(4-fluorobenzyl)-pyrazine-2-yl]-2-hydroxy acrylic acid methyl ester (0.70g, yield : 21%). 3-[5-(4-fluorobenzyl)-pyrazine-2-yl]-2-(2,2,2-trichloro-1,1-dimethylethoxycarbonyloxy)-acrylic acid methyl ester.

NMR(CDCI₃) δ: 1.98(6H, s), 3.76(2H, s), 4.15(3H, s), 6.93(1H, s), 6.98-7.04(2H, m), 7.20-7.25(2H, m), 8.42(1H, d, J=1.5Hz), 8.69(1H, d, J=1.5Hz). 3-[5-(4-fluorobenzyl)-pyrazine-2-yl]-2-hydroxyacrylic acid methyl ester

Melting point: 122-123°C

Elementary analysis as C ₁₅ H ₁₃ FN ₂ O ₃				
Calcd. (%)	C, 62.50;	H, 4.55;	N, 9.72;	F, 6.59.
Found (%)	C, 62.45;	H, 4.35;	N, 9.72;	F, 6.45.

NMR(CDCl₃) δ: 3.91(3H, s), 4.16(2H, s), 6.64(1H, s), 6.99-7.05(2H, m), 7.22-7.25(2H, m), 8.28(1H, s), 8.50(1H, s).
 (B-106) Using the above-mentioned compound B-105, by a similar method to (B-12), 4-[5-(4-fluorobenzyl)-pyrazine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one was obtained.
 Melting point: 223-225°C

Elementary analysis as C ₁₆ H ₁₄ FN ₃ O ₂				
Calcd. (%)	C, 64.21;	H, 4.71;	N, 14.04;	F, 6.35.
Found (%)	C, 63.65;	H, 4.31;	N, 13.89;	F, 6.19; Cl, 0.82.

NMR(CDCl₃) δ: 3.16(3H, s), 4.16(2H, s), 4.21(2H, s), 6.98-7.04(2H, m), 7.21-7.27(2H, m), 8.35(1H, s), 8.60(1H, s).

[0347] The following compound was prepared as well as above.

(B-106-a) 4-[5-(4-fluorobenzyl)-pyrazine-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one
 Melting point: 207 - 209°C


Elementary analysis as C ₁₈ H ₁₈ FN ₃ O ₂				
Calcd. (%)	C, 66.04;	H, 5.54;	N, 12.84;	F, 5.80.
Found (%)	C, 65.25;	H, 5.38;	N, 12.46;	F, 5.51.

NMR(CDCl₃) δ: 1.29(6H, d, J=6.9Hz), 4.16(2H, s), 4.18(2H, s), 4.55(1H, sept, J=6.9Hz), 6.98-7.04(2H, m), 7.21-7.26(2H, m), 8.34(1H, s), 8.74(1H, s).

Compound B-110

4-[4-(4-fluorobenzoyloxy)-[1,3,5]triazine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0348]



(B-107) According to Synthesis 1981,907, 2-chloro-4-methyl[1,3,5]triazine was synthesized.

NMR(CDCl₃) δ: 2.71(3H, s), 8.92(1H, s).

(B-108) To a solution of calcium carbonate (7.8g, 57mmol) in 4-fluorobenzyl alcohol (15ml), was added the above-mentioned compound (B-107) (7.4g, 57mmol) and the mixture was stirred at 90°C for 3 hours. Water was added to terminate the reaction, which was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexane : ethyl acetate=3:1-1:1) to give 2-(4-fluorobenzoyloxy)-4-methyl[1,3,5]triazine (3.3g, yield : 26%).

NMR(CDCl₃) δ: 2.60(3H, s), 5.44(2H, s), 7.32-7.36(2H, m), 7.43-7.48(2H, m), 8.77(1H, s).

(B-109) Using the above-mentioned compound B-108, according to the method of (B-11), 3-[4-(4-fluorobenzoyloxy)-[1,3,5]triazine-2-yl]-2-hydroxyacrylic acid ethyl ester was synthesized.

Melting point: 142-143°C

EP 1 422 218 A1

NMR(CDCl₃) δ: 1.40(3H, t, J=7.0Hz), 4.38(2H, q, J=7.0Hz), 5.47(2H, s), 6.54(1H, s), 7.05-7.11(2H, m), 7.44-7.48(2H, m), 8.80(1H, s).

(B-110) Using the above-mentioned compound B-109, according to the method of (B-12), 4-[4-(4-fluorobenzyloxy)-[1,3,5]triazine-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one was synthesized.

Melting point : 169-171°C

Elementary analysis as C ₁₅ H ₁₃ FN ₄ O ₃ 0.3H ₂ O				
Calcd. (%)	C, 56.00;	H, 4.26;	N, 17.42;	F, 5.91.
Found (%)	C, 55.92;	H, 3.89;	N, 17.58;	F, 5.62.

NMR(CDCl₃) δ: 3.17(3H, s), 4.20(2H, s), 5.47(2H, s), 7.05-7.11(2H, m), 7.44-7.48(2H, m), 8.82(1H, s).

[0349] The following compound was prepared as well as above.

(B-110-a) 4-[4-(4-fluorobenzyloxy)-[1,3,5]triazine-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 105-106°C


Elementary analysis as C ₁₇ H ₁₇ FN ₄ O ₃				
Calcd. (%)	C, 59.30;	H, 4.98;	N, 16.27;	F, 5.52.
Found (%)	C, 59.12;	H, 4.68;	N, 16.29;	F, 5.36.

NMR(CDCl₃) δ: 1.27(6H, d, J=6.7Hz), 4.15(2H, s), 4.57(1H, sept), 5.48(2H, s), 7.03-7.11(2H, m), 7.44-7.48(2H, m), 8.82(1H, s).

Compound B-112

4-[5-[2-(4-fluorophenyl)ethyl]-thiazole-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0350]



(B-111) According to WO 01/17968, 3-[5-[2-(4-fluorophenyl)ethyl]-thiazole-2-yl]-2-hydroxyacrylic acid ethyl ester was synthesized.

Melting point: 146-148°C

Elementary analysis as C ₁₆ H ₁₆ FNO ₃ S					
Calcd. (%)	C, 59.80;	H, 5.02;	N, 4.36;	F, 5.91;	S, 9.98.
Found (%)	C, 59.85;	H, 4.90;	N, 4.32;	F, 5.82;	S, 10.03.

NMR(CDCl₃) δ : 1.38(3H, t, J=7.1Hz), 2.95(2H, t, J=7.5Hz), 3.14(2H, t, J=7.5Hz), 4.36(2H, q, J=7.1Hz), 6.69(1H, s), 6.95-7.01(2H, m), 7.09-7.14(2H, m), 7.41(1H, s).

(B-112) Using the above-mentioned compound B-111, by a similar method to (B-12), 4-[5-[2-(4-fluorophenyl)ethyl]-thiazole-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one was obtained.

Melting point: 214-216°C

Elementary analysis as C ₁₆ H ₁₅ FN ₂ O ₂ S					
Calcd. (%)	C, 60.36;	H, 4.75;	N, 8.80;	F, 5.97;	S, 10.07.
Found (%)	C, 59.98;	H, 4.59;	N, 8.59;	F, 5.77;	S, 9.95.

NMR(CDCl₃) δ: 2.93(2H, t, J=7.6Hz), 2.98(3H, s), 3.15(2H, t, J=7.4Hz), 4.21(2H, s), 7.07-7.12(2H, m), 7.25-7.29(2H, m), 7.48(1H, s).

[0351] The following compound was prepared as well as above.

(B-112-a) 4-[5-[2-(4-fluorophenyl)ethyl]-thiazole-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one
Melting point: 208 - 210°C


Elementary analysis as C ₁₈ H ₁₉ FN ₂ O ₂ S					
Calcd. (%)	C, 62.41;	H, 5.53;	N, 8.09;	F, 5.48;	S, 9.26.
Found (%)	C, 62.21;	H, 5.51;	N, 8.02;	F, 5.39;	S, 9.24.

NMR(CDCl₃) δ: 1.28(6H, d, J=6.7Hz), 2.96(2H, t, J=7.4Hz), 3.16(2H, t, J=7.4Hz), 4.23(2H, s), 4.53(1H, sept, J=6.7Hz), 6.95-7.00(2H, m), 7.10-7.14(2H, m), 7.41(1H, s).

Compound B-117

4-[5-(4-fluorobenzyl)-thiazole-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one

[0352]



(B-113) According to J. Org. Chem. 1993, 58, 1696-1701, 3-(4-fluorophenyl)-propionic aldehyde was synthesized.

(B-114) To a solution of the above-mentioned compound B-113 (4.6g, 30mmol) in acetonitrile (120ml), tetrabutylammonium tribromide (14.5g, 30mmol) was added and the mixture was stirred at room temperature for 30 minutes. The solvent was evaporated under reduced pressure and water was added thereto, which was extracted with diethyl ether. The extract was washed and dried, then the solvent was evaporated under reduced pressure to give crude 2-bromo-3-(4-fluorophenyl)-propionic aldehyde (6.0g).

NMR(CDCl₃) δ: 3.14(1H, dd, J=7.8, 14.8Hz), 3.46(1H, dd, J=6.6, 14.8Hz), 4.41(1H, dt, J=2.4, 6.7Hz), 6.98-7.04(2H, m), 7.17-7.21(2H, m), 9.49(1H, s).

(B-115) To a solution of the above-mentioned crude product B-114 (6.0g) in acetonitrile (60ml), was added thioacetamide (3.9g, 52mmol) and the mixture was refluxed for 1 hour. A sodium hydrogen carbonate aqueous solution was added to neutralize the solution, which was extracted with diethyl ether. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column

EP 1 422 218 A1

chromatography (n-hexane : ethyl acetate=3:1) to give 5-(4-fluorobenzyl)-2-methylthiazole (3.8g, yield : 71%) .

NMR(CDCI₃) δ : 2.64(3H, s), 4.06(2H, s), 6.96-7.02(2H, m), 7.15-7.20(2H, m), 7.32(1H, s).

(B-116) Using the above-mentioned compound B-115, by a similar method to (B-11), 3-[5-(4-fluorobenzyl)-thiazole-2-yl]-2-hydroxyacrylic acid ethyl ester was obtained.

Melting point: 160-162°C

Elementary analysis as C ₁₅ H ₁₄ FN ₃ O ₃ S					
Calcd. (%)	C, 58.62;	H, 4.59;	N, 4.56;	F, 6.18;	S, 10.43.
Found (%)	C, 58.84;	H, 4.32;	N, 4.76;	F, 6.45;	S, 10.90.

NMR(CDCI₃) δ: 1.38(3H, t, J=7.1Hz), 4.13(2H, s), 4.35(2H, q, J=7.1Hz), 6.68(1H, s), 7.00-7.05(2H, m), 7.17-7.21(2H, m), 7.48(1H, s).

(B-117) Using the above-mentioned compound B-116, by a similar method to (B-12), 4-[5-(4-fluorobenzyl)-thiazole-2-yl]-3-hydroxy-1-methyl-1,5-dihydropyrrole-2-one was obtained.

Melting point: 222-224°C

Elementary analysis as C ₁₅ H ₁₃ FN ₂ O ₂ S					
Calcd. (%)	C, 59.20;	H, 4.31;	N, 9.20;	F, 6.24;	S, 10.54.
Found (%)	C, 57.01;	H, 4.08;	N, 8.68;	F, 5.91;	S, 10.06.

NMR(CDCI₃) δ: 2.98(3H, s), 4.19(2H, s), 4.22(2H, s), 7.11-7.17(2H, m), 7.30-7.35(2H, m), 7.60(1H, s).

[0353] The following compound was prepared as well as above.

(B-117-a) 4-[5-(4-fluorobenzyl)-thiazole-2-yl]-3-hydroxy-1-isopropyl-1,5-dihydropyrrole-2-one

Melting point: 212 - 214°C

Elementary analysis as C ₁₇ H ₁₇ FN ₂ O ₂ S					
Calcd. (%)	C, 61.43;	H, 5.16;	N, 8.43;	F, 5.72;	S, 9.65.
Found (%)	C, 61.17;	H, 5.06;	N, 8.30;	F, 5.62;	S, 9.58.


NMR(CDCI₃) δ: 1.26(6H, d, J=6.7Hz), 4.16(2H, s), 4.22(2H, s), 4.51(1H, sept, J=6.7Hz), 6.98-7.03(2H, m), 7.17-7.22(2H, m), 7.53(1H, s).

C group compound

Compound C-8

2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-4H-1-benzopyrane-4-one

[0354]



(C-1) To a suspension of 60% sodium hydride (3.61g, 90.3mmol) in dimethylformamide (50ml) , was added dropwise a solution of 2-bromophenol (15.1g, 87.3mmol) in dimethylformamide (50ml) under ice-cooling and the mixture was stirred at the same temperature for 40 minutes. Chloromethyl methyl ether (7.29ml, 96.0mmol) was added dropwise thereto, and the mixture was stirred for 45 minutes. Water was added to terminate the reaction, which was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was distilled under reduced pressure to give 1-bromo-2-methoxymethoxybenzene (17.7g, yield : 94%) .

boiling point: 67-68°C (0.7mmHg)

(C-2) To a solution of the above-mentioned compound C-1 (14.9g, 68.7mmol) in tetrahydrofuran (250ml) , was added dropwise an n-butyl lithium solution (1.55N, 46.5ml, 72.1mmol) at -78°C. The mixture was stirred at the same temperature for 20 minutes and a solution of zinc chloride in diethylether (1.0N, 72.1ml, 72.1mmol) was added dropwise thereto, which was stirred for 30 minutes. Chlorobenzyloxyacetyl (13.0ml, 82.4mmol) and tetrakis(triphenylphosphine) palladium(1.59g, 1.4mmol) were added thereto and the mixture was stirred for 2 hours with cooling to room temperature. After adding dilute hydrochloric acid, the mixture was extracted with ethyl acetate, washed and dried, then the solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate : n-hexane = 1:9-1:3) to give 2-benzyloxy-1-(2-methoxymethoxyphenyl)ethanone (10.2g, yield : 52%) .

NMR(CDCl₃)δ:3.43(3H, s), 4.69(2H, s), 4.73(2H, s) 5.22(2H, s), 7.05-7.18(2H, m), 7.27-7.49(6H, m), 7.86(1H, dd, J=1.8, 7.8Hz).

(C-3) To a solution of the above-mentioned compound C-2 (10.2g, 35.7mmol) in methyl alcohol (100ml), was added 2N hydrochloric acid (25ml) and the mixture was stirred at 50°C for 4 hours 30 minutes. Water (100ml) was added thereto, and the mixture was extracted with ethyl acetate, washed and dried, then the solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate : n-hexane=1:4) to give 2-benzyloxy-1-(2-hydroxyphenyl)etanone (7.89g, yield : 91%) .

NMR(CDCl₃)δ: 4.70(2H, s), 4.77(2H, s), 6.83-6.90(1H, m), 7.00(1H, dd, J = 1.2, 8.4Hz), 7.28-7.51(6H, m), 7.63(1H, dd, J=1.5, 8.1Hz), 11.9(1H, s).

(C-4) To a solution of the above-mentioned compound C-3 (7.64g, 31.6mmol) in pyridine (76ml) , was added ethyl chloro glyoxylic acetate (5.29ml, 47.4mmol) under ice-cooling. The mixture was stirred for 20 minutes while allowing to be at room temperature, then further stirred at 100°C for 37 hours. Water (5ml) was added thereto and the mixture was stirred at room temperature for 15 minutes and evaporated under reduced pressure, to which was added 1N hydrochloric acid, followed by extraction with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate : n-hexane=1:3) to give 3-benzyloxy-4-oxo-4H-chromene-2-carboxylic acid ethyl ester (3.48g, yield : 34%) .

NMR(CDCl₃)δ: 1.36(3H, t, J=7.2Hz), 4.40(2H, q, J=7.2Hz), 5.28(2H, s), 7.30-7.76(8H, m) 8.23-8.27(1H, m).

(C-5) To the above-mentioned compound C-4 (1.73g, 5.34mmol) in ethanol (16ml) , was added 2N sodium hydroxide aqueous solution (3ml) and the mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure and 2N hydrochloric acid (3.2ml) and water were added thereto, which was extracted with ethyl acetate, washed, and dried. The solvent was evaporated under reduced pressure and the residue was crystallized from ethyl acetate / n-hexane to give 3-benzyloxy-4-oxo-4H-chromene-2-carboxylic acid (1.24g, yield : 79%) .

Melting point: 145-146°C

NMR(CDCl₃)δ: 5.63(2H, s), 7.36-7.52(6H, m), 7.62-7.66(1H, m), 7.75-7.82(1H, m), 8.25(1H, dd, J=2.1, 7.8Hz).

(C-6) To a solution of the above-mentioned compound C-5 (157mg, 0.53mmol) in methylene chloride (3ml) , were added oxalylchloride (50 μl, 0.69mmol) and dimethylformamide (2μl) under ice-cooling and the mixture was stirred for 20 minutes while allowing to be at room temperature. The solution was concentrated under reduced pressure to give crude 3-benzyloxy-4-oxo-4H-chromene-2-carboxylic acid chloride.

(C-7) To a solution of the above-mentioned compound C-6 in chloroform(1ml), were added dichlorobis(acetonitrile) palladium(II) (12mg, 0.046mmol) and trimethylzinc compound (250mg) prepared below at room temperature and the mixture was stirred at the same temperature for 5 minutes and at 50°C for 20 minutes. Water was added thereto and the mixture was extracted with ethyl acetate, washed and dried. The solvent was evaporated and the residue was purified with silica gel column chromatography (ethyl acetate : n-hexane=1:4) . Crystallization from ethyl acetate / n-hexane gave 3-benzyloxy-2-[5-(4-fluorobenzyl)furan-2-carbonyl] chromene-4-one (82mg, yield : 21%) .

Melting point: 158°C

NMR(CDCl₃)δ: 4.02(2H, s), 5.24(2H, s), 6.96-7.76(13H, m), 8.30 (1H, dd, J=1.5, 8.1Hz).

(C-8) To a solution of the above-mentioned compound C-7 (79mg, 0.17mmol) in ethanol (2ml) and tetrahydrofuran (6ml) , was added 10% palladium-carbon (20mg) and the mixture was stirred at room temperature for 10 minutes under hydrogen atmosphere. After filtering off the palladium-carbon, the filtrate was concentrated under reduced pressure and the residue was crystallized from tetrahydrofuran / methyl alcohol to give 2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-4H-1-benzopyrane-4-one (45mg, yield : 71%) .

Melting point: 226-227°C

Elementary analysis as C ₂₁ H ₁₃ FO ₅			
Calcd. (%)	C, 69.23;	H, 3.60;	F, 5.21.
Found (%)	C, 69.00;	H, 3.53;	F, 5.15.

NMR(CDCl₃)δ: 4.14(2H, s), 6.32(1H, d, J=3.6Hz), 7.01-7.79(7H, m), 7.90(1H, d, J=3.6Hz), 8.30 (1H, dd, J=1.5, 8.1Hz), 11.86(1H, s).


(C-9) To a solution of bromofuran (500mg, 1.96mmol) in tetrahydrofuran (250ml), was added dropwise a n-butyl lithium solution (1.55N, 1.3ml, 2.02mmol) at -78°C and the mixture was stirred for 5 minutes. To the mixture was added dropwise a solution of trimethyltin chloride(423mg, 2.06mmol)in tetrahydrofuran(0.5ml)and the mixture was stirred at -78°C for 30 minutes and further stirred with warming to room temperature. Water was added thereto and the mixture was extracted with ethyl acetate, washed, and dried. The solvent was evaporated under reduced pressure to give the crude trimethyltin compound.

NMR(CDCl₃)δ: 0.20-0.40(9H, m), 3.98(2H, s), 5.92-5.96(1H, m), 6.46-6.50(1H, m), 6.94-7.22(4H, m).

Compound C-12

6-[(4-fluorobenzyl)oxy]-3-hydroxy(2-pyridine-2-yl)-4H-1-benzopyrane-4-one

[0355]



(C-10) To a suspension of 2', 5'-dihydroxyacetophenone (23.1g, 152mmol) and powder potassium carbonate (23.1g, 167mmol) in acetonitrile (400ml), was added 4-fluorobenzylbromide (18.9ml, 152mmol) at room temperature and the mixture was refluxed for 3 hours. The solution cooled to room temperature was filtered and the obtained solid products were washed with ethyl acetate. The filtrate and the ethyl acetate solution after washing were combined and concentrated under reduced pressure, to which was added an ammonium chloride aqueous solution, followed by extraction with ethyl acetate. The extract was washed and dried, then active carbon (10g) was added thereto, followed by filtration and concentration under reduced pressure. The residue was crystallized from methyl alcohol (100ml) to give 1-[5-(4-fluorobenzyl)oxy]-2-hydroxyphenyl]ethanone (30.3g, yield : 77%).

Melting point: 88.89°C

NMR(CDCl₃)δ: 2.60(3H, s), 5.00(2H, s), 6.90-7.45(7H, m), 11.87(1H, s).

(C-11) To a solution of the above-mentioned compound C-10(470mg, 1.81mmol) in ethanol (14ml), were added pyridine-2-aldehyde (202mg, 1.90mmol), and a 50% sodium hydroxide aqueous solution (0.490ml) and the mixture was stirred at room temperature for 43 hours. The solution was neutralized with 2N hydrochloric acid, which was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate : n-hexane=1:4) and crystallized from methyl alcohol / diisopropylether to give 1-[5-(4-fluorobenzyl)oxy]-2-hydroxyphenyl]-3-pyridine-2-yl propenone (157mg, yield : 25%).

Melting point: 118°C

NMR(CDCl₃)δ: 5.04(2H, s), 6.96-7.89(11H, m), 8.20(1H, d, J=15.3Hz), 8.70-8.75(1H, m).

(C-12) To a suspension of the above-mentioned compound C-11 (155mg, 0.44mmol) in methyl alcohol (7.5ml), were added 2N sodium hydroxide aqueous solution (0.89ml) and 30% hydrogen peroxide solution (0.151ml) and the mixture was stirred at room temperature for 30 minutes. The solution was neutralized with 2N hydrochloric acid; to which was added water and methyl alcohol. The precipitated crystals were filtered off. The crude crystals were washed with water, dried, and crystallized from methyl alcohol to give 6-[(4-fluorobenzyl)oxy]-3-hydroxy(2-pyridine-2-yl)-4H-1-benzopyrane-4-one (31mg, yield : 19%).

Melting point: 204-205°C


Elementary analysis as C ₁₉ H ₁₈ FN ₂ O ₄				
Calcd. (%)	C, 69.42;	H, 3.88;	N, 3.86;	F, 5.23.
Found (%)	C, 69.39;	H, 3.81;	N, 3.86;	F, 5.01.

NMR(CDCl₃)δ: 5.13(2H, s), 7.05-7.54(7H, m), 7.76(1H, d, J=3.0Hz), 8.00(1H, dd, J=1.5, 8.1Hz), 8.11-8.17(1H, m), 8.62-8.63(1H, m), 13.02(1H, brs).

Compound C-22

5-[(4-fluorobenzyl)oxy]-3-hydroxy(2-pyridine-2-yl)-4H-1-benzopyrane-4-one

[0356]



(C-13) To a suspension of 2', 6'-dihydroxyacetophenone (5.0g, 32.9mmol) and powder potassium carbonate (10.0g, 72.4mmol) in dimethylformamide (30ml) , was added iodomethane (7.1ml, 114mmol) at room temperature and the mixture was stirred at the same temperature overnight. To the solution was added 2N hydrochloric acid (45ml) and water (45ml) and the precipitated crystals were filtered off. The crude crystals were washed with water and dried, then crystallized from ethyl acetate / n-hexane to give 1-(2,6-dimethoxyphenyl)ethanone (4.2g, yield : 71%) .

Melting point: 69°C

NMR(CDCl₃)δ: 2.48(3H, s), 3.81(6H, s), 6.55(2H, d, J=8.1Hz), 7.26(1H, t, J=8.1Hz).

(C-14) To a solution of the above-mentioned compound C-13 (4.0g, 22.2mmol) in tetrahydrofuran (40ml) , was added phenyltrimethylammoniumtribromide (8.34g, 22.2mmol) over 10 minutes at room temperature and the mixture was stirred at the same temperature for 1 hour. Water was added thereto, and the mixture was extracted with ethyl acetate, washed, and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate:n-hexane=1:4). After allowing to stand at room temperature, the obtained solid residue was washed with diisopropylether to give 2-bromo-1-(2,6-dimethoxyphenyl) ethanone (4.22g yield : 70%) .

Melting point: 78-82°C

NMR(CDCl₃)δ: 3.82(6H, s), 4.38(2H, s), 6.57(2H, d, J=8.4Hz), 7.32(1H, t, J=8.4Hz).

(C-15) A suspension of benzoic acid (1.13g, 9.3mmol) and powder potassium carbonate (0.91g, 6.56mmol) in dimethylformamide (30ml) was stirred at 90°C for 1 hour and cooled to room temperature. The above-mentioned compound C-14 (2.0g, 7.7mmol) was added thereto and the mixture was stirred at 100°C for 30 minutes. To the

solution cooled to room temperature, was added water (120ml), then the precipitated crystals were filtered off, washed with water, and dried to give benzoic acid 2-(2,6-dimethoxyphenyl)-2-oxoethyl ester (2.0g, yield : 86%). NMR(CDCl₃)δ: 3.82(6H, s), 5.25(2H, s), 6.58(2H, d, J=8.4Hz), 7.33(1H, t, J=8.4Hz), 7.41-7.61(3H, m), 8.06-8.12 (2H, m).

(C-16) To a solution of the above-mentioned compound C-15 (1.5g, 4.99mmol) in methylene chloride (250ml), was added dropwise a tribromoborane - methylene chloride solution (1.0N, 4.99ml, 4.99mmol) at -78°C and the mixture was stirred at the same temperature for 15 minutes. To the solution was added water, which was extracted with ethyl acetate, washed, and dried. The solvent was evaporated under reduced pressure. After allowing to stand at room temperature, the obtained solid residue was washed with diisopropylether to give benzoic acid 2-(2-hydroxy-6-methoxyphenyl)-2-oxoethyl ester (1.14g yield : 80%)

NMR(CDCl₃)δ: 3.97(3H, s), 5.51(2H, s), 6.43(1H, d, J=8.1Hz), 6.61(1H, dd, J=1.2, 8.4Hz), 7.37-7.63(4H, m), 8.13-8.19(2H, m), 12.76(1H, s).

(C-17) To a solution of the above-mentioned compound C-18 (1.14g, 3.98mmol) in dimethylformamide (15ml), were added picolyl chloride hydrochloride (0.92g, 5.18mmol) and triethylamine (1.36ml, 9.75mmol) under ice-cooling and the mixture was stirred at room temperature for 30 minutes. Water was added thereto, and the mixture was extracted with ethyl acetate, washed, and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate : n-hexane=1:2-1:1) to give pyridine-2-carboxylic acid 2-(2-benzoyloxyacetyl)-3-methoxyphenyl ester (1.17g, yield: 75%).

NMR(CDCl₃)δ: 3.90(3H, s), 5.34(2H, s), 6.90(1H, d, J=8.4Hz), 6.99(1H, d, J=7.5Hz), 7.35-7.58(5H, m), 7.88(1H, dt, J=1.8, 7.8Hz), 7.95-8.01(2H, m), 8.26(1H, d, J=7.8Hz), 8.80-8.85(1H, m).

(C-18) To a solution of the above-mentioned compound C-17 (805mg, 2.06mmol) in dimethylformamide (8ml), was added 60% sodium hydride (205mg, 5.15mmol) under ice-cooling and the mixture was stirred at 55°C for 15 minutes. After cooling, the solution was poured into 2N hydrochloric acid (2.6ml) and ice water, then the mixture was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was dissolved into acetic acid (6ml), to which was added sulfuric acid (0.16ml) and the mixture was stirred at 60°C for 2 hours. After cooling, the solution was poured into ice water, which was neutralized with a saturated sodium hydrogen carbonate aqueous solution. The mixture was extracted with ethyl acetate and chloroform, washed, and dried. The residue was purified with silica gel column chromatography (chloroform:methyl alcohol=20:1) to give 3-hydroxy-5-methoxy-2-pyridine-2-ylchromene-4-one (234mg, yield : 42%).

NMR(CDCl₃)δ: 4.02(3H, s), 6.77(1H, d, J=8.1Hz), 7.11(1H, d, J=8.1Hz), 7.40(1H, ddd, J=1.2, 5.1, 7.5Hz), 7.56(1H, t, J=8.1Hz), 7.97(1H, dt, J=1.8, 8.1Hz), 8.07-8.12(1H, m), 8.61-8.66(1H, m), 12.48(1H, brs).

(C-19) To a suspension of the above-mentioned compound C-18 (234mg, 0.87mmol) and powder potassium carbonate (240mg, 1.74mmol) in dimethylformamide (7ml), was added chlorobenzoyl (0.20ml, 1.74mmol) at room temperature and the mixture was stirred at 115°C for 10 minutes. To the solution cooled to room temperature, was added water, and the mixture was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (chloroform:methyl alcohol=20:1) to give benzoic acid 5-methoxy-4-oxo-2-pyridine-2-yl-4H-chromene-3-yl ester (213mg, yield : 66%).

NMR(CDCl₃)δ: 3.98(3H, s), 6.84(1H, d, J=7.8 Hz), 7.21(1H, dd, J=0.9, 8.4Hz), 7.33-7.67 (5H, m), 7.80(1H, dt, J=1.8, 7.8Hz), 7.91-7.96(1H, m), 8.17-8.23(1H, m), 8.69-8.73(1H, m).

(C-20) To a solution of the above-mentioned compound C-19 (213mg, 0.57mmol) in methylene chloride (10ml), was added dropwise a solution of boron tribromide in methylene chloride (1.0N, 0.685ml, 0.685mmol) at -78°C and the mixture was stirred at the same temperature for 10 minutes. Water was added thereto and the mixture was extracted with ethyl acetate, washed, and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate : n-hexane=1:1) to give benzoic acid 5-hydroxy-4-oxo-2-pyridine-2-yl-4H-chromene-3-yl ester (66mg, yield : 32%).

NMR(CDCl₃)δ: 6.87(1H, d, J=8.4 Hz), 7.10(1H, d, J=8.7Hz), 7.35-7.70(5H, m), 7.84(1H, dt, J=1.8, 7.8Hz), 7.98(1H, d, J=8.1Hz), 8.18-8.24(1H, m), 8.61-8.66(1H, m), 12.04(1H, s).

(C-21) To a suspension of the above-mentioned compound C-20 (91mg, 0.25mmol) and powder potassium carbonate (53mg, 0.38mmol) in dimethylformamide (2ml), was added 4-fluorobenzylbromide (40μl, 0.32mmol) at room temperature and the mixture was stirred for 3 hours. Water was added thereto and the mixture was extracted with ethyl acetate, washed, and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate:n-hexane=1:1-1:2) to give benzoic acid 5-(4-fluorobenzoyloxy)-4-oxo-2-pyridine-2-yl-4H-chromene-3-yl ester (108mg).

(C-22) To a suspension of the above-mentioned compound C-21 (105mg, 0.23mmol) in ethanol (5ml), was added 2N sodium hydroxide aqueous solution (0.124ml) at 60°C and the mixture was stirred for 25 minutes. After cooling, the reaction mixture was neutralized with 2N hydrochloric acid. The precipitated crystals were filtered off, washed with water and ethanol and dried. The crude crystals were crystallized from methyl alcohol to give 5-[(4-fluorobenzoyloxy)-3-hydroxy(2-pyridine-2-yl)-4H-1-benzopyrane-4-one (30mg, yield : 33%).

Melting point: 213°C

Elementary analysis as $C_{21}H_{14}FNO_4 \cdot 0.1H_2O$


Calcd. (%)	C, 69.08;	H, 3.92;	N, 3.84;	F, 5.20
Found (%)	C, 68.98;	H, 3.81;	N, 3.85;	F, 5.01.

NMR($CDCl_3$) δ : 5.24(1H, s), 6.82(1H, d, J=8.1 Hz), 7.06-7.17(3H, m), 7.38-7.44(1H, m), 7.55(1H, t, J=8.1 Hz), 7.70-7.78(2H, m), 7.98(1H, dt, J=1.8, 8.1Hz), 8.10(1H, d, J=8.1Hz), 8.62-8.67(1H, m), 12.79(1H, brs).

Compound C-26

2-[5-(4-fluorobenzyl)-[1,3,4]-oxadiazole-2-yl]-3-hydroxy-4*H*-1-benzopyrane-4-one

[0357]



(C-23) To a solution of compound C-4 (1.73g, 5.34mmol) in methyl alcohol (16ml), was added a 2N sodium hydroxide aqueous solution (3ml) and the mixture was stirred at room temperature for 1 hour. The solution was neutralized with 2N hydrochloric acid, to which was added water, and the mixture was extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure to give crude 3-benzyloxybenzyloxy-4-oxo-4*H*-chromene-2-carboxylic acid (48mg).

(C-24) To a solution of the above-mentioned compound C-23(48mg) in diglyme (1ml), were added oxalylchloride (14 μ l, 0.16mmol) and dimethylformamide(2 μ l) under ice-cooling. The mixture was cooled to room temperature with stirring for 30 minutes to give a crude 3-benzyloxy-4-oxo-4*H*-chromene-2-carboxylic acid chloride solution.

(C-25) To the above-mentioned solution of (C-24), were added a tetrazole (25mg, 0.14mmol) mentioned below and pyridine(47 μ l, 0.58mmol) and the mixture was stirred at room temperature for 30 minutes and at 130°C for 15 minutes. After cooling, water was added thereto, then the precipitated crystals were filtered off, washed with water, and dried to give 3-benzyloxy-2-[5-(4-fluorobenzyl)-[1,3,4]-oxadiazole-2-yl]chromene-4-one(37mg, yield:62%).

NMR($CDCl_3$) δ : 4.23(2H, s), 5.36(2H, s), 6.98-7.78(12H, m), 8.25-8.30(1H, m).

(C-26) To a solution of compound C-25(34mg, 0.079mmol) in ethanol (2ml) and tetrahydrofuran(4ml), was added 10% palladium-carbon(8mg) and the mixture was stirred under hydrogen atmosphere at room temperature for 10 minutes. After removing the palladium-carbon by filtration, the solution was evaporated under reduced pressure. The residue was crystallized from methyl alcohol to give 2-[5-(4-fluorobenzyl)-[1,3,4]-oxadiazole-2-yl]-3-hydroxy-4*H*-1-benzopyrane-4-one (19mg, yield: 70%).

Melting point: 221°C

Elementary analysis as $C_{18}H_{11}FN_2O_4$

Calcd. (%)	C, 63.91;	H, 3.28;	N, 8.28;	F, 5.62.
Found (%)	C, 63.84;	H, 3.23;	N, 8.18;	F, 5.48.

NMR($CDCl_3$) δ : 4.36(2H, s), 7.04-7.13(2H, m), 7.34-7.60(5H, m), 8.13(1H, brs), 8.29(1H, dd, $J=1.2, 7.8$ Hz).

(C-27) To a solution of 4-fluorobenzylcyanide (7.5g, 55.5mmol) in dimethylformamide (75ml), were added ammonium chloride (5.9g, 111.0mmol) and sodium azide (7.2g, 111.0mmol) at room temperature and the mixture was stirred at 130°C for 3 hours. The mixture was cooled to room temperature and water was added thereto, followed by extraction with ethyl acetate. The extract was washed and dried, and then the solvent was evaporated under reduced pressure. The residue was washed with diisopropylether / n-hexane and dried to give 5-(4-fluorobenzyl)-2H-tetrazole (5.45g, yield: 55%).


Melting point: 158-159°C

NMR($CDCl_3$) δ : 4.29(2H, s), 7.13-7.36(4H, m).

Compound C-31a and C-31b

6-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(1H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one and 6-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(1-methyl-1H-imidazole-2-yl)-4H-1-benzopyrane-4-one

[0358]



(C-28) To a suspension of 60% sodium hydride (0.45g, 11.3mmol) in dimethylformamide (25ml), was added dropwise a solution of C-10 (2.64g, 10.2mmol) in dimethylformamide (25ml) under ice-cooling and the mixture was stirred at the same temperature for 20 minutes. Chloromethyl methyl ether (0.93ml, 12.3mmol) was added dropwise thereto and the mixture was stirred for 5 minutes, and further 25 minutes while warming to room temperature. Water was added thereto and the mixture was extracted with ethyl acetate, washed, and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate:n-hexane=1:5-1:3) to give 1-[5-(4-fluorobenzyl)oxy]-2-methoxymethoxyphenyl]etanone (2.93g, yield: 95%).

NMR($CDCl_3$) δ : 2.65(3H, s), 3.51(3H, s), 5.01(2H, s), 5.22(2H, s), 7.03-7.16(4H, m), 7.33-7.42(3H, m).

(C-29a) To a solution of the above-mentioned compound C-28 (304mg, 1.0mmol) and 1H-[1,2,4]triazole-2-aldehyde (145mg, 1.5mmol) in dioxane (4ml) and 99% ethanol (6ml), was added a 1N sodium hydroxide aqueous solution

(2ml) and the mixture was refluxed for 3 hours 20 minutes. An ammonium chloride aqueous solution was added thereto and the mixture was extracted with ethyl acetate, washed, and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (methyl alcohol:chloroform=3:97). Crystallization from ethyl acetate and diisopropylether gave 1-[5-(4-fluorobenzoyloxy)-2-methoxymethoxyphenyl]-3-(1*H* [1,2,4]triazole-3-yl)propanone (260mg, yield:68%).

Melting point: 114-116°C

NMR(CDCl₃) δ : 3.47(3H, s), 5.01(2H, s), 5.19(2H, s), 7.02-7.27(5H, m), 7.37-7.43(2H, m), 7.61(1H, d, J=15.6Hz), 7.88(1H, d, J=15.6Hz), 8.32(1H, br.s).

(C-29b) Using the above-mentioned compound C-28 (304mg, 1.0mmol) and 1-methyl-2-imidazole-2-aldehyde (166mg, 1.5mmol), according to the method of C-29a, crude 1-[5-(4-fluorobenzoyloxy)-2-methoxymethoxyphenyl]-3-(1-methyl-1*H*-imidazole-2-yl)propanone(434mg) was obtained, which was used in the next reaction without purification.

(C-30a) To a solution of the above-mentioned compound C-29a(202mg, 0.527mmol) in methyl alcohol(6ml), was added 2N hydrochloric acid(1.5ml) and the mixture was stirred at 50°C for 3 hours 20 minute. A sodium hydrogen carbonate aqueous solution was added thereto and the mixture was extracted with ethyl acetate, washed and dried. The solvent was evaporated under reduced pressure to give crude crystals of 1-[5-(4-fluorobenzoyloxy)-2-hydroxyphenyl]-3-(1*H*-[1,2,4]triazole-3-yl)propanone(183mg).

(C-30b) Using the above-mentioned compound C-29b (434mg), according to the method of C-30a, crude crystals of 1-[5-(4-fluorobenzoyloxy)-2-hydroxyphenyl]-3-(1-methyl-1*H*-imidazole-2-yl)propanone(355mg) was obtained, which was used in the next reaction without purification.

(C-31a) To a suspension of the above-mentioned compound C-30a(180mg, 0.53mmol) in methyl alcohol(8ml), were added a 2N sodium hydroxide aqueous solution(1.06ml) and 30% hydrogen peroxide solution(0.18ml) and the mixture were stirred at room temperature for 1 hour. A 2N hydrochloric acid(1.06ml) was added thereto and the mixture was stirred for 2 hours 20 minutes. The precipitated crystals were filtered off and washed with water to give crude crystals(121mg). Recrystallization from dimethylformamide / water gave 6-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(1*H*-[1,2,4]triazole-3-yl)-4*H*-1-benzopyrane-4-one(110mg, yield:59%).

Melting point:277°C (comp.)

Elementary analysis as C ₁₈ H ₁₂ FN ₃ O ₄ 0.4H ₂ O				
Calcd. (%)	C, 59.97;	H, 3.58;	N, 11.66;	F, 5.27.
Found (%)	C, 59.91;	H, 3.63;	N, 11.60;	F, 5.13.

NMR(DMSO-*d*₆) δ :5.23(2H, s), 7.22-7.28(2H, m), 7.48-7.59(5H, m), 7.69(1H, d, J=9.3Hz), 8.79(1H, br.s).

(C-31b) Using the above-mentioned compound C-30b(355mg), according to C-31a, 6-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(1-methyl-1*H*-imidazole-2-yl)-4*H*-1-benzopyrane-4-one(169mg, total yield of 3 processes:47%).

Melting point:239-242°C (methylene chloride / methyl alcohol).


Elementary analysis as C ₂₀ H ₁₅ FN ₂ O ₄				
Calcd. (%)	C, 65.57;	H, 4.13;	N, 7.65;	F, 5.19.
Found (%)	C, 65.64;	H, 4.08;	N, 7.65;	F, 5.09.

NMR(CDCl₃) δ :4.16(3H, s), 5.11(2H, s), 7.04(1H, d, J=0.9Hz), 7.06-7.12(2H, m), 7.21(1H, d, J=0.9Hz), 7.31(1H, dd, J=3.0, 9.3Hz), 7.39-7.46(3H, m), 7.75(1H, d, J=3.0Hz).

Compound C-35 and C-36

6-[(4-fluorobenzyl)oxy]-3-hydroxy-4*H*-1-benzopyrane-4-one-2-carboxylate ethyl ester and 6-[(4-fluorobenzyl)oxy]-3-hydroxy-4*H*-1-benzopyrane-4-one-2-carboxylic acid

[0359]



(C-32) To a solution of bromo hydroquinon (10.0 g, 52.9 mmol) in DMF(50 ml), was added 60% sodium hydride (4.44 g, 111.1 mmol) under ice-cooling and the mixture was stirred at room temperature for 30 minutes. Chloromethyl methyl ether(8.44 ml, 111.1 mmol) was added dropwise thereto under ice-cooling and the mixture was stirred at room temperature for 30 minutes. Water and 2N hydrochloric acid were added thereto and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, washed, and dried. The solvent was evaporated under reduced pressure and the residue was purified with column chromatography(ethyl acetate:n-hexane=1:19-1:9)to give 2-bromo-1,4-bismethoxymethylbenzene(11.4 g, yield :83%).

NMR(CDCl₃) δ : 3.47(3H, s), 3.52(3H, s), 5.10(2H, s), 5.17(2H, s), 6.93(1H, dd, J=2.7, 9.0Hz), 7.07(1H, d, J=9.0Hz), 7.27(1H, d, J=2.7Hz).

(C-33) To a solution of the above-mentioned compound C-32(2.0 g, 7.22 mmol)in tetrahydrofuran(40 ml), was added dropwise a n-butyl lithium-hexane solution(1.55N, 4.7 ml, 7.22 mmol)at -78°C and the mixture was stirred at the same temperature for 15 minutes. A zincchloride-tetrahydrofuran solution(1.3N, 5.6 ml, 7.22 mmol)was added dropwise and the mixture was stirred for 30 minutes. To the solution were added chloro(benzyloxy)acetyl (1.25 ml, 7.94 mmol)and tetrakis(triphenyl)phosphine palladium(0.83 g, 0.72 mmol) and the mixture was stirred for 1.5 hours under cooling to room temperature. Water and 2N hydrochloric acid were added thereto and the mixture was extracted with ethyl acetate, water and a sodium hydrogen carbonate aqueous solution, After washing with saturated brine, the mixture was dried and evaporated under reduced pressure. The residue was purified with column chromatography(ethyl acetate:n-hexane=1:9-1:3) to give a crude ketone(845 mg), which was dissolved into methyl alcohol 10 ml and 2N hydrochloric acid 3.0 ml was added thereto. The mixture was stirred at 60°C for 2 hours 30 minutes. After allowing to stand for cooling, water was added thereto, then the precipitated crystals were filtered off, washed with water, and dried to give 2-benzyloxyl-(2,5-dihydroxyphenyl)etanone(376 mg, yield : 20%).

NMR(CDCl₃) δ : 4.69(2H, s), 4.71(2H, s), 6.88-7.42 (8H, m), 11.5(1H,s)

(C-34) To a solution of the above-mentioned compound C-33 (370 mg, 1.43 mmol) in pyridine(6 ml), was added ethyl chloroglyoxylacetate (0.57 ml, 5.10 mmol) under ice-cooling and the mixture was stirred for 1 hour under cooling to room temperature and further stirred for 1 hour 30 minutes at 100°C. After cooling, water and 2N hydrochloric acid were added thereto and the mixture was extracted with ethyl acetate. The extract was washed with water, a sodium hydrogen carbonate aqueous solution, and saturated brine, and dried. The solvent was evaporated under reduced pressure and the residue was purified with column chromatography(ethyl acetate:n-hexane=1:2) to give 3,6-dihydroxy-4*H*-1-benzopyrane-4-one-2-carboxylate ethyl ester(109 mg, yield :22%).

NMR(CDCl₃) δ : 1.36(3H, t, J=6.9Hz), 4.40(2H, q, J=6.9Hz), 5.25(2H, s), 7.18(1H, brs), 7.30-7.76(7H, m), 7.83(1H, d, J=3.0Hz).

(C-35) To a solution of the above-mentioned compound C-34(120 mg, 0.35 mmol) in methyl alcohol(6 ml) and tetrahydrofuran(2 ml), was added 10% palladium-carbon (15 mg)under 1 atm hydrogen atomospher. The mixture was stirred at room temperature for 1 hour and filtered, then the solvent was evaporated under reduced pressure to give a residue(93 mg). The residue(33 mg)was dissolved in DMF 1 ml, and 60% sodium hydride(12 mg, 0.30 mmol) was added thereto under ice-cooling. The mixture was stirred at room temperature for 30 minutes and at 50°C for 30 minutes, then 4-fluorobenzylbromide (12 μ l, 96.3 μ mol)was added dropwise under ice-cooling.

EP 1 422 218 A1

The mixture was stirred at room temperature for 1 hour 30 minutes, then water and 2N hydrochloric acid were added thereto. The precipitated crystals were filtered off, washed with water, and dried. The crude crystals were recrystallized from chloroform / methyl alcohol to give 6-[(4-fluorobenzyl)oxy]-3-hydroxy-4*H*-1-benzopyrane-4-one-2-carboxylate ethyl ester(33 mg, yield :70%).

NMR(CDCl₃)δ: 1.49(3H, t, J=7.2Hz), 4.54(2H, q, J=7.2Hz), 5.11(2H, s), 7.06-7.13(2H, m), 7.37-7.53(4H, m), 7.66(1H, d, J=3.0Hz), 9.43(1H, s).

Melting point:190-192°C

Elementary analysis as C₁₉H₁₅FO₆ 0.1H₂O

Calcd. (%)	C, 63.37;	H, 4.25;	F, 5.28.
Found (%)	C, 63.31;	H, 4.18;	F, 5.43.

(C-36) To a solution of the above-mentioned compound C-35(31 mg, 86.5μmol)in DMSO(1.5 ml), was added a 2N sodium hydroxide aqueous solution 108 μl and the mixture was stirred at room temperature for 1 hour. 2N hydrochloric acid and water were added thereto and the precipitated crystals were filtered off, washed with water, and dried. The crude crystals were recrystallized from diisopropylether and methyl alcohol to give 6-[(4-fluorobenzyl)oxy]-3-hydroxy-4*H*-1-benzopyrane-4-one-2-carboxylic acid(18 mg, yield :62%).

NMR(DMSO-d₆)δ:5.21(2H, s), 7.21-7.67(7H, m).

Melting point:219-220°C


Elementary analysis as C₁₉H₁₅FO₆ 1.3H₂O

Calcd. (%)	C, 57.73;	H, 3.88;	F, 5.37.
Found (%)	C, 57.75;	H, 3.90;	F, 5.11.

Compound C-39

5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2*H*-[1,2,4]triazole-3-yl)-4*H*-1-benzopyrane-4-one

[0360]



(C-37) To a suspension of 2',6'-dihydroxyacetophenone(5.0 g, 32.9 mmol)and powder potassium carbonate (9.1 g, 65.7 mmol)in DMF(30 ml), was added 4-fluorobenzyl bromide(4.1 ml, 32.9 mmol)under ice-cooling and the mixture was stirred at room temperature for 4 hour. Water 30 ml and 2N hydrochloric acid 60 ml were added thereto and the precipitated crystals were filtered off, washed with water, methyl alcohol, and diisopropylether, and dried to give 1-[2-(4-fluorobenzyl)oxy]-6-hydroxyphenyl]ethanone(5.52 g, yield:65%).

NMR(CDCl₃)δ: 2.59(3H, s), 5.09(2H, s), 6.45(1H, d, J=8.4Hz), 6.60(1H, d, J=8.4Hz), 7.07-7.45(5H, m), 13.24(1H, s).

(C-38) To a solution of the above-mentioned compound C-37(1.0 g, 3.84 mmol)and 2-methyl 2*H*-[1,2,4]triazole-3-carboxylate ethyl ester (J. Am. Chem. Soc., 1972, 94, p5894, Heterocycles, 1990, 31, p1629)(1.2 g, 7.68 mmol) in DMF(20 ml), was added potassium tert-butoxide(1.72 mg, 15.4 mmol)under ice-cooling and the mixture was stirred at room temperature for 20 minutes. After ice-cooling the mixture, 2N hydrochloric acid 7.5 ml and water 33 ml were added thereto and the precipitated crystals were filtered off, washed with water, and dried. The obtained

crystals were suspended to a mixture of tetrahydrofuran(15 ml)and methyl alcohol(6 ml), then a solution of concentrated hydrochloric acid 1.3 ml in methyl alcohol(15 ml) was added thereto at room temperature and the mixture was stirred at 60°C for 40 minutes. After allowing to stand the mixture for cooling, 2N sodium hydroxide 7.7 ml and water 125 ml were added thereto, then the precipitated crystals were filtered off, washed with water, and dried to give 5-[(4-fluorobenzyl)oxy]-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one(1.16 g yield :86%).
NMR(CDCl₃)δ:4.29(3H, s), 5.25(2H, s), 6.92(1H, d, J=8.1Hz), 7.04(1H, s), 7.07-7.14(2H, m), 7.56-7.65(5H, m), 7.99(1H, s).

[0361] According to the method mentioned above, the following compounds were prepared.

(C-38a) 5-[(4-fluorobenzyl)oxy]-2-(1-methyl-1H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one
NMR(DMSO-d₆)δ: 4.00(3H, s), 5.25(2H, s), 6.75(1H, s), 7.12(1H, d, J=8.1Hz), 7.21-7.29(3H, m), 7.65-7.76(3H, m), 8.72(1H, s).

(C-38b) 5-[(4-fluorobenzyl)oxy]-2-(5-methyl-1H-[2,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one
NMR(DMSO-d₆)δ: 2.45(3H, s), 5.25(2H, s), 6.72(1H, s), 7.11(1H, d, J=8.1Hz), 7.21-7.29(3H, m), 7.65-7.76(3H, m).

(C-38c) 5-[(4-fluorobenzyl)oxy]-2-(1H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one
NMR(DMSO-d₆)δ: 5.26(2H, s), 6.79(1H, s), 7.12(1H, d, J=8.4Hz), 7.21-7.29(3H, m), 7.66-7.77(3H, m), 8.78(1H, s).

(C-38d) 5-[(4-fluorobenzyl)oxy]-2-(pyrimidine-2-yl)-4H-1-benzopyrane-4-one
NMR(CDCl₃)δ: 5.25(2H, s), 6.89(1H, s), 7.12(1H, d, J=8.4Hz), 7.07-7.14(2H, m), 7.31-7.43(3H, m), 7.51(1H, s), 7.56-7.66(3H, m), 8.95(2H, d, J=4.8Hz).

(C-39) To a solution of the above-mentioned compound C-38(500 mg, 1.42 mmol)in methylene chloride(25 ml), was added, under ice-cooling, an acetone solution containing dimethyldioxylane (0.076N, 18.7 ml, 1.42 mmol) prepared by the method mentioned in Chem. Ber., 1991, 124, p2377) and the mixture was stirred at room temperature for 28 hours. The solvent was evaporated under reduced pressure and the residue was dissolved in methylene chloride 25 ml, and p-toluenesulfonic acid 1 hydrate (325 mg, 1.87 mmol)was added thereto under ice-cooling and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure and the residue was suspended in methyl alcohol 25 ml, to which were added 2N sodium hydroxide 0.8 ml, saturated sodium hydrogen carbonate aqueous solution 4.0 ml, and water 20 ml under ice-cooling. The precipitated crystals were filtered off, washed with water, and dried to give 5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one(280 mg, yield :54%).

NMR(CDCl₃)δ: 3.97(3H, s), 5.29(2H, s), 7.10(1H, d, J=8.1Hz), 7.20-7.30(3H, m), 7.70-7.77(5H, m), 8.21(1H, s), 10.12(1H, brs).

Melting point:215-216°C

[0362] The following compounds were prepared according to the method mentioned above.

(C-39a) 5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(1-methyl-1H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one
NMR(DMSO-d₆)δ: 4.01(3H, s), 5.27(2H, s), 7.06(1H, d, J=8.1Hz), 7.17-7.30(3H, m), 7.66-7.77(3H, m), 8.78(1H, s), 9.56(1H, brs).

Melting point:264-266°C

(C-39b) 5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(5-methyl-1H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one
NMR(DMSO-d₆)δ: 2.47(3H, s), 5.27(2H, s), 7.05(1H, d, J=8.4Hz), 7.17-7.30(3H, m), 7.66-7.77(3H, m).

Melting point:289-292°C

(C-39c) 5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(1H-[1,2,4]triazole-3-yl)-4H-1-benzopyran-4-one
NMR(DMSO-d₆)δ: 5.28(2H, s), 7.07(1H, d, J=7.8Hz), 7.20-7.30(3H, m), 7.68-7.78(3H, m), 8.66(1H, brs).

Melting point:254-256°C


(C-39d) 5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(pyrimidine-2-yl)-4H-1-benzopyrane-4-one
NMR(CDCl₃)δ: 5.28(2H, s), 7.05(1H, d, J=8.1Hz), 7.22-7.31(3H, m), 7.65-7.80(4H, m), 9.10(2H, d, J=5.7Hz), 11.96(1H, brs).

Melting point:252-254°C

Compound C-41

3-hydroxy-2-(5-phenoxy pyrimidine-2-yl)-4H-1-benzopyrane-4-one

[0363]



(C-40) According to the method of compound C-38, 2'-hydroxyacetophenone (150 mg, 1.10 mmol) and 5-phenoxy pyrimidine-2-carboxylic acid (380 mg, 1.65 mmol) were subjected to cyclization reaction to give 2-(5-phenoxy pyrimidin-2-yl)-2'-hydroxyacetophenone (296 mg, yield :85%).

NMR(CDCl₃) δ : 7.12-7.75(9H, m), 8.24-8.28(1H, m), 8.63(2H, s).

(C-41) According to the method of compound C-39, the above-mentioned compound C-40 (150 mg, 0.42 mmol) was oxidized with dimethyldioxylane to give 3-hydroxy-2-(5-phenoxy pyrimidin-2-yl)-4H-1-benzopyran-4-one (32 mg, yield :20%).


NMR(CDCl₃) δ : 7.14-7.72(8H, m), 8.31-8.35(1H, m), 8.68(2H, s), 11.63(1H, s).

Melting point: 212°C

Compound C-48

5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylic acid dimethylamide

[0364]



(C-42) To a suspension of 2',4',6'-trihydroxyacetophenone (18.6 g, 100 mmol) and powder potassium carbonate (20.7 g, 150 mmol) in DMF (140 ml), was added 4-fluorobenzyl bromide (13.7 ml, 110 mmol) under ice-cooling and the mixture was stirred at room temperature for 1 hour 15 minutes. Water and 2N hydrochloric acid were added thereto and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, and dried, then the solvent was evaporated under reduced pressure. The residue was purified with column chro-

matography(ethyl acetate:n-hexane=1:3-1:2) to give crude crystals, which were washed with diisopropylether to give 1-[2-(4-fluorobenzyloxy)-4,6-dihydroxyphenyl]etanone(2.62 g, yield :10%).

NMR(CDCl₃)δ: 2.45(3H, s), 5.13(2H, s), 5.88(1H, d, J=1.5Hz), 6.07(1H, d, J=1.5Hz), 7.21-7.28(2H, m), 7.54-7.61(2H, m), 10.59(1H, brs), 13.81(1H, s).

(C-43) According to the method of compound C-38, the above-mentioned compound C-42(2.05 g, 7.42 mmol) and 2-methyl-2H-[1,2,4]triazole-3-carboxylate ethyl ester(2.30 g, 14.8 mmol) were subjected to cyclization reaction to give 5-[(4-fluorobenzyl)oxy]-7-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one(0.90 g, yield :33%).

NMR(DMSO-d₆)δ: 4.21(3H, s), 5.19(2H, s), 6.52-6.67(3H, m), 7.21-7.29(2H, m), 7.63-7.70(2H, m), 8.14(1H, s), 11.1(1H, brs).

(C-44) To a suspension of the above-mentioned compound C-43(0.90 g, 2.45 mmol) and triethylamine(1.02 ml, 7.35 mmol) in methylene chloride(140 ml), was added anhydrous trifluoromethanesulfonic acid(0.62 ml, 3.68 mmol) under ice-cooling and the mixture was stirred for 40 minutes. Ice water was added thereto and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, and dried, then the solvent was evaporated under reduced pressure. The residue was purified with column chromatography (ethyl acetate:n-hexane=1:1-2:1) to give trifluoromethanesulfonic acid 5-[(4-fluorobenzyl)oxy]-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-yl ester(1.13 g, yield :93%).

NMR(CDCl₃)δ: 4.28(3H, s), 5.26(2H, s), 6.81(1H, d, J=2.4Hz), 7.05-7.16(4H, m), 7.56-7.62(2H, m), 8.01(1H, s).

(C-45) To a suspension of the above-mentioned compound C-44(1.06 g, 2.12 mmol), acetic acid palladium(II)(48 mg, 0.21 mmol) and 1,3-bis(diphenylphosphino)propane(109 mg, 0.27 mmol) in DMSO (30 ml), were added at room temperature triethylamine(3.0 ml, 15.1 mmol), and methyl alcohol(10 ml) successively, and the mixture was stirred under added 1 atm CC atmosphere at 70°C for 55 minutes. After cooling, 2N hydrochloric acid 10 ml and water 70 ml were added thereto, and the precipitated crystals were filtered off, washed with water, and dried. The crude crystals were recrystallized from ethyl acetate / methyl alcohol to give 5-[(4-fluorobenzyl)oxy]-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylate methyl ester(486 mg, yield :56%).

NMR(CDCl₃)δ: 4.00(3H, s), 4.32(3H, s), 5.30(2H, s), 7.08-7.15(2H, m), 7.10(1H, s), 7.56(1H, d, J=1.5Hz), 7.61-7.67(2H, m), 7.77(1H, d, J=1.5Hz), 8.00(1H, s).

(C-46) To a solution of the above-mentioned compound C-45(325 mg, 0.79 mmol) in DMSO(16 ml), was added 2N sodium hydroxide aqueous solution 437μl and the mixture was stirred at room temperature for 2 hours. To the solution were added 2N hydrochloric acid and water, then the precipitated crystals were filtered, washed with water, and dried to give 5-[(4-fluorobenzyl)oxy]-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylic acid(300 mg, yield :86%).

NMR(DMSO-d₆)δ: 4.29(3H, s), 5.35(2H, s), 6.86(1H, d, J=1.2Hz), 7.23-7.31(2H, m), 7.57(1H, s), 7.68-7.77(2H, m), 7.83(1H, s), 8.18(1H, d, J=1.2Hz).

(C-47) To a solution of the above-mentioned compound C-46(140 mg, 0.35 mmol) in DMF(7 ml), were added at room temperature 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (75 mg, 0.40 mmol) and 1-hydroxybenzotriazole (55 mg, 0.35 mmol) and the mixture was stirred for 10 minutes. A 2N dimethylamine THF solution (195μl, 0.40 mmol) was added thereto, and the mixture was stirred for 40 minutes. To the solution were added 2N hydrochloric acid and ice water, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine and dried, then the solvent was evaporated under reduced pressure. The residue was purified with column chromatography(chloroform:methyl alcohol=50:1-20:1) to give 5-[(4-fluorobenzyl)oxy]-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylic acid dimethylamide(104 mg, yield :90%).

NMR(CDCl₃)δ: 2.93(3H, s), 3.14(3H, s), 4.28(3H, s), 5.27(2H, s), 6.91(1H, d, J=1.5Hz), 7.06(1H, s), 7.07-7.14(2H, m), 7.15(1H, d, J=1.5Hz), 7.57-7.63(2H, m), 8.00(1H, s).

(C-48) According to the method of compound C-39, the above-mentioned compound C-47(103 mg, 0.24 mmol) was oxidized with dimethyldioxylane to give 5-[(4 fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylic acid dimethylamide(15 mg, yield :14%).

NMR(DMSO-d₆)δ: 2.90(3H, s), 3.02(3H, s), 4.00(3H, s), 5.33(2H, s), 7.05(1H, s), 7.23-7.31(3H, m), 7.70-7.76(2H, m), 8.21(1H, s), 10.22(1H, brs).

Melting point:227-229°C

[0365] The following compounds were prepared according to the method above.

(C-48a) 5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1 benzopyrane-4-one-7-carboxylate methyl ester

NMR(DMSO-d₆)δ: 3.94(3H, s), 4.02(3H, s), 5.39(2H, s), 7.24-7.32(2H, m), 7.51(1H, s), 7.72-7.82(3H, m), 8.24(1H, s), 10.36(1H, brs).

Melting point: 253-255°C

(C-48b) 5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylic acid


NMR(DMSO- d_6) δ : 4.01(3H, s), 5.38(2H, s), 7.24-7.32(2H, m), 7.51(1H, s), 7.69(1H, s), 7.74-7.82(2H, m), 8.23(1H, s), 10.34(1H, brs).

Melting point: 280-282°C

Compound C-53

5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-8-carboxylate methyl ester

[0366]



(C-49) To a solution of compound C-37 (10.0 g, 38.4 mmol) in methylene chloride (150 ml), was added phenyltrimethylammonium tribromide (14.4 g, 38.4 mmol) under ice-cooling and the mixture was stirred for 2 hours 20 minutes. A 10% sodium hydrogen sulfate aqueous solution was added thereto and methylene chloride was evaporated under reduced pressure, to which was added water, followed by extraction with ethyl acetate. The extract was washed with water and saturated brine, and dried, then the solvent was evaporated under reduced pressure. The residue was crystallized from diisopropylether / ethyl acetate to give 1-[3-bromo-6-(4-fluorobenzyl)oxy]-2-hydroxyphenyl]ethanone (9.88 g, yield : 76%).

NMR(CDCl₃) δ : 2.60(3H, s), 5.09(2H, s), 6.42(1H, d, J=9.0Hz), 7.07-7.14(2H, m), 7.37-7.43(2H, m), 7.60(1H, d, J=9.0Hz), 14.02(1H, s).

(C-50) According to the method of compound C-38, cyclization using as starting materials the above-mentioned compound C-49 (150 mg, 11.8 mmol) and 2-methyl-2H-[1,2,4]triazole-3-carboxylate ethyl ester (3.66 g, 23.6 mmol) gave 8-bromo-5-[(4-fluorobenzyl)oxy]-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one (296 mg, yield : 85%).

NMR(CDCl₃) δ : 4.46(3H, s), 5.23(2H, s), 6.85(1H, d, J=9.0Hz), 7.06-7.14(2H, m), 7.18(1H, s), 7.55-7.62(2H, m), 7.81(1H, d, J=9.0Hz), 7.99(1H, s).

(C-51) According to the method of compound C-39, the above-mentioned compound C-50 (1.0 g, 0.42 mmol) as a starting material was oxidized with dimethyldioxysilane to give crude substituted 3-hydroxybenzopyranone (550 mg). The obtained compound was dissolved to DMF (15 ml) and 60% sodium hydride (54 mg, 1.35 mmol) was added thereto under ice cooling. The mixture was stirred at room temperature for 15 minutes and chloromethyl methyl ether (93 μ l, 1.35 mmol) was added dropwise under ice-cooling, and the mixture was stirred at room temperature for 30 minutes. To the solution was added ice water, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried, then the solvent was evaporated under reduced

pressure. The residue was purified with column chromatography(ethyl acetate:n-hexane=1:2)to give 8-bromo-5-[(4-fluorobenzyl)oxy]-3-methoxymethoxy-2-(2-methyl-2*H*-[1,2,4]triazole-3-yl)-4*H*-1-benzopyrane-4-one(119 mg, yield :13%).

NMR(CDCl₃)δ: 3.05(3H, s), 4.11(3H, s), 5.22(2H, s), 5.25(2H, s), 6.80(1H, d, J=9.0Hz), 7.07-7.14(2H, m), 7.56-7.61(2H, m), 7.80(1H, d, J=9.0Hz), 8.11(1H, s).

(C-52) To a suspension of the above-mentioned compound C-51(100 mg, 0.20 mmol), acetic acid palladium(II) (4.6 mg, 0.02 mmol) and 1,3-bis(diphenylphosphino)propane(10.5 mg, 0.025 mmol)in DMF(3 ml), wre added at room temperature triethylamine(0.28 ml, 2.04 mmol)and methyl alcohol(1.0 ml) successively, then the mixture was stirred under 1 atm CO atomospher at 70°C for 18 hours. After cooling, water 6 ml was added thereto, and the precipitated crystals were filtered off, washed with water, and dried. The crude crystals were purified with column chromatography(ethyl acetate:n-hexane=1:2-1:3) to give 5-[(4-fluorobenzyl)oxy]-3-methoxymethoxy-2-(2-methyl-2*H*-[1,2,4]triazole-3-yl)-4*H*-1-benzopyrane-4-one-8-carboxylate methyl ester(53 mg, yield :55%).

NMR(CDCl₃)δ: 3.03(3H, s), 3.90(3H, s), 4.11(3H, s), 5.22(2H, s), 5.33(2H, s), 6.91(1H, d, J=9.0Hz), 7.09-7.15(2H, m), 7.57-7.63(2H, m), 8.09(1H, s), 8.25(1H, d, J=9.0Hz).

(C-53) To a suspension of the above-mentioned compound C-52 in tetrahydrofuran(1 ml) and methyl alcohol(1 ml), was added a solution of concentrated hydrochloric acid 36 μl in methyl alcohol(0.5 ml) at room temperature, and the mixture was stirred at 50°C for 10 minutes. The mixture was ice-cooled, and saturated sodium hydrogen carbonate aqueous solution 0.5 ml and water 2 ml were added thereto, then the precipitated crystals were filtered off, washed with water, and dried to give 5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2*H*-[1,2,4]triazole-3-yl)-4*H*-1-benzopyrane-4-one-8-carboxylate methyl ester(38 mg, yield :84%).

NMR(CDCl₃)δ: 3.93(3H, s), 4.48(3H, s), 5.32(2H, s), 6.90(1H, d, J=9.0Hz), 7.09-7.15(2H, m), 7.66-7.72(2H, m), 8.05(1H, s), 8.25(1H, d, J=9.0Hz), 10.94(1H, brs).

Melting point:236-237°C

Elementary analysis as C ₂₁ H ₁₆ FN ₃ O ₆ 0.1H ₂ O				
Calcd. (%)	C, 59.05;	H, 3.82;	N, 9.84;	F, 4.45.
Found (%)	C, 58.92;	H, 3.78;	N, 9.62;	F, 4.45.

[0367] The following compound was prepared as well as above.


(C-53a) 8-bromo-5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2*H*-[1,2,4]triazole-3-yl)-4*H*-1-benzopyrane-4-one
NMR(CDCl₃)δ: 4.53(3H, s), 5.24(2H, s), 6.81(1H, d, J=9.0Hz), 7.08-7.14(2H, m), 7.65-7.70(2H, m), 7.82(1H, d, J=9.0Hz), 8.06(1H, s), 10.86(1H, brs).

Melting point:220-223°C

Compound C-57

5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylic acid amide

[0368]



(C-54) To a solution of compound C-48a (520 mg, 1.22 mmol) in DMF(10.4 ml), were added dropwise triethylamine (0.77 ml, 5.52 mmol) and chloromethyl methyl ether(0.28 ml, 3.69 mmol) at room temperature and the mixture was stirred for 1 hour 30 minute.

Water 15 ml was added thereto and the precipitated crystals were filtered off and dried to give 5-[(4-fluorobenzyl)oxy]-3-methoxymethoxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylate methyl ester(543 mg, yield :95%).

NMR(CDCl₃)δ: 2.99(3H, s), 3.97(3H, s), 4.03(3H, s), 5.20(2H, s), 5.31(2H, s), 7.08-7.16(2H, m), 7.52(1H, d, J=1.2Hz), 7.60-7.67(2H, m), 7.78(1H, d, J=1.2Hz), 8.10(1H, s).

(C-55) To a solution of the above-mentioned compound C-54(100 mg, 0.21 mmol) in DMSO(4 ml), was added a 2N sodium hydroxide aqueous solution 128μl and the mixture was stirred at room temperature for 30 minutes. 2N hydrochloric acid and water were added thereto and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine and dried, then the solvent was evaporated under reduced pressure. To the residue were added methyl alcohol(2 ml)and diisopropylether(4 ml)and the precipitated crystals were filtered off, washed with isopropylether, and dried to give 5-[(4-fluorobenzyl)oxy]-3-methoxymethoxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylic acid(78 g, yield :80%).

NMR(DMSO-d₆)δ: 2.91(3H, s), 3.99(3H, s), 5.08(2H, s), 5.37(2H, s), 7.24-7.33(2H, m), 7.55(1H, s), 7.65-7.76(3H, m), 8.25(1H, s).

(C-56) To a solution of the above-mentioned compound C-55(140 mg, 0.16 mmol)in DMF(3 ml), were added at room temperature 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (38 mg, 0.20 mmol) and 1-hydroxybenzotriazole (25 mg, 0.16 mmol) and the mixture was stirred for 10 minutes. To the mixture were added ammonium chloride (26 mg, 0.49 mmol) and triethylamine (92μl, 0.66 mmol) and the mixture was stirred for 45 hours. Water was added thereto and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, and dried, then the solvent was evaporated under reduced pressure. The residue was purified column chromatography(chloroform:methyl alcohol=20:1-15:1)to give 5-[(4-fluorobenzyl)oxy]-3-methoxymethoxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylic acid amide(62 mg, yield : 83%).

NMR(DMSO-d₆)δ: 2.89(3H, s), 3.98(3H, s), 5.07(2H, s), 5.35(2H, s), 7.25-7.33(2H, m), 7.56(1H, s), 7.68-7.75(3H, m), 8.25(1H, s), 8.27(1H, brs).

[0369] The following compound was prepared as well as above.

(C-56a) 5-[(4-fluorobenzyl)oxy]-3-methoxymethoxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylic acid methoxymethylamide

NMR(CDCl₃)δ: 2.99(3H, s), 3.38(3H, s), 3.50(3H, s), 4.03(3H, s), 5.20(2H, s), 5.29(2H, s), 7.07-7.15(2H, m), 7.17

(1H, d, J=1.2Hz), 7.43(1H, d, J=1.2Hz), 7.57-7.64(2H, m), 8.10(1H, s).

(C-57) According to the method of compound C-53, the above-mentioned compound C-56(61 mg, 0.13 mmol) as a starting material was deprotected to give 5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylic acid amide(37 mg, yield :67%).

NMR(DMSO- d_6) δ : 4.00(3H, s), 5.35(2H, s), 7.23-7.33(2H, m), 7.52(1H, s), 7.70-7.83(4H, m), 8.22(1H, s), 8.26(1H, brs), 10.28(1H, brs).

Melting point:257-258°C

[0370] The following compound was prepared as well as above.

(C-57a) 5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-7-carboxylic acid methoxymethylamide


NMR(CDCl₃) δ : 3.40(3H, s), 3.51(3H, s), 4.31(3H, s), 5.28(2H, s), 7.07-7.28(3H, m), 7.40(1H, s), 7.63-7.72(2H, m), 8.06(1H, s), 10.07(1H, brs).

Melting point:220-221°C

Compound C-60

5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-8-carboxylic acid dimethylamide

[0371]



(C-58) According to the method of compound C-55, compound C-52(120 mg, 0.26 mmol) as a starting material was hydrolyzed at the ester moiety to give 5-[(4-fluorobenzyl)oxy]-3-methoxymethoxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-8-carboxylic acid(57 mg, yield :49%).

NMR(CDCl₃) δ : 3.05(3H, s), 4.09(3H, s), 5.23(2H, s), 5.32(2H, s), 6.90(1H, d, J=9.0Hz), 7.08-7.17(2H, m), 7.56-7.64(2H, m), 8.14(1H, s), 8.27(1H, d, J=9.0Hz).

(C-59) According to the method of compound C-56, the above-mentioned compound C-58(56 mg, 0.12 mmol) as a starting material was subjected to amidation to give 5-[(4-fluorobenzyl)oxy]-3-methoxymethoxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-8-carboxylic acid dimethylamide(52 mg, yield :88%).

NMR(CDCl₃) δ : 3.00(3H, s), 3.01(3H, s), 3.11(3H, s), 4.01(3H, s), 5.21(2H, s), 5.29(2H, s), 6.92(1H, d, J=8.7Hz), 7.07-7.17(2H, m), 7.55-7.64(3H, m), 8.06(1H, s).

(C-60) According to the method of compound C-53, the above-mentioned compound C-59(51 mg, 0.11 mmol) as a starting material was deprotected to give 5-[(4-fluorobenzyl)oxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one-8-carboxylic acid dimethylamide(34 mg, yield :74%).


NMR(CDCl₃) δ : 2.95(3H, s), 3.16(3H, s), 4.21(3H, s), 5.27(2H, s), 6.91(1H, d, J=8.7Hz), 7.07-7.16(2H, m), 7.53(1H, d, J=8.7Hz), 7.64-7.72(2H, m), 8.06(1H, s), 10.41(1H, brs).

Melting point:246-247°C

Compound C-63

5-[2-(4-fluorophenyl)ethoxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one

[0372]



(C-61) According to the method of compound C-38, 2',6'-dihydroxyacetophenone (1.0 g, 6.57 mmol) and 2-methyl-2H-[1,2,4]triazole-3-carboxylate ethyl ester (2.0 g, 12.9 mmol) as starting materials, were subjected to cyclization to give 5-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one (1.13 g, yield : 71%).

NMR(CDCl₃) δ : 4.32(3H, s), 6.89(1H, dd, J=0.9, 8.4Hz), 6.98(1H, dd, J=0.9, 8.4Hz), 7.14(1H, s), 7.61(1H, t, J=8.4Hz), 8.00(1H, s), 12.34(1H, s).

(C-62) To a suspension of the above-mentioned compound C-62 (500 mg, 2.06 mmol), 2-(4-fluorophenyl)ethanol (0.52 ml, 4.16 mmol), and triphenylphosphine (1.08 g, 4.12 mmol) in tetrahydrofuran (10 ml), was added azodicarboxylic acid diisopropyl (0.81 ml, 4.11 mmol) under ice-cooling and the mixture was stirred at room temperature for 2 hours. To the solution were added water and ethyl acetate, and the precipitated crystals were filtered off, washed with water and ethyl acetate, and dried to give 5-[2-(4-fluorophenyl)ethoxy]-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one (523 mg, yield : 70%). The filtrate was extracted with ethyl acetate, and the extract was washed with saturated brine and water, and dried, then the solvent was evaporated under reduced pressure. To the residue was added ethyl acetate and the precipitated crystals were filtered off, washed with diisopropylether, and dried to give 5-[2-(4-fluorophenyl)ethoxy]-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one (122 mg, yield : 16%).

NMR(CDCl₃) δ : 3.23(2H, t, J=6.6Hz), 4.25(2H, t, J=6.6Hz), 4.28(3H, s), 6.82(1H, d, J=7.5Hz), 6.07-7.09(4H, m), 7.40-7.60(3H, m), 7.99(1H, s).

(C-63) According to the method of compound C-39, the above-mentioned compound C-62 (200 mg, 0.55 mmol) as a starting material was oxidized with dimethyldioxylane to give 5-[2-(4-fluorophenyl)ethoxy]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one (86 mg, yield : 41%).


NMR(CDCl₃) δ : 3.24(2H, t, J=6.3Hz), 4.26(2H, t, J=6.3Hz), 4.29(3H, s), 6.75(1H, d, J=8.1Hz), 6.97-7.08(3H, m), 7.44-7.58(3H, m), 8.05(1H, s), 9.72(1H, brs).

Melting point: 215-217°C

Compound C-66

5-[2-(4-fluorophenyl)ethyl]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyrane-4-one

[0373]



(C-64) To a solution of compound C-61 (500 mg, 2.06 mmol) and triethylamine (1.15 ml, 8.25 mmol) in methylene chloride (10 ml), was added anhydrous trifluoromethanesulfonic acid (0.69 ml, 4.10 mmol) under ice-cooling and the mixture was stirred for 1 hour 30 minutes. To the solution was added ice water and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine and dried, and the solvent was evaporated under reduced pressure. The residue was purified with column chromatography (ethyl acetate : n-hexane = 1:1) and recrystallized from acetone / hexane to give trifluoromethanesulfonic acid 2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyran-4-one-5-yl ester (495 mg, yield : 64%).

NMR(CDCl₃) δ : 4.31(3H, s), 7.14(1H, s), 7.31(1H, d, J=7.8Hz), 7.63(1H, dd, J=0.9, 8.7Hz), 7.77-7.83(1H, m), 8.02(1H, s).

(C-65) To a suspension of zinc (310 mg, 4.74 mmol) in tetrahydrofuran (2.0 ml), was added chlorotrimethylsilane (25 μ l, 0.27 mmol) at room temperature for 5 minutes. To the mixture was added a tetrahydrofuran (2.0 ml) solution containing 1-fluoro-4-(2-iodoethyl)benzene (1.0 g, 4.0 mmol), synthesized from 2-(4-fluorophenyl)ethanol according to the method of J. Org. Chem., 1979, 44, p1247, and the mixture was stirred at 40°C for 4 hour and allowed to stand at room temperature overnight. To a solution of compound C-64 (417 mg, 1.11 mmol) in tetrahydrofuran (8.3 ml), were added HMPA (1.0 ml), tetrakis(triphenyl)phosphine palladium (64 mg, 0.06 mmol) and the above-mentioned alkylzinc solution (2.8 ml) at 60°C for 2.5 hour. After cooling, water was added thereto, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, and dried, then the solvent was evaporated under reduced pressure. The residue was purified with column chromatography (ethyl acetate : n-hexane = 1:1) and recrystallized from ethyl acetate / hexane to give 5-[2-(4-fluorophenyl)ethyl]-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyran-4-one (256 mg, yield : 66%).

NMR(CDCl₃) δ : 2.90(2H, t, J=8.1Hz), 3.55(2H, t, J=8.1Hz), 4.32(3H, s), 6.93-7.02(2H, m), 7.09-7.14(3H, m), 7.22-7.29(2H, m), 7.41(1H, dd, J=1.2, 8.4Hz), 7.57(1H, dd, J=7.5, 8.4Hz), 8.01(1H, s).

(C-66) According to the method of compound C-39, the above-mentioned compound C-65 (200 mg, 0.57 mmol) was oxidized with dimethyldioxylane to give 5-[2-(4-fluorophenyl)ethyl]-3-hydroxy-2-(2-methyl-2H-[1,2,4]triazole-3-yl)-4H-1-benzopyran-4-one (99 mg, yield : 47%).


NMR(CDCl₃) δ : 2.91(2H, t, J=8.1Hz), 3.57(2H, t, J=8.1Hz), 4.36(3H, s), 6.93-7.02(2H, m), 7.10(1H, dd, J=1.2, 7.5Hz), 7.28-7.36(2H, m), 7.38(1H, dd, J=1.2, 8.7Hz), 7.56(1H, dd, J=7.5, 8.7Hz), 8.07(1H, s), 10.15(1H, brs).

Melting point: 192-193°C

Compound C-69

3-hydroxy-2-[1-(4-fluorobenzyl)-1H-[1,2,4]triazole-3-yl]-4H-1-benzopyrane-4-one

[0374]



(C-67) To a suspension of 1H-[1,2,4]triazole-3-carboxylate ethyl ester (Farmako, 1997, 52, p429) (1.0 g, 7.09 mmol) in ethanol (25 ml), were added 20% sodium ethoxide ethanol solution 3.3 ml and 4-fluorobenzyl bromide (0.93 ml, 7.46 mmol) under ice-cooling and the mixture was stirred for 1.5 hour. Further, the mixture was stirred at room temperature for 30 minutes and at 80°C for 40 minutes. After cooling, water was added to the solution and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate:n-hexane=1:1-1:3) to give 1-(4-fluorobenzyl)-1H-[1,2,4]triazole-3-carboxylate ethyl ester (754 mg, yield : 42%).

NMR(CDCl₃)δ: 1.44(3H, t, J=7.2Hz), 4.48(2H, t, J=7.2Hz), 5.39(2H, s), 7.00-7.13(2H, m), 7.25-7.34(2H, m), 8.08(1H, s).

(C-68) According to the method of compound C-38, 2'-hydroxyacetophenone (145 mg, 1.07 mmol) and the above-mentioned compound C-67 (533 mg, 2.14 mmol) as starting materials were subjected to cyclization to give 2-[1-(4-fluorobenzyl)-1H-[1,2,4]triazole-3-yl]-4H-1-benzopyran-4-one (205 mg, yield : 60%).

NMR(CDCl₃)δ: 5.43(2H, s), 7.07-7.16(2H, m), 7.31-7.47(3H, m), 7.64-7.75(2H, m), 8.14(1H, s), 8.22-8.27(1H, m).

(C-69) According to the method of compound C-39, the above-mentioned compound C-68 (204 mg, 0.63 mmol) as a starting material was oxidized with dimethyldioxylane to give 3-hydroxy-2-[1-(4-fluorobenzyl)-1H-[1,2,4]triazole-3-yl]-4H-1-benzopyran-4-one (137 mg, yield : 64%).


NMR(CDCl₃)δ: 5.49(2H, s), 7.09-7.18(2H, m), 7.34-7.46(3H, m), 7.63-7.75(2H, m), 8.22(1H, s), 8.30-8.36(1H, m), 9.45(1H, brs).

Melting point: 260-262°C

Compound C-71

3-hydroxy-4*H*-1-benzopyrane-4-one-2-carboxylic acid 4-fluorobenzylamide

[0375]



(C-70) To a solution of compound C-5(200 mg, 0.68 mmol) in DMF(4 ml), were added a room temperature 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (155 mg 0.81 mmol), 4-fluorobenzylamine (85 μ l, 0.74 mmol) and 1-hydroxybenzotriazole (10 mg 0.07 mmol) and the mixture was stirred at room temperature for 3 hour. To the solution was added water and 2N hydrochloric acid and the mixture was extracted with ethyl acetate. The extract was washed with a saturated sodium hydrogen carbonate aqueous solution and saturated brine, and dried. The solvent was evaporated under reduced pressure, to which was added diisopropylether(6 ml) and hexane(3 ml), then the precipitated crystals were filtered off, washed with diisopropylether, and dried to give 3-benzyloxy-4-oxo-4*H*-chromene-2-carboxylic acid 4-fluorobenzylamide(231 mg, yield :85%).

NMR(DMSO- d_6) δ : 4.45(2H, d, $J=6.0$ Hz), 5.15(2H, s), 7.07-7.16(2H, m), 7.30-7.46(7H, m), 7.51-7.58(1H, m), 7.70-7.76(1H, m), 7.84-7.91(1H, m), 8.14(1H, d, $J=7.8$ Hz), 9.33(1H, d, $J=6.0$ Hz).

(C-71) According to the method of compound C-8, the above-mentioned compound C-70(120 mg, 0.30 mmol)as a starting material was deprotected to give 3-hydroxy-4*H*-1-benzopyrane-4-one-2-carboxylic acid 4-fluorobenzylamide(62 mg, yield :67%). NMR(CDCl $_3$) δ : 4.67(2H, d, $J=6.0$ Hz), 7.04-7.14(2H, m), 7.34-7.49(4H, m), 7.67-7.75(1H, m), 7.84-7.91(1H, m), 8.28(1H, dd, $J=1.5, 8.1$ Hz), 10.72(1H, brs).


Melting point:235-236°C

D group compound

Compound D-5

2-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-3-hydroxy-1*H*-quinoline-4-one

[0376]



(D-1a,D-1b) To a solution of 2-ethoxycarbonyl-3-methoxy-1*H*-quinoline-4-one(1.236g, 5mmol), synthesized according to J.Heterocyclic Chem, 24, p1649, 1987, in dimethylformamide(10ml), was added potassium carbonate (691mg, 5mmol) and the mixture was stirred at room temperature for 5 minutes. Iodomethane(0.63ml, 10.1mmol) was added thereto, and the mixture was stirred for 2 hours. To the mixture was poured ice water, which was extracted with ethyl acetate 3 times. The extract was washed and dried, then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography(100g column B, toluene:acetone=24:1) to give 2-ethoxycarbonyl-3,4-dimethoxyquinoline(890mg, yield:34.1%) and 2-ethoxycarbonyl-3-methoxy-1-methylquinoline-4-one(1.583g, yield:60.6%).

D-1a: oily product

NMR(CDCl₃) δ :1.47(3H, t, J=7.2Hz), 3.98(3H, s), 4.22(3H, s), 4.54(2H, q, J=7.2Hz), 7.54-7.59(1H, m), 7.65-7.70(1H, m), 8.09-8.15(2H, m).

D-1b: Melting point:103°C

NMR(CDCl₃) δ :1.46(3H, t, J=7.2Hz), 3.72(3H, s), 3.97(3H, s), 4.53(2H, q, J=7.2Hz), 7.40(1H, m), 7.47(1H, d, J=8.7Hz), 7.70(1H, m), 8.52(1H, m).

(D-2) To a solution of the above-mentioned compound D-1a(885mg, 3.39mmol) in ethanol(4.5ml), was added hydrazine hydrate(0.34ml, 7.0mmol) and the mixture was stirred for 30 minutes and allowed to stand at room temperature overnight. The mixture was stirred at 90°C for 4 hour and water was added thereto, then the mixture was concentrated under reduced pressure and extracted with ethyl acetate. The extract was washed and dried, then the solvent was evaporated under reduced pressure to give 3,4-dimethoxyquinolinecarboxylic acid hydrazide (832mg, yield:99.3%).

NMR(CDCl₃) δ :2.79(3H, bs), 4.02(3H, s), 4.24(3H, s), 7.55-7.60(1H, m), 7.65-7.71(1H, m), 8.02(1H, d, J=8.4Hz), 8.14(1H, d, J=7.8Hz).

(D-3) To a solution of the above-mentioned compound D-2(826mg, 3.34mmol) and 4-fluorophenylacetic acid (592mg, 3.84mmol) in tetrahydrofuran(10ml), were added 1-hydroxybenzotriazole(90mg, 0.67mmol) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloric acid(768mg, 4mmol) and the mixture was stirred for 6 hours. To the solution was added ice water and the mixture was extracted with ethyl acetate, washed, dried, and concentrated under reduced pressure. Diethyl ether was added thereto and the precipitated crystals were filtered off to give 3,4-dimethoxyquinoline-2-carboxylic acid N-[2-(4-fluorophenyl)acetyl]hydrazide (968mg, yield:75.6%).

Melting point:172-173°C

NMR(CDCl₃) δ : 3.73(2H, s), 3.99(3H, s), 4.23(3H, s), 7.02-7.08(2H, m), 7.33-7.38(2H, m), 7.55-7.60(1H, m), 7.65-7.70(1H, m), 8.04(1H, d, J=8.4Hz), 8.12(1H, d, J=8.4Hz), 8.83(1H, bs), 10.35(1H, bs).

(D-4) To a solution of triphenylphosphine (738mg, 2.81mmol) in methylene chloride(15ml), was added a solution of bromine(0.144ml, 2.81mmol) in methylene chloride(2ml) under ice-cooling, and the mixture was stirred at room temperature for 30 minutes: After ice-cooling, a solution of triethylamine(0.82ml, 5.87mmol) in methylene chloride (2ml) was added dropwise, followed by adding the above-mentioned compound D-3(769mg, 2.01mmol), and the mixture was stirred for 1 hour 20 minutes. After further stirring at room temperature for 15 minutes, the solution was poured into ice water, and the mixture was extracted with chloroform. The extract was washed and dried, and the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (eluent: toluene:acetone=7:1) to give 2-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-3,4-dimethoxyquinoline(615mg, yield:83.9%).

Melting point:126°C

NMR(CDCl₃) δ : 3.99(3H, s), 4.27(3H, s), 4.36(2H, s), 7.02-7.08(2H, m), 7.36-7.41(2H, m), 7.57-7.63(1H, m), 7.68-7.74(1H, m), 8.12-8.19(2H, m).

(D-5) To a solution of sodium iodide(4.12g, 27.5mmol) in acetonitrile(116ml), was added trimethylchlorosilane (3.49ml, 27.5mmol) and the mixture was stirred for 20 minutes, followed by adding the above-mentioned compound D-4(628mg, 1.72mmol). After stirring for 40 minutes, the mixture was refluxed for 2 hours. The reaction mixture was poured into ice water, which was stirred at room temperature for 1 hour. The precipitated yellow crystals were filtered off and the obtained crude crystals(532mg, yield:91.7%) were dissolved into dimethylformamide(100ml) under heating. The mixture was filtered and concentrated to the volume of 30ml, to which was added water (20ml) and the mixture was allowed to stand at room temperature overnight. The precipitated crystals were filtered off to give 2-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-3-hydroxy-1*H*-quinoline-4-one(505mg, yield:87%).

Melting point:>300°C

Elementary analysis as C ₁₈ H ₁₂ FN ₃ O ₃				
Calcd. (%)	C, 64.09;	H, 3.59;	N, 12.46;	F, 5.63.
Found (%)	C, 64.05;	H, 3.49;	N, 12.54;	F, 5.46.


Calcd. (%)	C, 64.09;	H, 3.59;	N, 12.46;	F, 5.63.
Found (%)	C, 64.05;	H, 3.49;	N, 12.54;	F, 5.46.

NMR(DMSO-*d*₆) δ : 4.46(2H, s), 7.19-7.31(3H, m), 7.43-7.48(2H, m), 7.61-7.67(1H, m), 7.88(1H, d, J=8.7Hz), 8.13(1H, dd, J=1.2, 8.4Hz).

Compound D-9

2-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-3-hydroxy-1-methyl-1*H*-quinoline-4-one

[0377]



(D-6) To a solution of D-1b(1.21g, 4.63mmol)in ethanol(15.3ml), was added a 1N sodium hydroxide aqueous solution(15.3ml, 15.3mmol), and the mixture was refluxed for 2 hours.

After ice-cooling, water (25ml) and a 1N hydrochloric acid aqueous solution(18.5ml, 18.5mmol)were added to make the pH 1 to 2, and the precipitated crystals were filtered off and washed with water to give 3-methoxy-1-methyl-4-oxo-1,4-dihydroquinoline-2-carboxylic acid(1.122g, yield: 100%).

Melting point:155-156°C(decomp.)

NMR(DMSO- d_6) δ : 3.76(3H, s), 3.78(3H, s), 7.41-7.46(1H, m), 7.78-7.80(2H, m), 8.24-8.27(1H, m).

(D-7) To a solution of the above-mentioned compound D-7(997mg, 4.28mmol) and 4-fluorophenylacetic acid hydrazide(1.08g, 6.41mmol)in dimethylformamide(17ml), were added 1-hydroxybenzotriazole(866mg, 6.41mmol)and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloric acid(1.23g, 6.41mmol)and the mixture was stirred for 3 hours. 4-Fluorophenylacetic acid hydrazide (1.08g, 6.41mmol)was added thereto and the mixture was allowed to stand at room temperature overnight. To the solution was added ice water and the precipitated crystals were filtered off, washed with water to give 3-methoxy-1-methyl-4-oxo-1,4-dihydroquinoline-2-carboxylic acid N'-[2-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]hydrazide (969mg, yield:59%).

Melting point: 140-142-(solid)-212-213°C

NMR(CDCl₃) δ : 3.75(2H, s), 3.77(3H, s), 3.79(3H, s), 7.03-7.08(2H, m), 7.26-7.47(5H, m), 8.17(1H, dd, J=1.2, 8.4Hz), 8.44(1H, bs), 10.73(1H, bs).

(D-8) To a solution of triphenylphosphine(929mg, 3.54mmol)in methylene chloride(35ml)was added a solution of bromine(0.182ml, 3.54mmol) in methylene chloride(2ml) under ice-cooling, and the mixture was stirred at room temperature for 30 minutes. After ice-cooling, a solution of triethylamine(1.03ml, 7.37mmol)in methylene chloride (2ml) was added dropwise, and the above-mentioned compound D-7(905mg, 2.36mmol)was added thereto, and the mixture was stirred for 1 hour 30 minutes. The solution was poured into ice water, which was extracted with chloroform, and then the precipitated unreacted materials were filtered off. The extract was washed and dried, and then the solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography(100g column B, toluene:acetone=6:1)to give 2-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-3-methoxy-1-methyl-1*H*-quinoline-4-one(527mg, yield:55.1%).

Melting point:156-157 °C

NMR(CDCl₃) δ : 3.60(3H, s), 3.84(3H, s), 4.33(2H, s), 7.04-7.10(2H, m), 7.32-7.36(2H, m), 7.40-7.46(1H, m), 7.51(1H, d, J=8.7Hz), 7.71-7.77(1H, m), 8.53(1H, dd, J=1.5, 8.1Hz).

(D-9) To a solution of sodium iodide(1.62g, 10.8mmol)in acetonitrile(90ml), was added trimethylchlorosilane (1.36ml, 10.7mmol)at room temperature and the mixture was stirred for 30 minutes. The above-mentioned compound D-8(490mg, 1.34mmol)was added thereto and the mixture was stirred for 30 minutes and refluxed for 2 hours. After cooling, the reaction mixture was poured to ice water and the mixture was stirred at room temperature for 1 hour. The precipitated yellow crystals were filtered off as crude crystals(412mg, yield:87.5%). The crystals

were dissolved to methylene chloride, which was filtered with a millipore filter, and then the methylene chloride was concentrated in water bath while adding methyl alcohol thereto. After ice-cooling, the precipitated crystals were filtered off and washed with methyl alcohol to give 2-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-3-hydroxy-1-methyl-1*H*-quinoline-4-one (360mg, yield:76.4%).

Melting point:222°C

Elementary analysis as C₁₉H₁₄FN₃O₃

Calcd. (%) C, 64.95; H, 4.02; N, 11.96; F, 5.41.

Found (%) C, 64.96; H, 3.91; N, 11.96; F, 5.23.


NMR(CDCl₃)δ: 3.78(3H, s), 4.35(2H, s), 7.04-7.10(2H, m), 7.35-7.45(3H, m), 7.57(1H, d, J=8.7Hz), 7.73-7.78(1H, m), 8.47-8.50(1H, m).

E group compound

Compound E-8

2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxypyran-4-one

[0378]



(E-2) Hydroxymethyl product (E-1) (2.2g, 15.5mm) was dissolved in acetone (33ml). To the solution, were added potassium carbonate (6.4g, 46mm) and benzylbromide (3.2g, 18.7mm) and the mixture was refluxed under heating for 3 hours. After evaporating acetone, water was added thereto. The mixture was extracted with ethyl acetate, washed with water, dried with sodium sulfate, and then concentrated under reduced pressure. The residue was isolated and purified with silica gel column chromatography (ethyl acetate: n-hexane= 3:1) to give compound E-2 as oily product (1.4g, yield: 39%).

¹H-NMR(CDCl₃) δ 4.32(s,2H), 5.21(s,2H), 6.40(d,J=5.4Hz,1H), 7.37-7.38(m, 5H), 7.69(d,J=6.0Hz,1H) (E-3) Oxalylchloride (1.64g, 13mm) was dissolved in methylene chloride (15ml) and the solution cooled to -78 °C. To this solution, was added dropwise a solution of dimethylsulfoxide (2.1g, 26.9mm) in methylene chloride (10ml). After stirring at -78 °C for 15 minutes, a solution which alcohol product (E-2) (1.5g, 6.5mm) was dissolved in methylene chloride (10ml) was added thereto. After 30 minutes, triethylamine (5.3g, 42mm) was added thereto and the mixture stirred for 15 minutes. After warming to room temperature, ice water was added thereto and the mixture was extracted with ethyl acetate, washed with water, dried with sodium sulfate, and then concentrated under reduced pressure. The residue was isolated and purified with silica gel column chromatography (ethyl acetate: n-hexane =1:1) to give compound E-3 as oily product (1.39g, yield: 93%).

$^1\text{H-NMR}(\text{CDCl}_3)\delta$ 5.52(s,2H), 6.50(d,J=5.4Hz,1H), 7.36(s,5H), 7.75(d,J=5.7Hz,1H), 9.88(s,1H)

(E-5) 2-Furan-2-yl-[1.3]dioxolane (920mg, 6.6mm) was dissolved in dried tetrahydrofuran (20ml), and the solution cooled to -78°C . To this solution, was added dropwise a solution of 1.57mol/l n-butyl lithium-hexane solution (5.4ml, 8.5mm). After 15 minutes, a solution of γ -pyrone product (E-3) (1.5g, 6.5mm) in tetrahydrofuran (15ml) was added thereto. After 30 minutes, the mixture was warmed to 0°C . After saturated ammonium chloride aqueous solution was added thereto, the mixture was extracted with ethyl acetate, washed with water, and then concentrated under reduced pressure. The obtained residue was dissolved in methyl alcohol (10ml). 6N hydrochloric acid (2ml) was added thereto and the mixture was stirred at room temperature for 1 hour. The mixture was neutralized with sodium hydrogen carbonate, extracted with ethyl acetate, washed with water, dried with sodium sulfate, and then concentrated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate: n-hexane= 1:1) to give compound E-5 as oily product (730mg, yield: 35%).

$^1\text{H-NMR}(\text{CDCl}_3)\delta$ 5.22(d,J=11.1Hz, 1H), 5.27(d,J=11.1Hz,1H), 5.90(s,1H), 6.42(d,J=5.7Hz,1H), 6.44(d,J=3.6Hz, 1H), 7.17(d,J=3.6Hz,1H), 7.35-7.38(m,5H), 7.66(d,J=5.7Hz,1H), 9.58(s,1H)

(E-6) Oxalylchloride (570mg, 4.5mm) was dissolved in methylene chloride (10ml) and the solution was cooled to -78°C . A solution which dimethyl sulfoxide (700mg, 9mm) was dissolved in methylene chloride (5ml) was added dropwise and the mixture was stirred for 15 minutes. A solution of alcohol product (E-5) (730mg, 2.2mm) in methylene chloride (10ml) was added. After stirring for 30 minutes, triethylamine (1.8g, 18mm) was added dropwise thereto. After 15 minutes, the mixture was put to be 0°C and a saline solution was added thereto. The mixture was extracted with ethyl acetate, washed with water, dried with sodium sulfate, and then concentrated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate: n-hexane =2:1) to give product E-6 as oily product (610mg, yield: 84%).

$^1\text{H-NMR}(\text{d}_6\text{-DMSO})\delta$ 5.19(s,2H), 6.66(d,J=5.7Hz,1H), 7.20-7.27(m,5H), 7.64(d,J=3.6Hz,1H), 7.71(d,J=3.9Hz,1H), 8.29(d,J=5.7Hz,1H), 9.79(s,1H)

(E-7) Aldehyde product (E-6) (550mg, 1.7mm) was dissolved in dried tetrahydrofuran (22ml) and a solution of 1mol/l parafluorophenyl magnesium bromide in tetrahydrofuran (1.6ml, 1.7mm) were added thereto under ice-cooling. After stirring at room temperature for 15 minutes, ammonium chloride aqueous solution was added thereto. The mixture was extracted with ethyl acetate, washed with water, dried with sodium sulfate, and then concentrated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate: n-hexane =1:1) to give compound E-7 as oily product (413mg, yield: 58%).

$^1\text{H-NMR}(\text{d}_6\text{-DMSO})\delta$ 5.06(s,2H), 5.82(s,1H), 6.53(d,J=3.6Hz,1H), 6.58(d,J=5.4Hz,1H), 7.13-7.25(m,7H), 7.40-7.45(m,2H), 7.50(d,J=3.6Hz,1H), 8.20(d,J=5.7Hz,1H)

(E-8) Alcohol product (E-7)(290mg, 0.7mm) was dissolved in trifluoroacetic acid (6ml) and triethylsilane (0.7ml) added thereto under ice-cooling. After 30 minutes, the mixture was stirred at room temperature for 30 minutes. After concentrating under reduced pressure, the mixture was neutralized with sodium hydrogen carbonate, extracted with ethyl acetate, washed with water, dried with sodium sulfate, and then concentrated under reduced pressure. The residue was dissolved in acetone, treated with active carbon, and then recrystallized with ethyl acetate/isopropylether to give compound E-8 as pale yellow crystal (83mg, yield: 39%) of mp157-9.

$^1\text{H-NMR}(\text{d}_6\text{-DMSO})\delta$ 4.15(s,1H), 6.50(d,J=3.9Hz,1H), 6.51(d,J=5.4Hz,1H), 7.15-7.21(m,2H), 7.32-7.37(m,2H), 7.70(d,J=3.6Hz,1H), 8.22(d,J=5.7Hz,1H), 10.77(bris,1H)

Elementary analysis as($\text{C}_{17}\text{H}_{11}\text{FO}_5/0.3\text{H}_2\text{O}$)			
Calcd. (%)	C:63.87	H:3.66	F:5.94
Found (%)	C:63.85	H:3.27	F:6.27


m/z 313[M-H]⁻, m/z315[M+H]⁺, m/z359[M+2Na-H]⁺
IR(nujol)(cm⁻¹)3400, 1646,1608

EP 1 422 218 A1

Compound E-16

2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-6-methylpyrane-4-one

[0379]



(E-10) Kojic acid product E-9 (14.2g, 0.1mol) was dissolved in thionyl chloride (24g) and the solution was stirred at room temperature. After 10 minutes, solid content was washed with hexane to give white crystal (16.5g, yield: 100%).

¹H-NMR(CDCl₃) δ : 4.36(s,2H), 6.58(s,1H), 7.89(s,1H).

(E-11) The above-mentioned compound E-10 (16.5g, 0.1mol) was suspended in water (400ml). Zinc powder (13g, 0.2mol) and concentrated hydrochloric acid (10ml) were added thereto and the mixture was stirred at 75 °C for 1 hour. After cooling, zinc powder was removed by suction filtration and the filtrate was extracted with chloroform. After washing and drying, the solvent was evaporated under reduced pressure and the residue was crystallized with ether to give the compound (10.4g, yield: 82%).

¹H-NMR(CDCl₃) δ : 2.31(s,3H), 6.28(s,1H), 6.61(bs, 1H), 7.79(s,1H).

(E-12) The above-mentioned compound E-11 (10.4g, 82mmol) was dissolved in methyl alcohol (54ml). Sodium hydroxide solution (sodium hydroxide (4.2g) was dissolved in water (11ml)) and 37% formaldehyde solution (17ml) were added thereto and the mixture was stirred at room temperature for 25 hours. Methyl alcohol was evaporated under reduced pressure. The solution was acidified with concentrated hydrochloric acid and then sodium sulfate was added thereto. The mixture was diluted with tetrahydrofuran. To the solution, was added molecular sieve and the mixture was dried and filtered. The solvent was evaporated under reduced pressure and the residue was crystallized with chloroform to give the compound (8.1g, yield: 64%).

¹H-NMR(DMSO-d₆) δ : 2.26(s,3H), 4.39(s, 2H), 5.36(bs,1H), 6.22(s, 1H), 8.91(bs,1H).

(E-13) The above-mentioned compound E-12 (7.0g, 45mmol) was dissolved in acetone (150ml). Potassium carbonate (20g, 145mmol) and benzyl bromide (9.6g, 56mmol) were added thereto and the mixture was refluxed for 16 hours. After cooling, acetone was evaporated under reduced pressure and the residue was extracted with ethyl acetate. After washing and drying, the solvent was evaporated under reduced pressure and the residue was crystallized with ether to give the compound (8.5g, yield: 76%).

¹H-NMR(CDCl₃) δ : 2.26(s,3H), 4.28(s,2H), 5.21(s,2H), 6.21(s,1H), 7.38(m,5H).

(E-14) Oxalylchloride (8.6g, 67mmol) was dissolved in methylene chloride (80ml). To the solution, was added dropwise a solution of dimethyl sulfoxide (10.5g, 135mmol) in methylene chloride (50ml) at -78°C. After 15 minutes, a solution of the above-mentioned compound E-13 (8.3g, 34mmol) in methylene chloride (50ml) was added dropwise thereto at -78°C and the mixture was stirred at the same temperature for 30 minutes. Triethylamine (27g, 270mmol) was added thereto and warmed to room temperature. Water was added thereto and the mixture was extracted with chloroform. After washing and drying, the solvent was evaporated under reduced pressure and the residue was crystallized with isopropylether to give the compound (7.4g, yield: 90%).

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 2.32(s,3H), 5.49(s,2H), 6.30(s,1H), 7.35(m,5H), 9.84(s,1H).

(E-15) To a solution of 2-(4-fluorobenzyl)furanlithium salt synthesized as the synthetic method of A-6 in tetrahydrofuran (5mmol), added a solution of the above-mentioned compound E-14 (1.22g, 5mmol) in tetrahydrofuran at -78°C . The mixture was stirred at the same temperature for 30 minutes. The solution was added to ammonium chloride solution and extracted with ethyl acetate. After washing and drying, the solvent was evaporated under reduced pressure and the residue was dissolved in chloroform (30ml). To the solution, was added manganese dioxide (20g) and the mixture was stirred at 60°C for 15 minutes. The solution was filtered and the filtrate was dried and evaporated under reduced pressure. The residue was purified with column chromatography (ethyl acetate: n-hexane=1:1) to give the compound (1.15g, yield: 55%).

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 2.29(s,3H), 4.00(s,2H), 5.21(s,2H), 6.13(d,1H, $J=3.9\text{Hz}$), 6.30(d, 1H, $J=0.6\text{Hz}$), 6.98-7.04(m, 2H), 7.14(d, 1H, $J=3.6\text{Hz}$), 7.15-7.24(m,7H).

(E-16) The above-mentioned compound E-15 (3.78g, 9.0mmol) was dissolved in trifluoroacetic acid (30ml) and the mixture was stirred at room temperature for 30 minutes. The solvent was evaporated under reduced pressure. Ice water was added thereto and extracted with ethyl acetate. After washing and drying, the solvent evaporated under reduced pressure and the residue was recrystallized with methyl alcohol to give compound (1.8g, yield: 62%). $^1\text{H-NMR}(\text{DMSO}-d_6)$ δ : 2.36(s,3H), 4.15(s,2H), 6.41(s,1H), 6.52(d,1H, $J=3.6\text{Hz}$), 7.14-7.22(m, 2H), 7.30-7.38(m, 2H), 7.63(d, 1H, $J=3.6\text{Hz}$).


Melting point: $173-175^\circ\text{C}$

Elementary analysis as $\text{C}_{18}\text{H}_{13}\text{O}_5\text{F}$			
Calcd. (%)	C: 65.85	H: 3.99	F: 5.79
Found (%)	C:65.64	H:3.96	F:5.69

Compound E-24

2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-6-hydroxymethylpyrane-4-one

[0380]



(E-17) To a solution of kojic acid compound E-9 (44.9g, 316mmol) in DMF (400ml), were added imidazole (45.1g,

663mmol) and then chlorotert-butyldimethylsilane (100g, 663mmol) under ice-cooling. The mixture was warmed to room temperature and stirred for 30 minutes. Water was added thereto to stop the reaction and the mixture was extracted with diethyl ether. After washing with water and drying, the solvent was evaporated under reduced pressure to give 5-(tert-butyldimethylsilyloxy)-2-(tert-butyldimethylsilyloxymethyl)-pyrane-4-one.

¹H-NMR(CDCl₃) δ : 0.11(6H, s), 0.23(6H, s), 0.93(9H, s), 0.96(9H, s), 4.45(2H, s), 6.45(s, 1H), 7.62(s, 1H).

(E-18) To the above-mentioned compound E-17, was added 30% formic acid-chloroform solution (300ml) and the mixture was stirred for 1 hour. Water (300ml) was added thereto, extracted with chloroform, washed with water and dried. The solvent was evaporated under reduced pressure and precipitated crystal was washed with n-hexane to give 2-(tert-butyldimethylsilyloxymethyl)-5-hydroxypyrane-4-one (76.22g, yield: 94%).

Melting point: 121-122°C

¹H-NMR(CDCl₃) δ : 0.12(6H, s), 0.93(9H, s), 4.49(2H, s), 6.50(1H, bs), 6.57(s, 1H), 7.80(s, 1H).

(E-19) To a solution of the above-mentioned compound E-18 (76.22g, 297mmol) in methyl alcohol (500ml), were added sodium hydroxide solution (5N-aqueous solution, 59.4ml, 297mmol) and 37% formaldehyde aqueous solution (72.3g, 891mmol) under ice-cooling. Then the mixture was warmed to room temperature and stirred for 5 hours. Saturated ammonium chloride aqueous solution was added thereto to stop the reaction and methyl alcohol was evaporated under reduced pressure. The solution was extracted with chloroform, washed with water and dried. The precipitated crystal was washed with n-hexane to give 6-(tert-butyldimethylsilyloxymethyl)-3-hydroxy-2-hydroxymethylpyrane-4-one (74.47g, yield: 88%).

Melting point: 133-134°C

¹H-NMR(CDCl₃) δ : 0.12(6H, s), 0.94(9H, s), 4.53(2H, s), 4.70(2H, s), 6.56(1H, bs), 6.57(1H, s).

(E-20) The above-mentioned compound E-19 (74.47g, 260mmol) was dissolved in acetone (350ml). Potassium carbonate (35.9g, 260mmol) and benzyl bromide (44.5g, 260mmol) were added thereto and the mixture was refluxed for 2 hours. After cooling, acetone was evaporated under reduced pressure and the residue was extracted with ethyl acetate. After washing and drying, the solvent was evaporated under reduced pressure and the precipitated crystal was washed with n-hexane to give 3-benzyloxy-6-(tert-butyl-dimethylsilyloxymethyl)-2-hydroxymethylpyrane-4-one (89.08g, yield: 91%).

Melting point: 87-90°C

¹H-NMR(CDCl₃) δ : 0.11(6H, s), 0.93(9H, s), 4.26(2H, s), 4.46(2H, s), 5.22(2H, s), 6.51(1H, s), 7.38(5H, s).

(E-21) To a solution of the above-mentioned compound E-20 (89.08g, 237mmol) in chloroform (400ml), was added manganese dioxide (103g, 1.18mmol). The mixture was refluxed under heating for 2 hours. Manganese dioxide was filtered and dried. The solvent was evaporated under reduced pressure to give 3-benzyloxy-6-(tert-butyl-dimethylsilyloxymethyl)-4-oxo-4H-pyrane-2-carbaldehyde (87.7g, yield: 99%).

¹H-NMR(CDCl₃) δ : 0.11(6H, s), 0.93(9H, s), 4.51(2H, s), 5.51(2H, s), 6.63(1H, s), 7.36(s, 1H), 9.84(1H, s).

(E-22) With using the above-mentioned compound E-21 (34.8g, 93mmol) according to the synthetic method of E-15, 3-benzyloxy-6-(tert-butyl-dimethylsilyloxymethyl)-2-[5-(4-fluorobenzyl)furan-2-carbonyl]-pyrane-4-one (34.0g, yield: 67%) was given.

¹H-NMR(CDCl₃) δ : 0.11(6H, s), 0.93(9H, s), 4.00(2H, s), 4.47(2H, s), 5.23(2H, s), 6.13(1H, d, J=3.7Hz), 6.59(1H, s), 6.99-7.04(2H, m), 7.14-7.23(8H, m).

(E-23) The above-mentioned compound E-22 (34.0g, 62mmol) was dissolved in dioxane (300ml). 3N-hydrochloric acid aqueous solution (150ml) was added thereto. After stirring for 30 minutes, the mixture was extracted with ethyl acetate, washed and dried. The solvent was evaporated under reduced pressure. The precipitated crystal was washed with diethyl ether to give 3-benzyloxy-2-[5-(4-fluorobenzyl)furan-2-carbonyl]-6-hydroxymethylpyrane-4-one (26.2g, yield: 97%).

Melting point: 104-106°C

¹H-NMR(CDCl₃) δ : 3.99(2H, s), 4.48(2H, s), 5.21(2H, s), 6.12(1H, d, J=3.7Hz), 6.58(1H, s), 6.98-7.04(2H, m), 7.12-7.22(8H, m).

(E-24) With using the above-mentioned compound E-23 according to the synthetic method of E-16, 2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-6-hydroxymethylpyrane-4-one was synthesized.

Melting point: 193-195°C

Elementary analysis as C₁₈H₃₁O₆F

Calcd. (%) C: 62.79 H: 3.81

F: 5.52

Found (%) C: 62.73

H: 3.75


F: 5.32

¹H-NMR(CD₃OD) δ : 4.13(2H, s), 4.55(2H, s), 6.44(1H, d, J=3.7Hz), 6.57(1H, s), 7.03-7.09(2H, m), 7.30-7.35(2H, m), 7.86(1H, d, J=3.7Hz).

Compound E-26

2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-6-methoxymethylpyrane-4-one

[0381]



(E-25) To a solution of compound E-23 (217mg, 0.5mmol) in THF (1ml), added diazomethane ether solution under ice-cooling and then silica gel (100mg). Acetic acid was added thereto to stop the reaction. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate: n-hexane= 1:1) to give 3-benzyloxy-2-[5-(4-fluorobenzyl)furan-2-carbonyl]-6-methoxymethylpyrane-4-one (118mg, yield: 53%).

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 3.44(3H, s), 4.00(2H, s), 4.24(2H, s), 5.23(2H, s), 6.13(1H, d, $J=3.6\text{Hz}$), 6.54(1H, s), 6.98-7.04(2H, m), 7.16-7.26(8H, m).

(E-26) With using the above-mentioned compound E-25 according to the synthetic method of E-16, 2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-6-methoxymethylpyrane-4-one was synthesized.

Melting point: 147-148


Elementary analysis as $\text{C}_{19}\text{H}_{15}\text{O}_6\text{F}$			
Calcd. (%)	C: 63.69	H: 4.22	F: 5.30
Found (%)	C: 63.72	H: 4.27	F: 5.14

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 3.47(3H, s), 4.11(2H, s), 4.36(2H, s), 6.26(1H, d, $J=3.7\text{Hz}$), 6.50(1H, s), 7.01-7.07(2H, m), 7.22-7.26(2H, m), 7.76(1H, d, $J=3.7\text{Hz}$).

Compound E-28

6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylic acid

[0382]



(E-27) To a solution of compound E-23 (10g, 10mmol) in acetone (100ml), added dropwise 8N-Jones reagent aqueous solution ($\text{CrO}_3\text{-H}_2\text{SO}_4$, 13.8ml, 110mmol) under ice-cooling for 30 minutes and the mixture was warmed to room temperature. After stirring for 1 hour, isopropylalcohol was added thereto to stop the reaction and the insoluble product was filtered. Water was added thereto and the mixture was extracted with ethyl acetate, washed and dried. The solvent was evaporated under reduced pressure to give 5-benzyloxy-6-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-oxo-4H-pyran-2-carboxylic acid (8.29g, yield: 80%).

$^1\text{H-NMR}$ (DMSO- D_6) δ : 4.14(2H, s), 5.12(2H, s), 6.51(1H, d, $J=3.4\text{Hz}$), 7.09-7.35(10H, m). (E-28) With using the above-mentioned compound E-27 according to the synthetic method of E-16, 6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylic acid was synthesized.


Melting point: $>200^\circ\text{C}$ decomp.

$^1\text{H-NMR}$ (DMSO- D_6) δ : 4.17(2H, s), 6.59(1H, d, $J=3.4\text{Hz}$), 7.03(1H, s), 7.15-7.21(2H, m), 7.32-7.37(2H, m), 8.04(1H, d, $J=3.4\text{Hz}$).

Compound E-30

6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylate methyl ester

[0383]



(E-29) To a solution of compound E-27 (400mg, 0.89mmol) in THF (3ml), was added trimethylsilyldiazomethane (2.0mol/l in THF, 0.53ml, 1.07mmol). Acetic acid was added thereto to stop the reaction. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate: n-hexane = 3:1) to give 5-benzyloxy-6-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-oxo-4H-pyran-2-carboxylate methyl

EP 1 422 218 A1

ester (320mg, yield:78%).

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 3.95(3H, s), 4.02(2H, s), 5.29(2H, s), 6.16(1H, d, $J=3.8\text{Hz}$), 6.98-7.04(2H, m), 7.17-7.34(9H, m).

(E-30) With using the above-mentioned compound E-29 according to the synthetic method of E-16, 6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylate methyl ester was synthesized.

Melting point:174-176°C


Elementary analysis as $\text{C}_{19}\text{H}_{13}\text{O}_7\text{F}$			
Calcd. (%)	C: 61.30	H: 3.52	F: 5.10
Found (%)	C: 61.30	H: 3.52	F: 4.97

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 4.03(3H, s), 4.13(2H, s), 6.32(1H, d, $J=3.7\text{Hz}$), 7.01-7.07(2H, m), 7.21-7.28(3H, m), 8.23(1H, d, $J=3.7\text{Hz}$).

Compound E-32

6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylate benzylamide

[0384]



(E-31) To a solution of compound E-27 (224mg, 0.5mmol), HOBT (7mg, 0.05mmol) and WSCD (115mg, 0.6mmol) in DMF (3ml), was added benzylamine (4mg, 0.6mmol) at room temperature. After stirring 20 hours, water was added thereto to stop the reaction. The mixture was extracted with ethyl acetate, washed with water and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate: n-hexane =2:1) to give 5-benzyloxy-6-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-oxo-4H-pyran-2-carboxylate benzylamide (112mg, yield:42 %).

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 3.92(2H, s), 4.56(2H, d, $J=5.8\text{Hz}$), 5.24(2H, s), 6.12(1H, d, $J=3.7\text{Hz}$), 6.97-7.35(16H, m).

(E-32) Using the above-mentioned compound E-31 according to the synthetic method of E-16, 6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylate benzylamide was synthesized.

Melting point:195-197°C

Elementary analysis as $\text{C}_{25}\text{H}_{18}\text{O}_5\text{F}_1\text{N}_1$				
Calcd. (%)	C: 67.11	H: 4.06	F: 4.25	N: 3.13
Found (%)	C: 65.21	H: 4.06	F: 4.07	N: 3.04

$^1\text{H-NMR}(\text{CDCl}_3)$ δ : 3.72(2H, s), 4.63(2H, d, $J=5.8\text{Hz}$), 6.14(1H, d, $J=3.7\text{Hz}$), 6.99-7.35(10H, m), 7.70(1H, d, $J=3.7\text{Hz}$), 11.54(1H, bs).

[0385] According to the same method, the following compounds were synthesized.

(E-32-a) 6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylate methyl amide

EP 1 422 218 A1

Melting point:231-232°C

Elementary analysis as C ₁₉ H ₁₄ NO ₆ F				
Calcd. (%)	C: 61.46	H: 3.80	N: 3.77	F: 5.12
Found (%)	C: 61.26	H: 3.76	N: 3.71	F: 5.02

¹H-NMR(CDCI₃) δ : 2.97(d, 3H, J=4.8Hz), 4.14(s, 2H), 6.35(d, 1H, J=3.6Hz), 6.87(1H, bs), 7.03-7.09(m, 2H), 7.15(s, 1H), 7.19-7.27(m,2H), 7.87(d, 1H, J=3.6Hz).

(E-32-b) 6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylate ethyl amide

Melting point:217-219°C

Elementary analysis as C ₂₀ H ₁₆ O ₅ F ₁ N ₁				
Calcd. (%)	C: 62.34	H: 4.19	F: 4.93	N: 3.63
Found (%)	C: 62.46	H: 4.15	F: 4.79	N: 3.56

¹H-NMR(CDCI₃) δ : 1.25(3H, t, J=7.3Hz), 3.46(2H, m), 4.13(2H, s), 6.32(1H, d, J=3.7Hz), 6.78(1H, bs), 7.03-7.09(2H, m), 7.14(1H, s), 7.21-7.26(2H, m), 7.88(1H, d, J=4.0Hz), 11.30(1H, bs).

(E-32-c) 6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylate isopropylamide

Melting point:208-210°C

Elementary analysis as C ₂₁ H ₁₈ O ₆ F ₁ N ₁				
Calcd. (%)	C: 63.16	H: 4.54	F: 4.76	N: 3.51
Found (%)	C: 63.19	H: 4.54	F: 4.55	N: 3.40

¹H-NMR(CDCI₃) δ : 1.29(6H, d, J=6.7Hz), 4.12(2H, s), 4.26(1H, m), 6.29(1H, d, J=3.7Hz), 6.49(1H, d, J=7.9Hz), 7.02-7.09(2H, m), 7.13(1H, s), 7.21-7.27(2H, m), 7.89(1H, d, J=3.7Hz), 11.32(1H, bs).

(E-32-d) 6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylate phenylamide

Melting point:263-266°C

¹H-NMR(DMSO-D₆) δ : 4.17(2H, s), 6.58(1H, d, J=3.7Hz), 7.14-7.21(3H, m), 7.32-7.42(5H, m); 7.72(2H, d, J=7.6Hz), 7.98(1H, d, J=3.7Hz), 10.5(1H, s), 11.00(1H, bs).

(E-32-e) 6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylic acid(2-methoxyethyl)-amide

Melting point: 177-179°C

Elementary analysis as C ₂₁ H ₁₈ O ₇ F ₁ N ₁				
Calcd. (%)	C: 60.72	H: 4.37	F: 4.57	N: 3.37
Found (%)	C: 60.94	H: 4.30	F: 4.44	N: 3.31

¹H-NMR(CDCI₃) δ : 3.36(3H, s), 3.53-3.56(2H, m), 3.61-3.65(2H, m), 4.17(1H, s), 6.28(1H, d, J=3.7Hz), 7.02-7.08(2H, m), 7.15(1H, bs), 7.19-7.27(2H, m), 7.81(1H, d, J=3.7Hz), 11.65(1H, bs).

(E-32-f) 6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylate amide Melting point: 259-262°C

¹H-NMR(DMSO-D₆) δ : 4.16(2H, s), 6.57(1H, d, J=3.7Hz), 7.11(1H, s), 7.15-7.20(2H, m), 7.32-7.37(2H, m), 7.97(1H, d, J=3.7Hz), 8.13(1H, bs), 8.29(1H, bs), 10.92(1H, bs). (E-32-g) 2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-6-(piperidine-1-carbonyl)-pyran-4-one

Melting point:146-148°C

Elementary analysis as C ₂₃ H ₂₀ O ₆ F ₁ N ₁				
Calcd. (%)	C: 64.94	H: 4.74	F: 4.47	N: 3.29
Found (%)	C: 64.87	H: 4.82	F: 4.30	N: 3.17

¹H-NMR(CDCI₃) δ : 1.50-1.80(6H, m), 3.40-3.75(4H, m), 4.10(2H, s), 6.27(1H, d, J=3.7Hz), 6.57(1H, s), 7.01-7.06(2H, m), 7.21-7.26(2H, m), 7.80(1H, d, J=3.7Hz), 11.82(1H, bs).

(E-32-h) 6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carboxylate dimethylamide
Melting point: 182-183°C

Elementary analysis as C ₂₀ H ₁₆ NO ₆ F				
Calcd. (%)	C: 62.34	H: 4.19	N: 3.63	F: 4.93
Found (%)	C: 62.19	H: 4.16	N: 3.64	F: 4.73

¹H-NMR(CDCl₃) δ : 3.13(m, 6H), 4.10(s, 2H), 6.28(d, 1H, J=3.6Hz), 6.63(s, 1H), 7.00-7.07(m, 2H), 7.06-7.27(m, 2H), 7.83(d, 1H, J=3.6Hz), 11.81(s, 1H). (E-32-i) ({6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carbonyl}amino)ethyl acetate ester
Melting point: 150-151°C


Elementary analysis as C ₂₂ H ₁₈ NO ₆ F · 0.2H ₂ O				
Calcd. (%)	C: 59.12	H: 4.15	N: 3.13	F: 4.25
Found (%)	C: 58.87	H: 4.00	N: 3.15	F: 4.13

¹H-NMR(CDCl₃) δ : 1.32(t, 3H, J=7.2Hz), 4.14(m, 4H), 7.27(q, 2H, J=7.2Hz), 6.34(d, 1H, J=3.6Hz), 7.01-7.07(m, 2H), 7.19-7.26(m, 3H), 7.85(d, 1H, J=3.6Hz).

Compound E-37

N-{6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-yl-methyl}-acetamide

[0386]



(E-33) To a solution of compound E-23 (434mg, 1mmol) in methylene chloride (4ml), were added diisopropylethylamine (142mg, 1.1mmol) and then methanesulfonylchloride (126mg, 1.1mmol) under ice-cooling. After stirring for 10 minutes, water was added thereto to stop the reaction. The mixture was extracted with chloroform, washed and dried to give methanesulfonic acid 5-benzyloxy-6-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-oxo-4H-pyran-2-yl-methylester (521mg, yield: 100%).

¹H-NMR(CDCl₃) δ : 3.09(3H, s), 3.99(2H, s), 4.99(2H, s), 5.22(2H, s), 6.15(1H, d, J=3.6Hz), 6.59(1H, s), 6.98-7.04(2H, m), 7.16-7.23(8H, m).

(E-34) To a solution of the above-mentioned compound E-33 (256mg, 0.5mmol) in DMF (3ml), was added sodium azide (49mg, 0.75mmol) and the mixture was stirred for 1 hour. Water was added thereto to stop the reaction and the mixture was extracted with ethyl acetate, washed and dried to give 6-azidemethyl-3-benzyloxy-2-[5-(4-fluorobenzyl)furan-2-carbonyl]-pyran-4-one (228mg, yield: 99%). ¹H-NMR(CDCl₃) δ : 3.99(2H, s), 4.19(2H, s), 5.22(2H, s), 6.15(1H, d, J=3.6Hz), 6.50(1H, s), 6.98-7.04(2H, m), 7.15-7.26(8H, m).

(E-35, 36) To a solution of the above-mentioned compound E-34 (228mg, 0.5mmol) in THF (3ml), were added water (0.3ml) and then triphenylphosphine (292mg, 1mmol). After stirring at room temperature for 30 minutes, 4N-HCl/dioxane solution (0.25ml) was added thereto and the solvent was evaporated under reduced pressure. To the mixture, were added methylene chloride (3ml) and then acetic anhydride (102mg, 1mmol) under ice-cooling. To the mixture, was added triethylamine (101mg, 1mmol) at the same temperature. Water was added thereto to stop the reaction. The mixture was extracted with chloroform, washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate) to give

N-[5-benzyloxy-6-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-oxo-4H-pyran-2-ylmethyl]-acetoamide (177mg, yield: 74%).

¹H-NMR(CDCl₃) δ : 1.98(3H, s), 3.99(2H, s), 4.24(2H, d, J=6.1Hz), 5.16(2H, s), 6.13(1H, d, J=3.7Hz), 6.33(1H, s), 6.82(1H, bs), 6.98-7.05(2H, m), 7.15-7.35(8H, m).

(E-37) Using the above-mentioned compound E-36 (170mg, 0.36mmol) according to the synthetic method of E-16, N-[6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-yl-methyl]-acetoamide(110mg, 80%) was synthesized.

Melting point:263-265°C

¹H-NMR(DMSO-D₆) δ : 1.90(3H, s), 4.16(2H, s), 4.25(2H, d, J=5.6Hz), 6.39(1H, s), 6.52(1H, d, J=3.8Hz), 7.14-7.20(2H, m), 7.32-7.36(2H, m), 7.66(1H, d, J=3.4Hz), 8.53(1H, t, J=5.6Hz).

[0387] According to the same method, the following compounds were synthesized.

(E-37-a) N-[6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-ylmethyl]-3-methylbutylamide

¹H-NMR(CDCl₃) δ : 0.94(6H, d, J=4.2Hz), 2.10-2.18(3H, m), 4.10(2H, s), 4.23(2H, d, J=6.1), 6.22(1H, bs), 6.29(1H, d, J=4.0Hz), 6.37(1H, s), 7.01-7.08(2H, m), 7.22-7.26(2H, m); 7.78(1H, d, J=3.7Hz), 11.90(1H, s).

(E-37-b) N-[6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-ylmethyl]-2-methoxyacetamide

¹H-NMR(CDCl₃) δ : 3.44(3H, s), 3.97(2H, s), 4.11(2H, s), 4.45(2H, d, J=6.4), 6.43(1H, s), 7.01-7.08(3H, m), 7.22-7.26(2H, m), 7.75(1H, d, J=3.7Hz), 11.88(1H, s).

(E-37-c) N-[6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-ylmethyl]-benzamide

¹H-NMR(DMSO-d₆) δ : 4.12(2H, s), 4.49(2H, d, J=5.8), 6.34(1H, d, J=3.7Hz), 6.48(1H, s), 7.14-7.20(2H, m), 7.29-7.33(2H, m), 7.47-7.60(3H, m), 7.64(1H, d, J=3.7Hz), 7.88-7.91(2H, m), 9.18(1H, t, J=5.5Hz), 10.83(1H, s).


(E-37-d) N-[6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-ylmethyl]-benzenesulfonamide

¹H-NMR(DMSO-d₆) δ : 4.09(2H, d, J=5.8Hz), 4.17(2H, s), 6.42(1H, s), 6.52(1H, d, J=3.7Hz), 7.15-7.21(2H, m), 7.33-7.38(2H, m), 7.47-7.60(3H, m), 7.70(1H, d, J=3.7Hz), 7.75-7.78(2H, m), 8.54(1H, t, J=5.5Hz), 10.81(1H, bs).

Compound E-40

6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carbaldehyde O-methyloxime

[0388]



(E-38) To a solution of alcohol E-23 (1.00 g, 2.31 mmol) in chloroform (40 ml), was added manganese dioxide (4.02 g, 46.2 mmol) and the mixture was refluxed for 4 hours under heating. The insoluble product was separated with filtrate and the concentrated residue was dissolved in a solution of chloroform (40ml) under reduced pressure. Manganese dioxide (4.02 g, 46.2 mmol) was added thereto and the mixture was refluxed for 2 hours under heating. The insoluble product was separated with filtrate. The concentrated residue under reduced pressure was purified with silica gel column chromatography (toluene: acetone=2:1) and crystallized from acetone-diisopropylether to give 5-benzyloxy-6-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-oxo-4H-pyran-2-carbaldehyde (364 mg, yield:36%)

Melting point:69-72°C

NMR(CDCl₃) δ : 4.01 (2H, s), 5.29 (2H, s), 6.17 (1H, d, J=3.6Hz), 7.01 (2H, t like, J=8.7Hz) 7.06 (1H, s), 7.16-7.30

(8H, m), 9.67 (1H, s).

(E-39) To a solution of the above-mentioned compound E-38 (150 mg, 0.346 mmol) in ethanol (5 ml)-water (1 ml), were added sodium acetate (85 mg) and hydrochloric acid O-methylhydroxylamine (35 mg) and the mixture was stirred at 80 °C for 5 hours. Water was added thereto and extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure. The residue was purified with lobar column (size B) (toluene: ethyl acetate=5:1) and crystallized from ethyl acetate-diisopropylether to give 5-benzyloxy-6-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-oxo-4H-pyran-2-carbaldehyde O-methyloxime (103 mg, yield: 64%).

Melting point: 116-117°C

NMR(CDCl₃)δ: 4.01 (2H, s), 4.02 (3H, s), 5.27 (2H, s), 6.14 (1H, d, J=3.6Hz), 6.69 (1H, s), 7.00 (2H, t like, J=8.7Hz), 7.15-7.30 (7H, m), 7.73 (1H, s).

(E-40) The above-mentioned compound E-39 (132 mg, 0.286 mmol) was dissolved in trifluoroacetic acid (1 ml) and the solution was stirred at room temperature for 35 minutes. The residue that trifluoroacetic acid was evaporated under reduced pressure was dissolved in chloroform, washed with water twice and dried. The solvent was evaporated under reduced pressure. The residue was crystallized from tetrahydrofuran-diisopropylether to give 6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carbaldehyde O-methyloxime (100 mg, yield:94%).


Melting point: 180-182°C

NMR(CDCl₃) δ : 4.10 (3H, s), 4.12 (2H, s), 6.26 (1H, d, J=3.6Hz), 6.54 (1H, s), 7.04 (2H, t like, J=8.7Hz), 7.23-7.28 (2H, m), 7.80 (1H, s), 8.19 (1H, d, J=3.6Hz), 11.97 (1H, br. s).

Compound E-43

6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carbonitrile

[0389]



(E-41) To a solution of compound E-38 (264 mg, 0.611 mmol) in ethanol (5 ml)-water (1 ml), were added sodium acetate (150 mg) and hydroxylamine hydrochloride (51 mg) and the mixture was stirred at room temperature overnight. To a solution, water was added and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure to give crude crystal (250 mg) of 5-benzyloxy-6-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-oxo-4H-pyran-2-carbaldehyde oxime. This was used for the next reaction without purifying.

(E-42) To a solution of imidazole (250 mg) in methylene chloride (5 ml), was added thionyl chloride (0.067 ml) under ice-cooling and the mixture was stirred for 15 minutes. To the solution, was added a suspension of the above-mentioned compound E-41 (250 mg) in methylene chloride (10 ml) and the mixture was stirred under warming to room temperature for 51 minutes. Water was added to the solution and the mixture was extracted with chloroform. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (toluene: ethyl acetate=10:1) to give 5-benzyloxy-6-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-oxo-4H-pyran-2-carbonitrile (195 mg, 2 total yield of process: 74%).

NMR(CDCl₃) δ : 4.00 (2H, s), 5.26 (2H, s), 6.18 (1H, d, J=3.6Hz), 6.95 (1H, s), 7.02 (2H, t like, J=8.7Hz), 7.13-7.28 (8H, m).

(E-43) The above-mentioned compound E-42 (195 mg, 0.454 mmol) was dissolved in trifluoroacetic acid (2 ml) and the mixture was stirred at room temperature for 35 minutes. The residue which trifluoroacetic acid was evap-

orated under reduced pressure was dissolved in chloroform, washed with water twice and dried. The solvent was evaporated under reduced pressure. The residue was crystallized from tetrahydrofuran-diisopropylether to give 6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-carbonitrile (98 mg, yield: 64%).


Melting point: 190-194°C (decomp.)

NMR(CDCl₃) δ : 4.12 (3H, s), 6.35 (1H, d, J=3.9Hz), 6.95 (1H, s), 7.05 (2H, t like, J=8.7Hz), 7.23-7.29 (2H, m), 7.67 (1H, d, J=3.9Hz), 12.15 (1H, br. s).

Compound E-45

3-[6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-yl]ethyl acrylate

[0390]



(E-44) To a suspension of 60% sodium hydride (20 mg, 0.5 mmol) in tetrahydrofuran (2 ml), was added diethyl-phosphonoethyl acetate (0.119 ml) and the mixture was stirred at room temperature for 10 minutes. To the solution, was added a solution of compound E-38 (220 mg, 0.506 mmol) in tetrahydrofuran (3 ml) under ice-cooling and the mixture was stirred for 35 minutes. The solution added ammonium chloride aqueous solution was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with lobar column (size B) (toluene: ethyl acetate=5:1) to give 3-[5-benzyloxy[6-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-oxo-4H-pyran-2-yl]ethyl acrylate (149mg, yield: 58%).

Melting point: 104-106°C

NMR(CDCl₃) δ : 1.31 (3H, t, J=7.2Hz), 4.00 (2H, s), 4.26 (2H, q, J=7.2Hz), 5.25 (2H, s), 6.16 (1H, d, J=3.6Hz), 6.56 (1H, d, J=15.3Hz), 6.57 (1H, s), 7.00 (2H, t like, J=8.7Hz), 7.13-7.29 (9H, m).

(E-45) The above-mentioned compound E-44 (149 mg, 0.297 mmol) was dissolved in trifluoroacetic acid (1 ml) and the mixture was stirred at room temperature for 35 minutes. The residue which trifluoroacetic acid was evaporated under reduced pressure was dissolved, washed with water twice and dried. The solvent was evaporated under reduced pressure. The residue was crystallized from tetrahydrofuran-diisopropylether 3-[6-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-hydroxy-4-oxo-4H-pyran-2-yl]ethyl acrylate (99 mg, yield: 81%).


Melting point: 205-207°C

NMR(CDCl₃) δ : 1.33 (3H, t, J=6.9Hz), 4.17 (2H, s), 4.30 (2H, q, J=6.9Hz), 6.32 (1H, d, J=3.6Hz), 6.62 (1H, s), 6.83 (1H, d, J=15.6Hz), 7.04 (2H, t like, J=8.7Hz), 7.23-7.27 (2H, m), 7.30 (1H, d, J=15.6Hz), 7.62 (1H, d, J=3.6Hz), 11.85 (1H, br.s).

Compound E-50

5-bromo-2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxypyran-4-one

[0391]



(E-47) To a solution of 3-bromo-5-hydroxypyran-4-one E-46 (10.0g, 52.4mmol) synthesized according to the method described in reference (Heterocycles, 1992, 34, p1803) in methyl alcohol (40ml), was added sodium hydroxide (2.61g, 65.3mmol) aqueous solution (12ml) and the mixture was stirred for 5 minutes. 37% formaldehyde aqueous solution (10.6ml, 131mmol) was added dropwise thereto over 40 minutes and the mixture was stirred overnight. After removing formaldehyde and methyl alcohol under reduced pressure, methyl alcohol (40ml) and chlorobenzyl (7.2ml, 62.9mmol) were added to the residue and the mixture was stirred at 60°C for 2 hours. After cooling, the mixture was neutralized with 2M hydrochloric acid and methyl alcohol was evaporated under reduced pressure. The water layer was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure to give crude product (12.2g). To a solution of the obtained crude product (12.2g) and 2,2,6,6-tetramethylpiperidine-1-oxyl, free radical (613mg, 3.92mmol) in ethyl acetate (80ml), was added 1.0M sodium hydrogen carbonate aqueous solution (80ml, 80mmol). 10% sodium hypochlorite aqueous solution (58ml, 78.5mmol) was added dropwise thereto for 50 minutes with stirring hard under about 5°C. The water layer was divided, acidified with 2M hydrochloric acid and then extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure to give 3-benzyloxy-5-bromo-4-oxo-4H-pyran-2-carboxylic acid (6.26g, yield: 37%).

(E-48) To a solution of the above-mentioned compound E-47 (685mg, 2.11mmol) in dimethylformamide (5ml), were added 1,8-diazabicyclo[5.4.0]-7-undecen (0.35ml, 2.32mmol) and iodomethane (0.13ml, 2.53mmol) and the mixture was stirred at room temperature for 3 hours. Water was added to the solution and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure to give 3-benzyloxy-5-bromo-4-oxo-4H-pyran-2-carboxylate methyl ester (643mg, yield: 90%).

NMR(CDCl₃) δ: 3.89(3H, s), 5.32(2H, s), 7.32-7.40(2H, m), 7.44-7.49(2H, m), 8.11(1H, s).

(E-49) A solution of 2-bromo-5-(4-fluorobenzyl)furan (181mg, 0.708mmol) in tetrahydrofuran (5ml) was cooled to -78°C. 1.57M butyllithiumhexane solution (0.45ml, 0.649mmol) was added dropwise thereto. After stirring at the same temperature for 10 minutes, a solution of compound E-48 (200mg, 0.59mmol) in tetrahydrofuran (2ml) was added thereto and the mixture was stirred for 80 minutes. The saturated ammonium chloride aqueous solution was added thereto and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane/ ethyl acetate=3/1) to give 3-benzyloxy-5-bromo-2-[5-(4-fluorobenzyl)furan-2-carbonyl]pyran-4-one (109mg, yield: 38%).

NMR(CDCl₃) δ: 3.99(2H, s), 5.24(2H, s), 6.14(1H, d, J=3.6Hz), 6.97-7.05(2H, m), 7.13-7.21(3H, m), 7.21-7.26(5H, m), 8.11(1H, s).

(E-50) The above-mentioned compound E-49 (100mg, 0.207mmol) was dissolved in trifluoroacetic acid (2ml) and the mixture was stirred for 1 hour. The solvent was evaporated under reduced pressure. Water was added to the residue and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the obtained solid was recrystallized with the acetone-methyl alcohol mixture to give 5-bromo-2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxypyran-4-one (61mg, yield: 75%).

Melting point: 191-192°C


Elementary analysis as C ₁₇ H ₁₀ BrFO ₅				
Calcd. (%)	C, 51.93;	H, 2.56;	Br, 20.32;	F, 4.83.
Found (%)	C, 52.12;	H, 2.55;	Br, 20.37;	F, 4.66.

NMR(CDCl₃) δ : 4.11(2H, s), 6.28(1H, d, J=3.7Hz), 7.01-7.09(2H, m), 7.21-7.29(2H, m), 7.64(1H, d, J=3.7Hz), 8.16(1H, s), 11.92(1H, s).

Compound E-52

2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-5-phenylpyrane-4-one

[0392]



(E-51) To a solution of compound E-49 (250mg, 0.518mmol), phenylboronic acid (76mg, 0.622mmol) and tetrakis(triphenylphosphine) palladium (30mg, 0.0259mmol) in dimethoxyethane (4ml) ethanol (1ml), was added 2M sodium carbonate aqueous solution (0.93ml, 1.86mmol) and the mixture was fluxed under heating for 1 hour. After cooling, the saturated ammonium chloride aqueous solution was added thereto and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure. The residue was purified with silica gel column chromatography (n-hexane/ ethyl acetate=3/1) to give 3-benzyloxy-2-[5-(4-fluorobenzyl)furan-2-carbonyl]-5-phenylpyrane-4-one (67mg, yield: 27 %).

NMR(CDCl₃) δ : 4.02(2H, s), 5.25(2H, s), 6.15(1H, d, J=3.6Hz), 6.97-7.05(2H, m), 7.17-7.38(7H, m), 7.41-7.50(4H, m), 7.52-7.58(2H, m), 7.92(1H, s).

(E-52) According to the same method of example E-16, 2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-5-phenylpyrane-4-one (28mg, yield: 51%) was synthesized from the above-mentioned compound E-51 (67mg, 0.140mmol).

Melting point: 199-201°C


NMR(CDCl₃) δ : 4.12(2H, s), 6.27(1H, d, J=3.6Hz), 7.01-7.09(2H, m), 7.22-7.28(2H, m), 7.40-7.50(3H, m), 7.53-7.58(2H, m), 7.69(1H, d, J=3.6Hz), 7.98(1H, s), 11.68(1H, s).

F group compound

Compound F-4

5 3-[5-(4-fluorobenzyl)furan-2-carbonyl]-2-hydroxy-2-cyclohexene-1-one

[0393]



(F-3) To a lithiumbistrimethylsilylamide solution prepared from hexamethyldisilazane (0.23ml) and n-butyllithium (1.1mmol) in tetrahydrofuran (3ml), was added dropwise a solution of 2-(tert-butyldimethylsilyloxy)-2-cyclohexene-1-one(F-1)(226mg, 1.0mmol) synthesized according to the method described in reference (Tetrahedron, 1997, 53, p8963) in tetrahydrofuran (2ml) under cooling at -78°C. After stirring at the same temperature for 19 minutes, a solution of 5-(4-fluorobenzyl)furan-2- carboxylate chloride (F-2)(WO-00039086,example120) (120mg, 0.5mmol) in tetrahydrofuran (1ml) was added dropwise thereto. After stirring for 1 hour, the mixture was warmed to 0°C over 20 minutes. The ammonium chloride aqueous solution was added to the solution and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane: ethyl acetate=10:1-5:1) to give 2-(tert-butyldimethylsilyloxy)-6-[5-(4-fluorobenzyl)furan-2-carbonyl]-2-cyclohexene-1-one(189mg, yield:88%).

(F-4) To a solution of the above-mentioned compound F-3 (172mg, 0.40mmol) in tetrahydrofuran (1ml)-methyl alcohol (4ml), was added 2N- hydrochloric acid (1ml) and the mixture was stirred at room temperature for 15 minutes and then at 50°C for 1 hour. Ice water was added to the solution and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was crystallized from ethyl acetate diisopropylether to give 3-[5-(4-fluorobenzyl)furan-2-carbonyl]-2-hydroxy-2-cyclohexene-1-one (85mg, yield: 68%).

Melting point: 133-134°C

40

Elementary analysis as C ₁₈ H ₁₅ FO ₄			
Calcd. (%)	C, 68.78;	H, 4.81;	F, 6.04.
Found (%)	C, 68.56;	H, 54.77;	F, 5.90.

45 NMR(CDCl₃)δ:2.02-2.10 (2H, m), 2.61 (2H, t like, J=7Hz), 2.87 (2H, t, J=6.0Hz), 4.06 (2H, s), 6.22 (1H, J=3.6Hz), 7.03 (2H, t like, J=9Hz), 7.23 (2H, dd, J=8.3Hz, 5.3Hz) , 7.30 (1H, d, J=3.6Hz), 13.26 (1H, br.s). There was the mixture of three kinds of tautomers in CDCl₃ and the data of compound F-4, which had the highest presence ratio (70%), was shown.

50


55

G group compound

Compound G-7

6-[5-(4-fluorobenzyl)pyridine-2-yl]-5-hydroxy-2-methyl-1*H*-pyrimidine-4-one

[0394]



(G-1) 5-hydroxy-2-methylpyridine (10.9g, 100mmol) and pyridine (12.2ml, 150 mmol) was dissolved in methylene chloride (100ml) and trifluoromethanesulfonic acid anhydride (18.5ml, 120mmol) was added dropwise thereto under ice-cooling. After stirring at the same temperature for 1.5 hours, methyl alcohol (2ml) and then the saturated sodium hydrogen carbonate aqueous solution (150ml) were added thereto and the mixture was extracted with methylene chloride. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane: ethyl acetate=9:1-4:1) to give 2-methyl-5-(trifluoromethanesulfonyloxy)pyridine (23.0g, yield: 95%).

(G-2) To a solution of the above-mentioned compound G-1 (10.4g, 43.2 mmol) in tetrahydrofuran (130ml), were added 4-fluorobenzyl bromide/zinc-tetrahydrofuran solution (65 mmol) synthesized according to the method described in reference (J. Org. Chem., 1994, 59, p2671) and tetrakis(triphenylphosphine) palladium (2.4g) and the mixture was refluxed under heating for 5 hours. The solvent was evaporated under reduced pressure. Water and ethyl acetate was added to the residue and the insoluble product was filtrated with celite. The filtration was extracted with ethyl acetate and the residue was washed with water. The obtained solution of ethyl acetate was extracted with 1*n*- hydrochloric acid. The hydrochloric acid extract turned alkaline with 2*n*- sodium hydroxide aqueous solution. The solution was extracted with ethyl acetate, washed and dried. The residue which the solvent was evaporated was purified with silica gel column chromatography (n-hexane: ethyl acetate=2:1) to give 5-(4-fluorobenzyl)-2-methylpyridine (5.42g, yield: 62%).

NMR(CDC₃) δ : 2.53 (3H, s), 3.91 (2H, s), 6.96 (2H, t like, $J=8.7$ Hz), 7.06-7.15 (3H, m), 7.34 (1H, dd, $J=8.1$ Hz, 1.5Hz), 7.36 (1H, d, $J=1.5$ Hz).

(G-3) To a solution of the above-mentioned compound G-2 (4.64g, 22.9mmol) in pyridine (40ml), was added selenium dioxide (15.3g, 138mmol) and the mixture was refluxed under heating for 36 hours. Water and chloroform were added to the residue, which pyridine was evaporated under reduced pressure. The insoluble product was separated with filtrate. The filtration was extracted with chloroform and the extract was washed and dried. The

solvent was evaporated under reduced pressure. The residue was dissolved in toluene (50ml) and the solution was treated with active carbon (4g). The solvent was evaporated under reduced pressure to give crude product (5.6g) of 5-(4-fluorobenzyl)pyridine-2-carboxylic acid.

Furthermore, using 5-(4-fluorophenyl)pyridine-2-carboxylic acid was synthesized according to the method described in reference (JP1979-125681), 5-(4-fluorophenyl)pyridine-2-carboxylic acid was synthesized according to the same method.

(G-4) To a solution of the above-mentioned crude product G-3 (5.6g) in methyl alcohol (50ml), was added dropwise thionyl chloride (8.36ml, 115mmol) under ice-cooling. After adding dropwise, the mixture was refluxed under heating for 4 hours. Water and ethyl acetate were added thereto under ice-cooling. Sodium hydrogen carbonate (14g) was added gradually at the same temperature and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane: acetone=2:1) to give 5-(4-fluorobenzyl)pyridine-2-carboxylate methyl (3.40g, 2 total yield of process: 60%).

NMR(CDCl₃) δ : 4.00(3H, s), 4.04 (2H, s), 7.01 (2H, t like, J=8.7Hz), 7.10-7.16 (2H, m), 7.58 (1H, dd, J=7.8Hz, 2.4Hz), 8.06 (1H, d, J=7.8Hz), 8.62 (1H, d, J=2.4Hz).

According to the same method, 5-(4-fluorophenyl)pyridine-2-carboxylate methyl was synthesized.

NMR(CDCl₃) δ : 4.00 (3H, s), 7.03-7.16 (4H, m), 7.25 (1H, dd, J=8.7Hz, 2.4Hz), 8.10 (1H, dd, J=8.7Hz), 8.47 (1H, d, J=2.4Hz).

(G-5) To a solution of benzyloxyethyl acetate (521mg, 2.7mmol) in tetrahydrofuran (10ml), was added dropwise lithium(bis(trimethylsilyl)amido)tetrahydrofuran solution (2.7mmol) at -78°C. After stirring at the same temperature for 25 minutes, a solution of the above-mentioned compound G-4 (328mg, 1.34 mmol) in tetrahydrofuran (5ml) was added dropwise thereto and the mixture was stirred for 32 minutes. To the solution, was added saturated ammonium chloride aqueous solution and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane: acetone=3:1) to give 2-benzyloxy-3-[5-(4-fluorobenzyl)pyridine-2-yl]-3-oxo ethyl propionate (315mg, yield: 58%).

According to the same method, 2-benzyloxy-3-[5-(4-fluorophenyl)pyridine-2-yl]-3-oxo ethyl propionate was synthesized.

Furthermore, using [5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-carboxylate ethyl synthesized according to the method described in reference (Carbohydr. Res., 1994, 254, p91), 2-benzyloxy-3-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-3-oxo ethyl propionate was synthesized.

(G-6) The above-mentioned compound G-5 (315mg, 0.77 mmol) and acetoamidino hydrochloride (293mg, 3.1mmol) were dissolved in a solution of methyl alcohol (6ml). 28 % sodium methoxide-methyl alcohol solution (0.47ml) was added thereto and the mixture was refluxed under heating for 2 hours 25 minutes. To the solution, which cooled to room temperature, was added the saturated ammonium chloride aqueous solution and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was crystallized from ethyl acetate isopropylether to give 5-benzyloxy-6-[5-(4-fluorobenzyl)pyridine-2-yl]-2-methyl-1H-pyrimidine-4-one (164mg, yield: 53%).

NMR(CDCl₃) δ : 2.57 (3H, s), 4.01 (2H, s), 5.20 (2H, s), 7.01 (2H, t like, J=8.7Hz), 7.10-7.18 (2H, m), 7.20-7.27 (5H, m), 7.49 (1H, dd, J=8.1Hz, 2.1Hz), 7.88 (1H, d, J=8.1Hz), 8.64 (1H, d, J=2.1Hz).

The following compound was prepared as well as above.

5-benzyloxy-6-[5-(4-fluorophenyl)pyridine-2-yl]-2-methyl-1H-pyrimidine-4-one

NMR(CDCl₃) δ : 2.59 (3H, s), 5.21 (2H, s), 7.00-7.14 (4H, m), 7.21-7.31 (6H, m), 7.93 (1H, d, J=9.0Hz), 8.49 (1H, d, J=2.7Hz).

5-benzyloxy-6-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-2-methyl-1H-pyrimidine-4-one

NMR(CDCl₃) δ : 2.55 (3H, s), 4.23 (2H, s), 5.36 (2H, s), 7.23-7.40 (6H, m), 12.61 (1H, br.s).

(G-7) To a solution of the above-mentioned compound G-6 (102mg, 0.25mmol) in tetrahydrofuran (2ml)-methyl alcohol (2ml), was added 10 % palladium-carbon (13mg) and the mixture was stirred under hydrogen atmosphere at room temperature for 10 minutes. Chloroform (8ml) and methyl alcohol (3ml) was added to the solution. The precipitated crystal was dissolved in the solution and catalyst was separated with filtrate. The solvent was evaporated under reduced pressure and the crystalline residue was recrystallized from *N,N*-dimethylformamide to give 6-[5-(4-fluorobenzyl)pyridine-2-yl]-5-hydroxy-2-methyl-1H-pyrimidine-4-one (47mg, yield: 59%).

Melting point: >300°C

Elementary analysis as C ₁₇ H ₁₄ FN ₃ O ₂				
Calcd. (%)	C, 65.59;	H, 4.53;	N, 13.50;	F, 6.10.
Found (%)	C, 65.57;	H, 4.44;	N, 13.50;	F, 5.82.

Calcd. (%)	C, 65.59;	H, 4.53;	N, 13.50;	F, 6.10.
Found (%)	C, 65.57;	H, 4.44;	N, 13.50;	F, 5.82.

EP 1 422 218 A1

NMR(DMSO- d_6) δ :2.27 (3H, s), 4.07 (3H, s), 7.15 (2H, t like $J=9$ Hz), 7.30-7.38 (2H, m), 7.93 (1H, dd, $J=1.8$ Hz, 8.1Hz), 8.23 (1H, d, $J=8.1$ Hz), 8.59 (1H, d, $J=1.8$ Hz), 12.41 (1H, br.s), 13.82 (1H, br.s).

The following compound was prepared as well as above.

6-[5-(4-fluorophenoxy)pyridine-2-yl]-5-hydroxy-2-methyl-1*H*-pyrimidine-4-one (G-7-a)

Melting point:255-256°C

Elementary analysis as C ₁₆ H ₁₂ FN ₃ O ₃ 0.5H ₂ O				
Calcd. (%)	C, 59.63;	H, 4.07;	N, 13.04;	F, 5.89.
Found (%)	C, 59.71;	H, 4.04;	N, 12.93;	F, 5.74.

NMR(DMSO- d_6) δ :2.28 (3H, s), 7.22-7.36 (4H, m), 7.68 (1H, dd, $J=3$ Hz, 9Hz), 8.29 (1H, d, $J=9$ Hz), 8.47 (1H, d, $J=3$ Hz), 12.43 (1H, br.s), 13.23 (1H, br.s).

6-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-5-hydroxy-2-methyl-1*H*-pyrimidine-4-one (G-7-b)

Melting point:283-286°C

Elementary analysis as C ₁₄ H ₁₁ FN ₄ O ₃				
Calcd. (%)	C, 55.63;	H, 3.67;	N, 18.54;	F, 6.29.
Found (%)	C, 55.61;	H, 3.69;	N, 18.36;	F, 5.99.


NMR(DMSO- d_6) δ :2.25 (3H, s), 4.37 (2H, s), 7.20 (2H, t like $J=9$ Hz), 7.36-7.42 (2H, m).

H group compound

Compound H-7

3-hydroxy-1-isopropyl-4-(6-phenethylpyrimidine-4-yl)-1,5-dihydropyrrole-2-one

[0395]



(H-1) According to the method described in reference (Tetrahedron 1997,53(15),5617), 4-benzyloxy-1-methyl-5-oxo-2,5-dihydro-1*H*-pyrazole-3-carboxylate ethyl ester was synthesized.

Melting point:131-133°C

NMR(CDCl₃) δ : 1.39(3H, t, $J=7.0$ Hz), 3.58(3H, s), 4.40(2H, q, $J=7.0$ Hz), 5.03(2H, s), 7.33-7.39(5H, m).

(H-2) To a solution of sodium hydride (856mg, 21.4mmol) and dimethylformamide (25ml), was added the above-

mentioned compound H-1 (4.93g, 17.8mmol) and the mixture was stirred for 30 minutes. Chloromethoxymethylbenzene (3.35g, 21.4mmol) was added thereto under ice-cooling and the mixture was warmed to room temperature and stirred for 30 minutes. The ammonium chloride aqueous solution was added thereto to stop the reaction and the mixture was extracted with diethyl ether. The extract was washed and dried. The solvent was evaporated under reduced pressure to give 4-benzyloxy-2-benzyloxymethyl-1-methyl-5-oxo-2,5-dihydro-1H-pyrazole-3-carboxylate ethyl ester (6.68g, yield: 95%).

NMR(CDCl₃) δ : 1.40(3H, t, J=7.0Hz), 3.67(3H, s), 4.42(2H, q, J=7.0Hz), 4.73(2H, s), 5.05(2H, s), 5.33(2H, s), 7.26-7.44(10H, m).

(H-3) To a solution of the above-mentioned compound H-2 (6.68g, 16.8mmol) in methyl alcohol (50ml), was added 1N-lithium hydroxide aqueous solution (25.3ml, 25.3mmol).

The mixture was warmed to 60°C and stirred for 2 hours. Methyl alcohol was evaporated under reduced pressure and the water layer was washed with diethyl ether. The aqueous solution was acidified with citric acid and the mixture was extracted with ethyl acetate. The extract was washed and dried and the solvent was evaporated to give 4-benzyloxy-2-benzyloxymethyl-1-methyl-5-oxo-2,5-dihydro-1H-pyrazole-3-carboxylic acid (5.28g, yield: 85%).

NMR(DMSO-d₆) δ : 3.63(3H, s), 4.77(2H, s), 4.98(2H, s), 5.34(2H, s), 7.25-7.38(10H, m).

(H-4) A solution of the above-mentioned product H-3 (5.28g, 14.3mmol), 1-hydroxybenzotriazole (189mg, 1.4mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride (3.3g, 17.2mmol), N,O-dimethylhydroxyamine (1.68g, 17.2mmol) and triethylamine (1.74g, 17.2mmol) in dimethylformamide (50ml) was stirred at room temperature for 3 hours. Water was added thereto to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane-ethyl acetate=1:1-1:2) to give 4-benzyloxy-2-benzyloxymethyl-1-methyl-5-oxo-2,5-dihydro-1H-pyrazole-3-carboxylic acid methoxy-methyl-amide (3.89g, yield: 66%).

NMR(CDCl₃) δ : 3.37(3H, s), 3.63(3H, s), 3.76(3H, s), 4.75(2H, s), 5.12(2H, s), 5.32(2H, s), 7.26-7.37(10H, m).

(H-5) To a solution of 2-bromo-5-(4-fluorobenzyl)furan (2.41g, 9.45mmol) synthesized according to the method of example A-6 in THF (60ml), were added n-butyllithium (9.45mmol) at -78°C and then a solution of the above-mentioned compound H-4 (3.89g, 9.45mmol) in THF (10ml). The ammonium chloride aqueous solution was added thereto to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane-ethyl acetate=3:1-1:2) to give 4-benzyloxy-1-benzyloxymethyl-5-[5-(4-fluorobenzyl)furan-2-carbonyl]-2-methyl-1,2-dihydropyrazole-3-one (2.36g, yield: 47%).

NMR(CDCl₃) δ : 3.67(3H, s), 4.07(2H, s), 4.76(2H, s), 5.10(2H, s), 5.37(2H, s), 6.10(1H, d, J=3.6Hz), 6.97-7.03(2H, m), 7.21-7.36(10H, m), 7.45-7.48(2H, m), 7.69(1H, d, J=3.4Hz).

(H-6) To a solution of the above-mentioned compound H-5 (2.36g, 4.48mmol) in dioxane (205ml), was added 6N hydrochloric acid aqueous solution (20ml) and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexaneethyl acetate=1:1-0:1) to give 4-benzyloxy-5-[5-(4-fluorobenzyl)furan-2-carbonyl]-2-methyl-1,2-dihydropyrazole-3-one (1.56g, yield: 86%).

NMR(CDCl₃) δ : 3.61(3H, s), 4.06(2H, s), 5.09(2H, s), 6.11(1H, d, J=3.7Hz), 7.98-7.03(2H, m), 7.21-7.42(7H, m), 7.71(1H, d, J=3.1Hz).

(H-7) To a solution of the above-mentioned compound H-6 (837mg, 2.1mmol) in acetic acid (10ml), was added 47% hydrogen bromide aqueous solution (10ml) and the mixture was stirred at 50°C for 1 hour. The solvent was evaporated under reduced pressure and the residue was dissolved in ethyl acetate, washed with water and dried. The precipitated crystal obtained by evaporating solvent under reduced pressure was washed with n-hexane-ethyl acetate (2:1) to give 3-hydroxy-1-isopropyl-4-(6-phenethylpyrimidine-4-yl)-1,5-dihydropyrrole-2-one (476mg, yield: 72%).

Melting point: 156-159°C


Elementary analysis as C ₁₆ H ₁₃ FN ₂ O ₄				
Calcd. (%)	C, 60.76;	H, 4.14;	N, 8.86;	F, 6.01.
Found (%)	C, 60.94;	H, 4.16;	N, 8.66;	F, 5.86.

NMR(CDCl₃) δ : 3.77(3H, s), 4.09(2H, s), 6.21(1H, d, J=3.7Hz), 6.99-7.05(2H, m), 7.26-7.32(2H, m), 8.00(1H, d, J=3.7Hz).

Compound H-13

5-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-hydroxy-1,2-dimethyl-1,2-dihydropyrazole-3-one

[0396]



(H-8) According to the method described in reference (Tetrahedron 1997,53(15),5617), 4-methoxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrazole-3-carboxylate ethyl ester was synthesized.

Melting point: 99-100°C

NMR(CDCl₃) δ : 1.37(3H, t, J=7.0Hz), 3.67(3H, s), 3.84(3H, s), 4.38(2H, q, J=7.0Hz).

(H-9) Using the above-mentioned compound H-8 and iodo methane according to the synthetic method of (H-2), 4-methoxy-1,2-dimethyl-5-oxo-2,5-dihydro-1H-pyrazole-3-carboxylate ethyl ester was synthesized.

NMR(CDCl₃) δ : 1.41(3H, t, J=7.0Hz), 3.68(3H, s), 3.87(3H, s), 4.09(3H, s), 4.41(2H, q, J=7.0Hz).

(H-10) Using the above-mentioned compound H-9 according to the synthetic method of (H-3), the crude product of 4-methoxy-1,2-dimethyl-5-oxo-2,5-dihydro-1H-pyrazole-3-carboxylic acid was synthesized.

(H-11) Using the above-mentioned crude product H-10 according to the synthetic method of (H-4), 4-methoxy-1,2-dimethyl-5-oxo-2,5-dihydro-1H-pyrazole-3-carboxylic acid methoxy methyl-amide was synthesized.

NMR(CDCl₃) δ : 3.39(3H, s), 3.63(3H, s), 3.77(3H, s), 3.83(3H, s), 4.07(3H, s).

(H-12) Using the above-mentioned product H-11 according to the synthetic method of (H-5), 5-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-methoxy-1,2-dimethyl-1,2-dihydropyrazole-3-one was synthesized.

Melting point: 111-113°C

NMR(CDCl₃) δ : 3.69(3H, s), 3.89(3H, s), 4.06(2H, s), 4.11(3H, s), 6.09(1H, d, J=3.7Hz), 6.97-7.03(2H, m), 7.21-7.26(2H, m), 7.66(1H, d, J=3.7Hz).

(H-13) The above-mentioned compound H-12 (750mg, 2.18mmol) and pyridinehydrochloride (7.5g) were heated to 150°C for 12 minutes. Water was added thereto to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the precipitated crystal was recrystallized with n-hexane- ethyl acetate (2:1) to give (5-[5-(4-fluorobenzyl)furan-2-carbonyl]-4-hydroxy-1,2-dimethyl-1,2-dihydropyrazole-3-one (250mg, yield: 35%).

Melting point: 110-111°C

Elementary analysis as C ₁₇ H ₁₅ FN ₂ O ₄				
Calcd. (%)	C, 61.82;	H, 4.58;	N, 8.48;	F, 5.75.
Found (%)	C, 61.82;	H, 4.46;	N, 8.41;	F, 5.64.

NMR(CDCl₃) δ : 3.68(3H, s), 3.92(3H, s), 4.06(2H, s), 6.12(1H, d, J=3.4Hz), 6.97-7.03(2H, m), 7.21-7.26(2H, m), 7.71(1H, d, J=3.7Hz).

I group compound


Compound I-3

4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-5,6-dihydro-1H-pyridine-2-one

Compound I-4

1-ethyl-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-5,6-dihydro-1H-pyridine-2-one

[0397]



(I-1) Aluminum chloride (2.96g, 22.2mmol) was suspended in tetrahydrofuran (30ml) and sodium borohydride (1.41g, 37.3mmol) was added thereto under ice-cooling. After stirring for 10 minutes, (5-bromofuran-2-yl)-(4-fluorophenyl)metanone (2.00g, 7.43mmol) was added thereto and the mixture was refluxed under heating for 20 minutes. After cooling, water (60ml) was added dropwise to the solution and the mixture was extracted with diethyl ether. The extract was washed and dried. The solvent was evaporated under reduced pressure to give 2-bromo-5-(4-fluorobenzyl)furan. This residue was dissolved in tetrahydrofuran (40ml) and *n*-butyllithium (5.20ml, 8.16mmol) was added dropwise at -78°C. After 5 minutes, 2-oxo pyrrolidine-1-carboxylic acid tert-butylester (2.76g, 14.9mmol) in tetrahydrofuran (5ml) known by reference (Tetrahedron Lett., 36, 8949-8952 (1995)) was added thereto and the mixture was stirred for 2 hours. The saturated ammonium chloride aqueous solution was added to the solution to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane:ethyl acetate=3: 1) to give {4-[5-(4-fluorobenzyl)furan-2-yl]-4-oxobutyl}carbamic acid tert-butylester (1.95g, yield: 73%).

NMR(CDCl₃) δ : 1.42(9H, s), 1.89(2H, m), 2.81(2H, t, J=7.2Hz), 3.19(2H, m), 4.01(2H, s), 4.64(1H, brs), 6.09(1H, d, J=3.5Hz), 7.01(2H, m), 7.10(1H, d, J=3.5Hz), 7.21(2H, m).

(I-2) To a solution of the above-mentioned compound I-1 (900mg, 2.49mmol) and dimethyl oxalate (881mg, 7.46mmol) in toluene (20ml), was added sodium ethoxide (5.00mmol, 28% methyl alcohol solution) and the mixture was stirred at room temperature for 4 hours. 5N hydrochloric acid (5ml) was added to the solution to stop the reaction and the mixture was extracted with ethyl acetate-tetrahydrofuran. The extract was washed and dried and the solvent was evaporated under reduced pressure to give the crude product of 3-(4-fluorophenyl)-2-hydroxy-3-[5-(5-hydroxy-6-oxo-1,2,3,6-tetrahydropyridine-4-carbonyl)furan-2-yl]propenoic acid methylester.

(I-3) To a solution of the crude product of the above-mentioned compound I-2 in tetrahydrofuran (50ml), was added 1N lithium hydroxide aqueous solution (20ml) at 60°C and the mixture was stirred for 2 hours. 5N hydrochloric acid (4ml) was added to the solution to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure. The obtained precipitated crystal was recrystallized with methyl alcohol to give 4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-5,6-dihydro-1H-pyridine-2-one (138mg, yield: 18%).

Melting point: 166-168°C

Elementary analysis as C₁₇H₁₄FNO₄

Calcd. (%)	C, 64.76; H, 4.48; N, 4.44; F, 6.03.
Found (%)	C, 64.51; H, 4.55; N, 4.41; F, 5.88.

NMR(CDCl₃) δ : 2.96(2H, t, J=6.8Hz), 3.46(2H, dt, J=2.9, 6.8Hz), 4.05(2H, s), 6.22(1H, d, J=3.5Hz), 6.57(1H, brs), 7.03(2H, m), 7.21(2H, m), 7.29(1H, d, J=3.5Hz), 14.75(1H, brs).

(I-4) To a solution of the above-mentioned compound I-3 (336mg, 1.07mmol) and bromoethane (0.320ml, 4.29mmol) in tetrahydrofuran (27ml), was added a solution of potassiumbis(trimethylsilyl)amide (2.70mmol, 0.5Mtoluenesolution) and the mixture was refluxed under heating for 2.5 hours. 2N hydrochloric acid (30ml) was added to the solution to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (chloroform:methyl alcohol=50:1) to give 1-ethyl-4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-5,6-dihydro-1H-pyridine-2-one (184mg, yield: 50%).

NMR(CDCl₃) δ : 1.21(3H, t, J=7.2Hz), 2.92(2H, t, J=6.8Hz), 3.56(2H, t, J= 6.8Hz), 3.56(2H, q, J=7.2Hz), 4.04(2H, s), 6.21(1H, d, J=3.3Hz), 7.03(2H, m), 7.21(2H, m), 7.26(1H, d, J=3.3Hz), 14.51(1H, brs).

[0398] The following compound was prepared as well as above.

(I-4-a) 4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-5,6-dihydro-1H-pyridine-2-one

NMR(CDCl₃) δ : 2.94(2H, t, J=6.6Hz), 3.11(3H, s), 3.46(2H, t, J= 6.6Hz), 4.04(2H, s), 6.21(1H, d, J=3.3Hz), 7.03(2H, m), 7.21(2H, m), 7.26(1H, d, J=3.3Hz), 14.55(1H, brs).

(I-4-b) 4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-(2-methoxyethyl)-5,6-dihydro-1H-pyridine-2-one

NMR(CDCl₃) δ : 2.91(2H, t, J=6.6Hz), 3.55(2H, t, J= 6.6Hz), 3.61(3H, s), 3.56-3.70(4H, m), 4.04(2H, s), 6.20(1H, d, J=4.5Hz), 7.02(2H, m), 7.21(2H, m), 7.26(1H, d, J=4.5Hz), 14.64(1H, brs).

(I-4-c) 4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-(2-hydroxyethyl)-5,6-dihydro-1H-pyridine-2-one


NMR(CDCl₃) δ : 2.95(2H, t, J=6.6Hz), 3.56(2H, t, J= 6.6Hz), 3.66(2H, t, J=4.8Hz), 3.86(2H, t, J=4.8Hz), 4.04(2H, s), 6.21(1H, d, J=3.3Hz), 7.02(2H, m), 7.21(2H, m), 7.26(1H, d, J=3.3Hz), 14.71(1H, brs).

J group compound

Compound J-4

4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1H-pyridine-2-one

[0399]



(J-1) A suspension of 5-hydroxy-6-oxo-1,2,3,6-tetrahydropyridine-4-carboxylate ethyl ester (5.32g, 28.7mmol) known by reference (Org. Prep. Proced. Int., 29, 330-335 (1997)) and 10% palladium carbon (1.18g) in xylene (100ml) was refluxed under heating for 21 hours. The solution was diluted with chloroform:methyl alcohol and palladium carbon was removed with filtrate. The solvent was evaporated under reduced pressure to give a crude product of 3-hydroxy-2-oxo-1,2-dihydropyridine-4-carboxylate ethyl ester.

(J-2) To a solution of crude product of the above-mentioned compound J-1 and potassium carbonate (20.28g, 143.8mmol) in dimethylformamide (90ml), was added iodomethane (7.20ml, 116mmol) under ice-cooling and the

mixture was stirred at 50°C for 3 hours. 1N hydrochloric acid (135ml) was added to the solution to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried and the solvent was evaporated under reduced pressure to give 3-methoxy-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxylate ethyl ester (2.69g, yield :44%).

NMR(CDCl₃) δ : 1.39(3H, t, J=7.2Hz), 3.57(3H, s), 4.01(3H, s), 4.36(2H, q, J=7.2Hz), 6.33(1H, d, J=6.9Hz), 7.07(1H, d, J=6.9Hz).

(J-3) Aluminum chloride (4.84g, 36.3mmol) was suspended in tetrahydrofuran (50ml) and sodium borohydride (2.28g, 60.3mmol) was added thereto under ice-cooling. After stirring for 10 minutes, (5-bromofuran-2-yl)-(4-fluorophenyl)metanone (3.25g, 12.1mmol) was added thereto and the mixture was refluxed under heating for 20 minutes. After cooling, water (100ml) was added dropwise to the solution and the mixture was extracted with diethyl ether. The extract was washed and dried and the solvent was evaporated under reduced pressure to give 2-bromo-5-(4-fluorobenzyl)furan. This residue was dissolved in tetrahydrofuran (50ml) and n-butyllithium (8.00ml, 12.6mmol) was added dropwise thereto at -78°C. After 10 minutes, the above-mentioned compound J-2 (2.55g, 12.1mmol) in tetrahydrofuran (25ml) was added thereto and the mixture was stirred for 1 hour. The saturated ammonium chloride aqueous solution was added to the solution to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was diluted with methyl alcohol (50ml). 1N lithium hydroxide aqueous solution (25ml) was added thereto and the mixture was stirred at room temperature for 1 hour. 1N hydrochloric acid (20ml) was added to the solution to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane:ethyl acetate=1:2) to give 4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-methoxy-1-methyl-1H-pyridine-2-one (1.09g, yield: 27%).

NMR(CDCl₃) δ : 3.60(3H, s), 3.90(3H, s), 4.04(2H, s), 6.11(1H, d, J=6.9Hz), 6.12(1H, d, J=3.3Hz), 7.02(2H, m), 7.05(1H, d, J=3.3Hz), 7.12(1H, d, J=6.9Hz), 7.23(2H, m).

(J-4) To a solution of the above-mentioned compound J-3 (518mg, 1.52mmol) in methylene chloride (25ml), was added boron tribromide (4.50mmol, 1.0Mmethylene chloride solution) at -78°C and the mixture was stirred for 1.5 hours. Water (15ml) was added to the solution to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure. The precipitated crystal was recrystallized with ethanol to give 4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methyl-1H-pyridine-2-one(279mg, yield:56%).

Melting point:145-147°C


Elementary analysis as C ₁₈ H ₁₄ FNO ₄				
Calcd. (%)	C, 66.05;	H, 4.31;	N, 4.28;	F, 5.80.
Found (%)	C, 65.87;	H, 4.32;	N, 4.13;	F, 5.58.

NMR(CDCl₃) δ : 3.63(3H, s), 4.07(2H, s), 6.20(1H, d, J=3.9Hz), 6.57(1H, d, J=7.2Hz), 6.83(1H, d, J=7.2Hz), 7.03(2H, m), 7.24(2H, m), 7.29(1H, d, J=3.9Hz), 9.94(1H, brs).

Compound J-7

4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methoxymethyl-1H-pyridine-2-one

[0400]



(J-5) To a solution of the above-mentioned compound J-1 (3.66g, 20mmol) in dimethylformamide (80ml), was added sodium hydride (2.40g, 60mmol) under ice-cooling and the mixture was stirred for 20 minutes. Chloromethyl methyl ether (4.56ml, 60mmol) was added dropwise thereto. Then, the mixture was warmed to room temperature and stirred for 1 hour. To a mixture of ethyl acetate and sodium hydrogen carbonate aqueous solution, was added the solution under ice-cooling and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated and the residue was purified with silica gel column chromatography (n-hexane-ethyl acetate=3:1) to give 3-methoxymethoxy-1-methoxymethyl-2-oxo-1,2-dihydropyridine-4-carboxylate ethyl ester (1.47g, yield: 26%).

NMR(CDCl₃) δ : 1.31(3H, t, J=7.1Hz), 3.31(3H, s), 3.48(3H, s), 4.30(2H, q, J=7.1Hz), 5.25(2H, s), 5.32(2H, s), 6.32(1H, d, J=7.3Hz), 7.12(1H, d, J=7.3Hz).

(J-6) Aluminum chloride (3.25g, 24.4mmol) was suspended in tetrahydrofuran (22ml) and sodium borohydride (1.54g, 40.7mmol) was added thereto under ice-cooling. After stirring for 10 minutes, (5-bromofuran-2-yl)-(4-fluorophenyl)metanone (2.19g, 8.13mmol) was added thereto and the mixture was refluxed under heating for 30 minutes. After cooling, water (40ml) was added dropwise to the solution and the mixture was extracted with diethyl ether. The extract was washed and dried. The solvent was evaporated under reduced pressure to give the crude purified product (2.22g) of 2-bromo-5-(4-fluorobenzyl)furan. This residue was dissolved in tetrahydrofuran (30ml) and n-butyllithium (5.18ml, 8.13mmol) was added dropwise thereto at -78°C. After stirring for 10 minutes, a solution of the above-mentioned compound J-5 (1.47g, 5.42mmol) in tetrahydrofuran (3ml) was added thereto and the mixture was stirred for 90 minutes. Ammonium chloride aqueous solution and water were added to the solution at -78°C and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (ethyl acetate from n-hexane-ethyl acetate=3:1) to give 4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-methoxymethoxy-1-methoxymethyl-1H-pyridine-2-one (735mg, yield:34%).

NMR(CDCl₃) δ : 3.25(3H, s), 3.43(3H, s), 4.05(2H, s), 5.25(2H, s), 5.35(2H, s), 6.16(1H, d, J=3.4Hz), 6.20(1H, d, J=7.0Hz), 6.98-7.04(2H, m), 7.11(1H, d, J=3.7Hz), 7.20-7.29(3H, m).

(J-7) To a solution of the above-mentioned compound J-6 (141mg, 0.35mmol) in ethanol (5ml), was added 3N-hydrochloric acid (5ml) and the mixture was stirred for 1 hour. The solution was neutralized with sodium hydroxide aqueous solution and sodium hydrogen carbonate aqueous solution and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure. The obtained precipitated crystal was recrystallized with diisopropylether and ethanol and dried under reduced pressure to give 4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1-methoxymethyl-1H-pyridine-2-one (52mg, yield: 42%).

Melting point: 128-130°C

Elementary analysis as C ₁₉ H ₁₆ FN ₂ O ₅				
Calcd. (%)	C, 63.86;	H, 4.51;	N, 3.92;	F, 5.32.
Found (%)	C, 63.35;	H, 4.43;	N, 3.79;	F, 5.07.


EP 1 422 218 A1

NMR(CDCI₃) δ : 3.42(3H, s), 4.08(2H, s), 5.38(2H, s), 6.21(1H, d, J=3.7Hz), 6.64(1H, d, J=7.6Hz), 6.95(1H, d, J=7.6Hz), 7.01-7.06(2H, m), 7.22-7.27(2H, m), 7.32(1H, d, J=3.7Hz).

Compound J-8

4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1H-pyridine-2-one

[0401]



(J-8) To a solution of the above-mentioned compound J-6 (685mg, 1.71mmol) in methylene chloride (15ml), was added boron tribromide methylene chloride solution (5.13ml) at -78°C. The mixture was stirred for 90 minutes, warmed to 0°C and then stirred for 20 minutes. Water was added to the solution under ice-cooling and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated. The obtained precipitated crystal was washed with chloroform, recrystallized with ethanol and dried under reduced pressure to give 4-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1H-pyridine-2-one (301mg, yield: 56%).

Melting point: 229-231°C

Elementary analysis as C₁₇H₁₂FNO₄

Calcd. (%)	C, 65.18; H, 3.86; N, 4.47; F, 6.06.
Found (%)	C, 63.80; H, 3.75; N, 4.37; F, 5.77; Cl, 0.87.


NMR(DMSO-d₆) δ : 4.15(2H, s), 6.14(1H, d, J=6.7Hz), 6.44(1H, d, J=3.7Hz), 6.97(1H, d, J=6.7Hz), 7.19-7.25(3H, m), 7.35-7.40(2H, m), 9.76(1H, brs), 11.98(1H, brs).

K group compound

Compound K-4

4-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-3-hydroxy-1-methyl-1H-pyridine-2-one

[0402]



(K-1) To a solution of compound J-2 (1.00g, 4.73mmol) in ethanol (5ml), was added hydrazine monohydrate (1ml) and the mixture was refluxed under heating for 1 hour. The solvent was evaporated under reduced pressure to give crude product of 3-methoxy-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid hydrazide.

(K-2) To a suspension of crude product of the above-mentioned compound K-1, 4-fluorophenylacetic acid (1.12g, 7.12mmol) and 1-hydroxybenzotriazole (132mg, 0.977mmol) in dimethylformamide (10ml), was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride (1.36g, 7.09mmol) and the mixture was stirred at room temperature for 20 hours. Water (20ml) was added to the solution to stop the reaction and the mixture was extracted with chloroform. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (chloroform) to give 3-methoxy-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid N'-[2-(4-fluorophenyl) acetyl]-hydrazide (919mg, yield: 58%)
 NMR(CDCl₃) δ : 3.57(3H, s), 3.66(3H, s), 4.22(2H, s), 6.72(1H, d, J=7.2Hz), 7.04(2H, m), 7.12(1H, d, J=7.2Hz), 7.30(2H, m).

(K-3) To the above-mentioned compound K-2 (916mg, 2.75mmol), was added polyphosphoric acid (18g) and the mixture was stirred at 150°C for 1 hour. Ice water (50g) was added to the solution and the obtained precipitated crystal was washed with water and recrystallized with ethanol to give 4-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-3-methoxy-1-methyl-1H-pyridine-2-one (498mg, yield: 58%).

NMR(CDCl₃) δ : 3.59(3H, s), 4.01(3H, s), 4.28(2H, s), 6.69(1H, d, J=7.2Hz), 7.05(2H, m), 7.13(1H, d, J=7.2Hz), 7.35(2H, m).

(K-4) To a solution of the above-mentioned compound K-3 (261mg, 0.828mmol) in methylene chloride (25ml), was added boron tribromide (2.40mmol, 1.0M methylene chloride solution) under ice-cooling and the mixture was stirred for 75 minutes. Water (10ml) was added to the solution to stop the reaction and the mixture was extracted with chloroform. The extract was washed and dried. The solvent was evaporated under reduced pressure. The obtained precipitated crystal was recrystallized with chloroform:methyl alcohol to give 4-[5-(4-fluorobenzyl)-[1,3,4]oxadiazole-2-yl]-3-hydroxy-1-methyl-1H-pyridine-2-one (200mg, yield: 80%).

Melting point: 216-218°C

Elementary analysis as C ₁₅ H ₁₂ FN ₃ O ₃ (CHCl ₃) _{0.04}				
Calcd. (%)	C, 59.02;	H, 3.97;	N, 13.73;	Cl, 1.39; F, 6.21.
Found (%)	C, 59.10;	H, 3.92;	N, 13.68;	Cl, 1.20; F, 6.13.


NMR(DMSO-d₆) δ : 3.52(3H, s), 4.37(2H, s), 6.56(1H, d, J=7.5Hz), 7.19(2H, m), 7.27(1H, d, J=7.5Hz), 7.41(2H, m), 10.37(1H, brs).

L group compound

Compound L-4

2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1H-pyridine-4-one

[0403]



(L-1) To a solution of 3-hydroxy-4-methoxypyridine-2-carboxylic acid (2.85g, 16.8mmol) in ethanol (60ml) known by reference (Tetrahedron, 54, 12745-12774 (1998)), was added strong sulfuric acid (1ml) and the mixture was refluxed under heating for 75 hours. The solvent was evaporated under reduced pressure. Water (60ml) and potassium carbonate (1.6g) were added the obtained residue to neutralize and the mixture was extracted with chloroform. The extract was washed and dried. The solvent was evaporated under reduced pressure to give 3-hydroxy-

4-methoxypyridine-2-carboxylate ethyl ester (2.06g, yield: 62%).

NMR(CDCl₃) δ : 1.49(3H, t, J=7.2Hz), 3.97(3H, s), 4.54(2H, q, J=7.2Hz), 6.94(1H, d, J=5.1Hz), 8.19(1H, d, J=5.1Hz), 11.01(1H, brs).

(L-2) To a solution the above-mentioned compound L-1 (2.05g, 10.4mmol) and potassium carbonate (2.85g, 20.6mmol) in dimethylformamide (40ml), was added dimethyl sulfate (1.45ml, 15.3mmol) and the mixture was stirred at 80°C for 2 hours. 1N hydrochloric acid (30ml) and water (50ml) were added to the solution to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane: ethyl acetate=1:1) to give 3,4-dimethoxypyridine-2-carboxylate ethyl ester (1.08g, yield: 49%).

NMR(CDCl₃) δ : 1.43(3H, t, J=7.2Hz), 3.93(3H, s), 3.95(3H, s), 4.45(2H, q, J=7.2Hz), 6.95(1H, d, J=5.4Hz), 8.32(1H, d, J=5.4Hz).

(L-3) Aluminum chloride (3.06g, 22.9mmol) was suspended in tetrahydrofuran (30ml). Sodium borohydride (1.45g, 38.3mmol) was added thereto under ice-cooling. The mixture was stirred for 10 minutes. (5-bromofuran-2-yl)-(4-fluorophenyl)metanone (2.05g, 7.62mmol) was added thereto and the mixture was refluxed under heating for 20 minutes. After cooling, water (60ml) was added dropwise to the solution and the mixture was extracted with diethyl ether. The extract was washed and dried. The solvent was evaporated under reduced pressure to give 2-bromo-5-(4-fluorobenzyl)furan. This residue was dissolved in tetrahydrofuran (35ml). n-butyllithium (4.90ml, 7.64mmol) was added dropwise thereto at -78°C. After 10 minutes, tetrahydrofuran (15ml) of the above-mentioned compound L-2 (1.07g, 5.07mmol) was added thereto and the mixture was stirred for 1 hour. The saturated ammonium chloride aqueous solution was added to the solution to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane:ethyl acetate=1:1) to give (3,4-dimethoxypyridine-2-yl)-[5-(4-fluorobenzyl)furan-2-yl]metanone (1.53g, yield: 90%).

NMR(CDCl₃) δ : 3.90(3H, s), 3.96(3H, s), 4.05(2H, s), 6.09(1H, d, J=3.5Hz), 6.95(1H, d, J=5.6Hz), 7.00(2H, m), 7.03(1H, d, J=3.5Hz), 7.22(2H, m), 8.28(1H, d, J=5.6Hz).

(L-4) To a suspension of the above-mentioned compound L-3 (1.48g, 4.34mmol) and sodium iodide (5.22g, 34.8mmol) in acetonitrile (30ml), was added chlorotrimethylsilane (4.40ml, 34.7mmol) and the mixture was refluxed under heating for 3 hours. Water (30ml) and 10 % sodium hydrogen sulfate aqueous solution (30ml) were added to the solution to stop the reaction and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography. The solvent was evaporated from the fraction of the obtained product by eluting with ethyl acetate under reduced pressure and the obtained precipitated crystal was crystallized with toluene to give 2-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-1H-pyridine-4-one (448mg, yield: 33%).


NMR(CD₃OD) δ : 4.10(2H, s), 6.35(1H, d, J=3.6Hz), 6.69(1H, d, J=5.9Hz), 7.05(2H, m), 7.32(2H, m), 7.81(1H, d, J=5.9Hz), 7.84(1H, brs).

M group compound

Compound M-6

5-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-2-methyl-1H-pyridine-4-one

[0404]



(M-1) According to the method described in WO92/02523, 5-methoxy-6-methyl-4-oxo-1,4-dihydropyridine-3-carboxylate methyl ester was synthesized.

(M-2) A solution of the above-mentioned compound M-1 (980mg, 5.0mmol) in phosphorus oxychloride (5ml) was refluxed under heating for 30 minutes. The solvent was evaporated from the solution under reduced pressure and the residue was neutralized with sodium hydroxide aqueous solution. The mixture was extracted with ethyl acetate and the extract was washed and dried. The solvent was evaporated to give crude product (738mg) of 4-chloro-5-methoxy-6-methyl-nicotinate methylester.

NMR(CDCl₃) δ : 2.61(3H, s), 3.88(3H, s), 3.96(3H, s), 8.71(1H, s).

(M-3) To a solution of the above-mentioned crude product M-2 (738mg) in methyl alcohol (5ml), was added sodium methylate methyl alcohol solution (2.49ml) under ice-cooling. After stirring at room temperature for 2 hours, the mixture was warmed to 50°C and stirred for 2 hours. The solution was neutralized with ammonium chloride aqueous solution. Methyl alcohol was evaporated under reduced pressure and the residue was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated to give crude product (609mg) of 4,5-dimethoxy-6-methyl-nicotinate methylester.

NMR(CDCl₃) δ : 2.53(3H, s), 3.85(3H, s), 3.92(3H, s), 4.02(3H, s), 8.61(1H, s).

(M-4) A solution of the above-mentioned crude product M-3 (449mg) in sodium hydroxide (10ml) was refluxed under heating for 1 hour. The solution was neutralized with hydrochloric acid and the solvent was evaporated under reduced pressure. To a solution of the residue in methylene chloride (10ml), were added N,O-dimethylhydroxyamine hydrochloride (249mg, 2.56mmol) and 1-hydroxybenzotriazole (58mg, 0.43mmol). Triethylamine (357 μ l, 2.56mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride (491mg, 2.56mmol) were added thereto under ice-cooling and the mixture was warmed and stirred for 2 hours. The ammonium chloride aqueous solution was added to the solution and the mixture was extracted with chloroform. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane-ethyl acetate=1:1) to give 4,5-N-trimethoxy-6,N-dimethyl-nicotinamide (449mg, yield: 80%).

NMR(CDCl₃) δ : 2.51(3H, s), 3.34(3H, brs), 3.52(3H, brs), 3.83(3H, s), 4.00(3H, s), 8.13(1H, s).

(M-5) Aluminum chloride (2.02g, 15.0mmol) was suspended in tetrahydrofuran (20ml). Sodium borohydride (851mg, 22.5mmol) was added thereto under ice-cooling. After stirring for 10 minutes, (5-bromofuran-2-yl)-(4-fluorophenyl)metanone (2.02g, 7.5mmol) was added thereto and the mixture was refluxed under heating for 30 minutes. After cooling, water (20ml) was added dropwise to the solution and the mixture was extracted with diethyl ether. The extract was washed and dried. The solvent was evaporated under reduced pressure to give 2-bromo-5-(4-fluorobenzyl)furan (1.74g, yield: 91%). This residue (715mg, 2.80mmol) was dissolved in tetrahydrofuran (9ml). n-butyllithium (1.79ml, 2.80mmol) was added dropwise thereto at -78°C. After stirring for 5 minutes, a solution of the above-mentioned compound M-4 (449mg, 1.87mmol) in tetrahydrofuran (1ml) was added thereto and the mixture was stirred for 30 minutes. The ammonium chloride aqueous solution and water were added to the solution at -78°C and the mixture was extracted with ethyl acetate. The extract was washed and dried. The solvent was evaporated under reduced pressure and the residue was purified with silica gel column chromatography (n-hexane-ethyl acetate=1:1) to give (4,5-dimethoxy-6-methylpyridine-3-yl)-[5-(4-fluorobenzyl)furan-2-yl]-metanone (348mg, yield: 52%).

NMR(CDCl₃) δ : 2.54(3H, s), 3.84(3H, s), 3.91(3H, s), 4.05(2H, s), 6.15(1H, d, J=3.7Hz), 6.99-7.06(3H, m), 7.21-7.26(2H, m), 8.26(1H, s).


(M-6) To a solution of the above-mentioned compound M-5 (289mg, 0.81mmol) in methylene chloride (6ml), boron tribromide/methylene chloride solution (4.05ml) was added under ice-cooling. The mixture was stirred at 0°C for 30 minutes, warmed to room temperature and then stirred for 2 hours. 2n-hydrochloric acid (6ml) was added to the solution and the mixture was stirred for 10 minutes and neutralized with sodium hydrogen carbonate. The mixture was extracted with ethyl acetate and the extract was washed and dried. The solvent was evaporated and the obtained precipitated crystal was washed with chloroform, recrystallized with ethanol and dried under reduced pressure to give 5-[5-(4-fluorobenzyl)furan-2-carbonyl]-3-hydroxy-2-methyl-1H-pyridine-4-one (123mg, yield: 46%).

Melting point: 190-192°C

Elementary analysis as C ₁₈ H ₁₄ FNO ₄				
Calcd. (%)	C, 66.05;	H, 4.31;	N, 4.28;	F, 5.80.
Found (%)	C, 65.17;	H, 4.18;	N, 4.27;	F, 5.56.

NMR(DMSO-d₆) δ : 2.20(3H, s), 4.08(2H, s), 6.34(1H, d, J=3.7Hz), 7.14-7.20(2H, m), 7.25(1H, d, J=3.7Hz), 7.30-7.35(2H, m), 7.72(1H, s).

[0405] The compounds of the present invention include the following compounds which can be synthesized with a manner similar to that of the above examples.




[0406] The substituents of R¹, R², X, R⁴ and R⁵ of above compound include the following substitution group.

R¹ = H (1A), Me(1B), OMe(1C), Cl(1D), Ph(1E)

R² = H (2A), Me(2B), OMe(2C), Cl(2D), Ph(2E)

X = O(3A), NH(3B)



R⁵ = H (5A), Me(5B), OMe(5C), Cl(5D), Ph(5E)

[0407] The preferable combinations (R¹, R², X, R⁴, R⁵) of the substituents of above compound include the followings.

(1A, 2A, 3A, 4A, 5A), (1A, 2A, 3A, 4A, 5B), (1A, 2A, 3A, 4A, 5C), (1A, 2A, 3A, 4A, 5D), (1A, 2A, 3A, 4A, 5E), (1A, 2A, 3A, 4B, 5A), (1A, 2A, 3A, 4B, 5B), (1A, 2A, 3A, 4B, 5C), (1A, 2A, 3A, 4B, 5D), (1A, 2A, 3A, 4B, 5E), (1A, 2A, 3A, 4C, 5A), (1A, 2A, 3A, 4C, 5B), (1A, 2A, 3A, 4C, 5C), (1A, 2A, 3A, 4C, 5D), (1A, 2A, 3A, 4C, 5E), (1A, 2A, 3A, 4D, 5A), (1A, 2A, 3A, 4D, 5B), (1A, 2A, 3A, 4D, 5C), (1A, 2A, 3A, 4D, 5D), (1A, 2A, 3A, 4D, 5E), (1A, 2A, 3A, 4E, 5A), (1A, 2A, 3A, 4E, 5B), (1A, 2A, 3A, 4E, 5C), (1A, 2A, 3A, 4E, 5D), (1A, 2A, 3A, 4E, 5E), (1A, 2A, 3B, 4A, 5A), (1A, 2A, 3B, 4A, 5B), (1A, 2A, 3B, 4A, 5C), (1A, 2A, 3B, 4A, 5D), (1A, 2A, 3B, 4A, 5E), (1A, 2A, 3B, 4B, 5A), (1A, 2A, 3B, 4B, 5B), (1A, 2A, 3B, 4B, 5C), (1A, 2A, 3B, 4B, 5D), (1A, 2A, 3B, 4B, 5E), (1A, 2A, 3B, 4C, 5A), (1A, 2A, 3B, 4C, 5B), (1A, 2A, 3B, 4C, 5C), (1A, 2A, 3B, 4C, 5D), (1A, 2A, 3B, 4C, 5E), (1A, 2A, 3B, 4D, 5A), (1A, 2A, 3B, 4D, 5B), (1A, 2A, 3B, 4D, 5C), (1A, 2A, 3B, 4D, 5D), (1A, 2A, 3B, 4D, 5E), (1A, 2A, 3B, 4E, 5A), (1A, 2A, 3B, 4E, 5B), (1A, 2A, 3B, 4E, 5C), (1A, 2A, 3B, 4E, 5D), (1A, 2A, 3B, 4E, 5E), (1A, 2B, 3A, 4A, 5A), (1A, 2B, 3A, 4A, 5B), (1A, 2B, 3A, 4A, 5C), (1A, 2B, 3A, 4A, 5D), (1A, 2B, 3A, 4A, 5E), (1A, 2B, 3A, 4B, 5A), (1A, 2B, 3A, 4B, 5B), (1A, 2B, 3A, 4B, 5C), (1A, 2B, 3A, 4B, 5D), (1A, 2B, 3A, 4B, 5E), (1A, 2B, 3A, 4C, 5A), (1A, 2B, 3A, 4C, 5B), (1A, 2B, 3A, 4C, 5C), (1A, 2B, 3A, 4C, 5D), (1A, 2B, 3A, 4C, 5E), (1A, 2B, 3A, 4D, 5A), (1A, 2B, 3A, 4D, 5B), (1A, 2B, 3A, 4D, 5C), (1A, 2B, 3A, 4D, 5D), (1A, 2B, 3A, 4D, 5E), (1A, 2B, 3A, 4E, 5A), (1A, 2B, 3A, 4E, 5B), (1A, 2B, 3A, 4E, 5C), (1A, 2B, 3A, 4E, 5D), (1A, 2B, 3A, 4E, 5E), (1A, 2B, 3B, 4A, 5A), (1A, 2B, 3B, 4A, 5B), (1A, 2B, 3B, 4A, 5C), (1A, 2B, 3B, 4A, 5D), (1A, 2B, 3B, 4A, 5E), (1A, 2B, 3B, 4B, 5A), (1A, 2B, 3B, 4B, 5B), (1A, 2B, 3B, 4B, 5C), (1A, 2B, 3B, 4B, 5D), (1A, 2B, 3B, 4B, 5E), (1A, 2B, 3B, 4C, 5A), (1A, 2B, 3B, 4C, 5B), (1A, 2B, 3B, 4C, 5C), (1A, 2B, 3B, 4C, 5D), (1A, 2B, 3B, 4C, 5E), (1A, 2B, 3B, 4D, 5A), (1A, 2B, 3B, 4D, 5B), (1A, 2B, 3B, 4D, 5C), (1A, 2B, 3B, 4D, 5D), (1A, 2B, 3B, 4D, 5E), (1A, 2B, 3B, 4E, 5A), (1A, 2B, 3B, 4E, 5B), (1A, 2B, 3B, 4E, 5C), (1A, 2B, 3B, 4E, 5D), (1A, 2B, 3B, 4E, 5E), (1A, 2C, 3A, 4A, 5A), (1A, 2C, 3A, 4A, 5B), (1A, 2C, 3A, 4A, 5C), (1A, 2C, 3A, 4A, 5D), (1A, 2C, 3A, 4A, 5E), (1A, 2C, 3A, 4B, 5A), (1A, 2C, 3A, 4B, 5B), (1A, 2C, 3A, 4B, 5C), (1A, 2C, 3A, 4B, 5D), (1A, 2C, 3A, 4B, 5E), (1A, 2C, 3A, 4C, 5A), (1A, 2C, 3A, 4C, 5B), (1A, 2C, 3A, 4C, 5C), (1A, 2C, 3A, 4C, 5D), (1A, 2C, 3A, 4C, 5E), (1A, 2C, 3A, 4D, 5A), (1A, 2C, 3A, 4D, 5B), (1A, 2C, 3A, 4D, 5C), (1A, 2C, 3A, 4D, 5D), (1A, 2C, 3A, 4D, 5E), (1A, 2C, 3A, 4E, 5A), (1A, 2C, 3A, 4E, 5B), (1A, 2C, 3A, 4E, 5C), (1A, 2C, 3A, 4E, 5D), (1A, 2C, 3A, 4E, 5E), (1A, 2C, 3B, 4A, 5A), (1A, 2C, 3B, 4A, 5B), (1A, 2C, 3B, 4A, 5C), (1A, 2C, 3B, 4A, 5D), (1A, 2C, 3B, 4A, 5E), (1A, 2C, 3B, 4B, 5A), (1A, 2C, 3B, 4B, 5B), (1A, 2C, 3B, 4B, 5C), (1A, 2C, 3B, 4B, 5D), (1A, 2C, 3B, 4B, 5E), (1A, 2C, 3B, 4C, 5A), (1A, 2C, 3B, 4C, 5B), (1A, 2C, 3B, 4C, 5C), (1A, 2C, 3B, 4C, 5D), (1A, 2C, 3B, 4C, 5E), (1A, 2C, 3B, 4D, 5A), (1A, 2C, 3B, 4D, 5B), (1A, 2C, 3B, 4D, 5C), (1A, 2C, 3B, 4D, 5D), (1A, 2C, 3B, 4D, 5E), (1A, 2C, 3B, 4E, 5A), (1A, 2C, 3B, 4E, 5B), (1A, 2C, 3B, 4E, 5C), (1A, 2C, 3B, 4E, 5D), (1A, 2C, 3B, 4E, 5E).

(1A,2C,3B,4B,5E),(1A,2C,3B,4C,5A),(1A,2C,3B,4C,5B),(1A,2C,3B,4C, 5C),(1A,2C,3B,4C,5D),(1A,2C,3B,4C,5E),
 (1A,2C,3B,4D,5A),(1A,2C,3B,4D,5B),(1A,2C,3 B,4D,5C),(1A,2C,3B,4D,5D),(1A,2C,3B,4D,5E),(1A,2C,3B,4E,5A),
 (1A,2C,3B,4E,5B),(1A, 2C,3B,4E,5C),(1A,2C,3B,4E,5D),(1A,2C,3B,4E,5E),(1A,2D,3A,4A,5A),(1A,2D,3A,4A,5B),
 (1A,2D,3A,4A,5C),(1A,2D,3A,4A,5D),(1A,2D,3A,4A,5E),(1A,2D,3A,4B,5A),(1A,2D,3A,4B, 5B),(1A,2D,3A,4B,5C),
 5 (1A,2D,3A,4B,5D),(1A,2D,3A,4B,5E),(1A,2D,3A,4C,5A),(1A,2D,3 A,4C,5B),(1A,2D,3A,4C,5C),(1A,2D,3A,4C,5D),
 (1A,2D,3A,4C,5E),(1A,2D,3A,4D,5A),(1A, 2D,3A,4D,5B),(1A,2D,3A,4D,5C),(1A,2D,3A,4D,5D),(1A,2D,3A,4D,5E),
 (1A,2D,3A,4E,5A), (1A,2D,3A,4E,5B),(1A,2D,3A,4E,5C),(1A,2D,3A,4E,5D),(1A,2D,3A,4E,5E),(1A,2D,3B,4A, 5A),
 (1A,2D,3B,4A,5B),(1A,2D,3B,4A,5C),(1A,2D,3B,4A,5D),(1A,2D,3B,4A,5E),(1A,2D,3 B,4B,5A),(1A,2D,3B,4B,5B),
 (1A,2D,3B,4B,5C),(1A,2D,3B,4B,5D),(1A,2D,3B,4B,5E),(1A, 2D,3B,4C,5A),(1A,2D,3B,4C,5B),(1A,2D,3B,4C,5C),
 10 (1A,2D,3B,4C,5D),(1A,2D,3B,4C,5E), (1A,2D,3B,4D,5A),(1A,2D,3B,4D,5B),(1A,2D,3B,4D,5C),(1A,2D,3B,4D,5D),
 (1A,2D,3B,4D, 5E),(1A,2D,3B,4E,5A),(1A,2D,3B,4E,5B),(1A,2D,3B,4E,5C),(1A,2D,3B,4E,5D),(1A,2D,3 B,4E,5E),
 (1A,2E,3A,4A,5A),(1A,2E,3A,4A,5B),(1A,2E,3A,4A,5C),(1A,2E,3A,4A,5D),(1A, 2E,3A,4A,5E),(1A,2E,3A,4B,5A),(1A,
 2E,3A,4B,5B),(1A,2E,3A,4B,5C),(1A,2E,3A,4B,5D), (1A,2E,3A,4B,5E),(1A,2E,3A,4C,5A),(1A,2E,3A,4C,5B),(1A,2E,
 3A,4C,5C),(1A,2E,3A,4C, 5D),(1A,2E,3A,4C,5E),(1A,2E,3A,4D,5A),(1A,2E,3A,4D,5B),(1A,2E,3A,4D,5C),(1A,2E,3
 15 A,4D,5D),(1A,2E,3A,4D,5E),(1A,2E,3A,4E,5A),(1A,2E,3A,4E,5B),(1A,2E,3A,4E,5C),(1A, 2E,3A,4E,5D),(1A,2E,3A,
 4E,5E),(1A,2E,3B,4A,5A),(1A,2E,3B,4A,5B),(1A,2E,3B,4A,5C), (1A,2E,3B,4A,5D),(1A,2E,3B,4A,5E),(1A,2E,3B,4B,
 5A),(1A,2E,3B,4B,5B),(1A,2E,3B,4B, 5C),(1A,2E,3B,4B,5D),(1A,2E,3B,4B,5E),(1A,2E,3B,4C,5A),(1A,2E,3B,4C,5B),
 (1A,2E,3 B,4C,5C),(1A,2E,3B,4C,5D),(1A,2E,3B,4C,5E),(1A,2E,3B,4D,5A),(1A,2E,3B,4D,5B),(1A, 2E,3B,4D,5C),
 (1A,2E,3B,4D,5D),(1A,2E,3B,4D,5E),(1A,2E,3B,4E,5A),(1A,2E,3B,4E,5B), (1A,2E,3B,4E,5C),(1A,2E,3B,4E,5D),
 20 (1A,2E,3B,4E,5E),(1B,2A,3A,4A,5A),(1B,2A,3A,4A, 5B),(1B,2A,3A,4A,5C),(1B,2A,3A,4A,5D),(1B,2A,3A,4A,5E),(1B,
 2A,3A,4B,5A),(1B,2A,3 A,4B,5B),(1B,2A,3A,4B,5C),(1B,2A,3A,4B,5D),(1B,2A,3A,4B,5E),(1B,2A,3A,4C,5A),(1B, 2A,
 3A,4C,5B),(1B,2A,3A,4C,5C),(1B,2A,3A,4C,5D),(1B,2A,3A,4C,5E),(1B,2A,3A,4D,5A), (1B,2A,3A,4D,5B),(1B,2A,3A,
 4D,5C),(1B,2A,3A,4D,5D),(1B,2A,3A,4D,5E),(1B,2A,3A,4E, 5A),(1B,2A,3A,4E,5B),(1B,2A,3A,4E,5C),(1B,2A,3A,4E,
 5D),(1B,2A,3A,4E,5E),(1B,2A,3 B,4A,5A),(1B,2A,3B,4A,5B),(1B,2A,3B,4A,5C),(1B,2A,3B,4A,5D),(1B,2A,3B,4A,5E),
 25 (1B, 2A,3B,4B,5A),(1B,2A,3B,4B,5B),(1B,2A,3B,4B,5C),(1B,2A,3B,4B,5D),(1B,2A,3B,4B,5E), (1B,2A,3B,4C,5A),
 (1B,2A,3B,4C,5B),(1B,2A,3B,4C,5C),(1B,2A,3B,4C,5D),(1B,2A,3B,4C, 5E),(1B,2A,3B,4D,5A),(1B,2A,3B,4D,5B),
 (1B,2A,3B,4D,5C),(1B,2A,3B,4D,5D),(1B,2A,3 B,4D,5E),(1B,2A,3B,4E,5A),(1B,2A,3B,4E,5B),(1B,2A,3B,4E,5C),
 (1B,2A,3B,4E,5D),(1B, 2A,3B,4E,5E),(1B,2B,3A,4A,5A),(1B,2B,3A,4A,5B),(1B,2B,3A,4A,5C),(1B,2B,3A,4A,5D),
 (1B,2B,3A,4A,5E),(1B,2B,3A,4B,5A),(1B,2B,3A,4B,5B),(1B,2B,3A,4B,5C),(1B,2B,3A,4B, 5D),(1B,2B,3A,4B,5E),(1B,
 30 2B,3A,4C,5A),(1B,2B,3A,4C,5B),(1B,2B,3A,4C,5C),(1B,2B,3 A,4C,5D),(1B,2B,3A,4C,5E),(1B,2B,3A,4D,5A),(1B,2B,
 3A,4D,5B),(1B,2B,3A,4D,5C),(1B, 2B,3A,4D,5D),(1B,2B,3A,4D,5E),(1B,2B,3A,4E,5A),(1B,2B,3A,4E,5B),(1B,2B,3A,
 4E,5C), (1B,2B,3A,4E,5D),(1B,2B,3A,4E,5E),(1B,2B,3B,4A,5A),(1B,2B,3B,4A,5B),(1B,2B,3B,4A, 5C),(1B,2B,3B,4A,
 5D),(1B,2B,3B,4A,5E),(1B,2B,3B,4B,5A),(1B,2B,3B,4B,5B),(1B,2B,3 B,4B,5C),(1B,2B,3B,4B,5D),(1B,2B,3B,4B,5E),
 (1B,2B,3B,4C,5A),(1B,2B,3B,4C,5B),(1B, 2B,3B,4C,5C),(1B,2B,3B,4C,5D),(1B,2B,3B,4C,5E),(1B,2B,3B,4D,5A),
 35 (1B,2B,3B,4D,5B), (1B,2B,3B,4D,5C),(1B,2B,3B,4D,5D),(1B,2B,3B,4D,5E),(1B,2B,3B,4E,5A),(1B,2B,3B,4E, 5B),
 (1B,2B,3B,4E,5C),(1B,2B,3B,4E,5D),(1B,2B,3B,4E,5E),(1B,2C,3A,4A,5A),(1B,2C,3 A,4A,5B),(1B,2C,3A,4A,5C),
 (1B,2C,3A,4A,5D),(1B,2C,3A,4A,5E),(1B,2C,3A,4B,5A),(1B, 2C,3A,4B,5B),(1B,2C,3A,4B,5C),(1B,2C,3A,4B,5D),
 (1B,2C,3A,4B,5E),(1B,2C,3A,4C,5A), (1B,2C,3A,4C,5B),(1B,2C,3A,4C,5C),(1B,2C,3A,4C,5D),(1B,2C,3A,4C,5E),
 (1B,2C,3A,4D, 5A),(1B,2C,3A,4D,5B),(1B,2C,3A,4D,5C),(1B,2C,3A,4D,5D),(1B,2C,3A,4D,5E),(1B,2C,3 A,4E,5A),
 40 (1B,2C,3A,4E,5B),(1B,2C,3A,4E,5C),(1B,2C,3A,4E,5D),(1B,2C,3A,4E,5E),(1B, 2C,3B,4A,5A),(1B,2C,3B,4A,5B),
 (1B,2C,3B,4A,5C),(1B,2C,3B,4A,5D),(1B,2C,3B,4A,5E), (1B,2C,3B,4B,5A),(1B,2C,3B,4B,5B),(1B,2C,3B,4B,5C),
 (1B,2C,3B,4B,5D),(1B,2C,3B,4B, 5E),(1B,2C,3B,4C,5A),(1B,2C,3B,4C,5B),(1B,2C,3B,4C,5C),(1B,2C,3B,4C,5D),
 (1B,2C,3 B,4C,5E),(1B,2C,3B,4D,5A),(1B,2C,3B,4D,5B),(1B,2C,3B,4D,5C),(1B,2C,3B,4D,5D),(1B, 2C,3B,4D,5E),
 (1B,2C,3B,4E,5A),(1B,2C,3B,4E,5B),(1B,2C,3B,4E,5C),(1B,2C,3B,4E,5D), (1B,2C,3B,4E,5E),(1B,2D,3A,4A,5A),
 45 (1B,2D,3A,4A,5B),(1B,2D,3A,4A,5C),(1B,2D,3A,4A, 5D),(1B,2D,3A,4A,5E),(1B,2D,3A,4B,5A),(1B,2D,3A,4B,5B),
 (1B,2D,3A,4B,5C),(1B,2D,3 A,4B,5D),(1B,2D,3A,4B,5E),(1B,2D,3A,4C,5A),(1B,2D,3A,4C,5B),(1B,2D,3A,4C,5C),
 (1B, 2D,3A,4C,5D),(1B,2D,3A,4C,5E),(1B,2D,3A,4D,5A),(1B,2D,3A,4D,5B),(1B,2D,3A,4D,5C), (1B,2D,3A,4D,5D),
 (1B,2D,3A,4D,5E),(1B,2D,3A,4E,5A),(1B,2D,3A,4E,5B),(1B,2D,3A,4E, 5C),(1B,2D,3A,4E,5D),(1B,2D,3A,4E,5E),
 (1B,2D,3B,4A,5A),(1B,2D,3B,4A,5B),(1B,2D,3 B,4A,5C),(1B,2D,3B,4A,5D),(1B,2D,3B,4A,5E),(1B,2D,3B,4B,5A),
 50 (1B,2D,3B,4B,5B),(1B, 2D,3B,4B,5C),(1B,2D,3B,4B,5D),(1B,2D,3B,4B,5E),(1B,2D,3B,4C,5A),(1B,2D,3B,4C,5B),
 (1B,2D,3B,4C,5C),(1B,2D,3B,4C,5D),(1B,2D,3B,4C,5E),(1B,2D,3B,4D,5A),(1B,2D,3B,4D, 5B),(1B,2D,3B,4D,5C),
 (1B,2D,3B,4D,5D),(1B,2D,3B,4D,5E),(1B,2D,3B,4E,5A),(1B,2D,3 B,4E,5B),(1B,2D,3B,4E,5C),(1B,2D,3B,4E,5D),
 (1B,2D,3B,4E,5E),(1B,2E,3A,4A,5A),(1B, 2E,3A,4A,5B),(1B,2E,3A,4A,5C),(1B,2E,3A,4A,5D),(1B,2E,3A,4A,5E),(1B,
 2E,3A,4B,5A), (1B,2E,3A,4B,5B),(1B,2E,3A,4B,5C),(1B,2E,3A,4B,5D),(1B,2E,3A,4B,5E),(1B,2E,3A,4C, 5A),(1B,2E,
 55 3A,4C,5B),(1B,2E,3A,4C,5C),(1B,2E,3A,4C,5D),(1B,2E,3A,4C,5E),(1B,2E,3 A,4D,5A),(1B,2E,3A,4D,5B),(1B,2E,3A,
 4D,5C),(1B,2E,3A,4D,5D),(1B,2E,3A,4D,5E),(1B, 2E,3A,4E,5A),(1B,2E,3A,4E,5B),(1B,2E,3A,4E,5C),(1B,2E,3A,4E,
 5D),(1B,2E,3A,4E,5E), (1B,2E,3B,4A,5A),(1B,2E,3B,4A,5B),(1B,2E,3B,4A,5C),(1B,2E,3B,4A,5D),(1B,2E,3B,4A,
 5E),(1B,2E,3B,4B,5A),(1B,2E,3B,4B,5B),(1B,2E,3B,4B,5C),(1B,2E,3B,4B,5D),(1B,2E,3 B,4B,5E),(1B,2E,3B,4C,5A),


(1B,2E,3B,4C,5B),(1B,2E,3B,4C,5C),(1B,2E,3B,4C,5D),(1B, 2E,3B,4C,5E),(1B,2E,3B,4D,5A),(1B,2E,3B,4D,5B),
 (1B,2E,3B,4D,5C),(1B,2E,3B,4D,5D), (1B,2E,3B,4D,5E),(1B,2E,3B,4E,5A),(1B,2E,3B,4E,5B),(1B,2E,3B,4E,5C),
 (1B,2E,3B,4E, 5D),(1B,2E,3B,4E,5E),(1C,2A,3A,4A,5A),(1C,2A,3A,4A,5B),(1C,2A,3A,4A,5C),(1C,2A,3 A,4A,5D),
 (1C,2A,3A,4A,5E),(1C,2A,3A,4B,5A),(1C,2A,3A,4B,5B),(1C,2A,3A,4B,5C),(1C, 2A,3A,4B,5D),(1C,2A,3A,4B,5E),
 5 (1C,2A,3A,4C,5A),(1C,2A,3A,4C,5B),(1C,2A,3A,4C,5C), (1C,2A,3A,4C,5D),(1C,2A,3A,4C,5E),(1C,2A,3A,4D,5A),
 (1C,2A,3A,4D,5B),(1C,2A,3A,4D, 5C),(1C,2A,3A,4D,5D),(1C,2A,3A,4D,5E),(1C,2A,3A,4E,5A),(1C,2A,3A,4E,5B),
 (1C,2A,3 A,4E,5C),(1C,2A,3A,4E,5D),(1C,2A,3A,4E,5E),(1C,2A,3B,4A,5A),(1C,2A,3B,4A,5B),(1C, 2A,3B,4A,5C),
 (1C,2A,3B,4A,5D),(1C,2A,3B,4A,5E),(1C,2A,3B,4B,5A),(1C,2A,3B,4B,5B), (1C,2A,3B,4B,5C),(1C,2A,3B,4B,5D),
 (1C,2A,3B,4B,5E),(1C,2A,3B,4C,5A),(1C,2A,3B,4C, 5B),(1C,2A,3B,4C,5C),(1C,2A,3B,4C,5D),(1C,2A,3B,4C,5E),
 10 (1C,2A,3B,4D,5A),(1C,2A,3 B,4D,5B),(1C,2A,3B,4D,5C),(1C,2A,3B,4D,5D),(1C,2A,3B,4D,5E),(1C,2A,3B,4E,5A),
 (1C, 2A,3B,4E,5B),(1C,2A,3B,4E,5C),(1C,2A,3B,4E,5D),(1C,2A,3B,4E,5E),(1C,2B,3A,4A,5A), (1C,2B,3A,4A,5B),
 (1C,2B,3A,4A,5C),(1C,2B,3A,4A,5D),(1C,2B,3A,4A,5E),(1C,2B,3A,4B, 5A),(1C,2B,3A,4B,5B),(1C,2B,3A,4B,5C),
 (1C,2B,3A,4B,5D),(1C,2B,3A,4B,5E),(1C,2B,3 A,4C,5A),(1C,2B,3A,4C,5B),(1C,2B,3A,4C,5C),(1C,2B,3A,4C,5D),
 (1C,2B,3A,4C,5E),(1C, 2B,3A,4D,5A),(1C,2B,3A,4D,5B),(1C,2B,3A,4D,5C),(1C,2B,3A,4D,5D),(1C,2B,3A,4D,5E),
 15 (1C,2B,3A,4E,5A),(1C,2B,3A,4E,5B),(1C,2B,3A,4E,5C),(1C,2B,3A,4E,5D),(1C,2B,3A,4E, 5E),(1C,2B,3B,4A,5A),
 (1C,2B,3B,4A,5B),(1C,2B,3B,4A,5C),(1C,2B,3B,4A,5D),(1C,2B,3 B,4A,5E),(1C,2B,3B,4B,5A),(1C,2B,3B,4B,5B),
 (1C,2B,3B,4B,5C),(1C,2B,3B,4B,5D),(1C, 2B,3B,4B,5E),(1C,2B,3B,4C,5A),(1C,2B,3B,4C,5B),(1C,2B,3B,4C,5C),
 (1C,2B,3B,4C,5D),(1C,2B,3B,4C,5E),(1C,2B,3B,4D,5A),(1C,2B,3B,4D,5B),(1C,2B,3B,4D,5C),(1C,2B,3B,4D, 5D),
 (1C,2B,3B,4D,5E),(1C,2B,3B,4E,5A),(1C,2B,3B,4E,5B),(1C,2B,3B,4E,5C),(1C,2B,3 B,4E,5D),(1C,2B,3B,4E,5E),
 20 (1C,2C,3A,4A,5A),(1C,2C,3A,4A,5B),(1C,2C,3A,4A,5C),(1C, 2C,3A,4A,5D),(1C,2C,3A,4A,5E),(1C,2C,3A,4B,5A),
 (1C,2C,3A,4B,5B),(1C,2C,3A,4B,5C), (1C,2C,3A,4B,5D),(1C,2C,3A,4B,5E),(1C,2C,3A,4C,5A),(1C,2C,3A,4C,5B),
 (1C,2C,3A,4C, 5C),(1C,2C,3A,4C,5D),(1C,2C,3A,4C,5E),(1C,2C,3A,4D,5A),(1C,2C,3A,4D,5B),(1C,2C,3 A,4D,5C),
 (1C,2C,3A,4D,5D),(1C,2C,3A,4D,5E),(1C,2C,3A,4E,5A),(1C,2C,3A,4E,5B),(1C, 2C,3A,4E,5C),(1C,2C,3A,4E,5D),
 (1C,2C,3A,4E,5E),(1C,2C,3B,4A,5A),(1C,2C,3B,4A,5B), (1C,2C,3B,4A,5C),(1C,2C,3B,4A,5D),(1C,2C,3B,4A,5E),
 25 (1C,2C,3B,4B,5A),(1C,2C,3B,4B, 5B),(1C,2C,3B,4B,5C),(1C,2C,3B,4B,5D),(1C,2C,3B,4B,5E),(1C,2C,3B,4C,5A),
 (1C,2C,3 B,4C,5B),(1C,2C,3B,4C,5C),(1C,2C,3B,4C,5D),(1C,2C,3B,4C,5E),(1C,2C,3B,4D,5A),(1C, 2C,3B,4D,5B),
 (1C,2C,3B,4D,5C),(1C,2C,3B,4D,5D),(1C,2C,3B,4D,5E),(1C,2C,3B,4E,5A), (1C,2C,3B,4E,5B),(1C,2C,3B,4E,5C),
 (1C,2C,3B,4E,5D),(1C,2C,3B,4E,5E),(1C,2D,3A,4A, 5A),(1C,2D,3A,4A,5B),(1C,2D,3A,4A,5C),(1C,2D,3A,4A,5D),
 (1C,2D,3A,4A,5E),(1C,2D,3 A,4B,5A),(1C,2D,3A,4B,5B),(1C,2D,3A,4B,5C),(1C,2D,3A,4B,5D),(1C,2D,3A,4B,5E),
 30 (1C, 2D,3A,4C,5A),(1C,2D,3A,4C,5B),(1C,2D,3A,4C,5C),(1C,2D,3A,4C,5D),(1C,2D,3A,4C,5E), (1C,2D,3A,4D,5A),
 (1C,2D,3A,4D,5B),(1C,2D,3A,4D,5C),(1C,2D,3A,4D,5D),(1C,2D,3A,4D, 5E),(1C,2D,3A,4E,5A),(1C,2D,3A,4E,5B),
 (1C,2D,3A,4E,5C),(1C,2D,3A,4E,5D),(1C,2D,3 A,4E,5E),(1C,2D,3B,4A,5A),(1C,2D,3B,4A,5B),(1C,2D,3B,4A,5C),
 (1C,2D,3B,4A,5D),(1C, 2D,3B,4A,5E),(1C,2D,3B,4B,5A),(1C,2D,3B,4B,5B),(1C,2D,3B,4B,5C),(1C,2D,3B,4B,5D),
 (1C,2D,3B,4B,5E),(1C,2D,3B,4C,5A),(1C,2D,3B,4C,5B),(1C,2D,3B,4C,5C),(1C,2D,3B,4C, 5D),(1C,2D,3B,4C,5E),
 35 (1C,2D,3B,4D,5A),(1C,2D,3B,4D,5B),(1C,2D,3B,4D,5C),(1C,2D,3 B,4D,5D),(1C,2D,3B,4D,5E),(1C,2D,3B,4E,5A),
 (1C,2D,3B,4E,5B),(1C,2D,3B,4E,5C),(1C, 2D,3B,4E,5D),(1C,2D,3B,4E,5E),(1C,2E,3A,4A,5A),(1C,2E,3A,4A,5B),
 (1C,2E,3A,4A,5C), (1C,2E,3A,4A,5D),(1C,2E,3A,4A,5E),(1C,2E,3A,4B,5A),(1C,2E,3A,4B,5B),(1C,2E,3A,4B, 5C),
 (1C,2E,3A,4B,5D),(1C,2E,3A,4B,5E),(1C,2E,3A,4C,5A),(1C,2E,3A,4C,5B),(1C,2E,3 A,4C,5C),(1C,2E,3A,4C,5D),
 (1C,2E,3A,4C,5E),(1C,2E,3A,4D,5A),(1C,2E,3A,4D,5B),(1C, 2E,3A,4D,5C),(1C,2E,3A,4D,5D),(1C,2E,3A,4D,5E),
 40 (1C,2E,3A,4E,5A),(1C,2E,3A,4E,5B), (1C,2E,3A,4E,5C),(1C,2E,3A,4E,5D),(1C,2E,3A,4E,5E),(1C,2E,3B,4A,5A),
 (1C,2E,3B,4A, 5B),(1C,2E,3B,4A,5C),(1C,2E,3B,4A,5D),(1C,2E,3B,4A,5E),(1C,2E,3B,4B,5A),(1C,2E,3 B,4B,5B),
 (1C,2E,3B,4B,5C),(1C,2E,3B,4B,5D),(1C,2E,3B,4B,5E),(1C,2E,3B,4C,5A),(1C, 2E,3B,4C,5B),(1C,2E,3B,4C,5C),
 (1C,2E,3B,4C,5D),(1C,2E,3B,4C,5E),(1C,2E,3B,4D,5A), (1C,2E,3B,4D,5B),(1C,2E,3B,4D,5C),(1C,2E,3B,4D,5D),
 (1C,2E,3B,4D,5E),(1C,2E,3B,4E, 5A),(1C,2E,3B,4E,5B),(1C,2E,3B,4E,5C),(1C,2E,3B,4E,5D),(1C,2E,3B,4E,5E),
 45 (1D,2A,3 A,4A,5A),(1D,2A,3A,4A,5B),(1D,2A,3A,4A,5C),(1D,2A,3A,4A,5D),(1D,2A,3A,4A,5E),(1D, 2A,3A,4B,5A),
 (1D,2A,3A,4B,5B),(1D,2A,3A,4B,5C),(1D,2A,3A,4B,5D),(1D,2A,3A,4B,5E), (1D,2A,3A,4C,5A),(1D,2A,3A,4C,5B),
 (1D,2A,3A,4C,5C),(1D,2A,3A,4C,5D),(1D,2A,3A,4C, 5E),(1D,2A,3A,4D,5A),(1D,2A,3A,4D,5B),(1D,2A,3A,4D,5C),
 (1D,2A,3A,4D,5D),(1D,2A,3 A,4D,5E),(1D,2A,3A,4E,5A),(1D,2A,3A,4E,5B),(1D,2A,3A,4E,5C),(1D,2A,3A,4E,5D),
 (1D, 2A,3A,4E,5E),(1D,2A,3B,4A,5A),(1D,2A,3B,4A,5B),(1D,2A,3B,4A,5C),(1D,2A,3B,4A,5D), (1D,2A,3B,4A,5E),
 50 (1D,2A,3B,4B,5A),(1D,2A,3B,4B,5B),(1D,2A,3B,4B,5C),(1D,2A,3B,4B, 5D),(1D,2A,3B,4B,5E),(1D,2A,3B,4C,5A),
 (1D,2A,3B,4C,5B),(1D,2A,3B,4C,5C),(1D,2A,3 B,4C,5D),(1D,2A,3B,4C,5E),(1D,2A,3B,4D,5A),(1D,2A,3B,4D,5B),
 (1D,2A,3B,4D,5C),(1D, 2A,3B,4D,5D),(1D,2A,3B,4D,5E),(1D,2A,3B,4E,5A),(1D,2A,3B,4E,5B),(1D,2A,3B,4E,5C),
 (1D,2A,3B,4E,5D),(1D,2A,3B,4E,5E),(1D,2B,3A,4A,5A),(1D,2B,3A,4A,5B),(1D,2B,3A,4A, 5C),(1D,2B,3A,4A,5D),
 (1D,2B,3A,4A,5E),(1D,2B,3A,4B,5A),(1D,2B,3A,4B,5B),(1D,2B,3 A,4B,5C),(1D,2B,3A,4B,5D),(1D,2B,3A,4B,5E),
 55 (1D,2B,3A,4C,5A),(1D,2B,3A,4C,5B),(1D, 2B,3A,4C,5C),(1D,2B,3A,4C,5D),(1D,2B,3A,4C,5E),(1D,2B,3A,4D,5A),
 (1D,2B,3A,4D,5B), (1D,2B,3A,4D,5C),(1D,2B,3A,4D,5D),(1D,2B,3A,4D,5E),(1D,2B,3A,4E,5A),(1D,2B,3A,4E, 5B),
 (1D,2B,3A,4E,5C),(1D,2B,3A,4E,5D),(1D,2B,3A,4E,5E),(1D,2B,3B,4A,5A),(1D,2B,3 B,4A,5B),(1D,2B,3B,4A,5C),
 (1D,2B,3B,4A,5D),(1D,2B,3B,4A,5E),(1D,2B,3B,4B,5A),(1D, 2B,3B,4B,5B),(1D,2B,3B,4B,5C),(1D,2B,3B,4B,5D),

(1D,2B,3B,4B,5E),(1D,2B,3B,4C,5A), (1D,2B,3B,4C,5B),(1D,2B,3B,4C,5C),(1D,2B,3B,4C,5D),(1D,2B,3B,4C,5E),
 (1D,2B,3B,4D, 5A),(1D,2B,3B,4D,5B),(1D,2B,3B,4D,5C),(1D,2B,3B,4D,5D),(1D,2B,3B,4D,5E),(1D,2B,3 B,4E,5A),
 (1D,2B,3B,4E,5B),(1D,2B,3B,4E,5C),(1D,2B,3B,4E,5D),(1D,2B,3B,4E,5E),(1D, 2C,3A,4A,5A),(1D,2C,3A,4A,5B),
 (1D,2C,3A,4A,5C),(1D,2C,3A,4A,5D),(1D,2C,3A,4A,5E), (1D,2C,3A,4B,5A),(1D,2C,3A,4B,5B),(1D,2C,3A,4B,5C),
 5 (1D,2C,3A,4B,5D),(1D,2C,3A,4B, 5E),(1D,2C,3A,4C,5A),(1D,2C,3A,4C,5B),(1D,2C,3A,4C,5C),(1D,2C,3A,4C,5D),
 (1D,2C,3 A,4C,5E),(1D,2C,3A,4D,5A),(1D,2C,3A,4D,5B),(1D,2C,3A,4D,5C),(1D,2C,3A,4D,5D),(1D, 2C,3A,4D,5E),
 (1D,2C,3A,4E,5A),(1D,2C,3A,4E,5B),(1D,2C,3A,4E,5C),(1D,2C,3A,4E,5D), (1D,2C,3A,4E,5E),(1D,2C,3B,4A,5A),
 (1D,2C,3B,4A,5B),(1D,2C,3B,4A,5C),(1D,2C,3B,4A, 5D),(1D,2C,3B,4A,5E),(1D,2C,3B,4B,5A),(1D,2C,3B,4B,5B),
 (1D,2C,3B,4B,5C),(1D,2C,3 B,4B,5D),(1D,2C,3B,4B,5E),(1D,2C,3B,4C,5A),(1D,2C,3B,4C,5B),(1D,2C,3B,4C,5C),
 10 (1D, 2C,3B,4C,5D),(1D,2C,3B,4C,5E),(1D,2C,3B,4D,5A),(1D,2C,3B,4D,5B),(1D,2C,3B,4D,5C), (1D,2C,3B,4D,5D),
 (1D,2C,3B,4D,5E),(1D,2C,3B,4E,5A),(1D,2C,3B,4E,5B),(1D,2C,3B,4E, 5C),(1D,2C,3B,4E,5D),(1D,2C,3B,4E,5E),
 (1D,2D,3A,4A,5A),(1D,2D,3A,4A,5B),(1D,2D,3 A,4A,5C),(1D,2D,3A,4A,5D),(1D,2D,3A,4A,5E),(1D,2D,3A,4B,5A),
 (1D,2D,3A,4B,5B),(1D, 2D,3A,4B,5C),(1D,2D,3A,4B,5D),(1D,2D,3A,4B,5E),(1D,2D,3A,4C,5A),(1D,2D,3A,4C,5B),
 (1D,2D,3A,4C,5C),(1D,2D,3A,4C,5D),(1D,2D,3A,4C,5E),(1D,2D,3A,4D,5A),(1D,2D,3A,4D, 5B),(1D,2D,3A,4D,5C),
 15 (1D,2D,3A,4D,5D),(1D,2D,3A,4D,5E),(1D,2D,3A,4E,5A),(1D,2D,3 A,4E,5B),(1D,2D,3A,4E,5C),(1D,2D,3A,4E,5D),
 (1D,2D,3A,4E,5E),(1D,2D,3B,4A,5A),(1D, 2D,3B,4A,5B),(1D,2D,3B,4A,5C),(1D,2D,3B,4A,5D),(1D,2D,3B,4A,5E),
 (1D,2D,3B,4B,5A),(1D,2D,3B,4B,5B),(1D,2D,3B,4B,5C),(1D,2D,3B,4B,5D),(1D,2D,3B,4B,5E),(1D,2D,3B,4C, 5A),
 (1D,2D,3B,4C,5B),(1D,2D,3B,4C,5C),(1D,2D,3B,4C,5D),(1D,2D,3B,4C,5E),(1D,2D,3 B,4D,5A),(1D,2D,3B,4D,5B),
 (1D,2D,3B,4D,5C),(1D,2D,3B,4D,5D),(1D,2D,3B,4D,5E),(1D, 2D,3B,4E,5A),(1D,2D,3B,4E,5B),(1D,2D,3B,4E,5C),
 20 (1D,2D,3B,4E,5D),(1D,2D,3B,4E,5E), (1D,2E,3A,4A,5A),(1D,2E,3A,4A,5B),(1D,2E,3A,4A,5C),(1D,2E,3A,4A,5D),
 (1D,2E,3A,4A, 5E),(1D,2E,3A,4B,5A),(1D,2E,3A,4B,5B),(1D,2E,3A,4B,5C),(1D,2E,3A,4B,5D),(1D,2E,3 A,4B,5E),
 (1D,2E,3A,4C,5A),(1D,2E,3A,4C,5B),(1D,2E,3A,4C,5C),(1D,2E,3A,4C,5D),(1D, 2E,3A,4C,5E),(1D,2E,3A,4D,5A),
 (1D,2E,3A,4D,5B),(1D,2E,3A,4D,5C),(1D,2E,3A,4D,5D), (1D,2E,3A,4D,5E),(1D,2E,3A,4E,5A),(1D,2E,3A,4E,5B),
 (1D,2E,3A,4E,5C),(1D,2E,3A,4E, 5D),(1D,2E,3A,4E,5E),(1D,2E,3B,4A,5A),(1D,2E,3B,4A,5B),(1D,2E,3B,4A,5C),
 25 (1D,2E,3 B,4A,5D),(1D,2E,3B,4A,5E),(1D,2E,3B,4B,5A),(1D,2E,3B,4B,5B),(1D,2E,3B,4B,5C),(1D, 2E,3B,4B,5D),
 (1D,2E,3B,4B,5E),(1D,2E,3B,4C,5A),(1D,2E,3B,4C,5B),(1D,2E,3B,4C,5C), (1D,2E,3B,4C,5D),(1D,2E,3B,4C,5E),
 (1D,2E,3B,4D,5A),(1D,2E,3B,4D,5B),(1D,2E,3B,4D, 5C),(1D,2E,3B,4D,5D),(1D,2E,3B,4D,5E),(1D,2E,3B,4E,5A),
 (1D,2E,3B,4E,5B),(1D,2E,3 B,4E,5C),(1D,2E,3B,4E,5D),(1D,2E,3B,4E,5E),(1E,2A,3A,4A,5A),(1E,2A,3A,4A,5B),
 (1E, 2A,3A,4A,5C),(1E,2A,3A,4A,5D),(1E,2A,3A,4A,5E),(1E,2A,3A,4B,5A),(1E,2A,3A,4B,5B), (1E,2A,3A,4B,5C),
 30 (1E,2A,3A,4B,5D),(1E,2A,3A,4B,5E),(1E,2A,3A,4C,5A),(1E,2A,3A,4C, 5B),(1E,2A,3A,4C,5C),(1E,2A,3A,4C,5D),
 (1E,2A,3A,4C,5E),(1E,2A,3A,4D,5A),(1E,2A,3 A,4D,5B),(1E,2A,3A,4D,5C),(1E,2A,3A,4D,5D),(1E,2A,3A,4D,5E),
 (1E,2A,3A,4E,5A),(1E, 2A,3A,4E,5B),(1E,2A,3A,4E,5C),(1E,2A,3A,4E,5D),(1E,2A,3A,4E,5E),(1E,2A,3B,4A,5A),
 (1E,2A,3B,4A,5B),(1E,2A,3B,4A,5C),(1E,2A,3B,4A,5D),(1E,2A,3B,4A,5E),(1E,2A,3B,4B, 5A),(1E,2A,3B,4B,5B),(1E,
 35 2A,3B,4B,5C),(1E,2A,3B,4B,5D),(1E,2A,3B,4B,5E),(1E,2A,3 B,4C,5A),(1E,2A,3B,4C,5B),(1E,2A,3B,4C,5C),(1E,2A,
 3B,4C,5D),(1E,2A,3B,4C,5E),(1E, 2A,3B,4D,5A),(1E,2A,3B,4D,5B),(1E,2A,3B,4D,5C),(1E,2A,3B,4D,5D),(1E,2A,3B,
 4D,5E), (1E,2A,3B,4E,5A),(1E,2A,3B,4E,5B),(1E,2A,3B,4E,5C),(1E,2A,3B,4E,5D),(1E,2A,3B,4E, 5E),(1E,2B,3A,4A,
 5A),(1E,2B,3A,4A,5B),(1E,2B,3A,4A,5C),(1E,2B,3 A,4A,5D),(1E,2B,3 A,4A,5E),(1E,2B,3A,4B,5A),(1E,2B,3A,4B,5B),
 (1E,2B,3A,4B,5C),(1E,2B,3A,4B,5D),(1E, 2B,3A,4B,5E),(1E,2B,3A,4C,5A),(1E,2B,3A,4C,5B),(1E,2B,3A,4C,5C),
 (1E,2B,3A,4C,5D), (1E,2B,3A,4C,5E),(1E,2B,3A,4D,5A),(1E,2B,3A,4D,5B),(1E,2B,3A,4D,5C),(1E,2B,3A,4D, 5D),
 40 (1E,2B,3A,4D,5E),(1E,2B,3A,4E,5A),(1E,2B,3A,4E,5B),(1E,2B,3A,4E,5C),(1E,2B,3 A,4E,5D),(1E,2B,3A,4E,5E),(1E,
 2B,3B,4A,5A),(1E,2B,3B,4A,5B),(1E,2B,3B,4A,5C),(1E, 2B,3B,4A,5D),(1E,2B,3B,4A,5E),(1E,2B,3B,4B,5A),(1E,2B,
 3B,4B,5B),(1E,2B,3B,4B,5C), (1E,2B,3B,4B,5D),(1E,2B,3B,4B,5E),(1E,2B,3B,4C,5A),(1E,2B,3B,4C,5B),(1E,2B,3B,
 4C, 5C),(1E,2B,3B,4C,5D),(1E,2B,3B,4C,5E),(1E,2B,3B,4D,5A),(1E,2B,3B,4D,5B),(1E,2B,3 B,4D,5C),(1E,2B,3B,
 4D,5D),(1E,2B,3B,4D,5E),(1E,2B,3B,4E,5A),(1E,2B,3B,4E,5B),(1E, 2B,3B,4E,5C),(1E,2B,3B,4E,5D),(1E,2B,3B,4E,
 45 5E),(1E,2C,3A,4A,5A),(1E,2C,3A,4A,5B), (1E,2C,3A,4A,5C),(1E,2C,3A,4A,5D),(1E,2C,3A,4A,5E),(1E,2C,3A,4B,
 5A),(1E,2C,3A,4B, 5B),(1E,2C,3A,4B,5C),(1E,2C,3A,4B,5D),(1E,2C,3A,4B,5E),(1E,2C,3A,4C,5A),(1E,2C,3 A,4C,
 5B),(1E,2C,3A,4C,5C),(1E,2C,3A,4C,5D),(1E,2C,3A,4C,5E),(1E,2C,3A,4D,5B),(1E, 2C,3A,4D,5B),(1E,2C,3A,4D,
 5C),(1E,2C,3A,4D,5D),(1E,2C,3A,4D,5E),(1E,2C,3A,4E,5A), (1E,2C,3A,4E,5B),(1E,2C,3A,4E,5C),(1E,2C,3A,4E,
 5D),(1E,2C,3A,4E,5E),(1E,2C,3B,4A, 5A),(1E,2C,3B,4A,5B),(1E,2C,3B,4A,5C),(1E,2C,3B,4A,5D),(1E,2C,3B,4A,
 50 5E),(1E,2C,3 B,4B,5A),(1E,2C,3B,4B,5B),(1E,2C,3B,4B,5C),(1E,2C,3B,4B,5D),(1E,2C,3B,4B,5E),(1E, 2C,3B,4C,
 5A),(1E,2C,3B,4C,5B),(1E,2C,3B,4C,5C),(1E,2C,3B,4C,5D),(1E,2C,3B,4C,5E), (1E,2C,3B,4D,5A),(1E,2C,3B,4D,
 5B),(1E,2C,3B,4D,5C),(1E,2C,3B,4D,5D),(1E,2C,3B,4D, 5E),(1E,2C,3B,4E,5A),(1E,2C,3B,4E,5B),(1E,2C,3B,4E,
 5C),(1E,2C,3B,4E,5D),(1E,2C,3 B,4E,5E),(1E,2D,3A,4A,5A),(1E,2D,3A,4A,5B),(1E,2D,3A,4A,5C),(1E,2D,3A,4A,
 5D),(1E, 2D,3A,4A,5E),(1E,2D,3A,4B,5A),(1E,2D,3A,4B,5B),(1E,2D,3A,4B,5C),(1E,2D,3A,4B,5D), (1E,2D,3A,4B,
 55 5E),(1E,2D,3A,4C,5A),(1E,2D,3A,4C,5B),(1E,2D,3A,4C,5C),(1E,2D,3A,4C, 5D),(1E,2D,3A,4C,5E),(1E,2D,3A,4D,
 5A),(1E,2D,3A,4D,5B),(1E,2D,3A,4D,5C),(1E,2D,3 A,4D,5D),(1E,2D,3A,4D,5E),(1E,2D,3A,4E,5A),(1E,2D,3A,4E,
 5B),(1E,2D,3A,4E,5C),(1E, 2D,3A,4E,5D),(1E,2D,3A,4E,5E),(1E,2D,3B,4A,5A),(1E,2D,3B,4A,5B),(1E,2D,3B,4A,
 5C), (1E,2D,3B,4A,5D),(1E,2D,3B,4A,5E),(1E,2D,3B,4B,5A),(1E,2D,3B,4B,5B),(1E,2D,3B,4B, 5C),(1E,2D,3B,4B,

5D), (1E,2D,3B,4B,5E), (1E,2D,3B,4C,5A), (1E,2D,3B,4C,5B), (1E,2D,3B,4C,5C), (1E,2D,3B,4C,5D), (1E,2D,3B,4C,5E), (1E,2D,3B,4D,5A), (1E,2D,3B,4D,5B), (1E,2D,3B,4D,5C), (1E,2D,3B,4D,5D), (1E,2D,3B,4D,5E), (1E,2D,3B,4E,5A), (1E,2D,3B,4E,5B), (1E,2D,3B,4E,5C), (1E,2D,3B,4E,5D), (1E,2D,3B,4E,5E), (1E,2E,3A,4A,5A), (1E,2E,3A,4A,5B), (1E,2E,3A,4A,5C), (1E,2E,3A,4A,5D), (1E,2E,3A,4A,5E), (1E,2E,3A,4B,5A), (1E,2E,3A,4B,5B), (1E,2E,3A,4B,5C), (1E,2E,3A,4B,5D), (1E,2E,3A,4B,5E), (1E,2E,3A,4C,5A), (1E,2E,3A,4C,5B), (1E,2E,3A,4C,5C), (1E,2E,3A,4C,5D), (1E,2E,3A,4C,5E), (1E,2E,3A,4D,5A), (1E,2E,3A,4D,5B), (1E,2E,3A,4D,5C), (1E,2E,3A,4D,5D), (1E,2E,3A,4D,5E), (1E,2E,3A,4E,5A), (1E,2E,3A,4E,5B), (1E,2E,3A,4E,5C), (1E,2E,3A,4E,5D), (1E,2E,3A,4E,5E), (1E,2E,3B,4A,5A), (1E,2E,3B,4A,5B), (1E,2E,3B,4A,5C), (1E,2E,3B,4A,5D), (1E,2E,3B,4A,5E), (1E,2E,3B,4B,5A), (1E,2E,3B,4B,5B), (1E,2E,3B,4B,5C), (1E,2E,3B,4B,5D), (1E,2E,3B,4B,5E), (1E,2E,3B,4C,5A), (1E,2E,3B,4C,5B), (1E,2E,3B,4C,5C), (1E,2E,3B,4C,5D), (1E,2E,3B,4C,5E), (1E,2E,3B,4D,5A), (1E,2E,3B,4D,5B), (1E,2E,3B,4D,5C), (1E,2E,3B,4D,5D), (1E,2E,3B,4D,5E), (1E,2E,3B,4E,5A), (1E,2E,3B,4E,5B), (1E,2E,3B,4E,5C), (1E,2E,3B,4E,5D), (1E,2E,3B,4E,5E)

[0408] And (R¹, R², X, R⁴, R⁵) = (1A, 2A, 3A, 4A, 5A) is the compound which R¹ is 1A, R² is 2A, X is 3A, R⁴ is 4A and R⁵ is 5A. The other combinations are the same.

[0409] The compounds of the present invention include the following compounds. The following compounds are synthesized with a same manner similar to the above examples.



[0410] The substituents of R¹, R², R³, R⁴, X, R⁶ and R⁷ of above compound include the following substitution group.








R¹ = H (1A), Me(1B), OMe(1C), Cl(1D), Ph(1E)

R² = H (2A), Me(2B), OMe(2C), Cl(2D), Ph(2E)

R³ = H (3A), Me(3B), OMe(3C), Cl(3D), Ph(3E)

R⁴ = H (4A), Me(4B), OMe(4C), Cl(4D), Ph(4E)

X = O(3A), NH(3B)



[0411] The preferable combinations (R¹, R², R³, R⁴, X, R⁶, R⁷) of the substituents of above compound include the followings.

(1A, 2A, 3A, 4A, 5A, 6A, 7A), (1A, 2A, 3A, 4A, 5A, 6A, 7B), (1A, 2A, 3A, 4A, 5A, 6A, 7C), (1A, 2A, 3A, 4A, 5A, 6B, 7A), (1A, 2A, 3A, 4A, 5A, 6B, 7B), (1A, 2A, 3A, 4A, 5A, 6B, 7C), (1A, 2A, 3A, 4A, 5A, 6C, 7A), (1A, 2A, 3A, 4A, 5A, 6C, 7B), (1A, 2A, 3A, 4A, 5A, 6C, 7C), (1A, 2A, 3A, 4A, 5A, 6D, 7A), (1A, 2A, 3A, 4A, 5A, 6D, 7B), (1A, 2A, 3A, 4A, 5A, 6D, 7C), (1A, 2A, 3A, 4A, 5B, 6A, 7A), (1A, 2A, 3A,

243

2A,3C,4B,5A,6C,7C), (1A,2A,3C,4B,5A,6D,7A), (1A,2A,3C,4B,5A,6D,7B), (1A,2A,3C,4B,5A,6D,7C), (1A,2A,3C,4 B, 5B,6A,7A), (1A,2A,3C,4B,5B,6A,7B), (1A,2A,3C,4B,5B,6A,7C), (1A,2A,3C,4B,5B,6B,7A), (1A,2A,3C,4B,5B,6B,7B), (1A,2A,3C,4B,5B,6B,7C), (1A,2A,3C,4B,5B,6C,7A), (1A,2A,3C,4 B,5B,6C,7B), (1A,2A,3C,4B,5B,6C,7C), (1A,2A,3C, 4B,5B,6D,7A), (1A,2A,3C,4B,5B,6D,7B); (1A,2A,3C,4B,5B,6D,7C), (1A,2A,3C,4C,5A,6A,7A), (1A,2A,3C,4C,5A,6A, 7B), (1A,2A,3C,4 C,5A,6A,7C), (1A,2A,3C,4C,5A,6B,7A), (1A,2A,3C,4C,5A,6B,7B), (1A,2A,3C,4C,5A,6B,7C), (1A,2A, 3C,4C,5A,6C,7A), (1A,2A,3C,4C,5A,6C,7B), (1A,2A,3C,4C,5A,6C,7C), (1A,2A,3C,4 C,5A,6D,7A), (1A,2A,3C,4C,5A, 6D,7B), (1A,2A,3C,4C,5A,6D,7C), (1A,2A,3C,4C,5B,6A,7A), (1A,2A,3C,4C,5B,6A,7B), (1A,2A,3C,4C,5B,6A,7C), (1A, 2A,3C,4C,5B,6B,7A), (1A,2A,3C,4 C,5B,6B,7B), (1A,2A,3C,4C,5B,6B,7C), (1A,2A,3C,4C,5B,6C,7A), (1A,2A,3C,4C, 5B,6C,7B), (1A,2A,3C,4C,5B,6C,7C), (1A,2A,3C,4C,5B,6D,7A), (1A,2A,3C,4C,5B,6D,7B), (1A,2A,3C,4 C,5B,6D,7C), (1A,2A,3C,4D,5A,6A,7A), (1A,2A,3C,4D,5A,6A,7B), (1A,2A,3C,4D,5A,6A,7C), (1A,2A,3C,4D,5A,6B,7A), (1A,2A,3C, 4D,5A,6B,7B), (1A,2A,3C,4D,5A,6B,7C), (1A,2A,3C,4 D,5A,6C,7A), (1A,2A,3C,4D,5A,6C,7B), (1A,2A,3C,4D,5A,6C,7C), (1A,2A,3C,4D,5A,6D,7A), (1A,2A,3C,4D,5A,6D,7B), (1A,2A,3C,4D,5A,6D,7C), (1A,2A,3C,4D,5B,6A,7A), (1A,2A, 3C,4 D,5B,6A,7B), (1A,2A,3C,4D,5B,6A,7C), (1A,2A,3C,4D,5B,6B,7A), (1A,2A,3C,4D,5B,6B,7B), (1A,2A,3C,4D,5B, 6B,7C), (1A,2A,3C,4D,5B,6C,7A), (1A,2A,3C,4D,5B,6C,7B), (1A,2A,3C,4 D,5B,6C,7C), (1A,2A,3C,4D,5B,6D,7A), (1A, 2A,3C,4D,5B,6D,7B), (1A,2A,3C,4D,5B,6D,7C), (1A,2A,3C,4E,5A,6A,7A), (1A,2A,3C,4E,5A,6A,7B), (1A,2A,3C,4E, 5A,6A,7C), (1A,2A,3C,4 E,5A,6B,7A), (1A,2A,3C,4E,5A,6B,7B), (1A,2A,3C,4E,5A,6B,7C), (1A,2A,3C,4E,5A,6C,7A), (1A,2A,3C,4E,5A,6C,7B), (1A,2A,3C,4E,5A,6C,7C), (1A,2A,3C,4E,5A,6D,7A), (1A,2A,3C,4 E,5A,6D,7B), (1A,2A,3C, 4E,5A,6D,7C), (1A,2A,3C,4E,5B,6A,7A), (1A,2A,3C,4E,5B,6A,7B), (1A,2A,3C,4E,5B,6A,7C), (1A,2A,3C,4E,5B,6B,7A), (1A,2A,3C,4E,5B,6B,7B), (1A,2A,3C,4 E,5B,6B,7C), (1A,2A,3C,4E,5B,6C,7A), (1A,2A,3C,4E,5B,6C,7B), (1A,2A,3C,4E,5B,6C,7C), (1A,2A,3C,4E,5B,6D,7A), (1A,2A,3C,4E,5B,6D,7B), (1A,2A,3C,4E,5B,6D,7C), (1A,2A,3D,4 A,5A, 6A,7A), (1A,2A,3D,4A,5A,6A,7B), (1A,2A,3D,4A,5A,6A,7C), (1A,2A,3D,4A,5A,6B,7A), (1A,2A,3D,4A,5A,6B,7B), (1A, 2A,3D,4A,5A,6B,7C), (1A,2A,3D,4A,5A,6C,7A), (1A,2A,3D,4 A,5A,6C,7B), (1A,2A,3D,4A,5A,6C,7C), (1A,2A,3D,4A, 5A,6D,7A), (1A,2A,3D,4A,5A,6D,7B), (1A,2A,3D,4A,5A,6D,7C), (1A,2A,3D,4A,5B,6A,7A), (1A,2A,3D,4A,5B,6A,7B), (1A,2A,3D,4 A,5B,6A,7C), (1A,2A,3D,4A,5B,6B,7A), (1A,2A,3D,4A,5B,6B,7B), (1A,2A,3D,4A,5B,6B,7C), (1A,2A,3D, 4A,5B,6C,7A), (1A,2A,3D,4A,5B,6C,7B), (1A,2A,3D,4A,5B,6C,7C), (1A,2A,3D,4 A,5B,6D,7A), (1A,2A,3D,4A,5B,6D,7B), (1A,2A,3D,4A,5B,6D,7C), (1A,2A,3D,4A,5B,6E,7A), (1A,2A,3D,4A,5B,6E,7B), (1A,2A,3D,4A,5B,6E,7C), (1A,2A,3D,4B,5A,6A,7A), (1A,2A,3D,4B,5A,6A,7B), (1A,2A,3D,4B,5A,6A,7C), (1A,2A, 3D,4B,5A,6B,7A), (1A,2A,3D,4 B,5A,6B,7B), (1A,2A,3D,4B,5A,6B,7C), (1A,2A,3D,4B,5A,6C,7A), (1A,2A,3D,4B,5A,6C,7B), (1A,2A,3D,4B,5A, 6C,7C), (1A,2A,3D,4B,5A,6D,7A), (1A,2A,3D,4B,5A,6D,7B), (1A,2A,3D,4B,5A,6D,7C), (1A,2A,3D,4 B,5A,6D,7C), (1A, 2A,3D,4B,5B,6A,7A), (1A,2A,3D,4B,5B,6A,7B), (1A,2A,3D,4B,5B,6A,7C), (1A,2A,3D,4B,5B,6B,7A), (1A,2A,3D,4B,5B,6B,7B), (1A,2A,3D,4B,5B,6B,7C), (1A,2A,3D,4 B,5B,6C,7A), (1A,2A,3D,4B,5B,6C,7B), (1A,2A,3D,4B,5B,6C,7C), (1A, 2A,3D,4B,5B,6D,7A), (1A,2A,3D,4B,5B,6D,7B), (1A,2A,3D,4B,5B,6D,7C), (1A,2A,3D,4C,5A,6A,7A), (1A,2A,3D,4 C, 5A,6A,7B), (1A,2A,3D,4C,5A,6A,7C), (1A,2A,3D,4C,5A,6B,7A), (1A,2A,3D,4C,5A,6B,7B), (1A,2A,3D,4C,5A,6B,7C), (1A,2A,3D,4C,5A,6C,7A), (1A,2A,3D,4C,5A,6C,7B), (1A,2A,3D,4 C,5A,6C,7C), (1A,2A,3D,4C,5A,6D,7A), (1A,2A,3D, 4C,5A,6D,7B), (1A,2A,3D,4C,5A,6D,7C), (1A,2A,3D,4C,5B,6A,7A), (1A,2A,3D,4C,5B,6A,7B), (1A,2A,3D,4C,5B,6A, 7C), (1A,2A,3D,4 C,5B,6B,7A), (1A,2A,3D,4C,5B,6B,7B), (1A,2A,3D,4C,5B,6B,7C), (1A,2A,3D,4C,5B,6C,7A), (1A,2A, 3D,4C,5B,6C,7B), (1A,2A,3D,4C,5B,6C,7C), (1A,2A,3D,4C,5B,6D,7A), (1A,2A,3D,4 C,5B,6D,7B), (1A,2A,3D,4C,5B, 6D,7C), (1A,2A,3D,4D,5A,6A,7A), (1A,2A,3D,4D,5A,6A,7B), (1A,2A,3D,4D,5A,6A,7C), (1A,2A,3D,4D,5A,6B,7A), (1A, 2A,3D,4D,5A,6B,7B), (1A,2A,3D,4 D,5A,6B,7C), (1A,2A,3D,4D,5A,6C,7A), (1A,2A,3D,4D,5A,6C,7B), (1A,2A,3D,4D,5A,6C,7C), (1A,2A,3D,4D,5A,6D,7A), (1A,2A,3D,4D,5A,6D,7B), (1A,2A,3D,4D,5A,6D,7C), (1A,2A,3D,4 D,5B,6A,7A), (1A,2A,3D,4D,5B,6A,7B), (1A,2A,3D,4D,5B,6A,7C), (1A,2A,3D,4D,5B,6B,7A), (1A,2A,3D,4D,5B,6B,7B), (1A,2A,3D,4D,5B,6B,7C), (1A,2A,3D,4 D,5B,6C,7A), (1A,2A,3D,4D,5B,6C,7B), (1A,2A,3D,4D,5B,6C,7C), (1A,2A,3D,4D,5B,6D, 7A), (1A,2A,3D,4D,5B,6D,7B), (1A,2A,3D,4D,5B,6D,7C), (1A,2A,3D,4E,5A,6A,7A), (1A,2A,3D,4E,5A,6A,7B), (1A,2A, 3D,4 E,5A,6A,7C), (1A,2A,3D,4E,5A,6B,7A), (1A,2A,3D,4E,5A,6B,7B), (1A,2A,3D,4E,5A,6B,7C), (1A,2A,3D,4E,5A, 6C,7A), (1A,2A,3D,4E,5A,6C,7B), (1A,2A,3D,4E,5A,6C,7C), (1A,2A,3D,4 E,5A,6D,7A), (1A,2A,3D,4E,5A,6D,7B), (1A, 2A,3D,4E,5A,6D,7C), (1A,2A,3D,4E,5B,6A,7A), (1A,2A,3D,4E,5B,6A,7B), (1A,2A,3D,4E,5B,6A,7C), (1A,2A,3D,4E, 5B,6B,7A), (1A,2A,3D,4 E,5B,6B,7B), (1A,2A,3D,4E,5B,6B,7C), (1A,2A,3D,4E,5B,6C,7A), (1A,2A,3D,4E,5B,6C,7B), (1A,2A,3D,4E,5B,6C,7C), (1A,2A,3D,4E,5B,6D,7A), (1A,2A,3D,4 E,5B,6D,7B), (1A,2A,3D,4 E,5B,6D,7C), (1A,2A,3E,4A,5A,6A,7A), (1A,2A,3E,4A,5A,6A,7B), (1A,2A,3E,4A,5A,6A,7C), (1A,2A,3E,4A,5A,6B,7A), (1A,2A,3E,4A,5A,6B,7B), (1A,2A,3E,4 A,5A,6B,7C), (1A,2A,3E,4 A,5A,6C,7A), (1A,2A,3E,4A,5A,6C,7B), (1A,2A,3E,4A,5A,6C,7C), (1A,2A,3E, 4A,5A,6D,7A), (1A,2A,3E,4A,5A,6D,7B), (1A,2A,3E,4A,5A,6D,7C), (1A,2A,3E,4A,5B,6A,7A), (1A,2A,3E,4A,5B,6A,7B), (1A,2A,3E,4A,5B,6A,7C), (1A,2A,3E,4A,5B,6B,7A), (1A,2A,3E,4A,5B,6B,7B), (1A,2A,3E,4A,5B,6B,7C), (1A,2A, 3E,4A,5B,6C,7A), (1A,2A,3E,4A,5B,6C,7B), (1A,2A,3E,4 A,5B,6C,7C), (1A,2A,3E,4A,5B,6D,7A), (1A,2A,3E,4A,5B,6D, 7B), (1A,2A,3E,4A,5B,6D,7C), (1A,2A,3E,4B,5A,6A,7A), (1A,2A,3E,4B,5A,6A,7B), (1A,2A,3E,4B,5A,6A,7C), (1A,2A, 3E,4 B,5A,6B,7A), (1A,2A,3E,4B,5A,6B,7B), (1A,2A,3E,4B,5A,6B,7C), (1A,2A,3E,4B,5A,6C,7A), (1A,2A,3E,4B,5A,6C, 7B), (1A,2A,3E,4 B,5A,6C,7C), (1A,2A,3E,4B,5A,6D,7A), (1A,2A,3E,4 B,5A,6D,7B), (1A,2A,3E,4B,5A,6D,7C), (1A,2A, 3E,4B,5B,6A,7A), (1A,2A,3E,4B,5B,6A,7B), (1A,2A,3E,4B,5B,6A,7C), (1A,2A,3E,4B,5B,6B,7A), (1A,2A,3E,4B,5B,6B, 7B), (1A,2A,3E,4 B,5B,6B,7C), (1A,2A,3E,4B,5B,6C,7A), (1A,2A,3E,4B,5B,6C,7B), (1A,2A,3E,4B,5B,6C,7C), (1A,2A, 3E,4B,5B,6D,7A), (1A,2A,3E,4B,5B,6D,7B), (1A,2A,3E,4B,5B,6D,7C), (1A,2A,3E,4 C,5A,6A,7A), (1A,2A,3E,4C,5A,6A,

[illegible]

(1A,2B,3B,4C,5B,6D,7A),(1A,2B,3B,4C,5B,6D,7B), (1A,2B,3B,4C,5B,6D,7C),(1A,2B,3B,4D,5A,6A,7A),(1A,2B,3B,4D,5A,6A,7B),(1A,2B,3B,4 D,5A,6A,7C),(1A,2B,3B,4D,5A,6B,7A),(1A,2B,3B,4D,5A,6B,7B),(1A,2B,3B,4D,5A,6B,7C), (1A,2B,3B,4D,5A,6C,7A),(1A,2B,3B,4D,5A,6C,7B),(1A,2B,3B,4D,5A,6C,7C),(1A,2B,3B,4 D,5A,6D,7A),(1A,2B,3B,4D,5A,6D,7B),(1A,2B,3B,4D,5A,6D,7C),(1A,2B,3B,4D,5B,6A,7A), (1A,2B,3B,4D,5B,6A,7B),(1A,2B,3B,4D,5B,6A,7C),(1A,2B,3B,4D,5B,6B,7A),(1A,2B,3B,4 D,5B,6B,7B),(1A,2B,3B,4D,5B,6B,7C),(1A,2B,3B,4D,5B,6C,7A),(1A,2B,3B,4D,5B,6C,7B), (1A,2B,3B,4D,5B,6C,7C),(1A,2B,3B,4D,5B,6D,7A),(1A,2B,3B,4D,5B,6D,7B),(1A,2B,3B,4 D,5B,6D,7C),(1A,2B,3B,4E,5A,6A,7A),(1A,2B,3B,4E,5A,6A,7B),(1A,2B,3B,4E,5A,6A,7C), (1A,2B,3B,4E,5A,6B,7A),(1A,2B,3B,4E,5A,6B,7B),(1A,2B,3B,4E,5A,6B,7C),(1A,2B,3B,4 E,5A,6C,7A),(1A,2B,3B,4E,5A,6C,7B),(1A,2B,3B,4E,5A,6C,7C),(1A,2B,3B,4E,5A,6D,7A), (1A,2B,3B,4E,5A,6D,7B),(1A,2B,3B,4E,5A,6D,7C),(1A,2B,3B,4E,5B,6A,7A),(1A,2B,3B,4 E,5B,6A,7B),(1A,2B,3B,4E,5B,6A,7C),(1A,2B,3B,4E,5B,6B,7A),(1A,2B,3B,4E,5B,6B,7B), (1A,2B,3B,4E,5B,6B,7C),(1A,2B,3B,4E,5B,6C,7A),(1A,2B,3B,4E,5B,6C,7B),(1A,2B,3B,4 E,5B,6C,7C),(1A,2B,3B,4E,5B,6D,7A),(1A,2B,3B,4E,5B,6D,7B),(1A,2B,3B,4E,5B,6D,7C), (1A,2B,3C,4A,5A,6A,7A),(1A,2B,3C,4A,5A,6A,7B),(1A,2B,3C,4A,5A,6A,7C), (1A,2B,3C,4A,5A,6B,7A),(1A,2B,3C,4A,5A,6B,7B),(1A,2B,3C,4A,5A,6B,7C),(1A,2B,3C,4A,5A,6C,7A),(1A,2B,3C,4A,5A,6C,7B),(1A,2B,3C,4A,5A,6C,7C),(1A,2B,3C,4A,5A,6D,7A),(1A,2B,3C,4 A,5A,6D,7B),(1A,2B,3C,4A,5A,6D,7C),(1A,2B,3C,4A,5B,6A,7A),(1A,2B,3C,4A,5B,6A,7B), (1A,2B,3C,4A,5B,6A,7C),(1A,2B,3C,4A,5B,6B,7A),(1A,2B,3C,4A,5B,6B,7B),(1A,2B,3C,4A,5B,6B,7C), (1A,2B,3C,4A,5B,6C,7A),(1A,2B,3C,4A,5B,6C,7B),(1A,2B,3C,4A,5B,6C,7C),(1A,2B,3C,4A,5B,6D,7A),(1A,2B,3C,4A,5B,6D,7B), (1A,2B,3C,4A,5B,6D,7C),(1A,2B,3C,4A,5B,6E,7A),(1A,2B,3C,4A,5B,6E,7B),(1A,2B,3C,4A,5B,6E,7C),(1A,2B,3C,4A,5B,6F,7A),(1A,2B,3C,4A,5B,6F,7B),(1A,2B,3C,4A,5B,6F,7C), (1A,2B,3C,4B,5A,6A,7A),(1A,2B,3C,4B,5A,6A,7B),(1A,2B,3C,4B,5A,6A,7C),(1A,2B,3C,4B,5A,6B,7A),(1A,2B,3C,4B,5A,6B,7B),(1A,2B,3C,4B,5A,6B,7C),(1A,2B,3C,4B,5A,6C,7A),(1A,2B,3C,4B,5A,6C,7B),(1A,2B,3C,4B,5A,6C,7C),(1A,2B,3C,4B,5A,6D,7A),(1A,2B,3C,4B,5A,6D,7B), (1A,2B,3C,4B,5A,6D,7C),(1A,2B,3C,4B,5B,6A,7A),(1A,2B,3C,4B,5B,6A,7B),(1A,2B,3C,4 B,5B,6A,7C),(1A,2B,3C,4B,5B,6B,7A),(1A,2B,3C,4B,5B,6B,7B),(1A,2B,3C,4B,5B,6B,7C), (1A,2B,3C,4B,5B,6C,7A),(1A,2B,3C,4B,5B,6C,7B),(1A,2B,3C,4B,5B,6C,7C),(1A,2B,3C,4 B,5B,6D,7A),(1A,2B,3C,4B,5B,6D,7B),(1A,2B,3C,4B,5B,6D,7C),(1A,2B,3C,4C,5A,6A,7A), (1A,2B,3C,4C,5A,6A,7B),(1A,2B,3C,4C,5A,6A,7C),(1A,2B,3C,4C,5A,6B,7A),(1A,2B,3C,4C,5A,6B,7B),(1A,2B,3C,4 C,5A,6B,7C),(1A,2B,3C,4C,5A,6C,7A),(1A,2B,3C,4C,5A,6C,7B),(1A,2B,3C,4C,5A,6C,7C), (1A,2B,3C,4C,5A,6D,7A),(1A,2B,3C,4C,5A,6D,7B),(1A,2B,3C,4C,5A,6D,7C),(1A,2B,3C,4C,5B,6A,7A),(1A,2B,3C,4C,5B,6A,7B),(1A,2B,3C,4C,5B,6A,7C), (1A,2B,3C,4C,5B,6B,7A),(1A,2B,3C,4C,5B,6B,7B),(1A,2B,3C,4C,5B,6B,7C),(1A,2B,3C,4C,5B,6C,7A),(1A,2B,3C,4C,5B,6C,7B),(1A,2B,3C,4C,5B,6C,7C),(1A,2B,3C,4C,5B,6D,7A), (1A,2B,3C,4C,5B,6D,7B),(1A,2B,3C,4C,5B,6D,7C),(1A,2B,3C,4C,5B,6E,7A),(1A,2B,3C,4C,5B,6E,7B), (1A,2B,3C,4E,5A,6A,7A),(1A,2B,3C,4E,5A,6A,7B), (1A,2B,3C,4E,5A,6A,7C),(1A,2B,3C,4E,5A,6B,7A),(1A,2B,3C,4E,5A,6B,7B),(1A,2B,3C,4 E,5A,6B,7C),(1A,2B,3C,4E,5A,6C,7A),(1A,2B,3C,4E,5A,6C,7B),(1A,2B,3C,4E,5A,6C,7C), (1A,2B,3C,4E,5A,6D,7A),(1A,2B,3C,4E,5A,6D,7B),(1A,2B,3C,4E,5A,6D,7C),(1A,2B,3C,4 E,5B,6A,7A),(1A,2B,3C,4E,5B,6A,7B),(1A,2B,3C,4E,5B,6A,7C),(1A,2B,3C,4E,5B,6B,7A), (1A,2B,3C,4E,5B,6B,7B),(1A,2B,3C,4E,5B,6B,7C),(1A,2B,3C,4E,5B,6C,7A),(1A,2B,3C,4E,5B,6C,7B), (1A,2B,3C,4E,5B,6C,7C),(1A,2B,3C,4E,5B,6D,7A),(1A,2B,3C,4E,5B,6D,7B), (1A,2B,3C,4E,5B,6D,7C),(1A,2B,3D,4A,5A,6A,7A),(1A,2B,3D,4A,5A,6A,7B), (1A,2B,3D,4A,5A,6A,7C),(1A,2B,3D,4A,5A,6B,7A),(1A,2B,3D,4A,5A,6B,7B),(1A,2B,3D,4A,5A,6B,7C), (1A,2B,3D,4A,5A,6C,7A),(1A,2B,3D,4A,5A,6C,7B),(1A,2B,3D,4A,5A,6C,7C),(1A,2B,3D,4 A,5A,6D,7A),(1A,2B,3D,4A,5A,6D,7B),(1A,2B,3D,4A,5A,6D,7C),(1A,2B,3D,4A,5B,6A,7A), (1A,2B,3D,4A,5B,6A,7B),(1A,2B,3D,4A,5B,6A,7C),(1A,2B,3D,4A,5B,6B,7A),(1A,2B,3D,4A,5B,6B,7B), (1A,2B,3D,4A,5B,6B,7C),(1A,2B,3D,4A,5B,6C,7A),(1A,2B,3D,4A,5B,6C,7B),(1A,2B,3D,4A,5B,6C,7C),(1A,2B,3D,4A,5B,6D,7A),(1A,2B,3D,4A,5B,6D,7B), (1A,2B,3D,4A,5B,6D,7C),(1A,2B,3D,4A,5B,6E,7A),(1A,2B,3D,4A,5B,6E,7B), (1A,2B,3D,4B,5A,6A,7A),(1A,2B,3D,4B,5A,6A,7B),(1A,2B,3D,4B,5A,6A,7C), (1A,2B,3D,4B,5A,6B,7A),(1A,2B,3D,4B,5A,6B,7B),(1A,2B,3D,4B,5A,6B,7C),(1A,2B,3D,4B,5A,6C,7A),(1A,2B,3D,4B,5A,6C,7B),(1A,2B,3D,4B,5A,6C,7C),(1A,2B,3D,4B,5A,6D,7A), (1A,2B,3D,4B,5A,6D,7B),(1A,2B,3D,4B,5A,6D,7C),(1A,2B,3D,4B,5B,6A,7A),(1A,2B,3D,4B,5B,6A,7B), (1A,2B,3D,4B,5B,6A,7C),(1A,2B,3D,4B,5B,6B,7A),(1A,2B,3D,4B,5B,6B,7B), (1A,2B,3D,4B,5B,6B,7C), (1A,2B,3D,4B,5B,6C,7A),(1A,2B,3D,4B,5B,6C,7B),(1A,2B,3D,4 B,5B,6C,7C),(1A,2B,3D,4B,5B,6D,7A),(1A,2B,3D,4B,5B,6D,7B),(1A,2B,3D,4B,5B,6D,7C), (1A,2B,3D,4C,5A,6A,7A),(1A,2B,3D,4C,5A,6A,7B),(1A,2B,3D,4C,5A,6A,7C),(1A,2B,3D,4 C,5A,6B,7A),(1A,2B,3D,4C,5A,6B,7B),(1A,2B,3D,4C,5A,6B,7C),(1A,2B,3D,4C,5A,6C,7A), (1A,2B,3D,4C,5A,6C,7B),(1A,2B,3D,4C,5A,6C,7C),(1A,2B,3D,4C,5A,6D,7A),(1A,2B,3D,4 C,5A,6D,7B),(1A,2B,3D,4C,5A,6D,7C),(1A,2B,3D,4C,5B,6A,7A),(1A,2B,3D,4C,5B,6A,7B), (1A,2B,3D,4C,5B,6A,7C),(1A,2B,3D,4C,5B,6B,7A),(1A,2B,3D,4C,5B,6B,7B),(1A,2B,3D,4C,5B,6B,7C), (1A,2B,3D,4C,5B,6C,7A),(1A,2B,3D,4C,5B,6C,7B),(1A,2B,3D,4C,5B,6C,7C),(1A,2B,3D,4C,5B,6D,7A),(1A,2B,3D,4C,5B,6D,7B),(1A,2B,3D,4C,5B,6D,7C),(1A,2B,3D,4 D,5A,6A,7A), (1A,2B,3D,4D,5A,6A,7B),(1A,2B,3D,4D,5A,6A,7C),(1A,2B,3D,4D,5A,6B,7A), (1A,2B,3D,4D,5A,6B,7B),(1A,2B,3D,4D,5A,6B,7C),(1A,2B,3D,4D,5A,6C,7A),(1A,2B,3D,4D,5A,6C,7B), (1A,2B,3D,4D,5A,6C,7C),(1A,2B,3D,4D,5A,6D,7A),(1A,2B,3D,4D,5A,6D,7B), (1A,2B,3D,4D,5A,6D,7C),(1A,2B,3D,4D,5B,6A,7A),(1A,2B,3D,4D,5B,6A,7B),(1A,2B,

3D,4 D,5B,6A,7C),(1A,2B,3D,4D,5B,6B,7A),(1A,2B,3D,4D,5B,6B,7B),(1A,2B,3D,4D,5B,6B,7C), (1A,2B,3D,4D,5B,
6C,7A),(1A,2B,3D,4D,5B,6C,7B),(1A,2B,3D,4D,5B,6C,7C),(1A,2B,3D,4 D,5B,6D,7A),(1A,2B,3D,4D,5B,6D,7B),(1A,
2B,3D,4D,5B,6D,7C),(1A,2B,3D,4E,5A,6A,7A), (1A,2B,3D,4E,5A,6A,7B),(1A,2B,3D,4E,5A,6A,7C),(1A,2B,3D,4E,
5A,6B,7A),(1A,2B,3D,4 E,5A,6B,7B),(1A,2B,3D,4E,5A,6B,7C),(1A,2B,3D,4E,5A,6C,7A),(1A,2B,3D,4E,5A,6C,7B),
5 (1A,2B,3D,4E,5A,6C,7C),(1A,2B,3D,4E,5A,6D,7A),(1A,2B,3D,4E,5A,6D,7B),(1A,2B,3D,4 E,5A,6D,7C),(1A,2B,3D,
4E,5B,6A,7A),(1A,2B,3D,4E,5B,6A,7B),(1A,2B,3D,4E,5B,6A,7C), (1A,2B,3D,4E,5B,6B,7A),(1A,2B,3D,4E,5B,6B,
7B),(1A,2B,3D,4E,5B,6B,7C),(1A,2B,3D,4 E,5B,6C,7A),(1A,2B,3D,4E,5B,6C,7B),(1A,2B,3D,4E,5B,6C,7C),(1A,2B,
3D,4E,5B,6D,7A),(1A,2B,3D,4E,5B,6D,7B),(1A,2B,3D,4E,5B,6D,7C),(1A,2B,3E,4A,5A,6A,7A),(1A,2B,3E,4 A,5A,
6A,7B),(1A,2B,3E,4A,5A,6A,7C),(1A,2B,3E,4A,5A,6B,7A),(1A,2B,3E,4A,5A,6B,7B), (1A,2B,3E,4A,5A,6B,7C),(1A,
10 2B,3E,4A,5A,6C,7A),(1A,2B,3E,4A,5A,6C,7B),(1A,2B,3E,4 A,5A,6C,7C),(1A,2B,3E,4A,5A,6D,7A),(1A,2B,3E,4A,5A,
6D,7B),(1A,2B,3E,4A,5A,6D,7C) (1A,2B,3E,4A,5B,6A,7A),(1A,2B,3E,4A,5B,6A,7B),(1A,2B,3E,4A,5B,6A,7C),(1A,
2B,3E,4 A,5B,6B,7A),(1A,2B,3E,4A,5B,6B,7B),(1A,2B,3E,4A,5B,6B,7C),(1A,2B,3E,4A,5B,6C,7A), (1A,2B,3E,4A,5B,
6C,7B),(1A,2B,3E,4A,5B,6C,7C),(1A,2B,3E,4A,5B,6D,7A),(1A,2B,3E,4 A,5B,6D,7B),(1A,2B,3E,4A,5B,6D,7C),(1A,
2B,3E,4B,5A,6A,7A),(1A,2B,3E,4B,5A,6A,7B), (1A,2B,3E,4B,5A,6A,7C),(1A,2B,3E,4B,5A,6B,7A),(1A,2B,3E,4B,5A,
15 6B,7B),(1A,2B,3E,4 B,5A,6B,7C),(1A,2B,3E,4B,5A,6C,7A),(1A,2B,3E,4B,5A,6C,7B),(1A,2B,3E,4B,5A,6C,7C) (1A,
2B,3E,4B,5A,6D,7A),(1A,2B,3E,4B,5A,6D,7B),(1A,2B,3E,4B,5A,6D,7C),(1A,2B,3E,4 B,5B,6A,7A),(1A,2B,3E,4B,5B,
6A,7B),(1A,2B,3E,4B,5B,6A,7C),(1A,2B,3E,4B,5B,6B,7A), (1A,2B,3E,4B,5B,6B,7B),(1A,2B,3E,4B,5B,6B,7C),(1A,
2B,3E,4B,5B,6C,7A),(1A,2B,3E,4 B,5B,6C,7B),(1A,2B,3E,4B,5B,6C,7C),(1A,2B,3E,4B,5B,6D,7A),(1A,2B,3E,4B,5B,
6D,7B), (1A,2B,3E,4B,5B,6D,7C),(1A,2B,3E,4C,5A,6A,7A),(1A,2B,3E,4C,5A,6A,7B),(1A,2B,3E,4 C,5A,6A,7C),(1A,
20 2B,3E,4C,5A,6B,7A),(1A,2B,3E,4C,5A,6B,7B),(1A,2B,3E,4C,5A,6B,7C), (1A,2B,3E,4C,5A,6C,7A),(1A,2B,3E,4C,5A,
6C,7B),(1A,2B,3E,4C,5A,6C,7C),(1A,2B,3E,4 C,5A,6D,7A),(1A,2B,3E,4C,5A,6D,7B),(1A,2B,3E,4C,5A,6D,7C),(1A,
2B,3E,4C,5B,6A,7A), (1A,2B,3E,4C,5B,6A,7B),(1A,2B,3E,4C,5B,6A,7C),(1A,2B,3E,4C,5B,6B,7A),(1A,2B,3E,4 C,
5B,6B,7B),(1A,2B,3E,4C,5B,6B,7C),(1A,2B,3E,4C,5B,6C,7A),(1A,2B,3E,4C,5B,6C,7B), (1A,2B,3E,4C,5B,6C,7C),
(1A,2B,3E,4C,5B,6D,7A),(1A,2B,3E,4C,5B,6D,7B),(1A,2B,3E,4 C,5B,6D,7C),(1A,2B,3E,4D,5A,6A,7A),(1A,2B,3E,
25 4D,5A,6A,7B),(1A,2B,3E,4D,5A,6A,7C), (1A,2B,3E,4D,5A,6B,7A),(1A,2B,3E,4D,5A,6B,7B),(1A,2B,3E,4D,5A,6B,
7C),(1A,2B,3E,4 D,5A,6C,7A),(1A,2B,3E,4D,5A,6C,7B),(1A,2B,3E,4D,5A,6C,7C),(1A,2B,3E,4D,5A,6D,7A), (1A,2B,
3E,4D,5A,6D,7B),(1A,2B,3E,4D,5A,6D,7C),(1A,2B,3E,4D,5B,6A,7A),(1A,2B,3E,4 D,5B,6A,7B),(1A,2B,3E,4D,5B,
6A,7C),(1A,2B,3E,4D,5B,6B,7A),(1A,2B,3E,4D,5B,6B,7B), (1A,2B,3E,4D,5B,6B,7C),(1A,2B,3E,4D,5B,6C,7A),(1A,
30 2B,3E,4D,5B,6C,7B),(1A,2B,3E,4 D,5B,6C,7C),(1A,2B,3E,4D,5B,6D,7A),(1A,2B,3E,4D,5B,6D,7B),(1A,2B,3E,4D,
5B,6D,7C), (1A,2B,3E,4E,5A,6A,7A),(1A,2B,3E,4E,5A,6A,7B),(1A,2B,3E,4E,5A,6A,7C),(1A,2B,3E,4 E,5A,6B,7A),
(1A,2B,3E,4E,5A,6B,7B),(1A,2B,3E,4E,5A,6B,7C),(1A,2B,3E,4E,5A,6C,7A), (1A,2B,3E,4E,5A,6C,7B),(1A,2B,3E,
4E,5A,6C,7C),(1A,2B,3E,4E,5A,6D,7A),(1A,2B,3E,4 E,5A,6D,7B),(1A,2B,3E,4E,5A,6D,7C),(1A,2B,3E,4E,5B,6A,
7A),(1A,2B,3E,4E,5B,6A,7B), (1A,2B,3E,4E,5B,6A,7C),(1A,2B,3E,4E,5B,6B,7A),(1A,2B,3E,4E,5B,6B,7B),(1A,2B,
3E,4 E,5B,6B,7C),(1A,2B,3E,4E,5B,6C,7A),(1A,2B,3E,4E,5B,6C,7B),(1A,2B,3E,4E,5B,6C,7C), (1A,2B,3E,4E,5B,
35 6D,7A),(1A,2B,3E,4E,5B,6D,7B),(1A,2B,3E,4E,5B,6D,7C),(1A,2C,3A,4 A,5A,6A,7A),(1A,2C,3A,4A,5A,6A,7B),(1A,
2C,3A,4A,5A,6A,7C),(1A,2C,3A,4A,5A,6B,7A), (1A,2C,3A,4A,5A,6B,7B),(1A,2C,3A,4A,5A,6B,7C),(1A,2C,3A,4A,5A,
6C,7A),(1A,2C,3A,4 A,5A,6C,7A),(1A,2C,3A,4A,5A,6C,7B),(1A,2C,3A,4A,5A,6D,7A),(1A,2C,3A,4A,5A,6D,7B), (1A,
2C,3A,4A,5A,6D,7C),(1A,2C,3A,4A,5B,6A,7A),(1A,2C,3A,4A,5B,6A,7B),(1A,2C,3A,4 A,5B,6A,7C),(1A,2C,3A,4A,
5B,6B,7A),(1A,2C,3A,4A,5B,6B,7B),(1A,2C,3A,4A,5B,6B,7C), (1A,2C,3A,4A,5B,6C,7A),(1A,2C,3A,4A,5B,6C,7B),
40 (1A,2C,3A,4A,5B,6C,7C),(1A,2C,3A,4 A,5B,6D,7A),(1A,2C,3A,4A,5B,6D,7B),(1A,2C,3A,4A,5B,6D,7C),(1A,2C,3A,
4B,5A,6A,7A), (1A,2C,3A,4B,5A,6A,7B),(1A,2C,3A,4B,5A,6A,7C),(1A,2C,3A,4B,5A,6B,7A),(1A,2C,3A,4 B,5A,6B,
7B),(1A,2C,3A,4B,5A,6B,7C),(1A,2C,3A,4B,5A,6C,7A),(1A,2C,3A,4B,5A,6C,7B), (1A,2C,3A,4B,5A,6C,7C),(1A,2C,
3A,4B,5A,6D,7A),(1A,2C,3A,4B,5A

2C,3A,4E,5A,6C,7C),(1A,2C,3A,4 E,5A,6D,7A),(1A,2C,3A,4E,5A,6D,7B),(1A,2C,3A,4E,5A,6D,7C),(1A,2C,3A,4E,
 5B,6A,7A),(1A,2C,3A,4E,5B,6A,7B),(1A,2C,3A,4E,5B,6A,7C),(1A,2C,3A,4E,5B,6B,7A),(1A,2C,3A,4 E,5B,6B,7B),
 (1A,2C,3A,4E,5B,6B,7C),(1A,2C,3A,4E,5B,6C,7A),(1A,2C,3A,4E,5B,6C,7B),(1A,2C,3A,4E,5B,6C,7C),(1A,2C,3A,
 4E,5B,6D,7A),(1A,2C,3A,4E,5B,6D,7B),(1A,2C,3A,4 E,5B,6D,7C),(1A,2C,3B,4A,5A,6A,7A),(1A,2C,3B,4A,5A,6A,
 5B,6A,7A),(1A,2C,3B,4A,5A,6A,7C),(1A,2C,3B,4A,5A,6B,7A),(1A,2C,3B,4A,5A,6B,7B),(1A,2C,3B,4A,5A,6B,7C),(1A,2C,
 3B,4 A,5A,6C,7A),(1A,2C,3B,4A,5A,6C,7B),(1A,2C,3B,4A,5A,6C,7C),(1A,2C,3B,4A,5A,6D,7A),(1A,2C,3B,4A,5A,
 6D,7B),(1A,2C,3B,4A,5A,6D,7C),(1A,2C,3B,4A,5B,6A,7A),(1A,2C,3B,4 A,5B,6A,7B),(1A,2C,3B,4A,5B,6A,7C),(1A,
 2C,3B,4A,5B,6B,7A),(1A,2C,3B,4A,5B,6B,7B),(1A,2C,3B,4A,5B,6B,7C),(1A,2C,3B,4A,5B,6C,7A),(1A,2C,3B,4A,5B,
 6C,7B),(1A,2C,3B,4 A,5B,6C,7C),(1A,2C,3B,4A,5B,6D,7A),(1A,2C,3B,4A,5B,6D,7B),(1A,2C,3B,4A,5B,6D,7C),(1A,
 2C,3B,4B,5A,6A,7A),(1A,2C,3B,4B,5A,6A,7B),(1A,2C,3B,4B,5A,6A,7C),(1A,2C,3B,4 B,5A,6B,7A),(1A,2C,3B,4B,5A,
 6B,7B),(1A,2C,3B,4B,5A,6B,7C),(1A,2C,3B,4B,5A,6C,7A),(1A,2C,3B,4B,5A,6C,7B),(1A,2C,3B,4B,5A,6C,7C),(1A,
 2C,3B,4B,5A,6D,7A),(1A,2C,3B,4 B,5A,6D,7B),(1A,2C,3B,4B,5A,6D,7C),(1A,2C,3B,4B,5B,6A,7A),(1A,2C,3B,4B,
 5B,6A,7B),(1A,2C,3B,4B,5B,6A,7C),(1A,2C,3B,4B,5B,6B,7A),(1A,2C,3B,4B,5B,6B,7B),(1A,2C,3B,4 B,5B,6B,7C),
 (1A,2C,3B,4B,5B,6C,7A),(1A,2C,3B,4B,5B,6C,7B),(1A,2C,3B,4B,5B,6C,7C),(1A,2C,3B,4B,5B,6D,7A),(1A,2C,3B,
 4B,5B,6D,7B),(1A,2C,3B,4B,5B,6D,7C),(1A,2C,3B,4 C,5A,6A,7A),(1A,2C,3B,4C,5A,6A,7B),(1A,2C,3B,4C,5A,6A,
 7C),(1A,2C,3B,4C,5A,6B,7A),(1A,2C,3B,4C,5A,6B,7B),(1A,2C,3B,4C,5A,6B,7C),(1A,2C,3B,4C,5A,6C,7A),(1A,2C,
 3B,4 C,5A,6C,7B),(1A,2C,3B,4C,5A,6C,7C),(1A,2C,3B,4C,5A,6D,7A),(1A,2C,3B,4C,5A,6D,7B),(1A,2C,3B,4C,5A,
 6D,7C),(1A,2C,3B,4C,5B,6A,7A),(1A,2C,3B,4C,5B,6A,7B),(1A,2C,3B,4 C,5B,6A,7C),(1A,2C,3B,4C,5B,6B,7A),(1A,
 2C,3B,4C,5B,6B,7B),(1A,2C,3B,4C,5B,6B,7C),(1A,2C,3B,4C,5B,6C,7A),(1A,2C,3B,4C,5B,6C,7B),(1A,2C,3B,4C,5B,
 6C,7C),(1A,2C,3B,4 C,5B,6D,7A),(1A,2C,3B,4C,5B,6D,7B),(1A,2C,3B,4C,5B,6D,7C),(1A,2C,3B,4D,5A,6A,7A),
 (1A,2C,3B,4D,5A,6A,7B),(1A,2C,3B,4D,5A,6A,7C),(1A,2C,3B,4D,5A,6B,7A),(1A,2C,3B,4 D,5A,6B,7B),(1A,2C,3B,
 4D,5A,6B,7C),(1A,2C,3B,4D,5A,6C,7A),(1A,2C,3B,4D,5A,6C,7B),(1A,2C,3B,4D,5A,6C,7C),(1A,2C,3B,4D,5A,6D,
 7A),(1A,2C,3B,4D,5A,6D,7B),(1A,2C,3B,4 D,5A,6D,7C),(1A,2C,3B,4D,5B,6A,7A),(1A,2C,3B,4D,5B,6A,7B),(1A,2C,
 3B,4D,5B,6A,7C),(1A,2C,3B,4D,5B,6B,7A),(1A,2C,3B,4D,5B,6B,7B),(1A,2C,3B,4D,5B,6B,7C),(1A,2C,3B,4 D,5B,
 6C,7A),(1A,2C,3B,4D,5B,6C,7B),(1A,2C,3B,4D,5B,6C,7C),(1A,2C,3B,4D,5B,6D,7A),(1A,2C,3B,4D,5B,6D,7B),(1A,
 2C,3B,4D,5B,6D,7C),(1A,2C,3B,4E,5A,6A,7A),(1A,2C,3B,4 E,5A,6A,7B),(1A,2C,3B,4E,5A,6A,7C),(1A,2C,3B,4E,
 5A,6B,7A),(1A,2C,3B,4E,5A,6B,7B),(1A,2C,3B,4E,5A,6B,7C),(1A,2C,3B,4E,5A,6C,7A),(1A,2C,3B,4E,5A,6C,7B),
 (1A,2C,3B,4 E,5A,6C,7C),(1A,2C,3B,4E,5A,6D,7A),(1A,2C,3B,4E,5A,6D,7B),(1A,2C,3B,4E,5A,6D,7C),(1A,2C,3B,
 4E,5B,6A,7A),(1A,2C,3B,4E,5B,6A,7B),(1A,2C,3B,4E,5B,6A,7C),(1A,2C,3B,4 E,5B,6B,7A),(1A,2C,3B,4E,5B,6B,
 7B),(1A,2C,3B,4E,5B,6B,7C),(1A,2C,3B,4E,5B,6C,7A),(1A,2C,3B,4E,5B,6C,7B),(1A,2C,3B,4E,5B,6C,7C),(1A,2C,
 3B,4E,5B,6D,7A),(1A,2C,3B,4 E,5B,6D,7B),(1A,2C,3B,4E,5B,6D,7C),(1A,2C,3C,4A,5A,6A,7A),(1A,2C,3C,4A,5A,
 6A,7B),(1A,2C,3C,4A,5A,6A,7C),(1A,2C,3C,4A,5A,6B,7A),(1A,2C,3C,4A,5A,6B,7B),(1A,2C,3C,4 A,5A,6B,7C),(1A,
 2C,3C,4A,5A,6C,7A),(1A,2C,3C,4A,5A,6C,7B),(1A,2C,3C,4A,5A,6C,7C),(1A,2C,3C,4A,5A,6D,7A),(1A,2C,3C,4A,
 5A,6D,7B),(1A,2C,3C,4A,5A,6D,7C),(1A,2C,3C,4 A,5B,6A,7A),(1A,2C,3C,4A,5B,6A,7B),(1A,2C,3C,4A,5B,6A,7C),
 (1A,2C,3C,4A,5B,6B,7A),(1A,2C,3C,4A,5B,6B,7B),(1A,2C,3C,4A,5B,6B,7C),(1A,2C,3C,4A,5B,6C,7A),(1A,2C,3C,4
 A,5B,6C,7B),(1A,2C,3C,4A,5B,6C,7C),(1A,2C,3C,4A,5B,6D,7A),(1A,2C,3C,4A,5B,6D,7B),(1A,2C,3C,4A,5B,6D,7C),
 (1A,2C,3C,4B,5A,6A,7A),(1A,2C,3C,4B,5A,6A,7B),(1A,2C,3C,4 B,5A,6A,7C),(1A,2C,3C,4B,5A,6B,7A),(1A,2C,3C,
 4B,5A,6B,7B),(1A,2C,3C,4B,5A,6B,7C),(1A,2C,3C,4B,5A,6C,7A),(1A,2C,3C,4B,5A,6C,7B),(1A,2C,3C,4B,5A,6C,
 7C),(1A,2C,3C,4 B,5A,6D,7A),(1A,2C,3C,4B,5A,6D,7B),(1A,2C,3C,4B,5A,6D,7C),(1A,2C,3C,4B,5B,6A,7A),(1A,
 2C,3C,4B,5B,6A,7B),(1A,2C,3C,4B,5B,6A,7C),(1A,2C,3C,4B,5B,6B,7A),(1A,2C,3C,4 B,5B,6B,7B),(1A,2C,3C,4B,
 5B,6B,7C),(1A,2C,3C,4B,5B,6C,7A),(1A,2C,3C,4B,5B,6C,7B),(1A,2C,3C,4B,5B,6C,7C),(1A,2C,3C,4B,5B,6D,7A),
 (1A,2C,3C,4B,5B,6D,7B),(1A,2C,3C,4 B,5B,6D,7C),(1A,2C,3C,4C,5A,6A,7A),(1A,2C,3C,4C,5A,6A,7B),(1A,2C,3C,
 4C,5A,6A,7C),(1A,2C,3C,4C,5A,6B,7A),(1A,2C,3C,4C,5A,6B,7B),(1A,2C,3C,4C,5A,6B,7C),(1A,2C,3C,4 C,5A,6C,
 7A),(1A,2C,3C,4C,5A,6C,7B),(1A,2C,3C,4C,5A,6C,7C),(1A,2C,3C,4C,5A,6D,7A),(1A,2C,3C,4C,5A,6D,7B),(1A,2C,
 3C,4C,5A,6D,7C),(1A,2C,3C,4C,5B,6A,7A),(1A,2C,3C,4 C,5B,6A,7B),(1A,2C,3C,4C,5B,6A,7C),(1A,2C,3C,4C,5B,
 6B,7A),(1A,2C,3C,4C,5B,6B,7B),(1A,2C,3C,4C,5B,6B,7C),(1A,2C,3C,4C,5B,6C,7A),(1A,2C,3C,4C,5B,6C,7B),(1A,
 2C,3C,4 C,5B,6C,7C),(1A,2C,3C,4C,5B,6D,7A),(1A,2C,3C,4C,5B,6D,7B),(1A,2C,3C,4C,5B,6D,7C),(1A,2C,3C,4D,
 5A,6A,7A),(1A,2C,3C,4D,5A,6A,7B),(1A,2C,3C,4D,5A,6A,7C),(1A,2C,3C,4 D,5A,6B,7A),(1A,2C,3C,4D,5A,6B,7B),
 (1A,2C,3C,4D,5A,6B,7C),(1A,2C,3C,4D,5A,6C,7A),(1A,2C,3C,4D,5A,6C,7B),(1A,2C,3C,4D,5A,6C,7C),(1A,2C,3C,
 4D,5A,6D,7A),(1A,2C,3C,4 D,5A,6D,7B),(1A,2C,3C,4D,5A,6D,7C),(1A,2C,3C,4D,5B,6A,7A),(1A,2C,3C,4D,5B,6A,
 7B),(1A,2C,3C,4D,5B,6A,7C),(1A,2C,3C,4D,5B,6B,7A),(1A,2C,3C,4D,5B,6B,7B),(1A,2C,3C,4 D,5B,6B,7C),(1A,2C,
 3C,4D,5B,6C,7A),(1A,2C,3C,4D,5B,6C,7B),(1A,2C,3C,4D,5B,6C,7C),(1A,2C,3C,4D,5B,6D,7A),(1A,2C,3C,4D,5B,
 6D,7B),(1A,2C,3C,4D,5B,6D,7C),(1A,2C,3C,4 E,5A,6A,7A),(1A,2C,3C,4E,5A,6A,7B),(1A,2C,3C,4E,5A,6A,7C),(1A,
 2C,3C,4E,5A,6B,7A),(1A,2C,3C,4E,5A,6B,7B),(1A,2C,3C,4E,5A,6B,7C),(1A,2C,3C,4E,5A,6C,7A),(1A,2C,3C,4 E,
 5A,6C,7B),(1A,2C,3C,4E,5A,6C,7C),(1A,2C,3C,4E,5A,6D,7A),(1A,2C,3C,4E,5A,6D,7B),(1A,2C,3C,4E,5A,6D,7C),
 (1A,2C,3C,4E,5B,6A,7A),(1A,2C,3C,4E,5B,6A,7B),(1A,2C,3C,4 E,5B,6A,7C),(1A,2C,3C,4E,5B,6B,7A),(1A,2C,3C,
 4E,5B,6B,7B),(1A,2C,3C,4E,5B,6B,7C),(1A,2C,3C,4E,5B,6C,7A),(1A,2C,3C,4E,5B,6C,7B),(1A,2C,3C,4E,5B,6C,
 7C),(1A,2C,3C,4 E,5B,6D,7A),(1A,2C,3C,4E,5B,6D,7B),(1A,2C,3C,4E,5B,6D,7C),(1A,2C,3D,4A,5A,6A,7A),(1A,2C,

3D,4A,5A,6A,7B),(1A,2C,3D,4A,5A,6A,7C),(1A,2C,3D,4A,5A,6B,7A),(1A,2C,3D,4 A,5A,6B,7B),(1A,2C,3D,4A,5A,6B,7C),(1A,2C,3D,4A,5A,6C,7A),(1A,2C,3D,4A,5A,6C,7B),(1A,2C,3D,4A,5A,6C,7C),(1A,2C,3D,4A,5A,6D,7A),(1A,2C,3D,4A,5A,6D,7B),(1A,2C,3D,4 A,5A,6D,7C),(1A,2C,3D,4A,5B,6A,7A),(1A,2C,3D,4A,5B,6A,7B),(1A,2C,3D,4A,5B,6A,7C),(1A,2C,3D,4A,5B,6B,7A),(1A,2C,3D,4A,5B,6B,7B),(1A,2C,3D,4A,5B,6B,7C),(1A,2C,3D,4 A,5B,6C,7A),(1A,2C,3D,4A,5B,6C,7C),(1A,2C,3D,4A,5B,6D,7A),(1A,2C,3D,4A,5B,6D,7B),(1A,2C,3D,4A,5B,6D,7C),(1A,2C,3D,4B,5A,6A,7A),(1A,2C,3D,4 B,5A,6A,7B),(1A,2C,3D,4B,5A,6A,7C),(1A,2C,3D,4B,5A,6B,7A),(1A,2C,3D,4B,5A,6B,7B),(1A,2C,3D,4B,5A,6B,7C),(1A,2C,3D,4B,5A,6C,7A),(1A,2C,3D,4B,5A,6C,7B),(1A,2C,3D,4 B,5A,6C,7C),(1A,2C,3D,4B,5A,6D,7A),(1A,2C,3D,4B,5A,6D,7B),(1A,2C,3D,4B,5A,6D,7C),(1A,2C,3D,4B,5B,6A,7A),(1A,2C,3D,4B,5B,6A,7B),(1A,2C,3D,4B,5B,6A,7C),(1A,2C,3D,4B,5B,6B,7A),(1A,2C,3D,4B,5B,6B,7B),(1A,2C,3D,4B,5B,6B,7C),(1A,2C,3D,4B,5B,6C,7A),(1A,2C,3D,4B,5B,6C,7B),(1A,2C,3D,4B,5B,6C,7C),(1A,2C,3D,4B,5B,6D,7A),(1A,2C,3D,4 B,5B,6D,7B),(1A,2C,3D,4B,5B,6D,7C),(1A,2C,3D,4C,5A,6A,7A),(1A,2C,3D,4C,5A,6A,7B),(1A,2C,3D,4C,5A,6A,7C),(1A,2C,3D,4C,5A,6B,7A),(1A,2C,3D,4C,5A,6B,7B),(1A,2C,3D,4C,5A,6B,7C),(1A,2C,3D,4C,5A,6C,7A),(1A,2C,3D,4C,5A,6C,7B),(1A,2C,3D,4C,5A,6C,7C),(1A,2C,3D,4C,5A,6D,7A),(1A,2C,3D,4C,5A,6D,7B),(1A,2C,3D,4C,5A,6D,7C),(1A,2C,3D,4 C,5B,6A,7A),(1A,2C,3D,4C,5B,6A,7B),(1A,2C,3D,4C,5B,6A,7C),(1A,2C,3D,4C,5B,6B,7A),(1A,2C,3D,4C,5B,6B,7B),(1A,2C,3D,4C,5B,6B,7C),(1A,2C,3D,4C,5B,6C,7A),(1A,2C,3D,4 C,5B,6C,7B),(1A,2C,3D,4C,5B,6C,7C),(1A,2C,3D,4C,5B,6D,7A),(1A,2C,3D,4C,5B,6D,7B),(1A,2C,3D,4C,5B,6D,7C),(1A,2C,3D,4D,5A,6A,7A),(1A,2C,3D,4D,5A,6A,7B),(1A,2C,3D,4 D,5A,6A,7C),(1A,2C,3D,4D,5A,6B,7A),(1A,2C,3D,4D,5A,6B,7B),(1A,2C,3D,4D,5A,6B,7C),(1A,2C,3D,4D,5A,6C,7A),(1A,2C,3D,4D,5A,6C,7B),(1A,2C,3D,4D,5A,6C,7C),(1A,2C,3D,4D,5A,6D,7A),(1A,2C,3D,4D,5A,6D,7B),(1A,2C,3D,4D,5A,6D,7C),(1A,2C,3D,4D,5B,6A,7A),(1A,2C,3D,4D,5B,6A,7B),(1A,2C,3D,4D,5B,6A,7C),(1A,2C,3D,4D,5B,6B,7A),(1A,2C,3D,4D,5B,6B,7B),(1A,2C,3D,4D,5B,6B,7C),(1A,2C,3D,4D,5B,6C,7A),(1A,2C,3D,4D,5B,6C,7B),(1A,2C,3D,4D,5B,6C,7C),(1A,2C,3D,4D,5B,6D,7A),(1A,2C,3D,4D,5B,6D,7B),(1A,2C,3D,4 D,5B,6D,7C),(1A,2C,3D,4E,5A,6A,7A),(1A,2C,3D,4E,5A,6A,7B),(1A,2C,3D,4E,5A,6A,7C),(1A,2C,3D,4E,5A,6B,7A),(1A,2C,3D,4E,5A,6B,7B),(1A,2C,3D,4E,5A,6B,7C),(1A,2C,3D,4 E,5A,6C,7A),(1A,2C,3D,4E,5A,6C,7B),(1A,2C,3D,4E,5A,6C,7C),(1A,2C,3D,4E,5A,6D,7A),(1A,2C,3D,4E,5A,6D,7B),(1A,2C,3D,4E,5A,6D,7C),(1A,2C,3D,4E,5B,6A,7A),(1A,2C,3D,4 E,5B,6A,7B),(1A,2C,3D,4E,5B,6A,7C),(1A,2C,3D,4E,5B,6B,7A),(1A,2C,3D,4E,5B,6B,7B),(1A,2C,3D,4E,5B,6B,7C),(1A,2C,3D,4E,5B,6C,7A),(1A,2C,3D,4E,5B,6C,7B),(1A,2C,3D,4 E,5B,6C,7C),(1A,2C,3D,4E,5B,6D,7A),(1A,2C,3D,4E,5B,6D,7B),(1A,2C,3D,4E,5B,6D,7C),(1A,2C,3E,4A,5A,6A,7A),(1A,2C,3E,4A,5A,6A,7B),(1A,2C,3E,4A,5A,6A,7C),(1A,2C,3E,4A,5A,6B,7A),(1A,2C,3E,4A,5A,6B,7B),(1A,2C,3E,4A,5A,6B,7C),(1A,2C,3E,4A,5A,6C,7A),(1A,2C,3E,4A,5A,6C,7B),(1A,2C,3E,4A,5A,6C,7C),(1A,2C,3E,4A,5A,6D,7A),(1A,2C,3E,4A,5A,6D,7B),(1A,2C,3E,4A,5A,6D,7C),(1A,2C,3E,4A,5B,6A,7A),(1A,2C,3E,4A,5B,6A,7B),(1A,2C,3E,4A,5B,6A,7C),(1A,2C,3E,4A,5B,6B,7A),(1A,2C,3E,4A,5B,6B,7B),(1A,2C,3E,4A,5B,6B,7C),(1A,2C,3E,4A,5B,6C,7A),(1A,2C,3E,4A,5B,6C,7B),(1A,2C,3E,4A,5B,6C,7C),(1A,2C,3E,4A,5B,6D,7A),(1A,2C,3E,4 B,5A,6A,7A),(1A,2C,3E,4B,5A,6A,7B),(1A,2C,3E,4B,5A,6A,7C),(1A,2C,3E,4B,5A,6B,7A),(1A,2C,3E,4B,5A,6B,7B),(1A,2C,3E,4B,5A,6B,7C),(1A,2C,3E,4B,5A,6C,7A),(1A,2C,3E,4 B,5A,6C,7B),(1A,2C,3E,4B,5A,6C,7C),(1A,2C,3E,4B,5A,6D,7A),(1A,2C,3E,4B,5A,6D,7B),(1A,2C,3E,4B,5A,6D,7C),(1A,2C,3E,4B,5B,6A,7A),(1A,2C,3E,4B,5B,6A,7B),(1A,2C,3E,4 B,5B,6A,7C),(1A,2C,3E,4B,5B,6B,7A),(1A,2C,3E,4B,5B,6B,7B),(1A,2C,3E,4B,5B,6B,7C),(1A,2C,3E,4B,5B,6C,7A),(1A,2C,3E,4B,5B,6C,7B),(1A,2C,3E,4B,5B,6C,7C),(1A,2C,3E,4B,5B,6D,7A),(1A,2C,3E,4B,5B,6D,7B),(1A,2C,3E,4B,5B,6D,7C),(1A,2C,3E,4C,5A,6A,7A),(1A,2C,3E,4C,5A,6A,7B),(1A,2C,3E,4C,5A,6A,7C),(1A,2C,3E,4C,5A,6B,7A),(1A,2C,3E,4C,5A,6B,7B),(1A,2C,3E,4C,5A,6B,7C),(1A,2C,3E,4C,5A,6C,7A),(1A,2C,3E,4C,5A,6C,7B),(1A,2C,3E,4C,5A,6C,7C),(1A,2C,3E,4C,5A,6D,7A),(1A,2C,3E,4C,5A,6D,7B),(1A,2C,3E,4C,5A,6D,7C),(1A,2C,3E,4C,5A,6D,7A),(1A,2C,3E,4 C,5A,6D,7C),(1A,2C,3E,4C,5B,6A,7A),(1A,2C,3E,4C,5B,6A,7B),(1A,2C,3E,4C,5B,6A,7C),(1A,2C,3E,4C,5B,6B,7A),(1A,2C,3E,4C,5B,6B,7B),(1A,2C,3E,4C,5B,6B,7C),(1A,2C,3E,4 C,5B,6C,7A),(1A,2C,3E,4C,5B,6C,7B),(1A,2C,3E,4C,5B,6C,7C),(1A,2C,3E,4C,5B,6D,7A),(1A,2C,3E,4C,5B,6D,7B),(1A,2C,3E,4C,5B,6D,7C),(1A,2C,3E,4D,5A,6A,7A),(1A,2C,3E,4 D,5A,6A,7B),(1A,2C,3E,4D,5A,6A,7C),(1A,2C,3E,4D,5A,6B,7A),(1A,2C,3E,4D,5A,6B,7B),(1A,2C

[illegible]

1

†

2

2

3

3

4

4

5

5

(1A,2D,3C,4B,5B,6A,7A),(1A,2D,3C,4B,5B,6A,7B),(1A,2D,3C,4B,5B,6A,7C), (1A,2D,3C,4B,5B,6B,7A),(1A,2D,3C,4B,5B,6B,7B),(1A,2D,3C,4B,5B,6B,7C),(1A,2D,3C,4 B,5B,6C,7A),(1A,2D,3C,4B,5B,6C,7B),(1A,2D,3C,4B,5B,6C,7C),(1A,2D,3C,4B,5B,6D,7A), (1A,2D,3C,4B,5B,6D,7B),(1A,2D,3C,4B,5B,6D,7C),(1A,2D,3C,4C,5A,6A,7A),(1A,2D,3C,4 C,5A,6A,7B),(1A,2D,3C,4C,5A,6A,7C),(1A,2D,3C,4C,5A,6B,7A),(1A,2D,3C,4C,5A,6B,7B), (1A,2D,3C,4C,5A,6B,7C),(1A,2D,3C,4C,5A,6C,7A),(1A,2D,3C,4C,5A,6C,7B),(1A,2D,3C,4 C,5A,6C,7C),(1A,2D,3C,4C,5A,6D,7A),(1A,2D,3C,4C,5A,6D,7B),(1A,2D,3C,4C,5A,6D,7C), (1A,2D,3C,4C,5B,6A,7A),(1A,2D,3C,4C,5B,6A,7B),(1A,2D,3C,4C,5B,6A,7C),(1A,2D,3C,4C,5B,6B,7A),(1A,2D,3C,4C,5B,6B,7B),(1A,2D,3C,4C,5B,6B,7C),(1A,2D,3C,4C,5B,6C,7A),(1A,2D,3C,4C,5B,6C,7B),(1A,2D,3C,4C,5B,6C,7C),(1A,2D,3C,4C,5B,6D,7A),(1A,2D,3C,4 C,5B,6D,7B),(1A,2D,3C,4C,5B,6D,7C),(1A,2D,3C,4D,5A,6A,7A),(1A,2D,3C,4D,5A,6A,7B), (1A,2D,3C,4D,5A,6A,7C),(1A,2D,3C,4D,5A,6B,7A),(1A,2D,3C,4D,5A,6B,7B),(1A,2D,3C,4D,5A,6B,7C),(1A,2D,3C,4D,5A,6C,7A),(1A,2D,3C,4D,5A,6C,7B),(1A,2D,3C,4D,5A,6C,7C), (1A,2D,3C,4D,5A,6D,7A),(1A,2D,3C,4D,5A,6D,7B),(1A,2D,3C,4D,5A,6D,7C),(1A,2D,3C,4 D,5B,6A,7A),(1A,2D,3C,4D,5B,6A,7B),(1A,2D,3C,4D,5B,6A,7C),(1A,2D,3C,4D,5B,6B,7A), (1A,2D,3C,4D,5B,6B,7B),(1A,2D,3C,4D,5B,6B,7C),(1A,2D,3C,4D,5B,6C,7A),(1A,2D,3C,4 D,5B,6C,7B),(1A,2D,3C,4D,5B,6C,7C),(1A,2D,3C,4D,5B,6D,7A),(1A,2D,3C,4E,5A,6A,7A),(1A,2D,3C,4E,5A,6A,7B), (1A,2D,3C,4 E,5A,6A,7C),(1A,2D,3C,4E,5A,6B,7A),(1A,2D,3C,4E,5A,6B,7B),(1A,2D,3C,4E,5A,6B,7C), (1A,2D,3C,4E,5A,6C,7A),(1A,2D,3C,4E,5A,6C,7B),(1A,2D,3C,4E,5A,6C,7C),(1A,2D,3C,4 E,5A,6D,7A),(1A,2D,3C,4E,5A,6D,7B),(1A,2D,3C,4E,5A,6D,7C),(1A,2D,3C,4E,5B,6A,7A), (1A,2D,3C,4E,5B,6A,7B),(1A,2D,3C,4E,5B,6A,7C),(1A,2D,3C,4E,5B,6B,7A), (1A,2D,3C,4E,5B,6B,7B),(1A,2D,3C,4E,5B,6B,7C),(1A,2D,3C,4E,5B,6C,7A),(1A,2D,3C,4E,5B,6C,7B),(1A,2D,3C,4E,5B,6C,7C),(1A,2D,3C,4E,5B,6D,7A),(1A,2D,3C,4E,5B,6D,7B),(1A,2D,3C,4E,5B,6D,7C),(1A,2D,3D,4A,5A,6A,7A),(1A,2D,3D,4A,5A,6A,7B),(1A,2D,3D,4A,5A,6A,7C), (1A,2D,3D,4A,5A,6B,7A),(1A,2D,3D,4A,5A,6B,7B),(1A,2D,3D,4A,5A,6B,7C),(1A,2D,3D,4 A,5A,6C,7A),(1A,2D,3D,4A,5A,6C,7B),(1A,2D,3D,4A,5A,6C,7C),(1A,2D,3D,4A,5A,6D,7A), (1A,2D,3D,4A,5A,6D,7B),(1A,2D,3D,4A,5A,6D,7C),(1A,2D,3D,4A,5B,6A,7A),(1A,2D,3D,4 A,5B,6A,7B),(1A,2D,3D,4A,5B,6A,7C),(1A,2D,3D,4A,5B,6B,7A),(1A,2D,3D,4A,5B,6B,7B), (1A,2D,3D,4A,5B,6B,7C),(1A,2D,3D,4A,5B,6C,7A),(1A,2D,3D,4A,5B,6C,7B),(1A,2D,3D,4 A,5B,6C,7C),(1A,2D,3D,4A,5B,6D,7A),(1A,2D,3D,4A,5B,6D,7B),(1A,2D,3D,4A,5B,6D,7C), (1A,2D,3D,4B,5A,6A,7A),(1A,2D,3D,4B,5A,6A,7B),(1A,2D,3D,4B,5A,6A,7C),(1A,2D,3D,4B,5A,6B,7A), (1A,2D,3D,4B,5A,6B,7B),(1A,2D,3D,4B,5A,6B,7C),(1A,2D,3D,4B,5A,6C,7A),(1A,2D,3D,4B,5A,6C,7B),(1A,2D,3D,4B,5A,6C,7C),(1A,2D,3D,4B,5A,6D,7A),(1A,2D,3D,4B,5A,6D,7B),(1A,2D,3D,4 B,5A,6D,7C),(1A,2D,3D,4B,5B,6A,7A),(1A,2D,3D,4B,5B,6A,7B), (1A,2D,3D,4B,5B,6A,7C),(1A,2D,3D,4B,5B,6B,7A),(1A,2D,3D,4B,5B,6B,7B),(1A,2D,3D,4B,5B,6B,7C),(1A,2D,3D,4 B,5B,6C,7A),(1A,2D,3D,4B,5B,6C,7B),(1A,2D,3D,4B,5B,6C,7C),(1A,2D,3D,4B,5B,6D,7A),(1A,2D,3D,4B,5B,6D,7B),(1A,2D,3D,4B,5B,6D,7C),(1A,2D,3D,4 C,5A,6A,7A),(1A,2D,3D,4C,5A,6A,7B),(1A,2D,3D,4C,5A,6A,7C),(1A,2D,3D,4C,5A,6B,7A), (1A,2D,3D,4C,5A,6B,7B),(1A,2D,3D,4C,5A,6B,7C),(1A,2D,3D,4C,5A,6C,7A),(1A,2D,3D,4 C,5A,6C,7B),(1A,2D,3D,4C,5A,6C,7C),(1A,2D,3D,4C,5A,6D,7A),(1A,2D,3D,4C,5A,6D,7B), (1A,2D,3D,4C,5A,6D,7C),(1A,2D,3D,4C,5B,6A,7A),(1A,2D,3D,4C,5B,6A,7B),(1A,2D,3D,4 C,5B,6A,7C),(1A,2D,3D,4C,5B,6B,7A),(1A,2D,3D,4C,5B,6B,7B),(1A,2D,3D,4C,5B,6B,7C), (1A,2D,3D,4C,5B,6C,7A),(1A,2D,3D,4C,5B,6C,7B),(1A,2D,3D,4C,5B,6C,7C),(1A,2D,3D,4 C,5B,6D,7A),(1A,2D,3D,4C,5B,6D,7B),(1A,2D,3D,4C,5B,6D,7C),(1A,2D,3D,4D,5A,6A,7A), (1A,2D,3D,4D,5A,6A,7B),(1A,2D,3D,4D,5A,6A,7C),(1A,2D,3D,4D,5A,6B,7A),(1A,2D,3D,4D,5A,6B,7B),(1A,2D,3D,4D,5A,6B,7C),(1A,2D,3D,4D,5A,6C,7A),(1A,2D,3D,4D,5A,6C,7B),(1A,2D,3D,4D,5A,6C,7C),(1A,2D,3D,4D,5A,6D,7A),(1A,2D,3D,4D,5A,6D,7B),(1A,2D,3D,4D,5A,6D,7C),(1A,2D,3D,4 D,5A,6D,7C),(1A,2D,3D,4D,5B,6A,7A),(1A,2D,3D,4D,5B,6A,7B),(1A,2D,3D,4D,5B,6A,7C), (1A,2D,3D,4D,5B,6B,7A),(1A,2D,3D,4D,5B,6B,7B),(1A,2D,3D,4D,5B,6B,7C),(1A,2D,3D,4D,5B,6C,7A),(1A,2D,3D,4D,5B,6C,7B),(1A,2D,3D,4D,5B,6C,7C),(1A,2D,3D,4D,5B,6D,7A), (1A,2D,3D,4D,5B,6D,7B),(1A,2D,3D,4D,5B,6D,7C),(1A,2D,3D,4E,5A,6A,7A),(1A,2D,3D,4 E,5A,6A,7B),(1A,2D,3D,4E,5A,6A,7C),(1A,2D,3D,4E,5A,6B,7A),(1A,2D,3D,4E,5A,6B,7B), (1A,2D,3D,4E,5A,6B,7C),(1A,2D,3D,4E,5A,6C,7A),(1A,2D,3D,4E,5A,6C,7B),(1A,2D,3D,4 E,5A,6C,7C),(1A,2D,3D,4E,5A,6D,7A),(1A,2D,3D,4E,5A,6D,7B),(1A,2D,3D,4E,5A,6D,7C), (1A,2D,3D,4B,5B,6A,7A),(1A,2D,3D,4E,5B,6A,7B),(1A,2D,3D,4E,5B,6

2D,3E,4C,5A,6B,7C),(1A,2D,3E,4 C,5A,6C,7A),(1A,2D,3E,4C,5A,6C,7B),(1A,2D,3E,4C,5A,6C,7C),(1A,2D,3E,4C,
 5A,6D,7A),(1A,2D,3E,4C,5A,6D,7B),(1A,2D,3E,4C,5A,6D,7C),(1A,2D,3E,4C,5B,6A,7A),(1A,2D,3E,4 C,5B,6A,7B),
 (1A,2D,3E,4C,5B,6A,7C),(1A,2D,3E,4C,5B,6B,7A),(1A,2D,3E,4C,5B,6B,7B),(1A,2D,3E,4C,5B,6B,7C),(1A,2D,3E,
 4C,5B,6C,7A),(1A,2D,3E,4C,5B,6C,7B),(1A,2D,3E,4 C,5B,6C,7C),(1A,2D,3E,4C,5B,6D,7A),(1A,2D,3E,4C,5B,6D,
 5 7B),(1A,2D,3E,4C,5B,6D,7C),(1A,2D,3E,4D,5A,6A,7A),(1A,2D,3E,4D,5A,6A,7B),(1A,2D,3E,4D,5A,6A,7C),(1A,2D,
 3E,4 D,5A,6B,7A),(1A,2D,3E,4D,5A,6B,7B),(1A,2D,3E,4D,5A,6B,7C),(1A,2D,3E,4D,5A,6C,7A),(1A,2D,3E,4D,5A,
 6C,7B),(1A,2D,3E,4D,5A,6C,7C),(1A,2D,3E,4D,5A,6D,7A),(1A,2D,3E,4 D,5A,6D,7B),(1A,2D,3E,4D,5A,6D,7C),(1A,
 2D,3E,4D,5B,6A,7A),(1A,2D,3E,4D,5B,6A,7B),(1A,2D,3E,4D,5B,6A,7C),(1A,2D,3E,4D,5B,6B,7A),(1A,2D,3E,4D,
 5B,6B,7B),(1A,2D,3E,4 D,5B,6B,7C),(1A,2D,3E,4D,5B,6C,7A),(1A,2D,3E,4D,5B,6C,7B),(1A,2D,3E,4D,5B,6C,7C),
 10 (1A,2D,3E,4D,5B,6D,7A),(1A,2D,3E,4D,5B,6D,7B),(1A,2D,3E,4D,5B,6D,7C),(1A,2D,3E,4 E,5A,6A,7A),(1A,2D,3E,
 4E,5A,6A,7B),(1A,2D,3E,4E,5A,6A,7C),(1A,2D,3E,4E,5A,6B,7A),(1A,2D,3E,4E,5A,6B,7B),(1A,2D,3E,4E,5A,6B,
 7C),(1A,2D,3E,4E,5A,6C,7A),(1A,2D,3E,4 E,5A,6C,7B),(1A,2D,3E,4E,5A,6C,7C),(1A,2D,3E,4E,5A,6D,7A),(1A,2D,
 3E,4E,5A,6D,7B),(1A,2D,3E,4E,5A,6D,7C),(1A,2D,3E,4E,5B,6A,7A),(1A,2D,3E,4E,5B,6A,7B),(1A,2D,3E,4 E,5B,
 6A,7C),(1A,2D,3E,4E,5B,6B,7A),(1A,2D,3E,4E,5B,6B,7B),(1A,2D,3E,4E,5B,6B,7C),(1A,2D,3E,4E,5B,6C,7A),(1A,
 15 2D,3E,4E,5B,6C,7B),(1A,2D,3E,4E,5B,6C,7C),(1A,2D,3E,4 E,5B,6D,7A),(1A,2D,3E,4E,5B,6D,7B),(1A,2D,3E,4E,
 5B,6D,7C),(1A,2E,3A,4A,5A,6A,7A),(1A,2E,3A,4A,5A,6A,7B),(1A,2E,3A,4A,5A,6A,7C),(1A,2E,3A,4A,5A,6B,7A),
 (1A,2E,3A,4 A,5A,6B,7B),(1A,2E,3A,4A,5A,6B,7C),(1A,2E,3A,4A,5A,6C,7A),(1A,2E,3A,4A,5A,6C,7B),(1A,2E,3A,
 4A,5A,6D,7C),(1A,2E,3A,4A,5A,6D,7A),(1A,2E,3A,4A,5A,6D,7B),(1A,2E,3A,4 A,5A,6D,7C),(1A,2E,3A,4A,5B,6A,
 7A),(1A,2E,3A,4A,5B,6A,7B),(1A,2E,3A,4A,5B,6A,7C),(1A,2E,3A,4A,5B,6B,7A),(1A,2E,3A,4A,5B,6B,7B),(1A,2E,
 20 3A,4A,5B,6B,7C),(1A,2E,3A,4 A,5B,6C,7A),(1A,2E,3A,4A,5B,6C,7B),(1A,2E,3A,4A,5B,6C,7C),(1A,2E,3A,4A,5B,6D,
 7A),(1A,2E,3A,4A,5B,6D,7B),(1A,2E,3A,4A,5B,6D,7C),(1A,2E,3A,4B,5A,6A,7A),(1A,2E,3A,4 B,5A,6A,7B),(1A,2E,
 3A,4B,5A,6A,7C),(1A,2E,3A,4B,5A,6B,7A),(1A,2E,3A,4B,5A,6B,7B),(1A,2E,3A,4B,5A,6B,7C),(1A,2E,3A,4B,5A,6C,
 7A),(1A,2E,3A,4B,5A,6C,7B),(1A,2E,3A,4 B,5A,6C,7C),(1A,2E,3A,4B,5A,6D,7A),(1A,2E,3A,4B,5A,6D,7B),(1A,2E,
 3A,4B,5A,6D,7C),(1A,2E,3A,4B,5B,6A,7A),(1A,2E,3A,4B,5B,6A,7B),(1A,2E,3A,4B,5B,6A,7C),(1A,2E,3A,4 B,5B,6B,
 25 7A),(1A,2E,3A,4B,5B,6B,7B),(1A,2E,3A,4B,5B,6B,7C),(1A,2E,3A,4B,5B,6C,7A),(1A,2E,3A,4B,5B,6C,7B),(1A,2E,
 3A,4B,5B,6C,7C),(1A,2E,3A,4B,5B,6D,7A),(1A,2E,3A,4 B,5B,6D,7B),(1A,2E,3A,4B,5B,6D,7C),(1A,2E,3A,4C,5A,6A,
 7A),(1A,2E,3A,4C,5A,6A,7B),(1A,2E,3A,4C,5A,6A,7C),(1A,2E,3A,4C,5A,6B,7A),(1A,2E,3A,4C,5A,6B,7B),(1A,2E,
 3A,4 C,5A,6B,7C),(1A,2E,3A,4C,5A,6C,7A),(1A,2E,3A,4C,5A,6C,7B),(1A,2E,3A,4C,5A,6C,7C),(1A,2E,3A,4C,5A,
 6D,7A),(1A,2E,3A,4C,5A,6D,7B),(1A,2E,3A,4C,5A,6D,7C),(1A,2E,3A,4 C,5B,6A,7A),(1A,2E,3A,4C,5B,6A,7B),(1A,
 30 2E,3A,4C,5B,6A,7C),(1A,2E,3A,4C,5B,6B,7A),(1A,2E,3A,4C,5B,6B,7B),(1A,2E,3A,4C,5B,6B,7C),(1A,2E,3A,4C,5B,
 6C,7A),(1A,2E,3A,4 C,5B,6C,7B),(1A,2E,3A,4C,5B,6C,7C),(1A,2E,3A,4C,5B,6D,7A),(1A,2E,3A,4C,5B,6D,7B),(1A,
 2E,3A,4C,5B,6D,7C),(1A,2E,3A,4D,5A,6A,7A),(1A,2E,3A,4D,5A,6A,7B),(1A,2E,3A,4 D,5A,6A,7C),(1A,2E,3A,4D,
 5A,6B,7A),(1A,2E,3A,4D,5A,6B,7B),(1A,2E,3A,4D,5A,6B,7C),(1A,2E,3A,4D,5A,6C,7A),(1A,2E,3A,4D,5A,6C,7B),
 (1A,2E,3A,4D,5A,6C,7C),(1A,2E,3A,4 D,5A,6D,7A),(1A,2E,3A,4D,5A,6D,7B),(1A,2E,3A,4D,5A,6D,7C),(1A,2E,3A,
 35 4D,5B,6A,7A),(1A,2E,3A,4D,5B,6A,7B),(1A,2E,3A,4D,5B,6A,7C),(1A,2E,3A,4D,5B,6B,7A),(1A,2E,3A,4 D,5B,6B,
 7B),(1A,2E,3A,4D,5B,6B,7C),(1A,2E,3A,4D,5B,6C,7A),(1A,2E,3A,4D,5B,6C,7B),(1A,2E,3A,4D,5B,6C,7C),(1A,2E,
 3A,4D,5B,6D,7A),(1A,2E,3A,4D,5B,6D,7B),(1A,2E,3A,4 D,5B,6D,7C),(1A,2E,3A,4E,5A,6A,7A),(1A,2E,3A,4E,5A,6A,
 7B),(1A,2E,3A,4E,5A,6A,7C),(1A,2E,3A,4E,5A,6B,7A),(1A,2E,3A,4E,5A,6B,7B),(1A,2E,3A,4E,5A,6B,7C),(1A,2E,
 40 3A,4 E,5A,6C,7A),(1A,2E,3A,4E,5A,6C,7B),(1A,2E,3A,4E,5A,6C,7C),(1A,2E,3A,4E,5A,6D,7A),(1A,2E,3A,4E,5A,
 6D,7B),(1A,2E,3A,4E,5A,6D,7C),(1A,2E,3A,4E,5B,6A,7A),(1A,2E,3A,4 E,5B,6A,7B),(1A,2E,3A,4E,5B,6A,7C),(1A,
 2E,3A,4E,5B,6B,7A),(1A,2E,3A,4E,5B,6B,7B),(1A,2E,3A,4E,5B,6B,7C),(1A,2E,3A,4E,5B,6C,7A),(1A,2E,3A,4E,5B,
 6C,7B),(1A,2E,3A,4 E,5B,6C,7C),(1A,2E,3A,4E,5B,6D,7A),(1A,2E,3A,4E,5B,6D,7B),(1A,2E,3A,4E,5B,6D,7C),(1A,
 2E,3B,4A,5A,6A,7A),(1A,2E,3B,4A,5A,6A,7B),(1A,2E,3B,4A,5A,6A,7C),(1A,2E,3B,4 A,5A,6B,7A),(1A,2E,3B,4A,5A,
 6B,7B),(1A,2E,3B,4A,5A,6B,7C),(1A,2E,3B,4A,5A,6C,7A),(1A,2E,3B,4A,5A,6C,7B),(1A,2E,3B,4A,5A,6C,7C),(1A,
 45 2E,3B,4A,5A,6D,7A),(1A,2E,3B,4 A,5A,6D,7B),(1A,2E,3B,4A,5A,6D,7C),(1A,2E,3B,4A,5B,6A,7A),(1A,2E,3B,4A,5B,
 6A,7B),(1A,2E,3B,4A,5B,6A,7C),(1A,2E,3B,4A,5B,6B,7A),(1A,2E,3B,4A,5B,6B,7B),(1A,2E,3B,4 A,5B,6B,7C),(1A,
 2E,3B,4A,5B,6C,7A),(1A,2E,3B,4A,5B,6C,7B),(1A,2E,3B,4A,5B,6C,7C),(1A,2E,3B,4A,5B,6D,7A),(1A,2E,3B,4A,5B,
 6D,7B),(1A,2E,3B,4A,5B,6D,7C),(1A,2E,3B,4 B,5A,6A,7A),(1A,2E,3B,4B,5A,6A,7B),(1A,2E,3B,4B,5A,6A,7C),(1A,
 50 2E,3B,4B,5A,6B,7A),(1A,2E,3B,4B,5A,6B,7B),(1A,2E,3B,4B,5A,6B,7C),(1A,2E,3B,4B,5A,6C,7A),(1A,2E,3B,4 B,5A,
 6C,7B),(1A,2E,3B,4B,5A,6C,7C),(1A,2E,3B,4B,5A,6D,7A),(1A,2E,3B,4B,5A,6D,7B),(1A,2E,3B,4B,5A,6D,7C),(1A,
 2E,3B,4B,5B,6A,7A),(1A,2E,3B,4B,5B,6A,7B),(1A,2E,3B,4 B,5B,6A,7C),(1A,2E,3B,4B,5B,6B,7A),(1A,2E,3B,4B,5B,
 6B,7B),(1A,2E,3B,4B,5B,6B,7C),(1A,2E,3B,4B,5B,6C,7A),(1A,2E,3B,4B,5B,6C,7B),(1A,2E,3B,4B,5B,6C,7C),(1A,
 2E,3B,4 B,5B,6D,7A),(1A,2E,3B,4B,5B,6D,7B),(1A,2E,3B,4B,5B,6D,7C),(1A,2E,3B,4C,5A,6A,7A),(1A,2E,3B,4C,
 5A,6A,7B),(1A,2E,3B,4C,5A,6A,7C),(1A,2E,3B,4C,5A,6B,7A),(1A,2E,3B,4 C,5A,6B,7B),(1A,2E,3B,4C,5A,6B,7C),
 55 (1A,2E,3B,4C,5A,6C,7A),(1A,2E,3B,4C,5A,6C,7B),(1A,2E,3B,4C,5A,6C,7C),(1A,2E,3B,4C,5A,6D,7A),(1A,2E,3B,
 4C,5A,6D,7B),(1A,2E,3B,4 C,5A,6D,7C),(1A,2E,3B,4C,5B,6A,7A),(1A,2E,3B,4C,5B,6A,7B),(1A,2E,3B,4C,5B,6A,
 7C),(1A,2E,3B,4C,5B,6B,7A),(1A,2E,3B,4C,5B,6B,7B),(1A,2E,3B,4C,5B,6B,7C),(1A,2E,3B,4 C,5B,6C,7A),(1A,2E,
 3B,4C,5B,6C,7B),(1A,2E,3B,4C,5B,6C,7C),(1A,2E,3B,4C,5B,6D,7A),(1A,2E,3B,4C,5B,6D,7B),(1A,2E,3B,4C,5B,
 6D,7C)

6D,7C),(1A,2E,3B,4D,5A,6A,7A),(1A,2E,3B,4 D,5A,6A,7B),(1A,2E,3B,4D,5A,6A,7C),(1A,2E,3B,4D,5A,6B,7A),(1A,
2E,3B,4D,5A,6B,7B), (1A,2E,3B,4D,5A,6B,7C),(1A,2E,3B,4D,5A,6C,7A),(1A,2E,3B,4D,5A,6C,7B),(1A,2E,3B,4 D,
5A,6C,7C),(1A,2E,3B,4D,5A,6D,7A),(1A,2E,3B,4D,5A,6D,7B),(1A,2E,3B,4D,5A,6D,7C), (1A,2E,3B,4D,5B,6A,7A),
(1A,2E,3B,4D,5B,6A,7B),(1A,2E,3B,4D,5B,6A,7C),(1A,2E,3B,4 D,5B,6B,7A),(1A,2E,3B,4D,5B,6B,7B),(1A,2E,3B,
4D,5B,6B,7C),(1A,2E,3B,4D,5B,6C,7A), (1A,2E,3B,4D,5B,6C,7B),(1A,2E,3B,4D,5B,6C,7C),(1A,2E,3B,4D,5B,6D,
7A),(1A,2E,3B,4 D,5B,6D,7B),(1A,2E,3B,4D,5B,6D,7C),(1A,2E,3B,4E,5A,6A,7A),(1A,2E,3B,4E,5A,6A,7B), (1A,2E,
3B,4E,5A,6A,7C),(1A,2E,3B,4E,5A,6B,7A),(1A,2E,3B,4E,5A,6B,7B),(1A,2E,3B,4 E,5A,6B,7C),(1A,2E,3B,4E,5A,6C,
7A),(1A,2E,3B,4E,5A,6C,7B),(1A,2E,3B,4E,5A,6C,7C), (1A,2E,3B,4E,5A,6D,7A),(1A,2E,3B,4E,5A,6D,7B),(1A,2E,
3B,4E,5A,6D,7C),(1A,2E,3B,4 E,5B,6A,7A),(1A,2E,3B,4E,5B,6A,7B),(1A,2E,3B,4E,5B,6A,7C),(1A,2E,3B,4E,5B,6B,
7A), (1A,2E,3B,4E,5B,6B,7B),(1A,2E,3B,4E,5B,6B,7C),(1A,2E,3B,4E,5B,6C,7A),(1A,2E,3B,4 E,5B,6C,7B),(1A,2E,
3B,4E,5B,6C,7C),(1A,2E,3B,4E,5B,6D,7A),(1A,2E,3B,4E,5B,6D,7B), (1A,2E,3B,4E,5B,6D,7C),(1A,2E,3C,4A,5A,6A,
7A),(1A,2E,3C,4A,5A,6A,7B),(1A,2E,3C,4 A,5A,6A,7C),(1A,2E,3C,4A,5A,6B,7A),(1A,2E,3C,4A,5A,6B,7B),(1A,2E,
3C,4A,5A,6B,7C), (1A,2E,3C,4A,5A,6C,7A),(1A,2E,3C,4A,5A,6C,7B),(1A,2E,3C,4A,5A,6C,7C),(1A,2E,3C,4 A,5A,
6D,7A),(1A,2E,3C,4A,5A,6D,7B),(1A,2E,3C,4A,5A,6D,7C),(1A,2E,3C,4A,5B,6A,7A), (1A,2E,3C,4A,5B,6A,7B),(1A,
2E,3C,4A,5B,6A,7C),(1A,2E,3C,4A,5B,6B,7A),(1A,2E,3C,4 A,5B,6B,7B),(1A,2E,3C,4A,5B,6B,7C),(1A,2E,3C,4A,5B,
6C,7A),(1A,2E,3C,4A,5B,6C,7B), (1A,2E,3C,4A,5B,6C,7C),(1A,2E,3C,4A,5B,6D,7A),(1A,2E,3C,4A,5B,6D,7B),(1A,
2E,3C,4 A,5B,6D,7C),(1A,2E,3C,4B,5A,6A,7A),(1A,2E,3C,4B,5A,6A,7B),(1A,2E,3C,4B,5A,6A,7C), (1A,2E,3C,4B,
5A,6B,7A),(1A,2E,3C,4B,5A,6B,7B),(1A,2E,3C,4B,5A,6B,7C),(1A,2E,3C,4 B,5A,6C,7A),(1A,2E,3C,4B,4C,5A,6C,7B),
(1A,2E,3C,4B,5A,6C,7C),(1A,2E,3C,4B,5A,6D,7A), (1A,2E,3C,4B,5A,6D,7B),(1A,2E,3C,4B,5A,6D,7C),(1A,2E,3C,
4B,5B,6A,7A),(1A,2E,3C,4 B,5B,6A,7B),(1A,2E,3C,4B,5B,6A,7C),(1A,2E,3C,4B,5B,6B,7A),(1A,2E,3C,4B,5B,6B,
7B), (1A,2E,3C,4B,5B,6B,7C),(1A,2E,3C,4B,5B,6C,7A),(1A,2E,3C,4B,5B,6C,7B),(1A,2E,3C,4 B,5B,6C,7C),(1A,2E,
3C,4B,5B,6D,7A),(1A,2E,3C,4B,5B,6D,7B),(1A,2E,3C,4B,5B,6D,7C), (1A,2E,3C,4C,5A,6A,7A),(1A,2E,3C,4C,5A,
6A,7B),(1A,2E,3C,4C,5A,6A,7C),(1A,2E,3C,4 C,5A,6B,7A),(1A,2E,3C,4C,5A,6B,7B),(1A,2E,3C,4C,5A,6B,7C),(1A,
2E,3C,4C,5A,6C,7A), (1A,2E,3C,4C,5A,6C,7B),(1A,2E,3C,4C,5A,6C,7C),(1A,2E,3C,4C,5A,6D,7A),(1A,2E,3C,4 C,
5A,6D,7B),(1A,2E,3C,4C,5A,6D,7C),(1A,2E,3C,4C,5B,6A,7A),(1A,2E,3C,4C,5B,6A,7B), (1A,2E,3C,4C,5B,6A,7C),
(1A,2E,3C,4C,5B,6B,7A),(1A,2E,3C,4C,5B,6B,7B),(1A,2E,3C,4 C,5B,6B,7C),(1A,2E,3C,4C,5B,6C,7A),(1A,2E,3C,
4C,5B,6C,7B),(1A,2E,3C,4C,5B,6C,7C), (1A,2E,3C,4C,5B,6D,7A),(1A,2E,3C,4C,5B,6D,7B),(1A,2E,3C,4C,5B,6D,
7C),(1A,2E,3C,4 D,5A,6A,7A),(1A,2E,3C,4D,5A,6A,7B),(1A,2E,3C,4D,5A,6A,7C),(1A,2E,3C,4D,5A,6B,7A),(1A,2E,
3C,4D,5A,6B,7B),(1A,2E,3C,4D,5A,6B,7C),(1A,2E,3C,4D,5A,6C,7A),(1A,2E,3C,4 D,5A,6C,7B),(1A,2E,3C,4D,5A,
6C,7C),(1A,2E,3C,4D,5A,6D,7A),(1A,2E,3C,4D,5A,6D,7B), (1A,2E,3C,4D,5A,6D,7C),(1A,2E,3C,4D,5B,6A,7A),(1A,
2E,3C,4D,5B,6A,7B),(1A,2E,3C,4 D,5B,6A,7C),(1A,2E,3C,4D,5B,6B,7A),(1A,2E,3C,4D,5B,6B,7B),(1A,2E,3C,4D,
5B,6B,7C), (1A,2E,3C,4D,5B,6C,7A),(1A,2E,3C,4D,5B,6C,7B),(1A,2E,3C,4D,5B,6C,7C),(1A,2E,3C,4 D,5B,6D,7A),
(1A,2E,3C,4D,5B,6D,7B),(1A,2E,3C,4D,5B,6D,7C),(1A,2E,3C,4E,5A,6A,7A), (1A,2E,3C,4E,5A,6A,7B),(1A,2E,3C,
4E,5A,6A,7C),(1A,2E,3C,4E,5A,6B,7A),(1A,2E,3C,4 E,5A,6B,7B),(1A,2E,3C,4E,5A,6B,7C),(1A,2E,3C,4E,5A,6C,
7A),(1A,2E,3C,4E,5A,6C,7B), (1A,2E,3C,4E,5A,6C,7C),(1A,2E,3C,4E,5A,6D,7A),(1A,2E,3C,4E,5A,6D,7B),(1A,2E,
3C,4 E,5A,6D,7C),(1A,2E,3C,4E,5B,6A,7A),(1A,2E,3C,4E,5B,6A,7B),(1A,2E,3C,4E,5B,6A,7C), (1A,2E,3C,4E,5B,
6B,7A),(1A,2E,3C,4E,5B,6B,7B),(1A,2E,3C,4E,5B,6B,7C),(1A,2E,3C,4 E,5B,6C,7A),(1A,2E,3C,4E,5B,6C,7B),(1A,
2E,3C,4E,5B,6C,7C),(1A,2E,3C,4E,5B,6D,7A), (1A,2E,3C,4E,5B,6D,7B),(1A,2E,3C,4E,5B,6D,7C),(1A,2E,3D,4A,
5A,6A,7A),(1A,2E,3D,4 A,5A,6A,7B),(1A,2E,3D,4A,5A,6A,7C),(1A,2E,3D,4A,5A,6B,7A),(1A,2E,3D,4A,5A,6B,7B),
40 (1A,2E,3D,4A,5A,6B,7C),(1A,2E,3D,4A,5A,6C,7A),(1A,2E,3D,4A,5A,6C,7B),(1A,2E,3D,4 A,5A,6C,7C),(1A,2E,3D,
4A,5A,6D,7A),(1A,2E,3D,4A,5A,6D,7B),(1A,2E,3D,4A,5A,6D,7C), (1A,2E,3D,4A,5B,6A,7A),(1A,2E,3D,4A,5B,6A,
7B),(1A,2E,3D,4A,5B,6A,7C),(1A,2E,3D,4 A,5B,6B,7A),(1A,2E,3D,4A,5B,6B,7B),(1A,2E,3D,4A,5B,6B,7C),(1A,2E,
3D,4A,5B,6C,7A), (1A,2E,3D,4A,5B,6C,7B),(1A,2E,3D,4A,5B,6

3D,4D,5B,6B,7C),(1A,2E,3D,4D,5B,6C,7A),(1A,2E,3D,4D,5B,6C,7B),(1A,2E,3D,4 D,5B,6C,7C),(1A,2E,3D,4D,5B,6D,7A),(1A,2E,3D,4D,5B,6D,7B),(1A,2E,3D,4D,5B,6D,7C), (1A,2E,3D,4E,5A,6A,7A),(1A,2E,3D,4E,5A,6A,7B),(1A,2E,3D,4E,5A,6A,7C),(1A,2E,3D,4 E,5A,6B,7A),(1A,2E,3D,4E,5A,6B,7B),(1A,2E,3D,4E,5A,6B,7C),(1A,2E,3D,4E,5A,6C,7A), (1A,2E,3D,4E,5A,6C,7B),(1A,2E,3D,4E,5A,6C,7C),(1A,2E,3D,4E,5A,6D,7A),(1A,2E,3D,4 E,5A,6D,7B),(1A,2E,3D,4E,5A,6D,7C),(1A,2E,3D,4E,5B,6A,7A),(1A,2E,3D,4E,5B,6A,7B), (1A,2E,3D,4E,5B,6A,7C),(1A,2E,3D,4E,5B,6B,7A),(1A,2E,3D,4E,5B,6B,7B),(1A,2E,3D,4 E,5B,6B,7C),(1A,2E,3D,4E,5B,6C,7A),(1A,2E,3D,4E,5B,6C,7B),(1A,2E,3D,4E,5B,6C,7C), (1A,2E,3D,4E,5B,6D,7A),(1A,2E,3D,4E,5B,6D,7B),(1A,2E,3D,4E,5B,6D,7C),(1A,2E,3E,4 A,5A,6A,7A),(1A,2E,3E,4A,5A,6A,7B),(1A,2E,3E,4A,5A,6A,7C),(1A,2E,3E,4A,5A,6B,7A), (1A,2E,3E,4A,5A,6B,7B), (1A,2E,3E,4A,5A,6B,7C),(1A,2E,3E,4A,5A,6C,7A),(1A,2E,3E,4 A,5A,6C,7B),(1A,2E,3E,4A,5A,6C,7C),(1A,2E,3E,4A,5A,6D,7A),(1A,2E,3E,4A,5A,6D,7B), (1A,2E,3E,4A,5A,6D,7C),(1A,2E,3E,4A,5B,6A,7A),(1A,2E,3E,4A,5B,6A,7B), (1A,2E,3E,4 A,5B,6A,7C),(1A,2E,3E,4A,5B,6B,7A),(1A,2E,3E,4A,5B,6B,7B),(1A,2E,3E,4A,5B,6B,7C), (1A,2E,3E,4A,5B,6C,7A),(1A,2E,3E,4A,5B,6C,7B),(1A,2E,3E,4A,5B,6C,7C),(1A,2E,3E,4 A,5B,6D,7A),(1A,2E,3E,4A,5B,6D,7B),(1A,2E,3E,4A,5B,6D,7C),(1A,2E,3E,4A,5B,6D,7C), (1A,2E,3E,4B,5A,6A,7A), (1A,2E,3E,4B,5A,6A,7B),(1A,2E,3E,4B,5A,6A,7C),(1A,2E,3E,4B,5A,6B,7A),(1A,2E,3E,4 B,5A,6B,7B),(1A,2E,3E,4B,5A,6B,7C),(1A,2E,3E,4B,5A,6C,7A),(1A,2E,3E,4B,5A,6C,7B), (1A,2E,3E,4B,5A,6C,7C),(1A,2E,3E,4B,5A,6D,7A),(1A,2E,3E,4B,5A,6D,7B),(1A,2E,3E,4 B,5A,6D,7C),(1A,2E,3E,4B,5B,6A,7A),(1A,2E,3E,4B,5B,6A,7B),(1A,2E,3E,4B,5B,6A,7C), (1A,2E,3E,4B,5B,6B,7A),(1A,2E,3E,4B,5B,6B,7B),(1A,2E,3E,4B,5B,6B,7C), (1A,2E,3E,4 B,5B,6C,7A),(1A,2E,3E,4B,5B,6C,7B),(1A,2E,3E,4B,5B,6C,7C),(1A,2E,3E,4B,5B,6D,7A), (1A,2E,3E,4B,5B,6D,7B),(1A,2E,3E,4B,5B,6D,7C),(1A,2E,3E,4C,5A,6A,7A),(1A,2E,3E,4 C,5A,6A,7B),(1A,2E,3E,4C,5A,6A,7C),(1A,2E,3E,4C,5A,6B,7A),(1A,2E,3E,4C,5A,6B,7B), (1A,2E,3E,4C,5A,6B,7C),(1A,2E,3E,4C,5A,6C,7A),(1A,2E,3E,4C,5A,6C,7B),(1A,2E,3E,4 C,5A,6C,7C),(1A,2E,3E,4C,5A,6D,7A),(1A,2E,3E,4C,5A,6D,7B),(1A,2E,3E,4C,5A,6D,7C), (1A,2E,3E,4C,5B,6A,7A),(1A,2E,3E,4C,5B,6A,7B),(1A,2E,3E,4C,5B,6A,7C),(1A,2E,3E,4 C,5B,6B,7A),(1A,2E,3E,4C,5B,6B,7B),(1A,2E,3E,4C,5B,6B,7C),(1A,2E,3E,4C,5B,6C,7A), (1A,2E,3E,4C,5B,6C,7B),(1A,2E,3E,4C,5B,6C,7C),(1A,2E,3E,4C,5B,6D,7A),(1A,2E,3E,4 C,5B,6D,7B),(1A,2E,3E,4C,5B,6D,7C),(1A,2E,3E,4D,5A,6A,7A),(1A,2E,3E,4D,5A,6A,7B), (1A,2E,3E,4D,5A,6A,7C),(1A,2E,3E,4D,5A,6B,7A),(1A,2E,3E,4D,5A,6B,7B),(1A,2E,3E,4 D,5A,6B,7C),(1A,2E,3E,4D,5A,6C,7A),(1A,2E,3E,4D,5A,6C,7B),(1A,2E,3E,4D,5A,6C,7C), (1A,2E,3E,4D,5A,6D,7A),(1A,2E,3E,4D,5A,6D,7B),(1A,2E,3E,4D,5A,6D,7C),(1A,2E,3E,4 D,5B,6A,7A),(1A,2E,3E,4D,5B,6A,7B),(1A,2E,3E,4D,5B,6A,7C),(1A,2E,3E,4D,5B,6B,7A), (1A,2E,3E,4D,5B,6B,7B),(1A,2E,3E,4D,5B,6B,7C),(1A,2E,3E,4D,5B,6C,7A),(1A,2E,3E,4D,5B,6C,7B),(1A,2E,3E,4D,5B,6C,7C),(1A,2E,3E,4D,5B,6D,7A),(1A,2E,3E,4D,5B,6D,7B),(1A,2E,3E,4 E,5A,6A,7A),(1A,2E,3E,4E,5A,6A,7B),(1A,2E,3E,4E,5A,6A,7C), (1A,2E,3E,4E,5A,6B,7A),(1A,2E,3E,4E,5A,6B,7B),(1A,2E,3E,4E,5A,6B,7C), (1A,2E,3E,4E,5A,6C,7A),(1A,2E,3E,4E,5A,6C,7B),(1A,2E,3E,4E,5A,6C,7C),(1A,2E,3E,4 E,5A,6D,7A),(1A,2E,3E,4E,5A,6D,7B),(1A,2E,3E,4E,5A,6D,7C),(1A,2E,3E,4E,5B,6A,7A), (1A,2E,3E,4E,5B,6A,7B),(1A,2E,3E,4E,5B,6A,7C),(1A,2E,3E,4E,5B,6B,7A),(1A,2E,3E,4 E,5B,6B,7B),(1A,2E,3E,4E,5B,6B,7C),(1A,2E,3E,4E,5B,6C,7A),(1A,2E,3E,4E,5B,6C,7B), (1A,2E,3E,4E,5B,6C,7C),(1A,2E,3E,4E,5B,6D,7A),(1A,2E,3E,4E,5B,6D,7B),(1A,2E,3E,4 E,5B,6D,7C),(1B,2A,3A,4A,5A,6A,7A),(1B,2A,3A,4A,5A,6A,7B),(1B,2A,3A,4A,5A,6A,7C), (1B,2A,3A,4A,5A,6B,7A),(1B,2A,3A,4A,5A,6B,7B),(1B,2A,3A,4A,5A,6B,7C),(1B,2A,3A,4A,5A,6C,7A), (1B,2A,3A,4A,5A,6C,7B),(1B,2A,3A,4A,5A,6C,7C),(1B,2A,3A,4A,5A,6D,7A), (1B,2A,3A,4A,5A,6D,7B),(1B,2A,3A,4A,5A,6D,7C),(1B,2A,3A,4A,5B,6A,7A),(1B,2A,3A,4 A,5B,6A,7B),(1B,2A,3A,4A,5B,6A,7C),(1B,2A,3A,4A,5B,6B,7A),(1B,2A,3A,4A,5B,6B,7B), (1B,2A,3A,4A,5B,6B,7C),(1B,2A,3A,4A,5B,6C,7A),(1B,2A,3A,4A,5B,6C,7B),(1B,2A,3A,4 A,5B,6C,7C),(1B,2A,3A,4A,5B,6D,7A),(1B,2A,3A,4A,5B,6D,7B),(1B,2A,3A,4A,5B,6D,7C), (1B,2A,3A,4B,5A,6A,7A),(1B,2A,3A,4B,5A,6A,7B),(1B,2A,3A,4B,5A,6A,7C),(1B,2A,3A,4B,5A,6B,7A),(1B,2A,3A,4B,5A,6B,7B), (1B,2A,3A,4B,5A,6B,7C),(1B,2A,3A,4B,5A,6C,7A),(1B,2A,3A,4B,5A,6C,7B),(1B,2A,3A,4B,5A,6C,7C), (1B,2A,3A,4B,5A,6D,7A),(1B,2A,3A,4 B,5A,6D,7B),(1B,2A,3A,4B,5A,6D,7C),(1B,2A,3A,4B,5B,6A,7A),(1B,2A,3A,4B,5B,6A,7B), (1B,2A,3A,4B,5B,6A,7C),(1B,2A,3A,4B,5B,6B,7A),(1B,2A,3A,4B,5B,6B,7B),(1B,2A,3A,4 B,5B,6B,7C),(1B,2A,3A,4B,5B,6C,7A),(1B,2A,3A,4B,5B,6C,7B),(1B,2A,3A,4B,5B,6C,7C), (1B,2A,3A,4B,5B,6D,7A),(1B,2A,3A,4B,5B,6D,7B),(1B,2A,3A,4B,5B,6D,7C),(1B,2A,3A,4 C,5A,6A,7A),(1B,2A,3A,4C,5A,6A,7B),(1B,2A,3A,4C,5A,6A,7C),(1B,2A,3A,4C,5A,6B,7A), (1B,2A,3A,4C,5A,6B,7B),(1B,2A,3A,4C,5A,6B,7C),(1B,2A,3A,4C,5A,6C,7A),(1B,2A,3A,4C,5A,6C,7B),(1B,2A,3A,4C,5A,6C,7C),(1B,2A,3A,4C,5A,6D,7A),(1B,2A,3A,4C,5A,6D,7B), (1B,2A,3A,4C,5A,6D,7C),(1B,2A,3A,4C,5B,6A,7A),(1B,2A,3A,4C,5B,6A,7B),(1B,2A,3A,4 C,5B,6A,7C),(1B,2A,3A,4C,5B,6B,7A),(1B,2A,3A,4C,5B,6B,7B),(1B,2A,3A,4C,5B,6B,7C), (1B,2A,3A,4C,5B,6C,7A),(1B,2A,3A,4C,5B,6C,7B),(1B,2A,3A,4C,5B,6C,7C),(1B,2A,3A,4 C,5B,6D,7A),(1B,2A,3A,4C,5B,6D,7B),(1B,2A,3A,4C,5B,6D,7C),(1B,2A,3A,4D,5A,6A,7A), (1B,2A,3A,4D,5A,6A,7B),(1B,2A,3A,4D,5A,6A,7C),(1B,2A,3A,4D,5A,6B,7A),(1B,2A,3A,4 D,5A,6B,7B),(1B,2A,3A,4D,5A,6B,7C),(1B,2A,3A,4D,5A,6C,7A),(1B,2A,3A,4D,5A,6C,7B), (1B,2A,3A,4D,5A,6C,7C),(1B,2A,3A,4D,5A,6D,7A),(1B,2A,3A,4D,5A,6D,7B),(1B,2A,3A,4 D,5A,6D,7C),(1B,2A,3A,4D,5B,6A,7A),(1B,2A,3A,4D,5B,6A,7B),(1B,2A,3A,4D,5B,6A,7C), (1B,2A,3A,4D,5B,6B,7A),(1B,2A,3A,4D,5B,6B,7B),(1B,2A,3A,4D,5B,6B,7C),(1B,2A,3A,4D,5B,6C,7A),(1B,2A,3A,4D,5B,6C,7B), (1B,2A,3A,4D,5B,6C,7C),(1B,2A,3A,4D,5B,6D,7A), (1B,2A,3A,4D,5B,6D,7B),(1B,2A,3A,4D,5B,6D,7C),(1B,2A,3A,4E,5A,6A,7A),(1B,2A,3A,4E,5A,6A,7B), (1B,2A,3A,4E,5A,6A,7C),(1B,2A,3A,4E,5A,6B,7A),(1B,2A,3A,4E,5A,6B,7B), (1B,2A,3A,4E,5A,6B,7C),(1B,2A,3A,4E,5A,6C,7A),(1B,2A,3A,4E,5A,6C,7B), (1B,2A,3A,4 E,5A,6C,7C),(1B,2A,3A,4E,5A,6D,7A),(1B,2A,3A,4E,5A,6D,7B),(1B,2A,3A,4E,5A,6D,7C),

[illegible]

3D,4A,5A,6C,7A), (1B,2A,3D,4A,5A,6C,7B),(1B,2A,3D,4A,5A,6C,7C),(1B,2A,3D,4A,5A,6D,7A),(1B,2A,3D,4 A,5A,6D,7B),(1B,2A,3D,4A,5A,6D,7C),(1B,2A,3D,4A,5B,6A,7A),(1B,2A,3D,4A,5B,6A,7B), (1B,2A,3D,4A,5B,6A,7C),(1B,2A,3D,4A,5B,6B,7A),(1B,2A,3D,4A,5B,6B,7B),(1B,2A,3D,4 A,5B,6B,7C),(1B,2A,3D,4A,5B,6C,7A),(1B,2A,3D,4A,5B,6C,7B),(1B,2A,3D,4A,5B,6C,7C), (1B,2A,3D,4 B,5A,6A,7A),(1B,2A,3D,4B,5A,6A,7B),(1B,2A,3D,4B,5A,6A,7C),(1B,2A,3D,4B,5A,6B,7A), (1B,2A,3D,4B,5A,6B,7B),(1B,2A,3D,4B,5A,6B,7C),(1B,2A,3D,4B,5A,6C,7A),(1B,2A,3D,4 B,5A,6C,7B),(1B,2A,3D,4B,5A,6C,7C), (1B,2A,3D,4B,5A,6D,7A),(1B,2A,3D,4B,5A,6D,7B), (1B,2A,3D,4B,5A,6D,7C),(1B,2A,3D,4B,5B,6A,7A),(1B,2A,3D,4B,5B,6A,7B),(1B,2A,3D,4B,5B,6A,7C),(1B,2A,3D,4B,5B,6B,7A),(1B,2A,3D,4B,5B,6B,7B),(1B,2A,3D,4 B,5B,6B,7C),(1B,2A,3D,4B,5B,6C,7A),(1B,2A,3D,4B,5B,6C,7B),(1B,2A,3D,4B,5B,6C,7C),(1B,2A,3D,4B,5B,6D,7A),(1B,2A,3D,4B,5B,6D,7B),(1B,2A,3D,4B,5B,6D,7C),(1B,2A,3D,4C,5A,6A,7A),(1B,2A,3D,4C,5A,6A,7B), (1B,2A,3D,4C,5A,6A,7C),(1B,2A,3D,4C,5A,6B,7A),(1B,2A,3D,4 C,5A,6B,7B),(1B,2A,3D,4C,5A,6B,7C),(1B,2A,3D,4C,5A,6C,7A),(1B,2A,3D,4C,5A,6C,7B), (1B,2A,3D,4C,5A,6C,7C),(1B,2A,3D,4C,5A,6D,7A),(1B,2A,3D,4C,5A,6D,7B),(1B,2A,3D,4 C,5A,6D,7C),(1B,2A,3D,4C,5B,6A,7A),(1B,2A,3D,4C,5B,6A,7B),(1B,2A,3D,4C,5B,6A,7C), (1B,2A,3D,4C,5B,6B,7A),(1B,2A,3D,4C,5B,6B,7B),(1B,2A,3D,4C,5B,6B,7C),(1B,2A,3D,4 C,5B,6C,7A),(1B,2A,3D,4C,5B,6C,7B),(1B,2A,3D,4C,5B,6C,7C),(1B,2A,3D,4C,5B,6D,7A), (1B,2A,3D,4C,5B,6D,7B),(1B,2A,3D,4C,5B,6D,7C),(1B,2A,3D,4D,5A,6A,7A),(1B,2A,3D,4 D,5A,6A,7B),(1B,2A,3D,4D,5A,6A,7C),(1B,2A,3D,4D,5A,6B,7A),(1B,2A,3D,4D,5A,6B,7B), (1B,2A,3D,4D,5A,6B,7C),(1B,2A,3D,4D,5A,6C,7A),(1B,2A,3D,4D,5A,6C,7B),(1B,2A,3D,4 D,5A,6C,7C),(1B,2A,3D,4D,5A,6D,7A),(1B,2A,3D,4D,5A,6D,7B),(1B,2A,3D,4D,5A,6D,7C),(1B,2A,3D,4D,5B,6A,7A),(1B,2A,3D,4D,5B,6A,7B),(1B,2A,3D,4D,5B,6A,7C),(1B,2A,3D,4D,5B,6B,7A),(1B,2A,3D,4D,5B,6B,7B),(1B,2A,3D,4 D,5B,6B,7C),(1B,2A,3D,4D,5B,6C,7A),(1B,2A,3D,4D,5B,6C,7B),(1B,2A,3D,4D,5B,6C,7C),(1B,2A,3D,4D,5B,6D,7A),(1B,2A,3D,4 D,5B,6D,7B),(1B,2A,3D,4D,5B,6D,7C),(1B,2A,3D,4E,5A,6A,7A),(1B,2A,3D,4E,5A,6A,7B), (1B,2A,3D,4E,5A,6A,7C),(1B,2A,3D,4E,5A,6B,7A),(1B,2A,3D,4E,5A,6B,7B),(1B,2A,3D,4 E,5A,6B,7C),(1B,2A,3D,4E,5A,6C,7A),(1B,2A,3D,4E,5A,6C,7B),(1B,2A,3D,4E,5A,6C,7C), (1B,2A,3D,4E,5A,6D,7A),(1B,2A,3D,4E,5A,6D,7B),(1B,2A,3D,4E,5A,6D,7C),(1B,2A,3D,4 E,5B,6A,7A),(1B,2A,3D,4E,5B,6A,7B),(1B,2A,3D,4E,5B,6A,7C),(1B,2A,3D,4E,5B,6B,7A), (1B,2A,3D,4E,5B,6B,7B),(1B,2A,3D,4E,5B,6B,7C),(1B,2A,3D,4E,5B,6C,7A),(1B,2A,3D,4 E,5B,6C,7B),(1B,2A,3D,4E,5B,6C,7C),(1B,2A,3D,4E,5B,6D,7A),(1B,2A,3D,4E,5B,6D,7B), (1B,2A,3D,4E,5B,6D,7C),(1B,2A,3E,4A,5A,6A,7A),(1B,2A,3E,4A,5A,6A,7B), (1B,2A,3E,4A,5A,6A,7C),(1B,2A,3E,4A,5A,6B,7A),(1B,2A,3E,4A,5A,6B,7B),(1B,2A,3E,4A,5A,6B,7C),(1B,2A,3E,4A,5A,6C,7A),(1B,2A,3E,4A,5A,6C,7B),(1B,2A,3E,4A,5A,6C,7C),(1B,2A,3E,4A,5A,6D,7A),(1B,2A,3E,4A,5A,6D,7B),(1B,2A,3E,4A,5A,6D,7C),(1B,2A,3E,4A,5B,6A,7A), (1B,2A,3E,4A,5B,6A,7B),(1B,2A,3E,4A,5B,6A,7C),(1B,2A,3E,4A,5B,6B,7A),(1B,2A,3E,4 A,5B,6B,7B),(1B,2A,3E,4 A,5B,6B,7C),(1B,2A,3E,4A,5B,6C,7A),(1B,2A,3E,4A,5B,6C,7B),(1B,2A,3E,4A,5B,6C,7C),(1B,2A,3E,4A,5B,6D,7A),(1B,2A,3E,4A,5B,6D,7B),(1B,2A,3E,4A,5B,6D,7C),(1B,2A,3E,4 A,5B,6D,7C),(1B,2A,3E,4B,5A,6A,7A),(1B,2A,3E,4B,5A,6A,7B),(1B,2A,3E,4B,5A,6A,7C), (1B,2A,3E,4B,5A,6B,7A),(1B,2A,3E,4B,5A,6B,7B),(1B,2A,3E,4B,5A,6B,7C),(1B,2A,3E,4B,5A,6C,7A),(1B,2A,3E,4B,5A,6C,7B),(1B,2A,3E,4B,5A,6C,7C),(1B,2A,3E,4B,5A,6D,7A),(1B,2A,3E,4B,5A,6D,7B),(1B,2A,3E,4B,5A,6D,7C),(1B,2A,3E,4B,5B,6A,7A),(1B,2A,3E,4 B,5B,6A,7B),(1B,2A,3E,4B,5B,6A,7C),(1B,2A,3E,4B,5B,6B,7A),(1B,2A,3E,4B,5B,6B,7B), (1B,2A,3E,4B,5B,6B,7C),(1B,2A,3E,4B,5B,6C,7A),(1B,2A,3E,4B,5B,6C,7B),(1B,2A,3E,4B,5B,6D,7A),(1B,2A,3E,4B,5B,6D,7B),(1B,2A,3E,4B,5B,6D,7C),(1B,2A,3E,4C,5A,6A,7A),(1B,2A,3E,4C,5A,6A,7B),(1B,2A,3E,4C,5A,6A,7C),(1B,2A,3E,4C,5A,6B,7A),(1B,2A,3E,4C,5A,6B,7B),(1B,2A,3E,4C,5A,6B,7C),(1B,2A,3E,4C,5A,6C,7A),(1B,2A,3E,4C,5A,6C,7B),(1B,2A,3E,4C,5A,6C,7C),(1B,2A,3E,4C,5A,6D,7A),(1B,2A,3E,4 C,5A,6D,7B),(1B,2A,3E,4C,5A,6D,7C),(1B,2A,3E,4C,5B,6A,7A),(1B,2A,3E,4C,5B,6A,7B), (1B,2A,3E,4C,5B,6A,7C),(1B,2A,3E,4C,5B,6B,7A),(1B,2A,3E,4C,5B,6B,7B),(1B,2A,3E,4 C,5B,6B,7C),(1B,2A,3E,4C,5B,6C,7A),(1B,2A,3E,4C,5B,6C,7B),(1B,2A,3E,4C,5B,6C,7C), (1B,2A,3E,4C,5B,6D,7A),(1B,2A,3E,4C,5B,6D,7B),(1B,2A,3E,4C,5B,6D,7C),(1B,2A,3E,4 D,5A,6A,7A),(1B,2A,3E,4D,5A,6A,7B),(1B,2A,3E,4D,5A,6A,7C),(1B,2A,3E,4D,5A,6B,7A),(1B,2A,3E,4D,5A,6B,7B),(1B,2A,3E,4D,5A,6B,7C),(1B,2A,3E,4D,5A,6C,7A),(1B,2A,3E,4 D,5A,6C,7B),(1B,2A,3E,4D,5A,6C,7C),(1B,2A,3E,4D,5A,6D,7A),(1B,2A,3E,4D,5A,6D,7B), (1B,2

10

15

20

25

30

35

40

45

50

55

7A),(1B,2B,3A,4B,5A,6A,7B), (1B,2B,3A,4B,5A,6A,7C),(1B,2B,3A,4B,5A,6B,7A),(1B,2B,3A,4B,5A,6B,7B),(1B,2B,3A,4 B,5A,6B,7C),(1B,2B,3A,4B,5A,6C,7A),(1B,2B,3A,4B,5A,6C,7B),(1B,2B,3A,4B,5A,6C,7C), (1B,2B,3A,4B,5A,6D,7A),(1B,2B,3A,4B,5A,6D,7B),(1B,2B,3A,4B,5A,6D,7C),(1B,2B,3A,4 B,5B,6A,7A),(1B,2B,3A,4B,5B,6A,7B),(1B,2B,3A,4B,5B,6A,7C),(1B,2B,3A,4B,5B,6B,7A),(1B,2B,3A,4B,5B,6B,7B),(1B,2B,3A,4B,5B,6B,7C),(1B,2B,3A,4B,5B,6C,7A),(1B,2B,3A,4 B,5B,6C,7B),(1B,2B,3A,4B,5B,6C,7C),(1B,2B,3A,4B,5B,6D,7A),(1B,2B,3A,4B,5B,6D,7B), (1B,2B,3A,4B,5B,6D,7C),(1B,2B,3A,4C,5A,6A,7A),(1B,2B,3A,4C,5A,6A,7B),(1B,2B,3A,4 C,5A,6A,7C),(1B,2B,3A,4C,5A,6B,7A),(1B,2B,3A,4C,5A,6B,7B),(1B,2B,3A,4C,5A,6B,7C), (1B,2B,3A,4C,5A,6C,7A),(1B,2B,3A,4C,5A,6C,7B),(1B,2B,3A,4C,5A,6C,7C),(1B,2B,3A,4 C,5A,6D,7A),(1B,2B,3A,4C,5A,6D,7B),(1B,2B,3A,4C,5A,6D,7C),(1B,2B,3A,4C,5B,6A,7A), (1B,2B,3A,4C,5B,6A,7B),(1B,2B,3A,4C,5B,6A,7C),(1B,2B,3A,4C,5B,6B,7A),(1B,2B,3A,4 C,5B,6B,7B),(1B,2B,3A,4C,5B,6B,7C),(1B,2B,3A,4C,5B,6C,7A),(1B,2B,3A,4C,5B,6C,7B), (1B,2B,3A,4C,5B,6C,7C), (1B,2B,3A,4C,5B,6D,7A),(1B,2B,3A,4C,5B,6D,7B),(1B,2B,3A,4 C,5B,6D,7C),(1B,2B,3A,4D,5A,6A,7A),(1B,2B,3A,4D,5A,6A,7B),(1B,2B,3A,4D,5A,6A,7C), (1B,2B,3A,4D,5A,6B,7A),(1B,2B,3A,4D,5A,6B,7B),(1B,2B,3A,4D,5A,6B,7C),(1B,2B,3A,4D,5A,6C,7A),(1B,2B,3A,4D,5A,6C,7B),(1B,2B,3A,4D,5A,6C,7C),(1B,2B,3A,4D,5A,6D,7A), (1B,2B,3A,4D,5A,6D,7B),(1B,2B,3A,4D,5A,6D,7C),(1B,2B,3A,4D,5B,6A,7A),(1B,2B,3A,4 D,5B,6A,7B),(1B,2B,3A,4D,5B,6A,7C),(1B,2B,3A,4D,5B,6B,7A),(1B,2B,3A,4D,5B,6B,7B), (1B,2B,3A,4D,5B,6B,7C),(1B,2B,3A,4D,5B,6C,7A),(1B,2B,3A,4D,5B,6C,7B),(1B,2B,3A,4D,5B,6C,7C), (1B,2B,3A,4D,5B,6D,7A),(1B,2B,3A,4D,5B,6D,7B),(1B,2B,3A,4D,5B,6D,7C), (1B,2B,3A,4E,5A,6A,7A),(1B,2B,3A,4E,5A,6A,7B),(1B,2B,3A,4E,5A,6A,7C),(1B,2B,3A,4 E,5A,6B,7A),(1B,2B,3A,4E,5A,6B,7B),(1B,2B,3A,4E,5A,6B,7C),(1B,2B,3A,4E,5A,6C,7A), (1B,2B,3A,4E,5A,6C,7B),(1B,2B,3A,4E,5A,6C,7C),(1B,2B,3A,4E,5A,6D,7A),(1B,2B,3A,4 E,5A,6D,7B),(1B,2B,3A,4E,5A,6D,7C),(1B,2B,3A,4E,5B,6A,7A),(1B,2B,3A,4E,5B,6A,7B), (1B,2B,3A,4E,5B,6A,7C),(1B,2B,3A,4E,5B,6B,7A),(1B,2B,3A,4E,5B,6B,7B),(1B,2B,3A,4 E,5B,6B,7C),(1B,2B,3A,4E,5B,6C,7A),(1B,2B,3A,4E,5B,6C,7B),(1B,2B,3A,4E,5B,6C,7C), (1B,2B,3A,4E,5B,6D,7A),(1B,2B,3A,4E,5B,6D,7B),(1B,2B,3A,4E,5B,6D,7C),(1B,2B,3B,4 A,5A,6A,7A),(1B,2B,3B,4A,5A,6A,7B),(1B,2B,3B,4A,5A,6A,7C),(1B,2B,3B,4A,5A,6B,7A), (1B,2B,3B,4A,5A,6B,7B),(1B,2B,3B,4A,5A,6B,7C),(1B,2B,3B,4A,5A,6C,7A),(1B,2B,3B,4 A,5A,6C,7B),(1B,2B,3B,4A,5A,6C,7C),(1B,2B,3B,4A,5A,6D,7A),(1B,2B,3B,4A,5A,6D,7B), (1B,2B,3B,4A,5A,6D,7C),(1B,2B,3B,4A,5B,6A,7A),(1B,2B,3B,4A,5B,6A,7B),(1B,2B,3B,4 A,5B,6A,7C),(1B,2B,3B,4A,5B,6B,7A),(1B,2B,3B,4A,5B,6B,7B),(1B,2B,3B,4A,5B,6B,7C), (1B,2B,3B,4A,5B,6C,7A),(1B,2B,3B,4A,5B,6C,7B),(1B,2B,3B,4A,5B,6C,7C),(1B,2B,3B,4 A,5B,6D,7A),(1B,2B,3B,4A,5B,6D,7B),(1B,2B,3B,4A,5B,6D,7C),(1B,2B,3B,4B,5A,6A,7A), (1B,2B,3B,4B,5A,6A,7B),(1B,2B,3B,4B,5A,6A,7C),(1B,2B,3B,4B,5A,6B,7A),(1B,2B,3B,4B,5A,6B,7B), (1B,2B,3B,4B,5A,6B,7C),(1B,2B,3B,4B,5A,6C,7A),(1B,2B,3B,4B,5A,6C,7B),(1B,2B,3B,4B,5A,6C,7C),(1B,2B,3B,4B,5A,6D,7A),(1B,2B,3B,4B,5A,6D,7B), (1B,2B,3B,4B,5A,6D,7C),(1B,2B,3B,4B,5B,6A,7A),(1B,2B,3B,4B,5B,6A,7B),(1B,2B,3B,4B,5B,6A,7C), (1B,2B,3B,4B,5B,6B,7A),(1B,2B,3B,4B,5B,6B,7B),(1B,2B,3B,4B,5B,6B,7C),(1B,2B,3B,4 B,5B,6C,7A),(1B,2B,3B,4B,5B,6C,7B),(1B,2B,3B,4B,5B,6C,7C),(1B,2B,3B,4B,5B,6D,7A), (1B,2B,3B,4B,5B,6D,7B),(1B,2B,3B,4B,5B,6D,7C),(1B,2B,3B,4C,5A,6A,7A),(1B,2B,3B,4 C,5A,6A,7B),(1B,2B,3B,4C,5A,6A,7C),(1B,2B,3B,4C,5A,6B,7A),(1B,2B,3B,4C,5A,6B,7B), (1B,2B,3B,4C,5A,6B,7C),(1B,2B,3B,4C,5A,6C,7A),(1B,2B,3B,4C,5A,6C,7B),(1B,2B,3B,4 C,5A,6C,7C),(1B,2B,3B,4C,5A,6D,7A),(1B,2B,3B,4C,5A,6D,7B),(1B,2B,3B,4C,5A,6D,7C), (1B,2B,3B,4C,5B,6A,7A),(1B,2B,3B,4C,5B,6A,7B),(1B,2B,3B,4C,5B,6A,7C),(1B,2B,3B,4C,5B,6B,7A), (1B,2B,3B,4C,5B,6B,7B),(1B,2B,3B,4C,5B,6B,7C),(1B,2B,3B,4C,5B,6C,7A),(1B,2B,3B,4C,5B,6C,7B),(1B,2B,3B,4C,5B,6C,7C),(1B,2B,3B,4 C,5B,6D,7A),(1B,2B,3B,4C,5B,6D,7B),(1B,2B,3B,4D,5A,6A,7A),(1B,2B,3B,4D,5A,6A,7B), (1B,2B,3B,4D,5A,6A,7C),(1B,2B,3B,4D,5A,6B,7A),(1B,2B,3B,4D,5A,6B,7B),(1B,2B,3B,4 D,5A,6B,7C),(1B,2B,3B,4D,5A,6C,7A),(1B,2B,3B,4D,5A,6C,7B),(1B,2B,3B,4D,5A,6C,7C), (1B,2B,3B,4D,5A,6D,7A),(1B,2B,3B,4D,5A,6D,7B),(1B,2B,3B,4D,5A,6D,7C),(1B,2B,3B,4 D,5B,6A,7A),(1B,2B,3B,4D,5B,6A,7B),(1B,2B,3B,4D,5B,6A,7C),(1B,2B,3B,4D,5B,6B,7A), (1B,2B,3B,4D,5B,6B,7B),(1B,2B,3B,4D,5B,6B,7C),(1B,2B,3B,4D,5B,6C,7A),(1B,2B,3B,4 D,5B,6C,7B),(1B,2B,3B,4D,5B,6C,7C),(1B,2B,3B,4D,5B,6D,7A),(1B,2B,3B,4D,5B,6D,7B), (1B,2B,3B,4D,5B,6D,7C),(1B,2B,3B,4E,5A,6A,7A),(1B,2B,3B,4E,5A,6A,7B),(1B,2B,3B,4 E,5A,6A,7C),(1B,2B,3B,4E,5A,6B,7A),(1B,2B,3B,4E,5A,6B,7B),(1B,2B,3B,4E,5A,6B,7C), (1B,2B,3B,4E,5A,6C,7A),(1B,2B,3B,4E,5A,6C,7B),(1B,2B,3B,4E,5A,6C,7C),(1B,2B,3B,4 E,5A,6D,7A),(1B,2B,3B,4E,5A,6D,7B),(1B,2B,3B,4E,5A,6D,7C),(1B,2B,3B,4E,5B,6A,7A), (1B,2B,3B,4E,5B,6A,7B),(1B,2B,3B,4E,5B,6A,7C),(1B,2B,3B,4E,5B,6B,7A),(1B,2B,3B,4E,5B,6B,7B), (1B,2B,3B,4E,5B,6B,7C),(1B,2B,3B,4E,5B,6C,7A),(1B,2B,3B,4E,5B,6C,7B),(1B,2B,3B,4E,5B,6C,7C),(1B,2B,3B,4E,5B,6D,7A),(1B,2B,3B,4E,5B,6D,7B),(1B,2B,3B,4 E,5B,6D,7C),(1B,2B,3C,4A,5A,6A,7A),(1B,2B,3C,4A,5A,6A,7B),(1B,2B,3C,4A,5A,6A,7C), (1B,2B,3C,4A,5A,6B,7A),(1B,2B,3C,4A,5A,6B,7B),(1B,2B,3C,4A,5A,6B,7C),(1B,2B,3C,4 A,5A,6C,7A),(1B,2B,3C,4A,5A,6C,7B),(1B,2B,3C,4A,5A,6C,7C),(1B,2B,3C,4A,5B,6A,7A), (1B,2B,3C,4 A,5B,6A,7B),(1B,2B,3C,4A,5B,6A,7C),(1B,2B,3C,4A,5B,6B,7A),(1B,2B,3C,4A,5B,6B,7B), (1B,2B,3C,4A,5B,6B,7C),(1B,2B,3C,4A,5B,6C,7A),(1B,2B,3C,4A,5B,6C,7B),(1B,2B,3C,4 A,5B,6C,7C),(1B,2B,3C,4A,5B,6D,7A),(1B,2B,3C,4A,5B,6D,7B),(1B,2B,3C,4A,5B,6D,7C), (1B,2B,3C,4B,5A,6A,7A),(1B,2B,3C,4B,5A,6A,7B),(1B,2B,3C,4B,5A,6A,7C),(1B,2B,3C,4B,5A,6B,7A), (1B,2B,3C,4B,5A,6B,7B),(1B,2B,3C,4B,5A,6B,7C),(1B,2B,3C,4B,5A,6C,7A),(1B,2B,3C,4B,5A,6C,7B),(1B,2B,3C,4B,5A,6C,7C),(1B,2B,3C,4B,5A,6D,7A),(1B,2B,3C,4 B,5A,6D,7B),(1B,2B,3C,4B,5A,6D,7C),(1B,2B,3C,4B,5B,6A,7A),(1B,2B,3C,4B,5B,6A,7B), (1B,2B,3C,4B,5B,6A,7C),(1B,2B,3C,4B,5B,6B,7A),(1B,2B,3C,4B,5B,6B,7B),(1B,2B,3C,4 B,5B,6B,7C),(1B,2B,3C,4B,5B,6C,7A),(1B,2B,3C,4B,5B,6C,7B),(1B,2B,3C,4B,5B,6C,7C),

(1B,2B,3C,4B,5B,6C,7C), (1B,2B,3C,4B,5B,6D,7A),(1B,2B,3C,4B,5B,6D,7B),(1B,2B,3C,4B,5B,6D,7C),(1B,2B,3C,4 C,5A,6A,7A),(1B,2B,3C,4C,5A,6A,7B),(1B,2B,3C,4C,5A,6A,7C),(1B,2B,3C,4C,5A,6B,7A), (1B,2B,3C,4C,5A,6B,7B),
(1B,2B,3C,4C,5A,6B,7C),(1B,2B,3C,4C,5A,6C,7A),(1B,2B,3C,4 C,5A,6C,7B),(1B,2B,3C,4C,5A,6C,7C),(1B,2B,3C,
4C,5A,6D,7A),(1B,2B,3C,4C,5A,6D,7B), (1B,2B,3C,4C,5A,6D,7C),(1B,2B,3C,4C,5B,6A,7A),(1B,2B,3C,4C,5B,6A,
5 7B),(1B,2B,3C,4 C,5B,6A,7C),(1B,2B,3C,4C,5B,6B,7A),(1B,2B,3C,4C,5B,6B,7B),(1B,2B,3C,4C,5B,6B,7C), (1B,2B,
3C,4C,5B,6C,7A),(1B,2B,3C,4C,5B,6C,7B),(1B,2B,3C,4C,5B,6C,7C),(1B,2B,3C,4 C,5B,6D,7A),(1B,2B,3C,4C,5B,
6D,7B),(1B,2B,3C,4C,5B,6D,7C),(1B,2B,3C,4D,5A,6A,7A), (1B,2B,3C,4D,5A,6A,7B),(1B,2B,3C,4D,5A,6A,7C),(1B,
2B,3C,4D,5A,6B,7A),(1B,2B,3C,4 D,5A,6B,7C),(1B,2B,3C,4D,5A,6B,7C),(1B,2B,3C,4D,5A,6C,7A),(1B,2B,3C,4D,
5A,6C,7B), (1B,2B,3C,4D,5A,6C,7C),(1B,2B,3C,4D,5A,6D,7A),(1B,2B,3C,4D,5A,6D,7B),(1B,2B,3C,4 D,5A,6D,7C),
10 (1B,2B,3C,4D,5B,6A,7A),(1B,2B,3C,4D,5B,6A,7B),(1B,2B,3C,4D,5B,6A,7C), (1B,2B,3C,4D,5B,6B,7A),(1B,2B,3C,
4D,5B,6B,7B),(1B,2B,3C,4D,5B,6B,7C),(1B,2B,3C,4 D,5B,6C,7A),(1B,2B,3C,4D,5B,6C,7B),(1B,2B,3C,4D,5B,6C,
7C),(1B,2B,3C,4D,5B,6D,7A), (1B,2B,3C,4D,5B,6D,7B),(1B,2B,3C,4D,5B,6D,7C),(1B,2B,3C,4E,5A,6A,7A),(1B,2B,
3C,4 E,5A,6A,7B),(1B,2B,3C,4E,5A,6A,7C),(1B,2B,3C,4E,5A,6B,7A),(1B,2B,3C,4E,5A,6B,7B), (1B,2B,3C,4E,5A,
6B,7C),(1B,2B,3C,4E,5A,6C,7A),(1B,2B,3C,4E,5A,6C,7B),(1B,2B,3C,4 E,5A,6C,7C),(1B,2B,3C,4E,5A,6D,7A),(1B,
15 2B,3C,4E,5A,6D,7B),(1B,2B,3C,4E,5A,6D,7C), (1B,2B,3C,4E,5B,6A,7A),(1B,2B,3C,4E,5B,6A,7B),(1B,2B,3C,4E,
5B,6A,7C),(1B,2B,3C,4 E,5B,6B,7A),(1B,2B,3C,4E,5B,6B,7B),(1B,2B,3C,4E,5B,6B,7C),(1B,2B,3C,4E,5B,6C,7A),
(1B,2B,3C,4E,5B,6C,7B),(1B,2B,3C,4E,5B,6C,7C),(1B,2B,3C,4E,5B,6D,7A),(1B,2B,3C,4 E,5B,6D,7B),(1B,2B,3C,
4E,5B,6D,7C),(1B,2B,3D,4A,5A,6A,7A),(1B,2B,3D,4A,5A,6A,7B), (1B,2B,3D,4A,5A,6A,7C),(1B,2B,3D,4A,5A,6B,
20 7A),(1B,2B,3D,4A,5A,6B,7B),(1B,2B,3D,4 A,5A,6B,7C),(1B,2B,3D,4A,5A,6C,7A),(1B,2B,3D,4A,5A,6C,7B),(1B,2B,3D,
3D,4A,5A,6C,7C), (1B,2B,3D,4A,5A,6D,7A),(1B,2B,3D,4A,5A,6D,7B),(1B,2B,3D,4A,5A,6D,7C),(1B,2B,3D,4 A,5B,
6A,7A),(1B,2B,3D,4A,5B,6A,7B),(1B,2B,3D,4A,5B,6A,7C),(1B,2B,3D,4A,5B,6B,7A), (1B,2B,3D,4A,5B,6B,7B),(1B,
2B,3D,4A,5B,6B,7C),(1B,2B,3D,4A,5B,6C,7A),(1B,2B,3D,4 A,5B,6C,7B),(1B,2B,3D,4A,5B,6C,7C),(1B,2B,3D,4A,
5B,6D,7A),(1B,2B,3D,4A,5B,6D,7B), (1B,2B,3D,4A,5B,6D,7C),(1B,2B,3D,4B,5A,6A,7A),(1B,2B,3D,4B,5A,6A,7B),
(1B,2B,3D,4 B,5A,6A,7C),(1B,2B,3D,4B,5A,6B,7A),(1B,2B,3D,4B,5A,6B,7B),(1B,2B,3D,4B,5A,6B,7C),(1B,2B,3D,
25 4B,5A,6C,7A),(1B,2B,3D,4B,5A,6C,7B),(1B,2B,3D,4B,5A,6C,7C),(1B,2B,3D,4 B,5A,6D,7A),(1B,2B,3D,4B,5A,6D,
7B),(1B,2B,3D,4B,5A,6D,7C),(1B,2B,3D,4B,5B,6A,7A), (1B,2B,3D,4B,5B,6A,7B),(1B,2B,3D,4B,5B,6A,7C),(1B,2B,
3D,4B,5B,6B,7A),(1B,2B,3D,4 B,5B,6B,7B),(1B,2B,3D,4B,5B,6B,7C),(1B,2B,3D,4B,5B,6C,7A),(1B,2B,3D,4B,5B,
6C,7B), (1B,2B,3D,4B,5B,6C,7C),(1B,2B,3D,4B,5B,6D,7A),(1B,2B,3D,4B,5B,6D,7B),(1B,2B,3D,4 B,5B,6D,7C),(1B,
2B,3D,4C,5A,6A,7A),(1B,2B,3D,4C,5A,6A,7B),(1B,2B,3D,4C,5A,6A,7C), (1B,2B,3D,4C,5A,6B,7A),(1B,2B,3D,4C,
30 5A,6B,7B),(1B,2B,3D,4C,5A,6B,7C),(1B,2B,3D,4 C,5A,6C,7A),(1B,2B,3D,4C,5A,6C,7B),(1B,2B,3D,4C,5A,6C,7C),
(1B,2B,3D,4C,5A,6D,7A), (1B,2B,3D,4C,5A,6D,7B),(1B,2B,3D,4C,5A,6D,7C),(1B,2B,3D,4C,5B,6A,7A),(1B,2B,3D,4
C,5B,6A,7B),(1B,2B,3D,4C,5B,6A,7C),(1B,2B,3D,4C,5B,6B,7A),(1B,2B,3D,4C,5B,6B,7B), (1B,2B,3D,4C,5B,6B,7C),
(1B,2B,3D,4C,5B,6C,7A),(1B,2B,3D,4C,5B,6C,7B),(1B,2B,3D,4 C,5B,6C,7C),(1B,2B,3D,4C,5B,6D,7A),(1B,2B,3D,
35 4C,5B,6D,7B),(1B,2B,3D,4C,5B,6D,7C), (1B,2B,3D,4D,5A,6A,7A),(1B,2B,3D,4D,5A,6A,7B),(1B,2B,3D,4D,5A,6A,
7C),(1B,2B,3D,4 D,5A,6B,7A),(1B,2B,3D,4D,5A,6B,7B),(1B,2B,3D,4D,5A,6B,7C),(1B,2B,3D,4D,5A,6C,7A), (1B,2B,
3D,4D,5A,6C,7B),(1B,2B,3D,4D,5A,6C,7C),(1B,2B,3D,4D,5A,6D,7A),(1B,2B,3D,4 D,5A,6D,7B),(1B,2B,3D,4D,5A,
6D,7G),(1B,2B,3D,4D,5B,6A,7A),(1B,2B,3D,4D,5B,6A,7B), (1B,2B,3D,4D,5B,6A,7C),(1B,2B,3D,4D,5B,6B,7A),(1B,
2B,3D,4D,5B,6B,7B),(1B,2B,3D,4 D,5B,6B,7C),(1B,2B,3D,4D,5B,6C,7A),(1B,2B,3D,4D,5B,6C,7B),(1B,2B,3D,4D,
40 5B,6C,7C), (1B,2B,3D,4D,5B,6D,7A),(1B,2B,3D,4D,5B,6D,7B),(1B,2B,3D,4D,5B,6D,7C),(1B,2B,3D,4 E,5A,6A,7A),
(1B,2B,3D,4E,5A,6A,7B),(1B,2B,3D,4E,5A,6A,7C),(1B,2B,3D,4E,5A,6B,7A), (1B,2B,3D,4E,5A,6B,7B),(1B,2B,3D,
4E,5A,6B,7C),(1B,2B,3D,4E,5A,6C,7A),(1B,2B,3D,4 E,5A,6C,7B),(1B,2B,3D,4E,5A,6C,7C),(1B,2B,3D,4E,5A,6D,
7A),(1B,2B,3D,4E,5A,6D,7B); (1B,2B,3D,4E,5A,6D,7C),(1B,2B,3D,4E,5B,6A,7A),(1B,2B,3D,4E,5B,6A,7B),(1B,2

(1B,2B,3E,4C,5B,6A,7C),(1B,2B,3E,4C,5B,6B,7A), (1B,2B,3E,4C,5B,6B,7B),(1B,2B,3E,4C,5B,6B,7C),(1B,2B,3E,4C,5B,6C,7A),(1B,2B,3E,4 C,5B,6C,7B),(1B,2B,3E,4C,5B,6C,7C),(1B,2B,3E,4C,5B,6D,7A),(1B,2B,3E,4C,5B,6D,7B), (1B,2B,3E,4C,5B,6D,7C),(1B,2B,3E,4D,5A,6A,7A),(1B,2B,3E,4D,5A,6A,7B),(1B,2B,3E,4 D,5A,6A,7C),(1B,2B,3E,4D,5A,6B,7A),(1B,2B,3E,4D,5A,6B,7B),(1B,2B,3E,4D,5A,6B,7C), (1B,2B,3E,4D,5A,6C,7A),(1B,2B,3E,4D,5A,6C,7B),(1B,2B,3E,4D,5A,6C,7C),(1B,2B,3E,4 D,5A,6D,7A),(1B,2B,3E,4D,5A,6D,7B),(1B,2B,3E,4D,5A,6D,7C),(1B,2B,3E,4D,5B,6A,7A), (1B,2B,3E,4D,5B,6A,7B),(1B,2B,3E,4D,5B,6A,7C),(1B,2B,3E,4D,5B,6B,7A),(1B,2B,3E,4D,5B,6B,7B),(1B,2B,3E,4D,5B,6B,7C),(1B,2B,3E,4D,5B,6C,7A),(1B,2B,3E,4D,5B,6C,7B), (1B,2B,3E,4D,5B,6C,7C),(1B,2B,3E,4D,5B,6D,7A),(1B,2B,3E,4D,5B,6D,7B),(1B,2B,3E,4 D,5B,6D,7C),(1B,2B,3E,4E,5A,6A,7A),(1B,2B,3E,4E,5A,6A,7B),(1B,2B,3E,4E,5A,6A,7C), (1B,2B,3E,4E,5A,6B,7A),(1B,2B,3E,4E,5A,6B,7B),(1B,2B,3E,4E,5A,6B,7C),(1B,2B,3E,4 E,5A,6C,7A),(1B,2B,3E,4E,5A,6C,7B),(1B,2B,3E,4E,5A,6C,7C),(1B,2B,3E,4E,5A,6D,7A), (1B,2B,3E,4E,5A,6D,7B),(1B,2B,3E,4E,5A,6D,7C),(1B,2B,3E,4E,5B,6A,7A),(1B,2B,3E,4 E,5B,6A,7B),(1B,2B,3E,4E,5B,6A,7C),(1B,2B,3E,4E,5B,6B,7A),(1B,2B,3E,4E,5B,6B,7B), (1B,2B,3E,4E,5B,6B,7C),(1B,2B,3E,4E,5B,6C,7A),(1B,2B,3E,4E,5B,6C,7B),(1B,2B,3E,4 E,5B,6C,7C),(1B,2B,3E,4E,5B,6D,7A),(1B,2B,3E,4E,5B,6D,7B),(1B,2B,3E,4E,5B,6D,7C), (1B,2C,3A,4A,5A,6A,7A),(1B,2C,3A,4A,5A,6A,7B),(1B,2C,3A,4A,5A,6A,7C),(1B,2C,3A,4 A,5A,6B,7A),(1B,2C,3A,4A,5A,6B,7B),(1B,2C,3A,4A,5A,6B,7C),(1B,2C,3A,4A,5A,6C,7A), (1B,2C,3A,4A,5A,6C,7B),(1B,2C,3A,4A,5A,6C,7C),(1B,2C,3A,4A,5A,6D,7A),(1B,2C,3A,4 A,5A,6D,7B),(1B,2C,3A,4A,5A,6D,7C),(1B,2C,3A,4A,5B,6A,7A),(1B,2C,3A,4A,5B,6A,7B), (1B,2C,3A,4A,5B,6A,7C),(1B,2C,3A,4A,5B,6B,7A),(1B,2C,3A,4A,5B,6B,7B),(1B,2C,3A,4 A,5B,6B,7C),(1B,2C,3A,4A,5B,6C,7A),(1B,2C,3A,4A,5B,6C,7B),(1B,2C,3A,4A,5B,6C,7C), (1B,2C,3A,4A,5B,6D,7A),(1B,2C,3A,4A,5B,6D,7B),(1B,2C,3A,4 A,5B,6D,7C),(1B,2C,3A,4 B,5A,6A,7A),(1B,2C,3A,4B,5A,6A,7B),(1B,2C,3A,4B,5A,6A,7C), (1B,2C,3A,4B,5A,6B,7A),(1B,2C,3A,4B,5A,6B,7B),(1B,2C,3A,4B,5A,6B,7C),(1B,2C,3A,4B,5A,6C,7A), (1B,2C,3A,4B,5A,6C,7B),(1B,2C,3A,4B,5A,6C,7C),(1B,2C,3A,4B,5A,6D,7A),(1B,2C,3A,4B,5A,6D,7B), (1B,2C,3A,4B,5A,6D,7C),(1B,2C,3A,4B,5B,6A,7A),(1B,2C,3A,4B,5B,6A,7B),(1B,2C,3A,4 B,5B,6A,7C),(1B,2C,3A,4B,5B,6B,7A),(1B,2C,3A,4B,5B,6B,7B),(1B,2C,3A,4B,5B,6B,7C), (1B,2C,3A,4B,5B,6C,7A),(1B,2C,3A,4B,5B,6C,7B),(1B,2C,3A,4B,5B,6C,7C),(1B,2C,3A,4 B,5B,6D,7A),(1B,2C,3A,4B,5B,6D,7B),(1B,2C,3A,4B,5B,6D,7C),(1B,2C,3A,4C,5A,6A,7A), (1B,2C,3A,4C,5A,6A,7B),(1B,2C,3A,4C,5A,6A,7C),(1B,2C,3A,4C,5A,6B,7A),(1B,2C,3A,4 C,5A,6B,7B),(1B,2C,3A,4C,5A,6B,7C),(1B,2C,3A,4C,5A,6C,7A),(1B,2C,3A,4C,5A,6C,7B), (1B,2C,3A,4C,5A,6C,7C),(1B,2C,3A,4C,5A,6D,7A),(1B,2C,3A,4C,5A,6D,7B),(1B,2C,3A,4 C,5A,6D,7C),(1B,2C,3A,4C,5B,6A,7A),(1B,2C,3A,4C,5B,6A,7B),(1B,2C,3A,4C,5B,6A,7C), (1B,2C,3A,4C,5B,6B,7A),(1B,2C,3A,4C,5B,6B,7B),(1B,2C,3A,4C,5B,6B,7C),(1B,2C,3A,4 C,5B,6C,7A),(1B,2C,3A,4C,5B,6C,7B),(1B,2C,3A,4C,5B,6C,7C),(1B,2C,3A,4C,5B,6D,7A), (1B,2C,3A,4C,5B,6D,7B),(1B,2C,3A,4D,5A,6A,7A),(1B,2C,3A,4 D,5A,6A,7B),(1B,2C,3A,4D,5A,6A,7C),(1B,2C,3A,4D,5A,6B,7A),(1B,2C,3A,4D,5A,6B,7B), (1B,2C,3A,4D,5A,6B,7C),(1B,2C,3A,4D,5A,6C,7A),(1B,2C,3A,4D,5A,6C,7B),(1B,2C,3A,4D,5A,6C,7C), (1B,2C,3A,4D,5A,6D,7A),(1B,2C,3A,4D,5A,6D,7B),(1B,2C,3A,4D,5A,6D,7C), (1B,2C,3A,4D,5B,6A,7A),(1B,2C,3A,4D,5B,6A,7B),(1B,2C,3A,4D,5B,6A,7C),(1B,2C,3A,4 D,5B,6B,7A),(1B,2C,3A,4D,5B,6B,7B),(1B,2C,3A,4D,5B,6B,7C),(1B,2C,3A,4D,5B,6C,7A), (1B,2C,3A,4D,5B,6C,7B),(1B,2C,3A,4D,5B,6C,7C),(1B,2C,3A,4D,5B,6D,7A),(1B,2C,3A,4 D,5B,6D,7B),(1B,2C,3A,4D,5B,6D,7C),(1B,2C,3A,4E,5A,6A,7A),(1B,2C,3A,4E,5A,6A,7B), (1B,2C,3A,4E,5A,6A,7C),(1B,2C,3A,4E,5A,6B,7A),(1B,2C,3A,4E,5A,6B,7B),(1B,2C,3A,4 E,5A,6B,7C),(1B,2C,3A,4E,5A,6C,7A),(1B,2C,3A,4E,5A,6C,7B),(1B,2C,3A,4E,5A,6C,7C), (1B,2C,3A,4E,5A,6D,7A),(1B,2C,3A,4E,5A,6D,7B),(1B,2C,3A,4E,5A,6D,7C),(1B,2C,3A,4E,5B,6A,7A),(1B,2C,3A,4E,5B,6A,7B),(1B,2C,3A,4E,5B,6A,7C), (1B,2C,3A,4E,5B,6B,7A),(1B,2C,3A,4E,5B,6B,7B),(1B,2C,3A,4E,5B,6B,7C),(1B,2C,3A,4E,5B,6C,7A), (1B,2C,3A,4E,5B,6C,7B),(1B,2C,3A,4E,5B,6C,7C),(1B,2C,3A,4E,5B,6D,7A),(1B,2C,3A,4E,5B,6D,7B), (1B,2C,3A,4E,5B,6D,7C),(1B,2C,3B,4A,5A,6A,7A),(1B,2C,3B,4A,5A,6A,7B),(1B,2C,3B,4 A,5A,6A,7C),(1B,2C,3B,4A,5A,6B,7A),(1B,2C,3B,4A,5A,6B,7B),(1B,2C,3B,4A,5A,6B,7C), (1B,2C,3B,4A,5A,6C,7A),(1B,2C,3B,4A,5A,6C,7B),(1B,2C,3B,4A,5A,6C,7C),(1B,2C,3B,4 A,5A,6D,7A),(1B,2C,3B,4A,5A,6D,7B),(1B,2C,3B,4A,5A,6D,7C),(1B,2C,3B,4A,5B,6A,7A), (1B,2C,3B,4A,5B,6A,7B),(1B,2C,3B,4A,5B,6A,7C),(1B,2C,3B,4A,5B,6B,7A),(1B,2C,3B,4 A,5B,6B,7B),(1B,2C,3B,4A,5B,6B,7C),(1B,2C,3B,4A,5B,6C,7A),(1B,2C,3B,4A,5B,6C,7B), (1B,2C,3B,4A,5B,6C,7C),(1B,2C,3B,4B,5A,6A,7A),(1B,2C,3B,4B,5A,6A,7B),(1B,2C,3B,4B,5A,6A,7C), (1B,2C,3B,4B,5A,6B,7A),(1B,2C,3B,4B,5A,6B,7B),(1B,2C,3B,4B,5A,6B,7C),(1B,2C,3B,4B,5A,6C,7A), (1B,2C,3B,4B,5A,6C,7B),(1B,2C,3B,4B,5A,6C,7C),(1B,2C,3B,4B,5A,6D,7A), (1B,2C,3B,4B,5A,6D,7B),(1B,2C,3B,4B,5A,6D,7C),(1B,2C,3B,4 B,5B,6A,7A),(1B,2C,3B,4B,5B,6A,7B),(1B,2C,3B,4B,5B,6A,7C),(1B,2C,3B,4B,5B,6B,7A), (1B,2C,3B,4B,5B,6B,7B),(1B,2C,3B,4B,5B,6B,7C),(1B,2C,3B,4B,5B,6C,7A),(1B,2C,3B,4B,5B,6C,7B), (1B,2C,3B,4 B,5B,6C,7C),(1B,2C,3B,4B,5B,6D,7A),(1B,2C,3B,4B,5B,6D,7B),(1B,2C,3B,4B,5B,6D,7C), (1B,2C,3B,4C,5A,6A,7A),(1B,2C,3B,4C,5A,6A,7B),(1B,2C,3B,4C,5A,6A,7C),(1B,2C,3B,4 C,5A,6B,7A),(1B,2C,3B,4C,5A,6B,7B),(1B,2C,3B,4C,5A,6B,7C),(1B,2C,3B,4C,5A,6C,7A), (1B,2C,3B,4C,5A,6C,7B),(1B,2C,3B,4C,5A,6C,7C),(1B,2C,3B,4C,5A,6D,7A),(1B,2C,3B,4 C,5A,6D,7B),(1B,2C,3B,4C,5A,6D,7C),(1B,2C,3B,4C,5B,6A,7A),(1B,2C,3B,4C,5B,6A,7B), (1B,2C,3B,4C,5B,6A,7C),(1B,2C,3B,4C,5B,6B,7A),(1B,2C,3B,4C,5B,6B,7B),(1B,2C,3B,4 C,5B,6B,7C),(1B,2C,3B,4C,5B,6C,7A),(1B,2C,3B,4C,5B,6C,7B),(1B,2C,3B,4C,5B,6C,7C), (1B,2C,3B,4C,5B,6D,7A),(1B,2C,3B,4C,5B,6D,7B),(1B,2C,3B,4C,5B,6D,7C),(1B,2C,3B,4D,5A,6A,7A),(1B,2C,3B,4D,5A,6A,7B),(1B,2C,3B,4D,5A,6A,7C), (1B,2C,3B,4D,5A,6B,7A),(1B,2C,3B,4D,5A,6B,7B),(1B,2C,3B,4D,5A,6B,7C),(1B,2C,3B,4D,5A,6C,7A),(1B,2C,3B,4

[illegible]

↑

十

2

2

3

3

4

4

5

5

4E,5A,6A,7A),(1B,2C,3D,4E,5A,6A,7B),(1B,2C,3D,4 E,5A,6A,7C),(1B,2C,3D,4E,5A,6B,7A),(1B,2C,3D,4E,5A,6B,
 7B),(1B,2C,3D,4E,5A,6B,7C),(1B,2C,3D,4E,5A,6C,7A),(1B,2C,3D,4E,5A,6C,7B),(1B,2C,3D,4E,5A,6C,7C),(1B,2C,
 3D,4 E,5A,6D,7A),(1B,2C,3D,4E,5A,6D,7B),(1B,2C,3D,4E,5A,6D,7C),(1B,2C,3D,4E,5B,6A,7A),(1B,2C,3D,4E,5B,
 6A,7B),(1B,2C,3D,4E,5B,6A,7C),(1B,2C,3D,4E,5B,6B,7A),(1B,2C,3D,4 E,5B,6B,7B),(1B,2C,3D,4E,5B,6B,7C),(1B,
 5 2C,3D,4E,5B,6C,7A),(1B,2C,3D,4E,5B,6C,7B),(1B,2C,3D,4E,5B,6C,7C),(1B,2C,3D,4E,5B,6D,7A),(1B,2C,3D,4E,
 5B,6D,7B),(1B,2C,3D,4 E,5B,6D,7C),(1B,2C,3E,4A,5A,6A,7A),(1B,2C,3E,4A,5A,6A,7B),(1B,2C,3E,4A,5A,6A,7C),
 (1B,2C,3E,4A,5A,6B,7A),(1B,2C,3E,4A,5A,6B,7B),(1B,2C,3E,4A,5A,6B,7C),(1B,2C,3E,4 A,5A,6C,7A),(1B,2C,3E,
 4A,5A,6C,7B),(1B,2C,3E,4A,5A,6C,7C),(1B,2C,3E,4A,5A,6D,7A),(1B,2C,3E,4A,5A,6D,7B),(1B,2C,3E,4A,5A,6D,
 7C),(1B,2C,3E,4A,5B,6A,7A),(1B,2C,3E,4 A,5B,6A,7B),(1B,2C,3E,4A,5B,6A,7C),(1B,2C,3E,4A,5B,6B,7A),(1B,2C,
 10 3E,4A,5B,6B,7B),(1B,2C,3E,4A,5B,6B,7C),(1B,2C,3E,4A,5B,6C,7A),(1B,2C,3E,4A,5B,6C,7B),(1B,2C,3E,4 A,5B,
 6C,7C),(1B,2C,3E,4A,5B,6D,7A),(1B,2C,3E,4A,5B,6D,7B),(1B,2C,3E,4A,5B,6D,7C),(1B,2C,3E,4B,5A,6A,7A),(1B,
 2C,3E,4B,5A,6A,7B),(1B,2C,3E,4B,5A,6A,7C),(1B,2C,3E,4 B,5A,6B,7A),(1B,2C,3E,4B,5A,6B,7B),(1B,2C,3E,4B,5A,
 6B,7C),(1B,2C,3E,4B,5A,6C,7A),(1B,2C,3E,4B,5A,6C,7B),(1B,2C,3E,4B,5A,6C,7C),(1B,2C,3E,4B,5A,6D,7A),(1B,
 2C,3E,4 B,5A,6D,7B),(1B,2C,3E,4B,5A,6D,7C),(1B,2C,3E,4B,5B,6A,7A),(1B,2C,3E,4B,5B,6A,7B),(1B,2C,3E,4B,
 15 5B,6A,7C),(1B,2C,3E,4B,5B,6B,7A),(1B,2C,3E,4B,5B,6B,7B),(1B,2C,3E,4 B,5B,6B,7C),(1B,2C,3E,4B,5B,6C,7A),
 (1B,2C,3E,4B,5B,6C,7B),(1B,2C,3E,4B,5B,6C,7C),(1B,2C,3E,4B,5B,6D,7A),(1B,2C,3E,4B,5B,6D,7B),(1B,2C,3E,
 4B,5B,6D,7C),(1B,2C,3E,4 C,5A,6A,7A),(1B,2C,3E,4C,5A,6A,7B),(1B,2C,3E,4C,5A,6A,7C),(1B,2C,3E,4C,5A,6B,
 7A),(1B,2C,3E,4C,5A,6B,7B),(1B,2C,3E,4C,5A,6B,7C),(1B,2C,3E,4C,5A,6C,7A),(1B,2C,3E,4 C,5A,6C,7B),(1B,2C,
 20 3E,4C,5A,6C,7C),(1B,2C,3E,4C,5A,6D,7A),(1B,2C,3E,4C,5A,6D,7B),(1B,2C,3E,4C,5A,6D,7C),(1B,2C,3E,4C,5B,
 6A,7A),(1B,2C,3E,4C,5B,6A,7B),(1B,2C,3E,4 C,5B,6A,7C),(1B,2C,3E,4C,5B,6B,7A),(1B,2C,3E,4C,5B,6B,7B),(1B,
 2C,3E,4C,5B,6B,7C),(1B,2C,3E,4C,5B,6C,7A),(1B,2C,3E,4C,5B,6C,7B),(1B,2C,3E,4C,5B,6C,7C),(1B,2C,3E,4 C,
 5B,6D,7A),(1B,2C,3E,4C,5B,6D,7B),(1B,2C,3E,4C,5B,6D,7C),(1B,2C,3E,4D,5A,6A,7A),(1B,2C,3E,4D,5A,6A,7B),
 (1B,2C,3E,4D,5A,6A,7C),(1B,2C,3E,4D,5A,6B,7A),(1B,2C,3E,4 D,5A,6B,7B),(1B,2C,3E,4D,5A,6B,7C),(1B,2C,3E,
 4D,5A,6C,7A),(1B,2C,3E,4D,5A,6C,7B),(1B,2C,3E,4D,5A,6C,7C),(1B,2C,3E,4D,5A,6D,7A),(1B,2C,3E,4D,5A,6D,
 25 7B),(1B,2C,3E,4 D,5A,6D,7C),(1B,2C,3E,4D,5B,6A,7A),(1B,2C,3E,4D,5B,6A,7B),(1B,2C,3E,4D,5B,6A,7C),(1B,2C,
 3E,4D,5B,6B,7A),(1B,2C,3E,4D,5B,6B,7B),(1B,2C,3E,4D,5B,6B,7C),(1B,2C,3E,4 D,5B,6C,7A),(1B,2C,3E,4D,5B,
 6C,7B),(1B,2C,3E,4D,5B,6C,7C),(1B,2C,3E,4D,5B,6D,7A),(1B,2C,3E,4D,5B,6D,7B),(1B,2C,3E,4D,5B,6D,7C),(1B,
 2C,3E,4E,5A,6A,7A),(1B,2C,3E,4 E,5A,6A,7B),(1B,2C,3E,4E,5A,6A,7C),(1B,2C,3E,4E,5A,6B,7A),(1B,2C,3E,4E,5A,
 6B,7B),(1B,2C,3E,4E,5A,6B,7C),(1B,2C,3E,4E,5A,6C,7A),(1B,2C,3E,4E,5A,6C,7B),(1B,2C,3E,4 E,5A,6C,7C),(1B,
 30 2C,3E,4E,5A,6D,7A),(1B,2C,3E,4E,5A,6D,7B),(1B,2C,3E,4E,5A,6D,7C),(1B,2C,3E,4E,5B,6A,7A),(1B,2C,3E,4E,
 5B,6A,7B),(1B,2C,3E,4E,5B,6A,7C),(1B,2C,3E,4 E,5B,6B,7A),(1B,2C,3E,4E,5B,6B,7B),(1B,2C,3E,4E,5B,6B,7C),
 (1B,2C,3E,4E,5B,6C,7A),(1B,2C,3E,4E,5B,6C,7B),(1B,2C,3E,4E,5B,6C,7C),(1B,2C,3E,4E,5B,6D,7A),(1B,2C,3E,4
 E,5B,6D,7B),(1B,2C,3E,4E,5B,6D,7C),(1B,2D,3A,4A,5A,6A,7A),(1B,2D,3A,4A,5A,6A,7B),(1B,2D,3A,4A,5A,6A,7C),
 (1B,2D,3A,4A,5A,6B,7A),(1B,2D,3A,4A,5A,6B,7B),(1B,2D,3A,4 A,5A,6B,7C),(1B,2D,3A,4A,5A,6C,7A),(1B,2D,3A,
 35 4A,5A,6C,7B),(1B,2D,3A,4A,5A,6C,7C),(1B,2D,3A,4A,5A,6D,7A),(1B,2D,3A,4A,5A,6D,7B),(1B,2D,3A,4A,5A,6D,
 7C),(1B,2D,3A,4 A,5B,6A,7A),(1B,2D,3A,4A,5B,6A,7B),(1B,2D,3A,4A,5B,6A,7C),(1B,2D,3A,4A,5B,6B,7A),(1B,2D,
 3A,4A,5B,6B,7B),(1B,2D,3A,4A,5B,6B,7C),(1B,2D,3A,4A,5B,6C,7A),(1B,2D,3A,4 A,5B,6C,7B),(1B,2D,3A,4A,5B,
 6C,7C),(1B,2D,3A,4A,5B,6D,7A),(1B,2D,3A,4A,5B,6D,7B),(1B,2D,3A,4A,5B,6D,7C),(1B,2D,3A,4B,5A,6A,7A),(1B,
 2D,3A,4B,5A,6A,7B),(1B,2D,3A,4 B,5A,6A,7C),(1B,2D,3A,4B,5A,6B,7A),(1B,2D,3A,4B,5A,6B,7B),(1B,2D,3A,4B,5A,
 40 6B,7C),(1B,2D,3A,4B,5A,6C,7A),(1B,2D,3A,4B,5A,6C,7B),(1B,2D,3A,4B,5A,6C,7C),(1B,2D,3A,4 B,5A,6D,7A),(1B,
 2D,3A,4B,5A,6D,7B),(1B,2D,3A,4B,5A,6D,7C),(1B,2D,3A,4B,5B,6A,7A),(1B,2D,3A,4B,5B,6A,7B),(1B,2D,3A,4B,
 5B,6A,7C),(1B,2D,3A,4B,5B,6B,7A),(1B,2D,3A,4 B,5B,6B,7B),(1B,2D,3A,4B,5B,6B,7C),(1B,2D,3A,4B,5B,6C,7A),
 (1B,2D,3A,4B,5B,6C,7B),(1B,2D,3A,4B,5B,6C,7C),(1B,2D,3A,4B,5B,6D,7A),(1B,2D,3A,4B,5B,6D,7B),(1B,2D,3A,4
 B,5B,6D,7C),(1B,2D,3A,4C,5A,6A,7A),(1B,2D,3A,4C,5A,6A,7B),(1B,2D,3A,4C,5A,6A,7C),(1B,2D,3A,4C,5A,6B,7A),
 45 (1B,2D,3A,4C,5A,6B,7B),(1B,2D,3A,4C,5A,6B,7C),(1B,2D,3A,4 C,5A,6C,7A),(1B,2D,3A,4C,5A,6C,7B),(1B,2D,3A,
 4C,5A,6C,7C),(1B,2D,3A,4C,5A,6D,7A),(1B,2D,3A,4C,5A,6D,7B),(1B,2D,3A,4C,5A,6D,7C),(1B,2D,3A,4C,5B,6A,
 7A),(1B,2D,3A,4 C,5B,6A,7B),(1B,2D,3A,4C,5B,6A,7C),(1B,2D,3A,4C,5B,6B,7A),(1B,2D,3A,4C,5B,6B,7B),(1B,2D,
 3A,4C,5B,6B,7C),(1B,2D,3A,4C,5B,6C,7A),(1B,2D,3A,4C,5B,6C,7B),(1B,2D,3A,4 C,5B,6C,7C),(1B,2D,3A,4C,5B,
 6D,7A),(1B,2D,3A,4C,5B,6D,7B),(1B,2D,3A,4C,5B,6D,7C),(1B,2D,3A,4D,5A,6A,7A),(1B,2D,3A,4D,5A,6A,7B),(1B,
 50 2D,3A,4D,5A,6A,7C),(1B,2D,3A,4 D,5A,6B,7A),(1B,2D,3A,4D,5A,6B,7B),(1B,2D,3A,4D,5A,6B,7C),(1B,2D,3A,4D,
 5A,6C,7A),(1B,2D,3A,4D,5A,6C,7B),(1B,2D,3A,4D,5A,6C,7C),(1B,2D,3A,4D,5A,6D,7A),(1B,2D,3A,4 D,5A,6D,7B),
 (1B,2D,3A,4D,5A,6D,7C),(1B,2D,3A,4D,5B,6A,7A),(1B,2D,3A,4D,5B,6A,7B),(1B,2D,3A,4D,5B,6A,7C),(1B,2D,3A,
 4D,5B,6B,7A),(1B,2D,3A,4D,5B,6B,7B),(1B,2D,3A,4 D,5B,6B,7C),(1B,2D,3A,4D,5B,6C,7A),(1B,2D,3A,4D,5B,6C,
 7B),(1B,2D,3A,4D,5B,6C,7C),(1B,2D,3A,4D,5B,6D,7A),(1B,2D,3A,4D,5B,6D,7B),(1B,2D,3A,4D,5B,6D,7C),(1B,2D,
 55 3A,4 E,5A,6A,7A),(1B,2D,3A,4E,5A,6A,7B),(1B,2D,3A,4E,5A,6A,7C),(1B,2D,3A,4E,5A,6B,7A),(1B,2D,3A,4E,5A,
 6B,7B),(1B,2D,3A,4E,5A,6B,7C),(1B,2D,3A,4E,5A,6C,7A),(1B,2D,3A,4 E,5A,6C,7B),(1B,2D,3A,4E,5A,6C,7C),(1B,
 2D,3A,4E,5A,6D,7A),(1B,2D,3A,4E,5A,6D,7B),(1B,2D,3A,4E,5A,6D,7C),(1B,2D,3A,4E,5B,6A,7A),(1B,2D,3A,4E,
 5B,6A,7B),(1B,2D,3A,4 E,5B,6A,7C),(1B,2D,3A,4E,5B,6B,7A),(1B,2D,3A,4E,5B,6B,7B),(1B,2D,3A,4E,5B,6B,7C),

(1B,2D,3A,4E,5B,6C,7A),(1B,2D,3A,4E,5B,6C,7B),(1B,2D,3A,4E,5B,6C,7C),(1B,2D,3A,4 E,5B,6D,7A),(1B,2D,3A,4E,5B,6D,7B),(1B,2D,3A,4E,5B,6D,7C),(1B,2D,3B,4A,5A,6A,7A), (1B,2D,3B,4A,5A,6A,7B),(1B,2D,3B,4A,5A,6A,7C),(1B,2D,3B,4A,5A,6B,7A),(1B,2D,3B,4 A,5A,6B,7B),(1B,2D,3B,4A,5A,6B,7C),(1B,2D,3B,4A,5A,6C,7A),(1B,2D,3B,4A,5A,6C,7B), (1B,2D,3B,4A,5A,6C,7C),(1B,2D,3B,4A,5A,6D,7A),(1B,2D,3B,4A,5A,6D,7B),(1B,2D,3B,4 A,5A,6D,7C),(1B,2D,3B,4A,5B,6A,7A),(1B,2D,3B,4A,5B,6A,7B),(1B,2D,3B,4A,5B,6A,7C), (1B,2D,3B,4A,5B,6B,7A),(1B,2D,3B,4A,5B,6B,7B),(1B,2D,3B,4A,5B,6B,7C),(1B,2D,3B,4A,5B,6C,7A),(1B,2D,3B,4A,5B,6C,7B),(1B,2D,3B,4A,5B,6C,7C),(1B,2D,3B,4A,5B,6D,7A),(1B,2D,3B,4A,5B,6D,7B),(1B,2D,3B,4A,5B,6D,7C),(1B,2D,3B,4 B,5A,6A,7B),(1B,2D,3B,4B,5A,6A,7C),(1B,2D,3B,4B,5A,6B,7A),(1B,2D,3B,4B,5A,6B,7B),(1B,2D,3B,4B,5A,6B,7C),(1B,2D,3B,4B,5A,6C,7A),(1B,2D,3B,4B,5A,6C,7B),(1B,2D,3B,4 B,5A,6C,7C),(1B,2D,3B,4B,5A,6D,7A),(1B,2D,3B,4B,5A,6D,7B),(1B,2D,3B,4B,5A,6D,7C), (1B,2D,3B,4B,5B,6A,7A),(1B,2D,3B,4B,5B,6A,7B),(1B,2D,3B,4B,5B,6A,7C),(1B,2D,3B,4 B,5B,6B,7A),(1B,2D,3B,4B,5B,6B,7B),(1B,2D,3B,4B,5B,6B,7C),(1B,2D,3B,4B,5B,6C,7A), (1B,2D,3B,4B,5B,6C,7B),(1B,2D,3B,4B,5B,6C,7C),(1B,2D,3B,4B,5B,6D,7A),(1B,2D,3B,4 B,5B,6D,7B),(1B,2D,3B,4B,5B,6D,7C),(1B,2D,3B,4C,5A,6A,7A),(1B,2D,3B,4C,5A,6A,7B), (1B,2D,3B,4C,5A,6A,7C),(1B,2D,3B,4C,5A,6B,7A),(1B,2D,3B,4C,5A,6B,7B),(1B,2D,3B,4C,5A,6B,7C),(1B,2D,3B,4 C,5A,6B,7C),(1B,2D,3B,4C,5A,6C,7A),(1B,2D,3B,4C,5A,6C,7B),(1B,2D,3B,4C,5A,6C,7C), (1B,2D,3B,4C,5A,6D,7A),(1B,2D,3B,4C,5A,6D,7B),(1B,2D,3B,4C,5A,6D,7C),(1B,2D,3B,4 C,5B,6A,7A),(1B,2D,3B,4C,5B,6A,7B),(1B,2D,3B,4C,5B,6A,7C),(1B,2D,3B,4C,5B,6B,7A), (1B,2D,3B,4C,5B,6B,7B),(1B,2D,3B,4C,5B,6B,7C),(1B,2D,3B,4C,5B,6C,7A),(1B,2D,3B,4C,5B,6C,7B),(1B,2D,3B,4C,5B,6C,7C),(1B,2D,3B,4C,5B,6D,7A),(1B,2D,3B,4C,5B,6D,7B),(1B,2D,3B,4C,5B,6D,7C),(1B,2D,3B,4 D,5A,6A,7C),(1B,2D,3B,4D,5A,6B,7A),(1B,2D,3B,4D,5A,6B,7B),(1B,2D,3B,4D,5A,6B,7C), (1B,2D,3B,4D,5A,6C,7A),(1B,2D,3B,4D,5A,6C,7B),(1B,2D,3B,4D,5A,6C,7C),(1B,2D,3B,4 D,5A,6D,7A),(1B,2D,3B,4D,5A,6D,7B),(1B,2D,3B,4D,5A,6D,7C),(1B,2D,3B,4D,5B,6A,7A), (1B,2D,3B,4D,5B,6A,7B),(1B,2D,3B,4D,5B,6A,7C),(1B,2D,3B,4D,5B,6B,7A),(1B,2D,3B,4 D,5B,6B,7B),(1B,2D,3B,4D,5B,6B,7C),(1B,2D,3B,4D,5B,6C,7A),(1B,2D,3B,4D,5B,6C,7B), (1B,2D,3B,4D,5B,6C,7C),(1B,2D,3B,4D,5B,6D,7A),(1B,2D,3B,4D,5B,6D,7B),(1B,2D,3B,4 D,5B,6D,7C),(1B,2D,3B,4E,5A,6A,7A),(1B,2D,3B,4E,5A,6A,7B),(1B,2D,3B,4E,5A,6A,7C), (1B,2D,3B,4E,5A,6B,7A),(1B,2D,3B,4E,5A,6B,7B),(1B,2D,3B,4E,5A,6B,7C),(1B,2D,3B,4E,5A,6C,7A),(1B,2D,3B,4E,5A,6C,7B),(1B,2D,3B,4E,5A,6C,7C),(1B,2D,3B,4E,5A,6D,7A), (1B,2D,3B,4E,5A,6D,7B),(1B,2D,3B,4E,5A,6D,7C),(1B,2D,3B,4E,5B,6A,7A),(1B,2D,3B,4E,5B,6A,7B),(1B,2D,3B,4E,5B,6A,7C),(1B,2D,3B,4E,5B,6B,7A),(1B,2D,3B,4E,5B,6B,7B), (1B,2D,3B,4E,5B,6B,7C),(1B,2D,3B,4E,5B,6C,7A),(1B,2D,3B,4E,5B,6C,7B),(1B,2D,3B,4 E,5B,6C,7C),(1B,2D,3B,4E,5B,6D,7A),(1B,2D,3B,4E,5B,6D,7B),(1B,2D,3B,4E,5B,6D,7C), (1B,2D,3B,4E,5B,6E,7A),(1B,2D,3B,4E,5B,6E,7B),(1B,2D,3B,4E,5B,6E,7C),(1B,2D,3C,4A,5A,6A,7A),(1B,2D,3C,4A,5A,6A,7B),(1B,2D,3C,4A,5A,6A,7C),(1B,2D,3C,4 A,5A,6B,7A),(1B,2D,3C,4A,5A,6B,7B),(1B,2D,3C,4A,5A,6B,7C),(1B,2D,3C,4A,5A,6C,7A), (1B,2D,3C,4A,5A,6C,7B),(1B,2D,3C,4A,5A,6C,7C),(1B,2D,3C,4A,5A,6D,7A),(1B,2D,3C,4 A,5A,6D,7B),(1B,2D,3C,4A,5A,6D,7C),(1B,2D,3C,4A,5B,6A,7A),(1B,2D,3C,4A,5B,6A,7B), (1B,2D,3C,4A,5B,6A,7C),(1B,2D,3C,4A,5B,6B,7A),(1B,2D,3C,4A,5B,6B,7B),(1B,2D,3C,4 A,5B,6B,7C),(1B,2D,3C,4A,5B,6C,7A),(1B,2D,3C,4A,5B,6C,7B),(1B,2D,3C,4A,5B,6C,7C), (1B,2D,3C,4A,5B,6D,7A),(1B,2D,3C,4A,5B,6D,7B),(1B,2D,3C,4A,5B,6D,7C),(1B,2D,3C,4 B,5A,6A,7A),(1B,2D,3C,4B,5A,6A,7B),(1B,2D,3C,4B,5A,6A,7C),(1B,2D,3C,4B,5A,6B,7A), (1B,2D,3C,4B,5A,6B,7B),(1B,2D,3C,4B,5A,6B,7C),(1B,2D,3C,4B,5A,6C,7A),(1B,2D,3C,4 B,5A,6C,7B),(1B,2D,3C,4B,5A,6C,7C),(1B,2D,3C,4B,5A,6D,7A),(1B,2D,3C,4B,5A,6D,7B), (1B,2D,3C,4B,5A,6D,7C),(1B,2D,3C,4B,5B,6A,7A),(1B,2D,3C,4B,5B,6A,7B),(1B,2D,3C,4 B,5B,6A,7C),(1B,2D,3C,4B,5B,6B,7A),(1B,2D,3C,4B,5B,6B,7B),(1B,2D,3C,4B,5B,6B,7C), (1B,2D,3C,4B,5B,6C,7A),(1B,2D,3C,4B,5B,6C,7B),(1B,2D,3C,4B,5B,6C,7C),(1B,2D,3C,4 B,5B,6D,7A),(1B,2D,3C,4B,5B,6D,7B),(1B,2D,3C,4B,5B,6D,7C),(1B,2D,3C,4B,5B,6E,7A), (1B,2D,3C,4B,5B,6E,7B),(1B,2D,3C,4B,5B,6E,7C),(1B,2D,3C,4C,5A,6A,7A),(1B,2D,3C,4C,5A,6A,7B),(1B,2D,3C,4C,5A,6A,7C),(1B,2D,3C,4C,5A,6B,7A),(1B,2D,3C,4 C,5A,6B,7B),(1B,2D,3C,4C,5A,6B,7C),(1B,2D,3C,4C,5A,6C,7A),(1B,2D,3C,4C,5A,6C,7B), (1B,2D,3C,4C,5A,6C,7C),(1B,2D,3C,4C,5A,6D,7A),(1B,2D,3C,4C,5A,6D,7B),(1B,2D,3C,4 C,5A,6D,7C),(1B,2D,3C,4C,5B,6A,7A),(1B,2D,3C,4C,5B,6A,7B),(1B,2D,3C,4C,5B,6A,7C), (1B,2D,3C,4C,5B,6B

(1B,2D,3D,4A,5A,6D,7C),(1B,2D,3D,4A,5B,6A,7A), (1B,2D,3D,4A,5B,6A,7B),(1B,2D,3D,4A,5B,6A,7C),(1B,2D,3D,4A,5B,6B,7A),(1B,2D,3D,4 A,5B,6B,7B),(1B,2D,3D,4A,5B,6B,7C),(1B,2D,3D,4A,5B,6C,7A),(1B,2D,3D,4A,5B,6C,7B),(1B,2D,3D,4A,5B,6C,7C),(1B,2D,3D,4A,5B,6D,7A),(1B,2D,3D,4A,5B,6D,7B),(1B,2D,3D,4 A,5B,6D,7C),(1B,2D,3D,4B,5A,6A,7A),(1B,2D,3D,4B,5A,6A,7B),(1B,2D,3D,4B,5A,6A,7C), (1B,2D,3D,4B,5A,6B,7A),(1B,2D,3D,4B,5A,6B,7B),(1B,2D,3D,4B,5A,6B,7C),(1B,2D,3D,4 B,5A,6C,7A),(1B,2D,3D,4B,5A,6C,7B),(1B,2D,3D,4B,5A,6C,7C),(1B,2D,3D,4B,5A,6D,7A), (1B,2D,3D,4B,5A,6D,7B),(1B,2D,3D,4B,5A,6D,7C),(1B,2D,3D,4B,5B,6A,7A),(1B,2D,3D,4 B,5B,6A,7B),(1B,2D,3D,4B,5B,6A,7C),(1B,2D,3D,4B,5B,6B,7A),(1B,2D,3D,4B,5B,6B,7B), (1B,2D,3D,4B,5B,6B,7C),(1B,2D,3D,4B,5B,6C,7A),(1B,2D,3D,4B,5B,6C,7B),(1B,2D,3D,4 B,5B,6C,7C),(1B,2D,3D,4B,5B,6D,7A),(1B,2D,3D,4B,5B,6D,7B),(1B,2D,3D,4B,5B,6D,7C), (1B,2D,3D,4C,5A,6A,7A),(1B,2D,3D,4C,5A,6A,7B),(1B,2D,3D,4C,5A,6A,7C), (1B,2D,3D,4 C,5A,6B,7A),(1B,2D,3D,4C,5A,6B,7B),(1B,2D,3D,4C,5A,6B,7C),(1B,2D,3D,4C,5A,6C,7A), (1B,2D,3D,4C,5A,6C,7B),(1B,2D,3D,4C,5A,6C,7C),(1B,2D,3D,4C,5A,6D,7A),(1B,2D,3D,4 C,5A,6D,7B),(1B,2D,3D,4C,5A,6D,7C),(1B,2D,3D,4C,5B,6A,7A),(1B,2D,3D,4C,5B,6A,7B), (1B,2D,3D,4C,5B,6A,7C),(1B,2D,3D,4C,5B,6B,7A),(1B,2D,3D,4C,5B,6B,7B),(1B,2D,3D,4 C,5B,6B,7C),(1B,2D,3D,4C,5B,6C,7A),(1B,2D,3D,4C,5B,6C,7B),(1B,2D,3D,4C,5B,6C,7C), (1B,2D,3D,4C,5B,6D,7A),(1B,2D,3D,4C,5B,6D,7B),(1B,2D,3D,4C,5B,6D,7C),(1B,2D,3D,4 D,5A,6A,7A), (1B,2D,3D,4D,5A,6A,7B),(1B,2D,3D,4D,5A,6A,7C),(1B,2D,3D,4D,5A,6B,7A), (1B,2D,3D,4D,5A,6B,7B),(1B,2D,3D,4D,5A,6B,7C),(1B,2D,3D,4D,5A,6C,7A),(1B,2D,3D,4D,5A,6C,7B), (1B,2D,3D,4D,5A,6C,7C),(1B,2D,3D,4D,5A,6D,7A),(1B,2D,3D,4D,5A,6D,7B), (1B,2D,3D,4D,5A,6D,7C),(1B,2D,3D,4D,5B,6A,7A),(1B,2D,3D,4D,5B,6A,7B),(1B,2D,3D,4D,5B,6A,7C), (1B,2D,3D,4D,5B,6B,7A),(1B,2D,3D,4D,5B,6B,7B),(1B,2D,3D,4D,5B,6B,7C), (1B,2D,3D,4D,5B,6C,7A),(1B,2D,3D,4D,5B,6C,7B),(1B,2D,3D,4D,5B,6C,7C),(1B,2D,3D,4 D,5B,6D,7A),(1B,2D,3D,4D,5B,6D,7B),(1B,2D,3D,4D,5B,6D,7C),(1B,2D,3D,4E,5A,6A,7A), (1B,2D,3D,4E,5A,6A,7B),(1B,2D,3D,4E,5A,6A,7C),(1B,2D,3D,4E,5A,6B,7A),(1B,2D,3D,4 E,5A,6B,7B),(1B,2D,3D,4E,5A,6B,7C),(1B,2D,3D,4E,5A,6C,7A),(1B,2D,3D,4E,5A,6C,7B), (1B,2D,3D,4E,5A,6C,7C),(1B,2D,3D,4E,5A,6D,7A),(1B,2D,3D,4E,5A,6D,7B),(1B,2D,3D,4 E,5A,6D,7C),(1B,2D,3D,4E,5B,6A,7A),(1B,2D,3D,4E,5B,6A,7B),(1B,2D,3D,4E,5B,6A,7C), (1B,2D,3D,4E,5B,6B,7A),(1B,2D,3D,4E,5B,6B,7B),(1B,2D,3D,4E,5B,6B,7C),(1B,2D,3D,4 E,5B,6C,7A),(1B,2D,3D,4E,5B,6C,7B),(1B,2D,3D,4E,5B,6C,7C),(1B,2D,3D,4E,5B,6D,7A), (1B,2D,3D,4E,5B,6D,7B),(1B,2D,3D,4E,5B,6D,7C),(1B,2D,3E,4A,5A,6A,7A),(1B,2D,3E,4 A,5A,6A,7B),(1B,2D,3E,4A,5A,6A,7C),(1B,2D,3E,4A,5A,6B,7A),(1B,2D,3E,4A,5A,6B,7B), (1B,2D,3E,4A,5A,6B,7C),(1B,2D,3E,4A,5A,6C,7A),(1B,2D,3E,4 A,5A,6C,7B),(1B,2D,3E,4 A,5A,6C,7C),(1B,2D,3E,4A,5A,6D,7A),(1B,2D,3E,4A,5A,6D,7B),(1B,2D,3E,4A,5A,6D,7C), (1B,2D,3E,4A,5A,6E,7A),(1B,2D,3E,4A,5A,6E,7B),(1B,2D,3E,4A,5A,6E,7C),(1B,2D,3E,4A,5B,6A,7A),(1B,2D,3E,4A,5B,6A,7B),(1B,2D,3E,4A,5B,6A,7C),(1B,2D,3E,4A,5B,6B,7A),(1B,2D,3E,4A,5B,6B,7B),(1B,2D,3E,4A,5B,6B,7C),(1B,2D,3E,4 A,5B,6C,7A),(1B,2D,3E,4A,5B,6C,7B),(1B,2D,3E,4 A,5B,6C,7C),(1B,2D,3E,4A,5B,6D,7A),(1B,2D,3E,4A,5B,6D,7B),(1B,2D,3E,4 A,5B,6D,7C),(1B,2D,3E,4B,5A,6A,7A),(1B,2D,3E,4B,5A,6A,7B), (1B,2D,3E,4B,5A,6A,7C),(1B,2D,3E,4B,5A,6B,7A),(1B,2D,3E,4B,5A,6B,7B),(1B,2D,3E,4 B,5A,6B,7C),(1B,2D,3E,4B,5A,6C,7A),(1B,2D,3E,4B,5A,6C,7B),(1B,2D,3E,4B,5A,6C,7C), (1B,2D,3E,4B,5A,6D,7A),(1B,2D,3E,4B,5A,6D,7B),(1B,2D,3E,4B,5A,6D,7C),(1B,2D,3E,4 B,5B,6A,7A),(1B,2D,3E,4B,5B,6A,7B),(1B,2D,3E,4B,5B,6A,7C),(1B,2D,3E,4B,5B,6B,7A), (1B,2D,3E,4B,5B,6B,7B),(1B,2D,3E,4B,5B,6B,7C),(1B,2D,3E,4B,5B,6C,7A),(1B,2D,3E,4 B,5B,6C,7B),(1B,2D,3E,4B,5B,6C,7C),(1B,2D,3E,4B,5B,6D,7A),(1B,2D,3E,4B,5B,6D,7B), (1B,2D,3E,4B,5B,6D,7C),(1B,2D,3E,4C,5A,6A,7A),(1B,2D,3E,4C,5A,6A,7B),(1B,2D,3E,4 C,5A,6A,7C),(1B,2D,3E,4C,5A,6B,7A),(1B,2D,3E,4C,5A,6B,7B),(1B,2D,3E,4C,5A,6B,7C), (1B,2D,3E,4C,5A,6C,7A),(1B,2D,3E,4C,5A,6C,7B),(1B,2D,3E,4C,5A,6C,7C),(1B,2D,3E,4C,5A,6D,7A),(1B,2D,3E,4C,5A,6D,7B),(1B,2D,3E,4C,5A,6D,7C),(1B,2D,3E,4C,5B,6A,7A), (1B,2D,3E,4C,5B,6A,7B),(1B,2D,3E,4C,5B,6A,7C),(1B,2D,3E,4C,5B,6B,7A),(1B,2D,3E,4 C,5B,6B,7B),(1B,2D,3E,4C,5B,6B,7C),(1B,2D,3E,4C,5B,6C,7A),(1B,2D,3E,4C,5B,6C,7B), (1B,2D,3E,4C,5B,6C,7C),(1B,2D,3E,4C,5B,6D,7A),(1B,2D,3E,4C,5B,6D,7B),(1B,2D,3E,4 C,5B,6D,7C),(1B,2D,3E,4D,5A,6A,7A),(1B,2D,3E,4D,5A,6A,7B),(1B,2D,3E,4D,5A,6A,7C), (1B,2D,3E,4D,5A,6B,7A),(1B,2D,3E,4D,5A,6B,7B),(1B,2D,3E,4D,5A,6B,7C),(1B,2D,3E,4 D,5A,6C,7A),(1B,2D,3E,4D,5A,6C,7B),(1B,2D,3E,4D,5A,6C,7C),(1B,2D,3E,4D,5A,6D,7A), (1B,2D,3E,4D,5A,6D,7B),(1B,2D,3E,4D,5A,6D,7C),(1B,2D,3E,4D,5B,6A,7A),(1B,2D,3E,4 D,5B,6A,7B),(1B,2D,3E,4D,5B,6A,7C),(1B,2D,3E,4D,5B,6B,7A),(1B,2D,3E,4D,5B,6B,7B), (1B,2D,3E,4D,5B,6B,7C),(1B,2D,3E,4D,5B,6C,7A),(1B,2D,3E,4D,5B,6C,7B),(1B,2D,3E,4 D,5B,6C,7C),(1B,2D,3E,4D,5B,6D,7A),(1B,2D,3E,4D,5B,6D,7B),(1B,2D,3E,4D,5B,6D,7C), (1B,2D,3E,4E,5A,6A,7A),(1B,2D,3E,4E,5A,6A,7B),(1B,2D,3E,4E,5A,6A,7C),(1B,2D,3E,4E,5A,6B,7A),(1B,2D,3E,4E,5A,6B,7B),(1B,2D,3E,4E,5A,6B,7C), (1B,2D,3E,4E,5A,6C,7A),(1B,2D,3E,4E,5A,6C,7B),(1B,2D,3E,4E,5A,6C,7C),(1B,2D,3E,4E,5A,6D,7A), (1B,2D,3E,4E,5A,6D,7B),(1B,2D,3E,4E,5A,6D,7C),(1B,2D,3E,4E,5B,6A,7A),(1B,2D,3E,4E,5B,6A,7B), (1B,2D,3E,4E,5B,6A,7C),(1B,2D,3E,4E,5B,6B,7A),(1B,2D,3E,4E,5B,6B,7B),(1B,2D,3E,4E,5B,6B,7C),(1B,2D,3E,4E,5B,6C,7A),(1B,2D,3E,4E,5B,6C,7B),(1B,2D,3E,4E,5B,6C,7C), (1B,2D,3E,4E,5B,6D,7A),(1B,2D,3E,4E,5B,6D,7B),(1B,2D,3E,4E,5B,6D,7C),(1B,2E,3A,4 A,5A,6A,7A),(1B,2E,3A,4A,5A,6A,7B),(1B,2E,3A,4A,5A,6A,7C),(1B,2E,3A,4A,5A,6B,7A), (1B,2E,3A,4A,5A,6B,7B),(1B,2E,3A,4A,5A,6B,7C),(1B,2E,3A,4A,5A,6D,7A),(1B,2E,3A,4A,5A,6D,7B), (1B,2E,3A,4A,5A,6D,7C),(1B,2E,3A,4A,5B,6A,7A),(1B,2E,3A,4A,5B,6A,7B),(1B,2E,3A,4 A,5B,6A,7C),(1B,2E,3A,4A,5B,6B,7A),(1B,2E,3A,4A,5B,6B,7B),(1B,2E,3A,4A,5B,6B,7C), (1B,2E,3A,4A,5B,6C,7A),(1B,2E,3A,4A,5B,6C,7B),(1B,2E,3A,4A,5B,6C,7C),(1B,2E,3A,4 A,5B,6D,7A),(1B,2E,3A,4A,5B,6D,7B),(1B,2E,3A,4A,5B,6D,7C),(1B,2E,3A,4B,5A,6A,7A), (1B,2E,3A,4B,5A,6A,7B),(1B,2E,3A,4B,5A,6A,7C),(1B,2E,3A,4B,5A,6B,7A),(1B,2E,3A,4 B,5A,

264

B,5B,6D,7C),(1B,2E,3C,4C,5A,6A,7A),(1B,2E,3C,4C,5A,6A,7B),(1B,2E,3C,4C,5A,6A,7C),(1B,2E,3C,4C,5A,6B,7A),
 (1B,2E,3C,4C,5A,6B,7B),(1B,2E,3C,4C,5A,6B,7C),(1B,2E,3C,4 C,5A,6C,7A),(1B,2E,3C,4C,5A,6C,7B),(1B,2E,3C,
 4C,5A,6C,7C),(1B,2E,3C,4C,5A,6D,7A),(1B,2E,3C,4C,5A,6D,7B),(1B,2E,3C,4C,5A,6D,7C),(1B,2E,3C,4C,5B,6A,
 7A),(1B,2E,3C,4 C,5B,6A,7B),(1B,2E,3C,4C,5B,6A,7C),(1B,2E,3C,4C,5B,6B,7A),(1B,2E,3C,4C,5B,6B,7B),(1B,2E,
 5 3C,4C,5B,6B,7C),(1B,2E,3C,4C,5B,6C,7A),(1B,2E,3C,4C,5B,6C,7B),(1B,2E,3C,4 C,5B,6C,7C),(1B,2E,3C,4C,5B,
 6D,7A),(1B,2E,3C,4C,5B,6D,7B),(1B,2E,3C,4C,5B,6D,7C),(1B,2E,3C,4D,5A,6A,7A),(1B,2E,3C,4D,5A,6A,7B),(1B,
 2E,3C,4D,5A,6A,7C),(1B,2E,3C,4 D,5A,6B,7A),(1B,2E,3C,4D,5A,6B,7B),(1B,2E,3C,4D,5A,6B,7C),(1B,2E,3C,4D,
 5A,6C,7A),(1B,2E,3C,4D,5A,6C,7B),(1B,2E,3C,4D,5A,6C,7C),(1B,2E,3C,4D,5A,6D,7A),(1B,2E,3C,4 D,5A,6D,7B),
 (1B,2E,3C,4D,5A,6D,7C),(1B,2E,3C,4D,5B,6A,7A),(1B,2E,3C,4D,5B,6A,7B),(1B,2E,3C,4D,5B,6A,7C),(1B,2E,3C,
 10 4D,5B,6B,7A),(1B,2E,3C,4D,5B,6B,7B),(1B,2E,3C,4 D,5B,6B,7C),(1B,2E,3C,4D,5B,6C,7A),(1B,2E,3C,4D,5B,6C,
 7B),(1B,2E,3C,4D,5B,6C,7C),(1B,2E,3C,4D,5B,6D,7A),(1B,2E,3C,4D,5B,6D,7B),(1B,2E,3C,4D,5B,6D,7C),(1B,2E,
 3C,4 E,5A,6A,7A),(1B,2E,3C,4E,5A,6A,7B),(1B,2E,3C,4E,5A,6A,7C),(1B,2E,3C,4E,5A,6B,7A),(1B,2E,3C,4E,5A,
 6B,7B),(1B,2E,3C,4E,5A,6B,7C),(1B,2E,3C,4E,5A,6C,7A),(1B,2E,3C,4 E,5A,6C,7B),(1B,2E,3C,4E,5A,6C,7C),(1B,
 2E,3C,4E,5A,6D,7A),(1B,2E,3C,4E,5A,6D,7B),(1B,2E,3C,4E,5A,6D,7C),(1B,2E,3C,4E,5B,6A,7A),(1B,2E,3C,4E,
 15 5B,6A,7B),(1B,2E,3C,4 E,5B,6A,7C),(1B,2E,3C,4E,5B,6B,7A),(1B,2E,3C,4E,5B,6B,7B),(1B,2E,3C,4E,5B,6B,7C),
 (1B,2E,3C,4E,5B,6C,7A),(1B,2E,3C,4E,5B,6C,7B),(1B,2E,3C,4E,5B,6C,7C),(1B,2E,3C,4 E,5B,6D,7A),(1B,2E,3C,
 4E,5B,6D,7B),(1B,2E,3C,4E,5B,6D,7C),(1B,2E,3D,4A,5A,6A,7A),(1B,2E,3D,4A,5A,6A,7B),(1B,2E,3D,4A,5A,6A,
 7C),(1B,2E,3D,4A,5A,6B,7A),(1B,2E,3D,4 A,5A,6B,7B),(1B,2E,3D,4A,5A,6B,7C),(1B,2E,3D,4A,5A,6C,7A),(1B,2E,
 20 3D,4A,5A,6C,7B),(1B,2E,3D,4A,5A,6C,7C),(1B,2E,3D,4A,5A,6D,7A),(1B,2E,3D,4A,5A,6D,7B),(1B,2E,3D,4 A,5A,
 6D,7C),(1B,2E,3D,4A,5B,6A,7A),(1B,2E,3D,4A,5B,6A,7B),(1B,2E,3D,4A,5B,6A,7C),(1B,2E,3D,4A,5B,6B,7A),(1B,
 2E,3D,4A,5B,6B,7B),(1B,2E,3D,4A,5B,6B,7C),(1B,2E,3D,4 A,5B,6C,7A),(1B,2E,3D,4A,5B,6C,7B),(1B,2E,3D,4A,
 5B,6C,7C),(1B,2E,3D,4A,5B,6D,7A),(1B,2E,3D,4A,5B,6D,7B),(1B,2E,3D,4A,5B,6D,7C),(1B,2E,3D,4B,5A,6A,7A),
 (1B,2E,3D,4 B,5A,6A,7B),(1B,2E,3D,4B,5A,6A,7C),(1B,2E,3D,4B,5A,6B,7A),(1B,2E,3D,4B,5A,6B,7B),(1B,2E,3D,
 25 4B,5A,6B,7C),(1B,2E,3D,4B,5A,6C,7A),(1B,2E,3D,4B,5A,6C,7B),(1B,2E,3D,4 B,5A,6C,7C),(1B,2E,3D,4B,5A,6D,
 7A),(1B,2E,3D,4B,5A,6D,7B),(1B,2E,3D,4B,5A,6D,7C),(1B,2E,3D,4B,5B,6A,7A),(1B,2E,3D,4B,5B,6A,7B),(1B,2E,
 3D,4B,5B,6A,7C),(1B,2E,3D,4 B,5B,6B,7A),(1B,2E,3D,4B,5B,6B,7B),(1B,2E,3D,4B,5B,6B,7C),(1B,2E,3D,4B,5B,
 6C,7A),(1B,2E,3D,4B,5B,6C,7B),(1B,2E,3D,4B,5B,6C,7C),(1B,2E,3D,4B,5B,6D,7A),(1B,2E,3D,4 B,5B,6D,7B),(1B,
 2E,3D,4B,5B,6D,7C),(1B,2E,3D,4C,5A,6A,7A),(1B,2E,3D,4C,5A,6A,7B),(1B,2E,3D,4C,5A,6A,7C),(1B,2E,3D,4C,
 5A,6B,7A),(1B,2E,3D,4C,5A,6B,7B),(1B,2E,3D,4 C,5A,6B,7C),(1B,2E,3D,4C,5A,6C,7A),(1B,2E,3D,4C,5A,6C,7B),
 30 (1B,2E,3D,4C,5A,6C,7C),(1B,2E,3D,4C,5A,6D,7A),(1B,2E,3D,4C,5A,6D,7B),(1B,2E,3D,4C,5A,6D,7C),(1B,2E,3D,4
 C,5B,6A,7A),(1B,2E,3D,4C,5B,6A,7B),(1B,2E,3D,4C,5B,6A,7C),(1B,2E,3D,4C,5B,6B,7A),(1B,2E,3D,4C,5B,6B,7B),
 (1B,2E,3D,4C,5B,6B,7C),(1B,2E,3D,4C,5B,6C,7A),(1B,2E,3D,4 C,5B,6C,7B),(1B,2E,3D,4C,5B,6C,7C),(1B,2E,3D,
 4C,5B,6D,7A),(1B,2E,3D,4C,5B,6D,7B),(1B,2E,3D,4C,5B,6D,7C),(1B,2E,3D,4D,5A,6A,7A),(1B,2E,3D,4D,5A,6A,
 7B),(1B,2E,3D,4 D,5A,6A,7C),(1B,2E,3D,4D,5A,6B,7A),(1B,2E,3D,4D,5A,6B,7B),(1B,2E,3D,4D,5A,6B,7C),(1B,2E,
 35 3D,4D,5A,6C,7A),(1B,2E,3D,4D,5A,6C,7B),(1B,2E,3D,4D,5A,6C,7C),(1B,2E,3D,4 D,5A,6D,7A),(1B,2E,3D,4D,5A,
 6D,7B),(1B,2E,3D,4D,5A,6D,7C),(1B,2E,3D,4D,5B,6A,7A),(1B,2E,3D,4D,5B,6A,7B),(1B,2E,3D,4D,5B,6A,7C),(1B,
 2E,3D,4D,5B,6B,7A),(1B,2E,3D,4 D,5B,6B,7B),(1B,2E,3D,4D,5B,6B,7C),(1B,2E,3D,4D,5B,6C,7A),(1B,2E,3D,4D,
 5B,6C,7B),(1B,2E,3D,4D,5B,6C,7C),(1B,2E,3D,4D,5B,6D,7A),(1B,2E,3D,4D,5B,6D,7B),(1B,2E,3D,4 D,5B,6D,7C),
 (1B,2E,3D,4E,5A,6A,7A),(1B,2E,3D,4E,5A,6A,7B),(1B,2E,3D,4E,5A,6A,7C),(1B,2E,3D,4E,5A,6B,7A),(1B,2E,3D,
 40 4E,5A,6B,7B),(1B,2E,3D,4E,5A,6B,7C),(1B,2E,3D,4 E,5A,6C,7A),(1B,2E,3D,4E,5A,6C,7B),(1B,2E,3D,4E,5A,6C,
 7C),(1B,2E,3D,4E,5A,6D,7A),(1B,2E,3D,4E,5A,6D,7B),(1B,2E,3D,4E,5A,6D,7C),(1B,2E,3D,4E,5B,6A,7A),(1B,2E,
 3D,4 E,5B,6A,7B),(1B,2E,3D,4E,5B,6A,7C),(1B,2E,3D,4E,5B,6B,7A),(1B,2E,3D,4E,5B,6B,7B),(1B,2E,3D,4E,5B,
 6B,7C),(1B,2E,3D,4E,5B,6C,7A),(1B,2E,3D,4E,5B,6C,7B),(1B,2E,3D,4 E,5B,6C,7C),(1B,2E,3D,4E,5B,6D,7A),(1B,
 2E,3D,4E,5B,6D,7B),(1B,2E,3D,4E,5B,6D,7C),(1B,2E,3E,4A,5A,6A,7A),(1B,2E,3E,4A,5A,6A,7B),(1B,2E,3E,4A,5A,
 45 6A,7C),(1B,2E,3E,4 A,5A,6B,7A),(1B,2E,3E,4A,5A,6B,7B),(1B,2E,3E,4A,5A,6B,7C),(1B,2E,3E,4A,5A,6C,7A),(1B,
 2E,3E,4A,5A,6C,7B),(1B,2E,3E,4A,5A,6C,7C),(1B,2E,3E,4A,5A,6D,7A),(1B,2E,3E,4 A,5A,6D,7B),(1B,2E,3E,4A,5A,
 6D,7C),(1B,2E,3E,4A,5B,6A,7A),(1B,2E,3E,4A,5B,6A,7B),(1B,2E,3E,4A,5B,6A,7C),(1B,2E,3E,4A,5B,6B,7A),(1B,
 2E,3E,4A,5B,6B,7B),(1B,2E,3E,4 A,5B,6B,7C),(1B,2E,3E,4A,5B,6C,7A),(1B,2E,3E,4A,5B,6C,7B),(1B,2E,3E,4A,5B,
 6C,7C),(1B,2E,3E,4A,5B,6D,7A),(1B,2E,3E,4A,5B,6D,7B),(1B,2E,3E,4A,5B,6D,7C),(1B,2E,3E,4 B,5A,6A,7A),(1B,
 50 2E,3E,4B,5A,6A,7B),(1B,2E,3E,4B,5A,6A,7C),(1B,2E,3E,4B,5A,6B,7A),(1B,2E,3E,4B,5A,6B,7B),(1B,2E,3E,4B,5A,
 6B,7C),(1B,2E,3E,4B,5A,6C,7A),(1B,2E,3E,4 B,5A,6C,7B),(1B,2E,3E,4B,5A,6C,7C),(1B,2E,3E,4B,5A,6D,7A),(1B,
 2E,3E,4B,5A,6D,7B),(1B,2E,3E,4B,5A,6D,7C),(1B,2E,3E,4B,5B,6A,7A),(1B,2E,3E,4B,5B,6A,7B),(1B,2E,3E,4 B,5B,
 6A,7C),(1B,2E,3E,4B,5B,6B,7A),(1B,2E,3E,4B,5B,6B,7B),(1B,2E,3E,4B,5B,6B,7C),(1B,2E,3E,4B,5B,6C,7A),(1B,
 2E,3E,4B,5B,6C,7B),(1B,2E,3E,4B,5B,6C,7C),(1B,2E,3E,4 B,5B,6D,7A),(1B,2E,3E,4B,5B,6D,7B),(1B,2E,3E,4B,5B,
 55 6D,7C),(1B,2E,3E,4C,5A,6A,7A),(1B,2E,3E,4C,5A,6A,7B),(1B,2E,3E,4C,5A,6A,7C),(1B,2E,3E,4C,5A,6B,7A),(1B,
 2E,3E,4 C,5A,6B,7B),(1B,2E,3E,4C,5A,6B,7C),(1B,2E,3E,4C,5A,6C,7A),(1B,2E,3E,4C,5A,6C,7B),(1B,2E,3E,4C,
 5A,6C,7C),(1B,2E,3E,4C,5A,6D,7A),(1B,2E,3E,4C,5A,6D,7B),(1B,2E,3E,4 C,5A,6D,7C),(1B,2E,3E,4C,5B,6A,7A),
 (1B,2E,3E,4C,5B,6A,7B),(1B,2E,3E,4C,5B,6A,7C),(1B,2E,3E,4C,5B,6B,7A),(1B,2E,3E,4C,5B,6B,7B),(1B,2E,3E,

4C,5B,6B,7C),(1B,2E,3E,4 C,5B,6C,7A),(1B,2E,3E,4C,5B,6C,7B),(1B,2E,3E,4C,5B,6C,7C),(1B,2E,3E,4C,5B,6D,7A),
7A),(1B,2E,3E,4C,5B,6D,7B),(1B,2E,3E,4C,5B,6D,7C),(1B,2E,3E,4D,5A,6A,7A),(1B,2E,3E,4 D,5A,6A,7B),(1B,2E,
3E,4D,5A,6A,7C),(1B,2E,3E,4D,5A,6B,7A),(1B,2E,3E,4D,5A,6B,7B), (1B,2E,3E,4D,5A,6B,7C),(1B,2E,3E,4D,5A,
6C,7A),(1B,2E,3E,4D,5A,6C,7B),(1B,2E,3E,4 D,5A,6C,7C),(1B,2E,3E,4D,5A,6D,7A),(1B,2E,3E,4D,5A,6D,7B),(1B,
5 2E,3E,4D,5A,6D,7C), (1B,2E,3E,4D,5B,6A,7A),(1B,2E,3E,4D,5B,6A,7B),(1B,2E,3E,4D,5B,6A,7C),(1B,2E,3E,4 D,
5B,6B,7A),(1B,2E,3E,4D,5B,6B,7B),(1B,2E,3E,4D,5B,6B,7C),(1B,2E,3E,4D,5B,6C,7A), (1B,2E,3E,4D,5B,6C,7B),
(1B,2E,3E,4D,5B,6C,7C),(1B,2E,3E,4D,5B,6D,7A),(1B,2E,3E,4 D,5B,6D,7B),(1B,2E,3E,4D,5B,6D,7C),(1B,2E,3E,
4E,5A,6A,7A),(1B,2E,3E,4E,5A,6A,7B),(1B,2E,3E,4E,5A,6A,7C),(1B,2E,3E,4E,5A,6B,7A),(1B,2E,3E,4E,5A,6B,7B),
(1B,2E,3E,4 E,5A,6B,7C),(1B,2E,3E,4E,5A,6C,7A),(1B,2E,3E,4E,5A,6C,7B),(1B,2E,3E,4E,5A,6C,7C),(1B,2E,3E,
10 4E,5A,6D,7A),(1B,2E,3E,4E,5A,6D,7B),(1B,2E,3E,4E,5A,6D,7C),(1B,2E,3E,4 E,5B,6A,7A),(1B,2E,3E,4E,5B,6A,7B),
7B),(1B,2E,3E,4E,5B,6A,7C),(1B,2E,3E,4E,5B,6B,7A), (1B,2E,3E,4E,5B,6B,7B),(1B,2E,3E,4E,5B,6B,7C),(1B,2E,
3E,4E,5B,6C,7A),(1B,2E,3E,4 E,5B,6C,7B),(1B,2E,3E,4E,5B,6C,7C),(1B,2E,3E,4E,5B,6D,7A),(1B,2E,3E,4E,5B,6D,
7B), (1B,2E,3E,4E,5B,6D,7C),(1C,2A,3A,4A,5A,6A,7A),(1C,2A,3A,4A,5A,6A,7B),(1C,2A,3A,4 A,5A,6A,7C),(1C,2A,
3A,4A,5A,6B,7A),(1C,2A,3A,4A,5A,6B,7B),(1C,2A,3A,4A,5A,6B,7C), (1C,2A,3A,4A,5A,6C,7A),(1C,2A,3A,4A,5A,6C,
15 7B),(1C,2A,3A,4A,5A,6C,7C),(1C,2A,3A,4 A,5A,6D,7A),(1C,2A,3A,4A,5A,6D,7B),(1C,2A,3A,4A,5A,6D,7C),(1C,2A,
3A,4A,5B,6A,7A), (1C,2A,3A,4A,5B,6A,7B),(1C,2A,3A,4A,5B,6A,7C),(1C,2A,3A,4A,5B,6B,7A),(1C,2A,3A,4 A,5B,
6B,7B),(1C,2A,3A,4A,5B,6B,7C),(1C,2A,3A,4A,5B,6C,7A),(1C,2A,3A,4A,5B,6C,7B), (1C,2A,3A,4A,5B,6C,7C),(1C,
2A,3A,4A,5B,6D,7A),(1C,2A,3A,4A,5B,6D,7B),(1C,2A,3A,4 A,5B,6D,7C),(1C,2A,3A,4B,5A,6A,7A),(1C,2A,3A,4B,
20 5A,6A,7B),(1C,2A,3A,4B,5A,6A,7C), (1C,2A,3A,4B,5A,6B,7A),(1C,2A,3A,4B,5A,6B,7B),(1C,2A,3A,4B,5A,6B,7C),
(1C,2A,3A,4 B,5A,6C,7A),(1C,2A,3A,4B,5A,6C,7B),(1C,2A,3A,4B,5A,6C,7C),(1C,2A,3A,4B,5A,6D,7A),(1C,2A,3A,
4B,5A,6D,7B),(1C,2A,3A,4B,5A,6D,7C),(1C,2A,3A,4B,5B,6A,7A),(1C,2A,3A,4 B,5B,6A,7B),(1C,2A,3A,4B,5B,6A,
7C),(1C,2A,3A,4B,5B,6B,7A),(1C,2A,3A,4B,5B,6B,7B), (1C,2A,3A,4B,5B,6B,7C),(1C,2A,3A,4B,5B,6C,7A),(1C,2A,
3A,4B,5B,6C,7B),(1C,2A,3A,4 B,5B,6C,7C),(1C,2A,3A,4B,5B,6D,7A),(1C,2A,3A,4B,5B,6D,7B),(1C,2A,3A,4B,5B,
25 6D,7C), (1C,2A,3A,4C,5A,6A,7A),(1C,2A,3A,4C,5A,6A,7B),(1C,2A,3A,4C,5A,6A,7C),(1C,2A,3A,4 C,5A,6B,7A),(1C,
2A,3A,4C,5A,6B,7B),(1C,2A,3A,4C,5A,6B,7C),(1C,2A,3A,4C,5A,6C,7A), (1C,2A,3A,4C,5A,6C,7B),(1C,2A,3A,4C,
5A,6C,7C),(1C,2A,3A,4C,5A,6D,7A),(1C,2A,3A,4 C,5A,6D,7B),(1C,2A,3A,4C,5A,6D,7C),(1C,2A,3A,4C,5B,6A,7A),
(1C,2A,3A,4C,5B,6A,7B), (1C,2A,3A,4C,5B,6A,7C),(1C,2A,3A,4C,5B,6B,7A),(1C,2A,3A,4C,5B,6B,7B),(1C,2A,3A,4
C,5B,6B,7C),(1C,2A,3A,4C,5B,6C,7A),(1C,2A,3A,4C,5B,6C,7B),(1C,2A,3A,4C,5B,6C,7C), (1C,2A,3A,4C,5B,6D,
30 7A),(1C,2A,3A,4C,5B,6D,7B),(1C,2A,3A,4C,5B,6D,7C),(1C,2A,3A,4 D,5A,6A,7A),(1C,2A,3A,4D,5A,6A,7B),(1C,2A,
3A,4D,5A,6A,7C),(1C,2A,3A,4D,5A,6B,7A), (1C,2A,3A,4D,5A,6B,7B),(1C,2A,3A,4D,5A,6B,7C),(1C,2A,3A,4D,5A,
6C,7A),(1C,2A,3A,4 D,5A,6C,7B),(1C,2A,3A,4D,5A,6C,7C),(1C,2A,3A,4D,5A,6D,7A),(1C,2A,3A,4D,5A,6D,7B), (1C,
2A,3A,4D,5A,6D,7C),(1C,2A,3A,4D,5B,6A,7A),(1C,2A,3A,4D,5B,6A,7B),(1C,2A,3A,4 D,5B,6A,7C),(1C,2A,3A,4D,
5B,6B,7A),(1C,2A,3A,4D,5B,6B,7B),(1C,2A,3A,4D,5B,6B,7C), (1C,2A,3A,4D,5B,6C,7A),(1C,2A,3A,4D,5B,6C,7B),
(1C,2A,3A,4D,5B,6C,7C),(1C,2A,3A,4 D,5B,6D,7A),(1C,2A,3A,4D,5B,6D,7B),(1C,2A,3A,4D,5B,6D,7C),(1C,2A,3A,
35 4E,5A,6A,7A), (1C,2A,3A,4E,5A,6A,7B),(1C,2A,3A,4E,5A,6A,7C),(1C,2A,3A,4E,5A,6B,7A),(1C,2A,3A,4 E,5A,6B,
7B),(1C,2A,3A,4E,5A,6B,7C),(1C,2A,3A,4E,5A,6C,7A),(1C,2A,3A,4E,5A,6C,7B), (1C,2A,3A,4E,5A,6C,7C),(1C,2A,
3A,4E,5A,6D,7A),(1C,2A,3A,4E,5A,6D,7B),(1C,2A,3A,4 E,5A,6D,7C),(1C,2A,3A,4E,5B,6A,7A),(1C,2A,3A,4E,5B,
6A,7B),(1C,2A,3A,4E,5B,6A,7C), (1C,2A,3A,4E,5B,6B,7A),(1C,2A,3A,4E,5B,6B,7B),(1C,2A,3A,4E,5B,6B,7C),(1C,
2A,3A,4 E,5B,6C,7A),(1C,2A,3A,4E,5B,6C,7B),(1C,2A,3A,4E,5B,6C,7C),(1C,2A,3A,4E,5B,6D,7A),(1C,2A,3A,4E,
40 5B,6D,7B),(1C,2A,3A,4E,5B,6D,7C),(1C,2A,3B,4A,5A,6A,7A),(1C,2A,3B,4 A,5A,6A,7B),(1C,2A,3B,4A,5A,6A,7C),
(1C,2A,3B,4A,5A,6B,7A),(1C,2A,3B,4A,5A,6B,7B), (1C,2A,3B,4A,5A,6B,7C),(1C,2A,3B,4A,5A,6C,7A),(1C,2A,3B,
4A,5A,6C,7B),(1C,2A,3B,4 A,5A,6C,7C),(1C,2A,3B,4A,5A,6D,7A),(1C,2A,3B,4A,5A,6D,7B),(1C,2A,3B,4A,5A,6D,
7C), (1C,2A,3B,4A,5B,6A,7A),(1C,2A,

6D,7B),(1C,2A,3B,4D,5A,6D,7C),(1C,2A,3B,4D,5B,6A,7A),(1C,2A,3B,4 D,5B,6A,7B),(1C,2A,3B,4D,5B,6A,7C),(1C,
2A,3B,4D,5B,6B,7A),(1C,2A,3B,4D,5B,6B,7B), (1C,2A,3B,4D,5B,6B,7C),(1C,2A,3B,4D,5B,6C,7A),(1C,2A,3B,4D,
5B,6C,7B),(1C,2A,3B,4 D,5B,6C,7C),(1C,2A,3B,4D,5B,6D,7A),(1C,2A,3B,4D,5B,6D,7B),(1C,2A,3B,4D,5B,6D,7C),
(1C,2A,3B,4E,5A,6A,7A),(1C,2A,3B,4E,5A,6A,7B),(1C,2A,3B,4E,5A,6A,7C),(1C,2A,3B,4 E,5A,6B,7A),(1C,2A,3B,
5
4E,5A,6B,7B),(1C,2A,3B,4E,5A,6B,7C),(1C,2A,3B,4E,5A,6C,7A), (1C,2A,3B,4E,5A,6C,7B),(1C,2A,3B,4E,5A,6C,
7C),(1C,2A,3B,4E,5A,6D,7A),(1C,2A,3B,4 E,5A,6D,7B),(1C,2A,3B,4E,5A,6D,7C),(1C,2A,3B,4E,5B,6A,7A),(1C,2A,
3B,4E,5B,6A,7B), (1C,2A,3B,4E,5B,6A,7C),(1C,2A,3B,4E,5B,6B,7A),(1C,2A,3B,4E,5B,6B,7B),(1C,2A,3B,4 E,5B,
6B,7C),(1C,2A,3B,4E,5B,6C,7A),(1C,2A,3B,4E,5B,6C,7B),(1C,2A,3B,4E,5B,6C,7C),(1C,2A,3B,4E,5B,6D,7A),(1C,
2A,3B,4E,5B,6D,7B),(1C,2A,3B,4E,5B,6D,7C),(1C,2A,3C,4 A,5A,6A,7A),(1C,2A,3C,4A,5A,6A,7B),(1C,2A,3C,4A,
10
5A,6A,7C),(1C,2A,3C,4A,5A,6B,7A), (1C,2A,3C,4A,5A,6B,7B),(1C,2A,3C,4A,5A,6B,7C),(1C,2A,3C,4A,5A,6C,7A)
(1C,2A,3C,4 A,5A,6C,7B),(1C,2A,3C,4A,5A,6C,7C),(1C,2A,3C,4A,5A,6D,7A),(1C,2A,3C,4A,5A,6D,7B), (1C,2A,3C,
4A,5A,6D,7C),(1C,2A,3C,4A,5B,6A,7A),(1C,2A,3C,4A,5B,6A,7B),(1C,2A,3C,4 A,5B,6A,7C),(1C,2A,3C,4A,5B,6B,
7A),(1C,2A,3C,4A,5B,6B,7B),(1C,2A,3C,4A,5B,6B,7C), (1C,2A,3C,4A,5B,6C,7A),(1C,2A,3C,4A,5B,6C,7B),(1C,2A,
3C,4A,5B,6C,7C),(1C,2A,3C,4 A,5B,6D,7A),(1C,2A,3C,4A,5B,6D,7B),(1C,2A,3C,4A,5B,6D,7C),(1C,2A,3C,4B,5A,
15
6A,7A), (1C,2A,3C,4B,5A,6A,7B),(1C,2A,3C,4B,5A,6A,7C),(1C,2A,3C,4B,5A,6B,7A),(1C,2A,3C,4 B,5A,6B,7B),(1C,
2A,3C,4B,5A,6B,7C),(1C,2A,3C,4B,5A,6C,7A),(1C,2A,3C,4B,5A,6C,7B), (1C,2A,3C,4B,5A,6C,7C),(1C,2A,3C,4B,
5A,6D,7A),(1C,2A,3C,4B,5A,6D,7B),(1C,2A,3C,4 B,5A,6D,7C),(1C,2A,3C,4B,5B,6A,7A),(1C,2A,3C,4B,5B,6A,7B),
(1C,2A,3C,4B,5B,6A,7C), (1C,2A,3C,4B,5B,6B,7A),(1C,2A,3C,4B,5B,6B,7B),(1C,2A,3C,4B,5B,6B,7C),(1C,2A,3C,4
B,5B,6C,7A),(1C,2A,3C,4B,5B,6C,7B),(1C,2A,3C,4B,5B,6C,7C),(1C,2A,3C,4B,5B,6D,7A),(1C,2A,3C,4B,5B,6D,
20
7B),(1C,2A,3C,4B,5B,6D,7C),(1C,2A,3C,4C,5A,6A,7A),(1C,2A,3C,4 C,5A,6A,7B),(1C,2A,3C,4C,5A,6A,7C),(1C,2A,
3C,4C,5A,6B,7A),(1C,2A,3C,4C,5A,6B,7B), (1C,2A,3C,4C,5A,6B,7C),(1C,2A,3C,4C,5A,6C,7A),(1C,2A,3C,4C,5A,
6C,7B),(1C,2A,3C,4 C,5A,6C,7C),(1C,2A,3C,4C,5A,6D,7A),(1C,2A,3C,4C,5A,6D,7B),(1C,2A,3C,4C,5A,6D,7C), (1C,
2A,3C,4C,5B,6A,7A),(1C,2A,3C,4C,5B,6A,7B),(1C,2A,3C,4C,5B,6A,7C),(1C,2A,3C,4 C,5B,6B,7A),(1C,2A,3C,4C,
5B,6B,7B),(1C,2A,3C,4C,5B,6B,7C),(1C,2A,3C,4C,5B,6C,7A), (1C,2A,3C,4C,5B,6C,7B),(1C,2A,3C,4C,5B,6C,7C),
25
(1C,2A,3C,4C,5B,6D,7A),(1C,2A,3C,4 C,5B,6D,7B),(1C,2A,3C,4C,5B,6D,7C),(1C,2A,3C,4D,5A,6A,7A),(1C,2A,3C,
4D,5A,6A,7B), (1C,2A,3C,4D,5A,6A,7C),(1C,2A,3C,4D,5A,6B,7A),(1C,2A,3C,4D,5A,6B,7B),(1C,2A,3C,4 D,5A,6B,
7C),(1C,2A,3C,4D,5A,6C,7A),(1C,2A,3C,4D,5A,6C,7B),(1C,2A,3C,4D,5A,6C,7C),(1C,2A,3C,4D,5A,6D,7A),(1C,2A,
3C,4D,5A,6D,7B),(1C,2A,3C,4D,5A,6D,7C),(1C,2A,3C,4 D,5B,6A,7A),(1C,2A,3C,4D,5B,6A,7B),(1C,2A,3C,4D,5B,
30
6A,7C),(1C,2A,3C,4D,5B,6B,7A), (1C,2A,3C,4D,5B,6B,7B),(1C,2A,3C,4D,5B,6B,7C),(1C,2A,3C,4D,5B,6C,7A),(1C,
2A,3C,4 D,5B,6C,7B),(1C,2A,3C,4D,5B,6C,7C),(1C,2A,3C,4D,5B,6D,7A),(1C,2A,3C,4D,5B,6D,7B), (1C,2A,3C,4D,
5B,6D,7C),(1C,2A,3C,4E,5A,6A,7A),(1C,2A,3C,4E,5A,6A,7B),(1C,2A,3C,4 E,5A,6A,7C),(1C,2A,3C,4E,5A,6B,7A),
(1C,2A,3C,4E,5A,6B,7B),(1C,2A,3C,4E,5A,6B,7C), (1C,2A,3C,4E,5A,6C,7A),(1C,2A,3C,4E,5A,6C,7B),(1C,2A,3C,
4E,5A,6C,7C),(1C,2A,3C,4 E,5A,6D,7A),(1C,2A,3C,4E,5A,6D,7B),(1C,2A,3C,4E,5A,6D,7C),(1C,2A,3C,4E,5B,6A,
7A), (1C,2A,3C,4E,5B,6A,7B),(1C,2A,3C,4E,5B,6A,7C),(1C,2A,3C,4E,5B,6B,7A),(1C,2A,3C,4 E,5B,6B,7B),(1C,2A,
35
3C,4E,5B,6B,7C),(1C,2A,3C,4E,5B,6C,7A),(1C,2A,3C,4E,5B,6C,7B), (1C,2A,3C,4E,5B,6C,7C),(1C,2A,3C,4E,5B,
6D,7A),(1C,2A,3C,4E,5B,6D,7B),(1C,2A,3C,4 E,5B,6D,7C),(1C,2A,3D,4A,5A,6A,7A),(1C,2A,3D,4A,5A,6A,7B),(1C,
2A,3D,4A,5A,6A,7C), (1C,2A,3D,4A,5A,6B,7A),(1C,2A,3D,4A,5A,6B,7B),(1C,2A,3D,4A,5A,6B,7C),(1C,2A,3D,4 A,
5A,6C,7A),(1C,2A,3D,4A,5A,6C,7B),(1C,2A,3D,4A,5A,6C,7C),(1C,2A,3D,4A,5A,6D,7A),(1C,2A,3D,4A,5A,6D,7B),
(1C,2A,3D,4A,5A,6D,7C),(1C,2A,3D,4A,5B,6A,7A),(1C,2A,3D,4 A,5B,6A,7B),(1C,2A,3D,4A,5B,6A,7C),(1C,2A,3D,
40
4A,5B,6B,7A),(1C,2A,3D,4A,5B,6B,7B), (1C,2A,3D,4A,5B,6B,7C),(1C,2A,3D,4A,5B,6C,7A),(1C,2A,3D,4A,5B,6C,
7B),(1C,2A,3D,4 A,5B,6C,7C),(1C,2A,3D,4A,5B,6D,7A),(1C,2A,3D,4A,5B,6D,7B),(1C,2A,3D,4A,5B,6D,7C), (1C,2A,
3D,4B,5A,6A,7A),(1C,2A,3D,4B,5A,6A,7B),(1C,2A,3D,4B,5A,6A,7C),(1C,2A,3D,4 B,5A,6B,7A),(1C,2A,3D,4B,5A,
6

5A,6B,7A),(1C,2A,3D,4E,5A,6B,7B), (1C,2A,3D,4E,5A,6B,7C),(1C,2A,3D,4E,5A,6C,7A),(1C,2A,3D,4E,5A,6C,7B),
 (1C,2A,3D,4 E,5A,6C,7C),(1C,2A,3D,4E,5A,6D,7A),(1C,2A,3D,4E,5A,6D,7B),(1C,2A,3D,4E,5A,6D,7C), (1C,2A,3D,
 4E,5B,6A,7A),(1C,2A,3D,4E,5B,6A,7B),(1C,2A,3D,4E,5B,6A,7C),(1C,2A,3D,4 E,5B,6B,7A),(1C,2A,3D,4E,5B,6B,
 7B),(1C,2A,3D,4E,5B,6B,7C),(1C,2A,3D,4E,5B,6C,7A), (1C,2A,3D,4E,5B,6C,7B),(1C,2A,3D,4E,5B,6C,7C),(1C,2A,
 5 3D,4E,5B,6D,7A),(1C,2A,3D,4 E,5B,6D,7B),(1C,2A,3D,4E,5B,6D,7C),(1C,2A,3E,4A,5A,6A,7A),(1C,2A,3E,4A,5A,
 6A,7B), (1C,2A,3E,4A,5A,6A,7C),(1C,2A,3E,4A,5A,6B,7A),(1C,2A,3E,4A,5A,6B,7B),(1C,2A,3E,4 A,5A,6B,7C),(1C,
 2A,3E,4A,5A,6C,7A),(1C,2A,3E,4A,5A,6C,7B),(1C,2A,3E,4A,5A,6C,7C), (1C,2A,3E,4A,5A,6D,7A),(1C,2A,3E,4A,
 5A,6D,7B),(1C,2A,3E,4A,5A,6D,7C),(1C,2A,3E,4 A,5B,6A,7A),(1C,2A,3E,4A,5B,6A,7B),(1C,2A,3E,4A,5B,6A,7C),
 (1C,2A,3E,4A,5B,6B,7A), (1C,2A,3E,4A,5B,6B,7B),(1C,2A,3E,4A,5B,6B,7C),(1C,2A,3E,4A,5B,6C,7A),(1C,2A,3E,4
 10 A,5B,6C,7B),(1C,2A,3E,4A,5B,6C,7C),(1C,2A,3E,4A,5B,6D,7A),(1C,2A,3E,4A,5B,6D,7B), (1C,2A,3E,4A,5B,6D,7C),
 (1C,2A,3E,4B,5A,6A,7A),(1C,2A,3E,4B,5A,6A,7B),(1C,2A,3E,4 B,5A,6A,7C),(1C,2A,3E,4B,5A,6B,7A),(1C,2A,3E,
 4B,5A,6B,7B),(1C,2A,3E,4B,5A,6B,7C), (1C,2A,3E,4B,5A,6C,7A),(1C,2A,3E,4B,5A,6C,7B),(1C,2A,3E,4B,5A,6C,
 7C),(1C,2A,3E,4 B,5A,6D,7A),(1C,2A,3E,4B,5A,6D,7B),(1C,2A,3E,4B,5A,6D,7C),(1C,2A,3E,4B,5B,6A,7A), (1C,2A,
 3E,4B,5B,6A,7B),(1C,2A,3E,4B,5B,6A,7C),(1C,2A,3E,4B,5B,6B,7A),(1C,2A,3E,4 B,5B,6B,7B),(1C,2A,3E,4B,5B,6B,
 15 7C),(1C,2A,3E,4B,5B,6C,7A),(1C,2A,3E,4B,5B,6C,7B), (1C,2A,3E,4B,5B,6C,7C),(1C,2A,3E,4B,5B,6D,7A),(1C,2A,
 3E,4B,5B,6D,7B),(1C,2A,3E,4 B,5B,6D,7C),(1C,2A,3E,4C,5A,6A,7A),(1C,2A,3E,4C,5A,6A,7B),(1C,2A,3E,4C,5A,
 6A,7C), (1C,2A,3E,4C,5A,6B,7A),(1C,2A,3E,4C,5A,6B,7B),(1C,2A,3E,4C,5A,6B,7C),(1C,2A,3E,4 C,5A,6C,7A),(1C,
 2A,3E,4C,5A,6C,7B),(1C,2A,3E,4C,5A,6C,7C),(1C,2A,3E,4C,5A,6D,7A), (1C,2A,3E,4C,5A,6D,7B),(1C,2A,3E,4C,
 5A,6D,7C),(1C,2A,3E,4C,5B,6A,7A),(1C,2A,3E,4 C,5B,6A,7B),(1C,2A,3E,4C,5B,6A,7C),(1C,2A,3E,4C,5B,6B,7A),
 20 (1C,2A,3E,4C,5B,6B,7B), (1C,2A,3E,4C,5B,6B,7C),(1C,2A,3E,4C,5B,6C,7A),(1C,2A,3E,4C,5B,6C,7B),(1C,2A,3E,4
 C,5B,6C,7C),(1C,2A,3E,4C,5B,6D,7A),(1C,2A,3E,4C,5B,6D,7B),(1C,2A,3E,4C,5B,6D,7C), (1C,2A,3E,4D,5A,6A,
 7A),(1C,2A,3E,4D,5A,6A,7B),(1C,2A,3E,4D,5A,6A,7C),(1C,2A,3E,4 D,5A,6B,7A),(1C,2A,3E,4D,5A,6B,7B),(1C,2A,
 3E,4D,5A,6B,7C),(1C,2A,3E,4D,5A,6C,7A), (1C,2A,3E,4D,5A,6C,7B),(1C,2A,3E,4D,5A,6C,7C),(1C,2A,3E,4D,5A,
 6D,7A),(1C,2A,3E,4 D,5A,6D,7B),(1C,2A,3E,4D,5A,6D,7C),(1C,2A,3E,4D,5B,6A,7A),(1C,2A,3E,4D,5B,6A,7B), (1C,
 25 2A,3E,4D,5B,6A,7C),(1C,2A,3E,4D,5B,6B,7A),(1C,2A,3E,4D,5B,6B,7B),(1C,2A,3E,4 D,5B,6B,7C),(1C,2A,3E,4D,
 5B,6C,7A),(1C,2A,3E,4D,5B,6C,7B),(1C,2A,3E,4D,5B,6C,7C), (1C,2A,3E,4D,5B,6D,7A),(1C,2A,3E,4D,5B,6D,7B),
 (1C,2A,3E,4D,5B,6D,7C),(1C,2A,3E,4 E,5A,6A,7A),(1C,2A,3E,4E,5A,6A,7B),(1C,2A,3E,4E,5A,6A,7C),(1C,2A,3E,
 4E,5A,6B,7A), (1C,2A,3E,4E,5A,6B,7B),(1C,2A,3E,4E,5A,6B,7C),(1C,2A,3E,4E,5A,6C,7A),(1C,2A,3E,4 E,5A,6C,
 7B),(1C,2A,3E,4E,5A,6C,7C),(1C,2A,3E,4E,5A,6D,7A),(1C,2A,3E,4E,5A,6D,7B), (1C,2A,3E,4E,5A,6D,7C),(1C,2A,
 30 3E,4E,5B,6A,7A),(1C,2A,3E,4E,5B,6A,7B),(1C,2A,3E,4 E,5B,6A,7C),(1C,2A,3E,4E,5B,6B,7A),(1C,2A,3E,4E,5B,6B,
 7B),(1C,2A,3E,4E,5B,6B,7C), (1C,2A,3E,4E,5B,6C,7A),(1C,2A,3E,4E,5B,6C,7B),(1C,2A,3E,4E,5B,6C,7C),(1C,2A,
 3E,4 E,5B,6D,7A),(1C,2A,3E,4E,5B,6D,7B),(1C,2A,3E,4E,5B,6D,7C),(1C,2B,3A,4A,5A,6A,7A), (1C,2B,3A,4A,5A,
 6A,7B),(1C,2B,3A,4A,5A,6A,7C),(1C,2B,3A,4A,5A,6B,7A),(1C,2B,3A,4 A,5A,6B,7B),(1C,2B,3A,4A,5A,6B,7C),(1C,
 2B,3A,4A,5A,6C,7A),(1C,2B,3A,4A,5A,6C,7B), (1C,2B,3A,4A,5A,6C,7C),(1C,2B,3A,4A,5A,6D,7A),(1C,2B,3A,4A,
 35 5A,6D,7B),(1C,2B,3A,4 A,5A,6D,7C),(1C,2B,3A,4A,5B,6A,7A),(1C,2B,3A,4A,5B,6A,7B),(1C,2B,3A,4A,5B,6A,7C),
 (1C,2B,3A,4A,5B,6B,7A),(1C,2B,3A,4A,5B,6B,7B),(1C,2B,3A,4A,5B,6B,7C),(1C,2B,3A,4 A,5B,6C,7A),(1C,2B,3A,
 4A,5B,6C,7B),(1C,2B,3A,4A,5B,6C,7C),(1C,2B,3A,4A,5B,6D,7A), (1C,2B,3A,4A,5B,6D,7B),(1C,2B,3A,4A,5B,6D,
 7C),(1C,2B,3A,4B,5A,6A,7A),(1C,2B,3A,4 B,5A,6A,7B),(1C,2B,3A,4B,5A,6A,7C),(1C,2B,3A,4B,5A,6B,7A),(1C,2B,
 3A,4B,5A,6B,7B), (1C,2B,3A,4B,5A,6B,7C),(1C,2B,3A,4B,5A,6C,7A),(1C,2B,3A,4B,5A,6C,7B),(1C,2B,3A,4 B,5A,
 40 6C,7C),(1C,2B,3A,4B,5A,6D,7A),(1C,2B,3A,4B,5A,6D,7B),(1C,2B,3A,4B,5A,6D,7C), (1C,2B,3A,4B,5B,6A,7A),(1C,
 2B,3A,4B,5B,6A,7B),(1C,2B,3A,4B,5B,6A,7C),(1C,2B,3A,4 B,5B,6B,7A),(1C,2B,3A,4B,5B,6B,7B),(1C,2B,3A,4B,5B,
 6B,7C),(1C,2B,3A,4B,5B,6C,7A), (1C,2B,3A,4B,5B,6C,7B),(1C,2B,3A,4B,5B,6C,7C),(1C,2B,3A,4B,5B,6D,7A),(1C,
 2B,3A,4 B,5B,6D,7B),(1C,2B,3A,4B,5B,6D,7C),(1C,2B,3A,4C,5A,6A,7A),(1C,2B,3A,4C,5A,6A,7B), (1C,2B,3A,4C,
 5A,6A,7C),(1C,2B,3A,4C,5A,6B,7A),(1C,2B,3A,4C,5A,6B,7B),(1C,2B,3A,4 C,5A,6B,7C),(1C,2B,3A,4C,5A,6C,7A),
 45 (1C,2B,3A,4C,5A,6C,7B),(1C,2B,3A,4C,5A,6C,7C), (1C,2B,3A,4C,5A,6D,7A),(1C,2B,3A,4C,5A,6D,7B),(1C,2B,3A,
 4C,5A,6D,7C),(1C,2B,3A,4 C,5B,6A,7A),(1C,2B,3A,4C,5B,6A,7B),(1C,2B,3A,4C,5B,6A,7C),(1C,2B,3A,4C,5B,6B,
 7A), (1C,2B,3A,4C,5B,6B,7B),(1C,2B,3A,4C,5B,6B,7C),(1C,2B,3A,4C,5B,6C,7A),(1C,2B,3A,4 C,5B,6C,7B),(1C,2B,
 3A,4C,5B,6C,7C),(1C,2B,3A,4C,5B,6D,7A),(1C,2B,3A,4C,5B,6D,7B), (1C,2B,3A,4C,5B,6D,7C),(1C,2B,3A,4D,5A,
 6A,7A),(1C,2B,3A,4D,5A,6A,7B),(1C,2B,3A,4 D,5A,6A,7C),(1C,2B,3A,4D,5A,6B,7A),(1C,2B,3A,4D,5A,6B,7B),(1C,
 50 2B,3A,4D,5A,6B,7C), (1C,2B,3A,4D,5A,6C,7A),(1C,2B,3A,4D,5A,6C,7B),(1C,2B,3A,4D,5A,6C,7C),(1C,2B,3A,4 D,
 5A,6D,7A),(1C,2B,3A,4D,5A,6D,7B),(1C,2B,3A,4D,5A,6D,7C),(1C,2B,3A,4D,5B,6A,7A), (1C,2B,3A,4D,5B,6A,7B),
 (1C,2B,3A,4D,5B,6A,7C),(1C,2B,3A,4D,5B,6B,7A),(1C,2B,3A,4 D,5B,6B,7B),(1C,2B,3A,4D,5B,6B,7C),(1C,2B,3A,
 4D,5B,6C,7A),(1C,2B,3A,4D,5B,6C,7B), (1C,2B,3A,4D,5B,6C,7C),(1C,2B,3A,4D,5B,6D,7A),(1C,2B,3A,4D,5B,6D,
 7B),(1C,2B,3A,4 D,5B,6D,7C),(1C,2B,3A,4E,5A,6A,7A),(1C,2B,3A,4E,5A,6A,7B),(1C,2B,3A,4E,5A,6A,7C), (1C,2B,
 55 3A,4E,5A,6B,7A),(1C,2B,3A,4E,5A,6B,7B),(1C,2B,3A,4E,5A,6B,7C),(1C,2B,3A,4 E,5A,6C,7A),(1C,2B,3A,4E,5A,6C,
 7B),(1C,2B,3A,4E,5A,6C,7C),(1C,2B,3A,4E,5A,6D,7A), (1C,2B,3A,4E,5A,6D,7B),(1C,2B,3A,4E,5A,6D,7C),(1C,2B,
 3A,4E,5B,6A,7A),(1C,2B,3A,4 E,5B,6A,7B),(1C,2B,3A,4E,5B,6A,7C),(1C,2B,3A,4E,5B,6B,7A),(1C,2B,3A,4E,5B,6B,
 7B), (1C,2B,3A,4E,5B,6B,7C),(1C,2B,3A,4E,5B,6C,7A),(1C,2B,3A,4E,5B,6C,7B),(1C,2B,3A,4 E,5B,6C,7C),(1C,2B,

3A,4E,5B,6D,7A),(1C,2B,3A,4E,5B,6D,7B),(1C,2B,3A,4E,5B,6D,7C), (1C,2B,3B,4A,5A,6A,7A),(1C,2B,3B,4A,5A,
 6A,7B),(1C,2B,3B,4A,5A,6A,7C),(1C,2B,3B,4 A,5A,6B,7A),(1C,2B,3B,4A,5A,6B,7B),(1C,2B,3B,4A,5A,6B,7C),(1C,
 2B,3B,4A,5A,6C,7A), (1C,2B,3B,4A,5A,6C,7B),(1C,2B,3B,4A,5A,6C,7C),(1C,2B,3B,4A,5A,6D,7A),(1C,2B,3B,4 A,
 5A,6D,7B),(1C,2B,3B,4A,5A,6D,7C),(1C,2B,3B,4A,5B,6A,7A),(1C,2B,3B,4A,5B,6A,7B), (1C,2B,3B,4A,5B,6A,7C),
 5 (1C,2B,3B,4A,5B,6B,7A),(1C,2B,3B,4A,5B,6B,7B),(1C,2B,3B,4 A,5B,6B,7C),(1C,2B,3B,4A,5B,6C,7A),(1C,2B,3B,
 4A,5B,6C,7B),(1C,2B,3B,4A,5B,6C,7C), (1C,2B,3B,4A,5B,6D,7A),(1C,2B,3B,4A,5B,6D,7B),(1C,2B,3B,4A,5B,6D,
 7C),(1C,2B,3B,4 B,5A,6A,7A),(1C,2B,3B,4B,5A,6A,7B),(1C,2B,3B,4B,5A,6A,7C),(1C,2B,3B,4B,5A,6B,7A), (1C,2B,
 3B,4B,5A,6B,7B),(1C,2B,3B,4B,5A,6B,7C),(1C,2B,3B,4B,5A,6C,7A),(1C,2B,3B,4 B,5A,6C,7B),(1C,2B,3B,4B,5A,
 6C,7C),(1C,2B,3B,4B,5A,6D,7A),(1C,2B,3B,4B,5A,6D,7B), (1C,2B,3B,4B,5A,6D,7C),(1C,2B,3B,4B,5B,6A,7A),(1C,
 10 2B,3B,4B,5B,6A,7B),(1C,2B,3B,4 B,5B,6A,7C),(1C,2B,3B,4B,5B,6B,7A),(1C,2B,3B,4B,5B,6B,7B),(1C,2B,3B,4B,5B,
 6B,7C), (1C,2B,3B,4B,5B,6C,7A),(1C,2B,3B,4B,5B,6C,7B),(1C,2B,3B,4B,5B,6C,7C),(1C,2B,3B,4 B,5B,6D,7A),(1C,
 2B,3B,4B,5B,6D,7B),(1C,2B,3B,4B,5B,6D,7C),(1C,2B,3B,4C,5A,6A,7A), (1C,2B,3B,4C,5A,6A,7B),(1C,2B,3B,4C,
 5A,6A,7C),(1C,2B,3B,4C,5A,6B,7A),(1C,2B,3B,4 C,5A,6B,7B),(1C,2B,3B,4C,5A,6B,7C),(1C,2B,3B,4C,5A,6C,7A),
 15 (1C,2B,3B,4C,5A,6C,7B), (1C,2B,3B,4C,5A,6C,7C),(1C,2B,3B,4C,5A,6D,7A),(1C,2B,3B,4C,5A,6D,7B),(1C,2B,3B,4
 C,5A,6D,7C),(1C,2B,3B,4C,5B,6A,7A),(1C,2B,3B,4C,5B,6A,7B),(1C,2B,3B,4C,5B,6A,7C), (1C,2B,3B,4C,5B,6B,
 7A),(1C,2B,3B,4C,5B,6B,7B),(1C,2B,3B,4C,5B,6B,7C),(1C,2B,3B,4 C,5B,6C,7A),(1C,2B,3B,4C,5B,6C,7B),(1C,2B,
 3B,4C,5B,6C,7C),(1C,2B,3B,4C,5B,6D,7A), (1C,2B,3B,4C,5B,6D,7B),(1C,2B,3B,4C,5B,6D,7C),(1C,2B,3B,4D,5A,6B,7B), (1C,
 6A,7A),(1C,2B,3B,4 D,5A,6A,7B),(1C,2B,3B,4D,5A,6A,7C),(1C,2B,3B,4D,5A,6B,7A),(1C,2B,3B,4D,5A,6B,7B), (1C,
 2B,3B,4D,5A,6B,7C),(1C,2B,3B,4D,5A,6C,7A),(1C,2B,3B,4D,5A,6C,7B),(1C,2B,3B,4 D,5A,6C,7C),(1C,2B,3B,4D,
 20 5A,6D,7A),(1C,2B,3B,4D,5A,6D,7B),(1C,2B,3B,4D,5A,6D,7C), (1C,2B,3B,4D,5B,6A,7A),(1C,2B,3B,4D,5B,6A,7B),
 (1C,2B,3B,4D,5B,6A,7C),(1C,2B,3B,4 D,5B,6B,7A),(1C,2B,3B,4D,5B,6B,7B),(1C,2B,3B,4D,5B,6B,7C),(1C,2B,3B,
 4D,5B,6C,7A), (1C,2B,3B,4D,5B,6C,7B),(1C,2B,3B,4D,5B,6C,7C),(1C,2B,3B,4D,5B,6D,7A),(1C,2B,3B,4 D,5B,6D,
 7B),(1C,2B,3B,4D,5B,6D,7C),(1C,2B,3B,4E,5A,6A,7A),(1C,2B,3B,4E,5A,6A,7B), (1C,2B,3B,4E,5A,6A,7C),(1C,2B,
 3B,4E,5A,6B,7A),(1C,2B,3B,4E,5A,6B,7B),(1C,2B,3B,4 E,5A,6B,7C),(1C,2B,3B,4E,5A,6C,7A),(1C,2B,3B,4E,5A,6C,
 25 7B),(1C,2B,3B,4E,5A,6C,7C), (1C,2B,3B,4E,5A,6D,7A),(1C,2B,3B,4E,5A,6D,7B),(1C,2B,3B,4E,5A,6D,7C),(1C,2B,
 3B,4 E,5B,6A,7A),(1C,2B,3B,4E,5B,6A,7B),(1C,2B,3B,4E,5B,6A,7C),(1C,2B,3B,4E,5B,6B,7A), (1C,2B,3B,4E,5B,
 6B,7B),(1C,2B,3B,4E,5B,6B,7C),(1C,2B,3B,4E,5B,6C,7A),(1C,2B,3B,4 E,5B,6C,7B),(1C,2B,3B,4E,5B,6C,7C),(1C,
 2B,3B,4E,5B,6D,7A),(1C,2B,3B,4E,5B,6D,7B), (1C,2B,3B,4E,5B,6D,7C),(1C,2B,3C,4A,5A,6A,7A),(1C,2B,3C,4A,
 5A,6A,7B),(1C,2B,3C,4 A,5A,6A,7C),(1C,2B,3C,4A,5A,6B,7A),(1C,2B,3C,4A,5A,6B,7B),(1C,2B,3C,4A,5A,6B,7C),
 30 (1C,2B,3C,4A,5A,6C,7A),(1C,2B,3C,4A,5A,6C,7B),(1C,2B,3C,4A,5A,6C,7C),(1C,2B,3C,4 A,5A,6D,7A),(1C,2B,3C,
 4A,5A,6D,7B),(1C,2B,3C,4A,5A,6D,7C),(1C,2B,3C,4A,5B,6A,7A), (1C,2B,3C,4A,5B,6A,7B),(1C,2B,3C,4A,5B,6A,
 7C),(1C,2B,3C,4A,5B,6B,7A),(1C,2B,3C,4 A,5B,6B,7B),(1C,2B,3C,4A,5B,6B,7C),(1C,2B,3C,4A,5B,6C,7A),(1C,2B,
 3C,4A,5B,6C,7B), (1C,2B,3C,4A,5B,6C,7C),(1C,2B,3C,4A,5B,6D,7A),(1C,2B,3C,4A,5B,6D,7B),(1C,2B,3C,4 A,5B,
 6D,7C),(1C,2B,3C,4B,5A,6A,7A),(1C,2B,3C,4B,5A,6A,7B),(1C,2B,3C,4B,5A,6A,7C), (1C,2B,3C,4B,5A,6B,7A),(1C,
 35 2B,3C,4B,5A,6B,7B),(1C,2B,3C,4B,5A,6B,7C),(1C,2B,3C,4 B,5A,6C,7A),(1C,2B,3C,4B,5A,6C,7B),(1C,2B,3C,4B,
 5A,6C,7C),(1C,2B,3C,4B,5A,6D,7A), (1C,2B,3C,4B,5A,6D,7B),(1C,2B,3C,4B,5A,6D,7C),(1C,2B,3C,4B,5B,6A,7A),
 (1C,2B,3C,4 B,5B,6A,7B),(1C,2B,3C,4B,5B,6A,7C),(1C,2B,3C,4B,5B,6B,7A),(1C,2B,3C,4B,5B,6B,7B), (1C,2B,3C,
 4B,5B,6B,7C),(1C,2B,3C,4B,5B,6C,7A),(1C,2B,3C,4B,5B,6C,7B),(1C,2B,3C,4 B,5B,6C,7C),(1C,2B,3C,4B,5B,6D,
 7A),(1C,2B,3C,4B,5B,6D,7B),(1C,2B,3C,4B,5B,6D,7C), (1C,2B,3C,4C,5A,6A,7A),(1C,2B,3C,4C,5A,6A,7B),(1C,2B,
 40 3C,4C,5A,6A,7C),(1C,2B,3C,4 C,5A,6B,7A),(1C,2B,3C,4C,5A,6B,7B),(1C,2B,3C,4C,5A,6B,7C),(1C,2B,3C,4C,5A,
 6C,7A), (1C,2B,3C,4C,5A,6C,7B),(1C,2B,3C,4C,5A,6C,7C),(1C,2B,3C,4C,5A,6D,7A),(1C,2B,3C,4 C,5A,6D,7B),(1C,
 2B,3C,4C,5A,6D,7C),(1C,2B,3C,4C,5B,6A,7A),(1C,2B,3C,4C,5B,6A,7B), (1C,2B,3C,4C,5B,6A,7C),(1C,2B,3C,4C,
 5B,6B,7A),(1C,2B,3C,4C,5B,6B,7B),(1C,2B,3C,4 C,5B,6B,7C),(1C,2B,3C,4C,5B,6C,7A),(1C,2B,3C,4C,5B,6C,7B),
 45 (1C,2B,3C,4C,5B,6C,7C), (1C,2B,3C,4C,5B,6D,7A),(1C,2B,3C,4C,5B,6D,7B),(1C,2B,3C,4C,5B,6D,7C),(1C,2B,3C,
 4 D,5A,6A,7A),(1C,2B,3C,4D,5A,6A,7B),(1C,2B,3C,4D,5A,6A,7C),(1C,2B,3C,4D,5A,6B,7A), (1C,2B,3C,4D,5A,6B,
 7B),(1C,2B,3C,4D,5A,6B,7C),(1C,2B,3C,4D,5A,6C,7A),(1C,2B,3C,4 D,5A,6C,7B),(1C,2B,3C,4D,5A,6C,7C),(1C,2B,
 3C,4D,5A,6D,7A),(1C,2B,3C,4D,5A,6D,7B), (1C,2B,3C,4D,5A,6D,7C),(1C,2B,3C,4D,5B,6A,7A),(1C,2B,3C,4D,5B,
 6A,7B),(1C,2B,3C,4 D,5B,6A,7C),(1C,2B,3C,4D,5B,6B,7A),(1C,2B,3C,4D,5B,6B,7B),(1C,2B,3C,4D,5B,6B,7C), (1C,
 2B,3C,4D,5B,6C,7A),(1C,2B,3C,4D,5B,6C,7B),(1C,2B,3C,4D,5B,6C,7C),(1C,2B,3C,4 D,5B,6D,7A),(1C,2B,3C,4D,
 50 5B,6D,7B),(1C,2B,3C,4D,5B,6D,7C),(1C,2B,3C,4E,5A,6A,7A), (1C,2B,3C,4E,5A,6A,7B),(1C,2B,3C,4E,5A,6A,7C),
 (1C,2B,3C,4E,5A,6B,7A),(1C,2B,3C,4 E,5A,6B,7B),(1C,2B,3C,4E,5A,6B,7C),(1C,2B,3C,4E,5A,6C,7A),(1C,2B,3C,
 4E,5A,6C,7B), (1C,2B,3C,4E,5A,6C,7C),(1C,2B,3C,4E,5A,6D,7A),(1C,2B,3C,4E,5A,6D,7B),(1C,2B,3C,4 E,5A,6D,
 7C),(1C,2B,3C,4E,5B,6A,7A),(1C,2B,3C,4E,5B,6A,7B),(1C,2B,3C,4E,5B,6A,7C), (1C,2B,3C,4E,5B,6B,7A),(1C,2B,
 3C,4E,5B,6B,7B),(1C,2B,3C,4E,5B,6B,7C),(1C,2B,3C,4 E,5B,6C,7A),(1C,2B,3C,4E,5B,6C,7B),(1C,2B,3C,4E,5B,
 55 6C,7C),(1C,2B,3C,4E,5B,6D,7A), (1C,2B,3C,4E,5B,6D,7B),(1C,2B,3C,4E,5B,6D,7C),(1C,2B,3D,4A,5A,6A,7A),(1C,
 2B,3D,4 A,5A,6A,7B),(1C,2B,3D,4A,5A,6A,7C),(1C,2B,3D,4A,5A,6B,7A),(1C,2B,3D,4A,5A,6B,7B), (1C,2B,3D,4A,
 5A,6B,7C),(1C,2B,3D,4A,5A,6C,7A),(1C,2B,3D,4A,5A,6C,7B),(1C,2B,3D,4 A,5A,6C,7C),(1C,2B,3D,4A,5A,6D,7A),
 (1C,2B,3D,4A,5A,6D,7B),(1C,2B,3D,4A,5A,6D,7C), (1C,2B,3D,4A,5B,6A,7A),(1C,2B,3D,4A,5B,6A,7B),(1C,2B,3D,

270

6C,7B),(1C,2C,3A,4B,5A,6C,7C),(1C,2C,3A,4B,5A,6D,7A),(1C,2C,3A,4 B,5A,6D,7B),(1C,2C,3A,4B,5A,6D,7C),(1C,
 2C,3A,4B,5B,6A,7A),(1C,2C,3A,4B,5B,6A,7B), (1C,2C,3A,4B,5B,6A,7C),(1C,2C,3A,4B,5B,6B,7A),(1C,2C,3A,4B,
 5B,6B,7B),(1C,2C,3A,4 B,5B,6B,7C),(1C,2C,3A,4B,5B,6C,7A),(1C,2C,3A,4B,5B,6C,7B),(1C,2C,3A,4B,5B,6C,7C),
 (1C,2C,3A,4B,5B,6D,7A),(1C,2C,3A,4B,5B,6D,7B),(1C,2C,3A,4B,5B,6D,7C),(1C,2C,3A,4 C,5A,6A,7A),(1C,2C,3A,
 5 4C,5A,6A,7B),(1C,2C,3A,4C,5A,6A,7C),(1C,2C,3A,4C,5A,6B,7A), (1C,2C,3A,4C,5A,6B,7B),(1C,2C,3A,4C,5A,6B,
 7C),(1C,2C,3A,4C,5A,6C,7A),(1C,2C,3A,4 C,5A,6C,7B),(1C,2C,3A,4C,5A,6C,7C),(1C,2C,3A,4C,5A,6D,7A),(1C,2C,
 3A,4C,5A,6D,7B), (1C,2C,3A,4C,5A,6D,7C),(1C,2C,3A,4C,5B,6A,7A),(1C,2C,3A,4C,5B,6A,7B),(1C,2C,3A,4 C,5B,
 6A,7C),(1C,2C,3A,4C,5B,6B,7A),(1C,2C,3A,4C,5B,6B,7B),(1C,2C,3A,4C,5B,6B,7C), (1C,2C,3A,4C,5B,6C,7A),(1C,
 2C,3A,4C,5B,6C,7B),(1C,2C,3A,4C,5B,6C,7C),(1C,2C,3A,4 C,5B,6D,7A),(1C,2C,3A,4C,5B,6D,7B),(1C,2C,3A,4C,
 10 5B,6D,7C),(1C,2C,3A,4D,5A,6A,7A), (1C,2C,3A,4D,5A,6A,7B),(1C,2C,3A,4D,5A,6A,7C),(1C,2C,3A,4D,5A,6B,7A),
 (1C,2C,3A,4 D,5A,6B,7B),(1C,2C,3A,4D,5A,6B,7C),(1C,2C,3A,4D,5A,6C,7A),(1C,2C,3A,4D,5A,6C,7B), (1C,2C,3A,
 4D,5A,6C,7C),(1C,2C,3A,4D,5A,6D,7A),(1C,2C,3A,4D,5A,6D,7B),(1C,2C,3A,4 D,5A,6D,7C),(1C,2C,3A,4D,5B,6A,
 7A),(1C,2C,3A,4D,5B,6A,7B),(1C,2C,3A,4D,5B,6A,7C), (1C,2C,3A,4D,5B,6B,7A),(1C,2C,3A,4D,5B,6B,7B),(1C,2C,
 3A,4D,5B,6B,7C),(1C,2C,3A,4 D,5B,6C,7A),(1C,2C,3A,4D,5B,6C,7B),(1C,2C,3A,4D,5B,6C,7C),(1C,2C,3A,4D,5B,
 15 6D,7A), (1C,2C,3A,4D,5B,6D,7B),(1C,2C,3A,4D,5B,6D,7C),(1C,2C,3A,4E,5A,6A,7A),(1C,2C,3A,4 E,5A,6A,7B),(1C,
 2C,3A,4E,5A,6A,7C),(1C,2C,3A,4E,5A,6B,7A),(1C,2C,3A,4E,5A,6B,7B), (1C,2C,3A,4E,5A,6B,7C),(1C,2C,3A,4E,
 5A,6C,7A),(1C,2C,3A,4E,5A,6C,7B),(1C,2C,3A,4 E,5A,6C,7C),(1C,2C,3A,4E,5A,6D,7A),(1C,2C,3A,4E,5A,6D,7B),
 (1C,2C,3A,4E,5A,6D,7C), (1C,2C,3A,4E,5B,6A,7A),(1C,2C,3A,4E,5B,6A,7B),(1C,2C,3A,4E,5B,6A,7C),(1C,2C,3A,4,
 E,5B,6B,7A),(1C,2C,3A,4E,5B,6B,7B),(1C,2C,3A,4B,5B,6B,7C),(1C,2C,3A,4E,5B,6C,7A), (1C,2C,3A,4E,5B,6C,7B),
 20 (1C,2C,3A,4E,5B,6C,7C),(1C,2C,3A,4E,5B,6D,7A),(1C,2C,3A,4 E,5B,6D,7B),(1C,2C,3A,4E,5B,6D,7C),(1C,2C,3B,
 4A,5A,6A,7A),(1C,2C,3B,4A,5A,6A,7B), (1C,2C,3B,4A,5A,6A,7C),(1C,2C,3B,4A,5A,6B,7A),(1C,2C,3B,4A,5A,6B,
 7B),(1C,2C,3B,4 A,5A,6B,7C),(1C,2C,3B,4A,5A,6C,7A),(1C,2C,3B,4A,5A,6C,7B),(1C,2C,3B,4A,5A,6C,7C), (1C,2C,
 3B,4A,5A,6D,7A),(1C,2C,3B,4A,5A,6D,7B),(1C,2C,3B,4A,5A,6D,7C),(1C,2C,3B,4 A,5B,6A,7A),(1C,2C,3B,4A,5B,
 6A,7B),(1C,2C,3B,4A,5B,6A,7C),(1C,2C,3B,4A,5B,6B,7A), (1C,2C,3B,4A,5B,6B,7B),(1C,2C,3B,4A,5B,6B,7C),(1C,
 25 2C,3B,4A,5B,6C,7A),(1C,2C,3B,4 A,5B,6C,7B),(1C,2C,3B,4A,5B,6C,7C),(1C,2C,3B,4A,5B,6D,7A),(1C,2C,3B,4A,
 5B,6D,7B), (1C,2C,3B,4A,5B,6D,7C),(1C,2C,3B,4B,5A,6A,7A),(1C,2C,3B,4B,5A,6A,7B),(1C,2C,3B,4 B,5A,6A,7C),
 (1C,2C,3B,4B,5A,6B,7A),(1C,2C,3B,4B,5A,6B,7B),(1C,2C,3B,4B,5A,6B,7C), (1C,2C,3B,4B,5A,6C,7A),(1C,2C,3B,
 4B,5A,6C,7B),(1C,2C,3B,4B,5A,6C,7C),(1C,2C,3B,4 B,5A,6D,7A),(1C,2C,3B,4B,5A,6D,7B),(1C,2C,3B,4B,5A,6D,
 7C),(1C,2C,3B,4B,5B,6A,7A), (1C,2C,3B,4B,5B,6A,7B),(1C,2C,3B,4B,5B,6A,7C),(1C,2C,3B,4B,5B,6B,7A),(1C,2C,
 30 3B,4 B,5B,6B,7B),(1C,2C,3B,4B,5B,6B,7C),(1C,2C,3B,4B,5B,6C,7A),(1C,2C,3B,4B,5B,6C,7B), (1C,2C,3B,4B,5B,
 6C,7C),(1C,2C,3B,4B,5B,6D,7A),(1C,2C,3B,4B,5B,6D,7B),(1C,2C,3B,4 B,5B,6D,7C),(1C,2C,3B,4C,5A,6A,7A),(1C,
 2C,3B,4C,5A,6A,7B),(1C,2C,3B,4C,5A,6A,7C), (1C,2C,3B,4C,5A,6B,7A),(1C,2C,3B,4C,5A,6B,7B),(1C,2C,3B,4C,
 5A,6B,7C),(1C,2C,3B,4 C,5A,6C,7A),(1C,2C,3B,4C,5A,6C,7B),(1C,2C,3B,4C,5A,6C,7C),(1C,2C,3B,4C,5A,6D,7A),
 (1C,2C,3B,4C,5A,6D,7B),(1C,2C,3B,4C,5A,6D,7C),(1C,2C,3B,4C,5B,6A,7A),(1C,2C,3B,4 C,5B,6A,7B),(1C,2C,3B,
 35 4C,5B,6A,7C),(1C,2C,3B,4C,5B,6B,7A),(1C,2C,3B,4C,5B,6B,7B), (1C,2C,3B,4C,5B,6B,7C),(1C,2C,3B,4C,5B,6C,
 7A),(1C,2C,3B,4C,5B,6C,7B),(1C,2C,3B,4 C,5B,6C,7C),(1C,2C,3B,4C,5B,6D,7A),(1C,2C,3B,4C,5B,6D,7B),(1C,2C,
 3B,4C,5B,6D,7C), (1C,2C,3B,4D,5A,6A,7A),(1C,2C,3B,4D,5A,6A,7B),(1C,2C,3B,4D,5A,6A,7C),(1C,2C,3B,4 D,5A,
 6B,7A),(1C,2C,3B,4D,5A,6B,7B),(1C,2C,3B,4D,5A,6B,7C),(1C,2C,3B,4D,5A,6C,7A), (1C,2C,3B,4D,5A,6C,7B),(1C,
 2C,3B,4D,5A,6C,7C),(1C,2C,3B,4D,5A,6D,7A),(1C,2C,3B,4 D,5A,6D,7B),(1C,2C,3B,4D,5A,6D,7C),(1C,2C,3B,4D,
 40 5B,6A,7A),(1C,2C,3B,4D,5B,6A,7B), (1C,2C,3B,4D,5B,6A,7C),(1C,2C,3B,4D,5B,6B,7A),(1C,2C,3B,4D,5B,6B,7B),
 (1C,2C,3B,4 D,5B,6B,7C),(1C,2C,3B,4D,5B,6C,7A),(1C,2C,3B,4D,5B,6C,7B),(1C,2C,3B,4D,5B,6C,7C), (1C,2C,3B,
 4D,5B,6D,7A),(1C,2C,3B,4D,5B,6D,7B),(1C,2C,3B,4D,5B,6D,7C),(1C,2C,3B,4 E,5A,6A,7A),(1C,2C,3B,4E,5A,6A,
 7B),(1C,2C,3B,4E,5A,6A,7C),(1C,2C,3B,4E,5A,6B,7A), (1C,2C,3B,4E,5A,6B,7B),(1C,2C,3B,4E,5A,6B,7C),(1C,2C,
 3B,4E,5A,6C,7A),(1C,2C,3B,4 E,5A,6C,7B),(1C,2C,3B,4E,5A,6C,7C),(1C,2C,3B,4E,5A,6D,7A),(1C,2C,3B,4E,5A,
 45 6D,7B), (1C,2C,3B,4E,5A,6D,7C),(1C,2C,3B,4E,5B,6A,7A),(1C,2C,3B,4E,5B,6A,7B),(1C,2C,3B,4 E,5B,6A,7C),(1C,
 2C,3B,4E,5B,6B,7A),(1C,2C,3B,4E,5B,6B,7B),(1C,2C,3B,4E,5B,6B,7C), (1C,2C,3B,4E,5B,6C,7A),(1C,2C,3B,4E,
 5B,6C,7B),(1C,2C,3B,4E,5B,6C,7C),(1C,2C,3B,4 E,5B,6D,7A),(1C,2C,3B,4E,5B,6D,7B),(1C,2C,3B,4E,5B,6D,7C),
 (1C,2C,3C,4A,5A,6A,7A), (1C,2C,3C,4A,5A,6A,7B),(1C,2C,3C,4A,5A,6A,7C),(1C,2C,3C,4A,5A,6B,7A),(1C,2C,3C,4
 A,5A,6B,7B),(1C,2C,3C,4A,5A,6B,7C),(1C,2C,3C,4A,5A,6C,7A),(1C,2C,3C,4A,5A,6C,7B), (1C,2C,3C,4A,5A,6C,
 50 7C),(1C,2C,3C,4A,5A,6D,7A),(1C,2C,3C,4A,5A,6D,7B),(1C,2C,3C,4 A,5A,6D,7C),(1C,2C,3C,4A,5B,6A,7A),(1C,2C,
 3C,4A,5B,6A,7B),(1C,2C,3C,4A,5B,6A,7C), (1C,2C,3C,4A,5B,6B,7A),(1C,2C,3C,4A,5B,6B,7B),(1C,2C,3C,4A,5B,
 6B,7C),(1C,2C,3C,4 A,5B,6C,7A),(1C,2C,3C,4A,5B,6C,7B),(1C,2C,3C,4A,5B,6C,7C),(1C,2C,3C,4A,5B,6D,7A), (1C,
 2C,3C,4A,5B,6D,7B),(1C,2C,3C,4A,5B,6D,7C),(1C,2C,3C,4B,5A,6A,7A),(1C,2C,3C,4 B,5A,6A,7B),(1C,2C,3C,4B,
 5A,6A,7C),(1C,2C,3C,4B,5A,6B,7A),(1C,2C,3C,4B,5A,6B,7B), (1C,2C,3C,4B,5A,6B,7C),(1C,2C,3C,4B,5A,6C,7A),
 55 (1C,2C,3C,4B,5A,6C,7B),(1C,2C,3C,4 B,5A,6C,7C),(1C,2C,3C,4B,5A,6D,7A),(1C,2C,3C,4B,5A,6D,7B),(1C,2C,3C,
 4B,5A,6D,7C), (1C,2C,3C,4B,5B,6A,7A),(1C,2C,3C,4B,5B,6A,7B),(1C,2C,3C,4B,5B,6A,7C),(1C,2C,3C,4 B,5B,6B,
 7A),(1C,2C,3C,4B,5B,6B,7B),(1C,2C,3C,4B,5B,6B,7C),(1C,2C,3C,4B,5B,6C,7A), (1C,2C,3C,4B,5B,6C,7B),(1C,2C,
 3C,4B,5B,6C,7C),(1C,2C,3C,4B,5B,6D,7A),(1C,2C,3C,4 B,5B,6D,7B),(1C,2C,3C,4B,5B,6D,7C),(1C,2C,3C,4C,5A,

6A,7A),(1C,2C,3C,4C,5A,6A,7B), (1C,2C,3C,4C,5A,6A,7C),(1C,2C,3C,4C,5A,6B,7A),(1C,2C,3C,4C,5A,6B,7B),(1C,
2C,3C,4 C,5A,6B,7C),(1C,2C,3C,4C,5A,6C,7A),(1C,2C,3C,4C,5A,6C,7B),(1C,2C,3C,4C,5A,6C,7C), (1C,2C,3C,4C,
5A,6D,7A),(1C,2C,3C,4C,5A,6D,7B),(1C,2C,3C,4C,5A,6D,7C),(1C,2C,3C,4 C,5B,6A,7A),(1C,2C,3C,4C,5B,6A,7B),
(1C,2C,3C,4C,5B,6A,7C),(1C,2C,3C,4C,5B,6B,7A), (1C,2C,3C,4C,5B,6B,7B),(1C,2C,3C,4C,5B,6B,7C),(1C,2C,3C,
5
4C,5B,6C,7A),(1C,2C,3C,4 C,5B,6C,7B),(1C,2C,3C,4C,5B,6C,7C),(1C,2C,3C,4C,5B,6D,7A),(1C,2C,3C,4C,5B,6D,
7B), (1C,2C,3C,4C,5B,6D,7C),(1C,2C,3C,4D,5A,6A,7A),(1C,2C,3C,4D,5A,6A,7B),(1C,2C,3C,4 D,5A,6A,7C),(1C,
2C,3C,4D,5A,6B,7A),(1C,2C,3C,4D,5A,6B,7B),(1C,2C,3C,4D,5A,6B,7C), (1C,2C,3C,4D,5A,6C,7A),(1C,2C,3C,4D,
5A,6C,7B),(1C,2C,3C,4D,5A,6C,7C),(1C,2C,3C,4 D,5A,6D,7A),(1C,2C,3C,4C,5A,6D,7B),(1C,2C,3C,4D,5A,6D,7C),
(1C,2C,3C,4D,5B,6A,7A), (1C,2C,3C,4D,5B,6A,7B),(1C,2C,3C,4D,5B,6A,7C),(1C,2C,3C,4D,5B,6B,7A),(1C,2C,3C,
10
4 D,5B,6B,7B),(1C,2C,3C,4D,5B,6B,7C),(1C,2C,3C,4D,5B,6C,7A),(1C,2C,3C,4D,5B,6C,7B), (1C,2C,3C,4D,5B,6C,
7C),(1C,2C,3C,4D,5B,6D,7A),(1C,2C,3C,4D,5B,6D,7B),(1C,2C,3C,4 D,5B,6D,7C),(1C,2C,3C,4E,5A,6A,7A),(1C,2C,
3C,4E,5A,6A,7B),(1C,2C,3C,4E,5A,6A,7C), (1C,2C,3C,4E,5A,6B,7A),(1C,2C,3C,4E,5A,6B,7B),(1C,2C,3C,4E,5A,
6B,7C),(1C,2C,3C,4 E,5A,6C,7A),(1C,2C,3C,4E,5A,6C,7B),(1C,2C,3C,4E,5A,6C,7C),(1C,2C,3C,4E,5A,6D,7A), (1C,
2C,3C,4E,5A,6D,7B),(1C,2C,3C,4E,5A,6D,7C),(1C,2C,3C,4E,5B,6A,7A),(1C,2C,3C,4 E,5B,6A,7B),(1C,2C,3C,4E,
15
5B,6A,7C),(1C,2C,3C,4E,5B,6B,7A),(1C,2C,3C,4E,5B,6B,7B), (1C,2C,3C,4E,5B,6B,7C),(1C,2C,3C,4E,5B,6C,7A),
(1C,2C,3C,4E,5B,6C,7B),(1C,2C,3C,4 E,5B,6C,7C),(1C,2C,3C,4E,5B,6D,7A),(1C,2C,3C,4E,5B,6D,7B),(1C,2C,3C,
4E,5B,6D,7C), (1C,2C,3D,4A,5A,6A,7A),(1C,2C,3D,4A,5A,6A,7B),(1C,2C,3D,4A,5A,6A,7C),(1C,2C,3D,4 A,5A,6B,
7A),(1C,2C,3D,4A,5A,6B,7B),(1C,2C,3D,4A,5A,6B,7C),(1C,2C,3D,4A,5A,6C,7A), (1C,2C,3D,4A,5A,6C,7B),(1C,2C,
3D,4A,5A,6C,7C),(1C,2C,3D,4A,5A,6D,7A),(1C,2C,3D,4 A,5A,6D,7B),(1C,2C,3D,4A,5A,6D,7C),(1C,2C,3D,4A,5B,
20
6A,7A),(1C,2C,3D,4C,5A,6B,7A), (1C,2C,3D,4C,5A,6B,7C),(1C,2C,3D,4A,5B,6A,7C),(1C,2C,3D,4A,5B,6B,7A),(1C,2C,3D,4A,5B,6B,7B),(1C,
2C,3D,4 A,5B,6B,7C),(1C,2C,3D,4A,5B,6C,7A),(1C,2C,3D,4A,5B,6C,7B),(1C,2C,3D,4A,5B,6C,7C), (1C,2C,3D,4A,
5B,6D,7A),(1C,2C,3D,4A,5B,6D,7B),(1C,2C,3D,4A,5B,6D,7C),(1C,2C,3D,4 B,5A,6A,7A),(1C,2C,3D,4B,5A,6A,7B),
(1C,2C,3D,4B,5A,6A,7C),(1C,2C,3D,4B,5A,6B,7A), (1C,2C,3D,4B,5A,6B,7B),(1C,2C,3D,4B,5A,6B,7C),(1C,2C,3D,
25
4B,5A,6C,7A),(1C,2C,3D,4 B,5A,6C,7B),(1C,2C,3D,4B,5A,6C,7C),(1C,2C,3D,4B,5A,6D,7A),(1C,2C,3D,4B,5A,6D,
7B),(1C,2C,3D,4B,5A,6D,7C),(1C,2C,3D,4B,5B,6A,7A),(1C,2C,3D,4B,5B,6A,7B),(1C,2C,3D,4 B,5B,6A,7C),(1C,2C,
3D,4B,5B,6B,7A),(1C,2C,3D,4B,5B,6B,7B),(1C,2C,3D,4B,5B,6B,7C), (1C,2C,3D,4B,5B,6C,7A),(1C,2C,3D,4B,5B,
6C,7B),(1C,2C,3D,4B,5B,6C,7C),(1C,2C,3D,4 B,5B,6D,7A),(1C,2C,3D,4B,5B,6D,7B),(1C,2C,3D,4B,5B,6D,7C),(1C,
2C,3D,4C,5A,6A,7A), (1C,2C,3D,4C,5A,6A,7B),(1C,2C,3D,4C,5A,6A,7C),(1C,2C,3D,4C,5A,6B,7A),(1C,2C,3D,4 C,
30
5A,6B,7B),(1C,2C,3D,4C,5A,6B,7C),(1C,2C,3D,4C,5A,6C,7A),(1C,2C,3D,4C,5A,6C,7B),(1C,2C,3D,4C,5A,6C,7C),
(1C,2C,3D,4C,5A,6D,7A),(1C,2C,3D,4C,5A,6D,7B),(1C,2C,3D,4 C,5A,6D,7C),(1C,2C,3D,4C,5B,6A,7A),(1C,2C,3D,
4C,5B,6A,7B),(1C,2C,3D,4C,5B,6A,7C), (1C,2C,3D,4C,5B,6B,7A),(1C,2C,3D,4C,5B,6B,7B),(1C,2C,3D,4C,5B,6B,
7C),(1C,2C,3D,4 C,5B,6C,7A),(1C,2C,3D,4C,5B,6C,7B),(1C,2C,3D,4C,5B,6C,7C),(1C,2C,3D,4C,5B,6D,7A), (1C,
2C,3D,4C,5B,6D,7B),(1C,2C,3D,4C,5B,6D,7C),(1C,2C,3D,4D,5A,6A,7A),(1C,2C,3D,4 D,5A,6A,7B),(1C,2C,3D,4D,
35
5A,6A,7C),(1C,2C,3D,4D,5A,6B,7A),(1C,2C,3D,4D,5A,6B,7B), (1C,2C,3D,4D,5A,6B,7C),(1C,2C,3D,4D,5A,6C,7A),
(1C,2C,3D,4D,5A,6C,7B),(1C,2C,3D,4 D,5A,6C,7C),(1C,2C,3D,4D,5A,6D,7A),(1C,2C,3D,4D,5A,6D,7B),(1C,2C,3D,
4D,5A,6D,7C), (1C,2C,3D,4D,5B,6A,7A),(1C,2C,3D,4D,5B,6A,7B),(1C,2C,3D,4D,5B,6A,7C),(1C,2C,3D,4 D,5B,6B,
7A),(1C,2C,3D,4D,5B,6B,7B),(1C,2C,3D,4D,5B,6B,7C),(1C,2C,3D,4D,5B,6C,7A), (1C,2C,3D,4D,5B,6C,7B),(1C,2C,
40
3D,4D,5B,6C,7C),(1C,2C,3D,4D,5B,6D,7A),(1C,2C,3D,4 D,5B,6D,7B),(1C,2C,3D,4D,5B,6D,7C),(1C,2C,3D,4E,5A,
6A,7A),(1C,2C,3D,4C,5A,6A,7B), (1C,2C,3D,4E,5A,6A,7C),(1C,2C,3D,4E,5A,6B,7A),(1C,2C,3D,4E,5A,6B,7B),(1C,
2C,3D,4 E,5A,6B,7C),(1C,2C,3D,4E,5A,6C,7A),(1C,2C,3D,4E,5A,6C,7B),(1C,2C,3D,4E,5A,6C,7C), (1C,2C,3D,4E,
5A,6D,7A),(1C,2C,3D,4E,5A,6D,7B),(1C,2C,3D,4E,5A,6D,7C),(1C,2C,3D,4 E,5B,6A,7A),(1C,2C,3D,4E,5B,6A,7B),
(1C,2C,3D,4E,5B,6A,7C),(1C,2C,3D,4E,5B,6B,7A), (1C,2C,3D,4E,5B,6B,7B),(1C,2C,3D,4E,5B,6B,7C),(1C,2C,3D,
45
4E,5B,6C,7A),(1C,

3E,4 C,5B,6B,7C),(1C,2C,3E,4C,5B,6C,7A),(1C,2C,3E,4C,5B,6C,7B),(1C,2C,3E,4C,5B,6C,7C), (1C,2C,3E,4C,5B,
 6D,7A),(1C,2C,3E,4C,5B,6D,7B),(1C,2C,3E,4C,5B,6D,7C),(1C,2C,3E,4 D,5A,6A,7A),(1C,2C,3E,4D,5A,6A,7B),(1C,
 2C,3E,4D,5A,6A,7C),(1C,2C,3E,4D,5A,6B,7A), (1C,2C,3E,4D,5A,6B,7B),(1C,2C,3E,4D,5A,6B,7C),(1C,2C,3E,4D,
 5A,6C,7A),(1C,2C,3E,4 D,5A,6C,7B),(1C,2C,3E,4D,5A,6C,7C),(1C,2C,3E,4D,5A,6D,7A),(1C,2C,3E,4D,5A,6D,7B),
 5 (1C,2C,3E,4D,5A,6D,7C),(1C,2C,3E,4D,5B,6A,7A),(1C,2C,3E,4D,5B,6A,7B),(1C,2C,3E,4 D,5B,6A,7C),(1C,2C,3E,
 4D,5B,6B,7A),(1C,2C,3E,4D,5B,6B,7B),(1C,2C,3E,4D,5B,6B,7C), (1C,2C,3E,4D,5B,6C,7A),(1C,2C,3E,4D,5B,6C,
 7B),(1C,2C,3E,4D,5B,6C,7C),(1C,2C,3E,4 D,5B,6D,7A),(1C,2C,3E,4D,5B,6D,7B),(1C,2C,3E,4D,5B,6D,7C),(1C,2C,
 3E,4E,5A,6A,7A), (1C,2C,3E,4E,5A,6A,7B),(1C,2C,3E,4E,5A,6A,7C),(1C,2C,3E,4E,5A,6B,7A),(1C,2C,3E,4 E,5A,
 6B,7B),(1C,2C,3E,4E,5A,6B,7C),(1C,2C,3E,4E,5A,6C,7A),(1C,2C,3E,4E,5A,6C,7B), (1C,2C,3E,4E,5A,6C,7C),(1C,
 10 2C,3E,4E,5A,6D,7A),(1C,2C,3E,4E,5A,6D,7B),(1C,2C,3E,4 E,5A,6D,7C),(1C,2C,3E,4E,5B,6A,7A),(1C,2C,3E,4E,
 5B,6A,7B),(1C,2C,3E,4E,5B,6A,7C), (1C,2C,3E,4E,5B,6B,7A),(1C,2C,3E,4E,5B,6B,7B),(1C,2C,3E,4E,5B,6B,7C),
 (1C,2C,3E,4 E,5B,6C,7A),(1C,2C,3E,4E,5B,6C,7B),(1C,2C,3E,4E,5B,6C,7C),(1C,2C,3E,4E,5B,6D,7A), (1C,2C,3E,
 4E,5B,6D,7B),(1C,2C,3E,4E,5B,6D,7C),(1C,2D,3A,4A,5A,6A,7A),(1C,2D,3A,4 A,5A,6A,7B),(1C,2D,3A,4A,5A,6A,
 7C),(1C,2D,3A,4A,5A,6B,7A),(1C,2D,3A,4A,5A,6B,7B), (1C,2D,3A,4A,5A,6B,7C),(1C,2D,3A,4A,5A,6C,7A),(1C,2D,
 15 3A,4A,5A,6C,7B),(1C,2D,3A,4 A,5A,6C,7C),(1C,2D,3A,4A,5A,6D,7A),(1C,2D,3A,4A,5A,6D,7B),(1C,2D,3A,4A,5A,
 6D,7C), (1C,2D,3A,4A,5B,6A,7A),(1C,2D,3A,4A,5B,6A,7B),(1C,2D,3A,4A,5B,6A,7C),(1C,2D,3A,4 A,5B,6B,7A),(1C,
 2D,3A,4A,5B,6B,7B),(1C,2D,3A,4A,5B,6B,7C),(1C,2D,3A,4A,5B,6C,7A), (1C,2D,3A,4A,5B,6C,7B),(1C,2D,3A,4A,
 5B,6C,7C),(1C,2D,3A,4A,5B,6D,7A),(1C,2D,3A,4 A,5B,6D,7B),(1C,2D,3A,4A,5B,6D,7C),(1C,2D,3A,4B,5A,6A,7A),
 (1C,2D,3A,4B,5A,6A,7B), (1C,2D,3A,4B,5A,6A,7C),(1C,2D,3A,4B,5A,6B,7A),(1C,2D,3A,4B,5A,6B,7B),(1C,2D,3A,4
 20 B,5A,6B,7C),(1C,2D,3A,4B,5A,6C,7A),(1C,2D,3A,4B,5A,6C,7B),(1C,2D,3A,4B,5A,6C,7C), (1C,2D,3A,4B,5A,6D,
 7A),(1C,2D,3A,4B,5A,6D,7B),(1C,2D,3A,4B,5A,6D,7C),(1C,2D,3A,4 B,5B,6A,7A),(1C,2D,3A,4B,5B,6A,7B),(1C,2D,
 3A,4B,5B,6A,7C),(1C,2D,3A,4B,5B,6B,7A), (1C,2D,3A,4B,5B,6B,7B),(1C,2D,3A,4B,5B,6B,7C),(1C,2D,3A,4B,5B,
 6C,7A),(1C,2D,3A,4 B,5B,6C,7B),(1C,2D,3A,4B,5B,6C,7C),(1C,2D,3A,4B,5B,6D,7A),(1C,2D,3A,4B,5B,6D,7B), (1C,
 2D,3A,4B,5B,6D,7C),(1C,2D,3A,4C,5A,6A,7A),(1C,2D,3A,4C,5A,6A,7B),(1C,2D,3A,4 C,5A,6A,7C),(1C,2D,3A,4C,
 25 5A,6B,7A),(1C,2D,3A,4C,5A,6B,7B),(1C,2D,3A,4C,5A,6B,7C), (1C,2D,3A,4C,5A,6C,7A),(1C,2D,3A,4C,5A,6C,7B),
 (1C,2D,3A,4C,5A,6C,7C),(1C,2D,3A,4 C,5A,6D,7A),(1C,2D,3A,4C,5A,6D,7B),(1C,2D,3A,4C,5A,6D,7C),(1C,2D,3A,
 4C,5B,6A,7A), (1C,2D,3A,4C,5B,6A,7B),(1C,2D,3A,4C,5B,6A,7C),(1C,2D,3A,4C,5B,6B,7A),(1C,2D,3A,4 C,5B,6B,
 7B),(1C,2D,3A,4C,5B,6B,7C),(1C,2D,3A,4C,5B,6C,7A),(1C,2D,3A,4C,5B,6C,7B), (1C,2D,3A,4C,5B,6C,7C),(1C,2D,
 3A,4C,5B,6D,7A),(1C,2D,3A,4C,5B,6D,7B),(1C,2D,3A,4 C,5B,6D,7C),(1C,2D,3A,4D,5A,6A,7A),(1C,2D,3A,4D,5A,
 30 6A,7B),(1C,2D,3A,4D,5A,6A,7C), (1C,2D,3A,4D,5A,6B,7A),(1C,2D,3A,4D,5A,6B,7B),(1C,2D,3A,4D,5A,6B,7C),(1C,
 2D,3A,4 D,5A,6C,7A),(1C,2D,3A,4D,5A,6C,7B),(1C,2D,3A,4D,5A,6C,7C),(1C,2D,3A,4D,5A,6D,7A), (1C,2D,3A,4D,
 5A,6D,7B),(1C,2D,3A,4D,5A,6D,7C),(1C,2D,3A,4D,5B,6A,7A),(1C,2D,3A,4 D,5B,6A,7B),(1C,2D,3A,4D,5B,6A,7C),
 (1C,2D,3A,4D,5B,6B,7A),(1C,2D,3A,4D,5B,6B,7B), (1C,2D,3A,4D,5B,6B,7C),(1C,2D,3A,4D,5B,6C,7A),(1C,2D,3A,
 4D,5B,6C,7B),(1C,2D,3A,4 D,5B,6C,7C),(1C,2D,3A,4D,5B,6D,7A),(1C,2D,3A,4D,5B,6D,7B),(1C,2D,3A,4D,5B,6D,
 35 7C), (1C,2D,3A,4E,5A,6A,7A),(1C,2D,3A,4E,5A,6A,7B),(1C,2D,3A,4E,5A,6A,7C),(1C,2D,3A,4 E,5A,6B,7A),(1C,2D,
 3A,4E,5A,6B,7B),(1C,2D,3A,4E,5A,6B,7C),(1C,2D,3A,4E,5A,6C,7A), (1C,2D,3A,4E,5A,6C,7B),(1C,2D,3A,4E,5A,
 6C,7C),(1C,2D,3A,4E,5A,6D,7A),(1C,2D,3A,4 E,5A,6D,7B),(1C,2D,3A,4E,5A,6D,7C),(1C,2D,3A,4E,5B,6A,7A),(1C,
 2D,3A,4E,5B,6A,7B), (1C,2D,3A,4E,5B,6A,7C),(1C,2D,3A,4E,5B,6B,7A),(1C,2D,3A,4E,5B,6B,7B),(1C,2D,3A,4 E,
 5B,6B,7C),(1C,2D,3A,4E,5B,6C,7A),(1C,2D,3A,4E,5B,6C,7B),(1C,2D,3A,4E,5B,6C,7C), (1C,2D,3A,4E,5B,6D,7A),
 40 (1C,2D,3A,4E,5B,6D,7B),(1C,2D,3A,4E,5B,6D,7C),(1C,2D,3B,4 A,5A,6A,7A),(1C,2D,3B,4A,5A,6A,7B),(1C,2D,3B,
 4A,5A,6A,7C),(1C,2D,3B,4A,5A,6B,7A), (1C,2D,3B,4A,5A,6B,7B),(1C,2D,3B,4A,5A,6B,7C),(1C,2D,3B,4A,5A,6C,
 7A),(1C,2D,3B,4 A,5A,6C,7B),(1C,2D,3B,4A,5A,6C,7C),(1C,2D,3B,4A,5A,6D,7A),(1C,2D,3B,4A,5A,6D,7B), (1C,2D,
 3B,4A,5A,6D,7C),(1C,2D,3B,4A,5B,6A,7A),(1C,2D,3B,4A,5B,6A,7B),(1C,2D,3B,4 A,5B,6A,7C),(1C,2D,3B,4A,5B,
 6B,7A),(1C,2D,3B,4A,5B,6B,7B),(1C,2D,3B,4A,5B,6B,7C), (1C,2D,3B,4A,5B,6C,7A),(1C,2D,3B,4A,5B,6C,7B),(1C,
 45 2D,3B,4A,5B,6C,7C),(1C,2D,3B,4 A,5B,6D,7A),(1C,2D,3B,4A,5B,6D,7B),(1C,2D,3B,4A,5B,6D,7C),(1C,2D,3B,4B,
 5A,6A,7A), (1C,2D,3B,4B,5A,6A,7B),(1C,2D,3B,4B,5A,6A,7C),(1C,2D,3B,4B,5A,6B,7A),(1C,2D,3B,4 B,5A,6B,7B),
 (1C,2D,3B,4B,5A,6B,7C),(1C,2D,3B,4B,5A,6C,7A),(1C,2D,3B,4B,5A,6C,7B), (1C,2D,3B,4B,5A,6C,7C),(1C,2D,3B,
 4B,5A,6D,7A),(1C,2D,3B,4B,5A,6D,7B),(1C,2D,3B,4 B,5A,6D,7C),(1C,2D,3B,4B,5B,6A,7A),(1C,2D,3B,4B,5B,6A,
 7B),(1C,2D,3B,4B,5B,6A,7C), (1C,2D,3B,4B,5B,6B,7A),(1C,2D,3B,4B,5B,6B,7B),(1C,2D,3B,4B,5B,6B,7C),(1C,2D,
 50 3B,4 B,5B,6C,7A),(1C,2D,3B,4B,5B,6C,7B),(1C,2D,3B,4B,5B,6C,7C),(1C,2D,3B,4B,5B,6D,7A), (1C,2D,3B,4B,5B,
 6D,7B),(1C,2D,3B,4B,5B,6D,7C),(1C,2D,3B,4C,5A,6A,7A),(1C,2D,3B,4 C,5A,6A,7B),(1C,2D,3B,4C,5A,6A,7C),(1C,
 2D,3B,4C,5A,6B,7A),(1C,2D,3B,4C,5A,6B,7B), (1C,2D,3B,4C,5A,6B,7C),(1C,2D,3B,4C,5A,6C,7A),(1C,2D,3B,4C,
 5A,6C,7B),(1C,2D,3B,4 C,5A,6C,7C),(1C,2D,3B,4C,5A,6D,7A),(1C,2D,3B,4C,5A,6D,7B),(1C,2D,3B,4C,5A,6D,7C),
 (1C,2D,3B,4C,5B,6A,7A),(1C,2D,3B,4C,5B,6A,7B),(1C,2D,3B,4C,5B,6A,7C),(1C,2D,3B,4 C,5B,6B,7A),(1C,2D,3B,
 55 4C,5B,6B,7B),(1C,2D,3B,4C,5B,6B,7C),(1C,2D,3B,4C,5B,6C,7A), (1C,2D,3B,4C,5B,6C,7B),(1C,2D,3B,4C,5B,6C,
 7C),(1C,2D,3B,4C,5B,6D,7A),(1C,2D,3B,4 C,5B,6D,7B),(1C,2D,3B,4C,5B,6D,7C),(1C,2D,3B,4D,5A,6A,7A),(1C,2D,
 3B,4D,5A,6A,7B), (1C,2D,3B,4D,5A,6A,7C),(1C,2D,3B,4D,5A,6B,7A),(1C,2D,3B,4D,5A,6B,7B),(1C,2D,3B,4 D,5A,
 6B,7C),(1C,2D,3B,4D,5A,6C,7A),(1C,2D,3B,4D,5A,6C,7B),(1C,2D,3B,4D,5A,6C,7C), (1C,2D,3B,4D,5A,6D,7A),(1C,

2D,3B,4D,5A,6D,7B),(1C,2D,3B,4D,5A,6D,7C),(1C,2D,3B,4 D,5B,6A,7A),(1C,2D,3B,4D,5B,6A,7B),(1C,2D,3B,4D,
 5B,6A,7C),(1C,2D,3B,4D,5B,6B,7A), (1C,2D,3B,4D,5B,6B,7B),(1C,2D,3B,4D,5B,6B,7C),(1C,2D,3B,4D,5B,6C,7A),
 (1C,2D,3B,4 D,5B,6C,7B),(1C,2D,3B,4D,5B,6C,7C),(1C,2D,3B,4D,5B,6D,7A),(1C,2D,3B,4D,5B,6D,7B), (1C,2D,3B,
 4D,5B,6D,7C),(1C,2D,3B,4E,5A,6A,7A),(1C,2D,3B,4E,5A,6A,7B),(1C,2D,3B,4 E,5A,6A,7C),(1C,2D,3B,4E,5A,6B,
 5 7A),(1C,2D,3B,4E,5A,6B,7B),(1C,2D,3B,4E,5A,6B,7C), (1C,2D,3B,4E,5A,6C,7A),(1C,2D,3B,4E,5A,6C,7B),(1C,2D,
 3B,4E,5A,6C,7C),(1C,2D,3B,4 E,5A,6D,7A),(1C,2D,3B,4E,5A,6D,7B),(1C,2D,3B,4E,5A,6D,7C),(1C,2D,3B,4E,5B,
 6A,7A), (1C,2D,3B,4E,5B,6A,7B),(1C,2D,3B,4E,5B,6A,7C),(1C,2D,3B,4E,5B,6B,7A),(1C,2D,3B,4 E,5B,6B,7B),(1C,
 2D,3B,4E,5B,6B,7C),(1C,2D,3B,4E,5B,6C,7A),(1C,2D,3B,4E,5B,6C,7B), (1C,2D,3B,4E,5B,6C,7C),(1C,2D,3B,4E,
 5B,6D,7A),(1C,2D,3B,4E,5B,6D,7B),(1C,2D,3B,4 E,5B,6D,7C),(1C,2D,3C,4A,5A,6A,7A),(1C,2D,3C,4A,5A,6A,7B),
 10 (1C,2D,3C,4A,5A,6A,7C), (1C,2D,3C,4A,5A,6B,7A),(1C,2D,3C,4A,5A,6B,7B),(1C,2D,3C,4A,5A,6B,7C),(1C,2D,3C,4
 A,5A,6C,7A),(1C,2D,3C,4A,5A,6C,7B),(1C,2D,3C,4A,5A,6C,7C),(1C,2D,3C,4A,5A,6D,7A), (1C,2D,3C,4A,5A,6D,
 7B),(1C,2D,3C,4A,5A,6D,7C),(1C,2D,3C,4A,5B,6A,7A),(1C,2D,3C,4 A,5B,6A,7B),(1C,2D,3C,4A,5B,6A,7C),(1C,2D,
 3C,4A,5B,6B,7A),(1C,2D,3C,4A,5B,6B,7B), (1C,2D,3C,4A,5B,6B,7C),(1C,2D,3C,4A,5B,6C,7A),(1C,2D,3C,4A,5B,
 6C,7B),(1C,2D,3C,4 A,5B,6C,7C),(1C,2D,3C,4A,5B,6D,7A),(1C,2D,3C,4A,5B,6D,7B),(1C,2D,3C,4A,5B,6D,7C), (1C,
 15 2D,3C,4B,5A,6A,7A),(1C,2D,3C,4B,5A,6A,7B),(1C,2D,3C,4B,5A,6A,7C),(1C,2D,3C,4 B,5A,6B,7A),(1C,2D,3C,4B,
 5A,6B,7B),(1C,2D,3C,4B,5A,6B,7C),(1C,2D,3C,4B,5A,6C,7A), (1C,2D,3C,4B,5A,6C,7B),(1C,2D,3C,4B,5A,6C,7C),
 (1C,2D,3C,4B,5A,6D,7A),(1C,2D,3C,4 B,5A,6D,7B),(1C,2D,3C,4B,5A,6D,7C),(1C,2D,3C,4B,5B,6A,7A),(1C,2D,3C,
 4B,5B,6A,7B), (1C,2D,3C,4B,5B,6A,7C),(1C,2D,3C,4B,5B,6B,7A),(1C,2D,3C,4B,5B,6B,7B),(1C,2D,3C,4 B,5B,6B,
 7C),(1C,2D,3C,4B,5B,6C,7A),(1C,2D,3C,4B,5B,6C,7B),(1C,2D,3C,4B,5B,6C,7C), (1C,2D,3C,4B,5B,6D,7A),(1C,2D,
 20 3C,4B,5B,6D,7B),(1C,2D,3C,4B,5B,6D,7C),(1C,2D,3C,4 C,5A,6A,7A),(1C,2D,3C,4C,5A,6A,7B),(1C,2D,3C,4C,5A,
 6A,7C),(1C,2D,3C,4C,5A,6B,7A), (1C,2D,3C,4C,5A,6B,7B),(1C,2D,3C,4C,5A,6B,7C),(1C,2D,3C,4C,5A,6C,7A),(1C,
 2D,3C,4 C,5A,6C,7B),(1C,2D,3C,4C,5A,6C,7C),(1C,2D,3C,4C,5A,6D,7A),(1C,2D,3C,4C,5A,6D,7B), (1C,2D,3C,4C,
 5A,6D,7C),(1C,2D,3C,4C,5B,6A,7A),(1C,2D,3C,4C,5B,6A,7B),(1C,2D,3C,4 C,5B,6A,7C),(1C,2D,3C,4C,5B,6B,7A),
 (1C,2D,3C,4C,5B,6B,7B),(1C,2D,3C,4C,5B,6B,7C), (1C,2D,3C,4C,5B,6C,7A),(1C,2D,3C,4C,5B,6C,7B),(1C,2D,3C,
 25 4C,5B,6C,7C),(1C,2D,3C,4 C,5B,6D,7A),(1C,2D,3C,4C,5B,6D,7B),(1C,2D,3C,4C,5B,6D,7C),(1C,2D,3C,4D,5A,6A,
 7A),(1C,2D,3C,4D,5A,6A,7B),(1C,2D,3C,4D,5A,6A,7C),(1C,2D,3C,4D,5A,6B,7A),(1C,2D,3C,4 D,5A,6B,7B),(1C,2D,
 3C,4D,5A,6B,7C),(1C,2D,3C,4D,5A,6C,7A),(1C,2D,3C,4D,5A,6C,7B), (1C,2D,3C,4D,5A,6C,7C),(1C,2D,3C,4D,5A,
 6D,7A),(1C,2D,3C,4D,5A,6D,7B),(1C,2D,3C,4 D,5A,6D,7C),(1C,2D,3C,4D,5B,6A,7A),(1C,2D,3C,4D,5B,6A,7B),(1C,
 2D,3C,4D,5B,6A,7C), (1C,2D,3C,4D,5B,6B,7A),(1C,2D,3C,4D,5B,6B,7B),(1C,2D,3C,4D,5B,6B,7C),(1C,2D,3C,4 D,
 30 5B,6C,7A),(1C,2D,3C,4D,5B,6C,7B),(1C,2D,3C,4D,5B,6C,7C),(1C,2D,3C,4D,5B,6D,7A), (1C,2D,3C,4D,5B,6D,7B),
 (1C,2D,3C,4D,5B,6D,7C),(1C,2D,3C,4E,5A,6A,7A),(1C,2D,3C,4 E,5A,6A,7B),(1C,2D,3C,4E,5A,6A,7C),(1C,2D,3C,
 4E,5A,6B,7A),(1C,2D,3C,4E,5A,6B,7B), (1C,2D,3C,4E,5A,6B,7C),(1C,2D,3C,4E,5A,6C,7A),(1C,2D,3C,4E,5A,6C,
 7B),(1C,2D,3C,4 E,5A,6C,7C),(1C,2D,3C,4E,5A,6D,7A),(1C,2D,3C,4E,5A,6D,7B),(1C,2D,3C,4E,5A,6D,7C), (1C,2D,
 3C,4E,5B,6A,7A),(1C,2D,3C,4E,5B,6A,7B),(1C,2D,3C,4E,5B,6A,7C),(1C,2D,3C,4 E,5B,6B,7A),(1C,2D,3C,4E,5B,
 35 6B,7B),(1C,2D,3C,4E,5B,6B,7C),(1C,2D,3C,4E,5B,6C,7A), (1C,2D,3C,4E,5B,6C,7B),(1C,2D,3C,4E,5B,6C,7C),(1C,
 2D,3C,4E,5B,6D,7A),(1C,2D,3C,4 E,5B,6D,7B),(1C,2D,3C,4E,5B,6D,7C),(1C,2D,3D,4A,5A,6A,7A),(1C,2D,3D,4A,
 5A,6A,7B), (1C,2D,3D,4A,5A,6A,7C),(1C,2D,3D,4A,5A,6B,7A),(1C,2D,3D,4A,5A,6B,7B),(1C,2D,3D,4 A,5A,6B,7C),
 (1C,2D,3D,4A,5A,6C,7A),(1C,2D,3D,4A,5A,6C,7B),(1C,2D,3D,4A,5A,6C,7C), (1C,2D,3D,4A,5A,6D,7A),(1C,2D,3D,
 4A,5A,6D,7B),(1C,2D,3D,4A,5A,6D,7C),(1C,2D,3D,4 A,5B,6A,7A),(1C,2D,3D,4A,5B,6A,7B),(1C,2D,3D,4A,5B,6A,
 40 7C),(1C,2D,3D,4A,5B,6B,7A), (1C,2D,3D,4A,5B,6B,7B),(1C,2D,3D,4A,5B,6B,7C),(1C,2D,3D,4A,5B,6C,7A),(1C,2D,
 3D,4 A,5B,6C,7B),(1C,2D,3D,4A,5B,6C,7C),(1C,2D,3D,4A,5B,6D,7A),(1C,2D,3D,4A,5B,6D,7B), (1C,2D,3D,4A,5B,
 6D,7C),(1C,2D,3D,4B,5A,6A,7A),(1C,2D,3D,4B,5A,6A,7B),(1C,2D,3D,4 B,5A,6A,7C),(1C,2D,3D,4B,5A,6B,7A),(1C,
 2D,3D,4B,5A,6B,7B),(1C,2D,3D,4B,5A,6B,7C), (1C,2D,3D,4B,5A,6C,7A),(1C,2D,3D,4B,5A,6C,7B),(1C,2D,3D,4B,
 5A,6C,7C),(1C,2D,3D,4 B,5A,6D,7A),(1C,2D,3D,4B,5A,6D,7B),(1C,2D,3D,4B,5A,6D,7C),(1C,2D,3D,4B,5B,6A,7A),
 45 (1C,2D,3D,4B,5B,6A,7B),(1C,2D,3D,4B,5B,6A,7C),(1C,2D,3D,4B,5B,6B,7A),(1C,2D,3D,4 B,5B,6B,7B),(1C,2D,3D,
 4B,5B,6B,7C),(1C,2D,3D,4B,5B,6C,7A),(1C,2D,3D,4B,5B,6C,7B), (1C,2D,3D,4B,5B,6C,7C),(1C,2D,3D,4B,5B,6D,
 7A),(1C,2D,3D,4B,5B,6D,7B),(1C,2D,3D,4 B,5B,6D,7C),(1C,2D,3D,4C,5A,6A,7A),(1C,2D,3D,4C,5A,6A,7B),(1C,2D,
 3D,4C,5A,6A,7C), (1C,2D,3D,4C,5A,6B,7A),(1C,2D,3D,4C,5A,6B,7B),(1C,2D,3D,4C,5A,6B,7C),(1C,2D,3D,4 C,5A,
 50 6C,7A),(1C,2D,3D,4C,5A,6C,7B),(1C,2D,3D,4C,5A,6C,7C),(1C,2D,3D,4C,5A,6D,7A), (1C,2D,3D,4C,5A,6D,7B),(1C,
 2D,3D,4C,5A,6D,7C),(1C,2D,3D,4C,5B,6A,7A),(1C,2D,3D,4 C,5B,6A,7B),(1C,2D,3D,4C,5B,6A,7C),(1C,2D,3D,4C,
 5B,6B,7A),(1C,2D,3D,4C,5B,6B,7B), (1C,2D,3D,4C,5B,6B,7C),(1C,2D,3D,4C,5B,6C,7A),(1C,2D,3D,4C,5B,6C,7B),
 (1C,2D,3D,4 C,5B,6C,7C),(1C,2D,3D,4C,5B,6D,7A),(1C,2D,3D,4C,5B,6D,7B),(1C,2D,3D,4C,5B,6D,7C), (1C,2D,3D,
 4D,5A,6A,7A),(1C,2D,3D,4D,5A,6A,7B),(1C,2D,3D,4D,5A,6A,7C),(1C,2D,3D,4 D,5A,6B,7A),(1C,2D,3D,4D,5A,6B,
 7B),(1C,2D,3D,4D,5A,6B,7C),(1C,2D,3D,4D,5A,6C,7A), (1C,2D,3D,4D,5A,6C,7B),(1C,2D,3D,4D,5A,6C,7C),(1C,2D,
 55 3D,4D,5A,6D,7A),(1C,2D,3D,4 D,5A,6D,7B),(1C,2D,3D,4D,5A,6D,7C),(1C,2D,3D,4D,5B,6A,7A),(1C,2D,3D,4D,5B,
 6A,7B), (1C,2D,3D,4D,5B,6A,7C),(1C,2D,3D,4D,5B,6B,7A),(1C,2D,3D,4D,5B,6B,7B),(1C,2D,3D,4 D,5B,6B,7C),(1C,
 2D,3D,4D,5B,6C,7A),(1C,2D,3D,4D,5B,6C,7B),(1C,2D,3D,4D,5B,6C,7C), (1C,2D,3D,4D,5B,6D,7A),(1C,2D,3D,4D,
 5B,6D,7B),(1C,2D,3D,4D,5B,6D,7C),(1C,2D,3D,4 E,5A,6A,7A),(1C,2D,3D,4E,5A,6A,7B),(1C,2D,3D,4E,5A,6A,7C),

(1C,2D,3D,4E,5A,6B,7A),(1C,2D,3D,4E,5A,6B,7B),(1C,2D,3D,4E,5A,6B,7C),(1C,2D,3D,4E,5A,6C,7A),(1C,2D,3D,4E,5A,6C,7B),(1C,2D,3D,4E,5A,6C,7C),(1C,2D,3D,4E,5A,6D,7A),(1C,2D,3D,4E,5A,6D,7B), (1C,2D,3D,4E,5A,6D,7C),(1C,2D,3D,4E,5B,6A,7A),(1C,2D,3D,4E,5B,6A,7B),(1C,2D,3D,4 E,5B,6A,7C),(1C,2D,3D,4E,5B,6B,7A),(1C,2D,3D,4E,5B,6B,7B),(1C,2D,3D,4E,5B,6B,7C), (1C,2D,3D,4E,5B,6C,7A),(1C,2D,3D,4E,5B,6C,7B),(1C,2D,3D,4E,5B,6C,7C),(1C,2D,3D,4 E,5B,6D,7A),(1C,2D,3D,4E,5B,6D,7B),(1C,2D,3D,4E,5B,6D,7C),(1C,2D,3E,4A,5A,6A,7A), (1C,2D,3E,4A,5A,6A,7B),(1C,2D,3E,4A,5A,6A,7C),(1C,2D,3E,4A,5A,6B,7A),(1C,2D,3E,4 A,5A,6B,7B),(1C,2D,3E,4 A,5A,6B,7C),(1C,2D,3E,4A,5A,6C,7A),(1C,2D,3E,4A,5A,6C,7B), (1C,2D,3E,4A,5A,6C,7C),(1C,2D,3E,4A,5A,6D,7A),(1C,2D,3E,4 A,5A,6D,7B),(1C,2D,3E,4 A,5A,6D,7C),(1C,2D,3E,4A,5B,6A,7A),(1C,2D,3E,4A,5B,6A,7B),(1C,2D,3E,4A,5B,6A,7C),(1C,2D,3E,4 A,5B,6B,7A),(1C,2D,3E,4A,5B,6B,7B),(1C,2D,3E,4A,5B,6B,7C),(1C,2D,3E,4A,5B,6C,7A),(1C,2D,3E,4A,5B,6C,7B),(1C,2D,3E,4A,5B,6C,7C),(1C,2D,3E,4A,5B,6D,7A),(1C,2D,3E,4 B,5A,6A,7A),(1C,2D,3E,4 B,5A,6A,7B),(1C,2D,3E,4B,5A,6A,7C),(1C,2D,3E,4B,5A,6B,7A),(1C,2D,3E,4B,5A,6B,7B), (1C,2D,3E,4B,5A,6B,7C),(1C,2D,3E,4B,5A,6C,7A),(1C,2D,3E,4B,5A,6C,7B),(1C,2D,3E,4 B,5A,6C,7C),(1C,2D,3E,4B,5A,6D,7A),(1C,2D,3E,4B,5A,6D,7B),(1C,2D,3E,4B,5A,6D,7C), (1C,2D,3E,4B,5B,6A,7A),(1C,2D,3E,4B,5B,6A,7B),(1C,2D,3E,4B,5B,6A,7C),(1C,2D,3E,4 B,5B,6B,7A),(1C,2D,3E,4B,5B,6B,7B),(1C,2D,3E,4B,5B,6B,7C),(1C,2D,3E,4B,5B,6C,7A), (1C,2D,3E,4B,5B,6C,7B),(1C,2D,3E,4B,5B,6C,7C),(1C,2D,3E,4B,5B,6D,7A),(1C,2D,3E,4 B,5B,6D,7B),(1C,2D,3E,4B,5B,6D,7C),(1C,2D,3E,4C,5A,6A,7A),(1C,2D,3E,4C,5A,6A,7B), (1C,2D,3E,4C,5A,6A,7C),(1C,2D,3E,4C,5A,6B,7A),(1C,2D,3E,4C,5A,6B,7B),(1C,2D,3E,4 C,5A,6B,7C),(1C,2D,3E,4C,5A,6D,7A),(1C,2D,3E,4C,5A,6D,7B),(1C,2D,3E,4C,5A,6D,7C), (1C,2D,3E,4C,5B,6A,7A),(1C,2D,3E,4C,5B,6A,7B),(1C,2D,3E,4 C,5B,6A,7C),(1C,2D,3E,4C,5B,6B,7A),(1C,2D,3E,4C,5B,6B,7B),(1C,2D,3E,4C,5B,6B,7C), (1C,2D,3E,4C,5B,6C,7A),(1C,2D,3E,4C,5B,6C,7B),(1C,2D,3E,4C,5B,6C,7C),(1C,2D,3E,4C,5B,6D,7A),(1C,2D,3E,4C,5B,6D,7B), (1C,2D,3E,4C,5B,6D,7C),(1C,2D,3E,4D,5A,6A,7A),(1C,2D,3E,4D,5A,6A,7B),(1C,2D,3E,4 D,5A,6A,7C),(1C,2D,3E,4D,5A,6B,7A),(1C,2D,3E,4D,5A,6B,7B),(1C,2D,3E,4D,5A,6B,7C), (1C,2D,3E,4D,5A,6C,7A),(1C,2D,3E,4D,5A,6C,7B),(1C,2D,3E,4D,5A,6C,7C),(1C,2D,3E,4 D,5A,6D,7A),(1C,2D,3E,4D,5A,6D,7B),(1C,2D,3E,4D,5A,6D,7C),(1C,2D,3E,4D,5B,6A,7A), (1C,2D,3E,4D,5B,6A,7B),(1C,2D,3E,4D,5B,6A,7C),(1C,2D,3E,4D,5B,6B,7A),(1C,2D,3E,4 D,5B,6B,7B),(1C,2D,3E,4D,5B,6B,7C),(1C,2D,3E,4D,5B,6C,7A),(1C,2D,3E,4D,5B,6C,7B), (1C,2D,3E,4D,5B,6C,7C),(1C,2D,3E,4D,5B,6D,7A),(1C,2D,3E,4D,5B,6D,7B),(1C,2D,3E,4E,5A,6A,7A),(1C,2D,3E,4E,5A,6A,7B),(1C,2D,3E,4E,5A,6A,7C),(1C,2D,3E,4E,5A,6B,7A),(1C,2D,3E,4E,5A,6B,7B),(1C,2D,3E,4E,5A,6B,7C),(1C,2D,3E,4E,5A,6C,7A), (1C,2D,3E,4E,5A,6C,7B),(1C,2D,3E,4E,5A,6C,7C),(1C,2D,3E,4E,5A,6D,7A), (1C,2D,3E,4E,5A,6D,7B),(1C,2D,3E,4E,5A,6D,7C),(1C,2D,3E,4E,5B,6A,7A),(1C,2D,3E,4 E,5B,6A,7B),(1C,2D,3E,4E,5B,6A,7C),(1C,2D,3E,4E,5B,6B,7A),(1C,2D,3E,4E,5B,6B,7B), (1C,2D,3E,4E,5B,6B,7C),(1C,2D,3E,4E,5B,6C,7A),(1C,2D,3E,4E,5B,6C,7B),(1C,2D,3E,4 E,5B,6C,7C),(1C,2D,3E,4E,5B,6D,7A),(1C,2D,3E,4E,5B,6D,7B),(1C,2D,3E,4E,5B,6D,7C), (1C,2E,3A,4A,5A,6A,7A),(1C,2E,3A,4A,5A,6A,7B),(1C,2E,3A,4A,5A,6A,7C),(1C,2E,3A,4 A,5A,6B,7A),(1C,2E,3A,4A,5A,6B,7B),(1C,2E,3A,4A,5A,6B,7C),(1C,2E,3A,4A,5A,6C,7A), (1C,2E,3A,4A,5A,6C,7B),(1C,2E,3A,4A,5A,6C,7C),(1C,2E,3A,4A,5A,6D,7A),(1C,2E,3A,4 A,5A,6D,7B),(1C,2E,3A,4A,5A,6D,7C),(1C,2E,3A,4A,5B,6A,7A),(1C,2E,3A,4A,5B,6A,7B), (1C,2E,3A,4A,5B,6A,7C),(1C,2E,3A,4A,5B,6B,7A),(1C,2E,3A,4A,5B,6B,7B),(1C,2E,3A,4 A,5B,6B,7C),(1C,2E,3A,4A,5B,6C,7A),(1C,2E,3A,4A,5B,6C,7B), (1C,2E,3A,4A,5B,6D,7A),(1C,2E,3A,4A,5B,6D,7B),(1C,2E,3A,4A,5B,6D,7C),(1C,2E,3A,4A,5B,6C,7A),(1C,2E,3A,4A,5B,6C,7B),(1C,2E,3A,4A,5B,6C,7C), (1C,2E,3A,4A,5B,6D,7A),(1C,2E,3A,4A,5B,6D,7B),(1C,2E,3A,4A,5B,6D,7C),(1C,2E,3A,4C,5A,6A,7A), (1C,2E,3A,4C,5A,6A,7B),(1C,2E,3A,4C,5A,6A,7C),(1C,2E,3A,4C,5A,6B,7A),(1C,2E,3A,4C,5A,6B,7B), (1C,2E,3A,4C,5A,6B,7C),(1C,2E,3A,4C,5A,6C,7A),(1C,2E,3A,4C,5A,6C,7B), (1C,2E,3A,4C,5A,6C,7C),(1C,2E,3A,4C,5A,6D,7A),(1C,2E,3A,4C,5A,6D,7B),(1C,2E,3A,4 C,5A,6D,7C),(1C,2E,3A,4 C,5A,6C,7A),(1C,2E,3A,4C,5B,6A,7A),(1C,2E,3A,4C,5B,6A,7B),(1C,2E,3A,4C,5B,6A,7C),(1C,2E,3A,4C,5B,6B,7A),(1C,2E,3A,4C,5B,6B,7B),(1C,2E,3A,4C,5B,6B,7C), (1C,2E,3A,4C,5B,6C,7A),(1C,2E,3A,4C,5B,6C,7B),(1C,2E,3A,4C,5B,6C,7C),(1C,2E,3A,4C,5B,6D,7A),(1C,2E,3A,4C,5B,6D,7B),(1C,2E,3A,4C,5B,6D,7C),(1C,2E,3A,4D,5A,6A,7A),(1C,2E,3A,4 D,5A,6A,7B),(1C,2E,3A,4D,5A,6A,7C),(1C,2E,3A,4D,5A,6B,7A),(1C,2E,3A,4D,5A,

3A,4E,5B,6C,7C),(1C,2E,3A,4E,5B,6D,7A),(1C,2E,3A,4E,5B,6D,7B),(1C,2E,3A,4E,5B,6D,7C),(1C,2E,3B,4A,5A,6A,7A),(1C,2E,3B,4A,5A,6A,7B),(1C,2E,3B,4 A 5A,6A,7C),(1C,2E,3B,4A,5A,6B,7A),(1C,2E,3B,4A,5A,6B,7B),(1C,2E,3B,4A,5A,6B,7C),(1C,2E,3B,4A,5A,6C,7A),(1C,2E,3B,4A,5A,6C,7B),(1C,2E,3B,4A,5A,6C,7C),(1C,2E,3B,4 A 5A,6D,7A),(1C,2E,3B,4A,5A,6D,7B),(1C,2E,3B,4A,5A,6D,7C),(1C,2E,3B,4A,5B,6A,7A),(1C,2E,3B,4A,5B,6A,7B),(1C,2E,3B,4A,5B,6A,7C),(1C,2E,3B,4 A 5B,6B,7A),(1C,2E,3B,4A,5B,6B,7B),(1C,2E,3B,4 A 5B,6B,7C),(1C,2E,3B,4A,5B,6C,7A),(1C,2E,3B,4A,5B,6C,7B),(1C,2E,3B,4A,5B,6C,7C),(1C,2E,3B,4A,5B,6D,7A),(1C,2E,3B,4A,5B,6D,7B),(1C,2E,3B,4 A 5B,6D,7C),(1C,2E,3B,4B,5A,6A,7A),(1C,2E,3B,4B,5A,6A,7B),(1C,2E,3B,4B,5A,6A,7C),(1C,2E,3B,4B,5A,6B,7A),(1C,2E,3B,4B,5A,6B,7B),(1C,2E,3B,4B,5A,6B,7C),(1C,2E,3B,4B,5A,6C,7A),(1C,2E,3B,4B,5A,6C,7B),(1C,2E,3B,4B,5A,6C,7C),(1C,2E,3B,4B,5A,6D,7A),(1C,2E,3B,4B,5A,6D,7B),(1C,2E,3B,4B,5A,6D,7C),(1C,2E,3B,4B,5B,6A,7A),(1C,2E,3B,4B,5B,6A,7B),(1C,2E,3B,4B,5B,6A,7C),(1C,2E,3B,4B,5B,6B,7A),(1C,2E,3B,4B,5B,6B,7B),(1C,2E,3B,4B,5B,6B,7C),(1C,2E,3B,4B,5B,6C,7A),(1C,2E,3B,4B,5B,6C,7B),(1C,2E,3B,4B,5B,6C,7C),(1C,2E,3B,4B,5B,6D,7A),(1C,2E,3B,4B,5B,6D,7B),(1C,2E,3B,4B,5B,6D,7C),(1C,2E,3B,4C,5A,6A,7A),(1C,2E,3B,4C,5A,6A,7B),(1C,2E,3B,4C,5A,6A,7C),(1C,2E,3B,4C,5A,6B,7A),(1C,2E,3B,4C,5A,6B,7B),(1C,2E,3B,4C,5A,6B,7C),(1C,2E,3B,4C,5A,6C,7A),(1C,2E,3B,4C,5A,6C,7B),(1C,2E,3B,4C,5A,6C,7C),(1C,2E,3B,4C,5A,6D,7A),(1C,2E,3B,4 C 5A,6D,7B),(1C,2E,3B,4C,5A,6D,7C),(1C,2E,3B,4C,5B,6A,7A),(1C,2E,3B,4C,5B,6A,7B),(1C,2E,3B,4C,5B,6A,7C),(1C,2E,3B,4C,5B,6B,7A),(1C,2E,3B,4C,5B,6B,7B),(1C,2E,3B,4 C 5B,6B,7C),(1C,2E,3B,4C,5B,6C,7A),(1C,2E,3B,4C,5B,6C,7B),(1C,2E,3B,4C,5B,6C,7C),(1C,2E,3B,4C,5B,6D,7A),(1C,2E,3B,4C,5B,6D,7B),(1C,2E,3B,4C,5B,6D,7C),(1C,2E,3B,4 D 5A,6A,7A),(1C,2E,3B,4D,5A,6A,7B),(1C,2E,3B,4D,5A,6A,7C),(1C,2E,3B,4D,5A,6B,7A),(1C,2E,3B,4D,5A,6B,7B),(1C,2E,3B,4D,5A,6B,7C),(1C,2E,3B,4D,5A,6C,7A),(1C,2E,3B,4D,5A,6C,7B),(1C,2E,3B,4D,5A,6C,7C),(1C,2E,3B,4D,5A,6D,7A),(1C,2E,3B,4D,5A,6D,7B),(1C,2E,3B,4D,5A,6D,7C),(1C,2E,3B,4D,5B,6A,7A),(1C,2E,3B,4 D 5B,6A,7C),(1C,2E,3B,4D,5B,6B,7A),(1C,2E,3B,4D,5B,6B,7B),(1C,2E,3B,4D,5B,6B,7C),(1C,2E,3B,4D,5B,6C,7A),(1C,2E,3B,4D,5B,6C,7B),(1C,2E,3B,4D,5B,6C,7C),(1C,2E,3B,4 D 5B,6D,7A),(1C,2E,3B,4D,5B,6D,7B),(1C,2E,3B,4D,5B,6D,7C),(1C,2E,3B,4E,5A,6A,7A),(1C,2E,3B,4E,5A,6A,7B),(1C,2E,3B,4E,5A,6A,7C),(1C,2E,3B,4E,5A,6B,7A),(1C,2E,3B,4E,5A,6B,7B),(1C,2E,3B,4 E 5A,6B,7C),(1C,2E,3B,4E,5A,6B,7C),(1C,2E,3B,4E,5A,6B,7C),(1C,2E,3B,4E,5A,6C,7A),(1C,2E,3B,4E,5A,6C,7B),(1C,2E,3B,4E,5A,6C,7C),(1C,2E,3B,4E,5A,6D,7A),(1C,2E,3B,4E,5A,6D,7B),(1C,2E,3B,4 E 5A,6D,7C),(1C,2E,3B,4E,5B,6A,7A),(1C,2E,3B,4E,5B,6A,7B),(1C,2E,3B,4E,5B,6A,7C),(1C,2E,3B,4E,5B,6B,7A),(1C,2E,3B,4E,5B,6B,7B),(1C,2E,3B,4E,5B,6B,7C),(1C,2E,3B,4E,5B,6C,7A),(1C,2E,3B,4E,5B,6C,7B),(1C,2E,3B,4E,5B,6C,7C),(1C,2E,3B,4E,5B,6D,7A),(1C,2E,3B,4E,5B,6D,7B),(1C,2E,3B,4E,5B,6D,7C),(1C,2E,3C,4 A 5A,6A,7A),(1C,2E,3C,4 A 5A,6A,7B),(1C,2E,3C,4A,5A,6A,7C),(1C,2E,3C,4A,5A,6B,7A),(1C,2E,3C,4A,5A,6B,7B),(1C,2E,3C,4A,5A,6B,7C),(1C,2E,3C,4A,5A,6C,7A),(1C,2E,3C,4A,5A,6C,7B),(1C,2E,3C,4A,5A,6C,7C),(1C,2E,3C,4A,5A,6D,7A),(1C,2E,3C,4A,5A,6D,7B),(1C,2E,3C,4A,5A,6D,7C),(1C,2E,3C,4A,5B,6A,7A),(1C,2E,3C,4A,5B,6A,7B),(1C,2E,3C,4A,5B,6A,7C),(1C,2E,3C,4A,5B,6B,7A),(1C,2E,3C,4 A 5B,6B,7B),(1C,2E,3C,4A,5B,6B,7C),(1C,2E,3C,4A,5B,6C,7A),(1C,2E,3C,4A,5B,6C,7B),(1C,2E,3C,4A,5B,6C,7C),(1C,2E,3C,4A,5B,6D,7A),(1C,2E,3C,4A,5B,6D,7B),(1C,2E,3C,4 A 5B,6D,7C),(1C,2E,3C,4A,5B,6D,7C),(1C,2E,3C,4B,5A,6A,7A),(1C,2E,3C,4B,5A,6A,7B),(1C,2E,3C,4B,5A,6A,7C),(1C,2E,3C,4B,5A,6B,7A),(1C,2E,3C,4B,5A,6B,7B),(1C,2E,3C,4B,5A,6B,7C),(1C,2E,3C,4B,5A,6C,7A),(1C,2E,3C,4B,5A,6C,7B),(1C,2E,3C,4B,5A,6C,7C),(1C,2E,3C,4B,5A,6D,7A),(1C,2E,3C,4B,5A,6D,7B),(1C,2E,3C,4B,5A,6D,7C),(1C,2E,3C,4 B 5B,6A,7A),(1C,2E,3C,4B,5B,6A,7B),(1C,2E,3C,4B,5B,6A,7C),(1C,2E,3C,4B,5B,6B,7A),(1C,2E,3C,4B,5B,6B,7B),(1C,2E,3C,4B,5B,6B,7C),(1C,2E,3C,4B,5B,6C,7A),(1C,2E,3C,4B,5B,6C,7B),(1C,2E,3C,4B,5B,6C,7C),(1C,2E,3C,4B,5B,6D,7A),(1C,2E,3C,4B,5B,6D,7B),(1C,2E,3C,4B,5B,6D,7C),(1C,2E,3C,4C,5A,6A,7A),(1C,2E,3C,4 C 5A,6A,7C),(1C,2E,3C,4C,5A,6B,7A),(1C,2E,3C,4C,5A,6B,7B),(1C,2E,3C,4C,5A,6B,7C),(1C,2E,3C,4C,5A,6C,7A),(1C,2E,3C,4C,5A,6C,7B),(1C,2E,3C,4C,5A,6C,7C),(1C,2E,3C,4 C 5A,6D,7A),(1C,2E,3C,4C,5A,6D,7B),(1C,2E,3C,4C,5A,6D,7C),(1C,2E,3C,4C,5B,6A,7A),(1C,2E,3C,4C,5B,6A,7B),(1C,2E,3C,4C,5B,6A,7C),(1C,2E,3C,4C,5B,6B,7A),(1C,2E,3C,4C,5B,6B,7B),(1C,2E,3C,4 C 5B,6B,7C),(1C,2E,3C,4C,5B,6C,7A),(1C,2E,3C,4C,5B,6C,7B),(1C,2E,3C,4C,5B,6C,7C),(1C,2E,3C,4C,5B,6D,7A),(1C,2E

4A,5B,6A,7B),(1C,2E,3D,4 A,5B,6A,7C),(1C,2E,3D,4A,5B,6B,7A),(1C,2E,3D,4A,5B,6B,7B),(1C,2E,3D,4A,5B,6B,7C),
7C),(1C,2E,3D,4A,5B,6C,7A),(1C,2E,3D,4A,5B,6C,7B),(1C,2E,3D,4A,5B,6C,7C),(1C,2E,3D,4 A,5B,6D,7A),(1C,2E,
3D,4A,5B,6D,7B),(1C,2E,3D,4A,5B,6D,7C),(1C,2E,3D,4B,5A,6A,7A), (1C,2E,3D,4B,5A,6A,7B),(1C,2E,3D,4B,5A,
6A,7C),(1C,2E,3D,4B,5A,6B,7A),(1C,2E,3D,4 B,5A,6B,7B),(1C,2E,3D,4B,5A,6B,7C),(1C,2E,3D,4B,5A,6C,7A),(1C,
5 2E,3D,4B,5A,6C,7B), (1C,2E,3D,4B,5A,6C,7C),(1C,2E,3D,4B,5A,6D,7A),(1C,2E,3D,4B,5A,6D,7B),(1C,2E,3D,4 B,
5A,6D,7C),(1C,2E,3D,4B,5B,6A,7A),(1C,2E,3D,4B,5B,6A,7B),(1C,2E,3D,4B,5B,6A,7C), (1C,2E,3D,4B,5B,6B,7A),
(1C,2E,3D,4B,5B,6B,7B),(1C,2E,3D,4B,5B,6B,7C),(1C,2E,3D,4 B,5B,6C,7A),(1C,2E,3D,4B,5B,6C,7B),(1C,2E,3D,
4B,5B,6C,7C),(1C,2E,3D,4B,5B,6D,7A), (1C,2E,3D,4B,5B,6D,7B),(1C,2E,3D,4B,5B,6D,7C),(1C,2E,3D,4C,5A,6A,
7A),(1C,2E,3D,4 C,5A,6A,7B),(1C,2E,3D,4C,5A,6A,7C),(1C,2E,3D,4C,5A,6B,7A),(1C,2E,3D,4C,5A,6B,7B), (1C,2E,
10 3D,4C,5A,6B,7C),(1C,2E,3D,4C,5A,6C,7A),(1C,2E,3D,4C,5A,6C,7B),(1C,2E,3D,4 C,5A,6C,7C),(1C,2E,3D,4C,5,
6D,7A),(1C,2E,3D,4C,5A,6D,7B),(1C,2E,3D,4C,5A,6D,7C), (1C,2E,3D,4C,5B,6A,7A),(1C,2E,3D,4C,5B,6A,7B),(1C,
2E,3D,4C,5B,6A,7C),(1C,2E,3D,4 C,5B,6B,7A),(1C,2E,3D,4C,5B,6B,7B),(1C,2E,3D,4C,5B,6B,7C),(1C,2E,3D,4C,
5B,6C,7A), (1C,2E,3D,4C,5B,6C,7B),(1C,2E,3D,4C,5B,6C,7C),(1C,2E,3D,4C,5B,6D,7A),(1C,2E,3D,4 C,5B,6D,7B),
(1C,2E,3D,4C,5B,6D,7C),(1C,2E,3D,4D,5A,6A,7A),(1C,2E,3D,4D,5A,6A,7B), (1C,2E,3D,4D,5A,6A,7C),(1C,2E,3D,
15 4D,5A,6B,7A),(1C,2E,3D,4D,5A,6B,7B),(1C,2E,3D,4 D,5A,6B,7C),(1C,2E,3D,4D,5A,6C,7A),(1C,2E,3D,4D,5A,6C,
7B),(1C,2E,3D,4D,5A,6C,7C), (1C,2E,3D,4D,5A,6D,7A),(1C,2E,3D,4D,5A,6D,7B),(1C,2E,3D,4D,5A,6D,7C),(1C,2E,
3D,4 D,5B,6A,7A),(1C,2E,3D,4D,5B,6A,7B),(1C,2E,3D,4D,5B,6A,7C),(1C,2E,3D,4D,5B,6B,7A), (1C,2E,3D,4D,5B,
6B,7B),(1C,2E,3D,4D,5B,6B,7C),(1C,2E,3D,4D,5B,6C,7A),(1C,2E,3D,4 D,5B,6C,7B),(1C,2E,3D,4D,5B,6C,7C),(1C,
2E,3D,4D,5B,6D,7A),(1C,2E,3D,4D,5B,6D,7B), (1C,2E,3D,4D,5B,6D,7C),(1C,2E,3D,4E,5A,6A,7A),(1C,2E,3D,4E,
20 5A,6A,7B),(1C,2E,3D,4 E,5A,6A,7C),(1C,2E,3D,4E,5A,8B,7A),(1C,2E,3D,4E,5A,6B,7B),(1C,2E,3D,4E,5A,6B,7C),
(1C,2E,3D,4E,5A,6C,7A),(1C,2E,3D,4E,5A,6C,7B),(1C,2E,3D,4E,5A,6C,7C),(1C,2E,3D,4 E,5A,6D,7A),(1C,2E,3D,
4E,5A,6D,7B),(1C,2E,3D,4E,5A,6D,7C),(1C,2E,3D,4E,5B,6A,7A), (1C,2E,3D,4E,5B,6A,7B),(1C,2E,3D,4E,5B,6A,
7C),(1C,2E,3D,4E,5B,6B,7A),(1C,2E,3D,4 E,5B,6B,7B),(1C,2E,3D,4E,5B,6B,7C),(1C,2E,3D,4E,5B,6C,7A),(1C,2E,
3D,4E,5B,6C,7B), (1C,2E,3D,4E,5B,6C,7C),(1C,2E,3D,4E,5B,6D,7A),(1C,2E,3D,4E,5B,6D,7B),(1C,2E,3D,4 E,5B,
25 6D,7C),(1C,2E,3E,4A,5A,6A,7A),(1C,2E,3E,4A,5A,6A,7B),(1C,2E,3E,4A,5A,6A,7C), (1C,2E,3E,4A,5A,6B,7A),(1C,
2E,3E,4A,5A,6B,7B),(1C,2E,3E,4A,5A,6B,7C),(1C,2E,3E,4 A,5A,6C,7A),(1C,2E,3E,4A,5A,6C,7B),(1C,2E,3E,4A,5A,
6C,7C),(1C,2E,3E,4A,5A,6D,7A), (1C,2E,3E,4A,5A,6D,7B),(1C,2E,3E,4A,5A,6D,7C),(1C,2E,3E,4A,5B,6A,7A),(1C,
2E,3E,4 A,5B,6A,7B),(1C,2E,3E,4A,5B,6A,7C),(1C,2E,3E,4A,5B,6B,7A), (1C,2E,3E,4A,5B,6B,7B),(1C,2E,3E,4A,
5B,6B,7C),(1C,2E,3E,4A,5B,6C,7A),(1C,2E,3E,4 A,5B,6C,7B),(1C,2E,3E,4A,5B,6C,7C),(1C,2E,3E,4A,5B,6D,7A),
30 (1C,2E,3E,4A,5B,6D,7B), (1C,2E,3E,4A,5B,6D,7C),(1C,2E,3E,4B,5A,6A,7A),(1C,2E,3E,4B,5A,6A,7B),(1C,2E,3E,4
B,5A,6A,7C),(1C,2E,3E,4B,5A,6B,7A),(1C,2E,3E,4B,5A,6B,7B),(1C,2E,3E,4B,5A,6B,7C), (1C,2E,3E,4B,5A,6C,7A),
(1C,2E,3E,4B,5A,6C,7B),(1C,2E,3E,4B,5A,6C,7C),(1C,2E,3E,4 B,5A,6D,7A),(1C,2E,3E,4B,5A,6D,7B),(1C,2E,3E,
4B,5A,6D,7C),(1C,2E,3E,4B,5B,6A,7A), (1C,2E,3E,4B,5B,6A,7B),(1C,2E,3E,4B,5B,6A,7C),(1C,2E,3E,4B,5B,6B,
7A),(1C,2E,3E,4 B,5B,6B,7B),(1C,2E,3E,4B,5B,6B,7C),(1C,2E,3E,4B,5B,6C,7A),(1C,2E,3E,4B,5B,6C,7B), (1C,2E,
35 3E,4B,5B,6C,7C),(1C,2E,3E,4B,5B,6D,7A),(1C,2E,3E,4B,5B,6D,7B),(1C,2E,3E,4 B,5B,6D,7C),(1C,2E,3E,4C,5A,
6A,7A),(1C,2E,3E,4C,5A,6A,7B),(1C,2E,3E,4C,5A,6A,7C), (1C,2E,3E,4C,5A,6B,7A),(1C,2E,3E,4C,5A,6B,7B),(1C,
2E,3E,4C,5A,6B,7C),(1C,2E,3E,4 C,5A,6C,7A),(1C,2E,3E,4C,5A,6C,7B),(1C,2E,3E,4C,5A,6C,7C),(1C,2E,3E,4C,
5A,6D,7A), (1C,2E,3E,4C,5A,6D,7B),(1C,2E,3E,4C,5A,6D,7C),(1C,2E,3E,4C,5B,6A,7A),(1C,2E,3E,4 C,5B,6A,7B),
(1C,2E,3E,4C,5B,6A,7C),(1C,2E,3E,4C,5B,6B,7A),(1C,2E,3E,4C,5B,6B,7B), (1C,2E,3E,4C,5B,6B,7C),(1C,2E,3E,
40 4C,5B,6C,7A),(1C,2E,3E,4C,5B,6C,7B),(1C,2E,3E,4 C,5B,6C,7C),(1C,2E,3E,4C,5B,6D,7A),(1C,2E,3E,4C,5B,6D,
7B),(1C,2E,3E,4C,5B,6D,7C), (1C,2E,3E,4D,5A,6A,7A),(1C,2E,3E,4D,5A,6A,7B),(1C,2E,3E,4D,5A,6A,7C),(1C,2E,
3E,4 D,5A,6B,7A),(1C,2E,3E,4D,5A,6B,7B),(1C,2E,3E,4D,5A,6B,7C),(1C,2E,3E,4D,5A,6C,7A), (1C,2E,3E,4D,5A,
6C,7B),(1C,2E,3E,4D,5A,6C,7C),(1C,2E,3E,

6C,7A),(1D,2A,3A,4B,5A,6C,7B),(1D,2A,3A,4 B,5A,6C,7C),(1D,2A,3A,4B,5A,6D,7A),(1D,2A,3A,4B,5A,6D,7B),(1D,
2A,3A,4B,5A,6D,7C), (1D,2A,3A,4B,5B,6A,7A),(1D,2A,3A,4B,5B,6A,7B),(1D,2A,3A,4B,5B,6A,7C),(1D,2A,3A,4 B,
5B,6B,7A),(1D,2A,3A,4B,5B,6B,7B),(1D,2A,3A,4B,5B,6B,7C),(1D,2A,3A,4B,5B,6C,7A), (1D,2A,3A,4B,5B,6C,7B),
(1D,2A,3A,4B,5B,6C,7C),(1D,2A,3A,4B,5B,6D,7A),(1D,2A,3A,4 B,5B,6D,7B),(1D,2A,3A,4B,5B,6D,7C),(1D,2A,3A,
4C,5A,6A,7A),(1D,2A,3A,4C,5A,6A,7B), (1D,2A,3A,4C,5A,6A,7C),(1D,2A,3A,4C,5A,6B,7A),(1D,2A,3A,4C,5A,6B,
7B),(1D,2A,3A,4 C,5A,6B,7C),(1D,2A,3A,4C,5A,6C,7A),(1D,2A,3A,4C,5A,6C,7B),(1D,2A,3A,4C,5A,6C,7C), (1D,2A,
3A,4C,5A,6D,7A),(1D,2A,3A,4C,5A,6D,7B),(1D,2A,3A,4C,5A,6D,7C),(1D,2A,3A,4 C,5B,6A,7A),(1D,2A,3A,4C,5B,
6A,7B),(1D,2A,3A,4C,5B,6A,7C),(1D,2A,3A,4C,5B,6B,7A), (1D,2A,3A,4C,5B,6C,7B),(1D,2A,3A,4C,5B,6B,7C),(1D,
2A,3A,4C,5B,6C,7A),(1D,2A,3A,4 C,5B,6C,7B),(1D,2A,3A,4C,5B,6C,7C),(1D,2A,3A,4C,5B,6D,7A),(1D,2A,3A,4C,
5B,6D,7B), (1D,2A,3A,4C,5B,6D,7C),(1D,2A,3A,4D,5A,6A,7A),(1D,2A,3A,4D,5A,6A,7B),(1D,2A,3A,4 D,5A,6A,7C
(1D,2A,3A,4D,5A,6B,7A),(1D,2A,3A,4D,5A,6B,7B),(1D,2A,3A,4D,5A,6B,7C), (1D,2A,3A,4D,5A,6C,7A),(1D,2A,3A,
4D,5A,6C,7B),(1D,2A,3A,4D,5A,6C,7C),(1D,2A,3A,4 D,5A,6D,7A),(1D,2A,3A,4D,5A,6D,7B),(1D,2A,3A,4D,5A,6D,
7C),(1D,2A,3A,4D,5B,6A,7A), (1D,2A,3A,4D,5B,6A,7B),(1D,2A,3A,4D,5B,6A,7C),(1D,2A,3A,4D,5B,6B,7A),(1D,2A,
3A,4 D,5B,6B,7B),(1D,2A,3A,4D,5B,6B,7C),(1D,2A,3A,4D,5B,6C,7A),(1D,2A,3A,4D,5B,6C,7B), (1D,2A,3A,4D,5B,
6C,7C),(1D,2A,3A,4D,5B,6D,7A),(1D,2A,3A,4D,5B,6D,7B),(1D,2A,3A,4 D,5B,6D,7C),(1D,2A,3A,4E,5A,6A,7A),(1D,
2A,3A,4E,5A,6A,7B),(1D,2A,3A,4E,5A,6A,7C), (1D,2A,3A,4E,5A,6B,7A),(1D,2A,3A,4E,5A,6B,7B),(1D,2A,3A,4E,5A,
6B,7C),(1D,2A,3A,4 E,5A,6C,7A),(1D,2A,3A,4E,5A,6C,7B),(1D,2A,3A,4E,5A,6C,7C),(1D,2A,3A,4E,5A,6D,7A), (1D,
2A,3A,4E,5A,6D,7B),(1D,2A,3A,4E,5A,6D,7C),(1D,2A,3A,4E,5B,6A,7A),(1D,2A,3A,4 E,5B,6A,7B),(1D,2A,3A,4E,5B,
6A,7C),(1D,2A,3A,4E,5B,6B,7A),(1D,2A,3A,4E,5B,6B,7B), (1D,2A,3A,4E,5B,6B,7C),(1D,2A,3A,4E,5B,6C,7A),(1D,
2A,3A,4E,5B,6C,7B),(1D,2A,3A,4 E,5B,6C,7C),(1D,2A,3A,4E,5B,6D,7A),(1D,2A,3A,4E,5B,6D,7B),(1D,2A,3A,4E,
5B,6D,7C), (1D,2A,3B,4A,5A,6A,7A),(1D,2A,3B,4A,5A,6A,7B),(1D,2A,3B,4A,5A,6A,7C),(1D,2A,3B,4 A,5A,6B,7A),
(1D,2A,3B,4A,5A,6B,7B),(1D,2A,3B,4A,5A,6B,7C),(1D,2A,3B,4A,5A,6C,7A), (1D,2A,3B,4A,5A,6C,7B),(1D,2A,3B,
4A,5A,6C,7C),(1D,2A,3B,4A,5A,6D,7A),(1D,2A,3B,4 A,5A,6D,7B),(1D,2A,3B,4A,5A,6D,7C),(1D,2A,3B,4A,5B,6A,
7A),(1D,2A,3B,4A,5B,6A,7B), (1D,2A,3B,4A,5B,6A,7C),(1D,2A,3B,4A,5B,6B,7A),(1D,2A,3B,4A,5B,6B,7B),(1D,2A,
3B,4 A,5B,6B,7C),(1D,2A,3B,4A,5B,6C,7A),(1D,2A,3B,4A,5B,6C,7B),(1D,2A,3B,4A,5B,6C,7C), (1D,2A,3B,4A,5B,
6D,7A),(1D,2A,3B,4A,5B,6D,7B),(1D,2A,3B,4A,5B,6D,7C),(1D,2A,3B,4 B,5A,6A,7A),(1D,2A,3B,4B,5A,6A,7B),(1D,
2A,3B,4B,5A,6A,7C),(1D,2A,3B,4B,5A,6B,7A), (1D,2A,3B,4B,5A,6B,7B),(1D,2A,3B,4B,5A,6B,7C),(1D,2A,3B,4B,5A,
6C,7A),(1D,2A,3B,4 B,5A,6C,7B),(1D,2A,3B,4B,5A,6C,7C),(1D,2A,3B,4B,5A,6D,7A),(1D,2A,3B,4B,5A,6D,7B),(1D,
2A,3B,4B,5A,6D,7C),(1D,2A,3B,4B,5B,6A,7A),(1D,2A,3B,4B,5B,6A,7B),(1D,2A,3B,4 B,5B,6A,7C),(1D,2A,3B,4B,5B,
6B,7A),(1D,2A,3B,4B,5B,6B,7B),(1D,2A,3B,4B,5B,6B,7C), (1D,2A,3B,4B,5B,6C,7A),(1D,2A,3B,4B,5B,6C,7B),(1D,
2A,3B,4B,5B,6C,7C),(1D,2A,3B,4 B,5B,6D,7A),(1D,2A,3B,4B,5B,6D,7B),(1D,2A,3B,4B,5B,6D,7C),(1D,2A,3B,4C,
5A,6A,7A), (1D,2A,3B,4C,5A,6A,7B),(1D,2A,3B,4C,5A,6A,7C),(1D,2A,3B,4C,5A,6B,7A),(1D,2A,3B,4 C,5A,6B,7B),
(1D,2A,3B,4C,5A,6B,7C),(1D,2A,3B,4C,5A,6C,7A),(1D,2A,3B,4C,5A,6C,7B), (1D,2A,3B,4C,5A,6C,7C),(1D,2A,3B,
4C,5A,6D,7A),(1D,2A,3B,4C,5A,6D,7B),(1D,2A,3B,4 C,5A,6D,7C),(1D,2A,3B,4C,5B,6A,7A),(1D,2A,3B,4C,5B,6A,
7B),(1D,2A,3B,4C,5B,6A,7C), (1D,2A,3B,4C,5B,6B,7A),(1D,2A,3B,4C,5B,6B,7B),(1D,2A,3B,4C,5B,6B,7C),(1D,2A,
3B,4 C,5B,6C,7A),(1D,2A,3B,4C,5B,6C,7B),(1D,2A,3B,4C,5B,6C,7C),(1D,2A,3B,4C,5B,6D,7A), (1D,2A,3B,4C,5B,
6D,7B),(1D,2A,3B,4C,5B,6D,7C),(1D,2A,3B,4D,5A,6A,7A),(1D,2A,3B,4 D,5A,6A,7B),(1D,2A,3B,4D,5A,6A,7C),(1D,
2A,3B,4D,5A,6B,7A),(1D,2A,3B,4D,5A,6B,7B), (1D,2A,3B,4D,5A,6B,7C),(1D,2A,3B,4D,5A,6C,7A),(1D,2A,3B,4D,
5A,6C,7B),(1D,2A,3B,4 D,5A,6C,7C),(1D,2A,3B,4D,5A,6D,7A),(1D,2A,3B,4D,5A,6D,7B),(1D,2A,3B,4D,5A,6D,7C),
40 (1D,2A,3B,4D,5B,6A,7A),(1D,2A,3B,4D,5B,6A,7B),(1D,2A,3B,4D,5B,6A,7C),(1D,2A,3B,4 D,5B,6B,7A),(1D,2A,3B,
4D,5B,6B,7B),(1D,2A,3B,4D,5B,6B,7C),(1D,2A,3B,4D,5B,6C,7A), (1D,2A,3B,4D,5B,6C,7B),(1D,2A,3B,4D,5B,6C,
7C),(1D,2A,3B,4D,5B,6D,7A),(1D,2A,3B,4 D,5B,6D,7B),(1D,2A,3B,4D,5B,6D,7C),(1D,2A,3B,4E,5A,6A,7A),(1D,2A,
3B,4E,5A,6A,7B), (1D,2A,3B,4E,5A,6A,7C),(1D,2A,3B,4E,5A,6B,7A),(

3C,4C,5A,6A,7A),(1D,2A,3C,4C,5A,6A,7B),(1D,2A,3C,4C,5A,6A,7C),(1D,2A,3C,4 C,5A,6B,7A),(1D,2A,3C,4C,5A,
6B,7B),(1D,2A,3C,4C,5A,6B,7C),(1D,2A,3C,4C,5A,6C,7A), (1D,2A,3C,4C,5A,6C,7B),(1D,2A,3C,4C,5A,6C,7C),(1D,
2A,3C,4C,5A,6D,7A),(1D,2A,3C,4 C,5A,6D,7B),(1D,2A,3C,4C,5A,6D,7C),(1D,2A,3C,4C,5B,6A,7A),(1D,2A,3C,4C,
5B,6A,7B), (1D,2A,3C,4C,5B,6A,7C),(1D,2A,3C,4C,5B,6B,7A),(1D,2A,3C,4C,5B,6B,7B),(1D,2A,3C,4 C,5B,6B,7C),
5 (1D,2A,3C,4C,5B,6C,7A),(1D,2A,3C,4C,5B,6C,7B),(1D,2A,3C,4C,5B,6C,7C), (1D,2A,3C,4C,5B,6D,7A),(1D,2A,3C,
4C,5B,6D,7B),(1D,2A,3C,4C,5B,6D,7C),(1D,2A,3C,4 D,5A,6A,7A),(1D,2A,3C,4D,5A,6A,7B),(1D,2A,3C,4D,5A,6A,
7C),(1D,2A,3C,4D,5A,6B,7A), (1D,2A,3C,4D,5A,6B,7B),(1D,2A,3C,4D,5A,6B,7C),(1D,2A,3C,4D,5A,6C,7A),(1D,2A,
3C,4 D,5A,6C,7B),(1D,2A,3C,4D,5A,6C,7C),(1D,2A,3C,4D,5A,6D,7A),(1D,2A,3C,4D,5A,6D,7B), (1D,2A,3C,4D,5A,
6D,7C),(1D,2A,3C,4D,5B,6A,7A),(1D,2A,3C,4D,5B,6A,7B),(1D,2A,3C,4 D,5B,6A,7C),(1D,2A,3C,4D,5B,6B,7A),(1D,
10 2A,3C,4D,5B,6B,7B),(1D,2A,3C,4D,5B,6B,7C), (1D,2A,3C,4D,5B,6C,7A),(1D,2A,3C,4D,5B,6C,7B),(1D,2A,3C,4D,5B,6C,7C),
5B,6C,7C),(1D,2A,3C,4 D,5B,6D,7A),(1D,2A,3C,4D,5B,6D,7B),(1D,2A,3C,4D,5B,6D,7C),(1D,2A,3C,4E,5A,6A,7A),
(1D,2A,3C,4E,5A,6A,7B),(1D,2A,3C,4E,5A,6A,7C),(1D,2A,3C,4E,5A,6B,7A),(1D,2A,3C,4 E,5A,6B,7B),(1D,2A,3C,
4E,5A,6B,7C),(1D,2A,3C,4E,5A,6C,7A),(1D,2A,3C,4E,5A,6C,7B), (1D,2A,3C,4E,5A,6C,7C),(1D,2A,3C,4E,5A,6D,
7A),(1D,2A,3C,4E,5A,6D,7B),(1D,2A,3C,4 E,5A,6D,7C),(1D,2A,3C,4E,5B,6A,7A),(1D,2A,3C,4E,5B,6A,7B),(1D,2A,
15 3C,4E,5B,6A,7C), (1D,2A,3C,4E,5B,6B,7A),(1D,2A,3C,4E,5B,6B,7B),(1D,2A,3C,4E,5B,6B,7C),(1D,2A,3C,4 E,5B,
6C,7A),(1D,2A,3C,4E,5B,6C,7B),(1D,2A,3C,4E,5B,6C,7C),(1D,2A,3C,4E,5B,6D,7A), (1D,2A,3C,4E,5B,6D,7B),(1D,
2A,3C,4E,5B,6D,7C),(1D,2A,3D,4A,5A,6A,7A),(1D,2A,3D,4 A,5A,6A,7B),(1D,2A,3D,4A,5A,6A,7C),(1D,2A,3D,4A,
5A,6B,7A),(1D,2A,3D,4A,5A,6B,7B), (1D,2A,3D,4A,5A,6B,7C),(1D,2A,3D,4A,5A,6C,7A),(1D,2A,3D,4A,5A,6C,7B),
(1D,2A,3D,4 A,5A,6C,7C),(1D,2A,3D,4A,5A,6D,7A),(1D,2A,3D,4A,5A,6D,7B),(1D,2A,3D,4A,5A,6D,7C),(1D,2A,3D,
20 4A,5B,6A,7A),(1D,2A,3D,4A,5B,6A,7B),(1D,2A,3D,4 A,5B,6A,7C),(1D,2A,3D,4A,5B,6B,7A),(1D,2A,3D,4A,5B,6B,
7B),(1D,2A,3D,4A,5B,6B,7C), (1D,2A,3D,4A,5B,6C,7A),(1D,2A,3D,4A,5B,6C,7B),(1D,2A,3D,4A,5B,6C,7C),(1D,2A,
3D,4 A,5B,6D,7A),(1D,2A,3D,4A,5B,6D,7B),(1D,2A,3D,4A,5B,6D,7C),(1D,2A,3D,4B,5A,6A,7A), (1D,2A,3D,4B,5A,
6A,7B),(1D,2A,3D,4B,5A,6A,7C),(1D,2A,3D,4B,5A,6B,7A),(1D,2A,3D,4 B,5A,6B,7B),(1D,2A,3D,4B,5A,6B,7C),(1D,
2A,3D,4B,5A,6C,7A),(1D,2A,3D,4B,5A,6C,7B), (1D,2A,3D,4B,5A,6C,7C),(1D,2A,3D,4B,5A,6D,7A),(1D,2A,3D,4B,
25 5A,6D,7B),(1D,2A,3D,4 B,5A,6D,7C),(1D,2A,3D,4B,5B,6A,7A),(1D,2A,3D,4B,5B,6A,7B),(1D,2A,3D,4B,5B,6A,7C),
(1D,2A,3D,4B,5B,6B,7A),(1D,2A,3D,4B,5B,6B,7B),(1D,2A,3D,4B,5B,6B,7C),(1D,2A,3D,4 B,5B,6C,7A),(1D,2A,3D,
4B,5B,6C,7B),(1D,2A,3D,4B,5B,6C,7C),(1D,2A,3D,4B,5B,6D,7A), (1D,2A,3D,4B,5B,6D,7B),(1D,2A,3D,4B,5B,6D,
7C),(1D,2A,3D,4C,5A,6A,7A),(1D,2A,3D,4 C,5A,6A,7B),(1D,2A,3D,4C,5A,6A,7C),(1D,2A,3D,4C,5A,6B,7A),(1D,2A,
30 3B,4C,5A,6B,7B), (1D,2A,3D,4C,5A,6B,7C),(1D,2A,3D,4C,5A,6C,7A),(1D,2A,3D,4C,5A,6C,7B),(1D,2A,3D,4 C,5A,
6C,7C),(1D,2A,3D,4C,5A,6D,7A),(1D,2A,3D,4C,5A,6D,7B),(1D,2A,3D,4C,5A,6D,7C), (1D,2A,3D,4C,5B,6A,7A),(1D,
2A,3D,4C,5B,6A,7B),(1D,2A,3D,4C,5B,6A,7C),(1D,2A,3D,4 C,5B,6B,7A),(1D,2A,3D,4C,5B,6B,7B),(1D,2A,3D,4C,
5B,6B,7C),(1D,2A,3D,4C,5B,6C,7A), (1D,2A,3D,4C,5B,6C,7B),(1D,2A,3D,4C,5B,6C,7C),(1D,2A,3D,4C,5B,6D,7A),
(1D,2A,3D,4 C,5B,6D,7B),(1D,2A,3D,4C,5B,6D,7C),(1D,2A,3D,4D,5A,6A,7A),(1D,2A,3D,4D,5A,6A,7B), (1D,2A,3D,
35 4D,5A,6A,7C),(1D,2A,3D,4D,5A,6B,7A),(1D,2A,3D,4D,5A,6B,7B),(1D,2A,3D,4 D,5A,6B,7C),(1D,2A,3D,4D,5A,6C,
7A),(1D,2A,3D,4D,5A,6C,7B),(1D,2A,3D,4D,5A,6C,7C), (1D,2A,3D,4D,5A,6D,7A),(1D,2A,3D,4D,5A,6D,7B),(1D,2A,
3D,4D,5A,6D,7C),(1D,2A,3D,4 D,5B,6A,7A),(1D,2A,3D,4D,5B,6A,7B),(1C,2A,3D,4D,5B,6A,7C),(1D,2A,3D,4D,5B,
6B,7A), (1D,2A,3D,4D,5B,6B,7B),(1D,2A,3D,4D,5B,6B,7C),(1D,2A,3D,4D,5B,6C,7A),(1D,2A,3D,4 D,5B,6C,7B),(1D,
40 2A,3D,4D,5B,6C,7C),(1D,2A,3D,4D,5B,6D,7A),(1D,2A,3D,4D,5B,6D,7B), (1D,2A,3D,4D,5B,6D,7C),(1D,2A,3D,4E,
5A,6A,7A),(1D,2A,3D,4E,5A,6A,7B),(1D,2A,3D,4 E,5A,6A,7C),(1D,2A,3D,4E,5A,6B,7A),(1D,2A,3D,4E,5A,6B,7B),
(1D,2A,3D,4E,5A,6B,7C), (1D,2A,3D,4E,5A,6C,7A),(1D,2A,3D,4E,5A,6C,7B),(1D,2A,3D,4E,5A,6C,7C),(1D,2A,3D,4
E,5A,6D,7A),(1D,2A,3D,4E,5A,6D,7B),(1D,2A,3D,4E,5A,6D,7C),(1D,2A,3D,4E,5B,6A,7A), (1D,2A,3D,4E,5B,6A,
7B),(1D,2A,3D,4E,5B,6A,7C),(1D,2A,3D,4E,5B,6B,7A),(1D,2A,3D,4 E,5B,6B,7B),(1D,2A,3D,4E,5B,6B,7C),(1D,2A,
3D,4E,5B,6C,7A),(1D,2A,3D,4E,5B,6C,7B), (

5B,6B,7C),(1D,2A,3E,4C,5B,6C,7A),(1D,2A,3E,4C,5B,6C,7B),(1D,2A,3E,4C,5B,6C,7C),(1D,2A,3E,4 C,5B,6D,7A),
(1D,2A,3E,4C,5B,6D,7B),(1D,2A,3E,4C,5B,6D,7C),(1D,2A,3E,4D,5A,6A,7A),(1D,2A,3E,4D,5A,6A,7B),(1D,2A,3E,
4D,5A,6A,7C),(1D,2A,3E,4D,5A,6B,7A),(1D,2A,3E,4 D,5A,6B,7B),(1D,2A,3E,4D,5A,6B,7C),(1D,2A,3E,4D,5A,6C,
7A),(1D,2A,3E,4D,5A,6C,7B),(1D,2A,3E,4D,5A,6C,7C),(1D,2A,3E,4D,5A,6D,7A),(1D,2A,3E,4D,5A,6D,7B),(1D,2A,
3E,4 D,5A,6D,7C),(1D,2A,3E,4D,5B,6A,7A),(1D,2A,3E,4D,5B,6A,7B),(1D,2A,3E,4D,5B,6A,7C),(1D,2A,3E,4D,5B,
6B,7A),(1D,2A,3E,4D,5B,6B,7B),(1D,2A,3E,4D,5B,6B,7C),(1D,2A,3E,4 D,5B,6C,7A),(1D,2A,3E,4D,5B,6C,7B),(1D,
2A,3E,4D,5B,6C,7C),(1D,2A,3E,4D,5B,6D,7A),(1D,2A,3E,4D,5B,6D,7B),(1D,2A,3E,4D,5B,6D,7C),(1D,2A,3E,4E,
5A,6A,7A),(1D,2A,3E,4 E,5A,6A,7B),(1D,2A,3E,4E,5A,6A,7C),(1D,2A,3E,4E,5A,6B,7A),(1D,2A,3E,4E,5A,6B,7B),
(1D,2A,3E,4E,5A,6B,7C),(1D,2A,3E,4E,5A,6C,7A),(1D,2A,3E,4E,5A,6C,7B),(1D,2A,3E,4 E,5A,6C,7C),(1D,2A,3E,
4E,5A,6D,7A),(1D,2A,3E,4E,5A,6D,7B),(1D,2A,3E,4E,5A,6D,7C),(1D,2A,3E,4E,5B,6A,7A),(1D,2A,3E,4E,5B,6A,
7B),(1D,2A,3E,4E,5B,6A,7C),(1D,2A,3E,4 E,5B,6B,7A),(1D,2A,3E,4E,5B,6B,7B),(1D,2A,3E,4E,5B,6B,7C),(1D,2A,
3E,4E,5B,6C,7A),(1D,2A,3E,4E,5B,6C,7B),(1D,2A,3E,4E,5B,6C,7C),(1D,2A,3E,4E,5B,6D,7A),(1D,2A,3E,4 E,5B,
6D,7B),(1D,2A,3E,4E,5B,6D,7C),(1D,2B,3A,4A,5A,6A,7A),(1D,2B,3A,4A,5A,6A,7B),(1D,2B,3A,4A,5A,6A,7C),(1D,
2B,3A,4A,5A,6B,7A),(1D,2B,3A,4A,5A,6B,7B),(1D,2B,3A,4 A,5A,6B,7C),(1D,2B,3A,4A,5A,6C,7A),(1D,2B,3A,4A,5A,
6C,7B),(1D,2B,3A,4A,5A,6C,7C),(1D,2B,3A,4A,5A,6D,7A),(1D,2B,3A,4A,5A,6D,7B),(1D,2B,3A,4A,5A,6D,7C),(1D,
2B,3A,4 A,5B,6A,7A),(1D,2B,3A,4A,5B,6A,7B),(1D,2B,3A,4A,5B,6A,7C),(1D,2B,3A,4A,5B,6B,7A),(1D,2B,3A,4A,
5B,6B,7B),(1D,2B,3A,4A,5B,6B,7C),(1D,2B,3A,4A,5B,6C,7A),(1D,2B,3A,4 A,5B,6C,7B),(1D,2B,3A,4A,5B,6C,7C),
(1D,2B,3A,4A,5B,6D,7A),(1D,2B,3A,4A,5B,6D,7B),(1D,2B,3A,4A,5B,6D,7C),(1D,2B,3A,4B,5A,6A,7A),(1D,2B,3A,
4B,5A,6A,7B),(1D,2B,3A,4 B,5A,6A,7C),(1D,2B,3A,4B,5A,6B,7A),(1D,2B,3A,4B,5A,6B,7B),(1D,2B,3A,4B,5A,6B,7C),
(1D,2B,3A,4B,5A,6C,7A),(1D,2B,3A,4B,5A,6C,7B),(1D,2B,3A,4B,5A,6C,7C),(1D,2B,3A,4B,5A,6D,7A),(1D,2B,3A,4 B,5A,6D,7A),
(1D,2B,3A,4B,5A,6D,7B),(1D,2B,3A,4B,5A,6D,7C),(1D,2B,3A,4B,5B,6A,7A),(1D,2B,3A,4B,5B,6A,7B),(1D,2B,3A,4B,5B,6A,
7C),(1D,2B,3A,4B,5B,6B,7A),(1D,2B,3A,4 B,5B,6B,7B),(1D,2B,3A,4B,5B,6B,7C),(1D,2B,3A,4B,5B,6C,7A),(1D,2B,
3A,4B,5B,6C,7B),(1D,2B,3A,4B,5B,6C,7C),(1D,2B,3A,4B,5B,6D,7A),(1D,2B,3A,4B,5B,6D,7B),(1D,2B,3A,4 B,5B,
6D,7C),(1D,2B,3A,4C,5A,6A,7A),(1D,2B,3A,4C,5A,6A,7B),(1D,2B,3A,4C,5A,6A,7C),(1D,2B,3A,4C,5A,6B,7A),(1D,
2B,3A,4C,5A,6B,7B),(1D,2B,3A,4C,5A,6B,7C),(1D,2B,3A,4 C,5A,6C,7A),(1D,2B,3A,4C,5A,6C,7B),(1D,2B,3A,4C,
5A,6C,7C),(1D,2B,3A,4C,5A,6D,7A),(1D,2B,3A,4C,5A,6D,7B),(1D,2B,3A,4C,5A,6D,7C),(1D,2B,3A,4C,5B,6A,7A),
(1D,2B,3A,4 C,5B,6A,7B),(1D,2B,3A,4C,5B,6A,7C),(1D,2B,3A,4C,5B,6B,7A),(1D,2B,3A,4C,5B,6B,7B),(1D,2B,3A,
4C,5B,6B,7C),(1D,2B,3A,4C,5B,6C,7A),(1D,2B,3A,4C,5B,6C,7B),(1D,2B,3A,4 C,5B,6C,7C),(1D,2B,3A,4C,5B,6D,
7A),(1D,2B,3A,4C,5B,6D,7B),(1D,2B,3A,4C,5B,6D,7C),(1D,2B,3A,4D,5A,6A,7A),(1D,2B,3A,4D,5A,6A,7B),(1D,2B,
3A,4D,5A,6A,7C),(1D,2B,3A,4 D,5A,6B,7A),(1D,2B,3A,4D,5A,6B,7B),(1D,2B,3A,4D,5A,6B,7C),(1D,2B,3A,4D,5A,
6C,7A),(1D,2B,3A,4D,5A,6C,7B),(1D,2B,3A,4D,5A,6C,7C),(1D,2B,3A,4D,5A,6D,7A),(1D,2B,3A,4 D,5A,6D,7B),(1D,
2B,3A,4D,5A,6D,7C),(1D,2B,3A,4D,5B,6A,7A),(1D,2B,3A,4D,5B,6A,7B),(1D,2B,3A,4D,5B,6A,7C),(1D,2B,3A,4D,
5B,6B,7A),(1D,2B,3A,4D,5B,6B,7B),(1D,2B,3A,4 D,5B,6B,7C),(1D,2B,3A,4D,5B,6C,7A),(1D,2B,3A,4B,5B,6C,7B),
(1D,2B,3A,4D,5B,6C,7C),(1D,2B,3A,4D,5B,6D,7A),(1D,2B,3A,4D,5B,6D,7B),(1D,2B,3A,4D,5B,6D,7C),(1D,2B,3A,4
E,5A,6A,7A),(1D,2B,3A,4E,5A,6A,7B),(1D,2B,3A,4E,5A,6A,7C),(1D,2B,3A,4E,5A,6B,7A),(1D,2B,3A,4E,5A,6B,7B),
(1D,2B,3A,4E,5A,6B,7C),(1D,2B,3A,4E,5A,6C,7A),(1D,2B,3A,4 E,5A,6C,7B),(1D,2B,3A,4E,5A,6C,7C),(1D,2B,3A,
4E,5A,6D,7A),(1D,2B,3A,4E,5A,6D,7B),(1D,2B,3A,4E,5A,6D,7C),(1D,2B,3A,4E,5B,6A,7A),(1D,2B,3A,4E,5B,6A,
7B),(1D,2B,3A,4 E,5B,6A,7C),(1D,2B,3A,4E,5B,6B,7A),(1D,2B,3A,4E,5B,6B,7B),(1D,2B,3A,4E,5B,6B,7C),(1D,2B,
3A,4E,5B,6C,7A),(1D,2B,3A,4E,5B,6C,7B),(1D,2B,3A,4E,5B,6C,7C),(1D,2B,3A,4 E,5B,6D,7A),(1D,2B,3A,4E,5B,
6D,7B),(1D,2B,3A,4E,5B,6D,7C),(1D,2B,3B,4A,5A,6A,7A),(1D,2B,3B,4A,5A,6A,7B),(1D,2B,3B,4A,5A,6A,7C),(1D,
2B,3B,4A,5A,6B,7A),(1D,2B,3B,4 A,5A,6B,7B),(1D,2B,3B,4A,5A,6B,7C),(1D,2B,3B,4A,5A,6C,7A),(1D,2B,3B,4A,5A,
6C,7B),(1D,2B,3B,4A,5A,6C,7C),(1D,2B,3B,4A,5A,6D,7A),(1D,2B,3B,4A,5A,6D,7B),(1D,2B,3B,4 A,5A,6D,7C),(1D,
2B,3B,4A,5B,6A,7A),(1D,2B,3B,4A,5B,6A,7B),(1D,2B,3B,4A,5B,6

2B,3B,4D,5A,6D,7C),(1D,2B,3B,4D,5B,6A,7A), (1D,2B,3B,4D,5B,6A,7B),(1D,2B,3B,4D,5B,6A,7C),(1D,2B,3B,4D,
 5B,6B,7A),(1D,2B,3B,4 D,5B,6B,7B),(1D,2B,3B,4D,5B,6B,7C),(1D,2B,3B,4D,5B,6C,7A),(1D,2B,3B,4D,5B,6C,7B),
 (1D,2B,3B,4D,5B,6C,7C),(1D,2B,3B,4D,5B,6D,7A),(1D,2B,3B,4D,5B,6D,7B),(1D,2B,3B,4 D,5B,6D,7C),(1D,2B,3B,
 4E,5A,6A,7A),(1D,2B,3B,4E,5A,6A,7B),(1D,2B,3B,4E,5A,6A,7C), (1D,2B,3B,4E,5A,6B,7A),(1D,2B,3B,4E,5A,6B,
 7B),(1D,2B,3B,4E,5A,6B,7C),(1D,2B,3B,4 E,5A,6C,7A),(1D,2B,3B,4E,5A,6C,7B),(1D,2B,3B,4E,5A,6C,7C),(1D,2B,
 3B,4E,5A,6D,7A), (1D,2B,3B,4E,5A,6D,7B),(1D,2B,3B,4E,5A,6D,7C),(1D,2B,3B,4E,5B,6A,7A),(1D,2B,3B,4 E,5B,
 6A,7B),(1D,2B,3B,4E,5B,6A,7C),(1D,2B,3B,4E,5B,6B,7A),(1D,2B,3B,4E,5B,6B,7B), (1D,2B,3B,4E,5B,6B,7C),(1D,
 2B,3B,4E,5B,6C,7A),(1D,2B,3B,4E,5B,6C,7B),(1D,2B,3B,4 E,5B,6C,7C),(1D,2B,3B,4E,5B,6D,7A),(1D,2B,3B,4E,
 5B,6D,7B),(1D,2B,3B,4E,5B,6D,7C), (1D,2B,3C,4A,5A,6A,7A),(1D,2B,3C,4A,5A,6A,7B),(1D,2B,3C,4A,5A,6A,7C),
 10 (1D,2B,3C,4 A,5A,6B,7A),(1D,2B,3C,4A,5A,6B,7B),(1D,2B,3C,4A,5A,6B,7C), (1D,2B,3C,4A,5A,6C,7A),(1D,2B,3C,
 4A,5A,6C,7B),(1D,2B,3C,4A,5A,6C,7C),(1D,2B,3C,4 A,5A,6D,7A),(1D,2B,3C,4A,5A,6D,7B),(1D,2B,3C,4A,5A,6D,
 7C),(1D,2B,3C,4A,5B,6A,7A), (1D,2B,3C,4A,5B,6A,7B),(1D,2B,3C,4A,5B,6A,7C),(1D,2B,3C,4A,5B,6B,7A),(1D,2B,
 3C,4 A,5B,6B,7B),(1D,2B,3C,4A,5B,6B,7C),(1D,2B,3C,4A,5B,6C,7A),(1D,2B,3C,4A,5B,6C,7B), (1D,2B,3C,4A,5B,
 6C,7C),(1D,2B,3C,4A,5B,6D,7A),(1D,2B,3C,4A,5B,6D,7B),(1D,2B,3C,4 A,5B,6D,7C),(1D,2B,3C,4B,5A,6A,7A),(1D,
 15 2B,3C,4B,5A,6A,7B),(1D,2B,3C,4B,5A,6A,7C), (1D,2B,3C,4B,5A,6B,7A),(1D,2B,3C,4B,5A,6B,7B),(1D,2B,3C,4B,
 5A,6B,7C),(1D,2B,3C,4 B,5A,6C,7A),(1D,2B,3C,4B,5A,6C,7B),(1D,2B,3C,4B,5A,6C,7C),(1D,2B,3C,4B,5A,6D,7A),
 (1D,2B,3C,4B,5A,6D,7B),(1D,2B,3C,4B,5A,6D,7C),(1D,2B,3C,4B,5B,6A,7A),(1D,2B,3C,4 B,5B,6A,7B),(1D,2B,3C,
 4B,5B,6A,7C),(1D,2B,3C,4B,5B,6B,7A),(1D,2B,3C,4B,5B,6B,7B), (1D,2B,3C,4B,5B,6B,7C),(1D,2B,3C,4B,5B,6C,
 7A),(1D,2B,3C,4B,5B,6C,7B),(1D,2B,3C,4 B,5B,6C,7C),(1D,2B,3C,4B,5B,6D,7A),(1D,2B,3C,4B,5B,6D,7B),(1D,2B,
 20 3C,4B,5B,6D,7C), (1D,2B,3C,4C,5A,6A,7A),(1D,2B,3C,4C,5A,6A,7B),(1D,2B,3C,4C,5A,6A,7C),(1D,2B,3C,4 C,5A,
 6B,7A),(1D,2B,3C,4C,5A,6B,7B),(1D,2B,3C,4C,5A,6B,7C),(1D,2B,3C,4C,5A,6C,7A), (1D,2B,3C,4C,5A,6C,7B),(1D,
 2B,3C,4C,5A,6C,7C),(1D,2B,3C,4C,5A,6D,7A),(1D,2B,3C,4 C,5A,6D,7B),(1D,2B,3C,4C,5A,6D,7C),(1D,2B,3C,4C,
 5B,6A,7A),(1D,2B,3C,4C,5B,6A,7B), (1D,2B,3C,4C,5B,6A,7C),(1D,2B,3C,4C,5B,6B,7A),(1D,2B,3C,4C,5B,6B,7B),
 (1D,2B,3C,4 C,5B,6B,7C),(1D,2B,3C,4C,5B,6C,7A),(1D,2B,3C,4C,5B,6C,7B),(1D,2B,3C,4C,5B,6C,7C), (1D,2B,3C,
 25 4C,5B,6D,7A),(1D,2B,3C,4C,5B,6D,7B),(1D,2B,3C,4C,5B,6D,7C),(1D,2B,3C,4 D,5A,6A,7A),(1D,2B,3C,4D,5A,6A,
 7B),(1D,2B,3C,4D,5A,6A,7C),(1D,2B,3C,4D,5A,6B,7A), (1D,2B,3C,4D,5A,6B,7B),(1D,2B,3C,4D,5A,6B,7C),(1D,2B,
 3C,4D,5A,6C,7A),(1D,2B,3C,4 D,5A,6C,7B),(1D,2B,3C,4D,5A,6C,7C),(1D,2B,3C,4D,5A,6D,7A),(1D,2B,3C,4D,5A,
 6D,7B),(1D,2B,3C,4D,5A,6D,7C),(1D,2B,3C,4D,5B,6A,7A),(1D,2B,3C,4D,5B,6A,7B),(1D,2B,3C,4 D,5B,6A,7C),(1D,
 2B,3C,4D,5B,6B,7A),(1D,2B,3C,4D,5B,6B,7B),(1D,2B,3C,4D,5B,6B,7C), (1D,2B,3C,4D,5B,6C,7A),(1D,2B,3C,4D,
 30 5B,6C,7B),(1D,2B,3C,4D,5B,6C,7C),(1D,2B,3C,4 D,5B,6D,7A),(1D,2B,3C,4D,5B,6D,7B),(1D,2B,3C,4D,5B,6D,7C),
 (1D,2B,3C,4E,5A,6A,7A), (1D,2B,3C,4E,5A,6A,7B),(1D,2B,3C,4E,5A,6A,7C),(1D,2B,3C,4E,5A,6B,7A),(1D,2B,3C,4
 E,5A,6B,7B),(1D,2B,3C,4E,5A,6B,7C),(1D,2B,3C,4E,5A,6C,7A),(1D,2B,3C,4E,5A,6C,7B), (1D,2B,3C,4E,5A,6C,
 7C),(1D,2B,3C,4E,5A,6D,7A),(1D,2B,3C,4E,5A,6D,7B),(1D,2B,3C,4 E,5A,6D,7C),(1D,2B,3C,4E,5B,6A,7A),(1D,2B,
 3C,4E,5B,6A,7B),(1D,2B,3C,4E,5B,6A,7C), (1D,2B,3C,4E,5B,6B,7A),(1D,2B,3C,4E,5B,6B,7B),(1D,2B,3C,4E,5B,
 35 6B,7C),(1D,2B,3C,4 E,5B,6C,7A),(1D,2B,3C,4E,5B,6C,7B),(1D,2B,3C,4E,5B,6C,7C),(1D,2B,3C,4E,5B,6D,7A), (1D,
 2B,3C,4E,5B,6D,7B),(1D,2B,3C,4E,5B,6D,7C),(1D,2B,3D,4A,5A,6A,7A),(1D,2B,3D,4 A,5A,6A,7B),(1D,2B,3D,4A,
 5A,6A,7C),(1D,2B,3D,4A,5A,6B,7A),(1D,2B,3D,4A,5A,6B,7B), (1D,2B,3D,4A,5A,6B,7C),(1D,2B,3D,4A,5A,6C,7A),
 (1D,2B,3D,4A,5A,6C,7B),(1D,2B,3D,4 A,5A,6C,7C),(1D,2B,3D,4A,5A,6D,7A),(1D,2B,3D,4A,5A,6D,7B),(1D,2B,3D,
 4A,5A,6D,7C), (1D,2B,3D,4A,5B,6A,7A),(1D,2B,3D,4A,5B,6A,7B),(1D,2B,3D,4A,5B,6A,7C),(1D,2B,3D,4 A,5B,6B,
 40 7A),(1D,2B,3D,4A,5B,6B,7B),(1D,2B,3D,4A,5B,6B,7C),(1D,2B,3D,4A,5B,6C,7A), (1D,2B,3D,4A,5B,6C,7B),(1D,2B,
 3D,4A,5B,6C,7C),(1D,2B,3D,4A,5B,6D,7A),(1D,2B,3D,4 A,5B,6D,7B),(1D,2B,3D,4A,5B,6D,7C),(1D,2B,3D,4B,5A,
 6A,7A),(1D,2B,3D,4B,5A,6A,7B), (1D,2B,3D,4B,5A,6A,7C),(1D,2B,3D,4B,5A,6B,7A),(1D,2B,3D,4B,5A,6B,7B),(1D,
 2B,3D,4 B,5A,6B,7C),(1D,2B,3D,4B,5A,6C,7A),(1D,2B,3D,4B,5A,6C,7B),(1D,2B,3D,4B,5A,6C,7C), (1D,2B,3D,4B,
 5A,6D,7A),(1D,2B,3D,4B,5A,6D,7B),(1D,2B,3D,4B,5A,6D,7C),(1D,2B,3D,4 B,5B,6A,7A),(1D,2B,3D,4B,5B,6A,7B),
 45 (1D,2B,3D,4B,5B,6A,7C),(1D,2B,3D,4B,5B,6B,7A), (1D,2B,3D,4B,5B,6B,7B),(1D,2B,3D,4B,5B,6B,7C),(1D,2B,3D,
 4B,5B,6C,7A),(1D,2B,3D,4 B,5B,6C,7B),(1D,2B,3D,4B,5B,6C,7C),(1D,2B,3D,4B,5B,6D,7A),(1D,2B,3D,4B,5B,6D,
 7B), (1D,2B,3D,4B,5B,6D,7C),(1D,2B,3D,4C,5A,6A,7A),(1D,2B,3D,4C,5A,6A,7B),(1D,2B,3D,4 C,5A,6A,7C),(1D,2B,
 3D,4C,5A,6B,7A),(1D,2B,3D,4C,5A,6B,7B),(1D,2B,3D,4C,5A,6B,7C), (1D,2B,3D,4C,5A,6C,7A),(1D,2B,3D,4C,5A,
 6C,7B),(1D,2B,3D,4C,5A,6C,7C),(1D,2B,3D,4 C,5A,6D,7A),(1D,2B,3D,4C,5A,6D,7B),(1D,2B,3D,4C,5A,6D,7C),(1D,
 50 2B,3D,4C,5B,6A,7A), (1D,2B,3D,4C,5B,6A,7B),(1D,2B,3D,4C,5B,6A,7C),(1D,2B,3D,4C,5B,6B,7A),(1D,2B,3D,4 C,
 5B,6B,7B),(1D,2B,3D,4C,5B,6B,7C),(1D,2B,3D,4C,5B,6C,7A),(1D,2B,3D,4C,5B,6C,7B), (1D,2B,3D,4C,5B,6C,7C),
 (1D,2B,3D,4C,5B,6D,7A),(1D,2B,3D,4C,5B,6D,7B),(1D,2B,3D,4 C,5B,6D,7C),(1D,2B,3D,4D,5A,6A,7A),(1D,2B,3D,
 4D,5A,6A,7B),(1D,2B,3D,4D,5A,6A,7C), (1D,2B,3D,4D,5A,6B,7A),(1D,2B,3D,4D,5A,6B,7B),(1D,2B,3D,4D,5A,6B,
 7C),(1D,2B,3D,4 D,5A,6C,7A),(1D,2B,3D,4D,5A,6C,7B),(1D,2B,3D,4D,5A,6C,7C),(1D,2B,3D,4D,5A,6D,7A), (1D,2B,
 55 3D,4D,5A,6D,7B),(1D,2B,3D,4D,5A,6D,7C),(1D,2B,3D,4D,5B,6A,7A),(1D,2B,3D,4 D,5B,6A,7B),(1D,2B,3D,4D,5B,6A,
 7C),(1D,2B,3D,4D,5B,6B,7A),(1D,2B,3D,4D,5B,6B,7B), (1D,2B,3D,4D,5B,6B,7C),(1D,2B,3D,4D,5B,6C,7A),(1D,
 2B,3D,4D,5B,6C,7B),(1D,2B,3D,4 D,5B,6C,7C),(1D,2B,3D,4D,5B,6D,7A),(1D,2B,3D,4D,5B,6D,7B),(1D,2B,3D,4D,
 5B,6D,7C), (1D,2B,3D,4E,5A,6A,7A),(1D,2B,3D,4E,5A,6A,7B),(1D,2B,3D,4E,5A,6A,7C),(1D,2B,3D,4 E,5A,6B,7A),

282

3A,4E,5B,6D,7A),(1D,2C,3A,4 E,5B,6D,7B),(1D,2C,3A,4E,5B,6D,7C),(1D,2C,3B,4A,5A,6A,7A), (1D,2C,3B,4A,5A,6A,7B),(1D,2C,3B,4A,5A,6A,7C),(1D,2C,3B,4A,5A,6B,7A),(1D,2C,3B,4 A,5A,6B,7B),(1D,2C,3B,4A,5A,6B,7C),(1D,2C,3B,4A,5A,6C,7A),(1D,2C,3B,4A,5A,6C,7B), (1D,2C,3B,4A,5A,6C,7C),(1D,2C,3B,4A,5A,6D,7A),(1D,2C,3B,4A,5A,6D,7B),(1D,2C,3B,4 A,5A,6D,7C),(1D,2C,3B,4A,5B,6A,7A),(1D,2C,3B,4A,5B,6A,7B),(1D,2C,3B,4A,5B,6A,7C),
5 (1D,2C,3B,4A,5B,6B,7A),(1D,2C,3B,4A,5B,6B,7B),(1D,2C,3B,4A,5B,6B,7C),(1D,2C,3B,4 A,5B,6C,7A),(1D,2C,3B,4A,5B,6C,7B),(1D,2C,3B,4A,5B,6C,7C),(1D,2C,3B,4A,5B,6D,7A), (1D,2C,3B,4A,5B,6D,7B),(1D,2C,3B,4A,5B,6D,7C),(1D,2C,3B,4B,5A,6A,7A),(1D,2C,3B,4B,5A,6A,7B),(1D,2C,3B,4B,5A,6A,7C),(1D,2C,3B,4B,5A,6B,7A),(1D,2C,3B,4B,5A,6B,7B),(1D,2C,3B,4B,5A,6B,7C),(1D,2C,3B,4B,5A,6C,7A),(1D,2C,3B,4B,5A,6C,7B),(1D,2C,3B,4 B,5A,6C,7C),(1D,2C,3B,4B,5A,6D,7A),(1D,2C,3B,4B,5A,6D,7B),(1D,2C,3B,4B,5A,6D,7C), (1D,2C,3B,4B,5B,6A,7A),(1D,2C,3B,4B,5B,6A,7B),(1D,2C,3B,4B,5B,6A,7C),(1D,2C,3B,4 B,5B,6B,7A),(1D,2C,3B,4B,5B,6B,7B),(1D,2C,3B,4B,5B,6B,7C),(1D,2C,3B,4B,5B,6C,7A),(1D,2C,3B,4B,5B,6C,7B),(1D,2C,3B,4B,5B,6C,7C),(1D,2C,3B,4B,5B,6D,7A),(1D,2C,3B,4B,5B,6D,7B),(1D,2C,3B,4B,5B,6D,7C),(1D,2C,3B,4C,5A,6A,7A),(1D,2C,3B,4C,5A,6A,7B), (1D,2C,3B,4C,5A,6A,7C),(1D,2C,3B,4C,5A,6B,7A),(1D,2C,3B,4C,5A,6B,7B),(1D,2C,3B,4 C,5A,6B,7C),(1D,2C,3B,4C,5A,6C,7A),(1D,2C,3B,4C,5A,6C,7B),(1D,2C,3B,4C,5A,6C,7C), (1D,2C,3B,4C,5A,6D,7A),(1D,2C,3B,4C,5A,6D,7B),(1D,2C,3B,4C,5A,6D,7C),(1D,2C,3B,4 C,5B,6A,7A),(1D,2C,3B,4C,5B,6A,7B),(1D,2C,3B,4C,5B,6A,7C),(1D,2C,3B,4C,5B,6B,7A), (1D,2C,3B,4C,5B,6B,7B),(1D,2C,3B,4C,5B,6B,7C),(1D,2C,3B,4C,5B,6C,7A),(1D,2C,3B,4 C,5B,6C,7B),(1D,2C,3B,4C,5B,6C,7C),(1D,2C,3B,4C,5B,6D,7A),(1D,2C,3B,4C,5B,6D,7B), (1D,2C,3B,4C,5B,6D,7C),(1D,2C,3B,4C,5B,6D,7C),(1D,2C,3B,4D,5A,6A,7A),(1D,2C,3B,4D,5A,6A,7B),(1D,2C,3B,4D,5A,6A,7C),(1D,2C,3B,4D,5A,6B,7A),(1D,2C,3B,4D,5A,6B,7B),(1D,2C,3B,4D,5A,6B,7C),(1D,2C,3B,4D,5A,6C,7A),(1D,2C,3B,4D,5A,6C,7B),(1D,2C,3B,4D,5A,6C,7C),(1D,2C,3B,4 D,5A,6D,7A),(1D,2C,3B,4D,5A,6D,7B),(1D,2C,3B,4D,5A,6D,7C),(1D,2C,3B,4D,5B,6A,7A), (1D,2C,3B,4D,5B,6A,7B),(1D,2C,3B,4D,5B,6A,7C),(1D,2C,3B,4D,5B,6B,7A),(1D,2C,3B,4 D,5B,6B,7B),(1D,2C,3B,4D,5B,6B,7C),(1D,2C,3B,4D,5B,6C,7A),(1D,2C,3B,4D,5B,6C,7B), (1D,2C,3B,4D,5B,6C,7C),(1D,2C,3B,4D,5B,6D,7A),(1D,2C,3B,4D,5B,6D,7B),(1D,2C,3B,4 D,5B,6D,7C),(1D,2C,3B,4E,5A,6A,7A),(1D,2C,3B,4E,5A,6A,7B),(1D,2C,3B,4E,5A,6A,7C), (1D,2C,3B,4E,5A,6B,7A),(1D,2C,3B,4E,5A,6B,7B),(1D,2C,3B,4E,5A,6B,7C),(1D,2C,3B,4 E,5A,6C,7A),(1D,2C,3B,4E,5A,6C,7B),(1D,2C,3B,4E,5A,6C,7C),(1D,2C,3B,4E,5A,6D,7A), (1D,2C,3B,4E,5A,6D,7B),(1D,2C,3B,4E,5A,6D,7C),(1D,2C,3B,4E,5B,6A,7A),(1D,2C,3B,4 E,5B,6A,7B),(1D,2C,3B,4E,5B,6A,7C),(1D,2C,3B,4E,5B,6B,7A),(1D,2C,3B,4E,5B,6B,7B), (1D,2C,3B,4E,5B,6B,7C),(1D,2C,3B,4E,5B,6C,7A),(1D,2C,3B,4E,5B,6C,7B),(1D,2C,3B,4 E,5B,6C,7C),(1D,2C,3B,4E,5B,6D,7A),(1D,2C,3B,4E,5B,6D,7B),(1D,2C,3B,4E,5B,6D,7C), (1D,2C,3C,4A,5A,6A,7A),(1D,2C,3C,4A,5A,6A,7B),(1D,2C,3C,4A,5A,6A,7C),(1D,2C,3C,4 A,5A,6B,7A),(1D,2C,3C,4A,5A,6B,7B),(1D,2C,3C,4A,5A,6B,7C),(1D,2C,3C,4A,5A,6D,7A), (1D,2C,3C,4A,5A,6D,7B),(1D,2C,3C,4A,5A,6D,7C),(1D,2C,3C,4A,5B,6A,7A),(1D,2C,3C,4A,5B,6A,7B), (1D,2C,3C,4A,5B,6A,7C),(1D,2C,3C,4A,5B,6B,7A),(1D,2C,3C,4A,5B,6B,7B),(1D,2C,3C,4 A,5B,6B,7C),(1D,2C,3C,4A,5B,6C,7A),(1D,2C,3C,4A,5B,6C,7B),(1D,2C,3C,4A,5B,6C,7C), (1D,2C,3C,4A,5B,6D,7A),(1D,2C,3C,4A,5B,6D,7B),(1D,2C,3C,4A,5B,6D,7C),(1D,2C,3C,4 B,5A,6A,7A),(1D,2C,3C,4B,5A,6A,7B),(1D,2C,3C,4B,5A,6A,7C),(1D,2C,3C,4B,5A,6B,7A), (1D,2C,3C,4B,5A,6B,7B),(1D,2C,3C,4B,5A,6B,7C),(1D,2C,3C,4B,5A,6C,7A),(1D,2C,3C,4 B,5A,6C,7B),(1D,2C,3C,4B,5A,6C,7C),(1D,2C,3C,4B,5A,6D,7A),(1D,2C,3C,4B,5A,6D,7B), (1D,2C,3C,4B,5A,6D,7C),(1D,2C,3C,4B,5B,6A,7A),(1D,2C,3C,4B,5B,6A,7B),(1D,2C,3C,4 B,5B,6A,7C),(1D,2C,3C,4B,5B,6B,7A),(1D,2C,3C,4B,5B,6B,7B),(1D,2C,3C,4B,5B,6B,7C), (1D,2C,3C,4B,5B,6C,7A),(1D,2C,3C,4B,5B,6C,7B),(1D,2C,3C,4B,5B,6C,7C),(1D,2C,3C,4 B,5B,6D,7A),(1D,2C,3C,4B,5B,6D,7B),(1D,2C,3C,4B,5B,6D,7C),(1D,2C,3C,4C,5A,6A,7A), (1D,2C,3C,4C,5A,6A,7B),(1D,2C,3C,4C,5A,6A,7C),(1D,2C,3C,4C,5A,6B,7A),(1D,2C,3C,4 C,5A,6B,7B),(1D,2C,3C,4C,5A,6B,7C),(1D,2C,3C,4C,5A,6C,7A),(1D,2C,3C,4C,5A,6C,7B), (1D,2C,3C,4C,5A,6C,7C),(1D,2C,3C,4C,5A,6D,7A),(1D,2C,3C,4C,5A,6D,7B),(1D,2C,3C,4C,5A,6D,7C), (1D,2C,3C,4C,5B,6A,7A),(1D,2C,3C,4C,5B,6A,7B),(1D,2C,3C,4C,5B,6A,7C),(1D,2C,3C,4C,5B,6B,7A), (1D,2C,3C,4C,5B,6B,7B),(1D,2C,3C,4C,5B,6B,7C),(1D,2C,3C,4C,5B,6C,7A),(1D,2C,3C,4C,5B,6C,7B), (1D,2C,3C,4C,5B,6C,7C),(1D,2C,3C,4C,5B,6D,7A),(1D,2C,3C,4C,5B,6D,7B),(1D,2C,3C,4C,5B,6D,7C), (1D,2C,3C,4D,5A,6A,7A),(1D,2C,3C,4 D,5A,6A,7B),(1D,2C,3C,4D,5A,6A,7C),(1D,2C,3C,4D,5A,6B,7A),(1D,2C,3C,4D,5A,6B,7B), (1D,2C,3C,4D,5A,6B,7C),(1D,2C,3C,4D,5A,6C,7A),(1D,2C,3C,4D,5A,6C,7B),(1D,2C,3C,4D,5A,6C,7C), (1D,2C,3C,4D,5A,6D,7A),(1D,2C,3C,4D,5A,6D,7B),(1D,2C,3C,4D,5A,6D,7C),(1D,2C,3C,4D,5B,6A,7A),(1D,2C,3C,4D,5B,6A,7B),(1D,2C,3C,4 D,5B,6A,7C),(1D,2C,3C,4D,5B,6B,7A),(1D,2C,3C,4D,5B,6B,7B),(1D,2C,3C,4D,5B,6B,7C), (1D,2C,3C,4D,5B,6C,7A),(1D,2C,3C,4D,5B,6C,7B),(1D,2C,3C,4D,5B,6C,7C),(1D,2C,3C,4D,5B,6D,7A),(1D,2C,3C,4 D,5B,6D,7B),(1D,2C,3C,4D,5B,6D,7C),(1D,2C,3C,4E,5A,6A,7A),(1D,2C,3C,4E,5A,6A,7B), (1D,2C,3C,4E,5A,6A,7C),(1D,2C,3C,4E,5A,6B,7A),(1D,2C,3C,4E,5A,6B,7B),(1D,2C,3C,4 E,5A,6B,7C),(1D,2C,3C,4E,5A,6C,7A),(1D,2C,3C,4E,5A,6C,7B),(1D,2C,3C,4E,5A,6C,7C), (1D,2C,3C,4E,5A,6D,7A),(1D,2C,3C,4E,5A,6D,7B),(1D,2C,3C,4E,5A,6D,7C),(1D,2C,3C,4 E,5A,6D,7C),(1D,2C,3C,4 E,5B,6A,7A),(1D,2C,3C,4E,5B,6A,7B),(1D,2C,3C,4E,5B,6A,7C),(1D,2C,3C,4E,5B,6B,7A), (1D,2C,3C,4E,5B,6B,7B),(1D,2C,3C,4E,5B,6B,7C),(1D,2C,3C,4E,5B,6C,7A),(1D,2C,3C,4 E,5B,6C,7B),(1D,2C,3C,4E,5B,6C,7C),(1D,2C,3C,4E,5B,6D,7A),(1D,2C,3C,4E,5B,6D,7B), (1D,2C,3C,4E,5B,6D,7C),(1D,2C,3C,4E,5B,6D,7C),(1D,2C,3D,4A,5A,6A,7A),(1D,2C,3D,4A,5A,6A,7B), (1D,2C,3D,4A,5A,6A,7C),(1D,2C,3D,4A,5A,6B,7A),(1D,2C,3D,4A,5A,6B,7B), (1D,2C,3D,4A,5A,6B,7C),(1D,2C,3D,4A,5A,6C,7A),(1D,2C,3D,4A,5A,6C,7B),(1D,2C,3D,4A,5A,6C,7C),(1D,2C,3D,4A,5A,6D,7A),(1D,2C,3D,4A,5A,6D,7B),(1D,2C,3D,4A,5A,6D,7C),(1D,2C,3D,4A,5B,6A,7A), (1D,2C,3D,4A,5B,6A,7B),

(1D,2C,3D,4A,5B,6A,7C),(1D,2C,3D,4A,5B,6B,7A),(1D,2C,3D,4 A,5B,6B,7B),(1D,2C,3D,4A,5B,6B,7C),(1D,2C,3D,4A,5B,6C,7A),(1D,2C,3D,4A,5B,6C,7B),(1D,2C,3D,4A,5B,6C,7C),(1D,2C,3D,4A,5B,6D,7A),(1D,2C,3D,4A,5B,6D,7B),(1D,2C,3D,4 A,5B,6D,7C),(1D,2C,3D,4B,5A,6A,7A),(1D,2C,3D,4B,5A,6A,7B),(1D,2C,3D,4B,5A,6A,7C),(1D,2C,3D,4B,5A,6B,7A),(1D,2C,3D,4B,5A,6B,7B),(1D,2C,3D,4B,5A,6B,7C),(1D,2C,3D,4 B,5A,6C,7A),(1D,2C,3D,4B,5A,6C,7B),(1D,2C,3D,4B,5A,6C,7C),(1D,2C,3D,4B,5A,6D,7A),(1D,2C,3D,4B,5A,6D,7B),(1D,2C,3D,4B,5A,6D,7C),(1D,2C,3D,4B,5B,6A,7A),(1D,2C,3D,4 B,5B,6A,7B),(1D,2C,3D,4B,5B,6A,7C),(1D,2C,3D,4B,5B,6B,7A),(1D,2C,3D,4B,5B,6B,7B),(1D,2C,3D,4B,5B,6B,7C),(1D,2C,3D,4B,5B,6C,7A),(1D,2C,3D,4B,5B,6C,7B),(1D,2C,3D,4 B,5B,6C,7C),(1D,2C,3D,4B,5B,6D,7A),(1D,2C,3D,4B,5B,6D,7B),(1D,2C,3D,4B,5B,6D,7C),(1D,2C,3D,4C,5A,6A,7A),(1D,2C,3D,4C,5A,6A,7B),(1D,2C,3D,4C,5A,6A,7C),(1D,2C,3D,4C,5A,6B,7A),(1D,2C,3D,4C,5A,6B,7B),(1D,2C,3D,4C,5A,6B,7C),(1D,2C,3D,4 C,5A,6C,7A),(1D,2C,3D,4C,5A,6C,7B),(1D,2C,3D,4C,5A,6C,7C),(1D,2C,3D,4C,5A,6D,7A),(1D,2C,3D,4C,5A,6D,7B),(1D,2C,3D,4C,5A,6D,7C),(1D,2C,3D,4C,5B,6A,7A),(1D,2C,3D,4C,5B,6A,7B),(1D,2C,3D,4C,5B,6A,7C),(1D,2C,3D,4C,5B,6B,7A),(1D,2C,3D,4C,5B,6B,7B),(1D,2C,3D,4 C,5B,6B,7C),(1D,2C,3D,4C,5B,6C,7A),(1D,2C,3D,4C,5B,6C,7B),(1D,2C,3D,4C,5B,6C,7C),(1D,2C,3D,4C,5B,6D,7A),(1D,2C,3D,4C,5B,6D,7B),(1D,2C,3D,4C,5B,6D,7C),(1D,2C,3D,4C,5B,6D,7C),(1D,2C,3D,4 D,5A,6A,7A),(1D,2C,3D,4D,5A,6A,7B),(1D,2C,3D,4D,5A,6A,7C),(1D,2C,3D,4D,5A,6B,7A),(1D,2C,3D,4D,5A,6B,7B),(1D,2C,3D,4D,5A,6B,7C),(1D,2C,3D,4D,5A,6C,7A),(1D,2C,3D,4D,5A,6C,7B),(1D,2C,3D,4D,5A,6C,7C),(1D,2C,3D,4D,5A,6D,7A),(1D,2C,3D,4D,5A,6D,7B),(1D,2C,3D,4D,5A,6D,7C),(1D,2C,3D,4D,5B,6A,7A),(1D,2C,3D,4D,5B,6A,7B),(1D,2C,3D,4D,5B,6A,7C),(1D,2C,3D,4D,5B,6B,7A),(1D,2C,3D,4D,5B,6B,7B),(1D,2C,3D,4D,5B,6B,7C),(1D,2C,3D,4D,5B,6C,7A),(1D,2C,3D,4D,5B,6C,7B),(1D,2C,3D,4D,5B,6C,7C),(1D,2C,3D,4 D,5B,6D,7A),(1D,2C,3D,4D,5B,6D,7B),(1D,2C,3D,4D,5B,6D,7C),(1D,2C,3D,4D,5E,6A,7A),(1D,2C,3D,4D,5E,6A,7B),(1D,2C,3D,4D,5E,6A,7C),(1D,2C,3D,4E,5A,6A,7A),(1D,2C,3D,4E,5A,6A,7B),(1D,2C,3D,4E,5A,6A,7C),(1D,2C,3D,4E,5A,6B,7A),(1D,2C,3D,4E,5A,6B,7B),(1D,2C,3D,4E,5A,6B,7C),(1D,2C,3D,4E,5A,6C,7A),(1D,2C,3D,4E,5A,6C,7B),(1D,2C,3D,4E,5A,6C,7C),(1D,2C,3D,4E,5A,6D,7A),(1D,2C,3D,4E,5A,6D,7B),(1D,2C,3D,4E,5A,6D,7C),(1D,2C,3D,4E,5A,6D,7C),(1D,2C,3D,4E,5A,6B,7A),(1D,2C,3E,4 A,5A,6A,7B),(1D,2C,3E,4A,5A,6A,7C),(1D,2C,3E,4A,5A,6B,7A),(1D,2C,3E,4A,5A,6B,7B),(1D,2C,3E,4A,5A,6B,7C),(1D,2C,3E,4A,5A,6C,7A),(1D,2C,3E,4A,5A,6C,7B),(1D,2C,3E,4A,5A,6C,7C),(1D,2C,3E,4A,5A,6D,7A),(1D,2C,3E,4A,5A,6D,7B),(1D,2C,3E,4A,5A,6D,7C),(1D,2C,3E,4A,5A,6D,7C),(1D,2C,3E,4A,5B,6A,7A),(1D,2C,3E,4A,5B,6A,7B),(1D,2C,3E,4A,5B,6A,7C),(1D,2C,3E,4A,5B,6B,7A),(1D,2C,3E,4A,5B,6B,7B),(1D,2C,3E,4A,5B,6B,7C),(1D,2C,3E,4A,5B,6C,7A),(1D,2C,3E,4A,5B,6C,7B),(1D,2C,3E,4A,5B,6C,7C),(1D,2C,3E,4A,5B,6D,7A),(1D,2C,3E,4 A,5B,6D,7B),(1D,2C,3E,4A,5B,6D,7C),(1D,2C,3E,4B,5A,6A,7A),(1D,2C,3E,4B,5A,6A,7B),(1D,2C,3E,4B,5A,6A,7C),(1D,2C,3E,4B,5A,6B,7A),(1D,2C,3E,4B,5A,6B,7B),(1D,2C,3E,4 B,5A,6B,7C),(1D,2C,3E,4B,5A,6C,7A),(1D,2C,3E,4B,5A,6C,7B),(1D,2C,3E,4B,5A,6C,7C),(1D,2C,3E,4B,5A,6D,7A),(1D,2C,3E,4B,5A,6D,7B),(1D,2C,3E,4B,5A,6D,7C),(1D,2C,3E,4 B,5B,6A,7A),(1D,2C,3E,4B,5B,6A,7B),(1D,2C,3E,4B,5B,6A,7C),(1D,2C,3E,4B,5B,6B,7A),(1D,2C,3E,4B,5B,6B,7B),(1D,2C,3E,4B,5B,6B,7C),(1D,2C,3E,4B,5B,6C,7A),(1D,2C,3E,4 B,5B,6C,7B),(1D,2C,3E,4B,5B,6C,7C),(1D,2C,3E,4B,5B,6D,7A),(1D,2C,3E,4B,5B,6D,7B),(1D,2C,3E,4B,5B,6D,7C),(1D,2C,3E,4B,5B,6D,7C),(1D,2C,3E,4C,5A,6A,7A),(1D,2C,3E,4C,5A,6A,7B),(1D,2C,3E,4 C,5A,6A,7C),(1D,2C,3E,4C,5A,6B,7A),(1D,2C,3E,4C,5A,6B,7B),(1D,2C,3E,4C,5A,6B,7C),(1D,2C,3E,4C,5A,6C,7A),(1D,2C,3E,4C,5A,6C,7B),(1D,2C,3E,4C,5A,6C,7C),(1D,2C,3E,4C,5A,6D,7A),(1D,2C,3E,4C,5A,6D,7B),(1D,2C,3E,4C,5A,6D,7C),(1D,2C,3E,4C,5B,6A,7A),(1D,2C,3E,4C,5B,6A,7B),(1D,2C,3E,4 C,5B,6A,7C),(1D,2C,3E,4C,5B,6B,7A),(1D,2C,3E,4C,5B,6B,7B),(1D,2C,3E,4C,5B,6B,7C),(1D,2C,3E,4C,5B,6C,7A),(1D,2C,3E,4C,5B,6C,7B),(1D,2C,3E,4C,5B,6C,7C),(1D,2C,3E,4C,5B,6D,7A),(1D,2C,3E,4C,5B,6D,7B),(1D,2C,3E,4C,5B,6D,7C),(1D,2C,3E,4C,5B,6D,7C),(1D,2C,3E,4 C,5B,6D,7C),(1D,2C,3E,4D,5A,6A,7A),(1D,2C,3E,4D,5A,6A,7B),(1D,2C,3E,4D,5A,6A,7C),(1D,2C,3E,4D,5A,6B,7A),(1D,2C,3E,4D,5A,6B,7B),(1D,2C,3E,4D,5A,6B,7C),(1D,2C,3E,4 D,5A,6C,7A),(1D,2C,3E,4D,5A,6C,7B),(1D,2C,3E,4D,5A,6C,7C),(1D,2C,3E,4D,5A,6D,7A),(1D,2C,3E,4D,5A,6D,7B),(1D,2C,3E,4D,5A,6D,7C),(1D,2C,3E,4D,5B,6A,7A),(1D,2C,3E,4 D,5B,6A,7B),(1D,2C,3E,4D,5B,6A,7C),(1D,2C,3E,4D,5B,6B,7A),(1D,2C,3E,4D,5B,6B,7B),(1D,2C,3E,4D,5B,6B,7C),(1D,2C,3E,4D,5B,6C,7A),(1D,2C,3E,4D,5B,6C,7B

5A,6C,7A),(1D,2D,3A,4B,5A,6C,7B), (1D,2D,3A,4B,5A,6C,7C),(1D,2D,3A,4B,5A,6D,7A),(1D,2D,3A,4B,5A,6D,7B),
 (1D,2D,3A,4 B,5A,6D,7C),(1D,2D,3A,4B,5B,6A,7A),(1D,2D,3A,4B,5B,6A,7B),(1D,2D,3A,4B,5B,6A,7C), (1D,2D,3A,
 4B,5B,6B,7A),(1D,2D,3A,4B,5B,6B,7B),(1D,2D,3A,4B,5B,6B,7C),(1D,2D,3A,4 B,5B,6C,7A),(1D,2D,3A,4B,5B,6C,
 7B),(1D,2D,3A,4B,5B,6C,7C),(1D,2D,3A,4B,5B,6D,7A), (1D,2D,3A,4B,5B,6D,7B),(1D,2D,3A,4B,5B,6D,7C),(1D,2D,
 5 3A,4C,5A,6A,7A),(1D,2D,3A,4 C,5A,6A,7B),(1D,2D,3A,4C,5A,6A,7C),(1D,2D,3A,4C,5A,6B,7A),(1D,2D,3A,4C,5A,
 6B,7B), (1D,2D,3A,4C,5A,6B,7C),(1D,2D,3A,4C,5A,6C,7A),(1D,2D,3A,4C,5A,6C,7B),(1D,2D,3A,4 C,5A,6C,7C),(1D,
 2D,3A,4C,5A,6D,7A),(1D,2D,3A,4C,5A,6D,7B),(1D,2D,3A,4C,5A,6D,7C), (1D,2D,3A,4C,5B,6A,7A),(1D,2D,3A,4C,
 5B,6A,7B),(1D,2D,3A,4C,5B,6A,7C),(1D,2D,3A,4 C,5B,6B,7A),(1D,2D,3A,4C,5B,6B,7B),(1D,2D,3A,4C,5B,6B,7C),
 (1D,2D,3A,4C,5B,6C,7A),(1D,2D,3A,4C,5B,6C,7B),(1D,2D,3A,4C,5B,6C,7C),(1D,2D,3A,4C,5B,6D,7A),(1D,2D,3A,4
 10 C,5B,6D,7B),(1D,2D,3A,4C,5B,6D,7C),(1D,2D,3A,4D,5A,6A,7A),(1D,2D,3A,4D,5A,6A,7B), (1D,2D,3A,4D,5A,6A,
 7C),(1D,2D,3A,4D,5A,6B,7A),(1D,2D,3A,4D,5A,6B,7B),(1D,2D,3A,4 D,5A,6B,7C),(1D,2D,3A,4D,5A,6C,7A),(1D,2D,
 3A,4D,5A,6C,7B),(1D,2D,3A,4D,5A,6C,7C), (1D,2D,3A,4D,5A,6D,7A),(1D,2D,3A,4D,5A,6D,7B),(1D,2D,3A,4D,5A,
 6D,7C),(1D,2D,3A,4 D,5B,6A,7A),(1D,2D,3A,4D,5B,6A,7B),(1D,2D,3A,4D,5B,6A,7C),(1D,2D,3A,4D,5B,6B,7A), (1D,
 2D,3A,4D,5B,6B,7B),(1D,2D,3A,4D,5B,6B,7C),(1D,2D,3A,4D,5B,6C,7A),(1D,2D,3A,4 D,5B,6C,7B),(1D,2D,3A,4D,
 15 5B,6C,7C),(1D,2D,3A,4D,5B,6D,7A),(1D,2D,3A,4D,5B,6D,7B), (1D,2D,3A,4D,5B,6D,7C),(1D,2D,3A,4E,5A,6A,7A),
 (1D,2D,3A,4E,5A,6A,7B),(1D,2D,3A,4 E,5A,6A,7C),(1D,2D,3A,4E,5A,6B,7A),(1D,2D,3A,4E,5A,6B,7B),(1D,2D,3A,
 4E,5A,6B,7C), (1D,2D,3A,4E,5A,6C,7A),(1D,2D,3A,4E,5A,6C,7B),(1D,2D,3A,4E,5A,6C,7C),(1D,2D,3A,4 E,5A,6D,
 7A),(1D,2D,3A,4E,5A,6D,7B),(1D,2D,3A,4E,5A,6D,7C),(1D,2D,3A,4E,5B,6A,7A), (1D,2D,3A,4E,5B,6A,7B),(1D,2D,
 20 3A,4E,5B,6A,7C),(1D,2D,3A,4E,5B,6B,7A),(1D,2D,3A,4 E,5B,6B,7B),(1D,2D,3A,4E,5B,6B,7C),(1D,2D,3A,4E,5B,
 6C,7A),(1D,2D,3A,4E,5B,6C,7B), (1D,2D,3A,4E,5B,6C,7C),(1D,2D,3A,4E,5B,6D,7A),(1D,2D,3A,4E,5B,6D,7B),(1D,
 2D,3A,4 E,5B,6D,7C),(1D,2D,3B,4A,5A,6A,7A),(1D,2D,3B,4A,5A,6A,7B),(1D,2D,3B,4A,5A,6A,7C), (1D,2D,3B,4A,
 5A,6B,7A),(1D,2D,3B,4A,5A,6B,7B),(1D,2D,3B,4A,5A,6B,7C),(1D,2D,3B,4 A,5A,6C,7A),(1D,2D,3B,4A,5A,6C,7B),
 (1D,2D,3B,4A,5A,6C,7C),(1D,2D,3B,4A,5A,6D,7A), (1D,2D,3B,4A,5A,6D,7B),(1D,2D,3B,4A,5A,6D,7C),(1D,2D,3B,
 25 4A,5B,6A,7A),(1D,2D,3B,4 A,5B,6A,7B),(1D,2D,3B,4A,5B,6A,7C),(1D,2D,3B,4A,5B,6B,7A),(1D,2D,3B,4A,5B,6B,
 7B), (1D,2D,3B,4A,5B,6B,7C),(1D,2D,3B,4A,5B,6C,7A),(1D,2D,3B,4A,5B,6C,7B),(1D,2D,3B,4 A,5B,6C,7C),(1D,2D,
 3B,4A,5B,6D,7A),(1D,2D,3B,4A,5B,6D,7B),(1D,2D,3B,4A,5B,6D,7C), (1D,2D,3B,4B,5A,6A,7A),(1D,2D,3B,4B,5A,
 6A,7B),(1D,2D,3B,4B,5A,6A,7C),(1D,2D,3B,4 B,5A,6B,7A),(1D,2D,3B,4B,5A,6B,7B),(1D,2D,3B,4B,5A,6B,7C),(1D,
 2D,3B,4B,5A,6C,7A), (1D,2D,3B,4B,5A,6C,7B),(1D,2D,3B,4B,5A,6C,7C),(1D,2D,3B,4B,5A,6D,7A),(1D,2D,3B,4 B,
 30 5A,6D,7B),(1D,2D,3B,4B,5A,6D,7C),(1D,2D,3B,4B,5B,6A,7A),(1D,2D,3B,4B,5B,6A,7B), (1D,2D,3B,4B,5B,6A,7C),
 (1D,2D,3B,4B,5B,6B,7A),(1D,2D,3B,4B,5B,6B,7B),(1D,2D,3B,4 B,5B,6B,7C),(1D,2D,3B,4B,5B,6C,7A),(1D,2D,3B,
 4B,5B,6C,7B),(1D,2D,3B,4B,5B,6C,7C), (1D,2D,3B,4B,5B,6D,7A),(1D,2D,3B,4B,5B,6D,7B),(1D,2D,3B,4B,5B,6D,
 7C),(1D,2D,3B,4 C,5A,6A,7A),(1D,2D,3B,4C,5A,6A,7B),(1D,2D,3B,4C,5A,6A,7C),(1D,2D,3B,4C,5A,6B,7A), (1D,2D,
 3B,4C,5A,6B,7B),(1D,2D,3B,4C,5A,6B,7C),(1D,2D,3B,4C,5A,6C,7A),(1D,2D,3B,4 C,5A,6C,7B),(1D,2D,3B,4C,5A,
 35 6C,7C),(1D,2D,3B,4C,5A,6D,7A),(1D,2D,3B,4C,5A,6D,7B), (1D,2D,3B,4C,5A,6D,7C),(1D,2D,3B,4C,5B,6A,7A),(1D,
 2D,3B,4C,5B,6A,7B),(1D,2D,3B,4 C,5B,6A,7C),(1D,2D,3B,4C,5B,6B,7A),(1D,2D,3B,4C,5B,6B,7B),(1D,2D,3B,4C,
 5B,6B,7C), (1D,2D,3B,4C,5B,6C,7A),(1D,2D,3B,4C,5B,6C,7B),(1D,2D,3B,4C,5B,6C,7C),(1D,2D,3B,4 C,5B,6D,7A),
 (1D,2D,3B,4C,5B,6D,7B),(1D,2D,3B,4C,5B,6D,7C),(1D,2D,3B,4D,5A,6A,7A), (1D,2D,3B,4D,5A,6A,7B),(1D,2D,3B,
 4D,5A,6A,7C),(1D,2D,3B,4D,5A,6B,7A),(1D,2D,3B,4 D,5A,6B,7B),(1D,2D,3B,4D,5A,6B,7C),(1D,2D,3B,4D,5A,6C,
 40 7A),(1D,2D,3B,4D,5A,6C,7B), (1D,2D,3B,4D,5A,6C,7C),(1D,2D,3B,4D,5A,6D,7A),(1D,2D,3B,4D,5A,6D,7B),(1D,2D,
 3B,4 D,5A,6D,7C),(1D,2D,3B,4D,5B,6A,7A),(1D,2D,3B,4D,5B,6A,7B),(1D,2D,3B,4D,5B,6A,7C), (1D,2D,3B,4D,5B,
 6B,7A),(1D,2D,3B,4D,5B,6B,7B),(1D,2D,3B,4D,5B,6B,7C),(1D,2D,3B,4 D,5B,6C,7A),(1D,2D,3B,4D,5B,6C,7B),(1D,
 2D,3B,4D,5B,6C,7C),(1D,2D,3B,4D,5B,6D,7A), (1D,2D,3B,4D,5B,6D,7B),(1D,2D,3B,4D,5B,6B,7C),(1D,2D,3B,4E,
 5A,6A,7A),(1D,2D,3B,4 E,5A,6A,7B),(1D,2D,3B,4E,5A,6A,7C),(1D,2D,3B,4E,5A,6B,7A),(1D,2D,3B,4E,5A,6B,7B),
 (1D,2D,3B,4E,5A,6B,7C),(1D,2D,3B,4E,5A,6C,7A),(1D,2D,3B,4E,5A,6C,7B),(1D,2D,3B,4 E,5A,6C,7C),(1D,2D,3B,
 45 4E,5A,6D,7A),(1D,2D,3B,4E,5A,6D,7B),(1D,2D,3B,4E,5A,6D,7C), (1D,2D,3B,4E,5B,6A,7A),(1D,2D,3B,4E,5B,6A,
 7B),(1D,2D,3B,4E,5B,6A,7C),(1D,2D,3B,4 E,5B,6B,7A),(1D,2D,3B,4E,5B,6B,7B),(1D,2D,3B,4E,5B,6B,7C),(1D,2D,
 3B,4E,5B,6C,7A), (1D,2D,3B,4E,5B,6C,7B),(1D,2D,3B,4E,5B,6C,7C),(1D,2D,3B,4E,5B,6D,7A),(1D,2D,3B,4 E,5B,
 6D,7B),(1D,2D,3B,4E,5B,6D,7C),(1D,2D,3C,4A,5A,6A,7A),(1D,2D,3C,4A,5A,6A,7B), (1D,2D,3C,4A,5A,6A,7C),(1D,
 50 2D,3C,4A,5A,6B,7A),(1D,2D,3C,4A,5A,6B,7B),(1D,2D,3C,4 A,5A,6B,7C),(1D,2D,3C,4A,5A,6C,7A),(1D,2D,3C,4A,
 5A,6C,7B),(1D,2D,3C,4A,5A,6C,7C), (1D,2D,3C,4A,5A,6D,7A),(1D,2D,3C,4A,5A,6D,7B),(1D,2D,3C,4A,5A,6D,7C),
 (1D,2D,3C,4 A,5B,6A,7A),(1D,2D,3C,4A,5B,6A,7B),(1D,2D,3C,4A,5B,6A,7C),(1D,2D,3C,4A,5B,6B,7A), (1D,2D,3C,
 4A,5B,6B,7B),(1D,2D,3C,4A,5B,6B,7C),(1D,2D,3C,4A,5B,6C,7A),(1D,2D,3C,4 A,5B,6C,7B),(1D,2D,3C,4A,5B,6C,
 7C),(1D,2D,3C,4A,5B,6D,7A),(1D,2D,3C,4A,5B,6D,7B), (1D,2D,3C,4A,5B,6D,7C),(1D,2D,3C,4B,5A,6A,7A),(1D,2D,
 3C,4B,5A,6A,7B),(1D,2D,3C,4 B,5A,6A,7C),(1D,2D,3C,4B,5A,6B,7A),(1D,2D,3C,4B,5A,6B,7B),(1D,2D,3C,4B,5A,
 55 6B,7C), (1D,2D,3C,4B,5A,6C,7A),(1D,2D,3C,4B,5A,6C,7B),(1D,2D,3C,4B,5A,6C,7C),(1D,2D,3C,4 B,5A,6D,7A),(1D,
 2D,3C,4B,5A,6D,7B),(1D,2D,3C,4B,5A,6D,7C),(1D,2D,3C,4B,5B,6A,7A), (1D,2D,3C,4B,5B,6A,7B),(1D,2D,3C,4B,
 5B,6A,7C),(1D,2D,3C,4B,5B,6B,7A),(1D,2D,3C,4 B,5B,6B,7B),(1D,2D,3C,4B,5B,6B,7C),(1D,2D,3C,4B,5B,6C,7A),
 (1D,2D,3C,4B,5B,6C,7B), (1D,2D,3C,4B,5B,6C,7C),(1D,2D,3C,4B,5B,6D,7A),(1D,2D,3C,4B,5B,6D,7B),(1D,2D,3C,

4 B,5B,6D,7C),(1D,2D,3C,4C,5A,6A,7A),(1D,2D,3C,4C,5A,6A,7B),(1D,2D,3C,4C,5A,6A,7C), (1D,2D,3C,4C,5A,6B,7A),(1D,2D,3C,4C,5A,6B,7B),(1D,2D,3C,4C,5A,6B,7C),(1D,2D,3C,4 C,5A,6C,7A),(1D,2D,3C,4C,5A,6C,7B),(1D,2D,3C,4C,5A,6C,7C),(1D,2D,3C,4C,5A,6D,7A), (1D,2D,3C,4C,5A,6D,7B),(1D,2D,3C,4C,5A,6D,7C),(1D,2D,3C,4C,5B,6A,7A),(1D,2D,3C,4 C,5B,6A,7B),(1D,2D,3C,4C,5B,6A,7C),(1D,2D,3C,4C,5B,6B,7A),(1D,2D,3C,4C,5B,6B,7B), (1D,2D,3C,4C,5B,6B,7C),(1D,2D,3C,4C,5B,6C,7A),(1D,2D,3C,4C,5B,6C,7B),(1D,2D,3C,4 C,5B,6C,7C),(1D,2D,3C,4C,5B,6D,7A),(1D,2D,3C,4C,5B,6D,7B),(1D,2D,3C,4C,5B,6D,7C), (1D,2D,3C,4D,5A,6A,7A),(1D,2D,3C,4D,5A,6A,7B),(1D,2D,3C,4D,5A,6A,7C),(1D,2D,3C,4D,5A,6B,7A),(1D,2D,3C,4D,5A,6B,7B),(1D,2D,3C,4D,5A,6B,7C),(1D,2D,3C,4D,5A,6C,7A),(1D,2D,3C,4D,5A,6C,7B),(1D,2D,3C,4D,5A,6C,7C),(1D,2D,3C,4D,5A,6D,7A),(1D,2D,3C,4D,5A,6D,7B),(1D,2D,3C,4D,5A,6D,7C),(1D,2D,3C,4D,5B,6A,7A),(1D,2D,3C,4D,5B,6A,7B),(1D,2D,3C,4D,5B,6A,7C),(1D,2D,3C,4D,5B,6B,7A),(1D,2D,3C,4D,5B,6B,7B),(1D,2D,3C,4D,5B,6B,7C),(1D,2D,3C,4 D,5B,6B,7C),(1D,2D,3C,4D,5B,6C,7A),(1D,2D,3C,4D,5B,6C,7B),(1D,2D,3C,4D,5B,6C,7C), (1D,2D,3C,4D,5B,6D,7A),(1D,2D,3C,4D,5B,6D,7B),(1D,2D,3C,4D,5B,6D,7C),(1D,2D,3C,4 E,5A,6A,7A),(1D,2D,3C,4E,5A,6A,7B),(1D,2D,3C,4E,5A,6A,7C),(1D,2D,3C,4E,5A,6B,7A), (1D,2D,3C,4E,5A,6B,7B),(1D,2D,3C,4E,5A,6B,7C),(1D,2D,3C,4E,5A,6C,7A),(1D,2D,3C,4 E,5A,6C,7B),(1D,2D,3C,4E,5A,6C,7C),(1D,2D,3C,4E,5A,6D,7A),(1D,2D,3C,4E,5A,6D,7B), (1D,2D,3C,4E,5A,6D,7C),(1D,2D,3C,4E,5B,6A,7A),(1D,2D,3C,4E,5B,6A,7B),(1D,2D,3C,4 E,5B,6A,7C),(1D,2D,3C,4E,5B,6B,7A),(1D,2D,3C,4E,5B,6B,7B),(1D,2D,3C,4E,5B,6B,7C), (1D,2D,3C,4E,5B,6C,7A),(1D,2D,3C,4E,5B,6C,7B),(1D,2D,3C,4E,5B,6C,7C),(1D,2D,3C,4 E,5B,6D,7A),(1D,2D,3C,4E,5B,6D,7B),(1D,2D,3C,4E,5B,6D,7C),(1D,2D,3D,4A,5A,6A,7A), (1D,2D,3D,4A,5A,6A,7B),(1D,2D,3D,4A,5A,6A,7C),(1D,2D,3D,4A,5A,6B,7A),(1D,2D,3D,4A,5A,6B,7B),(1D,2D,3D,4A,5A,6B,7C),(1D,2D,3D,4A,5A,6C,7A),(1D,2D,3D,4A,5A,6C,7B), (1D,2D,3D,4A,5A,6C,7C),(1D,2D,3D,4A,5A,6D,7A),(1D,2D,3D,4A,5A,6D,7B),(1D,2D,3D,4A,5A,6D,7C),(1D,2D,3D,4A,5B,6A,7A),(1D,2D,3D,4A,5B,6A,7B),(1D,2D,3D,4A,5B,6A,7C), (1D,2D,3D,4A,5B,6B,7A),(1D,2D,3D,4A,5B,6B,7B),(1D,2D,3D,4A,5B,6B,7C),(1D,2D,3D,4 A,5B,6C,7A),(1D,2D,3D,4A,5B,6C,7B),(1D,2D,3D,4A,5B,6C,7C),(1D,2D,3D,4A,5B,6D,7A), (1D,2D,3D,4A,5B,6D,7B),(1D,2D,3D,4A,5B,6D,7C),(1D,2D,3D,4B,5A,6A,7A),(1D,2D,3D,4 B,5A,6A,7B),(1D,2D,3D,4B,5A,6A,7C),(1D,2D,3D,4B,5A,6B,7A),(1D,2D,3D,4B,5A,6B,7B), (1D,2D,3D,4B,5A,6B,7C),(1D,2D,3D,4B,5A,6C,7A),(1D,2D,3D,4B,5A,6C,7B),(1D,2D,3D,4 B,5A,6C,7C),(1D,2D,3D,4B,5A,6D,7A),(1D,2D,3D,4B,5A,6D,7B),(1D,2D,3D,4B,5A,6D,7C), (1D,2D,3D,4B,5B,6A,7A),(1D,2D,3D,4B,5B,6A,7B),(1D,2D,3D,4B,5B,6A,7C),(1D,2D,3D,4B,5B,6B,7A),(1D,2D,3D,4B,5B,6B,7B),(1D,2D,3D,4B,5B,6B,7C),(1D,2D,3D,4B,5B,6C,7A), (1D,2D,3D,4B,5B,6C,7B),(1D,2D,3D,4B,5B,6C,7C),(1D,2D,3D,4B,5B,6D,7A),(1D,2D,3D,4 B,5B,6D,7B),(1D,2D,3D,4B,5B,6D,7C),(1D,2D,3D,4C,5A,6A,7A),(1D,2D,3D,4C,5A,6A,7B), (1D,2D,3D,4C,5A,6A,7C),(1D,2D,3D,4C,5A,6B,7A),(1D,2D,3D,4C,5A,6B,7B),(1D,2D,3D,4 C,5A,6B,7C),(1D,2D,3D,4C,5A,6C,7A),(1D,2D,3D,4C,5A,6C,7B),(1D,2D,3D,4C,5A,6C,7C), (1D,2D,3D,4C,5A,6D,7A),(1D,2D,3D,4C,5A,6D,7B),(1D,2D,3D,4C,5A,6D,7C),(1D,2D,3D,4 C,5B,6A,7A),(1D,2D,3D,4C,5B,6A,7B),(1D,2D,3D,4C,5B,6A,7C),(1D,2D,3D,4C,5B,6B,7A), (1D,2D,3D,4C,5B,6B,7B),(1D,2D,3D,4C,5B,6B,7C),(1D,2D,3D,4C,5B,6C,7A),(1D,2D,3D,4 C,5B,6C,7B),(1D,2D,3D,4C,5B,6C,7C),(1D,2D,3D,4C,5B,6D,7A),(1D,2D,3D,4C,5B,6D,7B), (1D,2D,3D,4C,5B,6D,7C),(1D,2D,3D,4D,5A,6A,7A),(1D,2D,3D,4D,5A,6A,7B),(1D,2D,3D,4D,5A,6A,7C),(1D,2D,3D,4D,5A,6B,7A),(1D,2D,3D,4D,5A,6B,7B),(1D,2D,3D,4D,5A,6B,7C), (1D,2D,3D,4D,5A,6C,7A),(1D,2D,3D,4D,5A,6C,7B),(1D,2D,3D,4D,5A,6C,7C),(1D,2D,3D,4 D,5A,6D,7A),(1D,2D,3D,4D,5A,6D,7B),(1D,2D,3D,4D,5A,6D,7C),(1D,2D,3D,4D,5B,6A,7A), (1D,2D,3D,4D,5B,6A,7B),(1D,2D,3D,4D,5B,6A,7C),(1D,2D,3D,4D,5B,6B,7A),(1D,2D,3D,4D,5B,6B,7B),(1D,2D,3D,4D,5B,6B,7C),(1D,2D,3D,4D,5B,6C,7A),(1D,2D,3D,4D,5B,6C,7B), (1D,2D,3D,4D,5B,6C,7C),(1D,2D,3D,4D,5B,6D,7A),(1D,2D,3D,4D,5B,6D,7B),(1D,2D,3D,4D,5B,6D,7C),(1D,2D,3D,4E,5A,6A,7A),(1D,2D,3D,4E,5A,6A,7B),(1D,2D,3D,4E,5A,6A,7C), (1D,2D,3D,4E,5A,6B,7A),(1D,2D,3D,4E,5A,6B,7B),(1D,2D,3D,4E,5A,6B,7C),(1D,2D,3D,4 E,5A,6C,7A),(1D,2D,3D,4E,5A,6C,7B),(1D,2D,3D,4E,5A,6C,7C),(1D,2D,3D,4E,5A,6D,7A), (1D,2D,3D,4E,5A,6D,7B),(1D,2D,3D,4E,5A,6D,7C),(1D,2D,3D,4E,5A,6B,7A),(1D,2D,3D,4 E,5B,6A,7B),(1D,2D,3D,4E,5B,6A,7C),(1D,2D,3D,4E,5B,6B,7A),(1D,2D,3D,4E,5B,6B,7B), (1D,2D,3D,4E,5B,6B,7C),(1D,2D,3D,4E,5B,6C,7A),(1D,2D,3D,4E,5B,6C,7B),(1D,2D,3D,4 E,5B,6C,7C),(1D,2D,3D,4E,5B,6D,7A),(1D,2D,3D,4E,5B,6D,7B),(1D,2D,3D,4E,5B,6D,7C), (1D,

7A),(1D,2D,3E,4C,5B,6B,7B),(1D,2D,3E,4C,5B,6B,7C),(1D,2D,3E,4 C,5B,6C,7A),(1D,2D,3E,4C,5B,6G,7B),(1D,2D,
3E,4C,5B,6C,7C),(1D,2D,3E,4C,5B,6D,7A), (1D,2D,3E,4C,5B,6D,7B),(1D,2D,3E,4C,5B,6D,7C),(1D,2D,3E,4D,5A,
6A,7A),(1D,2D,3E,4 D,5A,6A,7B),(1D,2D,3E,4D,5A,6A,7C),(1D,2D,3E,4D,5A,6B,7A),(1D,2D,3E,4D,5A,6B,7B), (1D,
2D,3E,4D,5A,6B,7C),(1D,2D,3E,4D,5A,6C,7A),(1D,2D,3E,4D,5A,6C,7B),(1D,2D,3E,4 D,5A,6C,7C),(1D,2D,3E,4D,
5A,6D,7A),(1D,2D,3E,4D,5A,6D,7B),(1D,2D,3E,4D,5A,6D,7C), (1D,2D,3E,4D,5B,6A,7A),(1D,2D,3E,4D,5B,6A,7B),
(1D,2D,3E,4D,5B,6A,7C),(1D,2D,3E,4 D,5B,6B,7A),(1D,2D,3E,4D,5B,6B,7B),(1D,2D,3E,4D,5B,6B,7C),(1D,2D,3E,
4D,5B,6C,7A), (1D,2D,3E,4D,5B,6C,7B),(1D,2D,3E,4D,5B,6C,7C),(1D,2D,3E,4D,5B,6D,7A),(1D,2D,3E,4 D,5B,6D,
7B),(1D,2D,3E,4D,5B,6D,7C),(1D,2D,3E,4E,5A,6A,7A),(1D,2D,3E,4E,5A,6A,7B), (1D,2D,3E,4E,5A,6A,7C),(1D,2D,
3E,4E,5A,6B,7A),(1D,2D,3E,4E,5A,6B,7B),(1D,2D,3E,4 E,5A,6B,7C),(1D,2D,3E,4E,5A,6C,7A),(1D,2D,3E,4E,5A,
6C,7B),(1D,2D,3E,4E,5A,6C,7C), (1D,2D,3E,4E,5A,6D,7A),(1D,2D,3E,4E,5A,6D,7B),(1D,2D,3E,4E,5A,6D,7C),(1D,
2D,3E,4 E,5B,6A,7A),(1D,2D,3E,4E,5B,6A,7B),(1D,2D,3E,4E,5B,6A,7C),(1D,2D,3E,4E,5B,6B,7A), (1D,2D,3E,4E,
5B,6B,7B),(1D,2D,3E,4E,5B,6B,7C),(1D,2D,3E,4E,5B,6C,7A),(1D,2D,3E,4 E,5B,6C,7B),(1D,2D,3E,4E,5B,6C,7C),
(1D,2D,3E,4E,5B,6D,7A),(1D,2D,3E,4E,5B,6D,7B), (1D,2D,3E,4E,5B,6D,7C),(1D,2E,3A,4A,5A,6A,7A),(1D,2E,3A,
4A,5A,6A,7B),(1D,2E,3A,4 A,5A,6A,7C),(1D,2E,3A,4A,5A,6B,7A),(1D,2E,3A,4A,5A,6B,7B),(1D,2E,3A,4A,5A,6B,
7C), (1D,2E,3A,4A,5A,6C,7A),(1D,2E,3A,4A,5A,6C,7B),(1D,2E,3A,4A,5A,6C,7C),(1D,2E,3A,4 A,5A,6D,7A),(1D,2E,
3A,4A,5A,6D,7B),(1D,2E,3A,4A,5A,6D,7C),(1D,2E,3A,4A,5B,6A,7A), (1D,2E,3A,4A,5B,6A,7B),(1D,2E,3A,4A,5B,6A,
7C),(1D,2E,3A,4A,5B,6B,7A),(1D,2E,3A,4 A,5B,6B,7B),(1D,2E,3A,4A,5B,6B,7C),(1D,2E,3A,4A,5B,6C,7A),(1D,2E,
3A,4A,5B,6C,7B), (1D,2E,3A,4A,5B,6C,7C),(1D,2E,3A,4A,5B,6D,7A),(1D,2E,3A,4A,5B,6D,7B),(1D,2E,3A,4 A,5B,
6D,7C),(1D,2E,3A,4B,5A,6A,7A),(1D,2E,3A,4B,5A,6A,7B),(1D,2E,3A,4B,5A,6A,7C), (1D,2E,3A,4B,5A,6B,7A),(1D,
2E,3A,4B,5A,6B,7B),(1D,2E,3A,4B,5A,6B,7C),(1D,2E,3A,4 B,5A,6C,7A),(1D,2E,3A,4B,5A,6C,7B),(1D,2E,3A,4B,5A,
6C,7C),(1D,2E,3A,4B,5A,6D,7A), (1D,2E,3A,4B,5A,6D,7B),(1D,2E,3A,4B,5A,6D,7C),(1D,2E,3A,4B,5B,6A,7A),(1D,
2E,3A,4 B,5B,6A,7B),(1D,2E,3A,4B,5B,6A,7C),(1D,2E,3A,4B,5B,6B,7A),(1D,2E,3A,4B,5B,6B,7B), (1D,2E,3A,4B,
5B,6B,7C),(1D,2E,3A,4B,5B,6C,7A),(1D,2E,3A,4B,5B,6C,7B),(1D,2E,3A,4 B,5B,6C,7C),(1D,2E,3A,4B,5B,6D,7A),
(1D,2E,3A,4B,5B,6D,7B),(1D,2E,3A,4B,5B,6D,7C),. (1D,2E,3A,4C,5A,6A,7A),(1D,2E,3A,4C,5A,6A,7B),(1D,2E,3A,
4C,5A,6A,7C),(1D,2E,3A,4 C,5A,6B,7A),(1D,2E,3A,4C,5A,6B,7B),(1D,2E,3A,4C,5A,6B,7C),(1D,2E,3A,4C,5A,6C,
7A), (1D,2E,3A,4C,5A,6C,7B),(1D,2E,3A,4C,5A,6C,7C),(1D,2E,3A,4C,5A,6D,7A),(1D,2E,3A,4 C,5A,6D,7B),(1D,2E,
3A,4C,5A,6D,7C),(1D,2E,3A,4C,5B,6A,7A),(1D,2E,3A,4C,5B,6A,7B), (1D,2E,3A,4C,5B,6A,7C),(1D,2E,3A,4C,5B,
6B,7A),(1D,2E,3A,4C,5B,6B,7B),(1D,2E,3A,4 C,5B,6B,7C),(1D,2E,3A,4C,5B,6C,7A),(1D,2E,3A,4C,5B,6C,7B),(1D,
2E,3A,4C,5B,6C,7C), (1D,2E,3A,4C,5B,6D,7A),(1D,2E,3A,4C,5B,6D,7B),(1D,2E,3A,4C,5B,6D,7C),(1D,2E,3A,4 D,
5A,6A,7A),(1D,2E,3A,4D,5A,6A,7B),(1D,2E,3A,4D,5A,6A,7C),(1D,2E,3A,4D,5A,6B,7A), (1D,2E,3A,4D,5A,6B,7B),
(1D,2E,3A,4D,5A,6B,7C),(1D,2E,3A,4D,5A,6C,7A),(1D,2E,3A,4 D,5A,6C,7B),(1D,2E,3A,4D,5A,6C,7C),(1D,2E,3A,
4D,5A,6D,7A),(1D,2E,3A,4D,5A,6D,7B), (1D,2E,3A,4D,5A,6D,7C),(1D,2E,3A,4D,5B,6A,7A),(1D,2E,3A,4D,5B,6A,
7B),(1D,2E,3A,4 D,5B,6A,7C),(1D,2E,3A,4D,5B,6B,7A),(1D,2E,3A,4D,5B,6B,7B),(1D,2E,3A,4D,5B,6B,7C), (1D,2E,
3A,4D,5B,6C,7A),(1D,2E,3A,4D,5B,6C,7B),(1D,2E,3A,4D,5B,6C,7C),(1D,2E,3A,4 D,5B,6D,7A),(1D,2E,3A,4D,5B,
6D,7B),(1D,2E,3A,4D,5B,6D,7C),(1D,2E,3A,4E,5A,6A,7A), (1D,2E,3A,4E,5A,6A,7B),(1D,2E,3A,4E,5A,6A,7C),(1D,
2E,3A,4E,5A,6B,7A),(1D,2E,3A,4 E,5A,6B,7B),(1D,2E,3A,4E,5A,6B,7C),(1D,2E,3A,4E,5A,6C,7A),(1D,2E,3A,4E,5A,
6C,7B), (1D,2E,3A,4E,5A,6C,7C),(1D,2E,3A,4E,5A,6D,7A),(1D,2E,3A,4E,5A,6D,7B),(1D,2E,3A,4 E,5A,6D,7C),(1D,
2E,3A,4E,5B,6A,7A),(1D,2E,3A,4E,5B,6A,7B),(1D,2E,3A,4E,5B,6A,7C), (1D,2E,3A,4E,5B,6B,7A),(1D,2E,3A,4E,5B,
6B,7B),(1D,2E,3A,4E,5B,6B,7C),(1D,2E,3A,4 E,5B,6C,7A),(1D,2E,3A,4E,5B,6C,7B),(1D,2E,3A,4E,5B,6C,7C),(1D,
40 2E,3A,4E,5B,6D,7A), (1D,2E,3A,4E,5B,6D,7B),(1D,2E,3A,4E,5B,6D,7C),(1D,2E,3B,4A,5A,6A,7A),(1D,2E,3B,4 A,
5A,6A,7B),(1D,2E,3B,4A,5A,6A,7C),(1D,2E,3B,4A,5A,6B,7A),(1D,2E,3B,4A,5A,6B,7B), (1D,2E,3B,4A,5A,6B,7C),
(1D,2E,3B,4A,5A,6C,7A),(1D,2E,3B,4A,5A,6C,7B),(1D,2E,3B,4 A,5A,6C,7C),(1D,2E,3B,4A,5A,6D,7A),(1D,2E,3B,
4A,5A,6D,7B),(1D,2E,3B,4A,5A,6D,7C), (1D,2E,3B,4A,5B,6A,

288

5A,6A,7C),(1D,2E,3D,4E,5A,6B,7A),(1D,2E,3D,4E,5A,6B,7B), (1D,2E,3D,4E,5A,6B,7C),(1D,2E,3D,4E,5A,6C,7A),
(1D,2E,3D,4E,5A,6C,7B),(1D,2E,3D,4 E,5A,6C,7C),(1D,2E,3D,4E,5A,6D,7A),(1D,2E,3D,4E,5A,6D,7B),(1D,2E,3D,
4E,5A,6D,7C), (1D,2E,3D,4E,5B,6A,7A),(1D,2E,3D,4E,5B,6A,7B),(1D,2E,3D,4E,5B,6A,7C),(1D,2E,3D,4 E,5B,6B,
7A),(1D,2E,3D,4E,5B,6B,7B),(1D,2E,3D,4E,5B,6B,7C),(1D,2E,3D,4E,5B,6C,7A), (1D,2E,3D,4E,5B,6C,7B),(1D,2E,
3D,4E,5B,6C,7C),(1D,2E,3D,4E,5B,6D,7A),(1D,2E,3D,4 E,5B,6D,7B),(1D,2E,3D,4E,5B,6D,7C),(1D,2E,3E,4A,5A,
6A,7A),(1D,2E,3E,4A,5A,6A,7B), (1D,2E,3E,4A,5A,6A,7C),(1D,2E,3E,4A,5A,6B,7A),(1D,2E,3E,4A,5A,6B,7B),(1D,
2E,3E,4 A,5A,6B,7C),(1D,2E,3E,4A,5A,6C,7A),(1D,2E,3E,4A,5A,6C,7B),(1D,2E,3E,4A,5A,6C,7C), (1D,2E,3E,4A,
5A,6D,7A),(1D,2E,3E,4A,5A,6D,7B),(1D,2E,3E,4A,5A,6D,7C),(1D,2E,3E,4 A,5B,6A,7A),(1D,2E,3E,4A,5B,6A,7B),
(1D,2E,3E,4A,5B,6A,7C),(1D,2E,3E,4A,5B,6B,7A), (1D,2E,3E,4A,5B,6B,7B),(1D,2E,3E,4A,5B,6B,7C),(1D,2E,3E,
4A,5B,6C,7A),(1D,2E,3E,4 A,5B,6C,7B),(1D,2E,3E,4A,5B,6C,7C),(1D,2E,3E,4A,5B,6D,7A),(1D,2E,3E,4A,5B,6D,
7B), (1D,2E,3E,4A,5B,6D,7C),(1D,2E,3E,4B,5A,6A,7A),(1D,2E,3E,4B,5A,6A,7B),(1D,2E,3E,4 B,5A,6A,7C),(1D,2E,
3E,4B,5A,6B,7A),(1D,2E,3E,4B,5A,6B,7B),(1D,2E,3E,4B,5A,6B,7C), (1D,2E,3E,4B,5A,6C,7A),(1D,2E,3E,4B,5A,6C,
7B),(1D,2E,3E,4B,5A,6C,7C),(1D,2E,3E,4 B,5A,6D,7A),(1D,2E,3E,4B,5A,6D,7B),(1D,2E,3E,4B,5A,6D,7C),(1D,2E,
3E,4B,5B,6A,7A), (1D,2E,3E,4B,5B,6A,7B),(1D,2E,3E,4B,5B,6A,7C),(1D,2E,3E,4B,5B,6B,7A),(1D,2E,3E,4 B,5B,
6B,7B),(1D,2E,3E,4B,5B,6B,7C),(1D,2E,3E,4B,5B,6C,7A),(1D,2E,3E,4B,5B,6C,7B), (1D,2E,3E,4B,5B,6C,7C),(1D,
2E,3E,4B,5B,6D,7A),(1D,2E,3E,4B,5B,6D,7B),(1D,2E,3E,4 B,5B,6D,7C),(1D,2E,3E,4C,5A,6A,7A),(1D,2E,3E,4C,
5A,6A,7B),(1D,2E,3E,4C,5A,6A,7C), (1D,2E,3E,4C,5A,6B,7A),(1D,2E,3E,4C,5A,6B,7B),(1D,2E,3E,4C,5A,6B,7C),
(1D,2E,3E,4 C,5A,6C,7A),(1D,2E,3E,4C,5A,6C,7B),(1D,2E,3E,4C,5A,6C,7C),(1D,2E,3E,4C,5A,6D,7A), (1D,2E,3E,
4C,5A,6D,7B),(1D,2E,3E,4C,5A,6D,7C),(1D,2E,3E,4C,5B,6A,7A),(1D,2E,3E,4 C,5B,6A,7B),(1D,2E,3E,4C,5B,6A,
7C),(1D,2E,3E,4C,5B,6B,7A),(1D,2E,3E,4C,5B,6B,7B), (1D,2E,3E,4C,5B,6B,7C),(1D,2E,3E,4C,5B,6C,7A),(1D,2E,
3E,4C,5B,6C,7B),(1D,2E,3E,4 C,5B,6C,7C),(1D,2E,3E,4C,5B,6D,7A),(1D,2E,3E,4C,5B,6D,7B),(1D,2E,3E,4C,5B,
6D,7C), (1D,2E,3E,4D,5A,6A,7A),(1D,2E,3E,4D,5A,6A,7B),(1D,2E,3E,4D,5A,6A,7C),(1D,2E,3E,4 D,5A,6B,7A),(1D,
2E,3E,4D,5A,6B,7B),(1D,2E,3E,4D,5A,6B,7C),(1D,2E,3E,4D,5A,6C,7A), (1D,2E,3E,4D,5A,6C,7B),(1D,2E,3E,4D,
5A,6C,7C),(1D,2E,3E,4D,5A,6D,7A),(1D,2E,3E,4 D,5A,6D,7B),(1D,2E,3E,4D,5A,6D,7C),(1D,2E,3E,4D,5B,6A,7A),
(1D,2E,3E,4D,5B,6A,7B), (1D,2E,3E,4D,5B,6A,7C),(1D,2E,3E,4D,5B,6B,7A),(1D,2E,3E,4D,5B,6B,7B),(1D,2E,3E,4
D,5B,6B,7C),(1D,2E,3E,4D,5B,6C,7A),(1D,2E,3E,4D,5B,6C,7B),(1D,2E,3E,4D,5B,6C,7C), (1D,2E,3E,4D,5B,6D,
7A),(1D,2E,3E,4D,5B,6D,7B),(1D,2E,3E,4D,5B,6D,7C),(1D,2E,3E,4 E,5A,6A,7A),(1D,2E,3E,4E,5A,6A,7B),(1D,2E,
3E,4E,5A,6A,7C),(1D,2E,3E,4E,5A,6B,7A), (1D,2E,3E,4E,5A,6B,7B),(1D,2E,3E,4E,5A,6B,7C),(1D,2E,3E,4E,5A,6C,
7A),(1D,2E,3E,4 E,5A,6C,7B),(1D,2E,3E,4E,5A,6C,7C),(1D,2E,3E,4E,5A,6D,7A),(1D,2E,3E,4E,5A,6D,7B),(1D,2E,
3E,4E,5A,6D,7C),(1D,2E,3E,4E,5B,6A,7A),(1D,2E,3E,4E,5B,6A,7B),(1D,2E,3E,4 E,5B,6A,7C),(1D,2E,3E,4E,5B,6B,
7A),(1D,2E,3E,4E,5B,6B,7B),(1D,2E,3E,4E,5B,6B,7C), (1D,2E,3E,4E,5B,6C,7A),(1D,2E,3E,4E,5B,6C,7B),(1D,2E,
3E,4E,5B,6C,7C),(1D,2E,3E,4 E,5B,6D,7A),(1D,2E,3E,4E,5B,6D,7B),(1D,2E,3E,4E,5B,6D,7C),(1E,2A,3A,4A,5A,
6A,7A), (1E,2A,3A,4A,5A,6A,7B),(1E,2A,3A,4A,5A,6A,7C),(1E,2A,3A,4A,5A,6B,7A),(1E,2A,3A,4 A,5A,6B,7B),(1E,
2A,3A,4A,5A,6B,7C),(1E,2A,3A,4A,5A,6C,7A),(1E,2A,3A,4A,5A,6C,7B), (1E,2A,3A,4A,5A,6C,7C),(1E,2A,3A,4A,5A,
6D,7A),(1E,2A,3A,4A,5A,6D,7B),(1E,2A,3A,4 A,5A,6D,7C),(1E,2A,3A,4A,5B,6A,7A),(1E,2A,3A,4A,5B,6A,7B),(1E,
2A,3A,4A,5B,6A,7C), (1E,2A,3A,4A,5B,6B,7A),(1E,2A,3A,4A,5B,6B,7B),(1E,2A,3A,4A,5B,6B,7C),(1E,2A,3A,4 A,5B,
6C,7A),(1E,2A,3A,4A,5B,6C,7B),(1E,2A,3A,4A,5B,6C,7C),(1E,2A,3A,4A,5B,6D,7A), (1E,2A,3A,4A,5B,6D,7B),(1E,
2A,3A,4A,5B,6D,7C),(1E,2A,3A,4B,5A,6A,7A),(1E,2A,3A,4 B,5A,6A,7B),(1E,2A,3A,4B,5A,6A,7C),(1E,2A,3A,4B,5A,
6B,7A),(1E,2A,3A,4B,5A,6B,7B), (1E,2A,3A,4B,5A,6B,7C),(1E,2A,3A,4B,5A,6C,7A),(1E,2A,3A,4B,5A,6C,7B),(1E,
40 2A,3A,4 B,5A,6C,7C),(1E,2A,3A,4B,5A,6D,7A),(1E,2A,3A,4B,5A,6D,7B),(1E,2A,3A,4B,5A,6D,7C), (1E,2A,3A,4B,
5B,6A,7A),(1E,2A,3A,4B,5B,6A,7B),(1E,2A,3A,4B,5B,6A,7C),(1E,2A,3A,4 B,5B,6B,7A),(1E,2A,3A,4B,5B,6B,7B),
(1E,2A,3A,4B,5B,6B,7C),(1E,2A,3A,4B,5B,6C,7A), (1E,2A,3A,4B,5B,6C,7B),(1E,2A,3A,4B,5B,6C,7C),(1E,2A,3A,
4B,5B

7C),(1E,2A,3A,4E,5B,6D,7A),(1E,2A,3A,4E,5B,6D,7B),(1E,2A,3A,4E,5B,6D,7C), (1E,2A,3B,4A,5A,6A,7A),(1E,2A,
3B,4A,5A,6A,7B),(1E,2A,3B,4A,5A,6A,7C),(1E,2A,3B,4 A,5A,6B,7A),(1E,2A,3B,4A,5A,6B,7B),(1E,2A,3B,4A,5A,6B,
7C),(1E,2A,3B,4A,5A,6C,7A), (1E,2A,3B,4A,5A,6C,7B),(1E,2A,3B,4A,5A,6C,7C),(1E,2A,3B,4A,5A,6D,7A),(1E,2A,
3B,4 A,5A,6D,7B),(1E,2A,3B,4A,5A,6D,7C),(1E,2A,3B,4A,5B,6A,7A),(1E,2A,3B,4A,5B,6A,7B), (1E,2A,3B,4A,5B,6A,
5
7C),(1E,2A,3B,4A,5B,6B,7A),(1E,2A,3B,4A,5B,6B,7B),(1E,2A,3B,4 A,5B,6B,7C),(1E,2A,3B,4A,5B,6C,7A),(1E,2A,
3B,4A,5B,6C,7B),(1E,2A,3B,4A,5B,6C,7C), (1E,2A,3B,4A,5B,6D,7A),(1E,2A,3B,4A,5B,6D,7B),(1E,2A,3B,4A,5B,6D,
7C),(1E,2A,3B,4 B,5A,6A,7A),(1E,2A,3B,4B,5A,6A,7B),(1E,2A,3B,4B,5A,6A,7C),(1E,2A,3B,4B,5A,6B,7A), (1E,2A,
3B,4B,5A,6B,7B),(1E,2A,3B,4B,5A,6B,7C),(1E,2A,3B,4B,5A,6C,7A),(1E,2A,3B,4 B,5A,6C,7B),(1E,2A,3B,4B,5A,6C,
7C),(1E,2A,3B,4B,5A,6D,7A),(1E,2A,3B,4B,5A,6D,7B), (1E,2A,3B,4B,5A,6D,7C),(1E,2A,3B,4B,5B,6A,7A),(1E,2A,
10
3B,4B,5B,6A,7B),(1E,2A,3B,4 B,5B,6A,7C),(1E,2A,3B,4B,5B,6B,7A),(1E,2A,3B,4B,5B,6B,7B),(1E,2A,3B,4B,5B,6B,
7C), (1E,2A,3B,4B,5B,6C,7A),(1E,2A,3B,4B,5B,6C,7B),(1E,2A,3B,4B,5B,6C,7C),(1E,2A,3B,4 B,5B,6D,7A),(1E,2A,
3B,4B,5B,6D,7B),(1E,2A,3B,4B,5B,6D,7C),(1E,2A,3B,4C,5A,6A,7A), (1E,2A,3B,4C,5A,6A,7B),(1E,2A,3B,4C,5A,6A,
7C),(1E,2A,3B,4C,5A,6B,7A),(1E,2A,3B,4 C,5A,6B,7B),(1E,2A,3B,4C,5A,6B,7C),(1E,2A,3B,4C,5A,6C,7A),(1E,2A,
3B,4C,5A,6C,7B), (1E,2A,3B,4C,5A,6C,7C),(1E,2A,3B,4C,5A,6D,7A),(1E,2A,3B,4C,5A,6D,7B),(1E,2A,3B,4 C,5A,
15
6D,7C),(1E,2A,3B,4C,5B,6A,7A),(1E,2A,3B,4C,5B,6A,7B),(1E,2A,3B,4C,5B,6A,7C), (1E,2A,3B,4C,5B,6B,7A),(1E,
2A,3B,4C,5B,6B,7B),(1E,2A,3B,4C,5B,6B,7C),(1E,2A,3B,4 C,5B,6C,7A),(1E,2A,3B,4C,5B,6C,7B),(1E,2A,3B,4C,
5B,6C,7C),(1E,2A,3B,4C,5B,6D,7A), (1E,2A,3B,4C,5B,6D,7B),(1E,2A,3B,4C,5B,6D,7C),(1E,2A,3B,4D,5A,6A,7A),
(1E,2A,3B,4 D,5A,6A,7B),(1E,2A,3B,4D,5A,6A,7C),(1E,2A,3B,4D,5A,6B,7A),(1E,2A,3B,4D,5A,6B,7B), (1E,2A,3B,
4D,5A,6B,7C),(1E,2A,3B,4D,5A,6C,7A),(1E,2A,3B,4D,5A,6C,7B),(1E,2A,3B,4 D,5A,6C,7C),(1E,2A,3B,4D,5A,6D,7A),
20
7A),(1E,2A,3B,4D,5A,6D,7B),(1E,2A,3B,4D,5A,6D,7C), (1E,2A,3B,4D,5B,6A,7A),(1E,2A,3B,4D,5B,6A,7B),(1E,2A,
3B,4D,5B,6A,7C),(1E,2A,3B,4 D,5B,6B,7A),(1E,2A,3B,4D,5B,6B,7B),(1E,2A,3B,4D,5B,6B,7C),(1E,2A,3B,4D,5B,
6C,7A), (1E,2A,3B,4D,5B,6C,7B),(1E,2A,3B,4D,5B,6C,7C),(1E,2A,3B,4D,5B,6D,7A),(1E,2A,3B,4 D,5B,6D,7B),(1E,
2A,3B,4D,5B,6D,7C),(1E,2A,3B,4E,5A,6A,7A),(1E,2A,3B,4E,5A,6A,7B), (1E,2A,3B,4E,5A,6A,7C),(1E,2A,3B,4E,5A,
25
6B,7A),(1E,2A,3B,4E,5A,6B,7B), (1E,2A,3B,4E,5A,6B,7C),(1E,2A,3B,4E,5A,6C,7A),(1E,2A,3B,4E,5A,6C,7B),(1E,
2A,3B,4 E,5A,6C,7C),(1E,2A,3B,4E,5A,6D,7A),(1E,2A,3B,4E,5A,6D,7B),(1E,2A,3B,4E,5A,6D,7C), (1E,2A,3B,4E,
5B,6A,7A),(1E,2A,3B,4E,5B,6A,7B),(1E,2A,3B,4E,5B,6A,7C),(1E,2A,3B,4 E,5B,6B,7A),(1E,2A,3B,4E,5B,6B,7B),
(1E,2A,3B,4E,5B,6B,7C),(1E,2A,3B,4E,5B,6C,7A), (1E,2A,3B,4E,5B,6C,7B),(1E,2A,3B,4E,5B,6C,7C),(1E,2A,3B,
4E,5B,6D,7A),(1E,2A,3B,4 E,5B,6D,7B),(1E,2A,3B,4E,5B,6D,7C),(1E,2A,3C,4A,5A,6A,7A),(1E,2A,3C,4A,5A,6A,
30
7B), (1E,2A,3C,4A,5A,6A,7C),(1E,2A,3C,4A,5A,6B,7A),(1E,2A,3C,4A,5A,6B,7B),(1E,2A,3C,4 A,5A,6B,7C),(1E,2A,
3C,4A,5A,6C,7A),(1E,2A,3C,4A,5A,6C,7B),(1E,2A,3C,4A,5A,6C,7C), (1E,2A,3C,4A,5A,6D,7A),(1E,2A,3C,4A,5A,
6D,7B),(1E,2A,3C,4A,5A,6D,7C),(1E,2A,3C,4 A,5B,6A,7A),(1E,2A,3C,4A,5B,6A,7B),(1E,2A,3C,4A,5B,6A,7C),(1E,
2A,3C,4A,5B,6B,7A), (1E,2A,3C,4A,5B,6B,7B),(1E,2A,3C,4A,5B,6B,7C),(1E,2A,3C,4A,5B,6C,7A),(1E,2A,3C,4 A,
5B,6C,7B),(1E,2A,3C,4A,5B,6C,7C),(1E,2A,3C,4A,5B,6D,7A),(1E,2A,3C,4A,5B,6D,7B), (1E,2A,3C,4A,5B,6D,7C),
(1E,2A,3C,4B,5A,6A,7A),(1E,2A,3C,4B,5A,6A,7B),(1E,2A,3C,4 B,5A,6A,7C),(1E,2A,3C,4B,5A,6B,7A),(1E,2A,3C,
35
4B,5A,6B,7B),(1E,2A,3C,4B,5A,6B,7C). (1E,2A,3C,4B,5A,6C,7A),(1E,2A,3C,4B,5A,6C,7B),(1E,2A,3C,4B,5A,6C,
7C),(1E,2A,3C,4 B,5A,6D,7A),(1E,2A,3C,4B,5A,6D,7B),(1E,2A,3C,4B,5A,6D,7C),(1E,2A,3C,4B,5B,6A,7A), (1E,2A,
3C,4B,5B,6A,7B),(1E,2A,3C,4B,5B,6A,7C),(1E,2A,3C,4B,5B,6B,7A),(1E,2A,3C,4 B,5B,6B,7B),(1E,2A,3C,4B,5B,6B,
7C),(1E,2A,3C,4B,5B,6C,7A),(1E,2A,3C,4B,5B,6C,7B), (1E,2A,3C,4B,5B,6C,7C),(1E,2A,3C,4B,5B,6D,7A),(1E,2A,
3C,4B,5B,6D,7B),(1E,2A,3C,4 B,5B,6D,7C),(1E,2A,3C,4C,5A,6A,7A),(1E,2A,3C,4C,5A,6A,7B),(1E,2A,3C,4C,5A,
40
6A,7C), (1E,2A,3C,4C,5A,6B,7A),(1E,2A,3C,4C,5A,6B,7B),(1E,2A,3C,4C,5A,6B,7C),(1B,2A,3C,4 C,5A,6C,7A),(1E,
2A,3C,4C,5A,6C,7B),(1E,2A,3C,4C,5A,6C,7C),(1E,2A,3C,4C,5A,6D,7A), (1E,2A,3C,4C,5A,6D,7B),(1E,2A,3C,4C,
5A,6D,7C),(1E,2A,3C,4C,5B,6A,7A),(1E,2A,3C,4 C,5B,6A,7B),(1E,2A,3C,4C,5B,6A,7C),(1E,2A,3C,4C,5B,6B,7A),
(1E,2A,3C,4

(1E,2A,3D,4A,5B,6B,7A),(1E,2A,3D,4A,5B,6B,7B),(1E,2A,3D,4A,5B,6B,7C),(1E,2A,3D,4 A,5B,6C,7A),(1E,2A,3D,
4A,5B,6C,7B),(1E,2A,3D,4A,5B,6C,7C),(1E,2A,3D,4A,5B,6D,7A), (1E,2A,3D,4A,5B,6D,7B),(1E,2A,3D,4A,5B,6D,
7C),(1E,2A,3D,4B,5A,6A,7A),(1E,2A,3D,4 B,5A,6A,7B),(1E,2A,3D,4B,5A,6A,7C),(1E,2A,3D,4B,5A,6B,7A),(1E,2A,
3D,4B,5A,6B,7B), (1E,2A,3D,4B,5A,6B,7C),(1E,2A,3D,4B,5A,6C,7A),(1E,2A,3D,4B,5A,6C,7B),(1E,2A,3D,4 B,5A,
5 6C,7C),(1E,2A,3D,4B,5A,6D,7A),(1E,2A,3D,4B,5A,6D,7B),(1E,2A,3D,4B,5A,6D,7C), (1E,2A,3D,4B,5B,6A,7A),(1E,
2A,3D,4B,5B,6A,7B),(1E,2A,3D,4B,5B,6A,7C),(1E,2A,3D,4 B,5B,6B,7A),(1E,2A,3D,4B,5B,6B,7B),(1E,2A,3D,4B,5B,
6B,7C),(1E,2A,3D,4B,5B,6C,7A), (1E,2A,3D,4B,5B,6C,7B),(1E,2A,3D,4B,5B,6C,7C),(1E,2A,3D,4B,5B,6D,7A),(1E,
2A,3D,4 B,5B,6D,7B),(1E,2A,3D,4B,5B,6D,7C),(1E,2A,3D,4C,5A,6A,7A),(1E,2A,3D,4C,5A,6A,7B), (1E,2A,3D,4C,
5A,6A,7C),(1E,2A,3D,4C,5A,6B,7A),(1E,2A,3D,4C,5A,6B,7B),(1E,2A,3D,4 C,5A,6B,7C),(1E,2A,3D,4C,5A,6C,7A),(1E,2A,3D,
10 4C,5A,6C,7B),(1E,2A,3D,4C,5A,6C,7C), (1E,2A,3D,4C,5A,6D,7A),(1E,2A,3D,4C,5A,6D,7B),(1E,2A,3D,
4C,5A,6D,7C),(1E,2A,3D,4 C,5B,6A,7A),(1E,2A,3D,4C,5B,6A,7B),(1E,2A,3D,4C,5B,6A,7C),(1E,2A,3D,4C,5B,6B,
7A), (1E,2A,3D,4C,5B,6B,7B),(1E,2A,3D,4C,5B,6B,7C),(1E,2A,3D,4C,5B,6C,7A),(1E,2A,3D,4 C,5B,6C,7B),(1E,2A,
3D,4C,5B,6C,7C),(1E,2A,3D,4C,5B,6D,7A),(1E,2A,3D,4C,5B,6D,7B), (1E,2A,3D,4C,5B,6D,7C),(1E,2A,3D,4D,5A,
6A,7A),(1E,2A,3D,4D,5A,6A,7B),(1E,2A,3D,4 D,5A,6A,7C),(1E,2A,3D,4D,5A,6B,7A),(1E,2A,3D,4D,5A,6B,7B),(1E,
15 2A,3D,4D,5A,6B,7C), (1E,2A,3D,4D,5A,6C,7A),(1E,2A,3D,4D,5A,6C,7B),(1E,2A,3D,4D,5A,6C,7C),(1E,2A,3D,4 D,
5A,6D,7A),(1E,2A,3D,4D,5A,6D,7B),(1E,2A,3D,4D,5A,6D,7C),(1E,2A,3D,4D,5B,6A,7A), (1E,2A,3D,4D,5B,6A,7B),
(1E,2A,3D,4D,5B,6A,7C),(1E,2A,3D,4D,5B,6B,7A),(1E,2A,3D,4 D,5B,6B,7B),(1E,2A,3D,4D,5B,6B,7C),(1E,2A,3D,
4D,5B,6C,7A),(1E,2A,3D,4D,5B,6C,7B), (1E,2A,3D,4D,5B,6C,7C),(1E,2A,3D,4D,5B,6D,7A),(1E,2A,3D,4D,5B,6D,
7B),(1E,2A,3D,4 D,5B,6D,7C), (1E,2A,3D,4D,5A,6A,7A),(1E,2A,3D,4E,5A,6A,7B),(1E,2A,3D,4E,5A,6A,7C),(1E,2A,3D,4E,5A,6B,7A),(1E,2A,3D,4E,5A,6B,7B),(1E,2A,3D,4E,5A,6B,7C),(1E,2A,3D,4E,5A,6C,7A),(1E,2A,3D,4E,5A,
20 6C,7B),(1E,2A,3D,4E,5A,6C,7C),(1E,2A,3D,4E,5A,6D,7A), (1E,2A,3D,4E,5A,6D,7B),(1E,2A,3D,4E,5A,6D,7C),(1E,
2A,3D,4E,5B,6A,7A),(1E,2A,3D,4 E,5B,6A,7B),(1E,2A,3D,4E,5B,6A,7C),(1E,2A,3D,4E,5B,6B,7A),(1E,2A,3D,4E,5B,
6B,7B), (1E,2A,3D,4E,5B,6B,7C),(1E,2A,3D,4E,5B,6C,7A),(1E,2A,3D,4B,5B,6C,7B),(1E,2A,3D,4 E,5B,6C,7C),(1E,
2A,3D,4E,5B,6D,7A),(1E,2A,3D,4E,5B,6D,7B),(1E,2A,3D,4E,5B,6D,7C), (1E,2A,3E,4A,5A,6A,7A),(1E,2A,3E,4A,5A,
25 6A,7B),(1E,2A,3E,4A,5A,6A,7C),(1E,2A,3E,4 A,5A,6B,7A),(1E,2A,3E,4A,5A,6B,7B),(1E,2A,3E,4A,5A,6B,7C),(1E,
2A,3E,4A,5A,6C,7A), (1E,2A,3E,4A,5A,6C,7B),(1E,2A,3E,4A,5A,6C,7C),(1E,2A,3E,4A,5A,6D,7A),(1E,2A,3E,4 A,
5A,6D,7B),(1E,2A,3E,4A,5A,6D,7C),(1E,2A,3E,4A,5B,6A,7A),(1E,2A,3E,4A,5B,6A,7B), (1E,2A,3E,4A,5B,6A,7C),
(1E,2A,3E,4A,5B,6B,7A),(1E,2A,3E,4A,5B,6B,7B),(1E,2A,3E,4 A,5B,6B,7C),(1E,2A,3E,4A,5B,6C,7A),(1E,2A,3E,
4A,5B,6C,7B),(1E,2A,3E,4A,5B,6C,7C), (1E,2A,3E,4A,5B,6D,7A),(1E,2A,3E,4A,5B,6D,7B),(1E,2A,3E,4A,5B,6D,
30 7C),(1E,2A,3E,4 B,5A,6A,7A),(1E,2A,3E,4B,5A,6A,7B),(1E,2A,3E,4B,5A,6A,7C),(1E,2A,3E,4B,5A,6B,7A), (1E,2A,
3E,4B,5A,6B,7B),(1E,2A,3E,4B,5A,6B,7C),(1E,2A,3E,4B,5A,6C,7A),(1E,2A,3E,4 B,5A,6C,7B),(1E,2A,3E,4B,5A,6C,
7C),(1E,2A,3E,4B,5A,6D,7A),(1E,2A,3E,4B,5A,6D,7B), (1E,2A,3E,4B,5A,6D,7C),(1E,2A,3E,4B,5B,6A,7A),(1E,2A,
3E,4B,5B,6A,7B),(1E,2A,3E,4 B,5B,6A,7C),(1E,2A,3E,4B,5B,6B,7A),(1E,2A,3E,4B,5B,6B,7B),(1E,2A,3E,4B,5B,6B,
7C), (1E,2A,3E,4B,5B,6C,7A),(1E,2A,3E,4B,5B,6C,7B),(1E,2A,3E,4B,5B,6C,7C),(1E,2A,3E,4 B,5B,6D,7A),(1E,2A,
35 3E,4B,5B,6D,7B),(1E,2A,3E,4B,5B,6D,7C),(1E,2A,3E,4C,5A,6A,7A), (1E,2A,3E,4C,5A,6A,7B),(1E,2A,3E,4C,5A,6A,
7C),(1E,2A,3E,4C,5A,6B,7A),(1E,2A,3E,4 C,5A,6B,7B),(1E,2A,3E,4C,5A,6B,7C),(1E,2A,3E,4C,5A,6C,7A),(1E,2A,
3E,4C,5A,6C,7B), (1E,2A,3E,4C,5A,6C,7C),(1E,2A,3E,4C,5A,6D,7A),(1E,2A,3E,4C,5A,6D,7B),(1E,2A,3E,4 C,5A,
6D,7C),(1E,2A,3E,4C,5B,6A,7A),(1E,2A,3E,4C,5B,6A,7B),(1E,2A,3E,4C,5B,6A,7C), (1E,2A,3E,4C,5B,6B,7A),(1E,
40 2A,3E,4C,5B,6B,7B),(1E,2A,3E,4C,5B,6B,7C),(1E,2A,3E,4 C,5B,6C,7A),(1E,2A,3E,4C,5B,6C,7B),(1E,2A,3E,4C,
5B,6C,7C),(1E,2A,3E,4C,5B,6D,7A), (1E,2A,3E,4C,5B,6D,7B),(1E,2A,3E,4C,5B,6D,7C),(1E,2A,3E,4D,5A,6A,7A),
(1E,2A,3E,4 D,5A,6A,7B),(1E,2A,3E,4D,5A,6A,7C),(1E,2A,3E,4D,5A,6B,7A),(1E,2A,3E,4D,5A,6B,7B),(1E,2A,3E,
4D,5A,6B,7C),(1E,2A,3E,4D,5A,6C,7A),(1E,2A,3E,4D,5A,6C,7B),(1E,2A,3E,4 D,5A,6C,7C),(1E,2A,3E,4D,5A,6D,
7A),(1E,2A,3E,4D,5A,6D,7B),(1E,2A,3E,4

[illegible]

2B,3C,4C,5A,6B,7B), (1E,2B,3C,4C,5A,6B,7C), (1E,2B,3C,4C,5A,6C,7A), (1E,2B,3C,4C,5A,6C,7B), (1E,2B,3C,4 C,
 5A,6C,7C), (1E,2B,3C,4C,5A,6D,7A), (1E,2B,3C,4C,5A,6D,7B), (1E,2B,3C,4C,5A,6D,7C), (1E,2B,3C,4C,5B,6A,7A),
 (1E,2B,3C,4C,5B,6A,7B), (1E,2B,3C,4C,5B,6A,7C), (1E,2B,3C,4 C,5B,6B,7A), (1E,2B,3C,4C,5B,6B,7B), (1E,2B,3C,
 4C,5B,6B,7C), (1E,2B,3C,4C,5B,6C,7A), (1E,2B,3C,4C,5B,6C,7B), (1E,2B,3C,4C,5B,6C,7C), (1E,2B,3C,4C,5B,6D,
 5 7A), (1E,2B,3C,4 C,5B,6D,7B), (1E,2B,3C,4C,5B,6D,7C), (1E,2B,3C,4D,5A,6A,7A), (1E,2B,3C,4D,5A,6A,7B), (1E,2B,
 3C,4D,5A,6A,7C), (1E,2B,3C,4D,5A,6B,7A), (1E,2B,3C,4D,5A,6B,7B), (1E,2B,3C,4 D,5A,6B,7C), (1E,2B,3C,4D,5A,
 6C,7A), (1E,2B,3C,4D,5A,6C,7B), (1E,2B,3C,4D,5A,6C,7C), (1E,2B,3C,4D,5A,6D,7A), (1E,2B,3C,4D,5A,6D,7B), (1E,
 2B,3C,4D,5A,6D,7C), (1E,2B,3C,4 D,5B,6A,7A), (1E,2B,3C,4D,5B,6A,7B), (1E,2B,3C,4D,5B,6A,7C), (1E,2B,3C,4D,
 5B,6B,7A), (1E,2B,3C,4D,5B,6B,7B), (1E,2B,3C,4D,5B,6B,7C), (1E,2B,3C,4D,5B,6C,7A), (1E,2B,3C,4 D,5B,6C,7B),
 10 (1E,2B,3C,4D,5B,6C,7C), (1E,2B,3C,4D,5B,6D,7A), (1E,2B,3C,4D,5B,6D,7B), (1E,2B,3C,4D,5B,6D,7C), (1E,2B,3C,
 4E,5A,6A,7A), (1E,2B,3C,4E,5A,6A,7B), (1E,2B,3C,4 E,5A,6A,7C), (1E,2B,3C,4E,5A,6B,7A), (1E,2B,3C,4E,5A,6B,
 7B), (1E,2B,3C,4E,5A,6B,7C), (1E,2B,3C,4E,5A,6C,7A), (1E,2B,3C,4E,5A,6C,7B), (1E,2B,3C,4E,5A,6C,7C), (1E,2B,
 3C,4 E,5A,6D,7A), (1E,2B,3C,4E,5A,6D,7B), (1E,2B,3C,4E,5A,6D,7C), (1E,2B,3C,4E,5B,6A,7A), (1E,2B,3C,4E,5B,
 6A,7B), (1E,2B,3C,4E,5B,6A,7C), (1E,2B,3C,4E,5B,6B,7A), (1E,2B,3C,4 E,5B,6B,7B), (1E,2B,3C,4E,5B,6B,7C), (1E,
 15 2B,3C,4E,5B,6C,7A), (1E,2B,3C,4E,5B,6C,7B), (1E,2B,3C,4E,5B,6C,7C), (1E,2B,3C,4E,5B,6D,7A), (1E,2B,3C,4E,
 5B,6D,7B), (1E,2B,3C,4 E,5B,6D,7C), (1E,2B,3D,4A,5A,6A,7A), (1E,2B,3D,4A,5A,6A,7B), (1E,2B,3D,4A,5A,6A,7C),
 (1E,2B,3D,4A,5A,6B,7A), (1E,2B,3D,4A,5A,6B,7B), (1E,2B,3D,4A,5A,6B,7C), (1E,2B,3D,4 A,5A,6C,7A), (1E,2B,3D,
 4A,5A,6C,7B), (1E,2B,3D,4A,5A,6C,7C), (1E,2B,3D,4A,5A,6D,7A), (1E,2B,3D,4A,5A,6D,7B), (1E,2B,3D,4A,5A,6D,
 7C), (1E,2B,3D,4A,5B,6A,7A), (1E,2B,3D,4 A,5B,6A,7B), (1E,2B,3D,4A,5B,6A,7C), (1E,2B,3D,4A,5B,6B,7A), (1E,2B,
 20 3D,4A,5B,6B,7B), (1E,2B,3D,4A,5B,6B,7C), (1E,2B,3D,4A,5B,6C,7A), (1E,2B,3D,4A,5B,6C,7B), (1E,2B,3D,4 A,5B,
 6C,7C), (1E,2B,3D,4A,5B,6D,7A), (1E,2B,3D,4A,5B,6D,7B), (1E,2B,3D,4A,5B,6D,7C), (1E,2B,3D,4B,5A,6A,7A), (1E,
 2B,3D,4B,5A,6A,7B), (1E,2B,3D,4B,5A,6A,7C), (1E,2B,3D,4 B,5A,6B,7A), (1E,2B,3D,4B,5A,6B,7B), (1E,2B,3D,4B,5A,
 6B,7C), (1E,2B,3D,4B,5A,6C,7A), (1E,2B,3D,4B,5A,6C,7B), (1E,2B,3D,4B,5A,6C,7C), (1E,2B,3D,4B,5A,6D,7A), (1E,
 2B,3D,4 B,5A,6D,7B), (1E,2B,3D,4B,5A,6D,7C), (1E,2B,3D,4B,5B,6A,7A), (1E,2B,3D,4B,5B,6A,7B), (1E,2B,3D,4B,
 25 5B,6A,7C), (1E,2B,3D,4B,5B,6B,7A), (1E,2B,3D,4B,5B,6B,7B), (1E,2B,3D,4 B,5B,6B,7C), (1E,2B,3D,4B,5B,6C,7A),
 (1E,2B,3D,4B,5B,6C,7B), (1E,2B,3D,4B,5B,6C,7C), (1E,2B,3D,4B,5B,6D,7A), (1E,2B,3D,4B,5B,6D,7B), (1E,2B,3D,
 4B,5B,6D,7C), (1E,2B,3D,4 C,5A,6A,7A), (1E,2B,3D,4C,5A,6A,7B), (1E,2B,3D,4C,5A,6A,7C), (1E,2B,3D,4C,5A,6B,
 7A), (1E,2B,3D,4C,5A,6B,7B), (1E,2B,3D,4C,5A,6B,7C), (1E,2B,3D,4C,5A,6C,7A), (1E,2B,3D,4 C,5A,6C,7B), (1E,2B,
 30 3D,4C,5A,6C,7C), (1E,2B,3D,4C,5A,6D,7A), (1E,2B,3D,4C,5A,6D,7B), (1E,2B,3D,4C,5A,6D,7C), (1E,2B,3D,4C,5B,
 6A,7A), (1E,2B,3D,4C,5B,6A,7B), (1E,2B,3D,4 C,5B,6A,7C), (1E,2B,3D,4C,5B,6B,7A), (1E,2B,3D,4C,5B,6B,7B), (1E,
 2B,3D,4C,5B,6B,7C), (1E,2B,3D,4C,5B,6C,7A), (1E,2B,3D,4C,5B,6C,7B), (1E,2B,3D,4C,5B,6C,7C), (1E,2B,3D,4 C,
 5B,6D,7A), (1E,2B,3D,4C,5B,6D,7B), (1E,2B,3D,4C,5B,6D,7C), (1E,2B,3D,4D,5A,6A,7A), (1E,2B,3D,4D,5A,6A,7B),
 (1E,2B,3D,4D,5A,6A,7C), (1E,2B,3D,4D,5A,6B,7A), (1E,2B,3D,4 D,5A,6B,7B), (1E,2B,3D,4D,5A,6B,7C), (1E,2B,3D,
 4D,5A,6C,7A), (1E,2B,3D,4D,5A,6C,7B), (1E,2B,3D,4D,5A,6C,7C), (1E,2B,3D,4D,5A,6D,7A), (1E,2B,3D,4D,5A,6D,
 35 7B), (1E,2B,3D,4 D,5A,6D,7C), (1E,2B,3D,4D,5B,6A,7A), (1E,2B,3D,4D,5B,6A,7B), (1E,2B,3D,4D,5B,6A,7C), (1E,2B,
 3D,4D,5B,6B,7A), (1E,2B,3D,4D,5B,6B,7B), (1E,2B,3D,4D,5B,6B,7C), (1E,2B,3D,4 D,5B,6C,7A), (1E,2B,3D,4D,5B,
 6C,7B), (1E,2B,3D,4D,5B,6C,7C), (1E,2B,3D,4D,5B,6D,7A), (1E,2B,3D,4D,5B,6D,7B), (1E,2B,3D,4D,5B,6D,7C), (1E,
 2B,3D,4E,5A,6A,7A), (1E,2B,3D,4 E,5A,6A,7B), (1E,2B,3D,4E,5A,6A,7C), (1E,2B,3D,4E,5A,6B,7A), (1E,2B,3D,4E,5A,
 6B,7B), (1E,2B,3D,4E,5A,6B,7C), (1E,2B,3D,4E,5A,6C,7A), (1E,2B,3D,4E,5A,6C,7B), (1E,2B,3D,4 E,5A,6C,7C), (1E,
 40 2B,3D,4E,5A,6D,7A), (1E,2B,3D,4E,5A,6D,7B), (1E,2B,3D,4E,5A,6D,7C), (1E,2B,3D,4E,5B,6A,7A), (1E,2B,3D,4E,
 5B,6A,7B), (1E,2B,3D,4E,5B,6A,7C), (1E,2B,3D,4 E,5B,6B,7A), (1E,2B,3D,4E,5B,6B,7B), (1E,2B,3D,4E,5B,6B,7C),
 (1E,2B,3D,4E,5B,6C,7A), (1E,2B,3D,4E,5B,6C,7B), (1E,2B,3D,4E,5B,6C,7C), (1E,2B,3D,4E,5B,6D,7A), (1E,2B,3D,4
 E,5B,6D,7B), (1E,2B,3D,4E,5B,6D,7C), (1E,2B,3E,4A,5A,6A,7A), (1E,2B,3E,4A,5A,6A,7B), (1E,2B,3E,4A,5A,6A,7C),
 (1E,2B,3E,4A,5A,6B,7A), (1E,2B,3E,4A,5A,6B,7B), (1E,2B,3E,4 A,5A,6B,7C), (1E,2B,3E,4A,5A,6C,7A), (1E,2B,3E,
 45 4A,5A,6C,7B), (1E,2B,3E,4A,5A,6C,7C), (1E,2B,3E,4A,5A,6D,7A), (1E,2B,3E,4A,5A,6D,7B), (1E,2B,3E,4A,5A,6D,
 7C), (1E,2B,3E,4 A,5B,6A,7A), (1E,2B,3E,4A,5B,6A,7B), (1E,2B,3E,4A,5B,6A,7C), (1E,2B,3E,4A,5B,6B,7A), (1E,2B,
 3E,4A,5B,6B,7B), (1E,2B,3E,4A,5B,6B,7C), (1E,2B,3E,4A,5B,6C,7A), (1E,2B,3E,4 A,5B,6C,7B), (1E,2B,3E,4A,5B,6C,
 7C), (1E,2B,3E,4A,5B,6D,7A), (1E,2B,3E,4A,5B,6D,7B), (1E,2B,3E,4A,5B,6D,7C), (1E,2B,3E,4B,5A,6A,7A), (1E,2B,
 3E,4B,5A,6A,7B), (1E,2B,3E,4 B,5A,6A,7C), (1E,2B,3E,4B,5A,6B,7A), (1E,2B,3E,4B,5A,6B,7B), (1E,2B,3E,4B,5A,6B,
 50 7C), (1E,2B,3E,4B,5A,6C,7A), (1E,2B,3E,4B,5A,6C,7B), (1E,2B,3E,4B,5A,6C,7C), (1E,2B,3E,4 B,5A,6D,7A), (1E,2B,
 3E,4B,5A,6D,7B), (1E,2B,3E,4B,5A,6D,7C), (1E,2B,3E,4B,5B,6A,7A), (1E,2B,3E,4B,5B,6A,7B), (1E,2B,3E,4B,5B,6A,
 7C), (1E,2B,3E,4B,5B,6B,7A), (1E,2B,3E,4 B,5B,6B,7B), (1E,2B,3E,4B,5B,6B,7C), (1E,2B,3E,4B,5B,6C,7A), (1E,2B,
 3E,4B,5B,6C,7B), (1E,2B,3E,4B,5B,6C,7C), (1E,2B,3E,4B,5B,6D,7A), (1E,2B,3E,4B,5B,6D,7B), (1E,2B,3E,4 B,5B,
 6D,7C), (1E,2B,3E,4C,5A,6A,7A), (1E,2B,3E,4C,5A,6A,7B), (1E,2B,3E,4C,5A,6A,7C), (1E,2B,3E,4C,5A,6B,7A), (1E,
 55 2B,3E,4C,5A,6B,7B), (1E,2B,3E,4C,5A,6B,7C), (1E,2B,3E,4 C,5A,6C,7A), (1E,2B,3E,4C,5A,6C,7B), (1E,2B,3E,4C,
 5A,6C,7C), (1E,2B,3E,4C,5A,6D,7A), (1E,2B,3E,4C,5A,6D,7B), (1E,2B,3E,4C,5A,6D,7C), (1E,2B,3E,4C,5B,6A,7A),
 (1E,2B,3E,4 C,5B,6A,7B), (1E,2B,3E,4C,5B,6A,7C), (1E,2B,3E,4C,5B,6B,7A), (1E,2B,3E,4C,5B,6B,7B), (1E,2B,3E,
 4C,5B,6B,7C), (1E,2B,3E,4C,5B,6C,7A), (1E,2B,3E,4C,5B,6C,7B), (1E,2B,3E,4 C,5B,6C,7C), (1E,2B,3E,4C,5B,6D,

7A),(1E,2B,3E,4C,5B,6D,7B),(1E,2B,3E,4C,5B,6D,7C), (1E,2B,3E,4D,5A,6A,7A),(1E,2B,3E,4D,5A,6A,7B),(1E,2B,3E,4D,5A,6A,7C),(1E,2B,3E,4 D,5A,6B,7A),(1E,2B,3E,4D,5A,6B,7B),(1E,2B,3E,4D,5A,6B,7C),(1E,2B,3E,4D,5A,6C,7A), (1E,2B,3E,4D,5A,6C,7B),(1E,2B,3E,4D,5A,6C,7C),(1E,2B,3E,4D,5A,6D,7A),(1E,2B,3E,4 D,5A,6D,7B),(1E,2B,3E,4D,5A,6D,7C),(1E,2B,3E,4D,5B,6A,7A),(1E,2B,3E,4D,5B,6A,7B), (1E,2B,3E,4D,5B,6A,7C),(1E,2B,3E,4D,5B,6B,7A),(1E,2B,3E,4D,5B,6B,7B),(1E,2B,3E,4 D,5B,6B,7C),(1E,2B,3E,4D,5B,6C,7A),(1E,2B,3E,4D,5B,6C,7B), (1E,2B,3E,4D,5B,6C,7C), (1E,2B,3E,4D,5B,6D,7A),(1E,2B,3E,4D,5B,6D,7B),(1E,2B,3E,4D,5B,6D,7C),(1E,2B,3E,4 E,5A,6A,7A),(1E,2B,3E,4E,5A,6A,7B),(1E,2B,3E,4E,5A,6A,7C),(1E,2B,3E,4E,5A,6B,7A), (1E,2B,3E,4E,5A,6B,7B), (1E,2B,3E,4E,5A,6B,7C),(1E,2B,3E,4E,5A,6C,7A),(1E,2B,3E,4E,5A,6C,7B),(1E,2B,3E,4E,5A,6C,7C),(1E,2B,3E,4E,5A,6D,7A),(1E,2B,3E,4E,5A,6D,7B), (1E,2B,3E,4E,5A,6D,7C),(1E,2B,3E,4E,5B,6A,7A),(1E,2B,3E,4E,5B,6A,7B), (1E,2B,3E,4 E,5B,6A,7C),(1E,2B,3E,4E,5B,6B,7A),(1E,2B,3E,4E,5B,6B,7B),(1E,2B,3E,4E,5B,6B,7C), (1E,2B,3E,4E,5B,6C,7A),(1E,2B,3E,4E,5B,6C,7B),(1E,2B,3E,4E,5B,6C,7C),(1E,2B,3E,4 E,5B,6D,7A),(1E,2B,3E,4E,5B,6D,7B),(1E,2B,3E,4E,5B,6D,7C),(1E,2C,3A,4A,5A,6A,7A), (1E,2C,3A,4A,5A,6A,7B),(1E,2C,3A,4A,5A,6A,7C),(1E,2C,3A,4A,5A,6B,7A),(1E,2C,3A,4 A,5A,6B,7B),(1E,2C,3A,4 A,5A,6B,7C),(1E,2C,3A,4A,5A,6B,7C),(1E,2C,3A,4A,5A,6C,7A),(1E,2C,3A,4A,5A,6C,7B), (1E,2C,3A,4A,5A,6C,7C),(1E,2C,3A,4A,5A,6D,7A),(1E,2C,3A,4A,5A,6D,7B),(1E,2C,3A,4 A,5A,6D,7C),(1E,2C,3A,4A,5B,6A,7A),(1E,2C,3A,4A,5B,6A,7B),(1E,2C,3A,4A,5B,6A,7C), (1E,2C,3A,4A,5B,6B,7A),(1E,2C,3A,4A,5B,6B,7B),(1E,2C,3A,4A,5B,6B,7C),(1E,2C,3A,4A,5B,6C,7A),(1E,2C,3A,4A,5B,6C,7B),(1E,2C,3A,4A,5B,6C,7C),(1E,2C,3A,4A,5B,6D,7A), (1E,2C,3A,4A,5B,6D,7B),(1E,2C,3A,4A,5B,6D,7C),(1E,2C,3A,4B,5A,6A,7A),(1E,2C,3A,4 B,5A,6A,7B),(1E,2C,3A,4B,5A,6A,7C),(1E,2C,3A,4B,5A,6B,7A),(1E,2C,3A,4B,5A,6B,7B), (1E,2C,3A,4B,5A,6B,7C),(1E,2C,3A,4B,5A,6C,7A),(1E,2C,3A,4B,5A,6C,7B),(1E,2C,3A,4 B,5A,6C,7C),(1E,2C,3A,4B,5A,6D,7A),(1E,2C,3A,4B,5A,6D,7B),(1E,2C,3A,4B,5A,6D,7C), (1E,2C,3A,4B,5B,6A,7A),(1E,2C,3A,4B,5B,6A,7B),(1E,2C,3A,4B,5B,6A,7C), (1E,2C,3A,4 B,5B,6B,7A),(1E,2C,3A,4B,5B,6B,7B),(1E,2C,3A,4B,5B,6B,7C),(1E,2C,3A,4B,5B,6C,7A), (1E,2C,3A,4B,5B,6C,7B),(1E,2C,3A,4B,5B,6C,7C),(1E,2C,3A,4B,5B,6D,7A),(1E,2C,3A,4 B,5B,6D,7B),(1E,2C,3A,4B,5B,6D,7C),(1E,2C,3A,4C,5A,6A,7A),(1E,2C,3A,4C,5A,6A,7B), (1E,2C,3A,4C,5A,6A,7C),(1E,2C,3A,4C,5A,6B,7A),(1E,2C,3A,4C,5A,6B,7B),(1E,2C,3A,4 C,5A,6B,7C),(1E,2C,3A,4C,5A,6C,7A),(1E,2C,3A,4C,5A,6C,7B),(1E,2C,3A,4C,5A,6C,7C), (1E,2C,3A,4C,5A,6D,7A),(1E,2C,3A,4C,5A,6D,7B),(1E,2C,3A,4C,5A,6D,7C),(1E,2C,3A,4 C,5B,6A,7A),(1E,2C,3A,4C,5B,6A,7B),(1E,2C,3A,4C,5B,6A,7C),(1E,2C,3A,4C,5B,6B,7A), (1E,2C,3A,4C,5B,6B,7B),(1E,2C,3A,4C,5B,6B,7C),(1E,2C,3A,4C,5B,6C,7A),(1E,2C,3A,4C,5B,6C,7B),(1E,2C,3A,4C,5B,6C,7C),(1E,2C,3A,4C,5B,6D,7A), (1E,2C,3A,4C,5B,6D,7B), (1E,2C,3A,4C,5B,6D,7C),(1E,2C,3A,4D,5A,6A,7A),(1E,2C,3A,4D,5A,6A,7B),(1E,2C,3A,4D,5A,6A,7C),(1E,2C,3A,4D,5A,6B,7A),(1E,2C,3A,4D,5A,6B,7B),(1E,2C,3A,4D,5A,6B,7C), (1E,2C,3A,4D,5A,6C,7A),(1E,2C,3A,4D,5A,6C,7B),(1E,2C,3A,4 D,5A,6D,7A),(1E,2C,3A,4D,5A,6D,7B),(1E,2C,3A,4D,5A,6D,7C),(1E,2C,3A,4D,5B,6A,7A), (1E,2C,3A,4D,5B,6A,7B),(1E,2C,3A,4D,5B,6A,7C),(1E,2C,3A,4D,5B,6B,7A),(1E,2C,3A,4 D,5B,6B,7B),(1E,2C,3A,4D,5B,6B,7C),(1E,2C,3A,4D,5B,6C,7A),(1E,2C,3A,4D,5B,6C,7B), (1E,2C,3A,4D,5B,6C,7C),(1E,2C,3A,4D,5B,6D,7A),(1E,2C,3A,4D,5B,6D,7B),(1E,2C,3A,4 D,5B,6D,7C),(1E,2C,3A,4E,5A,6A,7A),(1E,2C,3A,4E,5A,6A,7B),(1E,2C,3A,4E,5A,6A,7C), (1E,2C,3A,4E,5A,6B,7A),(1E,2C,3A,4E,5A,6B,7B),(1E,2C,3A,4E,5A,6B,7C),(1E,2C,3A,4 E,5A,6C,7A),(1E,2C,3A,4E,5A,6C,7B),(1E,2C,3A,4E,5A,6C,7C),(1E,2C,3A,4E,5A,6D,7A), (1E,2C,3A,4E,5A,6D,7B),(1E,2C,3A,4E,5A,6D,7C),(1E,2C,3A,4E,5B,6A,7A),(1E,2C,3A,4 E,5B,6A,7B),(1E,2C,3A,4E,5B,6A,7C),(1E,2C,3A,4E,5B,6B,7A),(1E,2C,3A,4E,5B,6B,7B), (1E,2C,3A,4E,5B,6B,7C),(1E,2C,3A,4E,5B,6C,7A),(1E,2C,3A,4E,5B,6C,7B),(1E,2C,3A,4E,5B,6C,7C),(1E,2C,3A,4E,5B,6D,7A),(1E,2C,3A,4E,5B,6D,7B), (1E,2C,3A,4E,5B,6D,7C), (1E,2C,3B,4A,5A,6A,7A),(1E,2C,3B,4A,5A,6A,7B),(1E,2C,3B,4A,5A,6A,7C),(1E,2C,3B,4 A,5A,6B,7A),(1E,2C,3B,4A,5A,6B,7B),(1E,2C,3B,4A,5A,6B,7C),(1E,2C,3B,4A,5A,6C,7A), (1E,2C,3B,4A,5A,6C,7B),(1E,2C,3B,4A,5A,6C,7C),(1E,2C,3B,4 A,5A,6D,7A),(1E,2C,3B,4A,5A,6D,7B),(1E,2C,3B,4 A,5A,6D,7C),(1E,2C,3B,4A,5B,6A,7A),(1E,2C,3B,4A,5B,6A,7B), (1E,2C,3B,4A,5B,6A,7C),(1E,2C,3B,4A,5B,6B,7A),(1E,2C,3B,4A,5B,6B,7B),(1E,2C,3B,4 A,5B,6B,7C),(1E,2C,3B,4A,5B,6C,7A),(1E,2C,3B,4A,5B,6C,7B),(1E,2C,3B,4A,5B,6C,7C), (1E,2C,3B,4A,5B,6D,7A),(1E,2C,3B,4A,5B,6D,7B),(1E,2C,3B,4A,5B,6D,7C),(1E,2C,3B,4 B,5A,6A,7A),(1E,2C,3B,4B,5A,6A,7B),(1E,2C,3B,4B,5A,6A,7C),(1E,2C,3B,4B,5A,6B,7A), (1E,2C,3B,4B,5A,6B,7B),(1E,2C,3B,4B,5A,6B,7C),(1E,2C,3B,4B,5A,6C,7A),(1E,2C,3B,4B,5A,6C,7B),(1E,2C,3B,4B,5A,6C,7C),(1E,2C,3B,4B,5A,6D,7A), (1E,2C,3B,4B,5A,6D,7B), (1E,2C,3B,4B,5A,6D,7C),(1E,2C,3B,4B,5B,6A,7A),(1E,2C,3B,4B,5B,6A,7B),(1E,2C,3B,4B,5B,6A,7C),(1E,2C,3B,4B,5B,6B,7A),(1E,2C,3B,4B,5B,6B,7B), (1E,2C,3B,4B,5B,6B,7C), (1E,2C,3B,4B,5B,6C,7A),(1E,2C,3B,4B,5B,6C,7B),(1E,2C,3B,4B,5B,6C,7C),(1E,2C,3B,4 B,5B,6D,7A),(1E,2C,3B,4B,5B,6D,7B),(1E,2C,3B,4B,5B,6D,7C),(1E,2C,3B,4B,5B,6C,7A), (1E,2C,3B,4C,5A,6A,7A), (1E,2C,3B,4C,5A,6A,7B),(1E,2C,3B,4C,5A,6A,7C),(1E,2C,3B,4C,5A,6B,7A), (1E,2C,3B,4 C,5A,6B,7B),(1E,2C,3B,4C,5A,6B,7C),(1E,2C,3B,4C,5A,6C,7A),(1E,2C,3B,4C,5A,6C,7B), (1E,2C,3B,4C,5A,6C,7C),(1E,2C,3B,4C,5A,6D,7A),(1E,2C,3B,4C,5A,6D,7B),(1E,2C,3B,4 C,5A,6D,7C),(1E,2C,3B,4C,5B,6A,7A),(1E,2C,3B,4C,5B,6A,7B),(1E,2C,3B,4C,5B,6A,7C), (1E,2C,3B,4C,5B,6B,7A),(1E,2C,3B,4C,5B,6B,7B),(1E,2C,3B,4C,5B,6B,7C),(1E,2C,3B,4 C,5B,6C,7A),(1E,2C,3B,4C,5B,6C,7B),(1E,2C,3B,4C,5B,6C,7C),(1E,2C,3B,4C,5B,6D,7A), (1E,2C,3B,4C,5B,6D,7B),(1E,2C,3B,4C,5B,6D,7C),(1E,2C,3B,4D,5A,6A,7A),(1E,2C,3B,4 D,5A,6A,7B),(1E,2C,3B,4D,5A,6A,7C),(1E,2C,3B,4D,5A,6B,7A),(1E,2C,3B,4D,5A,6B,7B), (1E,2C,3B,4D,5A,6B,7C),(1E,2C,3B,4D,5A,6C,7A),(1E,2C,3B,4D,5A,6C,7B),(1E,2C,3B,4 D,5A,6C,7C),(1E,2C,3B,4D,5A,6D,7A),(1E,2C,3B,4D,5A,6D,7B),(1E,2C,3B,4D,5A,6D,7C), (1E,2C,3B,4D,5B,6A,7A),(1E,2C,3B,4D,5B,6A,7B),(1E,2C,3B,4D,5B,6A,7C),(1E,2C,3B,4

[illegible]

4E,5A,6C,7C),(1E,2C,3D,4E,5A,6D,7A),(1E,2C,3D,4 E,5A,6D,7B),(1E,2C,3D,4E,5A,6D,7C),(1E,2C,3D,4E,5B,6A,
 7A),(1E,2C,3D,4E,5B,6A,7B),(1E,2C,3D,4E,5B,6A,7C),(1E,2C,3D,4E,5B,6B,7A),(1E,2C,3D,4E,5B,6B,7B),(1E,2C,
 3D,4 E,5B,6B,7C),(1E,2C,3D,4E,5B,6C,7A),(1E,2C,3D,4E,5B,6C,7B),(1E,2C,3D,4E,5B,6C,7C),(1E,2C,3D,4E,5B,
 6D,7A),(1E,2C,3D,4E,5B,6D,7B),(1E,2C,3D,4E,5B,6D,7C),(1E,2C,3E,4 A,5A,6A,7A),(1E,2C,3E,4A,5A,6A,7B),(1E,
 5 2C,3E,4A,5A,6A,7C),(1E,2C,3E,4A,5A,6B,7A),(1E,2C,3E,4A,5A,6B,7B),(1E,2C,3E,4A,5A,6B,7C),(1E,2C,3E,4A,5A,
 6C,7A),(1E,2C,3E,4 A,5A,6C,7B),(1E,2C,3E,4A,5A,6C,7C),(1E,2C,3E,4A,5A,6D,7A),(1E,2C,3E,4A,5A,6D,7B),(1E,
 2C,3E,4A,5A,6D,7C),(1E,2C,3E,4A,5B,6A,7A),(1E,2C,3E,4A,5B,6A,7B),(1E,2C,3E,4 A,5B,6A,7C),(1E,2C,3E,4A,
 5B,6B,7A),(1E,2C,3E,4A,5B,6B,7B),(1E,2C,3E,4A,5B,6B,7C),(1E,2C,3E,4A,5B,6C,7A),(1E,2C,3E,4A,5B,6C,7B),
 (1E,2C,3E,4A,5B,6C,7C),(1E,2C,3E,4 A,5B,6D,7A),(1E,2C,3E,4A,5B,6D,7B),(1E,2C,3E,4A,5B,6D,7C),(1E,2C,3E,
 10 4B,5A,6A,7A),(1E,2C,3E,4B,5A,6A,7B),(1E,2C,3E,4B,5A,6A,7C),(1E,2C,3E,4B,5A,6B,7A),(1E,2C,3E,4 B,5A,6B,
 7B),(1E,2C,3E,4B,5A,6B,7C),(1E,2C,3E,4B,5A,6C,7A),(1E,2C,3E,4B,5A,6C,7B),(1E,2C,3E,4B,5A,6C,7C),(1E,2C,
 3E,4B,5A,6D,7A),(1E,2C,3E,4B,5A,6D,7B),(1E,2C,3E,4 B,5A,6D,7C),(1E,2C,3E,4B,5B,6A,7A),(1E,2C,3E,4B,5B,
 6A,7B),(1E,2C,3E,4B,5B,6A,7C),(1E,2C,3E,4B,5B,6B,7A),(1E,2C,3E,4B,5B,6B,7B),(1E,2C,3E,4B,5B,6B,7C),(1E,
 2C,3E,4 B,5B,6C,7A),(1E,2C,3E,4B,5B,6C,7B),(1E,2C,3E,4B,5B,6C,7C),(1E,2C,3E,4B,5B,6D,7A),(1E,2C,3E,4B,
 15 5B,6D,7B),(1E,2C,3E,4B,5B,6D,7C),(1E,2C,3E,4C,5A,6A,7A),(1E,2C,3E,4 C,5A,6A,7B),(1E,2C,3E,4C,5A,6A,7C),
 (1E,2C,3E,4C,5A,6B,7A),(1E,2C,3E,4C,5A,6B,7B),(1E,2C,3E,4C,5A,6B,7C),(1E,2C,3E,4C,5A,6C,7A),(1E,2C,3E,
 4C,5A,6C,7B),(1E,2C,3E,4 C,5A,6C,7C),(1E,2C,3E,4C,5A,6D,7A),(1E,2C,3E,4C,5A,6D,7B),(1E,2C,3E,4C,5A,6D,7C),
 (1E,2C,3E,4C,5B,6A,7A),(1E,2C,3E,4C,5B,6A,7B),(1E,2C,3E,4C,5B,6A,7C),(1E,2C,3E,4 C,5B,6B,7A),(1E,2C,
 20 3E,4C,5B,6B,7B),(1E,2C,3E,4C,5B,6B,7C),(1E,2C,3E,4C,5B,6C,7A),(1E,2C,3E,4C,5B,6C,7B),(1E,2C,3E,4C,5B,
 6C,7C),(1E,2C,3E,4C,5B,6D,7A),(1E,2C,3E,4 C,5B,6D,7B),(1E,2C,3E,4C,5B,6D,7C),(1E,2C,3E,4D,5A,6A,7A),(1E,
 2C,3E,4D,5A,6A,7B),(1E,2C,3E,4D,5A,6A,7C),(1E,2C,3E,4D,5A,6B,7A),(1E,2C,3E,4D,5A,6B,7B),(1E,2C,3E,4 D,
 5A,6B,7C),(1E,2C,3E,4D,5A,6C,7A),(1E,2C,3E,4D,5A,6C,7B),(1E,2C,3E,4D,5A,6C,7C),(1E,2C,3E,4D,5A,6D,7A),
 (1E,2C,3E,4D,5A,6D,7B),(1E,2C,3E,4D,5A,6D,7C),(1E,2C,3E,4 D,5B,6A,7A),(1E,2C,3E,4D,5B,6A,7B),(1E,2C,3E,
 25 4D,5B,6A,7C),(1E,2C,3E,4D,5B,6B,7A),(1E,2C,3E,4D,5B,6B,7B),(1E,2C,3E,4D,5B,6B,7C),(1E,2C,3E,4D,5B,6C,
 7A),(1E,2C,3E,4 D,5B,6C,7B),(1E,2C,3E,4D,5B,6C,7C),(1E,2C,3E,4D,5B,6D,7A),(1E,2C,3E,4D,5B,6D,7B),(1E,2C,
 3E,4D,5B,6D,7C),(1E,2C,3E,4E,5A,6A,7A),(1E,2C,3E,4E,5A,6A,7B),(1E,2C,3E,4 E,5A,6A,7C),(1E,2C,3E,4E,5A,
 6B,7A),(1E,2C,3E,4E,5A,6B,7B),(1E,2C,3E,4E,5A,6B,7C),(1E,2C,3E,4E,5A,6C,7A),(1E,2C,3E,4E,5A,6C,7B),(1E,
 2C,3E,4E,5A,6C,7C),(1E,2C,3E,4 E,5A,6D,7A),(1E,2C,3E,4E,5A,6D,7B),(1E,2C,3E,4E,5A,6D,7C),(1E,2C,3E,4E,
 5B,6A,7A),(1E,2C,3E,4E,5B,6A,7B),(1E,2C,3E,4E,5B,6A,7C),(1E,2C,3E,4E,5B,6B,7A),(1E,2C,3E,4 E,5B,6B,7B),
 30 (1E,2C,3E,4E,5B,6B,7C),(1E,2C,3E,4E,5B,6C,7A),(1E,2C,3E,4E,5B,6C,7B),(1E,2C,3E,4E,5B,6C,7C),(1E,2C,3E,
 4E,5B,6D,7A),(1E,2C,3E,4E,5B,6D,7B),(1E,2C,3E,4 E,5B,6D,7C),(1E,2D,3A,4A,5A,6A,7A),(1E,2D,3A,4A,5A,6A,
 7B),(1E,2D,3A,4A,5A,6A,7C),(1E,2D,3A,4A,5A,6B,7A),(1E,2D,3A,4A,5A,6B,7B),(1E,2D,3A,4A,5A,6B,7C),(1E,2D,
 3A,4 A,5A,6C,7A),(1E,2D,3A,4A,5A,6C,7B),(1E,2D,3A,4A,5A,6C,7C),(1E,2D,3A,4A,5A,6D,7A),(1E,2D,3A,4A,5A,
 6D,7B),(1E,2D,3A,4A,5A,6D,7C),(1E,2D,3A,4A,5B,6A,7A),(1E,2D,3A,4 A,5B,6A,7B),(1E,2D,3A,4A,5B,6A,7C),(1E,
 35 2D,3A,4A,5B,6B,7A),(1E,2D,3A,4A,5B,6B,7B),(1E,2D,3A,4A,5B,6B,7C),(1E,2D,3A,4A,5B,6C,7A),(1E,2D,3A,4A,5B,
 6C,7B),(1E,2D,3A,4 A,5B,6C,7C),(1E,2D,3A,4A,5B,6D,7A),(1E,2D,3A,4A,5B,6D,7B),(1E,2D,3A,4A,5B,6D,7C),(1E,
 2D,3A,4B,5A,6A,7A),(1E,2D,3A,4B,5A,6A,7B),(1E,2D,3A,4B,5A,6A,7C),(1E,2D,3A,4 B,5A,6B,7A),(1E,2D,3A,4B,5A,
 6B,7B),(1E,2D,3A,4B,5A,6B,7C),(1E,2D,3A,4B,5A,6C,7A),(1E,2D,3A,4B,5A,6C,7B),(1E,2D,3A,4B,5A,6C,7C),(1E,
 2D,3A,4B,5A,6D,7A),(1E,2D,3A,4 B,5A,6D,7B),(1E,2D,3A,4B,5A,6D,7C),(1E,2D,3A,4B,5B,6A,7A),(1E,2D,3A,4B,
 40 5B,6A,7B),(1E,2D,3A,4B,5B,6A,7C),(1E,2D,3A,4B,5B,6B,7A),(1E,2D,3A,4B,5B,6B,7B),(1E,2D,3A,4 B,5B,6B,7C),
 (1E,2D,3A,4B,5B,6C,7A),(1E,2D,3A,4B,5B,6C,7B),(1E,2D,3A,4B,5B,6C,7C),(1E,2D,3A,4B,5B,6D,7A),(1E,2D,3A,
 4B,5B,6D,7B),(1E,2D,3A,4B,5B,6D,7C),(1E,2D,3A,4 C,5A,6A,7A),(1E,2D,3A,4C,5A,6A,7B),(1E,2D,3A,4C,5A,6A,
 7C),(1E,2D,3A,4C,5A,6B,7A),(1E,2D,3A,4C,5A,6B,7B),(1E,2D,3A,4C,5A,6B,7C),(1E,2D,3A,4C,5A,6C,7A),(1E,2D,
 3A,4 C,5A,6C,7B),(1E,2D,3A,4C,5A,6C,7C),(1E,2D,3A,4C,5A,6D,7A),(1E,2D,3A,4C,5A,6D,7B),(1E,2D,3A,4C,5A,
 45 6D,7C),(1E,2D,3A,4C,5B,6A,7A),(1E,2D,3A,4C,5B,6A,7B),(1E,2D,3A,4 C,5B,6A,7C),(1E,2D,3A,4C,5B,6B,7A),(1E,
 2D,3A,4C,5B,6B,7B),(1E,2D,3A,4C,5B,6B,7C),(1E,2D,3A,4C,5B,6C,7A),(1E,2D,3A,4C,5B,6C,7B),(1E,2D,3A,4C,
 5B,6C,7C),(1E,2D,3A,4 C,5B,6D,7A),(1E,2D,3A,4C,5B,6D,7B),(1E,2D,3A,4C,5B,6D,7C),(1E,2D,3A,4D,5A,6A,7A),
 (1E,2D,3A,4D,5A,6A,7B),(1E,2D,3A,4D,5A,6A,7C),(1E,2D,3A,4D,5A,6B,7A),(1E,2D,3A,4 D,5A,6B,7B),(1E,2D,3A,
 4D,5A,6B,7C),(1E,2D,3A,4D,5A,6C,7A),(1E,2D,3A,4D,5A,6C,7B),(1E,2D,3A,4D,5A,6C,7C),(1E,2D,3A,4D,5A,6D,
 50 7A),(1E,2D,3A,4D,5A,6D,7B),(1E,2D,3A,4 D,5A,6D,7C),(1E,2D,3A,4D,5B,6A,7A),(1E,2D,3A,4D,5B,6A,7B),(1E,2D,
 3A,4D,5B,6A,7C),(1E,2D,3A,4D,5B,6B,7A),(1E,2D,3A,4D,5B,6B,7B),(1E,2D,3A,4D,5B,6B,7C),(1E,2D,3A,4 D,5B,
 6C,7A),(1E,2D,3A,4D,5B,6C,7B),(1E,2D,3A,4D,5B,6C,7C),(1E,2D,3A,4D,5B,6D,7A),(1E,2D,3A,4D,5B,6D,7B),(1E,
 2D,3A,4D,5B,6D,7C),(1E,2D,3A,4E,5A,6A,7A),(1E,2D,3A,4 E,5A,6A,7B),(1E,2D,3A,4E,5A,6A,7C),(1E,2D,3A,4E,
 5A,6B,7A),(1E,2D,3A,4E,5A,6B,7B),(1E,2D,3A,4E,5A,6B,7C),(1E,2D,3A,4E,5A,6C,7A),(1E,2D,3A,4E,5A,6C,7B),
 55 (1E,2D,3A,4 E,5A,6C,7C),(1E,2D,3A,4E,5A,6D,7A),(1E,2D,3A,4E,5A,6D,7B),(1E,2D,3A,4E,5A,6D,7C),(1E,2D,3A,
 4E,5B,6A,7A),(1E,2D,3A,4E,5B,6A,7B),(1E,2D,3A,4E,5B,6A,7C),(1E,2D,3A,4 E,5B,6B,7A),(1E,2D,3A,4E,5B,6B,
 7B),(1E,2D,3A,4E,5B,6B,7C),(1E,2D,3A,4E,5B,6C,7A),(1E,2D,3A,4E,5B,6C,7B),(1E,2D,3A,4E,5B,6C,7C),(1E,2D,
 3A,4E,5B,6D,7A),(1E,2D,3A,4 E,5B,6D,7B),(1E,2D,3A,4E,5B,6D,7C),(1E,2D,3B,4A,5A,6A,7A),(1E,2D,3B,4A,5A,

6A,7B), (1E,2D,3B,4A,5A,6A,7C),(1E,2D,3B,4A,5A,6B,7A),(1E,2D,3B,4A,5A,6B,7B),(1E,2D,3B,4 A,5A,6B,7C),(1E,
2D,3B,4A,5A,6C,7A),(1E,2D,3B,4A,5A,6C,7B),(1E,2D,3B,4A,5A,6C,7C), (1E,2D,3B,4A,5A,6D,7A),(1E,2D,3B,4A,
5A,6D,7B),(1E,2D,3B,4A,5A,6D,7C),(1E,2D,3B,4 A,5B,6A,7A),(1E,2D,3B,4A,5B,6A,7B),(1E,2D,3B,4A,5B,6A,7C),
(1E,2D,3B,4A,5B,6B,7A), (1E,2D,3B,4A,5B,6B,7B),(1E,2D,3B,4A,5B,6B,7C),(1E,2D,3B,4A,5B,6C,7A),(1E,2D,3B,4
5 A,5B,6C,7B),(1E,2D,3B,4A,5B,6C,7C),(1E,2D,3B,4A,5B,6D,7A),(1E,2D,3B,4A,5B,6D,7B), (1E,2D,3B,4A,5B,6D,7C),
(1E,2D,3B,4B,5A,6A,7A),(1E,2D,3B,4B,5A,6A,7B),(1E,2D,3B,4 B,5A,6A,7C),(1E,2D,3B,4B,5A,6B,7A),(1E,2D,3B,
4B,5A,6B,7B),(1E,2D,3B,4B,5A,6B,7C), (1E,2D,3B,4B,5A,6C,7A),(1E,2D,3B,4B,5A,6C,7B),(1E,2D,3B,4B,5A,6C,
7C),(1E,2D,3B,4 B,5A,6D,7A),(1E,2D,3B,4B,5A,6D,7B),(1E,2D,3B,4B,5A,6D,7C),(1E,2D,3B,4B,5B,6A,7A), (1E,2D,
3B,4B,5B,6A,7B),(1E,2D,3B,4B,5B,6A,7C),(1E,2D,3B,4B,5B,6B,7A),(1E,2D,3B,4 B,5B,6B,7B),(1E,2D,3B,4B,5B,6B,
10 7C),(1E,2D,3B,4B,5B,6C,7A),(1E,2D,3B,4B,5B,6C,7B), (1E,2D,3B,4B,5B,6C,7C),(1E,2D,3B,4B,5B,6D,7A),(1E,2D,
3B,4B,5B,6D,7B),(1E,2D,3B,4 B,5B,6D,7C),(1E,2D,3B,4C,5A,6A,7A),(1E,2D,3B,4C,5A,6A,7B),(1E,2D,3B,4C,5A,
6A,7C), (1E,2D,3B,4C,5A,6B,7A),(1E,2D,3B,4C,5A,6B,7B),(1E,2D,3B,4C,5A,6B,7C),(1E,2D,3B,4 C,5A,6C,7A),(1E,
2D,3B,4C,5A,6C,7B),(1E,2D,3B,4C,5A,6C,7C),(1E,2D,3B,4C,5A,6D,7A), (1E,2D,3B,4C,5A,6D,7B),(1E,2D,3B,4C,
5A,6D,7C),(1E,2D,3B,4C,5B,6A,7A),(1E,2D,3B,4 C,5B,6A,7B),(1E,2D,3B,4C,5B,6A,7C),(1E,2D,3B,4C,5B,6B,7A),
15 (1E,2D,3B,4C,5B,6B,7B), (1E,2D,3B,4C,5B,6B,7C),(1E,2D,3B,4C,5B,6C,7A),(1E,2D,3B,4C,5B,6C,7B),(1E,2D,3B,4
C,5B,6C,7C),(1E,2D,3B,4C,5B,6D,7A),(1E,2D,3B,4C,5B,6D,7B),(1E,2D,3B,4C,5B,6D,7C), (1E,2D,3B,4D,5A,6A,
7A),(1E,2D,3B,4D,5A,6A,7B),(1E,2D,3B,4D,5A,6A,7C),(1E,2D,3B,4 D,5A,6B,7A),(1E,2D,3B,4D,5A,6B,7B),(1E,2D,
3B,4D,5A,6B,7C),(1E,2D,3B,4D,5A,6C,7A), (1E,2D,3B,4D,5A,6C,7B),(1E,2D,3B,4D,5A,6C,7C),(1E,2D,3B,4D,5A,
6D,7A),(1E,2D,3B,4 D,5A,6D,7B),(1E,2D,3B,4D,5A,6D,7C),(1E,2D,3B,4D,5B,6A,7A),(1E,2D,3B,4D,5B,6A,7B), (1E,
20 2D,3B,4D,5B,6A,7C),(1E,2D,3B,4D,5B,6B,7A),(1E,2D,3B,4D,5B,6B,7B),(1E,2D,3B,4 D,5B,6B,7C),(1E,2D,3B,4D,
5B,6C,7A),(1E,2D,3B,4D,5B,6C,7B),(1E,2D,3B,4D,5B,6C,7C), (1E,2D,3B,4D,5B,6D,7A),(1E,2D,3B,4D,5B,6D,7B),
(1E,2D,3B,4D,5B,6D,7C),(1E,2D,3B,4 E,5A,6A,7A),(1E,2D,3B,4E,5A,6A,7B),(1E,2D,3B,4E,5A,6A,7C),(1E,2D,3B,
4E,5A,6B,7A), (1E,2D,3B,4E,5A,6B,7B),(1E,2D,3B,4E,5A,6B,7C),(1E,2D,3B,4E,5A,6C,7A),(1E,2D,3B,4 E,5A,6C,
7B),(1E,2D,3B,4E,5A,6C,7C),(1E,2D,3B,4E,5A,6D,7A),(1E,2D,3B,4E,5A,6D,7B), (1E,2D,3B,4E,5A,6D,7C),(1E,2D,
25 3B,4E,5B,6A,7A),(1E,2D,3B,4E,5B,6A,7B),(1E,2D,3B,4 E,5B,6A,7C),(1E,2D,3B,4E,5B,6B,7A),(1E,2D,3B,4E,5B,6B,
7B),(1E,2D,3B,4E,5B,6B,7C), (1E,2D,3B,4E,5B,6C,7A),(1E,2D,3B,4E,5B,6C,7B),(1E,2D,3B,4E,5B,6C,7C),(1E,2D,
3B,4 E,5B,6D,7A),(1E,2D,3B,4E,5B,6D,7B),(1E,2D,3B,4E,5B,6D,7C),(1E,2D,3C,4A,5A,6A,7A), (1E,2D,3C,4A,5A,
6A,7B),(1E,2D,3C,4A,5A,6A,7C),(1E,2D,3C,4A,5A,6B,7A),(1E,2D,3C,4 A,5A,6B,7B),(1E,2D,3C,4A,5A,6B,7C),(1E,
2D,3C,4A,5A,6C,7A),(1E,2D,3C,4A,5A,6C,7B), (1E,2D,3C,4A,5A,6C,7C),(1E,2D,3C,4A,5A,6D,7A),(1E,2D,3C,4A,
30 5A,6D,7B),(1E,2D,3C,4 A,5A,6D,7C),(1E,2D,3C,4A,5B,6A,7A),(1E,2D,3C,4A,5B,6A,7B),(1E,2D,3C,4A,5B,6A,7C),
(1E,2D,3C,4A,5B,6B,7A),(1E,2D,3C,4A,5B,6B,7B),(1E,2D,3C,4A,5B,6B,7C),(1E,2D,3C,4 A,5B,6C,7A),(1E,2D,3C,
4A,5B,6C,7B),(1E,2D,3C,4A,5B,6C,7C),(1E,2D,3C,4A,5B,6D,7A), (1E,2D,3C,4A,5B,6D,7B),(1E,2D,3C,4A,5B,6D,
7C),(1E,2D,3C,4B,5A,6A,7A),(1E,2D,3C,4 B,5A,6A,7B),(1E,2D,3C,4B,5A,6A,7C),(1E,2D,3C,4B,5A,6B,7A),(1E,2D,
3C,4B,5A,6B,7B), (1E,2D,3C,4B,5A,6B,7C),(1E,2D,3C,4B,5A,6C,7A),(1E,2D,3C,4B,5A,6C,7B),(1E,2D,3C,4 B,5A,
35 6C,7C),(1E,2D,3C,4B,5A,6D,7A),(1E,2D,3C,4B,5A,6D,7B),(1E,2D,3C,4B,5A,6D,7C), (1E,2D,3C,4B,5B,6A,7A),(1E,
2D,3C,4B,5B,6A,7B),(1E,2D,3C,4B,5B,6A,7C),(1E,2D,3C,4 B,5B,6B,7A),(1E,2D,3C,4B,5B,6B,7B),(1E,2D,3C,4B,
5B,6B,7C),(1E,2D,3C,4B,5B,6C,7A), (1E,2D,3C,4B,5B,6C,7B),(1E,2D,3C,4B,5B,6C,7C),(1E,2D,3C,4B,5B,6D,7A),
(1E,2D,3C,4 B,5B,6D,7B),(1E,2D,3C,4B,5B,6D,7C),(1E,2D,3C,4C,5A,6A,7A),(1E,2D,3C,4C,5A,6A,7B),(1E,2D,3C,
4C,5A,6A,7C),(1E,2D,3C,4C,5A,6B,7A),(1E,2D,3C,4C,5A,6B,7B),(1E,2D,3C,4 C,5A,6B,7C),(1E,2D,3C,4C,5A,6C,
40 7A),(1E,2D,3C,4C,5A,6C,7B),(1E,2D,3C,4C,5A,6C,7C), (1E,2D,3C,4C,5A,6D,7A),(1E,2D,3C,4C,5A,6D,7B),(1E,2D,
3C,4C,5A,6D,7C),(1E,2D,3C,4 C,5B,6A,7A),(1E,2D,3C,4C,5B,6A,7B),(1E,2D,3C,4C,5B,6A,7C),(1E,2D,3C,4C,5B,
6B,7A), (1E,2D,3C,4C,5B,6B,7B),(1E,2D,3C,4C,5B,6B,7C),(1E,2D,3C,4C,5B,6C,7A),(1E,2D,3C,4 C,5B,6C,7B),(1E,
2D,3C,4C,5B,6C,7C),(1E,2D,3C,4C,5B,6D,7

7

7

2

2

3

3

4

4

5

5


(1E,2D,3D,4A,5B,6C,7B),(1E,2D,3D,4 A,5B,6C,7C),(1E,2D,3D,4A,5B,6D,7A),(1E,2D,3D,4A,5B,6D,7B),(1E,2D,3D,4A,5B,6D,7C),(1E,2D,3D,4B,5A,6A,7A),(1E,2D,3D,4B,5A,6A,7B),(1E,2D,3D,4B,5A,6A,7C),(1E,2D,3D,4 B,5A,6B,7A),(1E,2D,3D,4B,5A,6B,7B),(1E,2D,3D,4B,5A,6B,7C),(1E,2D,3D,4B,5A,6C,7A),(1E,2D,3D,4B,5A,6C,7B),(1E,2D,3D,4B,5A,6C,7C),(1E,2D,3D,4B,5A,6D,7A),(1E,2D,3D,4 B,5A,6D,7B),(1E,2D,3D,4B,5A,6D,7C),(1E,2D,3D,4B,5B,6A,7A),(1E,2D,3D,4B,5B,6A,7B),(1E,2D,3D,4B,5B,6A,7C),(1E,2D,3D,4B,5B,6B,7A),(1E,2D,3D,4 B,5B,6B,7C),(1E,2D,3D,4B,5B,6C,7A),(1E,2D,3D,4B,5B,6C,7B),(1E,2D,3D,4B,5B,6C,7C),(1E,2D,3D,4B,5B,6D,7A),(1E,2D,3D,4B,5B,6D,7B),(1E,2D,3D,4B,5B,6D,7C),(1E,2D,3D,4 C,5A,6A,7A),(1E,2D,3D,4C,5A,6A,7B),(1E,2D,3D,4C,5A,6A,7C),(1E,2D,3D,4C,5A,6B,7A),(1E,2D,3D,4C,5A,6B,7B),(1E,2D,3D,4C,5A,6B,7C),(1E,2D,3D,4C,5A,6C,7A),(1E,2D,3D,4 C,5A,6C,7B),(1E,2D,3D,4C,5A,6C,7C),(1E,2D,3D,4C,5A,6D,7A),(1E,2D,3D,4C,5A,6D,7B),(1E,2D,3D,4C,5A,6D,7C),(1E,2D,3D,4C,5B,6A,7A),(1E,2D,3D,4C,5B,6A,7B),(1E,2D,3D,4 C,5B,6A,7C),(1E,2D,3D,4C,5B,6B,7A),(1E,2D,3D,4C,5B,6B,7B),(1E,2D,3D,4C,5B,6B,7C),(1E,2D,3D,4C,5B,6C,7A),(1E,2D,3D,4C,5B,6C,7B),(1E,2D,3D,4C,5B,6C,7C),(1E,2D,3D,4 C,5B,6D,7A),(1E,2D,3D,4C,5B,6D,7B),(1E,2D,3D,4C,5B,6D,7C),(1E,2D,3D,4D,5A,6A,7A),(1E,2D,3D,4D,5A,6A,7B),(1E,2D,3D,4D,5A,6A,7C),(1E,2D,3D,4D,5A,6B,7A),(1E,2D,3D,4D,5A,6B,7B),(1E,2D,3D,4D,5A,6B,7C),(1E,2D,3D,4D,5A,6C,7A),(1E,2D,3D,4D,5A,6C,7B),(1E,2D,3D,4D,5A,6C,7C),(1E,2D,3D,4D,5A,6D,7A),(1E,2D,3D,4D,5A,6D,7B),(1E,2D,3D,4 D,5A,6D,7C),(1E,2D,3D,4D,5B,6A,7A),(1E,2D,3D,4D,5B,6A,7B),(1E,2D,3D,4D,5B,6A,7C),(1E,2D,3D,4D,5B,6B,7A),(1E,2D,3D,4D,5B,6B,7B),(1E,2D,3D,4D,5B,6B,7C),(1E,2D,3D,4D,5B,6C,7A),(1E,2D,3D,4D,5B,6C,7B),(1E,2D,3D,4D,5B,6C,7C),(1E,2D,3D,4D,5B,6D,7A),(1E,2D,3D,4D,5B,6D,7B),(1E,2D,3D,4D,5B,6D,7C),(1E,2D,3D,4E,5A,6A,7A),(1E,2D,3D,4E,5A,6A,7B),(1E,2D,3D,4E,5A,6A,7C),(1E,2D,3D,4E,5A,6B,7A),(1E,2D,3D,4E,5A,6B,7B),(1E,2D,3D,4E,5A,6B,7C),(1E,2D,3D,4E,5A,6C,7A),(1E,2D,3D,4E,5A,6C,7B),(1E,2D,3D,4 E,5A,6C,7C),(1E,2D,3D,4E,5A,6D,7A),(1E,2D,3D,4E,5A,6D,7B),(1E,2D,3D,4E,5A,6D,7C),(1E,2D,3D,4E,5B,6A,7A),(1E,2D,3D,4E,5B,6A,7B),(1E,2D,3D,4E,5B,6A,7C),(1E,2D,3D,4 E,5B,6B,7A),(1E,2D,3D,4E,5B,6B,7B),(1E,2D,3D,4E,5B,6B,7C),(1E,2D,3D,4E,5B,6C,7A),(1E,2D,3D,4E,5B,6C,7B),(1E,2D,3D,4E,5B,6C,7C),(1E,2D,3D,4E,5B,6D,7A),(1E,2D,3D,4 E,5B,6D,7B),(1E,2D,3D,4E,5B,6D,7C),(1E,2D,3E,4A,5A,6A,7A),(1E,2D,3E,4A,5A,6A,7B),(1E,2D,3E,4A,5A,6A,7C),(1E,2D,3E,4A,5A,6B,7A),(1E,2D,3E,4A,5A,6B,7B),(1E,2D,3E,4A,5A,6B,7C),(1E,2D,3E,4A,5A,6C,7A),(1E,2D,3E,4A,5A,6C,7B),(1E,2D,3E,4A,5A,6C,7C),(1E,2D,3E,4A,5A,6D,7A),(1E,2D,3E,4A,5A,6D,7B),(1E,2D,3E,4A,5A,6D,7C),(1E,2D,3E,4A,5A,6D,7C),(1E,2D,3E,4A,5B,6A,7A),(1E,2D,3E,4A,5B,6A,7B),(1E,2D,3E,4A,5B,6A,7C),(1E,2D,3E,4A,5B,6B,7A),(1E,2D,3E,4A,5B,6B,7B),(1E,2D,3E,4A,5B,6B,7C),(1E,2D,3E,4A,5B,6C,7A),(1E,2D,3E,4A,5B,6C,7B),(1E,2D,3E,4A,5B,6C,7C),(1E,2D,3E,4A,5B,6D,7A),(1E,2D,3E,4A,5B,6D,7B),(1E,2D,3E,4A,5B,6D,7C),(1E,2D,3E,4B,5A,6A,7A),(1E,2D,3E,4B,5A,6A,7B),(1E,2D,3E,4 B,5A,6A,7C),(1E,2D,3E,4B,5A,6B,7A),(1E,2D,3E,4B,5A,6B,7B),(1E,2D,3E,4B,5A,6B,7C),(1E,2D,3E,4 B,5A,6D,7A),(1E,2D,3E,4B,5A,6D,7B),(1E,2D,3E,4B,5A,6D,7C),(1E,2D,3E,4B,5B,6A,7A),(1E,2D,3E,4B,5B,6A,7B),(1E,2D,3E,4 B,5B,6B,7A),(1E,2D,3E,4B,5B,6B,7B),(1E,2D,3E,4B,5B,6B,7C),(1E,2D,3E,4B,5B,6C,7A),(1E,2D,3E,4B,5B,6C,7B),(1E,2D,3E,4B,5B,6C,7C),(1E,2D,3E,4B,5B,6D,7A),(1E,2D,3E,4B,5B,6D,7B),(1E,2D,3E,4 B,5B,6D,7C),(1E,2D,3E,4C,5A,6A,7A),(1E,2D,3E,4C,5A,6A,7B),(1E,2D,3E,4C,5A,6A,7C),(1E,2D,3E,4C,5A,6B,7A),(1E,2D,3E,4C,5A,6B,7B),(1E,2D,3E,4C,5A,6B,7C),(1E,2D,3E,4 C,5A,6C,7A),(1E,2D,3E,4C,5A,6C,7B),(1E,2D,3E,4C,5A,6C,7C),(1E,2D,3E,4C,5A,6D,7A),(1E,2D,3E,4C,5A,6D,7B),(1E,2D,3E,4C,5A,6D,7C),(1E,2D,3E,4C,5B,6A,7A),(1E,2D,3E,4C,5B,6A,7B),(1E,2D,3E,4C,5B,6A,7C),(1E,2D,3E,4C,5B,6B,7A),(1E,2D,3E,4 C,5B,6B,7B),(1E,2D,3E,4C,5B,6B,7C),(1E,2D,3E,4C,5B,6C,7A),(1E,2D,3E,4C,5B,6C,7B),(1E,2D,3E,4 C,5B,6C,7C),(1E,2D,3E,4C,5B,6D,7A),(1E,2D,3E,4C,5B,6D,7B),(1E,2D,3E,4C,5B,6D,7C),(1E,2D,3E,4D,5A,6A,7A),(1E,2D,3E,4D,5A,6A,7B),(1E,2D,3E,4D,5A,6A,7C),(1E,2D,3E,4 D,5A,6B,7A),(1E,2D,3E,4D,5A,6B,7B),(1E,2D,3E,4D,5A,6B,7C),(1E,2D,3E,4D,5A,6C,7A),(1E,2D,3E,4D,5A,6C,7B),(1E,2D,3E,4D,5A,6C,7C),(1E,2D,3E,4D,5A,6D,7A),(1E,2D,3E,4D,5A,6D,7B),(1E,2D,3E,4 D,5A,6D,7C),(1E,2D,3E,4D,5B,6A,7A),(1E,2D,3E,4D,5B,6A,7B),(1E,2D,3E,4D,5B,6A,7C),(1E,2D,3E,4D,5B,6B,7A),(1E,2D,3E,4D,5B,6B,7B),(1E,2D,3E,4D,5B,6B,7C),(1E,2D,3E,4D,5B,6C,7A),(1E,2D,3E,4D,5B,6C,7B),(1E,2D,3E,4D,5B,6C,7C),(1E,2D,3E,4D,5B,6D,7A),(1E,2D,3E,4D,5B,6D,7B),(1E,2D,3E,4 D,5B,6D,7C),(1E,2D,3E,4E,5A,6A,7A),(1E,2D,3E,4E,5A,6A,7B

5B,6A,7A),(1E,2E,3A,4B,5B,6A,7B),(1E,2E,3A,4B,5B,6A,7C),(1E,2E,3A,4 B,5B,6B,7A),(1E,2E,3A,4B,5B,6B,7B),
 (1E,2E,3A,4B,5B,6B,7C),(1E,2E,3A,4B,5B,6C,7A), (1E,2E,3A,4B,5B,6C,7B),(1E,2E,3A,4B,5B,6C,7C),(1E,2E,3A,
 4B,5B,6D,7A),(1E,2E,3A,4 B,5B,6D,7B),(1E,2E,3A,4B,5B,6D,7C),(1E,2E,3A,4C,5A,6A,7A),(1E,2E,3A,4C,5A,6A,
 7B), (1E,2E,3A,4C,5A,6A,7C),(1E,2E,3A,4C,5A,6B,7A),(1E,2E,3A,4C,5A,6B,7B),(1E,2E,3A,4 C,5A,6B,7C),(1E,2E,
 5 3A,4C,5A,6C,7A),(1E,2E,3A,4C,5A,6C,7B),(1E,2E,3A,4C,5A,6C,7C), (1E,2E,3A,4C,5A,6D,7A),(1E,2E,3A,4C,5A,
 6D,7B),(1E,2E,3A,4C,5A,6D,7C),(1E,2E,3A,4 C,5B,6A,7A),(1E,2E,3A,4C,5B,6A,7B),(1E,2E,3A,4C,5B,6A,7C),(1E,
 2E,3A,4C,5B,6B,7A), (1E,2E,3A,4C,5B,6B,7B),(1E,2E,3A,4C,5B,6B,7C),(1E,2E,3A,4C,5B,6C,7A),(1E,2E,3A,4 C,
 5B,6C,7B),(1E,2E,3A,4C,5B,6C,7C),(1E,2E,3A,4C,5B,6D,7A),(1E,2E,3A,4C,5B,6D,7B), (1E,2E,3A,4C,5B,6D,7C),
 (1E,2E,3A,4D,5A,6A,7A),(1E,2E,3A,4D,5A,6A,7B),(1E,2E,3A,4 D,5A,6A,7C),(1E,2E,3A,4D,5A,6B,7A),(1E,2E,3A,
 10 4D,5A,6B,7B),(1E,2E,3A,4D,5A,6B,7C), (1E,2E,3A,4D,5A,6C,7A),(1E,2E,3A,4D,5A,6C,7B),(1E,2E,3A,4D,5A,6C,
 7C),(1E,2E,3A,4 D,5A,6D,7A),(1E,2E,3A,4D,5A,6D,7B),(1E,2E,3A,4D,5A,6D,7C),(1E,2E,3A,4D,5B,6A,7A), (1E,2E,
 3A,4D,5B,6A,7B),(1E,2E,3A,4D,5B,6A,7C),(1E,2E,3A,4D,5B,6B,7A),(1E,2E,3A,4 D,5B,6B,7B),(1E,2E,3A,4D,5B,6B,
 7C),(1E,2E,3A,4D,5B,6C,7A),(1E,2E,3A,4D,5B,6C,7B), (1E,2E,3A,4D,5B,6C,7C),(1E,2E,3A,4D,5B,6D,7A),(1E,2E,
 3A,4D,5B,6D,7B),(1E,2E,3A,4 D,5B,6D,7C),(1E,2E,3A,4E,5A,6A,7A),(1E,2E,3A,4E,5A,6A,7B),(1E,2E,3A,4E,5A,6A,
 15 7C), (1E,2E,3A,4E,5A,6B,7A),(1E,2E,3A,4E,5A,6B,7B),(1E,2E,3A,4E,5A,6B,7C),(1E,2E,3A,4 E,5A,6C,7A),(1E,2E,
 3A,4E,5A,6C,7B),(1E,2E,3A,4E,5A,6C,7C),(1E,2E,3A,4E,5A,6D,7A), (1E,2E,3A,4E,5A,6D,7B),(1E,2E,3A,4E,5A,6D,
 7C),(1E,2E,3A,4E,5B,6A,7A),(1E,2E,3A,4 E,5B,6A,7B),(1E,2E,3A,4E,5B,6A,7C),(1E,2E,3A,4E,5B,6B,7A),(1E,2E,
 3A,4E,5B,6B,7B), (1E,2E,3A,4E,5B,6B,7C),(1E,2E,3A,4E,5B,6C,7A),(1E,2E,3A,4E,5B,6C,7B),(1E,2E,3A,4 E,5B,6C,
 7C),(1E,2E,3A,4E,5B,6D,7A),(1E,2E,3A,4E,5B,6D,7B),(1E,2E,3A,4E,5B,6D,7C), (1E,2E,3B,4A,5A,6A,7A),(1E,2E,
 20 3B,4A,5A,6A,7B),(1E,2E,3B,4A,5A,6A,7C),(1E,2E,3B,4 A,5A,6B,7A),(1E,2E,3B,4A,5A,6B,7B),(1E,2E,3B,4A,5A,6B,
 7C),(1E,2E,3B,4A,5A,6C,7A), (1E,2E,3B,4A,5A,6C,7B),(1E,2E,3B,4A,5A,6C,7C),(1E,2E,3B,4A,5A,6D,7A),(1E,2E,
 3B,4 A,5A,6D,7B),(1E,2E,3B,4A,5A,6D,7C),(1E,2E,3B,4A,5B,6A,7A),(1E,2E,3B,4A,5B,6A,7B), (1E,2E,3B,4A,5B,6A,
 7C),(1E,2E,3B,4A,5B,6B,7A),(1E,2E,3B,4A,5B,6B,7B),(1E,2E,3B,4 A,5B,6B,7C),(1E,2E,3B,4A,5B,6C,7A),(1E,2E,
 3B,4A,5B,6C,7B),(1E,2E,3B,4A,5B,6C,7C), (1E,2E,3B,4A,5B,6D,7A),(1E,2E,3B,4A,5B,6D,7B),(1E,2E,3B,4A,5B,6D,
 25 7C),(1E,2E,3B,4 B,5A,6A,7A),(1E,2E,3B,4B,5A,6A,7B),(1E,2E,3B,4B,5A,6A,7C),(1E,2E,3B,4B,5A,6B,7A), (1E,2E,
 3B,4B,5A,6B,7B),(1E,2E,3B,4B,5A,6B,7C),(1E,2E,3B,4B,5A,6C,7A),(1E,2E,3B,4 B,5A,6C,7B),(1E,2E,3B,4B,5A,6C,
 7C),(1E,2E,3B,4B,5A,6D,7A),(1E,2E,3B,4B,5A,6D,7B), (1E,2E,3B,4B,5A,6D,7C),(1E,2E,3B,4B,5B,6A,7A),(1E,2E,
 3B,4B,5B,6A,7B),(1E,2E,3B,4 B,5B,6A,7C),(1E,2E,3B,4B,5B,6B,7A),(1E,2E,3B,4B,5B,6B,7B),(1E,2E,3B,4B,5B,6B,
 7C), (1E,2E,3B,4B,5B,6C,7A),(1E,2E,3B,4B,5B,6C,7B),(1E,2E,3B,4B,5B,6C,7C),(1E,2E,3B,4 B,5B,6D,7A),(1E,2E,
 30 3B,4B,5B,6D,7B),(1E,2E,3B,4B,5B,6D,7C),(1E,2E,3B,4C,5A,6A,7A), (1E,2E,3B,4C,5A,6A,7B),(1E,2E,3B,4C,5A,6A,
 7C),(1E,2E,3B,4C,5A,6B,7A),(1E,2E,3B,4 C,5A,6B,7B),(1E,2E,3B,4C,5A,6B,7C),(1E,2E,3B,4C,5A,6C,7A),(1E,2E,
 3B,4C,5A,6C,7B), (1E,2E,3B,4C,5A,6C,7C),(1E,2E,3B,4C,5A,6D,7A),(1E,2E,3B,4C,5A,6D,7B),(1E,2E,3B,4 C,5A,
 6D,7C),(1E,2E,3B,4C,5B,6A,7A),(1E,2E,3B,4C,5B,6A,7B),(1E,2E,3B,4C,5B,6A,7C), (1E,2E,3B,4C,5B,6B,7A),(1E,
 2E,3B,4C,5B,6B,7B),(1E,2E,3B,4C,5B,6B,7C),(1E,2E,3B,4 C,5B,6C,7A),(1E,2E,3B,4C,5B,6C,7B),(1E,2E,3B,4C,
 35 5B,6C,7C),(1E,2E,3B,4C,5B,6D,7A), (1E,2E,3B,4C,5B,6D,7B),(1E,2E,3B,4C,5B,6D,7C),(1E,2E,3B,4D,5A,6A,7A),
 (1E,2E,3B,4 D,5A,6A,7B),(1E,2E,3B,4D,5A,6A,7C),(1E,2E,3B,4D,5A,6B,7A), (1E,2E,3B,4D,5A,6B,7B),(1E,2E,3B,
 4D,5A,6B,7C),(1E,2E,3B,4D,5A,6C,7A),(1E,2E,3B,4 D,5A,6C,7B),(1E,2E,3B,4D,5A,6C,7C),(1E,2E,3B,4D,5A,6D,
 7A),(1E,2E,3B,4D,5A,6D,7B), (1E,2E,3B,4D,5A,6D,7C),(1E,2E,3B,4D,5B,6A,7A),(1E,2E,3B,4D,5B,6A,7B),(1E,2E,
 3B,4 C,5B,6A,7C),(1E,2E,3B,4D,5B,6B,7A),(1E,2E,3B,4D,5B,6B,7B),(1E,2E,3B,4D,5B,6B,7C), (1E,2E,3B,4D,5B,
 40 6C,7A),(1E,2E,3B,4D,5B,6C,7B),(1E,2E,3B,4D,5B,6C,7C),(1E,2E,3B,4 D,5B,6D,7A),(1E,2E,3B,4D,5B,6D,7B),(1E,
 2E,3B,4D,5B,6D,7C),(1E,2E,3B,4E,5A,6A,7A), (1E,2E,3B,4E,5A,6A,7B),(1E,2E,3B,4E,5A,6A,7C),(1E,2E,3B,4E,5A,
 6B,7A),(1E,2E,3B,4 E,5A,6B,7B),(1E,2E,3B,4E,5A,6B,7C),(1E,2E,3B,4E,5A,6C,7A),(1E,2E,3B,4E,5A,6C,7B), (1E,
 2E,3B,4E,5A,6C,7C),(1E,2E,3B,4E,5A,6D,7A),(1E,2E,3B,4E,5A,6D,7B),(1E,2E,3B,4 E,5A,6D,7C),(1E,2E,3B,4E,5B,
 6A,7A),(1E,2E,3B,4E,5B,6A,7B),(1E,2E,3B,4E,5B,6A,7C), (1E,2E,3B,4E,5B,6B,7A),(1E,2E,3B,4E,5B,6B,7B),(1E,
 45 2E,3B,4E,5B,6B,7C),(1E,2E,3B,4 E,5B,6C,7A),(1E,2E,3B,4E,5B,6C,7B),(1E,2E,3B,4E,5B,6C,7C),(1E,2E,3B,4E,5B,
 6D,7A), (1E,2E,3B,4E,5B,6D,7B),(1E,2E,3B,4E,5B,6D,7C),(1E,2E,3C,4A,5A,6A,7A),(1E,2E,3C,4 A,5A,6A,7B),(1E,
 2E,3C,4A,5A,6A,7C),(1E,2E,3C,4A,5A,6B,7A),(1E,2E,3C,4A,5A,6B,7B), (1E,2E,3C,4A,5A,6B,7C),(1E,2E,3C,4A,5A,
 6C,7A),(1E,2E,3C,4A,5A,6C,7B),(1E,2E,3C,4 A,5A,6C,7C),(1E,2E,3C,4A,5A,6D,7A),(1E,2E,3C,4A,5A,6D,7B),(1E,
 2E,3C,4A,5A,6D,7C), (1E,2E,3C,4A,5B,6A,7A),(1E,2E,3C,4A,5B,6A,7B),(1E,2E,3C,4A,5B,6A,7C),(1E,2E,3C,4 A,
 50 5B,6B,7A),(1E,2E,3C,4A,5B,6B,7B),(1E,2E,3C,4A,5B,6B,7C),(1E,2E,3C,4A,5B,6C,7A), (1E,2E,3C,4A,5B,6C,7B),
 (1E,2E,3C,4A,5B,6C,7C),(1E,2E,3C,4A,5B,6D,7A),(1E,2E,3C,4 A,5B,6D,7B),(1E,2E,3C,4A,5B,6D,7C),(1E,2E,3C,
 4B,5A,6A,7A),(1E,2E,3C,4B,5A,6A,7B), (1E,2E,3C,4B,5A,6A,7C),(1E,2E,3C,4B,5A,6B,7A),(1E,2E,3C,4B,5A,6B,
 7B),(1E,2E,3C,4 B,5A,6B,7C),(1E,2E,3C,4B,5A,6C,7A),(1E,2E,3C,4B,5A,6C,7B),(1E,2E,3C,4B,5A,6C,7C), (1E,2E,
 3C,4B,5A,6D,7A),(1E,2E,3C,4B,5A,6D,7B),(1E,2E,3C,4B,5A,6D,7C),(1E,2E,3C,4 B,5B,6A,7A),(1E,2E,3C,4B,5B,
 55 6A,7B),(1E,2E,3C,4B,5B,6A,7C),(1E,2E,3C,4B,5B,6B,7A), (1E,2E,3C,4B,5B,6B,7B),(1E,2E,3C,4B,5B,6B,7C),(1E,
 2E,3C,4B,5B,6C,7A),(1E,2E,3C,4 B,5B,6C,7B),(1E,2E,3C,4B,5B,6C,7C),(1E,2E,3C,4B,5B,6D,7A),(1E,2E,3C,4B,
 5B,6D,7B), (1E,2E,3C,4B,5B,6D,7C),(1E,2E,3C,4C,5A,6A,7A),(1E,2E,3C,4C,5A,6A,7B),(1E,2E,3C,4 C,5A,6A,7C),
 (1E,2E,3C,4C,5A,6B,7A),(1E,2E,3C,4C,5A,6B,7B),(1E,2E,3C,4C,5A,6B,7C), (1E,2E,3C,4C,5A,6C,7A),(1E,2E,3C,

4C,5A,6C,7B),(1E,2E,3C,4C,5A,6C,7C),(1E,2E,3C,4 C,5A,6D,7A),(1E,2E,3C,4C,5A,6D,7B),(1E,2E,3C,4C,5A,6D,7C),
7C),(1E,2E,3C,4C,5B,6A,7A),(1E,2E,3C,4C,5B,6A,7B),(1E,2E,3C,4C,5B,6A,7C),(1E,2E,3C,4C,5B,6B,7A),(1E,2E,
3C,4 C,5B,6B,7B),(1E,2E,3C,4C,5B,6B,7C),(1E,2E,3C,4C,5B,6C,7A),(1E,2E,3C,4C,5B,6C,7B),(1E,2E,3C,4C,5B,
6C,7C),(1E,2E,3C,4C,5B,6D,7A),(1E,2E,3C,4C,5B,6D,7B),(1E,2E,3C,4 C,5B,6D,7C),(1E,2E,3C,4D,5A,6A,7A),(1E,
5 2E,3C,4D,5A,6A,7B),(1E,2E,3C,4D,5A,6A,7C),(1E,2E,3C,4D,5A,6B,7A),(1E,2E,3C,4D,5A,6B,7B),(1E,2E,3C,4D,
5A,6B,7C),(1E,2E,3C,4 D,5A,6C,7A),(1E,2E,3C,4D,5A,6C,7B),(1E,2E,3C,4D,5A,6C,7C),(1E,2E,3C,4D,5A,6D,7A),
(1E,2E,3C,4D,5A,6D,7B),(1E,2E,3C,4D,5A,6D,7C),(1E,2E,3C,4D,5B,6A,7A),(1E,2E,3C,4 D,5B,6A,7B),(1E,2E,3C,
4D,5B,6A,7C),(1E,2E,3C,4D,5B,6B,7A),(1E,2E,3C,4D,5B,6B,7B),(1E,2E,3C,4D,5B,6B,7C),(1E,2E,3C,4D,5B,6C,7A),
10 (1E,2E,3C,4D,5B,6C,7B),(1E,2E,3C,4 D,5B,6C,7C),(1E,2E,3C,4D,5B,6D,7A),(1E,2E,3C,4D,5B,6D,7B),(1E,2E,3C,4D,5B,6D,7C),
(1E,2E,3C,4E,5A,6A,7A),(1E,2E,3C,4E,5A,6A,7B),(1E,2E,3C,4E,5A,6A,7C),(1E,2E,3C,4E,5A,6B,7A),(1E,2E,3C,4E,5A,6B,7B),
(1E,2E,3C,4E,5A,6B,7C),(1E,2E,3C,4E,5A,6C,7A),(1E,2E,3C,4E,5A,6C,7B),(1E,2E,3C,4E,5A,6C,7C),(1E,2E,3C,4E,5A,6D,7A),
(1E,2E,3C,4E,5A,6D,7B),(1E,2E,3C,4E,5A,6D,7C),(1E,2E,3C,4E,5B,6A,7A),(1E,2E,3C,4E,5B,6A,7B),(1E,2E,3C,4E,5B,6A,7C),
(1E,2E,3C,4E,5B,6B,7A),(1E,2E,3C,4E,5B,6B,7B),(1E,2E,3C,4E,5B,6B,7C),(1E,2E,3C,4 E,5B,6B,7C),(1E,2E,3C,4E,5B,6C,7A),
15 (1E,2E,3C,4E,5B,6C,7B),(1E,2E,3C,4E,5B,6C,7C),(1E,2E,3C,4E,5B,6D,7A),(1E,2E,3C,4E,5B,6D,7B),(1E,2E,3C,4E,5B,6D,7C),
(1E,2E,3D,4 A,5A,6A,7A),(1E,2E,3D,4A,5A,6A,7B),(1E,2E,3D,4A,5A,6A,7C),(1E,2E,3D,4A,5A,6B,7A),(1E,2E,3D,4A,5A,6B,7B),
(1E,2E,3D,4A,5A,6B,7C),(1E,2E,3D,4A,5A,6C,7A),(1E,2E,3D,4A,5A,6C,7B),(1E,2E,3D,4A,5A,6C,7C),(1E,2E,3D,4A,5A,6D,7A),
(1E,2E,3D,4A,5A,6D,7B),(1E,2E,3D,4A,5B,6A,7A),(1E,2E,3D,4A,5B,6A,7B),(1E,2E,3D,4A,5B,6A,7C),(1E,2E,3D,4A,5B,6B,7A),
20 (1E,2E,3D,4A,5B,6B,7B),(1E,2E,3D,4A,5B,6B,7C),(1E,2E,3D,4A,5B,6C,7A),(1E,2E,3D,4A,5B,6C,7B),(1E,2E,3D,4A,5B,6C,7C),
(1E,2E,3D,4A,5B,6D,7A),(1E,2E,3D,4 A,5B,6D,7A),(1E,2E,3D,4A,5B,6D,7B),(1E,2E,3D,4A,5B,6D,7C),(1E,2E,3D,4B,5A,6A,7A),
(1E,2E,3D,4B,5A,6A,7B),(1E,2E,3D,4B,5A,6A,7C),(1E,2E,3D,4B,5A,6B,7A),(1E,2E,3D,4 B,5A,6B,7B),(1E,2E,3D,4B,5A,6B,7C),
(1E,2E,3D,4B,5A,6B,7C),(1E,2E,3D,4B,5A,6C,7A),(1E,2E,3D,4B,5A,6C,7B),(1E,2E,3D,4B,5A,6C,7C),(1E,2E,3D,4B,5A,6D,7A),
(1E,2E,3D,4B,5A,6D,7B),(1E,2E,3D,4 B,5A,6D,7C),(1E,2E,3D,4B,5B,6A,7A),(1E,2E,3D,4B,5B,6A,7B),(1E,2E,3D,4B,5B,6B,7A),
25 (1E,2E,3D,4B,5B,6B,7B),(1E,2E,3D,4B,5B,6B,7C),(1E,2E,3D,4B,5B,6C,7A),(1E,2E,3D,4B,5B,6C,7B),(1E,2E,3D,4B,5B,6C,7C),
(1E,2E,3D,4B,5B,6D,7A),(1E,2E,3D,4B,5B,6D,7B),(1E,2E,3D,4C,5A,6A,7A),(1E,2E,3D,4 C,5A,6A,7B),(1E,2E,3D,4C,5A,6A,7C),
(1E,2E,3D,4C,5A,6B,7A),(1E,2E,3D,4C,5A,6B,7B),(1E,2E,3D,4C,5A,6B,7C),(1E,2E,3D,4C,5A,6C,7A),(1E,2E,3D,4C,5A,6C,7B),
(1E,2E,3D,4C,5A,6C,7C),(1E,2E,3D,4 C,5A,6C,7C),(1E,2E,3D,4C,5A,6D,7A),(1E,2E,3D,4C,5A,6D,7B),(1E,2E,3D,4C,5A,6D,7C),
30 (1E,2E,3D,4C,5B,6A,7A),(1E,2E,3D,4C,5B,6A,7B),(1E,2E,3D,4C,5B,6A,7C),(1E,2E,3D,4 C,5B,6B,7A),(1E,2E,3D,4C,5B,6B,7B),
(1E,2E,3D,4C,5B,6B,7C),(1E,2E,3D,4C,5B,6C,7A),(1E,2E,3D,4C,5B,6C,7B),(1E,2E,3D,4C,5B,6C,7C),(1E,2E,3D,4C,5B,6D,7A),
(1E,2E,3D,4C,5B,6D,7B),(1E,2E,3D,4D,5A,6A,7A),(1E,2E,3D,4D,5A,6A,7B),(1E,2E,3D,4D,5A,6A,7C),(1E,2E,3D,4D,5A,6A,7C),
(1E,2E,3D,4D,5A,6A,7C),(1E,2E,3D,4D,5A,6B,7A),(1E,2E,3D,4D,5A,6B,7B),(1E,2E,3D,4D,5A,6B,7C),(1E,2E,3D,4D,5A,6C,7A),
(1E,2E,3D,4D,5A,6C,7B),(1E,2E,3D,4D,5A,6C,7C),(1E,2E,3D,4D,5A,6D,7A),(1E,2E,3D,4D,5A,6D,7B),(1E,2E,3D,4D,5A,6D,7C),
35 (1E,2E,3D,4D,5A,6D,7C),(1E,2E,3D,4D,5B,6A,7A),(1E,2E,3D,4D,5B,6A,7B),(1E,2E,3D,4D,5B,6A,7C),(1E,2E,3D,4D,5B,6B,7A),
(1E,2E,3D,4D,5B,6B,7B),(1E,2E,3D,4D,5B,6B,7C),(1E,2E,3D,4D,5B,6C,7A),(1E,2E,3D,4D,5B,6C,7B),(1E,2E,3D,4D,5B,6C,7C),
(1E,2E,3D,4D,5B,6D,7A),(1E,2E,3D,4D,5B,6D,7B),(1E,2E,3D,4D,5B,6D,7C),(1E,2E,3D,4D,5B,6D,7A),(1E,2E,3D,4D,5B,6D,7B),
(1E,2E,3D,4D,5B,6D,7C),(1E,2E,3D,4E,5A,6A,7A),(1E,2E,3D,4E,5A,6A,7B),(1E,2E,3D,4 E,5A,6A,7C),(1E,2E,3D,4E,5A,6B,7A),
(1E,2E,3D,4E,5A,6B,7B),(1E,2E,3D,4E,5A,6B,7C),(1E,2E,3D,4E,5A,6C,7A),(1E,2E,3D,4E,5A,6C,7B),(1E,2E,3D,4E,5A,6C,7C),
40 (1E,2E,3D,4E,5A,6D,7A),(1E,2E,3D,4E,5A,6D,7B),(1E,2E,3D,4E,5A,6D,7C),(1E,2E,3D,4E,5B,6A,7A),(1E,2E,3D,4E,5B,6A,7B),
(1E,2E,3D,4E,5B,6A,7C),(1E,2E,3D,4E,5B,6B,7A),(1E,2E,3D,4E,5B,6B,7B),(1E,2E,3D,4E,5B,6B,7C),(1E,2E,3D,4E,5B,6C,7A),
(1E,2E,3D,4E,5B,6C,7B),(1E,2E,3D,4E,5B,6

(1E,2E,3E,4D,5A,6A,7B), (1E,2E,3E,4D,5A,6A,7C), (1E,2E,3E,4D,5A,6B,7A), (1E,2E,3E,4D,5A,6B,7B), (1E,2E,3E,4D,5A,6B,7C), (1E,2E,3E,4D,5A,6C,7A), (1E,2E,3E,4D,5A,6C,7B), (1E,2E,3E,4D,5A,6C,7C), (1E,2E,3E,4D,5A,6D,7A), (1E,2E,3E,4D,5A,6D,7B), (1E,2E,3E,4D,5A,6D,7C), (1E,2E,3E,4D,5B,6A,7A), (1E,2E,3E,4D,5B,6A,7B), (1E,2E,3E,4D,5B,6A,7C), (1E,2E,3E,4D,5B,6B,7A), (1E,2E,3E,4D,5B,6B,7B), (1E,2E,3E,4D,5B,6B,7C), (1E,2E,3E,4D,5B,6C,7A), (1E,2E,3E,4D,5B,6C,7B), (1E,2E,3E,4D,5B,6C,7C), (1E,2E,3E,4D,5B,6D,7A), (1E,2E,3E,4D,5B,6D,7B), (1E,2E,3E,4D,5B,6D,7C), (1E,2E,3E,4E,5A,6A,7A), (1E,2E,3E,4E,5A,6A,7B), (1E,2E,3E,4E,5A,6A,7C), (1E,2E,3E,4E,5A,6B,7A), (1E,2E,3E,4E,5A,6B,7B), (1E,2E,3E,4E,5A,6B,7C), (1E,2E,3E,4E,5A,6C,7A), (1E,2E,3E,4E,5A,6C,7B), (1E,2E,3E,4E,5A,6C,7C), (1E,2E,3E,4E,5A,6D,7A), (1E,2E,3E,4E,5A,6D,7B), (1E,2E,3E,4E,5A,6D,7C), (1E,2E,3E,4E,5B,6A,7A), (1E,2E,3E,4E,5B,6A,7B), (1E,2E,3E,4E,5B,6A,7C), (1E,2E,3E,4E,5B,6B,7A), (1E,2E,3E,4E,5B,6B,7B), (1E,2E,3E,4E,5B,6B,7C), (1E,2E,3E,4E,5B,6C,7A), (1E,2E,3E,4E,5B,6C,7B), (1E,2E,3E,4E,5B,6C,7C), (1E,2E,3E,4E,5B,6D,7A), (1E,2E,3E,4E,5B,6D,7B), (1E,2E,3E,4E,5B,6D,7C)

[0412] And (R¹, R², R³, R⁴, X, R⁶, R⁷) = (1A, 2A, 3A, 4A, 5A, 6A, 7A) is the compound which R¹ is 1A, R² is 2A, R³ is 3A, R⁴ is 4A, X is 5A, R⁶ is 6A and R⁷ is 7A. The other combinations are the same.





[0413] The substituents of R¹, R², X, R³ and R⁴ of above compound include the following substitution group.

R¹ = H (1A), Me(1B), CH₂OH(1C), CH₂OMe(1D), COOH(1E), COOMe(1F), CONHMe(1G)

R² = H (2A), Me(2B), CH₂OH(2C), CH₂OMe(2D), COOH(2E), COOMe(2F), CONHMe(2G)

X = O (XA), NH(XB)



[0414] The preferable combinations (R¹, R², X, R³, R⁴) of the substituents of above compound include the followings.
 (1A, 2A, XA, 3A, 4A), (1A, 2A, XA, 3A, 4B), (1A, 2A, XA, 3A, 4C), (1A, 2A, XA, 3B, 4A), (1A, 2A, XA, 3B, 4B), (1A, 2A, XA, 3B, 4C), (1A, 2A, XA, 3C, 4A), (1A, 2A, XA, 3C, 4B), (1A, 2A, XA, 3C, 4C), (1A, 2A, XA, 3D, 4A), (1A, 2A, XA, 3D, 4B), (1A, 2A, XA, 3D, 4C), (1A, 2A, XB, 3A, 4A), (1A, 2A, XB, 3A, 4B), (1A, 2A, XB, 3A, 4C), (1A, 2A, XB, 3B, 4A), (1A, 2A, XB, 3B, 4B), (1A, 2A, XB, 3B, 4C), (1A, 2A, XB, 3C, 4A), (1A, 2A, XB, 3C, 4B), (1A, 2A, XB, 3C, 4C), (1A, 2A, XB, 3D, 4A), (1A, 2A, XB, 3D, 4B), (1A, 2A, XB, 3D, 4C), (1A, 2B, XA, 3A, 4A), (1A, 2B, XA, 3A, 4B), (1A, 2B, XA, 3A, 4C), (1A, 2B, XA, 3B, 4A), (1A, 2B, XA, 3B, 4B), (1A, 2B, XA, 3B, 4C), (1A, 2B, XA, 3C, 4A), (1A, 2B, XA, 3C, 4B), (1A, 2B, XA, 3C, 4C), (1A, 2B, XA, 3D, 4A), (1A, 2B, XA, 3D, 4B), (1A, 2B, XA, 3D, 4C), (1A, 2B, XB, 3A, 4A), (1A, 2B, XB, 3A, 4B), (1A, 2B, XB, 3A, 4C), (1A, 2B, XB, 3B, 4A), (1A, 2B, XB, 3B, 4B), (1A, 2B, XB, 3B, 4C), (1A, 2B, XB, 3C, 4A), (1A, 2B, XB, 3C, 4B), (1A, 2B, XB, 3C, 4C), (1A, 2B, XB, 3D, 4A), (1A, 2B, XB, 3D, 4B), (1A, 2B, XB, 3D, 4C), (1A, 2C, XA, 3A, 4A), (1A, 2C, XA, 3A, 4B), (1A, 2C, XA, 3A, 4C), (1A, 2C, XA, 3B, 4A), (1A, 2C, XA, 3B, 4B), (1A, 2C, XA, 3B, 4C), (1A, 2C, XA, 3C, 4A), (1A, 2C, XA, 3C, 4B), (1A, 2C, XA, 3C, 4C), (1A, 2C, XA, 3D, 4A), (1A, 2C, XA, 3D, 4B), (1A, 2C, XA, 3D, 4C), (1A, 2C, XB, 3A, 4A), (1A, 2C, XB, 3A, 4B), (1A, 2C, XB, 3A, 4C), (1A, 2C, XB, 3B, 4A), (1A, 2C, XB, 3B, 4B), (1A, 2C, XB, 3B, 4C), (1A, 2C, XB, 3C, 4A), (1A, 2C, XB, 3C, 4B), (1A, 2C, XB, 3C, 4C), (1A, 2C, XB, 3D, 4A), (1A, 2C, XB, 3D, 4B), (1A, 2C, XB, 3D, 4C)

[illegible]

[illegible]

5

10

15

20

25

30

35

40

45

50

55

4B), (IF, 2G, XA, 3C, 4C), (IF, 2G, XA, 3D, 4A), (IF, 2G, XA, 3D, 4B), (IF, 2G, XA, 3D, 4C), (IF, 2G, XB, 3A, 4A), (IF, 2G, XB, 3A, 4B), (IF, 2G, XB, 3A, 4C), (IF, 2G, XB, 3B, 4A), (IF, 2G, XB, 3B, 4B), (IF, 2G, XB, 3B, 4C), (IF, 2G, XB, 3C, 4A), (IF, 2G, XB, 3C, 4B), (IF, 2G, XB, 3C, 4C), (IF, 2G, XB, 3D, 4A), (IF, 2G, XB, 3D, 4B), (IF, 2G, XB, 3D, 4C), (1G, 2A, XA, 3A, 4A), (1G, 2A, XA, 3A, 4B), (1G, 2A, XA, 3A, 4C), (1G, 2A, XA, 3B, 4A), (1G, 2A, XA, 3B, 4B), (1G, 2A, XA, 3B, 4C), (1G, 2A, XA, 3C, 4A), (1G, 2A, XA, 3C, 4B), (1G, 2A, XA, 3C, 4C), (1G, 2A, XA, 3D, 4A), (1G, 2A, XA, 3D, 4B), (1G, 2A, XA, 3D, 4C), (1G, 2A, XB, 3A, 4A), (1G, 2A, XB, 3A, 4B), (1G, 2A, XB, 3A, 4C), (1G, 2A, XB, 3B, 4A), (1G, 2A, XB, 3B, 4B), (1G, 2A, XB, 3B, 4C), (1G, 2A, XB, 3C, 4A), (1G, 2A, XB, 3C, 4B), (1G, 2A, XB, 3C, 4C), (1G, 2A, XB, 3D, 4A), (1G, 2A, XB, 3D, 4B), (1G, 2A, XB, 3D, 4C), (1G, 2B, XA, 3A, 4A), (1G, 2B, XA, 3A, 4B), (1G, 2B, XA, 3A, 4C), (1G, 2B, XA, 3B, 4A), (1G, 2B, XA, 3B, 4B), (1G, 2B, XA, 3B, 4C), (1G, 2B, XA, 3C, 4A), (1G, 2B, XA, 3C, 4B), (1G, 2B, XA, 3C, 4C), (1G, 2B, XA, 3D, 4A), (1G, 2B, XA, 3D, 4B), (1G, 2B, XA, 3D, 4C), (1G, 2B, XB, 3A, 4A), (1G, 2B, XB, 3A, 4B), (1G, 2B, XB, 3A, 4C), (1G, 2B, XB, 3B, 4A), (1G, 2B, XB, 3B, 4B), (1G, 2B, XB, 3B, 4C), (1G, 2B, XB, 3C, 4A), (1G, 2B, XB, 3C, 4B), (1G, 2B, XB, 3C, 4C), (1G, 2B, XB, 3D, 4A), (1G, 2B, XB, 3D, 4B), (1G, 2B, XB, 3D, 4C), (1G, 2C, XA, 3A, 4A), (1G, 2C, XA, 3A, 4B), (1G, 2C, XA, 3A, 4C), (1G, 2C, XA, 3B, 4A), (1G, 2C, XA, 3B, 4B), (1G, 2C, XA, 3B, 4C), (1G, 2C, XA, 3C, 4A), (1G, 2C, XA, 3C, 4B), (1G, 2C, XA, 3C, 4C), (1G, 2C, XA, 3D, 4A), (1G, 2C, XA, 3D, 4B), (1G, 2C, XA, 3D, 4C), (1G, 2C, XB, 3A, 4A), (1G, 2C, XB, 3A, 4B), (1G, 2C, XB, 3A, 4C), (1G, 2C, XB, 3B, 4A), (1G, 2C, XB, 3B, 4B), (1G, 2C, XB, 3B, 4C), (1G, 2C, XB, 3C, 4A), (1G, 2C, XB, 3C, 4B), (1G, 2C, XB, 3C, 4C), (1G, 2C, XB, 3D, 4A), (1G, 2C, XB, 3D, 4B), (1G, 2C, XB, 3D, 4C), (1G, 2D, XA, 3A, 4A), (1G, 2D, XA, 3A, 4B), (1G, 2D, XA, 3A, 4C), (1G, 2D, XA, 3B, 4A), (1G, 2D, XA, 3B, 4B), (1G, 2D, XA, 3B, 4C), (1G, 2D, XA, 3C, 4A), (1G, 2D, XA, 3C, 4B), (1G, 2D, XA, 3C, 4C), (1G, 2D, XA, 3D, 4A), (1G, 2D, XA, 3D, 4B), (1G, 2D, XA, 3D, 4C), (1G, 2D, XB, 3A, 4A), (1G, 2D, XB, 3A, 4B), (1G, 2D, XB, 3A, 4C), (1G, 2D, XB, 3B, 4A), (1G, 2D, XB, 3B, 4B), (1G, 2D, XB, 3B, 4C), (1G, 2D, XB, 3C, 4A), (1G, 2D, XB, 3C, 4B), (1G, 2D, XB, 3C, 4C), (1G, 2D, XB, 3D, 4A), (1G, 2D, XB, 3D, 4B), (1G, 2D, XB, 3D, 4C), (1G, 2E, XA, 3A, 4A), (1G, 2E, XA, 3A, 4B), (1G, 2E, XA, 3A, 4C), (1G, 2E, XA, 3B, 4A), (1G, 2E, XA, 3B, 4B), (1G, 2E, XA, 3B, 4C), (1G, 2E, XA, 3C, 4A), (1G, 2E, XA, 3C, 4B), (1G, 2E, XA, 3C, 4C), (1G, 2E, XA, 3D, 4A), (1G, 2E, XA, 3D, 4B), (1G, 2E, XA, 3D, 4C), (1G, 2E, XB, 3A, 4A), (1G, 2E, XB, 3A, 4B), (1G, 2E, XB, 3A, 4C), (1G, 2E, XB, 3B, 4A), (1G, 2E, XB, 3B, 4B), (1G, 2E, XB, 3B, 4C), (1G, 2E, XB, 3C, 4A), (1G, 2E, XB, 3C, 4B), (1G, 2E, XB, 3C, 4C), (1G, 2E, XB, 3D, 4A), (1G, 2E, XB, 3D, 4B), (1G, 2E, XB, 3D, 4C), (1G, 2F, XA, 3A, 4A), (1G, 2F, XA, 3A, 4B), (1G, 2F, XA, 3A, 4C), (1G, 2F, XA, 3B, 4A), (1G, 2F, XA, 3B, 4B), (1G, 2F, XA, 3B, 4C), (1G, 2F, XA, 3C, 4A), (1G, 2F, XA, 3C, 4B), (1G, 2F, XA, 3C, 4C), (1G, 2F, XA, 3D, 4A), (1G, 2F, XA, 3D, 4B), (1G, 2F, XA, 3D, 4C), (1G, 2F, XB, 3A, 4A), (1G, 2F, XB, 3A, 4B), (1G, 2F, XB, 3A, 4C), (1G, 2F, XB, 3B, 4A), (1G, 2F, XB, 3B, 4B), (1G, 2F, XB, 3B, 4C), (1G, 2F, XB, 3C, 4A), (1G, 2F, XB, 3C, 4B), (1G, 2F, XB, 3C, 4C), (1G, 2F, XB, 3D, 4A), (1G, 2F, XB, 3D, 4B), (1G, 2F, XB, 3D, 4C), (1G, 2G, XA, 3A, 4A), (1G, 2G, XA, 3A, 4B), (1G, 2G, XA, 3A, 4C), (1G, 2G, XA, 3B, 4A), (1G, 2G, XA, 3B, 4B), (1G, 2G, XA, 3B, 4C), (1G, 2G, XA, 3C, 4A), (1G, 2G, XA, 3C, 4B), (1G, 2G, XA, 3C, 4C), (1G, 2G, XA, 3D, 4A), (1G, 2G, XA, 3D, 4B), (1G, 2G, XA, 3D, 4C), (1G, 2G, XB, 3A, 4A), (1G, 2G, XB, 3A, 4B), (1G, 2G, XB, 3A, 4C), (1G, 2G, XB, 3B, 4A), (1G, 2G, XB, 3B, 4B), (1G, 2G, XB, 3B, 4C), (1G, 2G, XB, 3C, 4A), (1G, 2G, XB, 3C, 4B), (1G, 2G, XB, 3C, 4C), (1G, 2G, XB, 3D, 4A), (1G, 2G, XB, 3D, 4B), (1G, 2G, XB, 3D, 4C)

[0415] And $(R^1, R^2, X, R^3, R^4) = (1A, 2A, XA, 3A, 4A)$ is the compound which R^1 is 1A, R^2 is 2A, X is XA, R^3 is 3A and R^4 is 4A. The other combinations are the same.

40 Experimental example

[0416] The inhibitory activities against integrase of the compounds in the present invention have been determined by the assay described below.

45 (1) Preparation of DNA solutions.

[0417] Substrate DNA and target DNA, which sequences were indicated below, were synthesized by Amersham Pharmacia Biotech and dissolved in KTE buffer (composition: 100 mM KCl, 1 mM EDTA, 10 mM Tris-HCl (pH 7.6)) at concentration of 2 pmol/ μ l and 5 pmol/ μ l, respectively. The DNA solutions were annealed with each complement by slowly cooling after heating.

(Substrate DNA)

[0418]

5'- Biotin-ACC CTT TTA GTC AGT GTG GAA AAT CTC TAG CAG T-3'

3'- GAA AAT CAG TCA CAC CTT TTA GAG ATC GTC A-5'

(Target DNA)

[0419]

5'- TGA CCA AGG GCT AAT TCA CT-Dig-3'

3'-Dig-ACT GGT TCC CGA TTA AGT GA -5'

(2) Calculations of the percent inhibitions (the IC_{50} values of test compounds)

[0420] Streptavidin, obtained from Vector Laboratories, was dissolved in 0.1 M carbonate buffer (composition: 90 mM Na_2CO_3 , 10 mM $NaHCO_3$) at concentration of 40 μ g/ml. After coating each well of microtiter plates (obtained from NUNC) with 50 μ l of the above solution at 4 °C over night, each well was washed twice with PBS (composition: 13.7 mM NaCl, 0.27 mM KCl, 0.43 mM Na_2HPO_4 , 0.14 mM KH_2PO_4) and blocked with 300 μ l of 1% skim milk in PBS for 30 min. Additionally, each well was washed twice with PBS and added 50 μ l of substrate DNA solution (0.04 pmol/ μ l) diluted to one fiftieth with NTE buffer (composition: 1M NaCl, 10mM Tris-HCl (pH8.0), 1mM EDTA). The microtiter plates were kept at room temperature for 30 min. Then, each well was washed twice with PBS and once with H_2O .

[0421] Subsequently, in the each well prepared above were added 45 μ l of the reaction buffer prepared from 12 μ l of the buffer (composition: 150 mM MOPS (pH 7.2), 75 mM $MnCl_2$, 50 mM 2-mercaptoethanol, 25% glycerol, 500 μ g/ml bovine serum albumin-fraction V), 1 μ l of target DNA (5 pmol/ μ l), and 32 μ l of the distilled water. Additionally, 6 μ l of either a test compound in DMSO or DMSO for positive control (PC) was mixed with the above reaction buffer, then 9 μ l of an integrase solution (30 pmol) was added and mixed well. In the well of negative control (NC) was added 9 μ l of the integrase dilution buffer (composition: Hepes (pH7.6), 400 mM potassium glutamate, 1 mM EDTA, 0.1 % NP-40, 20 % glycerol, 1 mM DTT, 4 M urea).

[0422] The microtiter plates were incubated at 30 °C for 1 hour. The reaction solution was removed and each well was washed twice with PBS. Subsequently, each well of the microtiter plates was filled with 100 μ l of anti-digoxigenin antibody labeled with alkaline phosphatase (Sheep Fab fragment: obtained from Boehringer) and incubated at 30 °C for 1 hour. Then, each well was washed twice with 0.05 % Tween20 in PBS and once with PBS. Next, 150 μ l of the Alkaline phosphatase reaction buffer (composition: 10 mM *p*-Nitrophenylphosphate (obtained from Vector Laboratories), 5 mM $MgCl_2$, 100 mM NaCl, 100 mM Tris-HCl (pH 9.5)) was added in each well. The microtiter plates were incubated at 30 °C for 2 hours. The optical density (OD) at 405 nm of each well was measured and the percent inhibition was determined by the following expression.

[0423] The percent inhibition (%) = $100[1 - ((C \text{ abs.} - NC \text{ abs.}) / (PC \text{ abs.} - NC \text{ abs.}))]$

C abs.: the OD of the well of the

NC abs.: the OD of the negative control (NC)

PC abs.: the OD of the positive control (PC)

[0424] When the percent inhibition (%) is X % at the concentration of x μ g/ml and the percent inhibition (%) is Y % at the concentration of y μ g/ml, one of which is more than 50% and the other is less than 50 %, IC_{50} can be determined by the following expression.

$$IC_{50}(\mu\text{g/ml}) = x - \{(X-50)(x-y)/(X-Y)\}$$

[0425] The IC_{50} values, the concentration of the compounds at percent inhibition 50 %, are shown in the following Table 1. Compound No. in the Table 1 is the same as compound No. of the above example.

Table 1

compound No.	IC_{50} (μ g/ml)	compound No.	IC_{50} (μ g/ml)
A-7	0.76	C-26	0.36
A-12-a	0.33	C-39	0.23

EP 1 422 218 A1

Table 1 (continued)

compound No.	IC ₅₀ (μg/ml)	compound No.	IC ₅₀ (μg/ml)
A-17	0.80	D-5	0.45
A-17-c	0.94	E-8	0.14
A-50	0.16	E-16	0.12
A-141-k	0.68	F-4	0.57
A-158	0.67	G-7	0.48
B-6-a	1.6	H-7	0.68
B-6-d	2.4	I-4	0.50
B-12	0.29	J-4	0.26
B-12-b	0.21	K-4	0.57
B-29	0.12	L-4	0.49
B-68	0.22	M-6	2.9
C-22	0.48		

[0426] The compounds of the present invention except the above compounds had the same or more integrase inhibitory activities.

[0427] And the compounds of the present invention have high stability against metabolism and they are superior inhibitory agents against integrase.

Formulation Example

[0428] It is to be noted that the following Formulation Examples 1 to 8 are mere illustration, but not intended to limit the scope of the invention. The term "active ingredient" means the compounds of the present invention, the tautomers, the prodrugs thereof, their pharmaceutical acceptable salts, or their solvate.

Formulation Example 1

Hard gelatin capsules are prepared using of the following ingredients:

[0429]

	Dose (mg/capsule)
Active ingredient	250
Starch, dried	200
Magnesium stearate	10
Total	460 mg

Formulation Example 2

A tablet is prepared using of the following ingredients:

[0430]

	Dose (mg/tablet)
Active ingredient	250
Cellulose, microcrystals	400
Silicon dioxide, fumed	10
Stearic acid	5

EP 1 422 218 A1

(continued)

	Dose (mg/tablet)
Total	665 mg

[0431] The components are blended and compressed to form tablets each weighing 665 mg.

Formulation Example 3

An aerosol solution is prepared containing the following components:

[0432]

	Weight
Active ingredient	0.25
Ethanol	25.75
Propellant 22 (chlorodifluoromethane)	74.00
Total	100.00

[0433] The active ingredient is mixed with ethanol and the admixture added to a portion of the propellant 22, cooled to -30 °C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.

Formulation Example 4

Tablets, each containing 60 mg of active ingredient, are made as follows.

[0434]

Active ingredient	60 mg
Starch	45 mg
Microcrystals cellulose	35 mg
Polyvinylpyrrolidone (as 10% solution in water)	4 mg
Sodium carboxymethyl starch	4.5 mg
Magnesium stearate	0.5 mg
Talc	1 mg
Total	150 mg

[0435] The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve, and the mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the admixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

Formulation Example 5

Capsules, each containing 80 mg of active ingredient, are made as follows:

[0436]

Active ingredient	80 mg
Starch	59 mg

EP 1 422 218 A1

(continued)

Microcrystals cellulose	59 mg
Magnesium stearate	2 mg
Total	200 mg

[0437] The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.

Formulation Example 6

Suppositories, each containing 225 mg of active ingredient, are made as follows:

[0438]

Active ingredient	225 mg
Saturated fatty acid glycerides	2000 mg
Total	2225 mg

[0439] The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2g capacity and allowed to cool.

Formulation Example 7

Suspensions, each containing 50 mg of active ingredient, are made as follows:

[0440]

Active ingredient	50 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 ml
Benzoic acid solution	0.10 ml
Flavor	q.v.
Color	q.v.
Purified water to total	5 ml

[0441] The active ingredient is passed through a No. 45 U.S. sieve, and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.

Formulation Example 8

An intravenous formulation may be prepared as follows:

[0442]

Active ingredient	100 mg
Isotonic saline	1000 ml


[0443] The solution of the above ingredients is generally administered intravenously to a subject at a rate of 1 ml per minute.

Industrial Applicability


[0444] The compounds of the present invention have inhibitory activities against integrase and useful for treatment of AIDS as an antiviral agent and an anti-HIV agent.

Claims


1. A pharmaceutical composition containing as an active ingredient a compound of formula (I):



(wherein, R^C and R^D taken together with the neighboring carbon atoms form a ring which may be a condensed ring, Y is hydroxy, mercapto or amino; Z is O, S or NH; R^A is a group shown by



(wherein, C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is non-substituted N atom; the broken line shows the presence or absence of a bond.) or by




(wherein, X is O, S or NH; R^B is a substituent selected from substitution group A); at least one of the ring formed by R^C and R^D , C ring or R^B is substituted with a group of $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 and Z^3 are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene; Z^2 is a bond, optionally substituted alkylene, optionally substituted alkenylene, $-\text{CH}(\text{OH})-$, $-\text{S}-$, $-\text{S}-\text{O}-$, $-\text{SO}_2-$, $-\text{SO}_2\text{NR}^2-$, $-\text{NR}^2\text{SO}_2-$, $-\text{O}-$, $-\text{NR}^2-$, $-\text{NR}^2\text{CO}-$, $-\text{CONR}^2-$, $-\text{C}(=\text{O})-\text{O}-$, $-\text{O}-\text{C}(=\text{O})-$ or $-\text{CO}-$; R^2 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heteroaryl; R^1 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle); the ring formed by R^C and R^D , C ring or R^B is optionally substituted with a non-interfering substituent at any position other than that where the group of $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1 , Z^2 , Z^3 and R^1 are the same as defined above) locates;

substitution group A consists of: hydrogen, halogen, alkoxy, carbonyl, carboxy, alkyl, alkoxy, alkoxyalkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthioalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkyl carbonyl, alkyl carbonyloxy, hydrazino, morpholino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl alkyl, optionally substituted aryl oxy, optionally substituted heteroaryl oxy, optionally substituted aryl thio, optionally substituted


heteroaryl thio, optionally substituted aralkyloxy, optionally substituted heteroaryl alkyl oxy, optionally substituted aralkylthio, optionally substituted heteroaryl alkylthio, optionally substituted aryl oxyalkyl, optionally substituted heteroaryl oxyalkyl, optionally substituted aryl thioalkyl, optionally substituted heteroaryl thioalkyl, optionally substituted arylsulfonyl, optionally substituted heteroarylsulfonyl, optionally substituted aralkylsulfonyl and optionally substituted heteroaryl alkylsulfonyl), its prodrug, or a pharmaceutically acceptable salt or solvate thereof, for use as an integrase inhibitor.

2. A pharmaceutical composition of Claim 1 wherein the ring formed by R^C and R^D is a 5- to 6-membered ring which may contain a hetero atom(s) and be condensed with.
3. A pharmaceutical composition of Claim 2 wherein the ring formed by R^C and R^D is a 5- to 6-membered ring which may contain a hetero atom(s) of O and/or N and be condensed with a benzene ring.
4. A pharmaceutical composition of Claim 3 wherein the ring formed by R^C and R^D is a 5-membered ring which contains a hetero atom(s) of N.
5. A pharmaceutical composition of Claim 3 wherein the ring formed by R^C and R^D is a 6-membered ring which contains a hetero atom(s) of O and is condensed with a benzene ring.
6. A pharmaceutical composition of Claim 3 wherein the ring formed by R^C and R^D is a 6-membered ring which contains a hetero atom(s) of N and is condensed with a benzene ring.
7. A pharmaceutical composition of Claim 3 wherein the ring formed by R^C and R^D is a 6-membered ring which contains a hetero atom(s) of O.
8. A pharmaceutical composition of Claim 3 wherein the ring formed by R^C and R^D is a 6-membered ring which contains a hetero atom(s) of N.
9. A pharmaceutical composition of Claim 1 wherein the ring formed by R^C and R^D is a 6-membered carbocycle.
10. A pharmaceutical composition of Claim 4 which contains as an active ingredient a compound of formula (II-1):




(wherein, Y, Z, C ring, Z^1 , Z^2 , Z^3 , R^1 and the broken line is the same as Claim 1; R^3 , R^4 , R^5 and R^{19} are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

11. A pharmaceutical composition of Claim 4 which contains as an active ingredient a compound of formula (III-1):




15 (wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as Claim 1; R⁵, R⁶, R⁷ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

12. A pharmaceutical composition of Claim 3 which contains as an active ingredient a compound of formula (II-2):




35 (wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line is the same as Claim 1; R³, R⁴ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

13. A pharmaceutical composition of Claim 3 which contains as an active ingredient a compound of formula (III-2):




55 (wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ is the same as Claim 1; R⁶, R⁷ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

14. A pharmaceutical composition of Claim 3 which contains as an active ingredient a compound of formula (IV-1):




15 (wherein, Y, Z, C ring and the broken line are the same as Claim 1; R^8, R^9 and R^{10} are each independently a non-interfering substituent; at least one of R^E and R^F is shown by $-Z^1-Z^2-Z^3-R^1$ (wherein, Z^1, Z^2, Z^3 and R^1 are the same as Claim 1) and the other is a non-interfering substituent, or R^E and R^F taken together with the neighboring carbon atoms may form a ring shown by :




35 (wherein, R^{11} to R^{13} are each independently a non-interfering substituent, Z^1, Z^2, Z^3 and R^1 are the same as Claim 1), its prodrug or pharmaceutically acceptable salt or solvate thereof.

15. A pharmaceutical composition of Claim 5 which contains as an active ingredient a compound of formula (IV-2) :




55 (wherein, Y, Z, C ring, Z^1, Z^2, Z^3, R^1 and the broken line are the same as Claim 1; R^8 to R^{13} are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

16. A pharmaceutical composition of Claim 3 which contains as an active ingredient a compound of formula (V-1) :




(wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as Claim 1 ; R⁹ and R¹⁰ are each independently a non-interfering substituent ; R^E and R^F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms may form a ring shown by :




(wherein, R¹¹ to R¹⁴ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof..

17. A pharmaceutical composition of Claim 5 which contains as an active ingredient a compound of formula (V-2) :




(wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as Claim 1 ; R⁹ to R¹⁴ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

18. A pharmaceutical composition of Claim 3 which contains as an active ingredient a compound of formula (VI-1) :




(wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as Claim 1 ; R⁹, R¹⁰ and R¹⁵ are each independently a non-interfering substituent ; R^E and R^F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms may form a ring shown by




(wherein, R¹¹ to R¹⁴ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

19. , A pharmaceutical composition of Claim 6 which contains as an active ingredient a compound of formula(VI-2):




(wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as Claim 1 ; R⁹ to R¹⁵ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof).

20. A pharmaceutical composition of Claim 3 which contains as an active ingredient a compound of formula(VII-1) :




15 (wherein, X, Y, Z, R^B , Z^1 , Z^2 , Z^3 and R^1 are the same as Claim 1; W^1 is -O or -N(R^G); R^G is a non-interfering substituent; R^6 and R^7 are each independently a non-interfering substituent; R^E and R^F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms form a ring shown by




(wherein, R^{11} to R^{14} are each independently a non-interfering substituent)), its prodrug or pharmaceutically acceptable salt or solvate thereof.

30 **21.** A pharmaceutical composition of Claim 3 which contains as an active ingredient a compound of formula (VII-2) :




45 (wherein, X, Y, Z, R^B , Z^1 , Z^2 , Z^3 and R^1 are the same as Claim 1; W^1 is -O or -N(R^G); R^G is a non-interfering substituent; R^6 , R^7 , R^{11} to R^{14} are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

50 **22.** A pharmaceutical composition of Claim 3 which contains as an active ingredient a compound of formula (VII-3):




15 (wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as Claim 1 ; W¹ is -O or -N(-R^G)- ; R^G is a non-interfering substituent ; R⁶ and R⁷ are each independently a non-interfering substituent ; R^E and R^F are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

23. A pharmaceutical composition of Claim 9 which contains as an active ingredient a compound of formula (VIII-1) :




35 (wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁶ and R⁷ are each independently a non-interfering substituent ; R^E and R^F are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

24. A pharmaceutical composition of Claim 9 which contains as an active ingredient a compound of formula (VIII-2) :




55 (wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as Claim 1 ; R^E and R^F are each independently a non-interfering substituent ; R⁹ and R¹⁰ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

25. A pharmaceutical composition of Claim 8 which contains as an active ingredient a compound of formula (IX-1):




15 (wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as Claim 1; R⁶ and R⁷ are each independently a non-interfering substituent; R^F and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or its solvate thereof.

20 26. A pharmaceutical composition of Claim 8 which contains as an active ingredient a compound of formula (IX-2):




35 (wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as Claim 1; R⁹ and R¹⁰ are each independently a non-interfering substituent; R^F and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

40 27. A pharmaceutical composition of Claim 4 which contains as an active ingredient a compound of formula (X-1):




55 (wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as Claim 1; R⁵, R⁵, R⁶ and R⁷ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

28. A pharmaceutical composition of Claim 4 which contains as an active ingredient a compound of formula (X-2):




15 (wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as Claim 1 ; R⁵, R^{5'}, R⁹ and R¹⁰ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

29. A pharmaceutical composition of Claim 7 which contains as an active ingredient a compound of formula(XI-1):




35 (wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁶, R⁷, R^F and R^G are each independently a non-interfering substituent ; the broken line (—) shows the presence or absence of a bond), its prodrug or pharmaceutically acceptable salt or solvate thereof.

30. A pharmaceutical composition of Claim 7 which contains as an active ingredient a compound of formula(XI-2):




55 (wherein, Y, Z, C ring, Z¹, Z², Z³, R¹ and the broken line are the same as Claim 1 ; R⁹, R¹⁰, R^F and R^G are each independently a non-interfering substituent ; the broken line(—) shows the presence or absence of a bond), its prodrug or pharmaceutically acceptable salt or solvate thereof.

31. A pharmaceutical composition of Claim 8 which contains as an active ingredient a compound of formula(XII-1):




15 (wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as Claim 1; R⁵, R⁶, R⁷, R^F and R^G are each independently a non-interfering substituent; the broken line(—) shows the presence or absence of a bond), its prodrug or pharmaceutically acceptable salt or solvate thereof.

20 32. A pharmaceutical composition of Claim 8 which contains as an active ingredient a compound of formula(XII-2):




35 (wherein, Y, Z, C ring, Z¹, Z², Z³, and R¹ are the same as Claim 1; R⁶, R⁹, R¹⁰, R^F and R^G are each independently a non-interfering substituent; the broken line(—) shows the presence or absence of a bond), its prodrug or pharmaceutically acceptable salt or solvate thereof.

40 33. A pharmaceutical composition of Claim 8 which contains as an active ingredient a compound of formula(XIII-1):



55 (wherein, X, Y, Z, R^B, Z¹, Z², Z³ and R¹ are the same as Claim 1; R⁵, R⁶, R⁷ and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

34. A pharmaceutical composition of Claim 8 which contains as an active ingredient a compound of formula(XIII-2):




(wherein, Y, Z, C ring, Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁵, R⁹, R¹⁰ and R⁶ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

35. A pharmaceutical composition of any one of Claims 1 to 34, wherein the non-interfering substituents are independently selected from hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxyalkyl, nitro, hydroxy, hydroxyalkyl, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthioalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, oxo, thioxo, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkylcarbonyl, alkylcarbonyloxy, hydrazino, morpholino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted arylthio, optionally substituted heteroarylthio, optionally substituted aralkyloxy, optionally substituted heteroarylalkyloxy, optionally substituted aralkylthio, optionally substituted heteroarylalkylthio, optionally substituted aryloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted arylthioalkyl, optionally substituted heteroarylthioalkyl, optionally substituted arylsulfonyl, optionally substituted heteroarylsulfonyl, optionally substituted aralkylsulfonyl and optionally substituted heteroarylalkylsulfonyl.


36. A method for prevention or treatment of AIDS or AIDS-related complication, comprising administration of a pharmaceutical composition of any one of Claims 1 to 35.

37. Use of a compound of any one of Claims 1 to 35 for preparing a pharmaceutical composition as an integrase inhibitor.


38. A compound of formula(I-Q) : Q-Z¹-Z²-Z³-R¹, its prodrug or pharmaceutically acceptable salt or solvate thereof, wherein, Z¹, Z², Z³ and R¹ are the same as Claim 1 ; Q is shown by any one of the following formulae :




(wherein, C ring is the same as Claim 1 ; Y is hydroxy; Z is O ; R³, R⁴, R⁶ and R¹⁹ are the same as Claim 10),




(wherein, X is O; Y and Z are the same as above; R⁵, R⁶, R⁷ and R¹⁹ are the same as Claim 11; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle),



(wherein, C ring is the same as Claim 1; Y and Z are the same as above; R³, R⁴ and R¹⁹ are the same as Claim 10),




(wherein, X, Y, Z and R^B are the same as above; R⁶, R⁷ and R¹⁹ are the same as Claim 11),




(wherein, C ring is the same as Claim 1; Y and Z are the same as above; R⁸ to R¹⁰ are the same as Claim 14;


W¹ is the same as Claim 20 ; R¹⁶ is a non-interfering substituent),




(wherein, C ring is the same as Claim 1 ; Y and Z are the same as above ; R⁸ to R¹³ are the same as Claim 14 ; W¹ is the same as Claim 20),




(wherein, C ring is the same as Claim 1 ; Y and Z are the same as above ; R⁹ to R¹⁴ is the same as Claim 16 ; W¹ is the same as Claim 20),




(wherein, C ring is the same as Claim 1 ; Y and Z are the same as above ; W¹ is the same as Claim 20 ; R⁹ and R¹⁰ are the same as Claim 14 ; R¹⁷ and R¹⁸ are each independently a non-interfering substituent),




(wherein, X, Y, Z and R^B are the same as above ; W¹ is the same as Claim 20 ; R⁶ and R⁷ are the same as Claim 11 ; R¹¹ to R¹⁴ are the same as Claim 16),




(wherein, X, Y, Z and R^B are the same as above ; W¹ is the same as Claim 20 ; R⁶ and R⁷ are the same as Claim 11 ; R¹⁷ and R¹⁸ are each independently a non-interfering substituent) :




(wherein, X, Y, Z and R^B are the same as above ; R⁶ and R⁷ are the same as Claim 11 ; R¹⁷ and R¹⁸ are each independently a non-interfering substituent),




(wherein, C ring is the same as Claim 1 ; Y and Z are the same as above; R⁹ and R¹⁰ are the same as Claim 14 ; R¹⁷ and R¹⁸ are the same as defined above),



(wherein, X, Y, Z and R^B are the same as above ; R⁵ is the same as Claim 10 ; R⁶ and R⁷ are the same as Claim 11 ; R¹⁷ and R¹⁸ are the same as defined above),




(wherein, C ring is the same as Claim 1 ; Y and Z are the same as above ; R⁵ is the same as Claim 10 ; R⁹ and R¹⁰ are the same as Claim 14 ; R¹⁷ and R¹⁸ are the same as defined above),




EP 1 422 218 A1


(wherein, X, Y, Z and R^B are the same as above ; R⁵ and R^{5'} are the same as Claim 27 ; R⁶ and R⁷ are the same as Claim 11),




(wherein, C ring is the same as Claim 1 ; Y and Z are the same as above ; R⁵ and R^{5'} are the same as Claim 27 ; R⁹ and R¹⁰ are the same as Claim 14) :




(wherein, X, Y, Z and R^B are the same as above ; R⁶ and R⁷ are the same as Claim 11 ; R¹⁷ and R¹⁸ are the same as above, the broken line(---) shows the presence or absence of a bond),




(wherein, C ring is the same as Claim 1 ; Y and Z are the same as above ; R⁹ and R¹⁰ are the same as Claim 14 ; R¹⁷ and R¹⁸ are the same as above, the broken line(---) shows the presence or absence of a bond),




(wherein, X, Y, Z and R^B are the same as above; R^5 , R^6 and R^7 are the same as Claim 11; R^{17} and R^{18} are the same as above, the broken line(---) shows the presence or absence of a bond),



(wherein, C ring is the same as Claim 1; Y and Z are the same as above; R^5 is the same as Claim 10; R^9 and R^{10} are the same as Claim 14; R^{17} and R^{18} are the same as above, the broken line(---) shows the presence or absence of a bond),




(wherein, X, Y, Z and R^B are the same as above; R^5 , R^6 and R^7 are the same as Claim 11; R^{18} is the same as defined above), and




EP 1 422 218 A1

(wherein, C ring is the same as Claim 1 ; Y and Z are the same as above ; R⁶ is the same as Claim 10 ; R⁹ and R¹⁰ are the same as Claim 14 ; R¹⁸ is the same as defined above);
provided that excluded are compounds, wherein Z¹ is a bond, Z² is -O-, Z³ is methylene, R¹ is phenyl, and Q is a group of the formula:




(wherein, R⁸ to R¹³ are hydrogens, Y is hydroxy, Z is O, W is - O -, and C ring is quinoline-2-yl) or the formula:



wherein, R⁹ and R¹⁰ are the same as above, R¹⁷ is alkyl, R¹⁸ is hydrogen, Y is hydroxy, Z is O, C ring is dihydropyrimidine).

39. A compound of Claim 38, shown by formula (II-1) :




(wherein, Y is hydroxy ; Z is O ; C ring, Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R³, R⁴, R⁵ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

40. A compound of Claim 39, wherein Z¹ and Z³ are each independently a bond or alkylene; Z² is a bond or - O -; R¹ is optionally substituted aryl or optionally substituted heteroaryl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

41. A compound of Claim 39, wherein C ring is pyrimidine-4-yl or 1,3,4-oxadiazole-2-yl; Z¹ is a bond; Z² is - O - or alkylene; Z³ is a bond or alkylene; R¹ is aryl optionally substituted with halogen; R³, R⁴ and R¹⁹ are hydrogens; R⁵ is alkyl, aralkyl, cycloalkyl, aryl or alkoxy, its prodrug or pharmaceutically acceptable salt or solvate thereof.

42. A compound of Claim 38, shown by formula (III-1):




(wherein, X is O; Y is hydroxy; Z is O; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle; Z¹, Z², Z³ and R¹ are the same as Claim 1; R⁵, R⁶, R⁷ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

43. A compound of Claim 39 or 42, wherein, R⁵ is hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxyalkyl, alkenyl, alkoxycarbonylalkyl or heteroarylalkyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

44. A compound of above 42, wherein R^B is fran-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

45. A compound of above 42, wherein R^B is aryl or fran-2-yl; Z¹ and Z³ are bonds; Z² is alkylene; R¹ is aryl optionally substituted with halogen; R⁶, R⁷ and R¹⁹ are hydrogens; R⁵ is alkyl, cycloalkyl, alkoxy, aryl optionally substituted with alkoxy, hydroxyalkyl, alkenyl, aralkyl, alkoxycarbonylalkyl, or pyridine-2-ylmethyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

46. A compound of Claim 38, shown by formula (II-2):




(wherein, Y is hydroxy; Z is O; C ring, Z¹, Z², Z³ and R¹ are the same as Claim 1; R³, R⁴ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

47. A compound of Claim 46, wherein Z¹ and Z³ are each independently a bond or alkylene; Z² is a bond or -O-; R¹ is optionally substituted aryl or optionally substituted heteroaryl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

48. A compound of Claim 46, wherein C ring is pyrimidine-4-yl or 1,3,4-oxadiazole-2-yl; Z¹ is a bond; Z² is -O or alkylene; Z³ is a bond or alkylene; R¹ is aryl optionally substituted with halogen; R³, R⁴ and R¹⁹ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

49. A compound of Claim 38 shown by formula (III-2):




(wherein, X is O; Y is hydroxy; Z is O; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle; Z¹, Z², Z³ and R¹ are the same as Claim 1; R⁶, R⁷ and R¹⁹ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

50. A compound of Claim 49, wherein R^B is fran-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

51. A compound of Claim 49, wherein R^B is aryl or fran-2-yl; Z¹ and Z³ are bonds; Z² is alkylene; R¹ is aryl optionally substituted with halogen; R⁶, R⁷ and R¹⁹ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

52. A compound of Claim 38, shown by formula (IV-2):




(wherein, Y is hydroxy; Z is O; C ring, Z¹, Z², Z³ and R¹ are the same as Claim 1; R⁸ to R¹³ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

53. A compound of Claim 52, wherein C ring is pyridine-2-yl, 1,2,4-triazole-3-yl or imidazole-2-yl optionally substituted

with alkyl ; Z¹ is a bond ; Z² is - O - ; Z³ is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁸ to R¹³ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

54. A compound of Claim 38, shown by formula (V-2):




(wherein, Y is hydroxy ; Z is O ; C ring, Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁹ to R¹⁴ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

55. A compound of Claim 52 or 54, wherein Z¹ and Z³ are each independently a bond or alkylene ; Z² is a bond or - O - ; R¹ is optionally substituted aryl or optionally substituted heteroaryl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

56. A compound of Claim 54, wherein C ring is 1,3,4-oxadiazole-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁹ to R¹⁴ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

57. A compound of Claim 38, shown by formula (VI-2):




(wherein, Y is hydroxy ; Z is O ; C ring, Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁹ to R¹⁵ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

58. A compound of Claim 57, wherein, R¹⁵ is hydrogen or alkyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

59. A compound of Claim 57, wherein C ring is 1,3,4-oxadiazole-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁹ to R¹⁴ are hydrogens ; R¹⁵ is hydrogen or alkyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

60. A compound of Claim 38, shown by formula (VII-4) :




(wherein, X is O ; Y is hydroxy ; Z is O ; W² is -O or -N H- ; R^B is optionally substituted aryl , optionally substituted heteroaryl , optionally substituted cycloalkyl , optionally substituted cycloalkenyl or optionally substituted heterocycle ; Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁶, R⁷, R¹¹ to R¹⁴ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

61. A compound of Claim 60, wherein R^B is fran-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

62. A compound of Claim 60, wherein R^B is fran-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁶, R⁷, R¹¹ to R¹⁴ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

63. A compound of Claim 38, shown by formula (VII-5):




(wherein, X is O ; Y is hydroxy ; Z is O ; W² is -O or -NH- ; R^B is optionally substituted aryl , optionally substituted heteroaryl , optionally substituted cycloalkyl , optionally substituted cycloalkenyl or optionally substituted heterocycle ; Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁶, R⁷, R^E and R^F are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

64. A compound of Claim 63, wherein, R^B is fran-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

65. A compound of Claim 63, wherein, R^B is fran-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁶, R⁷, R^E and R^F are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

66. A compound of Claim 38, shown by formula (VIII-1) :




(wherein, X is O; Y is hydroxy; Z is O; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle; Z¹, Z², Z³ and R¹ are the same as Claim 1; R⁶, R⁷, R^E and R^F are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

67. A compound of Claim 66, wherein R^B is *fran*-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.


68. A compound of Claim 66, wherein R^B is *fran*-2-yl; Z¹ and Z³ are bonds; Z² is alkylene; R¹ is aryl optionally substituted with halogen; R⁶, R⁷, R^E and R^F are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

69. A compound of Claim 38, shown by formula (VIII-2):



(wherein, Y is hydroxy; Z is O; C ring, Z¹, Z², Z³ and R¹ are the same as Claim 1; R⁹, R¹⁰, R^E and R^F are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

70. A compound of Claim 38, shown by formula (IX-1):




(wherein, X is O ; Y is hydroxy ; Z is O ; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle; Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁶, R⁷, R^F and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

71. A compound of Claim 70, wherein, R^B is *fran*-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.


72. A compound of Claim 70, wherein, R^B is *fran*-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁶, R⁷, R^F and R^G are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

73. A compound of Claim 38, shown by formula (IX-2):



(wherein, Y is hydroxy ; Z is O ; C ring, Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁹, R¹⁰, R^F and R^G are each independently a non-interfering substituent, provided that when R^G is hydrogen and R^F is alkyl, C ring is not dihydropyrimidine), its prodrug or pharmaceutically acceptable salt or solvate thereof.

74. A compound of Claim 38, shown by formula (X-1):




(wherein, X is O ; Y is hydroxy ; Z is O ; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle; Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁵, R^{5'}, R⁶ and R⁷ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

75. A compound of Claim 74, wherein R^B is *fran*-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.


76. A compound of Claim 74, wherein R^B is *fran*-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁶, R⁷, R⁵ and R^{5'} are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

77. A compound of Claim 38, shown by formula (X-2):



(wherein, Y is hydroxy ; Z is O ; C ring, Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁵, R^{5'}, R⁹ and R¹⁰ are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

78. A compound of Claim 38, shown by formula (XI-1):




(wherein, X is O; Y is hydroxy ; Z is O; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle ; Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁶, R⁷, R^F and R^G are each independently a non-interfering substituent, the broken line (—) shows the presence or absence of a bond), its prodrug or pharmaceutically acceptable salt or solvate thereof.

79. A compound of Claim 78, wherein, R^B is fran-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

80. A compound of Claim 78, wherein, R^B is fran-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁶, R⁷, R^F and R^G are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

81. A compound of Claim 38, shown by (XI-2):



82. A compound of Claim 38, shown by (XII-1):




83. A compound of Claim 82, wherein, R^B is fran-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

85. A compound of Claim 38, shown by formula (XII-2):



86. A compound of Claim 38, shown by formula (XIII-1):




(wherein, X is O ; Y is hydroxy ; Z is O ; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle; Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁵, R⁶, R⁷ and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

87. A compound of Claim 86, wherein, R^B is *fr*-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

88. A compound of Claim 86, wherein, R^B is *fr*-2-yl ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is aryl optionally substituted with halogen ; R⁶, R⁷ and R^G are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

89. A compound of Claim 38, shown by formula (XIII-2):



(wherein, Y is hydroxy ; Z is O ; C ring, Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁵, R⁹, R¹⁰ and R^G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.

90. A compound of Claim 38, 39, 46, 52, 54, 57, 69, 73, 77, 81, 85 or 89, wherein C ring is optionally substituted pyridine-2-yl, optionally substituted pyrimidine-4-yl, optionally substituted 1,3,4-oxadiazole-2-yl, optionally substituted 1,2,4-triazole-3-yl or optionally substituted imidazole-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

91. A compound of Claim 38, (39), (46), (52), (54), (57), (69), (73), (77), (81), (85) or (89), wherein Z¹ and Z³ are each independently a bond or alkylene ; Z² is a bond or -O - ; R¹ is optionally substituted aryl or optionally substituted heteroaryl, its prodrug or pharmaceutically acceptable salt or solvate thereof

92. A compound of Claim 38, (39), (46), (52), (54), (57), (69), (73), (77), (81), (85) or (89), wherein C ring is pyrimidine-4-yl or 1,3,4-oxadiazole-2-yl; Z¹ is a bond; Z² is -O or alkylene ; Z³ is a bond or alkylene ; R¹ is aryl optionally substituted with halogen ; R³, R⁴ and R¹⁹ are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.

93. A compound of Claim 38, (39), (42), (46), (49), (52), (54), (57), (60), (63), (66), (69), (70), (73), (74), (77), (78), (81), (82), (85), (86) or (89), wherein each non-interfering substituent is independently selected from hydrogen, halogen, alkoxy, alkoxy carbonyl, carboxy, alkyl, alkoxy, alkoxy alkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally sub-


stituted amino, alkylthio, alkylthio alkyl, haloalkyl, haloalkoxy, haloalkoxy alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, oxo, thio, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkyl carbonyl, alkyl carbonyloxy, hydrazino, morpholino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl alkyl, optionally substituted aryl oxy, optionally substituted heteroaryl oxy, optionally substituted aryl thio, optionally substituted heteroaryl thio, optionally substituted aralkyloxy, optionally substituted heteroaryl alkyl oxy, optionally substituted aralkylthio, optionally substituted heteroaryl alkylthio, optionally substituted aryl oxyalkyl, optionally substituted heteroaryl oxyalkyl, optionally substituted aryl thioalkyl, optionally substituted heteroaryl thioalkyl, optionally substituted arylsulfonyl, optionally substituted heteroarylsulfonyl, optionally substituted aralkylsulfonyl and optionally substituted heteroaryl alkylsulfonyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

94. A compound of Claim 38, (39), (42), (46), (49), (52), (54), (57), (60), (63), (66), (69), (70), (73), (74), (77), (78), (81), (82), (85), (86) or (89), wherein Z^1 , Z^2 and Z^3 are not bonds at the same, its prodrug or pharmaceutically acceptable salt or solvate thereof.

95. A compound of Claim 94, wherein R^1 is phenyl optionally substituted with halogen, Z^1 is a bond, Z^2 is alkylene or -O-, Z^3 is a bond or alkylene, its prodrug or pharmaceutically acceptable salt or solvate thereof.


96. A compound of Claim 95, wherein R^1 is 4-fluorophenyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.

97. A compound of the formula (I) :




(wherein, R^C and R^D taken together with the neighboring carbon atoms form 5- or 6-membered heterocycle which may contain O and/or N atom and be condensed with a benzene ring; Y is hydroxy, mercapto or amino; Z is O, S or NH;

R^A is shown of the formula :



(wherein, C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is unsubstituted N atom. the broken line shows the presence or absence of a bond.) or the formula :



(wherein, X is O, S or NH ; R^B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle) ; at least one of the ring formed by R^C and R^D, C ring and R^B is substituted with a group of the formula : -Z¹-Z²-Z³-R¹ (wherein, Z¹ and Z³ are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene ; Z² is a bond, optionally substituted alkylene, optionally substituted alkenylene, -CH(OH)-, -S-, -SO-, -SO₂-, -SO₂N(R²)-, -N(R²)SO₂-, -O-, -N(R²)-, -N(R²)CO-, -CON(R²)-, -C(=O)-O-, -O-C(=O) or -CO- ; R² is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heteroaryl ; R¹ is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle) ; and

the ring formed by R^C and R^D, C ring or R^B is optionally substituted with 1 to 3 substituents selected from hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxyalkyl, alkenyl, alkoxyalkonylalkyl, heteroarylalkyl and hydroxy, at any position except where the above the formula : -Z¹-Z²-Z³-R¹ (wherein, Z¹, Z², Z³ and R¹ are the same as defined above) locates, its prodrug or pharmaceutically acceptable salt or solvate thereof.

98. A compound of Claim 97, wherein the ring formed by R^C and R^D is 5- or 6-membered heterocycle which may contain O and/or N atom and be condensed with benzene ring ; Y is hydroxy ; Z is O ; X is O ; the ring formed by R^C and R^D is optionally substituted with 1 to 3 substituents selected from hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxy alkyl, optionally substituted amino, hydroxyalkyl, alkenyl, alkoxyalkonylalkyl and heteroaryl alkyl, and C ring and R^B are each independently optionally substituted with 1 to 3 substituents selected from alkyl, amino, halogen and hydroxy, its prodrug or pharmaceutically acceptable salt or solvate thereof.

99. A compound of Claim 97 or 98, wherein at least one of the ring formed by R^C and R^D, C ring and R^B is substituted with a group of the formula : -Z¹-Z²-Z³-R¹ (wherein Z¹ is a bond or alkylene ; Z² is alkylene or -O- ; Z³ is a bond or alkylene ; R¹ is optionally substituted aryl or optionally substituted heteroaryl), its prodrug or pharmaceutically acceptable salt or solvate thereof.

100. A pharmaceutical composition comprising a compound of any one of Claims 38 to 99, its prodrug or pharmaceutically acceptable salt or solvate thereof.

101. A pharmaceutical composition of Claim 100 which is an enzyme inhibitor.

102. A pharmaceutical composition of Claim 100 which is a nucleic acid-related enzyme inhibitor.

103. A pharmaceutical composition of Claim 100 which is an HIV integrase inhibitor.

104. A pharmaceutical composition of Claim 100 which is an anti-HIV agent.

105. A pharmaceutical composition of Claim 100 which is a critical prevention or treatment agent for AIDS or a AIDS-related complication.


106. A mixture of a pharmaceutical composition of Claim 103 in combination with a reverse transcriptase inhibitor and/or a protease inhibitor.

107. A pharmaceutical composition of Claim 100 which can enhance the anti-HIV activity of a reverse transcriptase inhibitor and/or a protease inhibitor.


108. A method for prevention or treatment of AIDS or a AIDS-related complication which comprises administration of a compound of any one of Claims 38 to 99.

109. Use of a compound of any one of Claims 38 to 99 for preparing a pharmaceutical composition as an integrase inhibitor.

110. A process for preparing a compound of the formula (III-1) :



(wherein, X, Y, Z, R^B, R⁵ to R⁷, R¹⁹, Z¹ to Z³ and R¹ are the same as defined below) which comprises reacting a compound of the formula (K) :



(wherein, X is O ; Y is hydroxy ; Z is O ; L is a leaving group ; R^B, Z¹, Z², Z³ and R¹ are the same as Claim 1 ; R⁶ and R⁷ are the same as Claim 11) with a compound of the formula : R⁵NH₂ (wherein, R⁵ is a non-interfering substituent) and a compound of the formula : R¹⁹CHO (wherein, R¹⁹ is a non-interfering substituent).

111. A process for preparing a compound of the formula (III-1) of Claim 110, wherein, R^B is heteroaryl ; R⁶ and R⁷ do not substitute on R^B ; L is alkoxy ; Z¹ and Z³ are bonds ; Z² is alkylene ; R¹ is optionally substituted phenyl.

112. A process for preparing a compound of the formula (III-1) of Claim 110, wherein Z² is methylene ; R¹ is 4-fluorophenyl.

113. A process for preparing a compound of the formula (III-1) of Claim 112, wherein the compound of the formula (K) is 4-[5-(4-fluorobenzyl)fran-2-yl]-2-hydroxy-4-oxo-2-butenic acid alkyl ester.

114. A process for preparing a compound of the formula (III-1) of Claim 110 to 113, wherein compounds shown of the formula: R⁵NH₂ and R¹⁹CHO are selected from the following groups;
compound of the formula : R⁵NH₂

cyclopropylamine, cyclobutylamine, cyclopentylamine, cycloleucine, cyclohexylamine, 1-aminocyclohexanecarboxylic acid, 1-ethylcyclohexylamine, 1,2-diaminocyclohexan, 2-methylcyclohexylamine, 2,3-dimethylcyclohexylamine, 4-methylcyclohexylamine, aminomethylcyclohexan, 1,3-cyclohexan bis(methylamine), 1-amino-5,6,7,8-tetrahydronaphthalene, 1,2,3,4-tetrahydro-1-naphthylamine, cyclooctylamine, 2-amino-1-propene-1,1,3-tricarbonitril, diaminomaleonitril, S-methyl-L-cysteine, L-aspartic acid, L-leucine, DL-homoserine, D-methionine, L-allylglycine, L-glutamic acid, 2-amino-1,3,4-thiadiazole, 2-amino-5-mercapto-1,3,4-thiadiazole, 2-amino-5-ethyl-1,3,4-thiadiazole, 3,5-dimethylpyrazole-1-carboamide, 5-amino-3-methylisoxazole, 3-amino-5-methylisoxazole, 2-(2-amino ethyl)-1-methylpyrrolidine, 1-(2-amino ethyl)pyrrolidine, 1-(3-amino propyl)-2-pyrrolidinone, furfurylamine, 1-aminoindan, 5-aminoindan, 1-naphthylamine, 2-naphthylamine, cycloheptylamine, D-tert-leucine, DL-valine, DL-isoleucine, D-serine, guanidoacetic acid, creatine, D-allothreonine, 2-amino-2-methyl-1,3-propanediol, tris(hydroxy methyl)aminomethane, DL-2-amino-3-methyl-1-butanol, L-isoleucinol, D-leucinol, L-methioninol, DL-penicillamine, DL-cysteine, DL-homocysteine, 1-acetyl-3-thiosemicarbazide, 1-acetyl-2-thiourea, N-methylthiourea, ethylthiourea, allylthiourea, dithioxamide, histamine, 3-amino-1,2,4-triazole, 3-amino-5-mercapto-1,2,4-triazole, 3-amino-5-methylthiol, 2,4-triazole, 3,5-diamino-1,2,4-triazole, 3-aminopyrazole, 3-amino-4-cyano-

pyrazole, 3-aminopyrazole-4-carboxylic acid, L-prolineamide, 2-amino-2-thiazoline, 2-aminothiazole, 2-amino-5-nitrothiazole, 2-amino-4-methylthiazole, D-cycloserine, tetrahydrofurfurylamine, 2-aminopurine, 2-aminobenzimidazole, 5-amino indole, 4-aminopyrazolo[3,4-D]pyrimidine, 6-aminoindazole, 8-azaadenine, 3,4-methylenedioxyaniline, N-(2-aminoethyl)piperazine, nipecotamide, 4-(aminomethyl) piperidine, 5-aminouracil, 5-azacytosine,

5 cytosine, 5-fluorocytosine, 4-amino-2,6-dihydroxypyrimidine, 2-aminopyrimidine, 2-amino-4-chloro-6-methylpyrimidine, 2-amino-4,6-dihydroxypyrimidine, 2-amino-4-hydroxy-6-methylpyrimidine, 4-chloro-2,6-diaminopyrimidine, 2,4-diamino-6-hydroxypyrimidine, 2,4,6-triaminopyrimidine, 2-amino-4-methylpyrimidine, 2-amino-4,6-dimethylpyrimidine, 2-amino-5-nitro pyrimidine, 4-aminopyrimidine, 4,5-diaminopyrimidine, 4,5-diamino-6-hydroxy pyrimidine, pyrazineamide, aminopyrazine, 3-aminopyrazine E-2-carboxylic acid, 4-(2-aminoethyl)morpholine, N-(3-aminopropyl)morpholine, nicotineamide N-oxide, 3-amino-2-chloropyridine, 5-amino-2-chloropyridine,

10 5-amino-2-methoxypyridine, 3-hydroxypicolineamide, 2-aminopyridine, 2-amino-3-nitropyridine, 2-amino-3-hydroxy pyridine, 2-aminonicotinic acid, 2,3-diaminopyridine, 2-amino-3-methylpyridine, 2-amino-4-methylpyridine, 2-amino-4,6-dimethylpyridine, 2-amino-5-chloropyridine, 2-amino-5-nitropyridine, 6-aminonicotinic acid, 6-aminonicotinamide, 2-amino-5-methylpyridine, 2,6-diaminopyridine, 2-amino-6-methylpyridine, 6-methylnicotinamide, 2-(aminomethyl)pyridine, 2-(2-aminoethyl)pyridine, nicotinamide, thionicotinamide, 3-aminopyridine, 3,4-diaminopyridine, 3-(aminomethyl)pyridine, isonicotinamide, 4-aminopyridine, 4-(aminomethyl)pyridine, 3-amino-1,2,4-triazine, 3-amino -5,6-dimethyl-1,2,4-triazine, 1-(2-aminoethyl)piperidine, 3-aminoquinoline, 5-aminoquinoline, 6-aminoquinoline, 8-aminoquinoline, 5-aminoisoquinoline, nitroguanidine, cyanamide, thiosemicarbazide, aniline, 2-aminobenzonitril, 2-fluoro aniline, 2,4-difluoroaniline, 2,4,5-trifluoroaniline, 2,4,6-trifluoroaniline, 2,5-difluoro aniline, 2-fluoro-5-methylaniline, 2,6-difluoroaniline, 2-chloroaniline, 2-chloro-4-methylaniline, 2-chloro-5-methylaniline, 2-chloro-6-methylaniline, O-nitroaniline, anisidine, O-phenetidine, 2-aminophenol, 6-amino-m-cresol, 2-amino-4-chlorophenol, 2-amino-4-methylphenol, 2-aminothiophenol, 2-(methylthio)aniline, anthranilic acid, 2'-aminoacetophenone, 2-isopropenylaniline, 2-isopropylaniline, o-phenylenediamine, 3,4-diaminotoluene, 4,5-dimethyl-1,2-phenylenediamine, o-toluidine, 2,3-dimethylaniline, 4-methoxy-2-methylaniline, 2,4-dimethylaniline, 2,4,6-tri methylaniline, 2,5-dimethylaniline, 2-isopropyl-6-methylaniline, 2,6-dimethylaniline, 2-aminobenzyl alcohol, 2-ethylaniline, 2-ethyl-6-methylaniline, 2,6-diethylaniline, 2-aminophenetyl alcohol, 3-aminobenzonitril, 3-fluoroaniline, 3-fluoro-o-anisidine, 3-fluoro-2-methylaniline, 3,4-difluoroaniline, 3-fluoro-4-methylaniline, 3,5-difluoro aniline, 5-fluoro-2-methylaniline, 3-chloroaniline, 3-chloro-2-methylaniline, 3-chloro-4-fluoroaniline, 3-chloro-4-methylaniline, 5-chloro-2-methylaniline, m-nitroaniline, m-anisidine, m-phenetidine, 3-aminophenol, 3-amino -o-cresol, 3-aminothiophenol, 3-(methylthio)aniline, 3-aminobenzoic acid, 3-aminoacetophenone, 3-(1-hydroxy ethyl) aniline, m-phenylenediamine, 2,6-diaminotoluene, 2,4-diaminotoluene, m-toluidine, 3,4-dimethylaniline, 3,5-dimethylaniline, 2-methoxy-5-methylaniline, 3-aminobenzyl alcohol, 3-ethylaniline, 4-aminobenzonitril, 4-fluoroaniline, 4-fluoro-2-methylaniline, 4-chloroaniline, 4-chloro-2-methylaniline, p-nitroaniline, N,N-dimethylp-phenylenediamine, p-anisidine, p-phenetidine, 4-aminophenol, 4-amino-m-cresol, 4-amino-2,5-dimethylphenol, 4-amino-o-cresol, 4-aminothiophenol, 4-(methylthio)aniline, 4-aminobenzoic acid, 4-aminoacetophenone, 4-tert-butylaniline, 4-isopropylaniline, p-phenylenediamine, p-toluidine, 4-aminophenylacetoneitrile, 4-ethylaniline, 4-aminophenetyl alcohol, 4-propylaniline, 4-N-butylaniline, formamide, hydroxyurea, phenylurea, cyanoacetylurea, methylurea, allylurea, allylurea, N-butylurea, N,N-dimethylurea, 1,1-diethylurea, phenylcarbamate, tert-butylcarbamate, methylcarbamate, ethylcarbamate, butylcarbamate, benzamide, 2-fluorobenzamide, salicylamide, 2-aminobenzamide, O-toluamide, 3-fluorobenzamide, 3-aminobenzamide, m-toluamide, 4-fluorobenzamide, 4-hydroxybenzamide, 4-aminobenzamide, p-toluamide, ethyl oxamate, oxamide, 2,2,2-trifluoroacetamide, trimethylacetamide, 2,2-dichloroacetamide, 2-chloropropionamide, lactamide, methacrylamide, isobutylamide, urea, acetamide, cyanoacetamide, 2-bromoacetamide, fluoroacetamide, 2-chloro acetamide, N-acetylglucineamide, acrylic amide, cinnamamide, malonamide, propionamide, 3-chloropropionamide, 2-aminoisobutanoic acid, tert-utylamine,

45 2-amino-2-methyl-1-propanol, tert-octylamine, 1,2-diamino-2-methylpropane, tert-amyl amine, 1,1-diethylpropar-gylamine, thiobenzamide, (R)-(-)-2-phenylglycinol, thiourea, DL- α -methylbenzylamine, thioacetamide, 3-aminocrotonitril, methyl 3-aminocrotonate, ethyl 3-aminocrotonate, D-alanine, 1,2-dimethylpropylamine, isopropylamine, 2-amino-1-methoxypropane, DL-2-amino-1-propanol, ethyl 3-amino butylate, DL- β -amino -n-butanoic acid, 1,3-dimethylbutylamine, 1,2-diaminopropane, 1-methyl-3-phenylpropylamine, 2-amino-6-methylheptane, DL-2-amino butanoic acid, sec-butylamine, (+/-)-2-amino -1-butanol, 3-amino pentane, D-norvaline, D-norleucine, 2-aminoheptane, 2-amino-octane, methylamine, benzylamine, 2-fluorobenzylamine, 2-chlorobenzylamine, 2-methoxybenzylamine, 2-methylbenzylamine, 3-fluorobenzyl amine, 3-methoxybenzylamine, 3-methylbenzylamine, m-xylylenediamine, 4-fluorobenzylamine, 4-chlorobenzylamine, 4-methoxybenzylamine, 4-methylbenzyl amine, glycine, 2,2,2-trifluoroethyl amine, aminoacetoaldehyde dimethyl acetal, amino acetoaldehyde diethyl acetal, 2-amino-1-phenylethanol, DL-isoserine, 1-amino-2-propanol, 3-amino-1,2-propanediol, DL-4-amino-3-hydroxybutanoic acid, 1,3-diamino-2-hydroxypropane, 2-phenylpropylamine, DL-3-aminoisobutanoic acid, isobutylamine, 2-methylbutylamine, 2-ethylhexylamine, ethylamine, N-phenylethylenediamine, N-acetylethylenediamine, N-isopropylethylenediamine, N-methylethylenediamine, N-ethylethylenediamine, 2-(2-aminoethylamino)ethanol, diethylene-

diamine, N-(n-propyl)ethylenediamine, N,N-dimethylethylenediamine, N,N-diethylethylenediamine, tris(2-aminoethyl)amine, 2-methoxyethylamine, 2-(2-aminoethoxy)ethanol, ethanolamine, phenethylamine, thyramine, 2-(4-aminophenyl)ethylamine, 2-(p-tri l)ethylamine, taurine, propargylamine, allylamine, β -alanine, 3,3-dimethylbutylamine, isoamylamine, ethylenediamine, propylamine, N-isopropyl-1,3-propanediamine, N-methyl-1,3-propanediamine, N-(2-aminoethyl)-1,3-propanediamine, N-propyl-1,3-propanediamine, 3,3'-diaminodipropylamine, N,N-dimethyl-1,3-propanediamine, N,N-bis(3-aminopropyl)methylamine, N,N-diethyl-1,3-propanediamine, 3-isopropoxypropylamine, 3-ethoxypropylamine, 3-amino -1-propanol, 3-phenylpropylamine, 4-aminobutanoic acid, 1,3-diaminopropane, 4-amino -1-butanol, 4-phenylbutylamine, 5-aminovaleic acid, 1,4-diaminobutane, N-amylamine, 5-amino-1-pentanol, 6-aminocaproic acid, 1,5-diaminopentane, hexylamine, 6-amino-1-hexanol, 7-aminoheptanoic acid, 1,6-hexandiamine, n-heptylamine, 1,7-diaminoheptane, octylamine, 1,8-diaminooctane, nonylamine, cyclohexane carboamide, 2,2-dimethyl-1,3-propanediamine, 2-n-propylaniline, DL-2-amino-1-pentanol, DL-2-amino-1-hexanol, 1-(3-aminopropyl)imidazole, p-xylylenediamine, 1-amino cyclopropane-1-carboxylic acid, cyanothioacetamide, 2,4-difluorobenzylamine, 2,5-difluorobenzylamine, 2,6-difluorobenzylamine, 3,4-difluorobenzylamine, 2-methyl-3-thiosemicarbazide, 5-amino-2-methoxyphenol, 4-sec-butylaniline, 2,3-difluoroaniline, thiophene-2-carboamide, 1-amino-1-cyclopentanemethanol, 3-methyladenine, 1-methyladenine, 4-chloro-2-fluoroaniline, 5-amino-1-ethylpyrazole, 2,3-diaminotoluene, butylamine, 4-chloro-o-phenylenediamine, 1-(trimethylsilylmethyl)urea, 2,3,4-trifluoro aniline, 2-(1-cyclohexanyl)ethylamine, 3-amino-2-butenethioamide, 2,3,6-trifluoro aniline, 1,5-diamino-2-methylpentane, amidinothiourea, 3-ethynylaniline, N,N-bis(2-hydroxyethyl)ethylenediamine, 3-methoxypropylamine, 4-aminostyrene, 2-amino-6-fluorobenzonitrile, 3-amino-5-hydroxypyrazole, 2,4-diamino-6-methyl-1,3,5-triazine, pyridine-2-carboamide, 1-aminoisoquinoline, 4-chloro-1,3-phenylenediamine, 2-chloro ethylcarbamate, amide fumarate, acetoacetamide, N-N-butylethylenediamine, 3-butoxypropylamine, cyclopropanemethylamine, 5-aminoindazole, 2,4-diamino pyrimidine, α -ethylbenzylamine, 3-aminoisoxazole, chlorodifluoroacetamide, 1,8-diamino-3,6-dioxaoctane, 2-sec-butylaniline, 3-chlorobenzylamine, 2-fluoro-4-methylaniline, 1-(4-fluorophenyl)ethylamine, 4-aminophthalonitrile, adenine, 2-chloro-4-fluoroaniline, semicarbazide, (R)-(-)-1-cyclohexylethylamine, 5-amino-o-cresol, N,N,2,2-tetramethyl-1,3-propanediamine, 2,2-diethoxyacetamide, 3-amino-5,5-dimethyl-2-cyclohexane-1-one, propylcarbamate, glycolamide, 2-amino-1,3-propanediol, thiophene-2-ethylamine, 2,5-dimethyl-1,4-phenylenediamine, 2-amino-4-methoxy-6-methyl-1,3,5-triazine, 2-phenoxyethylamine, 4-amino-2-mercaptopyrimidine, creatinine, 2-amino-4-methoxy-6-methylpyrimidine, 3,5-difluorobenzylamine, (1R,2R)-(-)-1,2-diaminocyclohexane, (1S,2S)-(+)-1,2-diaminocyclohexane, D-aspartic acid, DL-aspartic acid, DL-leucine, D-leucine, L-homoserine, DL-methionine, L-methionine, DL-allylglycine, D-glutamic acid, L-leucinol, DL-threonine, cis-1,2-diamino cyclohexane, trans-1,2-cyclohexanediamine, L-tert-leucine, D-valine, L-valine, D-iso leucine, L-isoleucine, DL-serine, L-serine, L-allo-threonine, D-threonine, L-threonine, L-valinol, D-valinol, L-cysteine, DL-cycloserine, L-cycloserine, L-asparagine, (S)-(+)-2-phenylglycinol, (R)-(+)-1-phenylethylamine, L-(-)- α -methylbenzylamine, DL-alanine, L-alanine, L-alaninol, D-alaninol, D-(-)-2-aminobutanoic acid, L- α -amino -n-butanoic acid, (R)-(-)-2-aminobutane, (S)-(+)-2-aminobutane, (S)-(+)-2-amino-1-butanol, (R)-(-)-2-amino-1-butanol, DL-norvaline, L-norvaline, DL-norleucine, L-norleucine, (R)-(-)-1-amino -2-propanol, (S)-(+)-1-amino-2-propanol, (S)-(-)-2-methylbutylamine, DL-lysine, L-lysine, DL-tert-leucine, (S)-(+)-1-cyclohexylethylamine, ethyl thiooxamate, 2-amino-5-methylbenzyl alcohol, 2-amino-3-methylbenzyl alcohol, 3-amino-2-methylbenzyl alcohol, 3-fluoro-4-methoxyaniline, 3-amino-4-methylbenzyl alcohol, 5-methoxy-2-methylaniline, 2-amino-m-cresol, trans-1,4-diaminocyclohexane, 3-amino-5-methylpyrazole, 2,3-diaminophenol, 1-piperidinecarboamide, 6-amino-1-methyluracil, 3-fluorophenethylamine, 2-aminobenzylamine, 2-methoxy-6-methylaniline, 2-fluoro phenethylamine, 4-aminobenzylamine, 1-acetylguanidine, D-homoserine, 2-amino-5-methylthiazole, (S)-(+)-tetrahydrofurfurylamine, 2-aminobenzyl cyanide, 4-amino-2-chlorophenol, 2-amino-4,5-dicyanoimidazole, 4-amino-6-methoxypyrimidine, 2-tert-butylaniline, 2-(4-fluorophenyl)ethylamine, 1,3-diamino pentane, 2-amino-1-methylbenzimidazole, 5-methylfurfurylamine, (R)-(+)-1-(p-tri l)ethylamine, (S)-(-)-1-(p-tri l)ethylamine, 3-amino-1,2,4-triazole-5-carboxylic acid, muscimol, 4-ethynylaniline, 2-amino-4-methylbenzonitrile, 2-amino-5-methylthio-1,3,4-thiadiazole, 1-(aminocarbonyl)-1-cyclopropanecarboxylic acid, cis-4-aminocyclohexane carboxylic acid, (S)-(+)-2-(aminomethyl)pyrrolidine, 5-amino-4-nitroimidazole, 3-amino -1-propanolvinyl ether, thioethylene diamine, isopropyl-diethylene triamine, L-tert-leucinol, N-methyl-1,2-phenylenediamine, (R)-(-)-tetrahydrofurfurylamine, L-(-)-lactamide, (R)-(+)- lactamide, (S)-(+)-2,2-dimethylcyclopropanecarboamide, (1S,2R)-(-)-cis-1-amino-2-indanol, (1R,2S)-(+)-cis-1-amino-2-indanol, (R)-(-)-1-aminoindane, (S)-(+)-1-aminoindane, (R)-2-phenyl-1-propylamine, (S)-2-phenyl-1-propylamine, D-methioninol, (R)-2-amino-1-phenylethanol, 2-amino-4,5-dimethyl-3-furancarboxynitrile, N-hexylethylenediamine, (S)-(-)-4-amino-2-hydroxybutanoic acid, (S)-3-amino-1,2-propanediol, (R)-3-amino-1,2-propanediol, 4-aminoindole, (R)-(-)-tert-leucinol and 2-amino-5-fluoropyridine.

compound of the formula : R¹⁹ CHO

formaldehyde, ethyl 2-formyl-1-cyclopropanecarboxylate, cyclohexanecarbaldehyde, 1,2,3,6-tetrahydrobenzaldehyde, 1-methylpyrrole-2-carboxaldehyde, furfural, 5-nitro-2-furaldehyde, 5-methylfurfural, 5-hydroxymethyl-2-furaldehyde, 3-(2-furyl)acrolein, benzaldehyde, 2-fluorobenzaldehyde, 2-chloro benzaldehyde, o-anise alde-

hyde, salicyl aldehyde, 3-fluoro-2-hydroxybenzaldehyde, 2,3-dihydroxybenzaldehyde, 2,5-dihydroxybenzaldehyde, o-naphthal aldehyde, o-tol aldehyde, 2,4-dimethylbenzaldehyde, mesitaldehyde, 2,5-dimethylbenzaldehyde, 3-cyanobenzaldehyde, 3-fluorobenzaldehyde, 3-chlorobenzaldehyde, 3-methoxybenzaldehyde, 3-hydroxybenzaldehyde, 3,4-dihydroxybenzaldehyde, isonaphthalaldehyde, m-tolaldehyde, 4-cyanobenzaldehyde, 4-fluorobenzaldehyde, 4-chlorobenzaldehyde, 4-dimethylaminobenzaldehyde, p-anisaldehyde, imidazole-2-carbaldehyde, pyrrole-2-carbaldehyde, 2-thiophenecarbaldehyde, 3-methylthiophene-2-carbaldehyde, 5-methyl-2-thiophenecarbaldehyde, 3-thiophenecarbaldehyde, indole-3-carbaldehyde, 2-pyridinecarbaldehyde, 6-methyl-2-pyridinecarbaldehyde, 3-pyridinecarbaldehyde, 4-pyridinecarbaldehyde, 4-hydroxybenzaldehyde, terenaphthalaldehyde, cuminaldehyde, p-tolaldehyde, 4-ethyl benzaldehyde, glyoxal, glyoxylic acid, methyl glyoxal, trimethylacetoaldehyde, D-(-)-erythrose, 2-phenylpropionaldehyde, methacrolein, 3-ethoxymethacrolein, alpha-methylcinnamaldehyde, trans-2-methyl-2-butenal, 2-methyl-2-pentenal, isobutylaldehyde, 2,6-dimethyl-5-hepten-1-ol, 2-methylbutylaldehyde, 2-ethylbutylaldehyde, 2-methylpentanal, 2-ethylhexanal, acetoaldehyde, chloro acetoaldehyde, phenylacetoaldehyde, phenylpropargyl aldehyde, acrolein, 3-(dimethylamino) acrolein, trans-cinnamaldehyde, crotonaldehyde, 2,4-hexadienal, trans,trans-2,4-heptadienal, trans,trans-2,4-nonadienal, trans-2-hexanal, trans-2,cis-6-nonadien-1-al, trans-2-heptenal, trans-2-octanal, trans-2-nonanal, isovaleraldehyde, propionaldehyde, 3-phenylpropionaldehyde, 3-(methylthio)propionaldehyde, butylaldehyde, glutaraldehyde, valeraldehyde, hexanal, heptaldehyde, octanal, nonanal, trans-2-pentenal, 2,4-dimethyl-2,6-heptadienal, 2,6-pyridinedicarbaldehyde, 2-ethylacrolein, 3-methyl-2-butenal, 2,3-difluorobenzaldehyde, 2,6-difluorobenzaldehyde, 2,4-difluorobenzaldehyde, 2,5-difluorobenzaldehyde, 3,4-difluorobenzaldehyde, 3,5-difluorobenzaldehyde, 3-furaldehyde, 3,5,5-trimethylhexanal, 3-phenylbutylaldehyde, 2,2-dimethyl-4-pentenal, 2,4-dihydroxybenzaldehyde, cyclopropanecarbaldehyde, 4-hydroxy-3-methylbenzaldehyde, benzo[b]furan-2-carbaldehyde, 3,5-dihydroxybenzaldehyde, 3,4-dimethylbenzaldehyde, 2-cyanobenzaldehyde, 5-ethyl-2-furaldehyde, 2-hydroxy-3-methylbenzaldehyde, 3,3-dimethylbutylaldehyde, 5-chloro-2-thiophenecarbaldehyde, 3,4-dihydro-2H-pyran-2-carbaldehyde, D-glyceroaldehyde, DL-glyceroaldehyde, 3-fluoro-2-methylbenzaldehyde, 3-dimethylamino-2-methyl-2-propenal, 3,5-dimethylbenzaldehyde, 4,5-dimethyl-2-furancarbaldehyde, 4-vinylbenzaldehyde, 2,6-dimethylbenzaldehyde, 2-octanal, dimethoxyacetoaldehyde, 2-deoxy-D-ribose, 2-formyl thiazole, 5-ethyl-2-thiophenecarbaldehyde, glyoxylic acid, 4-pyridinecarbaldehyde-N-oxide, 5-norbornene-2-carbaldehyde, 4-formylimidazole, 5-methylimidazole-4-carbaldehyde, 5-formyluracil, 2,3-thiophenedicarbaldehyde, thiophene-2,5-dicarbaldehyde, 2,3-o-isopropylidene-D-glyceroaldehyde, 2-hydroxy-5-methylbenzaldehyde, 1-cyclohexane-1-carbaldehyde, 2,3-dimethylbenzaldehyde, 1-methyl-2-imidazolecarbaldehyde, vinylbenzaldehyde, 4-fluoro-3-methylbenzaldehyde, 3-fluoro-4-methylbenzaldehyde, tetrahydrofuran-3-carbaldehyde, 2-fluoro-5-formyl benzonitrile, indole-5-carbaldehyde, 4-acetylbenzaldehyde, 3-vinylbenzaldehyde and 2-fluoro-5-methylbenzaldehyde.

115.A process for preparing a compound of the formula (III-1) of Claim 110, wherein the compound of formula (K) is 4-[5-(4-fluorobenzyl)franz-2-yl]-2-hydroxy-4-oxo-2-butenic acid alkyl ester and compounds shown of the formula: R^5NH_2 and $R^{19}C HO$ are each selected from the groups of above (114).

116.A compound of formula (III-1) prepared by the process of any one of Claims 110 to 114.

117.A compound of formula (III-1) prepared by the process of Claim 115.

118.A library of compounds prepared by the process of Claim 115.

119.A pharmaceutical composition comprising as an effective ingredient a compound of Claim 117.

120.A pharmaceutical composition as an integrase inhibitor comprising as an effective ingredient a compound of Claim 117.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/08108

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl. ⁷ C07D207/38, 403/04, 405/04, 405/06, 413/04, 401/04, 413/06, 407/06, 417/06, 409/06, 403/06, 409/14, 311/56, 307/46, A61K31/4025, 31/4245, 31/4427, 31/4709, 31/506, According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl. ⁷ C07D207/38, 403/04, 405/04, 405/06, 413/04, 401/04, 413/06, 407/06, 417/06, 409/06, 403/06, 409/14, 311/56, 307/46, A61K31/4025, 31/4245, 31/4427, 31/4709, 31/506, Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA(STN), REGISTRY(STN), WPIDS(STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 6-100445 A (Banyu Pharmaceutical Co., Ltd.), 12 April, 1994 (12.04.94), Claims (Family: none)	97-102
X	Silhankova, Alexandra; Hulvova, Jana; Trska, Petr; Ferles, Miloslav, Studies in the pyridine series. Part LVIII. Condensation reactions of 2,4- and 2, 6-dimethylpyridines and their 1-oxides, Collect. Czech. Chem. Commun. (1989), 54(6), 1687-704, page 1694	38, 46, 47, 97-100
X	Pham Huu Chanh; Soka, In; Couquelet, J.M.; Couquelet, J.D.; Thibault, A.; Cros, J., Pharmacological aspects of pyrazoline derivatives from 2-hydroxybuty- nolides, Arzneim.-Forsch. (1976), 26(11), 2050-2, table 1	38, 46, 47, 97-100
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 09 September, 2002 (09.09.02)		Date of mailing of the international search report 01 October, 2002 (01.10.02)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/08108

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Andreichikov, Yu. S.; Gein, V.L.; Kon'shina, L.O.; Shapet'ko, N.N., Five-membered-ring 2,3-dioxoheterocycles. XIV. Synthesis of 1,4-disubstituted 5-aryltetrahydropyrrole-2,3-diones by reaction of diethoxalylacetone with azomethines, Zh. Org. Khim. (1989), 25(12), 2494-500, compounds IX-XII	97-100
X	Sklyarova, I.V.; Koznetsov, V.A.; Garabadzhiu, A.V.; Glibin, E.N.; Ginzburg, O.F., Synthesis of actinomycin analogs. XVII. Actinomycin amides containing a benzimidazole fragment, Zh. Org. Khim. (1989), 25(1), 186-9, compounds Ia, o	97-99
X	Elben, Ulrich; Voegtle, Fritz, 'Cryptomycins' - crown ether analogs of the actinomycins, J.Chem. Res. (S), (1978), (9), 316-17, compound (2)	97-99
X	Betail, G.; Tronche, P.; Coulet, M.; Couquelet, J.; Payard, M., Induction of antinuclear antibodies. Study of new molecules with a hydrazine structure or their analogs in mice, Ann. Pharm. Fr. (1978), 36(7-8), 317-22, compound 4	38, 46, 47, 97-100
A	WO 00/39086 A (Shionogi & Co., Ltd.), 06 July, 2000 (06.07.00), Full text & EP 1142872 A	1-120

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/08108

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 36, 108

because they relate to subject matter not required to be searched by this Authority, namely:

Claims 36 and 108 pertain to a method for treatment of the human body by therapy.

2. ☒ Claims Nos.: 1-120

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

(See extra sheet)

3. ☐ Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/08108

Continuation of Box No. I-2 of continuation of first sheet (1)

The term "non-interfering substituent" used in the claims is unclear as to what structure is implied, even when the statements in the description are investigated. This term hence makes the scope of the compound and medicine of the invention unclear.

Consequently, the claims and the description do not comply with the given requirements to such a degree that a meaningful international search can be made.

In this international search report, a search was made through prior art documents with respect to the compounds specified in the description.

Continuation of A. CLASSIFICATION OF SUBJECT MATTER
(International Patent Classification (IPC))

Int.Cl⁷ 31/422, 31/427, 31/4178, 31/4155, 31/4439, 31/501, 31/497,
31/53, 31/4433, 31/4196, 31/366, 31/443, 31/352, 31/4015,
A61P31/12, 31/18, 43/00//C07D307/54

(According to International Patent Classification (IPC) or to both national classification and IPC)

Continuation of B. FIELDS SEARCHED

Minimum Documentation Searched (International Patent Classification (IPC))

Int.Cl⁷ 31/422, 31/427, 31/4178, 31/4155, 31/4439, 31/501, 31/497,
31/53, 31/4433, 31/4196, 31/366, 31/443, 31/352, 31/4015,
C07D307/54

Minimum documentation searched (classification system followed by classification symbols)